CA3059446A1 - Methods for the treatment of subjects having a hepatitis b virus (hbv) infection - Google Patents
Methods for the treatment of subjects having a hepatitis b virus (hbv) infection Download PDFInfo
- Publication number
- CA3059446A1 CA3059446A1 CA3059446A CA3059446A CA3059446A1 CA 3059446 A1 CA3059446 A1 CA 3059446A1 CA 3059446 A CA3059446 A CA 3059446A CA 3059446 A CA3059446 A CA 3059446A CA 3059446 A1 CA3059446 A1 CA 3059446A1
- Authority
- CA
- Canada
- Prior art keywords
- hbv
- rnai agent
- subject
- hbsag
- dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000700721 Hepatitis B virus Species 0.000 title claims abstract description 373
- 238000000034 method Methods 0.000 title claims abstract description 219
- 208000015181 infectious disease Diseases 0.000 title claims abstract description 72
- 238000011282 treatment Methods 0.000 title claims abstract description 69
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 263
- 230000009368 gene silencing by RNA Effects 0.000 claims abstract description 184
- 108091030071 RNAI Proteins 0.000 claims abstract description 183
- 229960005486 vaccine Drugs 0.000 claims abstract description 148
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 115
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 100
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 100
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 100
- 101710132601 Capsid protein Proteins 0.000 claims abstract description 98
- 229940023143 protein vaccine Drugs 0.000 claims abstract description 97
- 230000014509 gene expression Effects 0.000 claims abstract description 96
- 108091007433 antigens Proteins 0.000 claims abstract description 84
- 102000036639 antigens Human genes 0.000 claims abstract description 84
- 239000000427 antigen Substances 0.000 claims abstract description 78
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 70
- 229920001184 polypeptide Polymers 0.000 claims abstract description 56
- 239000013604 expression vector Substances 0.000 claims abstract description 27
- 125000003729 nucleotide group Chemical group 0.000 claims description 228
- 239000002773 nucleotide Substances 0.000 claims description 204
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 110
- 210000002966 serum Anatomy 0.000 claims description 92
- 150000001413 amino acids Chemical class 0.000 claims description 88
- 239000003446 ligand Substances 0.000 claims description 72
- 239000013598 vector Substances 0.000 claims description 70
- 239000002671 adjuvant Substances 0.000 claims description 68
- -1 AGX-1009 Chemical compound 0.000 claims description 67
- 239000000203 mixture Substances 0.000 claims description 58
- 230000002163 immunogen Effects 0.000 claims description 51
- 239000012634 fragment Substances 0.000 claims description 50
- 108020004414 DNA Proteins 0.000 claims description 43
- 230000000692 anti-sense effect Effects 0.000 claims description 40
- 108091034117 Oligonucleotide Proteins 0.000 claims description 39
- 108091081021 Sense strand Proteins 0.000 claims description 39
- 230000003612 virological effect Effects 0.000 claims description 28
- 238000009472 formulation Methods 0.000 claims description 27
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims description 26
- 241001183012 Modified Vaccinia Ankara virus Species 0.000 claims description 26
- 230000003247 decreasing effect Effects 0.000 claims description 23
- 238000001514 detection method Methods 0.000 claims description 22
- OVRNDRQMDRJTHS-KEWYIRBNSA-N N-acetyl-D-galactosamine Chemical class CC(=O)N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-KEWYIRBNSA-N 0.000 claims description 21
- 229960000980 entecavir Drugs 0.000 claims description 19
- YXPVEXCTPGULBZ-WQYNNSOESA-N entecavir hydrate Chemical compound O.C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)C1=C YXPVEXCTPGULBZ-WQYNNSOESA-N 0.000 claims description 19
- 238000003556 assay Methods 0.000 claims description 17
- 239000003112 inhibitor Substances 0.000 claims description 16
- 230000004044 response Effects 0.000 claims description 16
- 101710142246 External core antigen Proteins 0.000 claims description 15
- 229910019142 PO4 Inorganic materials 0.000 claims description 15
- 230000003278 mimic effect Effects 0.000 claims description 15
- 239000010452 phosphate Substances 0.000 claims description 14
- 229910052717 sulfur Inorganic materials 0.000 claims description 14
- 241000700605 Viruses Species 0.000 claims description 13
- 239000013603 viral vector Substances 0.000 claims description 13
- 108010092853 peginterferon alfa-2a Proteins 0.000 claims description 10
- 102000037982 Immune checkpoint proteins Human genes 0.000 claims description 9
- 108091008036 Immune checkpoint proteins Proteins 0.000 claims description 9
- 210000000234 capsid Anatomy 0.000 claims description 9
- VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 claims description 9
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims description 8
- 102100039390 Toll-like receptor 7 Human genes 0.000 claims description 8
- JLKJXDOWBVVABZ-UHFFFAOYSA-N [[1-[(2-aminopurin-9-yl)methyl]cyclopropyl]oxymethyl-(2,2-dimethylpropanoyloxymethoxy)phosphoryl]oxymethyl 2,2-dimethylpropanoate Chemical compound C1=NC2=CN=C(N)N=C2N1CC1(OCP(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)CC1 JLKJXDOWBVVABZ-UHFFFAOYSA-N 0.000 claims description 8
- 229960004308 acetylcysteine Drugs 0.000 claims description 8
- 229940035032 monophosphoryl lipid a Drugs 0.000 claims description 8
- 229960004693 tenofovir disoproxil fumarate Drugs 0.000 claims description 8
- 241000702421 Dependoparvovirus Species 0.000 claims description 7
- 239000012648 POLY-ICLC Substances 0.000 claims description 7
- 229940044665 STING agonist Drugs 0.000 claims description 7
- 102000008235 Toll-Like Receptor 9 Human genes 0.000 claims description 7
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 claims description 7
- 102100033110 Toll-like receptor 8 Human genes 0.000 claims description 7
- 229940037003 alum Drugs 0.000 claims description 7
- PDXMFTWFFKBFIN-XPWFQUROSA-N cyclic di-AMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]3[C@@H](O)[C@H](N4C5=NC=NC(N)=C5N=C4)O[C@@H]3COP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 PDXMFTWFFKBFIN-XPWFQUROSA-N 0.000 claims description 7
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 7
- 229940115270 poly iclc Drugs 0.000 claims description 7
- 230000028327 secretion Effects 0.000 claims description 7
- LDEKQSIMHVQZJK-CAQYMETFSA-N tenofovir alafenamide Chemical compound O([P@@](=O)(CO[C@H](C)CN1C2=NC=NC(N)=C2N=C1)N[C@@H](C)C(=O)OC(C)C)C1=CC=CC=C1 LDEKQSIMHVQZJK-CAQYMETFSA-N 0.000 claims description 7
- 229960004946 tenofovir alafenamide Drugs 0.000 claims description 7
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical group OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 claims description 6
- 230000002458 infectious effect Effects 0.000 claims description 6
- 229910052760 oxygen Inorganic materials 0.000 claims description 6
- 241000701161 unidentified adenovirus Species 0.000 claims description 6
- 241000701022 Cytomegalovirus Species 0.000 claims description 5
- 101001043807 Homo sapiens Interleukin-7 Proteins 0.000 claims description 5
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 claims description 5
- 108010078049 Interferon alpha-2 Proteins 0.000 claims description 5
- 241000725643 Respiratory syncytial virus Species 0.000 claims description 5
- 229940118555 Viral entry inhibitor Drugs 0.000 claims description 5
- 239000000556 agonist Substances 0.000 claims description 5
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 claims description 5
- PKFDLKSEZWEFGL-MHARETSRSA-N c-di-GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]3[C@@H](O)[C@H](N4C5=C(C(NC(N)=N5)=O)N=C4)O[C@@H]3COP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 PKFDLKSEZWEFGL-MHARETSRSA-N 0.000 claims description 5
- 229940124765 capsid inhibitor Drugs 0.000 claims description 5
- 102000052622 human IL7 Human genes 0.000 claims description 5
- 229960003507 interferon alfa-2b Drugs 0.000 claims description 5
- 229960001627 lamivudine Drugs 0.000 claims description 5
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 claims description 5
- GKTNLYAAZKKMTQ-UHFFFAOYSA-N n-[bis(dimethylamino)phosphinimyl]-n-methylmethanamine Chemical compound CN(C)P(=N)(N(C)C)N(C)C GKTNLYAAZKKMTQ-UHFFFAOYSA-N 0.000 claims description 5
- MIXCUJKCXRNYFM-UHFFFAOYSA-M sodium;diiodomethanesulfonate;n-propyl-n-[2-(2,4,6-trichlorophenoxy)ethyl]imidazole-1-carboxamide Chemical compound [Na+].[O-]S(=O)(=O)C(I)I.C1=CN=CN1C(=O)N(CCC)CCOC1=C(Cl)C=C(Cl)C=C1Cl MIXCUJKCXRNYFM-UHFFFAOYSA-M 0.000 claims description 5
- GWFOVSGRNGAGDL-FSDSQADBSA-N 2-amino-9-[(1r,2r,3s)-2,3-bis(hydroxymethyl)cyclobutyl]-3h-purin-6-one Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1C[C@H](CO)[C@H]1CO GWFOVSGRNGAGDL-FSDSQADBSA-N 0.000 claims description 4
- 102000004127 Cytokines Human genes 0.000 claims description 4
- 108090000695 Cytokines Proteins 0.000 claims description 4
- XQSPYNMVSIKCOC-NTSWFWBYSA-N Emtricitabine Chemical compound C1=C(F)C(N)=NC(=O)N1[C@H]1O[C@@H](CO)SC1 XQSPYNMVSIKCOC-NTSWFWBYSA-N 0.000 claims description 4
- 101000831496 Homo sapiens Toll-like receptor 3 Proteins 0.000 claims description 4
- 101000800483 Homo sapiens Toll-like receptor 8 Proteins 0.000 claims description 4
- 108010050904 Interferons Proteins 0.000 claims description 4
- 102000014150 Interferons Human genes 0.000 claims description 4
- 241001631646 Papillomaviridae Species 0.000 claims description 4
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 claims description 4
- 108010021501 Theradigm-HBV Proteins 0.000 claims description 4
- 101800001530 Thymosin alpha Proteins 0.000 claims description 4
- 102100024324 Toll-like receptor 3 Human genes 0.000 claims description 4
- SCTJKHUUZLXJIP-RUZDIDTESA-N [(2r)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethyl-(3-hexadecoxypropoxy)phosphinic acid Chemical compound N1=CN=C2N(C[C@@H](C)OCP(O)(=O)OCCCOCCCCCCCCCCCCCCCC)C=NC2=C1N SCTJKHUUZLXJIP-RUZDIDTESA-N 0.000 claims description 4
- KDNSSKPZBDNJDF-UHFFFAOYSA-N [1-[(2-aminopurin-9-yl)methyl]cyclopropyl]oxymethylphosphonic acid Chemical compound C12=NC(N)=NC=C2N=CN1CC1(OCP(O)(O)=O)CC1 KDNSSKPZBDNJDF-UHFFFAOYSA-N 0.000 claims description 4
- WOZSCQDILHKSGG-UHFFFAOYSA-N adefovir depivoxil Chemical compound N1=CN=C2N(CCOCP(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)C=NC2=C1N WOZSCQDILHKSGG-UHFFFAOYSA-N 0.000 claims description 4
- 229960003205 adefovir dipivoxil Drugs 0.000 claims description 4
- 229950002782 besifovir Drugs 0.000 claims description 4
- 229960005338 clevudine Drugs 0.000 claims description 4
- GBBJCSTXCAQSSJ-XQXXSGGOSA-N clevudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1[C@H](F)[C@@H](O)[C@H](CO)O1 GBBJCSTXCAQSSJ-XQXXSGGOSA-N 0.000 claims description 4
- 229960000366 emtricitabine Drugs 0.000 claims description 4
- 229960004396 famciclovir Drugs 0.000 claims description 4
- GGXKWVWZWMLJEH-UHFFFAOYSA-N famcyclovir Chemical compound N1=C(N)N=C2N(CCC(COC(=O)C)COC(C)=O)C=NC2=C1 GGXKWVWZWMLJEH-UHFFFAOYSA-N 0.000 claims description 4
- LLYJISDUHFXOHK-GOCONZMPSA-N ferroptocide Chemical compound C[C@@H]1CC[C@@]23C[C@@H](C(=O)[C@]2([C@@]1([C@@H](C[C@H]([C@@H]3C)C4=CCN5C(=O)N(C(=O)N5C4)C6=CC=CC=C6)OC(=O)CCl)C)O)O LLYJISDUHFXOHK-GOCONZMPSA-N 0.000 claims description 4
- 229960002963 ganciclovir Drugs 0.000 claims description 4
- 229940079322 interferon Drugs 0.000 claims description 4
- 229950005339 lobucavir Drugs 0.000 claims description 4
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 4
- 229940115272 polyinosinic:polycytidylic acid Drugs 0.000 claims description 4
- 229960000311 ritonavir Drugs 0.000 claims description 4
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 claims description 4
- 229960005311 telbivudine Drugs 0.000 claims description 4
- IQFYYKKMVGJFEH-CSMHCCOUSA-N telbivudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1O[C@@H](CO)[C@H](O)C1 IQFYYKKMVGJFEH-CSMHCCOUSA-N 0.000 claims description 4
- 239000000277 virosome Substances 0.000 claims description 4
- KBDWGFZSICOZSJ-UHFFFAOYSA-N 5-methyl-2,3-dihydro-1H-pyrimidin-4-one Chemical group N1CNC=C(C1=O)C KBDWGFZSICOZSJ-UHFFFAOYSA-N 0.000 claims description 3
- 208000035657 Abasia Diseases 0.000 claims description 3
- 239000012275 CTLA-4 inhibitor Substances 0.000 claims description 3
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 3
- 208000000666 Fowlpox Diseases 0.000 claims description 3
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims description 3
- 241000713869 Moloney murine leukemia virus Species 0.000 claims description 3
- 239000012270 PD-1 inhibitor Substances 0.000 claims description 3
- 239000012668 PD-1-inhibitor Substances 0.000 claims description 3
- 241000709664 Picornaviridae Species 0.000 claims description 3
- 241001505332 Polyomavirus sp. Species 0.000 claims description 3
- 241000287219 Serinus canaria Species 0.000 claims description 3
- 241000700584 Simplexvirus Species 0.000 claims description 3
- 108010060825 Toll-Like Receptor 7 Proteins 0.000 claims description 3
- 108010060752 Toll-Like Receptor 8 Proteins 0.000 claims description 3
- 102000008230 Toll-like receptor 3 Human genes 0.000 claims description 3
- 108010060885 Toll-like receptor 3 Proteins 0.000 claims description 3
- 241000700618 Vaccinia virus Species 0.000 claims description 3
- 108091008108 affimer Proteins 0.000 claims description 3
- 229960003852 atezolizumab Drugs 0.000 claims description 3
- 229950002916 avelumab Drugs 0.000 claims description 3
- 229950009791 durvalumab Drugs 0.000 claims description 3
- 229960005386 ipilimumab Drugs 0.000 claims description 3
- 229960003301 nivolumab Drugs 0.000 claims description 3
- 229940121655 pd-1 inhibitor Drugs 0.000 claims description 3
- 108010092851 peginterferon alfa-2b Proteins 0.000 claims description 3
- 229960002621 pembrolizumab Drugs 0.000 claims description 3
- 239000001226 triphosphate Substances 0.000 claims description 3
- 241001430294 unidentified retrovirus Species 0.000 claims description 3
- MPCAJMNYNOGXPB-UHFFFAOYSA-N 1,5-Anhydro-mannit Natural products OCC1OCC(O)C(O)C1O MPCAJMNYNOGXPB-UHFFFAOYSA-N 0.000 claims description 2
- 108091036055 CccDNA Proteins 0.000 claims description 2
- 241000700629 Orthopoxvirus Species 0.000 claims description 2
- 125000001921 locked nucleotide group Chemical group 0.000 claims description 2
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical group CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 claims description 2
- PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 7
- 125000000539 amino acid group Chemical group 0.000 claims 2
- 230000001737 promoting effect Effects 0.000 claims 2
- 239000012271 PD-L1 inhibitor Substances 0.000 claims 1
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 claims 1
- 229940121656 pd-l1 inhibitor Drugs 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 abstract description 9
- 210000004027 cell Anatomy 0.000 description 120
- 108090000623 proteins and genes Proteins 0.000 description 110
- 150000002632 lipids Chemical class 0.000 description 81
- 125000005647 linker group Chemical group 0.000 description 77
- 108020004459 Small interfering RNA Proteins 0.000 description 75
- 239000002502 liposome Substances 0.000 description 61
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical group C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 60
- 102000004169 proteins and genes Human genes 0.000 description 55
- 229940024606 amino acid Drugs 0.000 description 54
- 102100020870 La-related protein 6 Human genes 0.000 description 52
- 108050008265 La-related protein 6 Proteins 0.000 description 52
- 230000028993 immune response Effects 0.000 description 45
- 238000002255 vaccination Methods 0.000 description 43
- 210000004185 liver Anatomy 0.000 description 36
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 35
- 239000002245 particle Substances 0.000 description 35
- 239000000562 conjugate Substances 0.000 description 34
- 238000012384 transportation and delivery Methods 0.000 description 34
- 241001465754 Metazoa Species 0.000 description 32
- 230000007423 decrease Effects 0.000 description 31
- 235000012000 cholesterol Nutrition 0.000 description 30
- 108020004999 messenger RNA Proteins 0.000 description 30
- 150000001875 compounds Chemical class 0.000 description 29
- 230000004048 modification Effects 0.000 description 29
- 238000012986 modification Methods 0.000 description 29
- 230000009467 reduction Effects 0.000 description 28
- 241000699670 Mus sp. Species 0.000 description 27
- 239000002777 nucleoside Chemical class 0.000 description 27
- 235000000346 sugar Nutrition 0.000 description 27
- 201000010099 disease Diseases 0.000 description 26
- 239000002253 acid Substances 0.000 description 25
- 208000002672 hepatitis B Diseases 0.000 description 25
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 description 23
- 238000003776 cleavage reaction Methods 0.000 description 23
- 230000007017 scission Effects 0.000 description 23
- 230000008685 targeting Effects 0.000 description 23
- 230000000694 effects Effects 0.000 description 22
- 230000001225 therapeutic effect Effects 0.000 description 22
- 210000001519 tissue Anatomy 0.000 description 22
- 239000003814 drug Substances 0.000 description 21
- 239000004055 small Interfering RNA Substances 0.000 description 21
- 210000004369 blood Anatomy 0.000 description 20
- 239000008280 blood Substances 0.000 description 20
- 230000005764 inhibitory process Effects 0.000 description 20
- 239000000523 sample Substances 0.000 description 20
- 210000001744 T-lymphocyte Anatomy 0.000 description 17
- 150000001720 carbohydrates Chemical class 0.000 description 17
- 239000012071 phase Substances 0.000 description 17
- 230000010076 replication Effects 0.000 description 17
- 238000011269 treatment regimen Methods 0.000 description 17
- 230000005867 T cell response Effects 0.000 description 16
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 16
- 235000014633 carbohydrates Nutrition 0.000 description 16
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 16
- 238000002360 preparation method Methods 0.000 description 16
- 230000000295 complement effect Effects 0.000 description 15
- 150000002148 esters Chemical class 0.000 description 15
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 15
- 150000003833 nucleoside derivatives Chemical class 0.000 description 15
- 229920001223 polyethylene glycol Polymers 0.000 description 15
- 239000004094 surface-active agent Substances 0.000 description 15
- 208000000419 Chronic Hepatitis B Diseases 0.000 description 14
- 108091026890 Coding region Proteins 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 14
- 102000008100 Human Serum Albumin Human genes 0.000 description 13
- 108091006905 Human Serum Albumin Proteins 0.000 description 13
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 13
- 239000002202 Polyethylene glycol Substances 0.000 description 13
- 108091027967 Small hairpin RNA Proteins 0.000 description 13
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 13
- 238000011160 research Methods 0.000 description 13
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 12
- 238000011161 development Methods 0.000 description 12
- 125000000217 alkyl group Chemical group 0.000 description 11
- 125000002091 cationic group Chemical group 0.000 description 11
- 238000001727 in vivo Methods 0.000 description 11
- 230000002401 inhibitory effect Effects 0.000 description 11
- 229910052698 phosphorus Inorganic materials 0.000 description 11
- 229940021747 therapeutic vaccine Drugs 0.000 description 11
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 10
- 102000004190 Enzymes Human genes 0.000 description 10
- 108090000790 Enzymes Proteins 0.000 description 10
- 108091028043 Nucleic acid sequence Proteins 0.000 description 10
- 230000005875 antibody response Effects 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 10
- 235000021317 phosphate Nutrition 0.000 description 10
- 230000001629 suppression Effects 0.000 description 10
- 238000013518 transcription Methods 0.000 description 10
- 229940021995 DNA vaccine Drugs 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 230000015556 catabolic process Effects 0.000 description 9
- 238000006731 degradation reaction Methods 0.000 description 9
- 210000003494 hepatocyte Anatomy 0.000 description 9
- 210000002865 immune cell Anatomy 0.000 description 9
- 239000012528 membrane Substances 0.000 description 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 9
- 150000002772 monosaccharides Chemical group 0.000 description 9
- 244000052769 pathogen Species 0.000 description 9
- 230000001717 pathogenic effect Effects 0.000 description 9
- 239000013612 plasmid Substances 0.000 description 9
- 210000003491 skin Anatomy 0.000 description 9
- 230000035897 transcription Effects 0.000 description 9
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 8
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 8
- 229930024421 Adenine Natural products 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 8
- 229960000643 adenine Drugs 0.000 description 8
- 230000008901 benefit Effects 0.000 description 8
- 229910052799 carbon Inorganic materials 0.000 description 8
- 229940104302 cytosine Drugs 0.000 description 8
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 8
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 8
- 125000003835 nucleoside group Chemical group 0.000 description 8
- 239000000816 peptidomimetic Substances 0.000 description 8
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 8
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 8
- 229920000768 polyamine Polymers 0.000 description 8
- 102000040430 polynucleotide Human genes 0.000 description 8
- 108091033319 polynucleotide Proteins 0.000 description 8
- 239000002157 polynucleotide Substances 0.000 description 8
- 239000000758 substrate Substances 0.000 description 8
- 229940035893 uracil Drugs 0.000 description 8
- LDGWQMRUWMSZIU-LQDDAWAPSA-M 2,3-bis[(z)-octadec-9-enoxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC\C=C/CCCCCCCC LDGWQMRUWMSZIU-LQDDAWAPSA-M 0.000 description 7
- 108010041986 DNA Vaccines Proteins 0.000 description 7
- 108700026244 Open Reading Frames Proteins 0.000 description 7
- 238000011529 RT qPCR Methods 0.000 description 7
- 150000007513 acids Chemical class 0.000 description 7
- 125000004429 atom Chemical group 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- 210000000170 cell membrane Anatomy 0.000 description 7
- 230000001413 cellular effect Effects 0.000 description 7
- 230000021615 conjugation Effects 0.000 description 7
- MWRBNPKJOOWZPW-CLFAGFIQSA-N dioleoyl phosphatidylethanolamine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(=O)OCCN)OC(=O)CCCCCCC\C=C/CCCCCCCC MWRBNPKJOOWZPW-CLFAGFIQSA-N 0.000 description 7
- 208000035475 disorder Diseases 0.000 description 7
- 238000009826 distribution Methods 0.000 description 7
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 7
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 7
- 210000000987 immune system Anatomy 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 210000005229 liver cell Anatomy 0.000 description 7
- 239000000693 micelle Substances 0.000 description 7
- 210000000056 organ Anatomy 0.000 description 7
- 239000008194 pharmaceutical composition Substances 0.000 description 7
- 150000003904 phospholipids Chemical class 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 6
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 6
- 102000000574 RNA-Induced Silencing Complex Human genes 0.000 description 6
- 108010016790 RNA-Induced Silencing Complex Proteins 0.000 description 6
- 230000002378 acidificating effect Effects 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 6
- 230000000875 corresponding effect Effects 0.000 description 6
- 230000001086 cytosolic effect Effects 0.000 description 6
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 6
- 238000009396 hybridization Methods 0.000 description 6
- 230000002209 hydrophobic effect Effects 0.000 description 6
- 230000003834 intracellular effect Effects 0.000 description 6
- 238000001990 intravenous administration Methods 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- 239000002105 nanoparticle Substances 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- 125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 230000002459 sustained effect Effects 0.000 description 6
- 229940124597 therapeutic agent Drugs 0.000 description 6
- 229940088594 vitamin Drugs 0.000 description 6
- 229930003231 vitamin Natural products 0.000 description 6
- 235000013343 vitamin Nutrition 0.000 description 6
- 239000011782 vitamin Substances 0.000 description 6
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 5
- 239000004380 Cholic acid Substances 0.000 description 5
- 108090000371 Esterases Proteins 0.000 description 5
- 101000991410 Homo sapiens Nucleolar and spindle-associated protein 1 Proteins 0.000 description 5
- 102100034349 Integrase Human genes 0.000 description 5
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 description 5
- 102100030991 Nucleolar and spindle-associated protein 1 Human genes 0.000 description 5
- 108091093037 Peptide nucleic acid Proteins 0.000 description 5
- 108010039918 Polylysine Proteins 0.000 description 5
- 108091028664 Ribonucleotide Proteins 0.000 description 5
- 206010058874 Viraemia Diseases 0.000 description 5
- 150000001408 amides Chemical group 0.000 description 5
- 239000000074 antisense oligonucleotide Substances 0.000 description 5
- 238000012230 antisense oligonucleotides Methods 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 235000019416 cholic acid Nutrition 0.000 description 5
- 229960002471 cholic acid Drugs 0.000 description 5
- 210000001163 endosome Anatomy 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 5
- 229910052739 hydrogen Inorganic materials 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- NFQBIAXADRDUGK-KWXKLSQISA-N n,n-dimethyl-2,3-bis[(9z,12z)-octadeca-9,12-dienoxy]propan-1-amine Chemical compound CCCCC\C=C/C\C=C/CCCCCCCCOCC(CN(C)C)OCCCCCCCC\C=C/C\C=C/CCCCC NFQBIAXADRDUGK-KWXKLSQISA-N 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 239000002736 nonionic surfactant Substances 0.000 description 5
- 238000003199 nucleic acid amplification method Methods 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 229920000656 polylysine Polymers 0.000 description 5
- 230000003389 potentiating effect Effects 0.000 description 5
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 5
- 239000002336 ribonucleotide Substances 0.000 description 5
- 125000002652 ribonucleotide group Chemical group 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 238000007920 subcutaneous administration Methods 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 102000004506 Blood Proteins Human genes 0.000 description 4
- 108010017384 Blood Proteins Proteins 0.000 description 4
- 108020004638 Circular DNA Proteins 0.000 description 4
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 102000007330 LDL Lipoproteins Human genes 0.000 description 4
- 108010007622 LDL Lipoproteins Proteins 0.000 description 4
- 108700001237 Nucleic Acid-Based Vaccines Proteins 0.000 description 4
- 108091005804 Peptidases Proteins 0.000 description 4
- 102000035195 Peptidases Human genes 0.000 description 4
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 4
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 4
- 108010067390 Viral Proteins Proteins 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- 125000001931 aliphatic group Chemical group 0.000 description 4
- 125000002947 alkylene group Chemical group 0.000 description 4
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 description 4
- 125000002619 bicyclic group Chemical group 0.000 description 4
- 239000003613 bile acid Substances 0.000 description 4
- 229960002685 biotin Drugs 0.000 description 4
- 235000020958 biotin Nutrition 0.000 description 4
- 239000011616 biotin Substances 0.000 description 4
- 229940030156 cell vaccine Drugs 0.000 description 4
- 230000004700 cellular uptake Effects 0.000 description 4
- 229940106189 ceramide Drugs 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 208000019425 cirrhosis of liver Diseases 0.000 description 4
- 238000002648 combination therapy Methods 0.000 description 4
- 229920001577 copolymer Polymers 0.000 description 4
- 239000000412 dendrimer Substances 0.000 description 4
- 229920000736 dendritic polymer Polymers 0.000 description 4
- 239000003599 detergent Substances 0.000 description 4
- 210000003162 effector t lymphocyte Anatomy 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 125000000623 heterocyclic group Chemical group 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 4
- 238000011532 immunohistochemical staining Methods 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 239000000178 monomer Substances 0.000 description 4
- 230000002688 persistence Effects 0.000 description 4
- 125000004437 phosphorous atom Chemical group 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 4
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 4
- 230000009269 systemic vascular permeability Effects 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- 230000001052 transient effect Effects 0.000 description 4
- SLKDGVPOSSLUAI-PGUFJCEWSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine zwitterion Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCCN)OC(=O)CCCCCCCCCCCCCCC SLKDGVPOSSLUAI-PGUFJCEWSA-N 0.000 description 3
- 239000013607 AAV vector Substances 0.000 description 3
- 101800002011 Amphipathic peptide Proteins 0.000 description 3
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 3
- 229920000858 Cyclodextrin Polymers 0.000 description 3
- 108010042407 Endonucleases Proteins 0.000 description 3
- 102000003886 Glycoproteins Human genes 0.000 description 3
- 108090000288 Glycoproteins Proteins 0.000 description 3
- 208000037262 Hepatitis delta Diseases 0.000 description 3
- 108090001090 Lectins Proteins 0.000 description 3
- 102000004856 Lectins Human genes 0.000 description 3
- 108010077850 Nuclear Localization Signals Proteins 0.000 description 3
- 208000037581 Persistent Infection Diseases 0.000 description 3
- 239000004698 Polyethylene Substances 0.000 description 3
- 229930003427 Vitamin E Natural products 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- XVIYCJDWYLJQBG-UHFFFAOYSA-N acetic acid;adamantane Chemical compound CC(O)=O.C1C(C2)CC3CC1CC2C3 XVIYCJDWYLJQBG-UHFFFAOYSA-N 0.000 description 3
- 239000012190 activator Substances 0.000 description 3
- 125000002252 acyl group Chemical group 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 238000004220 aggregation Methods 0.000 description 3
- 125000003342 alkenyl group Chemical group 0.000 description 3
- 150000008051 alkyl sulfates Chemical class 0.000 description 3
- 125000000304 alkynyl group Chemical group 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 125000000129 anionic group Chemical group 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 238000009833 condensation Methods 0.000 description 3
- 230000005494 condensation Effects 0.000 description 3
- 230000001268 conjugating effect Effects 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 125000000753 cycloalkyl group Chemical group 0.000 description 3
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 3
- 230000003413 degradative effect Effects 0.000 description 3
- 229960003724 dimyristoylphosphatidylcholine Drugs 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 238000012377 drug delivery Methods 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 235000019152 folic acid Nutrition 0.000 description 3
- 239000011724 folic acid Substances 0.000 description 3
- 229930182830 galactose Natural products 0.000 description 3
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 3
- 230000030279 gene silencing Effects 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
- 230000006058 immune tolerance Effects 0.000 description 3
- 238000009169 immunotherapy Methods 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 239000002523 lectin Substances 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 210000004940 nucleus Anatomy 0.000 description 3
- 230000009437 off-target effect Effects 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 229940023041 peptide vaccine Drugs 0.000 description 3
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 3
- 150000008300 phosphoramidites Chemical class 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 229940023867 prime-boost vaccine Drugs 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 235000019833 protease Nutrition 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000003362 replicative effect Effects 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- JJICLMJFIKGAAU-UHFFFAOYSA-M sodium;2-amino-9-(1,3-dihydroxypropan-2-yloxymethyl)purin-6-olate Chemical compound [Na+].NC1=NC([O-])=C2N=CN(COC(CO)CO)C2=N1 JJICLMJFIKGAAU-UHFFFAOYSA-M 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 3
- 238000011830 transgenic mouse model Methods 0.000 description 3
- 230000032258 transport Effects 0.000 description 3
- 150000004043 trisaccharides Chemical class 0.000 description 3
- 229940126580 vector vaccine Drugs 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 235000019165 vitamin E Nutrition 0.000 description 3
- 229940046009 vitamin E Drugs 0.000 description 3
- 239000011709 vitamin E Substances 0.000 description 3
- RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 description 2
- QGVQZRDQPDLHHV-DPAQBDIFSA-N (3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthrene-3-thiol Chemical compound C1C=C2C[C@@H](S)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 QGVQZRDQPDLHHV-DPAQBDIFSA-N 0.000 description 2
- CITHEXJVPOWHKC-UUWRZZSWSA-N 1,2-di-O-myristoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC CITHEXJVPOWHKC-UUWRZZSWSA-N 0.000 description 2
- SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 description 2
- LVNGJLRDBYCPGB-UHFFFAOYSA-N 1,2-distearoylphosphatidylethanolamine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(COP([O-])(=O)OCC[NH3+])OC(=O)CCCCCCCCCCCCCCCCC LVNGJLRDBYCPGB-UHFFFAOYSA-N 0.000 description 2
- BIABMEZBCHDPBV-MPQUPPDSSA-N 1,2-palmitoyl-sn-glycero-3-phospho-(1'-sn-glycerol) Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCCCCCCCCCC BIABMEZBCHDPBV-MPQUPPDSSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- FZWGECJQACGGTI-UHFFFAOYSA-N 2-amino-7-methyl-1,7-dihydro-6H-purin-6-one Chemical compound NC1=NC(O)=C2N(C)C=NC2=N1 FZWGECJQACGGTI-UHFFFAOYSA-N 0.000 description 2
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
- OXOWTLDONRGYOT-UHFFFAOYSA-M 4-(dimethylamino)butanoate Chemical compound CN(C)CCCC([O-])=O OXOWTLDONRGYOT-UHFFFAOYSA-M 0.000 description 2
- RYVNIFSIEDRLSJ-UHFFFAOYSA-N 5-(hydroxymethyl)cytosine Chemical compound NC=1NC(=O)N=CC=1CO RYVNIFSIEDRLSJ-UHFFFAOYSA-N 0.000 description 2
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 2
- UJBCLAXPPIDQEE-UHFFFAOYSA-N 5-prop-1-ynyl-1h-pyrimidine-2,4-dione Chemical compound CC#CC1=CNC(=O)NC1=O UJBCLAXPPIDQEE-UHFFFAOYSA-N 0.000 description 2
- HCGHYQLFMPXSDU-UHFFFAOYSA-N 7-methyladenine Chemical compound C1=NC(N)=C2N(C)C=NC2=N1 HCGHYQLFMPXSDU-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- 102100037435 Antiviral innate immune response receptor RIG-I Human genes 0.000 description 2
- 101710127675 Antiviral innate immune response receptor RIG-I Proteins 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- 101710117545 C protein Proteins 0.000 description 2
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 2
- 101710139375 Corneodesmosin Proteins 0.000 description 2
- 102100031673 Corneodesmosin Human genes 0.000 description 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 2
- 229930105110 Cyclosporin A Natural products 0.000 description 2
- 108010036949 Cyclosporine Proteins 0.000 description 2
- 150000008574 D-amino acids Chemical class 0.000 description 2
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 2
- 230000004543 DNA replication Effects 0.000 description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical group O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102000004533 Endonucleases Human genes 0.000 description 2
- 102100023387 Endoribonuclease Dicer Human genes 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 2
- 229940126656 GS-4224 Drugs 0.000 description 2
- 229930186217 Glycolipid Natural products 0.000 description 2
- 241000724709 Hepatitis delta virus Species 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 101000907904 Homo sapiens Endoribonuclease Dicer Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 229930010555 Inosine Natural products 0.000 description 2
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 2
- 101710203526 Integrase Proteins 0.000 description 2
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- SMEROWZSTRWXGI-UHFFFAOYSA-N Lithocholsaeure Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 SMEROWZSTRWXGI-UHFFFAOYSA-N 0.000 description 2
- 102000043129 MHC class I family Human genes 0.000 description 2
- 108091054437 MHC class I family Proteins 0.000 description 2
- 102000043131 MHC class II family Human genes 0.000 description 2
- 108091054438 MHC class II family Proteins 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 2
- BKAYIFDRRZZKNF-VIFPVBQESA-N N-acetylcarnosine Chemical compound CC(=O)NCCC(=O)N[C@H](C(O)=O)CC1=CN=CN1 BKAYIFDRRZZKNF-VIFPVBQESA-N 0.000 description 2
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 101710163270 Nuclease Proteins 0.000 description 2
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 2
- REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 2
- 102100034574 P protein Human genes 0.000 description 2
- 101710181008 P protein Proteins 0.000 description 2
- KPKZJLCSROULON-QKGLWVMZSA-N Phalloidin Chemical compound N1C(=O)[C@@H]([C@@H](O)C)NC(=O)[C@H](C)NC(=O)[C@H](C[C@@](C)(O)CO)NC(=O)[C@H](C2)NC(=O)[C@H](C)NC(=O)[C@@H]3C[C@H](O)CN3C(=O)[C@@H]1CSC1=C2C2=CC=CC=C2N1 KPKZJLCSROULON-QKGLWVMZSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 101710177166 Phosphoprotein Proteins 0.000 description 2
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
- 229920002873 Polyethylenimine Polymers 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 101710149951 Protein Tat Proteins 0.000 description 2
- RADKZDMFGJYCBB-UHFFFAOYSA-N Pyridoxal Chemical compound CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 108010083644 Ribonucleases Proteins 0.000 description 2
- 102000006382 Ribonucleases Human genes 0.000 description 2
- 101710147732 Small envelope protein Proteins 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 230000024932 T cell mediated immunity Effects 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 108700019146 Transgenes Proteins 0.000 description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 2
- 101150003160 X gene Proteins 0.000 description 2
- 101710086987 X protein Proteins 0.000 description 2
- DSNRWDQKZIEDDB-GCMPNPAFSA-N [(2r)-3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-2-[(z)-octadec-9-enoyl]oxypropyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C/CCCCCCCC DSNRWDQKZIEDDB-GCMPNPAFSA-N 0.000 description 2
- RLXCFCYWFYXTON-JTTSDREOSA-N [(3S,8S,9S,10R,13S,14S,17R)-3-hydroxy-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-16-yl] N-hexylcarbamate Chemical group C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC(OC(=O)NCCCCCC)[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 RLXCFCYWFYXTON-JTTSDREOSA-N 0.000 description 2
- NONFBHXKNNVFMO-UHFFFAOYSA-N [2-aminoethoxy(tetradecanoyloxy)phosphoryl] tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OP(=O)(OCCN)OC(=O)CCCCCCCCCCCCC NONFBHXKNNVFMO-UHFFFAOYSA-N 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 230000033289 adaptive immune response Effects 0.000 description 2
- 125000004450 alkenylene group Chemical group 0.000 description 2
- 125000002877 alkyl aryl group Chemical group 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 2
- 125000003368 amide group Chemical group 0.000 description 2
- 239000003945 anionic surfactant Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 125000003710 aryl alkyl group Chemical group 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000003833 bile salt Substances 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000013060 biological fluid Substances 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000007969 cellular immunity Effects 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- RUDATBOHQWOJDD-BSWAIDMHSA-N chenodeoxycholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-BSWAIDMHSA-N 0.000 description 2
- 229960001091 chenodeoxycholic acid Drugs 0.000 description 2
- 150000003841 chloride salts Chemical class 0.000 description 2
- 230000007882 cirrhosis Effects 0.000 description 2
- 238000011284 combination treatment Methods 0.000 description 2
- 239000013068 control sample Substances 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 230000000120 cytopathologic effect Effects 0.000 description 2
- 230000005860 defense response to virus Effects 0.000 description 2
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 2
- 239000005547 deoxyribonucleotide Substances 0.000 description 2
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 238000001125 extrusion Methods 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 229960000304 folic acid Drugs 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 150000002270 gangliosides Chemical class 0.000 description 2
- 125000003827 glycol group Chemical group 0.000 description 2
- 125000001475 halogen functional group Chemical group 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 208000029570 hepatitis D virus infection Diseases 0.000 description 2
- 125000001072 heteroaryl group Chemical group 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 210000005007 innate immune system Anatomy 0.000 description 2
- 229960003786 inosine Drugs 0.000 description 2
- 239000000138 intercalating agent Substances 0.000 description 2
- 210000003292 kidney cell Anatomy 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000008206 lipophilic material Substances 0.000 description 2
- SMEROWZSTRWXGI-HVATVPOCSA-N lithocholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 SMEROWZSTRWXGI-HVATVPOCSA-N 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 230000005923 long-lasting effect Effects 0.000 description 2
- 230000004726 long-term protective immunity Effects 0.000 description 2
- 210000003712 lysosome Anatomy 0.000 description 2
- 230000001868 lysosomic effect Effects 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 108091070501 miRNA Proteins 0.000 description 2
- 239000002679 microRNA Substances 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 2
- 229960002009 naproxen Drugs 0.000 description 2
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000002853 nucleic acid probe Substances 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- ONTNXMBMXUNDBF-UHFFFAOYSA-N pentatriacontane-17,18,19-triol Chemical compound CCCCCCCCCCCCCCCCC(O)C(O)C(O)CCCCCCCCCCCCCCCC ONTNXMBMXUNDBF-UHFFFAOYSA-N 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 150000004713 phosphodiesters Chemical class 0.000 description 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 229920001308 poly(aminoacid) Polymers 0.000 description 2
- 230000008488 polyadenylation Effects 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000001294 propane Substances 0.000 description 2
- 229940021993 prophylactic vaccine Drugs 0.000 description 2
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000002797 proteolythic effect Effects 0.000 description 2
- ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical compound C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 description 2
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 229920002477 rna polymer Polymers 0.000 description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 229940063673 spermidine Drugs 0.000 description 2
- 229940063675 spermine Drugs 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 125000000547 substituted alkyl group Chemical group 0.000 description 2
- 125000004434 sulfur atom Chemical group 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000007910 systemic administration Methods 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 150000003568 thioethers Chemical class 0.000 description 2
- 229940113082 thymine Drugs 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- ZMANZCXQSJIPKH-UHFFFAOYSA-O triethylammonium ion Chemical compound CC[NH+](CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-O 0.000 description 2
- 125000002948 undecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- 210000002845 virion Anatomy 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- 229940045997 vitamin a Drugs 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical group CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical group C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 1
- DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical group C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 description 1
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Chemical group C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 description 1
- OQQOAWVKVDAJOI-UHFFFAOYSA-N (2-dodecanoyloxy-3-hydroxypropyl) dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCC(CO)OC(=O)CCCCCCCCCCC OQQOAWVKVDAJOI-UHFFFAOYSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- KJTPWUVVLPCPJD-AUWJEWJLSA-N (2z)-7-amino-2-[(4-hydroxy-3,5-dimethylphenyl)methylidene]-5,6-dimethoxy-3h-inden-1-one Chemical compound O=C1C=2C(N)=C(OC)C(OC)=CC=2C\C1=C\C1=CC(C)=C(O)C(C)=C1 KJTPWUVVLPCPJD-AUWJEWJLSA-N 0.000 description 1
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 description 1
- FYADHXFMURLYQI-UHFFFAOYSA-N 1,2,4-triazine Chemical class C1=CN=NC=N1 FYADHXFMURLYQI-UHFFFAOYSA-N 0.000 description 1
- ZIZMDHZLHJBNSQ-UHFFFAOYSA-N 1,2-dihydrophenazine Chemical compound C1=CC=C2N=C(C=CCC3)C3=NC2=C1 ZIZMDHZLHJBNSQ-UHFFFAOYSA-N 0.000 description 1
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Chemical group OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 1
- 229940035437 1,3-propanediol Drugs 0.000 description 1
- PLKOSISDOAHHCI-QYCRHRGJSA-N 1-[2,3-bis[(9z,12z)-octadeca-9,12-dienoxy]propyl]-4-methylpiperazine Chemical compound CCCCC\C=C/C\C=C/CCCCCCCCOCC(OCCCCCCCC\C=C/C\C=C/CCCCC)CN1CCN(C)CC1 PLKOSISDOAHHCI-QYCRHRGJSA-N 0.000 description 1
- MZMNEDXVUJLQAF-UHFFFAOYSA-N 1-o-tert-butyl 2-o-methyl 4-hydroxypyrrolidine-1,2-dicarboxylate Chemical compound COC(=O)C1CC(O)CN1C(=O)OC(C)(C)C MZMNEDXVUJLQAF-UHFFFAOYSA-N 0.000 description 1
- TZMSYXZUNZXBOL-UHFFFAOYSA-N 10H-phenoxazine Chemical compound C1=CC=C2NC3=CC=CC=C3OC2=C1 TZMSYXZUNZXBOL-UHFFFAOYSA-N 0.000 description 1
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 1
- UHUHBFMZVCOEOV-UHFFFAOYSA-N 1h-imidazo[4,5-c]pyridin-4-amine Chemical compound NC1=NC=CC2=C1N=CN2 UHUHBFMZVCOEOV-UHFFFAOYSA-N 0.000 description 1
- WALUVDCNGPQPOD-UHFFFAOYSA-M 2,3-di(tetradecoxy)propyl-(2-hydroxyethyl)-dimethylazanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCOCC(C[N+](C)(C)CCO)OCCCCCCCCCCCCCC WALUVDCNGPQPOD-UHFFFAOYSA-M 0.000 description 1
- VEPOHXYIFQMVHW-XOZOLZJESA-N 2,3-dihydroxybutanedioic acid (2S,3S)-3,4-dimethyl-2-phenylmorpholine Chemical compound OC(C(O)C(O)=O)C(O)=O.C[C@H]1[C@@H](OCCN1C)c1ccccc1 VEPOHXYIFQMVHW-XOZOLZJESA-N 0.000 description 1
- AZUHIVLOSAPWDM-UHFFFAOYSA-N 2-(1h-imidazol-2-yl)-1h-imidazole Chemical compound C1=CNC(C=2NC=CN=2)=N1 AZUHIVLOSAPWDM-UHFFFAOYSA-N 0.000 description 1
- QSHACTSJHMKXTE-UHFFFAOYSA-N 2-(2-aminopropyl)-7h-purin-6-amine Chemical compound CC(N)CC1=NC(N)=C2NC=NC2=N1 QSHACTSJHMKXTE-UHFFFAOYSA-N 0.000 description 1
- PIINGYXNCHTJTF-UHFFFAOYSA-N 2-(2-azaniumylethylamino)acetate Chemical group NCCNCC(O)=O PIINGYXNCHTJTF-UHFFFAOYSA-N 0.000 description 1
- PLWXKAOZQSMLOO-AEHJODJJSA-N 2-amino-9-[(2r,3s,4r,5r)-4-dihydroxyphosphinothioyloxy-3-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purin-6-one Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](CO)[C@@H](OP(O)(O)=S)[C@]1(O)F PLWXKAOZQSMLOO-AEHJODJJSA-N 0.000 description 1
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- OHXPGWPVLFPUSM-KLRNGDHRSA-N 3,7,12-trioxo-5beta-cholanic acid Chemical compound C1CC(=O)C[C@H]2CC(=O)[C@H]3[C@@H]4CC[C@H]([C@@H](CCC(O)=O)C)[C@@]4(C)C(=O)C[C@@H]3[C@]21C OHXPGWPVLFPUSM-KLRNGDHRSA-N 0.000 description 1
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 1
- ILBCSMHIEBDGJY-UHFFFAOYSA-N 3-[4-(3-aminopropylamino)butylamino]propylcarbamic acid Chemical compound NCCCNCCCCNCCCNC(O)=O ILBCSMHIEBDGJY-UHFFFAOYSA-N 0.000 description 1
- BVZVICBYYOYVEP-MAZCIEHSSA-N 3-[bis[(9z,12z)-octadeca-9,12-dienyl]amino]propane-1,2-diol Chemical compound CCCCC\C=C/C\C=C/CCCCCCCCN(CC(O)CO)CCCCCCCC\C=C/C\C=C/CCCCC BVZVICBYYOYVEP-MAZCIEHSSA-N 0.000 description 1
- HIAJCGFYHIANNA-QIZZZRFXSA-N 3b-Hydroxy-5-cholenoic acid Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@@H](CCC(O)=O)C)[C@@]1(C)CC2 HIAJCGFYHIANNA-QIZZZRFXSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-dimethylaminopyridine Substances CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 1
- OVONXEQGWXGFJD-UHFFFAOYSA-N 4-sulfanylidene-1h-pyrimidin-2-one Chemical compound SC=1C=CNC(=O)N=1 OVONXEQGWXGFJD-UHFFFAOYSA-N 0.000 description 1
- ZLAQATDNGLKIEV-UHFFFAOYSA-N 5-methyl-2-sulfanylidene-1h-pyrimidin-4-one Chemical compound CC1=CNC(=S)NC1=O ZLAQATDNGLKIEV-UHFFFAOYSA-N 0.000 description 1
- KXBCLNRMQPRVTP-UHFFFAOYSA-N 6-amino-1,5-dihydroimidazo[4,5-c]pyridin-4-one Chemical compound O=C1NC(N)=CC2=C1N=CN2 KXBCLNRMQPRVTP-UHFFFAOYSA-N 0.000 description 1
- DCPSTSVLRXOYGS-UHFFFAOYSA-N 6-amino-1h-pyrimidine-2-thione Chemical compound NC1=CC=NC(S)=N1 DCPSTSVLRXOYGS-UHFFFAOYSA-N 0.000 description 1
- QNNARSZPGNJZIX-UHFFFAOYSA-N 6-amino-5-prop-1-ynyl-1h-pyrimidin-2-one Chemical compound CC#CC1=CNC(=O)N=C1N QNNARSZPGNJZIX-UHFFFAOYSA-N 0.000 description 1
- LOSIULRWFAEMFL-UHFFFAOYSA-N 7-deazaguanine Chemical compound O=C1NC(N)=NC2=C1CC=N2 LOSIULRWFAEMFL-UHFFFAOYSA-N 0.000 description 1
- HRYKDUPGBWLLHO-UHFFFAOYSA-N 8-azaadenine Chemical compound NC1=NC=NC2=NNN=C12 HRYKDUPGBWLLHO-UHFFFAOYSA-N 0.000 description 1
- LPXQRXLUHJKZIE-UHFFFAOYSA-N 8-azaguanine Chemical compound NC1=NC(O)=C2NN=NC2=N1 LPXQRXLUHJKZIE-UHFFFAOYSA-N 0.000 description 1
- 229960005508 8-azaguanine Drugs 0.000 description 1
- MSSXOMSJDRHRMC-UHFFFAOYSA-N 9H-purine-2,6-diamine Chemical compound NC1=NC(N)=C2NC=NC2=N1 MSSXOMSJDRHRMC-UHFFFAOYSA-N 0.000 description 1
- 108010062307 AAVALLPAVLLALLAP Proteins 0.000 description 1
- 206010059193 Acute hepatitis B Diseases 0.000 description 1
- 241001164825 Adeno-associated virus - 8 Species 0.000 description 1
- 108090000531 Amidohydrolases Proteins 0.000 description 1
- 102000004092 Amidohydrolases Human genes 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 229940122361 Bisphosphonate Drugs 0.000 description 1
- 241000204432 Candidatus Sodalis pierantonius str. SOPE Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 206010057573 Chronic hepatic failure Diseases 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Chemical group CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- XULFJDKZVHTRLG-JDVCJPALSA-N DOSPA trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F.CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)CCNC(=O)C(CCCNCCCN)NCCCN)OCCCCCCCC\C=C/CCCCCCCC XULFJDKZVHTRLG-JDVCJPALSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical class S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 108700006830 Drosophila Antp Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 208000010334 End Stage Liver Disease Diseases 0.000 description 1
- 102100031780 Endonuclease Human genes 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical class OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 108010035713 Glycodeoxycholic Acid Proteins 0.000 description 1
- WVULKSPCQVQLCU-UHFFFAOYSA-N Glycodeoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCC(O)=O)C)C1(C)C(O)C2 WVULKSPCQVQLCU-UHFFFAOYSA-N 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 241000285387 HBV genotype A Species 0.000 description 1
- 241000285366 HBV genotype D Species 0.000 description 1
- 241000700739 Hepadnaviridae Species 0.000 description 1
- 108700024845 Hepatitis B virus P Proteins 0.000 description 1
- 208000005331 Hepatitis D Diseases 0.000 description 1
- 206010019755 Hepatitis chronic active Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000780643 Homo sapiens Protein argonaute-2 Proteins 0.000 description 1
- 108010070875 Human Immunodeficiency Virus tat Gene Products Proteins 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 101710128836 Large T antigen Proteins 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108010007013 Melanocyte-Stimulating Hormones Proteins 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 102000015728 Mucins Human genes 0.000 description 1
- 108010063954 Mucins Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- BACYUWVYYTXETD-UHFFFAOYSA-N N-Lauroylsarcosine Chemical compound CCCCCCCCCCCC(=O)N(C)CC(O)=O BACYUWVYYTXETD-UHFFFAOYSA-N 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 108700019961 Neoplasm Genes Proteins 0.000 description 1
- 102000048850 Neoplasm Genes Human genes 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- KYRVNWMVYQXFEU-UHFFFAOYSA-N Nocodazole Chemical compound C1=C2NC(NC(=O)OC)=NC2=CC=C1C(=O)C1=CC=CS1 KYRVNWMVYQXFEU-UHFFFAOYSA-N 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 108091007494 Nucleic acid- binding domains Proteins 0.000 description 1
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 108010009711 Phalloidine Proteins 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 108010069381 Platelet Endothelial Cell Adhesion Molecule-1 Proteins 0.000 description 1
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 108010020346 Polyglutamic Acid Proteins 0.000 description 1
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical class CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 229940096437 Protein S Drugs 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 102100034207 Protein argonaute-2 Human genes 0.000 description 1
- 101000781681 Protobothrops flavoviridis Disintegrin triflavin Proteins 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- 239000004373 Pullulan Substances 0.000 description 1
- 102000007615 Pulmonary Surfactant-Associated Protein A Human genes 0.000 description 1
- 108010007100 Pulmonary Surfactant-Associated Protein A Proteins 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 108010066717 Q beta Replicase Proteins 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 1
- 241000269435 Rana <genus> Species 0.000 description 1
- 241001068295 Replication defective viruses Species 0.000 description 1
- 108010057163 Ribonuclease III Proteins 0.000 description 1
- 102000003661 Ribonuclease III Human genes 0.000 description 1
- 101150010882 S gene Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 108091027568 Single-stranded nucleotide Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 101100054666 Streptomyces halstedii sch3 gene Proteins 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 241000272534 Struthio camelus Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical class OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 108010061174 Thyrotropin Proteins 0.000 description 1
- 102000011923 Thyrotropin Human genes 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 101800001690 Transmembrane protein gp41 Proteins 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- QGZHQRNBDZDKFW-FJGDRVTGSA-N [(2r,3r,4s,5r)-5-(2,4-dioxopyrimidin-1-yl)-4-fluoro-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] dihydrogen phosphate Chemical compound O[C@]1(F)[C@H](OP(O)(O)=O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 QGZHQRNBDZDKFW-FJGDRVTGSA-N 0.000 description 1
- SQXGRYKQXLPVFG-AEHJODJJSA-N [(2r,3r,4s,5r)-5-(2-amino-6-oxo-3h-purin-9-yl)-4-fluoro-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] dihydrogen phosphate Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](OP(O)(O)=O)[C@]1(O)F SQXGRYKQXLPVFG-AEHJODJJSA-N 0.000 description 1
- PTESHFKYBQMNFR-FJGDRVTGSA-N [(2r,3r,4s,5r)-5-(4-amino-2-oxopyrimidin-1-yl)-4-fluoro-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] dihydrogen phosphate Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@](F)(O)[C@H](OP(O)(O)=O)[C@@H](CO)O1 PTESHFKYBQMNFR-FJGDRVTGSA-N 0.000 description 1
- KLVQSNKMLGBSHV-GIWSHQQXSA-N [(2r,3r,4s,5r)-5-(6-aminopurin-9-yl)-4-fluoro-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] dihydrogen phosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](OP(O)(O)=O)[C@]1(O)F KLVQSNKMLGBSHV-GIWSHQQXSA-N 0.000 description 1
- LEBBDRXHHNYZIA-LDUWYPJVSA-N [(2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] n-[(z)-1,3-dihydroxyoctadec-4-en-2-yl]carbamate Chemical compound CCCCCCCCCCCCC\C=C/C(O)C(CO)NC(=O)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O LEBBDRXHHNYZIA-LDUWYPJVSA-N 0.000 description 1
- HIHOWBSBBDRPDW-PTHRTHQKSA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] n-[2-(dimethylamino)ethyl]carbamate Chemical compound C1C=C2C[C@@H](OC(=O)NCCN(C)C)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HIHOWBSBBDRPDW-PTHRTHQKSA-N 0.000 description 1
- TTWXVHUYMARJHI-KWXKLSQISA-N [(6Z,9Z,29Z,32Z)-20-[(dimethylamino)methyl]octatriaconta-6,9,29,32-tetraen-19-yl] carbamate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCCC(CN(C)C)C(OC(N)=O)CCCCCCCC\C=C/C\C=C/CCCCC TTWXVHUYMARJHI-KWXKLSQISA-N 0.000 description 1
- 238000004847 absorption spectroscopy Methods 0.000 description 1
- 125000000641 acridinyl group Chemical class C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 231100000354 acute hepatitis Toxicity 0.000 description 1
- 208000037628 acute hepatitis B virus infection Diseases 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 125000005024 alkenyl aryl group Chemical group 0.000 description 1
- 125000005217 alkenylheteroaryl group Chemical group 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000005083 alkoxyalkoxy group Chemical group 0.000 description 1
- 125000004948 alkyl aryl alkyl group Chemical group 0.000 description 1
- 150000004996 alkyl benzenes Chemical class 0.000 description 1
- 125000005213 alkyl heteroaryl group Chemical group 0.000 description 1
- 125000005600 alkyl phosphonate group Chemical group 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 125000005025 alkynylaryl group Chemical group 0.000 description 1
- 125000004419 alkynylene group Chemical group 0.000 description 1
- 150000001409 amidines Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 125000005122 aminoalkylamino group Chemical group 0.000 description 1
- 239000002280 amphoteric surfactant Substances 0.000 description 1
- 229960003473 androstanolone Drugs 0.000 description 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-N anhydrous guanidine Natural products NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 125000005018 aryl alkenyl group Chemical group 0.000 description 1
- 125000005015 aryl alkynyl group Chemical group 0.000 description 1
- 229960005261 aspartic acid Drugs 0.000 description 1
- 238000002820 assay format Methods 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- 238000000429 assembly Methods 0.000 description 1
- RHISNKCGUDDGEG-UHFFFAOYSA-N bactenecin Chemical compound CCC(C)C1NC(=O)C(C(C)C)NC(=O)C(C(C)C)NC(=O)C(C(C)CC)NC(=O)C(CCCN=C(N)N)NC(=O)C(NC(=O)C(CC(C)C)NC(=O)C(N)CCCN=C(N)N)CSSCC(C(=O)NC(CCCN=C(N)N)C(O)=O)NC(=O)C(C(C)C)NC(=O)C(CCCN=C(N)N)NC1=O RHISNKCGUDDGEG-UHFFFAOYSA-N 0.000 description 1
- 108010016341 bactenecin Proteins 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000037429 base substitution Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000008436 biogenesis Effects 0.000 description 1
- 150000004663 bisphosphonates Chemical class 0.000 description 1
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Chemical group C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 description 1
- 229940116229 borneol Drugs 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 210000004671 cell-free system Anatomy 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- BHONFOAYRQZPKZ-LCLOTLQISA-N chembl269478 Chemical compound C([C@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCCNC(N)=N)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(O)=O)C1=CC=CC=C1 BHONFOAYRQZPKZ-LCLOTLQISA-N 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 229940099352 cholate Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000016350 chronic hepatitis B virus infection Diseases 0.000 description 1
- 208000011444 chronic liver failure Diseases 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 238000007398 colorimetric assay Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000009295 crossflow filtration Methods 0.000 description 1
- 201000003278 cryoglobulinemia Diseases 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- JVHIPYJQMFNCEK-UHFFFAOYSA-N cytochalasin Natural products N1C(=O)C2(C(C=CC(C)CC(C)CC=C3)OC(C)=O)C3C(O)C(=C)C(C)C2C1CC1=CC=CC=C1 JVHIPYJQMFNCEK-UHFFFAOYSA-N 0.000 description 1
- ZMAODHOXRBLOQO-UHFFFAOYSA-N cytochalasin-A Natural products N1C(=O)C23OC(=O)C=CC(=O)CCCC(C)CC=CC3C(O)C(=C)C(C)C2C1CC1=CC=CC=C1 ZMAODHOXRBLOQO-UHFFFAOYSA-N 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 229960002997 dehydrocholic acid Drugs 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 229940009976 deoxycholate Drugs 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 230000000368 destabilizing effect Effects 0.000 description 1
- UMGXUWVIJIQANV-UHFFFAOYSA-M didecyl(dimethyl)azanium;bromide Chemical compound [Br-].CCCCCCCCCC[N+](C)(C)CCCCCCCCCC UMGXUWVIJIQANV-UHFFFAOYSA-M 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- PSLWZOIUBRXAQW-UHFFFAOYSA-M dimethyl(dioctadecyl)azanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC PSLWZOIUBRXAQW-UHFFFAOYSA-M 0.000 description 1
- UAKOZKUVZRMOFN-JDVCJPALSA-M dimethyl-bis[(z)-octadec-9-enyl]azanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCC[N+](C)(C)CCCCCCCC\C=C/CCCCCCCC UAKOZKUVZRMOFN-JDVCJPALSA-M 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- 229960005160 dimyristoylphosphatidylglycerol Drugs 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- ZGSPNIOCEDOHGS-UHFFFAOYSA-L disodium [3-[2,3-di(octadeca-9,12-dienoyloxy)propoxy-oxidophosphoryl]oxy-2-hydroxypropyl] 2,3-di(octadeca-9,12-dienoyloxy)propyl phosphate Chemical compound [Na+].[Na+].CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COP([O-])(=O)OCC(O)COP([O-])(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC ZGSPNIOCEDOHGS-UHFFFAOYSA-L 0.000 description 1
- BPHQZTVXXXJVHI-AJQTZOPKSA-N ditetradecanoyl phosphatidylglycerol Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCCCCCCCC BPHQZTVXXXJVHI-AJQTZOPKSA-N 0.000 description 1
- NAGJZTKCGNOGPW-UHFFFAOYSA-N dithiophosphoric acid Chemical class OP(O)(S)=S NAGJZTKCGNOGPW-UHFFFAOYSA-N 0.000 description 1
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Chemical group C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 230000010502 episomal replication Effects 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 229940014144 folate Drugs 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 125000003843 furanosyl group Chemical group 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000000799 fusogenic effect Effects 0.000 description 1
- 229920000370 gamma-poly(glutamate) polymer Polymers 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000012226 gene silencing method Methods 0.000 description 1
- 229940074049 glyceryl dilaurate Drugs 0.000 description 1
- 229940074045 glyceryl distearate Drugs 0.000 description 1
- 125000005908 glyceryl ester group Chemical group 0.000 description 1
- WVULKSPCQVQLCU-BUXLTGKBSA-N glycodeoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 WVULKSPCQVQLCU-BUXLTGKBSA-N 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 108700025184 hepatitis B virus X Proteins 0.000 description 1
- 125000004447 heteroarylalkenyl group Chemical group 0.000 description 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 1
- 125000005312 heteroarylalkynyl group Chemical group 0.000 description 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 1
- 125000004449 heterocyclylalkenyl group Chemical group 0.000 description 1
- 125000004415 heterocyclylalkyl group Chemical group 0.000 description 1
- 229940031689 heterologous vaccine Drugs 0.000 description 1
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 108091008039 hormone receptors Proteins 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 150000007857 hydrazones Chemical class 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000000951 immunodiffusion Effects 0.000 description 1
- 238000000760 immunoelectrophoresis Methods 0.000 description 1
- 230000028802 immunoglobulin-mediated neutralization Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- USSYUMHVHQSYNA-SLDJZXPVSA-N indolicidin Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O)CC1=CNC2=CC=CC=C12 USSYUMHVHQSYNA-SLDJZXPVSA-N 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 210000003963 intermediate filament Anatomy 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- DDVBPZROPPMBLW-ZJBINBEQSA-N latrunculin a Chemical compound C([C@H]1[C@@]2(O)C[C@H]3C[C@H](O2)CC[C@@H](/C=C\C=C/CC\C(C)=C/C(=O)O3)C)SC(=O)N1 DDVBPZROPPMBLW-ZJBINBEQSA-N 0.000 description 1
- DDVBPZROPPMBLW-UHFFFAOYSA-N latrunculin-A Natural products O1C(=O)C=C(C)CCC=CC=CC(C)CCC(O2)CC1CC2(O)C1CSC(=O)N1 DDVBPZROPPMBLW-UHFFFAOYSA-N 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 238000007834 ligase chain reaction Methods 0.000 description 1
- 150000002634 lipophilic molecules Chemical class 0.000 description 1
- 108700040422 lipopolylysine Proteins 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 231100000832 liver cell necrosis Toxicity 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 125000002960 margaryl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 238000010208 microarray analysis Methods 0.000 description 1
- 210000003632 microfilament Anatomy 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 239000008185 minitablet Substances 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- XVUQPECVOGMPRU-ZPPAUJSGSA-N n,n-dimethyl-1,2-bis[(9z,12z)-octadeca-9,12-dienoxy]propan-1-amine Chemical compound CCCCC\C=C/C\C=C/CCCCCCCCOC(C)C(N(C)C)OCCCCCCCC\C=C/C\C=C/CCCCC XVUQPECVOGMPRU-ZPPAUJSGSA-N 0.000 description 1
- OZBZDYGIYDRTBV-RSLAUBRISA-N n,n-dimethyl-1,2-bis[(9z,12z,15z)-octadeca-9,12,15-trienoxy]propan-1-amine Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCCOC(C)C(N(C)C)OCCCCCCCC\C=C/C\C=C/C\C=C/CC OZBZDYGIYDRTBV-RSLAUBRISA-N 0.000 description 1
- GLGLUQVVDHRLQK-WRBBJXAJSA-N n,n-dimethyl-2,3-bis[(z)-octadec-9-enoxy]propan-1-amine Chemical compound CCCCCCCC\C=C/CCCCCCCCOCC(CN(C)C)OCCCCCCCC\C=C/CCCCCCCC GLGLUQVVDHRLQK-WRBBJXAJSA-N 0.000 description 1
- UKXOXMLXFQEEQJ-KWXKLSQISA-N n,n-dimethyl-2,3-bis[[(9z,12z)-octadeca-9,12-dienyl]sulfanyl]propan-1-amine Chemical compound CCCCC\C=C/C\C=C/CCCCCCCCSCC(CN(C)C)SCCCCCCCC\C=C/C\C=C/CCCCC UKXOXMLXFQEEQJ-KWXKLSQISA-N 0.000 description 1
- ZUHZZVMEUAUWHY-UHFFFAOYSA-N n,n-dimethylpropan-1-amine Chemical compound CCCN(C)C ZUHZZVMEUAUWHY-UHFFFAOYSA-N 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- QNILTEGFHQSKFF-UHFFFAOYSA-N n-propan-2-ylprop-2-enamide Chemical compound CC(C)NC(=O)C=C QNILTEGFHQSKFF-UHFFFAOYSA-N 0.000 description 1
- 229940042880 natural phospholipid Drugs 0.000 description 1
- 230000003041 necroinflammatory effect Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 229950006344 nocodazole Drugs 0.000 description 1
- QTNLALDFXILRQO-UHFFFAOYSA-N nonadecane-1,2,3-triol Chemical group CCCCCCCCCCCCCCCCC(O)C(O)CO QTNLALDFXILRQO-UHFFFAOYSA-N 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000030147 nuclear export Effects 0.000 description 1
- 238000001613 nuclear run-on assay Methods 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 229940023146 nucleic acid vaccine Drugs 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- HEGSGKPQLMEBJL-RKQHYHRCSA-N octyl beta-D-glucopyranoside Chemical compound CCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HEGSGKPQLMEBJL-RKQHYHRCSA-N 0.000 description 1
- 125000002811 oleoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 1
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 210000004738 parenchymal cell Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- MCYTYTUNNNZWOK-LCLOTLQISA-N penetratin Chemical compound C([C@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCCNC(N)=N)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CC=CC=C1 MCYTYTUNNNZWOK-LCLOTLQISA-N 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- 239000000863 peptide conjugate Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 238000009522 phase III clinical trial Methods 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 150000008298 phosphoramidates Chemical class 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920000962 poly(amidoamine) Polymers 0.000 description 1
- 229920002627 poly(phosphazenes) Polymers 0.000 description 1
- 108010064470 polyaspartate Proteins 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 125000005575 polycyclic aromatic hydrocarbon group Chemical group 0.000 description 1
- 229920002643 polyglutamic acid Polymers 0.000 description 1
- 229920000166 polytrimethylene carbonate Chemical group 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 150000004032 porphyrins Chemical class 0.000 description 1
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 229940048914 protamine Drugs 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 229960003581 pyridoxal Drugs 0.000 description 1
- 235000008164 pyridoxal Nutrition 0.000 description 1
- 239000011674 pyridoxal Substances 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000012950 reanalysis Methods 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000002265 redox agent Substances 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 125000006853 reporter group Chemical group 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- COFLCBMDHTVQRA-UHFFFAOYSA-N sapphyrin Chemical compound N1C(C=2NC(C=C3N=C(C=C4NC(=C5)C=C4)C=C3)=CC=2)=CC=C1C=C1C=CC5=N1 COFLCBMDHTVQRA-UHFFFAOYSA-N 0.000 description 1
- 108700004121 sarkosyl Proteins 0.000 description 1
- 239000002924 silencing RNA Substances 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- QPILZZVXGUNELN-UHFFFAOYSA-M sodium;4-amino-5-hydroxynaphthalene-2,7-disulfonate;hydron Chemical group [Na+].OS(=O)(=O)C1=CC(O)=C2C(N)=CC(S([O-])(=O)=O)=CC2=C1 QPILZZVXGUNELN-UHFFFAOYSA-M 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 150000003445 sucroses Chemical class 0.000 description 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-N sulfamic acid Chemical group NS(O)(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-N 0.000 description 1
- 150000003456 sulfonamides Chemical group 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 150000003457 sulfones Chemical group 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- RJVBVECTCMRNFG-ANKJNSLFSA-N swinholide a Chemical compound C1[C@H](OC)C[C@H](C)O[C@H]1CC[C@H](C)[C@H](O)[C@H](C)[C@@H]1[C@@H](C)[C@H](O)C[C@H](O)[C@H](C)[C@@H](OC)C[C@H](CC=C2)O[C@@H]2C[C@@H](O)C/C=C(\C)/C=C/C(=O)O[C@H]([C@@H](C)[C@@H](O)[C@@H](C)CC[C@@H]2O[C@@H](C)C[C@H](C2)OC)[C@@H](C)[C@H](O)C[C@H](O)[C@H](C)[C@@H](OC)C[C@H](CC=C2)O[C@@H]2C[C@@H](O)C/C=C(\C)/C=C/C(=O)O1 RJVBVECTCMRNFG-ANKJNSLFSA-N 0.000 description 1
- GDACDJNQZCXLNU-UHFFFAOYSA-N swinholide-A Natural products C1C(OC)CC(C)OC1CCC(C)C(O)C(C)C1C(C)C(O)CC(O)C(C)C(OC)CC(CC=C2)OC2CC(O)CC=C(C)C=CC(=O)O1 GDACDJNQZCXLNU-UHFFFAOYSA-N 0.000 description 1
- 210000002437 synoviocyte Anatomy 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 238000012385 systemic delivery Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- WBWWGRHZICKQGZ-GIHLXUJPSA-N taurocholic acid Chemical compound C([C@@H]1C[C@H]2O)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@H](O)C1 WBWWGRHZICKQGZ-GIHLXUJPSA-N 0.000 description 1
- 229960004556 tenofovir Drugs 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- 150000004044 tetrasaccharides Chemical class 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- ZEMGGZBWXRYJHK-UHFFFAOYSA-N thiouracil Chemical compound O=C1C=CNC(=S)N1 ZEMGGZBWXRYJHK-UHFFFAOYSA-N 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 229960000874 thyrotropin Drugs 0.000 description 1
- 230000001748 thyrotropin Effects 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 238000007492 two-way ANOVA Methods 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000008957 viral persistence Effects 0.000 description 1
- 230000006490 viral transcription Effects 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
- SFVVQRJOGUKCEG-OPQSFPLASA-N β-MSH Chemical compound C1C[C@@H](O)[C@H]2C(COC(=O)[C@@](O)([C@@H](C)O)C(C)C)=CCN21 SFVVQRJOGUKCEG-OPQSFPLASA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3515—Lipophilic moiety, e.g. cholesterol
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3521—Methyl
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
- C12N2310/3533—Halogen
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
Abstract
The present invention provides methods for the treatment of a subject having a Hepatitis B virus (HBV) infection, e.g., a chronic HBV infection, using a combination of an RNAi agent that targets HBV and an HBV vaccine. It is disclosed a RNAi agent and an HBV vaccine for use in treatment of HBV infection, comprising sequentially administering to the subject having an HBV infection: a) an RNAi agent that inhibits expression of at least three HBV transcripts, wherein the RNAi agent forms a double stranded region; b) a protein-based vaccine comprising a first HBV core antigen (HBcAg) polypeptide, and a first HBV surface antigen (HBsAg) polypeptide; and c) a nucleic acid-based vaccine comprising an expression vector construct encoding a second HBcAg polypeptide, and/or a second HBsAg polypeptide, wherein the second HBcAg polypeptide, and/or the second HBsAg polypeptide, shares at least one epitope with at least one of the first HBcAg polypeptide, and/or the first HBsAg polypeptide.
Description
METHODS FOR THE TREATMENT OF SUBJECTS HAVING A HEPATITIS B VIRUS
(HBV) INFECTION
RELATED APPLICATIONS
This application claims the benefit of priority to U.S. Provisional Patent Application No.
62/486,618, filed on April 18, 2017, U.S. Provisional Patent Application No.
62/553,358, filed on September 1, 2017, U.S. Provisional Patent Application No. 62/646,978, filed on March 23, 2018, and U.S. Provisional Patent Application No. 62/655,862, filed on April 11, 2018.
The entire contents of each of the foregoing provisional patent applications are incorporated herein by reference.
SEQUENCE LISTING
The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on April 12, 2018, is named 121301-07220_SL.txt and is 429,841 bytes in size.
BACKGROUND OF THE INVENTION
Hepatitis B virus (HBV) is an enveloped DNA virus that infects the liver that causes hepatocellular necrosis, inflammation, and is a major risk factor for development of cirrhosis and hepatocellular carcinoma (HCC). The World Health Organization (WHO) estimates that there are 240 million chronically HBV infected individuals worldwide largely in low to middle income countries and that about 650,000 people will die annually of complications from HBV
infection. Although an effective HBV vaccine is available and efforts to vaccinate infants at birth have been effective in reducing incidence and prevalence of HBV infection, such programs do not have a demonstrable effect on death rates for years (WHO Guidelines for prevention, care and treatment of persons with chronic Hepatitis B Infection, 2015 at apps.who.inthris/bitstream/10665/154590/1/9789241549059_eng.pdf?ua=1&ua=1).
A number of therapeutic agents have been developed for the treatment of HBV
that effectively reduce the disease burden of HBV infection, but they are not typically curative as they do not fully eliminate all replicative forms of the virus including the covalently closed circular DNA
(cccDNA) that resides in the hepatocyte nucleus and becomes a template for viral replication and transcription of viral RNAs. Nucleotide and nucleoside analogs, typically considered to be the gold standard for treatment of chronic HBV infection due to their safety and efficacy, are effective in suppressing HBV replication, but they do not eliminate cccDNA, do not prevent expression of viral proteins, must be dosed chronically, and can result in the development of resistance. Further, treatment with nucleot(s)ide inhibitors does not fully mitigate the risk of the development of hepatocellular carcinoma (HCC) which remains significant (about 7% in 5-7 years despite treatment).
Interferon-based therapies can result in sero-conversion and cure of about 10-15% of patients allowing discontinuation of treatment, but the agents have severe side effects and must be refrigerated for long term storage making them less desirable for use in countries where HBV infection is most prevalent.
Treatment of chronic HBV is further complicated by the ability of HBV to evade or suppress the immune response resulting in persistence of the infection. The HBV
proteins have immune-inhibitory properties, with hepatitis B s antigen (HBsAg) comprising the overwhelming majority of HBV protein in the circulation of HBV infected subjects. Additionally, while the removal (via seroconversion) of hepatitis B e antigen (HBeAg) or reductions in serum viremia are not correlated with the development of sustained control of HBV infection off treatment, the removal of serum HBsAg from the blood (and seroconversion) in HBV infection is a well-recognized prognostic indicator of antiviral response to treatment which will lead to control of HBV
infection off treatment.
However, this only occurs in a small fraction of patients receiving immunotherapy. Therefore, it is possible, although rare, for patients to mount a sufficiently robust immune response to suppress or clear an HBV infection resulting in at least a functional cure of the disease.
SUMMARY OF THE INVENTION
The invention provides RNAi agents and HBV vaccines for use in treatment of hepatitis B
virus (HBV) infection and methods for the treatment of a subject having a hepatitis B virus (HBV) infection, e.g., a chronic HBV infection, which includes a combination therapy or treatment regimen including an RNAi agent targeting at least one HBV transcript and a therapeutic vaccination.
Accordingly, in one aspect, the present invention provides RNAi agents and HBV
vaccines for use in treatment of hepatitis B virus (HBV) infection and methods for treating a subject having a hepatitis B virus (HBV) infection, e.g., a chronic HBV infection. The methods include a regimen which includes administering, e.g., sequentially administering, to the subject having the HBV
infection, an RNAi agent that targets at least three HBV transcripts, wherein the RNAi agent comprises a sense strand and an antisense strand; a protein-based vaccine comprising an HBV core antigen (HBcAg) and an HBV surface antigen (HBsAg); and a nucleic acid-based vaccine comprising an expression construct encoding an HBcAg or an HBsAg, wherein the construct encodes a protein that shares an epitope with the protein-based vaccine, thereby treating the subject.
In another aspect, the present invention provides a regimen for treating a subject having a hepatitis B virus (HBV) infection, e.g., a chronic HBV infection. The regimen includes the use of an RNAi agent that targets at least three HBV transcripts, wherein the RNAi agent comprises a sense strand and an antisense strand; a protein-based vaccine comprising an HBV core antigen (HBcAg) and an HBV surface antigen (HBsAg); and a nucleic acid-based vaccine comprising an expression construct encoding an HBcAg or an HBsAg, wherein the construct encodes a protein that shares an epitope with the protein-based vaccine.
In one embodiment, the HBcAg protein, or immunogenic fragment thereof, shares an epitope with the HBV core antigen (HBcAg) polypeptide, or immunogenic fragment thereof, present in the protein-based vaccine and/or the HBsAg protein, or immunogenic fragment thereof, shares an epitope
(HBV) INFECTION
RELATED APPLICATIONS
This application claims the benefit of priority to U.S. Provisional Patent Application No.
62/486,618, filed on April 18, 2017, U.S. Provisional Patent Application No.
62/553,358, filed on September 1, 2017, U.S. Provisional Patent Application No. 62/646,978, filed on March 23, 2018, and U.S. Provisional Patent Application No. 62/655,862, filed on April 11, 2018.
The entire contents of each of the foregoing provisional patent applications are incorporated herein by reference.
SEQUENCE LISTING
The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on April 12, 2018, is named 121301-07220_SL.txt and is 429,841 bytes in size.
BACKGROUND OF THE INVENTION
Hepatitis B virus (HBV) is an enveloped DNA virus that infects the liver that causes hepatocellular necrosis, inflammation, and is a major risk factor for development of cirrhosis and hepatocellular carcinoma (HCC). The World Health Organization (WHO) estimates that there are 240 million chronically HBV infected individuals worldwide largely in low to middle income countries and that about 650,000 people will die annually of complications from HBV
infection. Although an effective HBV vaccine is available and efforts to vaccinate infants at birth have been effective in reducing incidence and prevalence of HBV infection, such programs do not have a demonstrable effect on death rates for years (WHO Guidelines for prevention, care and treatment of persons with chronic Hepatitis B Infection, 2015 at apps.who.inthris/bitstream/10665/154590/1/9789241549059_eng.pdf?ua=1&ua=1).
A number of therapeutic agents have been developed for the treatment of HBV
that effectively reduce the disease burden of HBV infection, but they are not typically curative as they do not fully eliminate all replicative forms of the virus including the covalently closed circular DNA
(cccDNA) that resides in the hepatocyte nucleus and becomes a template for viral replication and transcription of viral RNAs. Nucleotide and nucleoside analogs, typically considered to be the gold standard for treatment of chronic HBV infection due to their safety and efficacy, are effective in suppressing HBV replication, but they do not eliminate cccDNA, do not prevent expression of viral proteins, must be dosed chronically, and can result in the development of resistance. Further, treatment with nucleot(s)ide inhibitors does not fully mitigate the risk of the development of hepatocellular carcinoma (HCC) which remains significant (about 7% in 5-7 years despite treatment).
Interferon-based therapies can result in sero-conversion and cure of about 10-15% of patients allowing discontinuation of treatment, but the agents have severe side effects and must be refrigerated for long term storage making them less desirable for use in countries where HBV infection is most prevalent.
Treatment of chronic HBV is further complicated by the ability of HBV to evade or suppress the immune response resulting in persistence of the infection. The HBV
proteins have immune-inhibitory properties, with hepatitis B s antigen (HBsAg) comprising the overwhelming majority of HBV protein in the circulation of HBV infected subjects. Additionally, while the removal (via seroconversion) of hepatitis B e antigen (HBeAg) or reductions in serum viremia are not correlated with the development of sustained control of HBV infection off treatment, the removal of serum HBsAg from the blood (and seroconversion) in HBV infection is a well-recognized prognostic indicator of antiviral response to treatment which will lead to control of HBV
infection off treatment.
However, this only occurs in a small fraction of patients receiving immunotherapy. Therefore, it is possible, although rare, for patients to mount a sufficiently robust immune response to suppress or clear an HBV infection resulting in at least a functional cure of the disease.
SUMMARY OF THE INVENTION
The invention provides RNAi agents and HBV vaccines for use in treatment of hepatitis B
virus (HBV) infection and methods for the treatment of a subject having a hepatitis B virus (HBV) infection, e.g., a chronic HBV infection, which includes a combination therapy or treatment regimen including an RNAi agent targeting at least one HBV transcript and a therapeutic vaccination.
Accordingly, in one aspect, the present invention provides RNAi agents and HBV
vaccines for use in treatment of hepatitis B virus (HBV) infection and methods for treating a subject having a hepatitis B virus (HBV) infection, e.g., a chronic HBV infection. The methods include a regimen which includes administering, e.g., sequentially administering, to the subject having the HBV
infection, an RNAi agent that targets at least three HBV transcripts, wherein the RNAi agent comprises a sense strand and an antisense strand; a protein-based vaccine comprising an HBV core antigen (HBcAg) and an HBV surface antigen (HBsAg); and a nucleic acid-based vaccine comprising an expression construct encoding an HBcAg or an HBsAg, wherein the construct encodes a protein that shares an epitope with the protein-based vaccine, thereby treating the subject.
In another aspect, the present invention provides a regimen for treating a subject having a hepatitis B virus (HBV) infection, e.g., a chronic HBV infection. The regimen includes the use of an RNAi agent that targets at least three HBV transcripts, wherein the RNAi agent comprises a sense strand and an antisense strand; a protein-based vaccine comprising an HBV core antigen (HBcAg) and an HBV surface antigen (HBsAg); and a nucleic acid-based vaccine comprising an expression construct encoding an HBcAg or an HBsAg, wherein the construct encodes a protein that shares an epitope with the protein-based vaccine.
In one embodiment, the HBcAg protein, or immunogenic fragment thereof, shares an epitope with the HBV core antigen (HBcAg) polypeptide, or immunogenic fragment thereof, present in the protein-based vaccine and/or the HBsAg protein, or immunogenic fragment thereof, shares an epitope
2 with the HBV surface antigen (HBsAg) polypeptide, or immunogenic fragment thereof, present in the protein-based vaccine.
In certain embodiments, the RNAi agent comprises at least one modified nucleotide.
In certain embodiments, the nucleic acid-based vaccine comprises an expression construct encoding an HBcAg and an HBsAg.
In certain embodiments, the RNAi agent targeting HBV is administered to the subject at least two times.
In certain embodiments, the RNAi agent targeting HBV administered to the subject decreases HBsAg in the serum of the subject by at least 0.5 log 10 IU/ml. In certain embodiments, the subject has at least a 0.5 10g10 IU/ml decrease in HBsAg in serum prior to administration of the first dose of the protein based vaccine. In certain embodiments, the subject has at least a 1 10g10 IU/ml decrease in HBsAg in serum prior to administration of the first dose of the protein based vaccine. In certain embodiments, the subject has an HBsAg of 2 log 10 IU/ml or less in serum prior to administration of the vaccine.
In certain embodiments, the RNAi agent is administered to the subject no more than once per week. In certain embodiments, the RNAi agent is administered to the subject no more than once every four weeks.
In certain embodiments, the RNAi ageint is administered to the subject at a dose of 0.01 mg/kg to 10 mg/kg; or 0.5 mg/kg to 50 mg/kg; or 10 mg/kg to 30 mg/kg. In certain embodiments, the RNAi agent is administered to the subject at a dose selected from 0.5 mg/kg, 1 mg/kg, 1.5 mg/kg, 3 mg/kg, 5 mg/kg, 10 mg/kg, and 30 mg/kg. In some embodiments, a dose of the RNAi agent is administered to the subject about once per week; about one every two weeks;
about once every three weeks; about once every four weeks; or a dose of the RNAi agent is administered to the subject not more than once per week; or a dose of the RNAi agent is administered to the subject no more than once every four weeks.
In certain embodiments, the protein-based vaccine comprises an amino acid sequence of at least one determinant of HBsAg and at least one determinant of HBcAg.
In certain embodiments, the nucleic acid-based vaccine comprising an expression vector construct encoding an HBcAg or an HBsAg encodes an amino acid sequence comprising at least one determinant of HBsAg or at least one determinant of HBcAg In certain embodiments, the determinant of HBsAg comprises a sequence at least 90%
identical to amino acids 124 to 147 of SEQ ID NO: 22. In certain embodiments, the determinant of HBsAg comprises a sequence at least 90% identical to amino acids 99 to 168 of SEQ ID NO: 23.
In certain embodiments, the determinant of HBcAg comprises a sequence comprising amino acid 80 of SEQ ID NO: 24. In certain embodiments, the sequence comprising amino acid 80 of SEQ
ID NO: 24 comprises an amino acid sequence at lest 90% identical to at least amino acids 70 to 90 of SEQ ID NO: 24. In certain embodiments, the determinant of HBcAg comprises a sequence comprising amino acid 138 of SEQ ID NO: 24. In certain embodiments, the sequence comprising
In certain embodiments, the RNAi agent comprises at least one modified nucleotide.
In certain embodiments, the nucleic acid-based vaccine comprises an expression construct encoding an HBcAg and an HBsAg.
In certain embodiments, the RNAi agent targeting HBV is administered to the subject at least two times.
In certain embodiments, the RNAi agent targeting HBV administered to the subject decreases HBsAg in the serum of the subject by at least 0.5 log 10 IU/ml. In certain embodiments, the subject has at least a 0.5 10g10 IU/ml decrease in HBsAg in serum prior to administration of the first dose of the protein based vaccine. In certain embodiments, the subject has at least a 1 10g10 IU/ml decrease in HBsAg in serum prior to administration of the first dose of the protein based vaccine. In certain embodiments, the subject has an HBsAg of 2 log 10 IU/ml or less in serum prior to administration of the vaccine.
In certain embodiments, the RNAi agent is administered to the subject no more than once per week. In certain embodiments, the RNAi agent is administered to the subject no more than once every four weeks.
In certain embodiments, the RNAi ageint is administered to the subject at a dose of 0.01 mg/kg to 10 mg/kg; or 0.5 mg/kg to 50 mg/kg; or 10 mg/kg to 30 mg/kg. In certain embodiments, the RNAi agent is administered to the subject at a dose selected from 0.5 mg/kg, 1 mg/kg, 1.5 mg/kg, 3 mg/kg, 5 mg/kg, 10 mg/kg, and 30 mg/kg. In some embodiments, a dose of the RNAi agent is administered to the subject about once per week; about one every two weeks;
about once every three weeks; about once every four weeks; or a dose of the RNAi agent is administered to the subject not more than once per week; or a dose of the RNAi agent is administered to the subject no more than once every four weeks.
In certain embodiments, the protein-based vaccine comprises an amino acid sequence of at least one determinant of HBsAg and at least one determinant of HBcAg.
In certain embodiments, the nucleic acid-based vaccine comprising an expression vector construct encoding an HBcAg or an HBsAg encodes an amino acid sequence comprising at least one determinant of HBsAg or at least one determinant of HBcAg In certain embodiments, the determinant of HBsAg comprises a sequence at least 90%
identical to amino acids 124 to 147 of SEQ ID NO: 22. In certain embodiments, the determinant of HBsAg comprises a sequence at least 90% identical to amino acids 99 to 168 of SEQ ID NO: 23.
In certain embodiments, the determinant of HBcAg comprises a sequence comprising amino acid 80 of SEQ ID NO: 24. In certain embodiments, the sequence comprising amino acid 80 of SEQ
ID NO: 24 comprises an amino acid sequence at lest 90% identical to at least amino acids 70 to 90 of SEQ ID NO: 24. In certain embodiments, the determinant of HBcAg comprises a sequence comprising amino acid 138 of SEQ ID NO: 24. In certain embodiments, the sequence comprising
3 amino acid 80 of SEQ ID NO: 14 comprises an amino acid sequence at lest 90%
identical to at least amino acids 128 to 143 of SEQ ID NO: 24. In certain embodiments, the determinant of HBcAg comprises an amino acid sequence at least 90% identical to at least 40, 50, 60, 70, 80, 90, or 100 contiguous amino acids of SEQ ID NO: 24. In certain embodiments, the determinant of HBcAg comprises a sequence at least 90% identical to amino acids 18 to 143 of SEQ ID
NO: 24.
In certain embodiments, the protein-based vaccine administered to the subject comprises a dose of 0.1 lig to 1.0 mg of the HBcAg and a dose of 0.1 lig to 1.0 mg of HBsAg. In some embodiments, a dose of the protein-based vaccine is administered to the subject about once per week;
about one every two weeks; about once every three weeks; about once every four weeks; or a dose of the protein-based vaccine is administered to the subject no more than once per week; or a dose of the protein-based vaccine is administered to the subject no more than once every four weeks.
In certain embodiments, the HBcAg protein and the HBsAg protein are present in a single formulation. In certain embodiments, the HBcAg protein and the HBsAg protein are not present in a single formulation. In certain embodiments, the protein-based vaccine comprises an adjuvant. In some embodiments, the adjuvant stimulates a balanced Th1/Th2 response. In certain embodiments, the adjuvant is selected from monophosphoryl lipid A (MPL), poly(I:C), polyICLC
adjuvant, CpG DNA, polyICLC adjuvant ,a STING agonist, c-di-AMP, c-di-GMP, c-di-CMP; short, blunt-ended 5'-triphosphate dsRNA (3pRNA) Rig-Iligand, poly[di(sodiumcarboxylatoethylphenoxy)phosphazene]
(PCEP)), alum, virosomes, cytokines, IL-12, A502, A503, A504, MF59, ISCOMATRIX
, IC31 , or Rig-I ligand. In certain embodiments, the adjuvant is selected from polyI:C
adjuvant, a CpG adjuvant, a STING agonist, or a PCEP adjuvant.
In certain embodiments, the protein based vaccine is administered to the subject at least two times. In certain embodiments, the protein-based vaccine is administered to the subject no more than once every two weeks. In certain embodiments, the protein-based vaccine is administered to the subject no sooner than the day on which the final dose of the RNAi agent has been administered to the subject. In certain embodiments, the protein-based vaccine is administered to the subject on the same day on which the final dose of the RNAi agent has been administered to the subject. In certain embodiments, the protein based vaccine is administered to the subject no later than one month after the final dose of the RNAi agent has been administered to the subject. In certain embodiments, the protein based vaccine is administered to the subject no later than two months after the final dose of the RNAi agent has been administered to the subject. In certain embodiments, the protein based vaccine is administered to the subject no later than three months after the final dose of the RNAi agent has been administered to the subject.
In certain embodiments the methods of the invention further comprise determining the serum HBsAg level after administration of at least one dose of the RNAi agent and prior to administration of the protein based vaccine. That is, the serum HBsAg level is determined in the subject after administration of at least one dose of the RNAi agent and prior to administration of the protein based vaccine.
identical to at least amino acids 128 to 143 of SEQ ID NO: 24. In certain embodiments, the determinant of HBcAg comprises an amino acid sequence at least 90% identical to at least 40, 50, 60, 70, 80, 90, or 100 contiguous amino acids of SEQ ID NO: 24. In certain embodiments, the determinant of HBcAg comprises a sequence at least 90% identical to amino acids 18 to 143 of SEQ ID
NO: 24.
In certain embodiments, the protein-based vaccine administered to the subject comprises a dose of 0.1 lig to 1.0 mg of the HBcAg and a dose of 0.1 lig to 1.0 mg of HBsAg. In some embodiments, a dose of the protein-based vaccine is administered to the subject about once per week;
about one every two weeks; about once every three weeks; about once every four weeks; or a dose of the protein-based vaccine is administered to the subject no more than once per week; or a dose of the protein-based vaccine is administered to the subject no more than once every four weeks.
In certain embodiments, the HBcAg protein and the HBsAg protein are present in a single formulation. In certain embodiments, the HBcAg protein and the HBsAg protein are not present in a single formulation. In certain embodiments, the protein-based vaccine comprises an adjuvant. In some embodiments, the adjuvant stimulates a balanced Th1/Th2 response. In certain embodiments, the adjuvant is selected from monophosphoryl lipid A (MPL), poly(I:C), polyICLC
adjuvant, CpG DNA, polyICLC adjuvant ,a STING agonist, c-di-AMP, c-di-GMP, c-di-CMP; short, blunt-ended 5'-triphosphate dsRNA (3pRNA) Rig-Iligand, poly[di(sodiumcarboxylatoethylphenoxy)phosphazene]
(PCEP)), alum, virosomes, cytokines, IL-12, A502, A503, A504, MF59, ISCOMATRIX
, IC31 , or Rig-I ligand. In certain embodiments, the adjuvant is selected from polyI:C
adjuvant, a CpG adjuvant, a STING agonist, or a PCEP adjuvant.
In certain embodiments, the protein based vaccine is administered to the subject at least two times. In certain embodiments, the protein-based vaccine is administered to the subject no more than once every two weeks. In certain embodiments, the protein-based vaccine is administered to the subject no sooner than the day on which the final dose of the RNAi agent has been administered to the subject. In certain embodiments, the protein-based vaccine is administered to the subject on the same day on which the final dose of the RNAi agent has been administered to the subject. In certain embodiments, the protein based vaccine is administered to the subject no later than one month after the final dose of the RNAi agent has been administered to the subject. In certain embodiments, the protein based vaccine is administered to the subject no later than two months after the final dose of the RNAi agent has been administered to the subject. In certain embodiments, the protein based vaccine is administered to the subject no later than three months after the final dose of the RNAi agent has been administered to the subject.
In certain embodiments the methods of the invention further comprise determining the serum HBsAg level after administration of at least one dose of the RNAi agent and prior to administration of the protein based vaccine. That is, the serum HBsAg level is determined in the subject after administration of at least one dose of the RNAi agent and prior to administration of the protein based vaccine.
4
5 In certain embodiments the methods of the invention further comprise determining the serum HBeAg level after administration of at least one dose of the RNAi agent and prior to administration of the protein based vaccine. That is, the serum HBeAg level is determined in the subject after administration of at least one dose of the RNAi agent and prior to administration of the protein based vaccine.
In certain embodiments the methods of the invention further comprise determining the serum HBsAg level and the HBeAg level after administration of at least one dose of the RNAi agent and prior to administration of the protein based vaccine. That is, the serum HBsAg level and the serum HBeAg level are determined in the subject after administration of at least one dose of the RNAi agent and prior to administration of the protein based vaccine.
In certain embodiments, the nucleic acid-based vaccine comprises at least one expression vector construct encoding both an HBcAg and an HBsAg. In certain embodiments, the expression construct promotes expression of HBcAg and HBsAg from a single promoter. In other embodiments, the expression construct promotes expression of HBcAg and HBsAg from separate promoters.
In certain embodiments, at least one promoter is selected from a respiratory syncytial virus (RSV) promoter, a cytomegalovirus (CMV) promoter, a PH5 promoter, and an H1 promoter. In certain embodiments, the expression construct comprises a viral vector. In certain embodiments, the viral vector is selected from adenovirus vector; retrovirus vector, lentiviral vector, moloney murine leukemia virus vector, adeno- associated virus vector; herpes simplex virus vector; SV 40 vector;
polyoma virus vector; papilloma virus vector; picornavirus vector; pox virus vector, orthopox virus vector, vaccinia virus vector, modified vaccinia virus Ankara (MVA) vector, avipox vector, canary pox vector, fowl pox vector, adenovirus vector, and Epstein Barr virus vector.
In certain embodiments, the viral vector is an MVA vector.
In certain emboidments, the nucleic acid-based vaccine administered to the subject comprises a tissue-culture infectious dose (TCID50) of 106 to 101 TCID50; or 106 to 109 TCID50; or 106 to 108 In certain embodiments, the nucleic acid-based vector is administered to the subject no sooner than two weeks after administration of the final dose of the protein-based vaccine is administered to the subject.
In certain embodiments, the methods further comprise determining the serum HBsAg level after administration of at least one dose of the RNAi agent and prior to administration of the nucleic acid-based vaccine. That is, the serum HBsAg level is determined in the subject after administration of at least one dose of the RNAi agent and prior to administration of the nucleic acid-based vaccine.
In certain embodiments, the nucleic acid-based vaccine is administered to the subject after a further decrease of at least 0.5 log 10 of serum HBsAg after at least one dose of the protein-based vaccine is administered to the subject. In certain embodiments of the regimen, a single dose of the nucleic-acid based vaccine is administered to the subject.
In certain embodiments, the methods further comprise determining the serum HBeAg level after administration of at least one dose of the RNAi agent and prior to administration of the nucleic acid-based vaccine. That is, the serum HBeAg level is determined in the subject after administration of at least one dose of the RNAi agent and prior to administration of the nucleic acid-based vaccine.
In certain embodiments, the nucleic acid-based vaccine is administered to the subject after a further decrease of at least 0.5 log 10 of serum HBeAg after at least one dose of the protein-based vaccine is administered to the subject. In certain embodiments of the regimen, a single dose of the nucleic-acid based vaccine is administered to the subject.
In certain embodiments, the methods further comprise determining the serum HBsAg level .. and the HBeAg level after administration of at least one dose of the RNAi agent and prior to administration of the nucleic acid-based vaccine. That is, the serum HBsAg level and the serum HBeAg level are determined in the subject after administration of at least one dose of the RNAi agent and prior to administration of the nucleic acid-based vaccine. In certain embodiments, the nucleic acid-based vaccine is administered to the subject after a further decrease of at least 0.5 log 10 of .. serum HBsAg and serum HBeAg after at least one dose of the protein-based vaccine is administered to the subject. In certain embodiments of the regimen, a single dose of the nucleic-acid based vaccine is administered to the subject.
In certain embodiments, the methods further comprise administering a nucleot(s)ide analog to the subject at least prior to administration of the iRNA targeted to HBV. In certain embodiments, the .. nucleot(s)ide analog is administered throughout the entire regimen. In certain embodiments, the nucleot(s)ide analog is selected from Tenofovir disoproxil fumarate (TDF), Tenofovir alafenamide (TAF), Lamivudine, Adefovir dipivoxil, Entecavir (ETV), Telbivudine, AGX-1009, emtricitabine, clevudine, ritonavir, dipivoxil, lobucavir, famvir, FTC, N-Acetyl-Cysteine (NAC), PC1323, theradigm-HBV, thymosin-alpha, and ganciclovir, besifovir (ANA-380/LB-80380), and tenofovir-exaliades (TLX/CMX157).
In certain embodiments, the subject has serum HBsAg below 3000 IU/ml prior to administration of the RNAi agent. In certain embodiments, the subject has serum HBsAg below 4000 IU/ml prior to administration of the RNAi agent. In certain embodiments, subject has serum HBsAg below 5000 IU/ml prior to administration of the RNAi agent.
In certain embodiments, the subject has a reduction of HBsAg level of at least 2 logio scales after administration of the RNAi agent and prior to administration of the first dose of a protein-based vaccine. In certain embodiments, the subject has a reduction of HBeAg level of at least 1 logio scale after administration of the RNAi agent and prior to administration of the first dose of a protein-based vaccine. In certain embodiments, the subject has a reduction of HBsAg level of at least 2 logio scales .. and a reduction of HBeAg level of at least 1 logio scale after administration of the RNAi agent and prior to administration of the first dose of a protein-based vaccine.
In certain embodiments, the subject has a reduction of HBsAg level to 500 IU/ml or less after administration of the RNAi agent and prior to administration of a first dose of the protein based
In certain embodiments the methods of the invention further comprise determining the serum HBsAg level and the HBeAg level after administration of at least one dose of the RNAi agent and prior to administration of the protein based vaccine. That is, the serum HBsAg level and the serum HBeAg level are determined in the subject after administration of at least one dose of the RNAi agent and prior to administration of the protein based vaccine.
In certain embodiments, the nucleic acid-based vaccine comprises at least one expression vector construct encoding both an HBcAg and an HBsAg. In certain embodiments, the expression construct promotes expression of HBcAg and HBsAg from a single promoter. In other embodiments, the expression construct promotes expression of HBcAg and HBsAg from separate promoters.
In certain embodiments, at least one promoter is selected from a respiratory syncytial virus (RSV) promoter, a cytomegalovirus (CMV) promoter, a PH5 promoter, and an H1 promoter. In certain embodiments, the expression construct comprises a viral vector. In certain embodiments, the viral vector is selected from adenovirus vector; retrovirus vector, lentiviral vector, moloney murine leukemia virus vector, adeno- associated virus vector; herpes simplex virus vector; SV 40 vector;
polyoma virus vector; papilloma virus vector; picornavirus vector; pox virus vector, orthopox virus vector, vaccinia virus vector, modified vaccinia virus Ankara (MVA) vector, avipox vector, canary pox vector, fowl pox vector, adenovirus vector, and Epstein Barr virus vector.
In certain embodiments, the viral vector is an MVA vector.
In certain emboidments, the nucleic acid-based vaccine administered to the subject comprises a tissue-culture infectious dose (TCID50) of 106 to 101 TCID50; or 106 to 109 TCID50; or 106 to 108 In certain embodiments, the nucleic acid-based vector is administered to the subject no sooner than two weeks after administration of the final dose of the protein-based vaccine is administered to the subject.
In certain embodiments, the methods further comprise determining the serum HBsAg level after administration of at least one dose of the RNAi agent and prior to administration of the nucleic acid-based vaccine. That is, the serum HBsAg level is determined in the subject after administration of at least one dose of the RNAi agent and prior to administration of the nucleic acid-based vaccine.
In certain embodiments, the nucleic acid-based vaccine is administered to the subject after a further decrease of at least 0.5 log 10 of serum HBsAg after at least one dose of the protein-based vaccine is administered to the subject. In certain embodiments of the regimen, a single dose of the nucleic-acid based vaccine is administered to the subject.
In certain embodiments, the methods further comprise determining the serum HBeAg level after administration of at least one dose of the RNAi agent and prior to administration of the nucleic acid-based vaccine. That is, the serum HBeAg level is determined in the subject after administration of at least one dose of the RNAi agent and prior to administration of the nucleic acid-based vaccine.
In certain embodiments, the nucleic acid-based vaccine is administered to the subject after a further decrease of at least 0.5 log 10 of serum HBeAg after at least one dose of the protein-based vaccine is administered to the subject. In certain embodiments of the regimen, a single dose of the nucleic-acid based vaccine is administered to the subject.
In certain embodiments, the methods further comprise determining the serum HBsAg level .. and the HBeAg level after administration of at least one dose of the RNAi agent and prior to administration of the nucleic acid-based vaccine. That is, the serum HBsAg level and the serum HBeAg level are determined in the subject after administration of at least one dose of the RNAi agent and prior to administration of the nucleic acid-based vaccine. In certain embodiments, the nucleic acid-based vaccine is administered to the subject after a further decrease of at least 0.5 log 10 of .. serum HBsAg and serum HBeAg after at least one dose of the protein-based vaccine is administered to the subject. In certain embodiments of the regimen, a single dose of the nucleic-acid based vaccine is administered to the subject.
In certain embodiments, the methods further comprise administering a nucleot(s)ide analog to the subject at least prior to administration of the iRNA targeted to HBV. In certain embodiments, the .. nucleot(s)ide analog is administered throughout the entire regimen. In certain embodiments, the nucleot(s)ide analog is selected from Tenofovir disoproxil fumarate (TDF), Tenofovir alafenamide (TAF), Lamivudine, Adefovir dipivoxil, Entecavir (ETV), Telbivudine, AGX-1009, emtricitabine, clevudine, ritonavir, dipivoxil, lobucavir, famvir, FTC, N-Acetyl-Cysteine (NAC), PC1323, theradigm-HBV, thymosin-alpha, and ganciclovir, besifovir (ANA-380/LB-80380), and tenofovir-exaliades (TLX/CMX157).
In certain embodiments, the subject has serum HBsAg below 3000 IU/ml prior to administration of the RNAi agent. In certain embodiments, the subject has serum HBsAg below 4000 IU/ml prior to administration of the RNAi agent. In certain embodiments, subject has serum HBsAg below 5000 IU/ml prior to administration of the RNAi agent.
In certain embodiments, the subject has a reduction of HBsAg level of at least 2 logio scales after administration of the RNAi agent and prior to administration of the first dose of a protein-based vaccine. In certain embodiments, the subject has a reduction of HBeAg level of at least 1 logio scale after administration of the RNAi agent and prior to administration of the first dose of a protein-based vaccine. In certain embodiments, the subject has a reduction of HBsAg level of at least 2 logio scales .. and a reduction of HBeAg level of at least 1 logio scale after administration of the RNAi agent and prior to administration of the first dose of a protein-based vaccine.
In certain embodiments, the subject has a reduction of HBsAg level to 500 IU/ml or less after administration of the RNAi agent and prior to administration of a first dose of the protein based
6 vaccine. In certain embodiments, the subject has a reduction of HBsAg level to 200 IU/ml or less after administration of the RNAi agent and prior to administration of a first dose of the protein based vaccine. In certain embodiments, the subject has a reduction of HBsAg level to 100 IU/ml or less after administration of the RNAi agent and prior to administration of a first dose of the protein based vaccine.
In certain embodiments, the subject has a reduction of HBeAg level to 500 IU/ml or less after administration of the RNAi agent and prior to administration of a first dose of the protein based vaccine. In certain embodiments, the subject has a reduction of HBeAg level to 200 IU/ml or less after administration of the RNAi agent and prior to administration of a first dose of the protein based vaccine. In certain embodiments, the subject has a reduction of HBeAg level to 100 IU/ml or less after administration of the RNAi agent and prior to administration of a first dose of the protein based vaccine.
In certain embodiments, the subject has a reduction of HBsAg level and HBeAg level to 500 IU/ml or less after administration of the RNAi agent and prior to administration of a first dose of the protein based vaccine. In certain embodiments, the subject has a reduction of HBsAg level and HBeAg level to 200 IU/ml or less after administration of the RNAi agent and prior to administration of a first dose of the protein based vaccine. In certain embodiments, the subject has a reduction of HBsAg level and HBeAg level to 100 IU/ml or less after administration of the RNAi agent and prior to administration of a first dose of the protein based vaccine.
In certain embodiments, the level of serum HBsAg and HBeAg in the subject are decreased to below the level of detection using a clinical assay for at least three months after the end of the dose of the nucleic acid-based vaccine. In certain embodiments, the level of serum HBsAg and HBeAg in the subject are decreased to below the level of detection using a clinical assay for at least six months after the end of the dose of the nucleic acid-based vaccine.
In certain embodiments, serum HBsAg in the subject is decreased to below the level of detection using a clinical assay for at least six months after the end of the dose of the nucleic acid-based vaccine.
In certain embodiments, the methods further comprise administration of an immune stimulator to the subject. In certain embodiments, the immune stimulator is selected from the group pegylated interferon alfa 2a (PEG-IFN-alpha-2a), Interferon alfa-2b, PEG-IFN-alpha-2b, Interferon lambda a recombinant human interleukin-7, and a Toll-like receptor 3, 7, 8 or 9 (TLR3, TLR7, TLR8, TLR9) agonist, a viral entry inhibitor, Myrcludex, an oligonucleotide that inhibits the secretion or release of HBsAg, REP 9AC, a capsid inhibitor, Bay41-4109, NVR-1221, a cccDNA
inhibitor, IHVR-25) a viral capsid, an MVA capsid, an immune checkpoint regulator, an CTLA-4 inhibitor, ipilimumab, a PD-1 inhibitor, Nivolumab, Pembrolizumab, BGB-A317 antibody, a PD-Li inhibitor, atezolizumab, avelumab, durvalumab, and an affimer biotherapeutic.
In certain embodiments of the regimen, the subject is human.
In certain embodiments, the subject has a reduction of HBeAg level to 500 IU/ml or less after administration of the RNAi agent and prior to administration of a first dose of the protein based vaccine. In certain embodiments, the subject has a reduction of HBeAg level to 200 IU/ml or less after administration of the RNAi agent and prior to administration of a first dose of the protein based vaccine. In certain embodiments, the subject has a reduction of HBeAg level to 100 IU/ml or less after administration of the RNAi agent and prior to administration of a first dose of the protein based vaccine.
In certain embodiments, the subject has a reduction of HBsAg level and HBeAg level to 500 IU/ml or less after administration of the RNAi agent and prior to administration of a first dose of the protein based vaccine. In certain embodiments, the subject has a reduction of HBsAg level and HBeAg level to 200 IU/ml or less after administration of the RNAi agent and prior to administration of a first dose of the protein based vaccine. In certain embodiments, the subject has a reduction of HBsAg level and HBeAg level to 100 IU/ml or less after administration of the RNAi agent and prior to administration of a first dose of the protein based vaccine.
In certain embodiments, the level of serum HBsAg and HBeAg in the subject are decreased to below the level of detection using a clinical assay for at least three months after the end of the dose of the nucleic acid-based vaccine. In certain embodiments, the level of serum HBsAg and HBeAg in the subject are decreased to below the level of detection using a clinical assay for at least six months after the end of the dose of the nucleic acid-based vaccine.
In certain embodiments, serum HBsAg in the subject is decreased to below the level of detection using a clinical assay for at least six months after the end of the dose of the nucleic acid-based vaccine.
In certain embodiments, the methods further comprise administration of an immune stimulator to the subject. In certain embodiments, the immune stimulator is selected from the group pegylated interferon alfa 2a (PEG-IFN-alpha-2a), Interferon alfa-2b, PEG-IFN-alpha-2b, Interferon lambda a recombinant human interleukin-7, and a Toll-like receptor 3, 7, 8 or 9 (TLR3, TLR7, TLR8, TLR9) agonist, a viral entry inhibitor, Myrcludex, an oligonucleotide that inhibits the secretion or release of HBsAg, REP 9AC, a capsid inhibitor, Bay41-4109, NVR-1221, a cccDNA
inhibitor, IHVR-25) a viral capsid, an MVA capsid, an immune checkpoint regulator, an CTLA-4 inhibitor, ipilimumab, a PD-1 inhibitor, Nivolumab, Pembrolizumab, BGB-A317 antibody, a PD-Li inhibitor, atezolizumab, avelumab, durvalumab, and an affimer biotherapeutic.
In certain embodiments of the regimen, the subject is human.
7 In certain embodiments of the regimen, the RNAi agent targets four transcripts of HBV. In certain embodiments, the RNAi agent is selected from an iRNA in Appendix A. In certain embodiments, the RNAi agent is selected from any of the agents in any one of Tables 2-11 in Appendix A. In certain embodiments, the RNAi agent targets at least 15 contiguous nucleotides of nucleotides 206-228, 207-229, 210-232, 212-234, 214-236, 215-237, 216-238, 226-248, 245-267, 250-272, 252-274, 253-275, 254-276, 256-278, 258-280, 263-285, 370-392, 373-395, 375-397, 401-423, 405-427, 410-432, 411-433, 422-444, 424-446, 425-447, 426-448, 731-753, 734-756, 1174-1196, 1250-1272, 1255-1277, 1256-1278, 1545-1567, 1547-1569, 1551-1571, 1577-1597, 1579-1597, 1580-1598, 1806-1825, 1812-1831, 1814-1836, 1829-1851, 1831-1853, 1857-1879, 1864-1886, 2259-2281, 2298-2320, or 2828-2850 of SEQ ID NO: 1 (NC_003977.1). In certain embodiments, the RNAi agent targets at least 15 contiguous nucleotides of nucleotides 1579-1597 or 1812-1831 of SEQ
ID NO: 1 (NC_003977.1). In certain embodiments, the RNAi agent targets nucleotides 1579-1597 or 1812-1831 of SEQ ID NO: 1 (NC_003977.1).
In certain embodiments, the antisense strand of the RNAi agent comprises a nucleotide sequence of at least 15 contiguous nucleotides of UGUGAAGCGAAGUGCACACUU (SEQ
ID NO:
25) or AGGUGAAAAAGUUGCAUGGUGUU (SEQ ID NO: 26). In certain embodiments, the antisense strand of the RNAi agent comprises a nucleotide sequence of at least 19 contiguous nucleotides of UGUGAAGCGAAGUGCACACUU (SEQ ID NO: 25) or AGGUGAAAAAGUUGCAUGGUGUU (SEQ ID NO: 26). In certain embodiments, the antisense strand of the RNAi agent comprises a nucleotide sequence of UGUGAAGCGAAGUGCACACUU
(SEQ ID NO: 25) or AGGUGAAAAAGUUGCAUGGUGUU (SEQ ID NO: 26).
In certain embodiments, the sense strand of the RNAi agent comprises a nucleotide sequence of at least 15 contiguous nucleotides of GUGUGCACUUCGCUUCACA (SEQ ID NO: 27) or CACCAUGCAACUUUUUCACCU (SEQ ID NO: 28). In certain embodiments, the sense strand of the RNAi agent comprises a nucleotide sequence of at least 19 contiguous nucleotides of GUGUGCACUUCGCUUCACA (SEQ ID NO: 27) or CACCAUGCAACUUUUUCACCU (SEQ ID
NO: 28). In certain embodiments, the sense strand of the RNAi agent comprises a nucleotide sequence of GUGUGCACUUCGCUUCACA (SEQ ID NO: 27) or CACCAUGCAACUUUUUCACCU (SEQ
ID NO: 28).
In certain embodiments, the antisense strand of the RNAi agent comprises a nucleotide sequence of at least 15 contiguous nucleotides of UGUGAAGCGAAGUGCACACUU (SEQ
ID NO:
25) and the sense strand comprises a nucleotide sequence of at least 15 contiguous nucleotides of GUGUGCACUUCGCUUCACA (SEQ ID NO: 27). In certain embodiments, the antisense strand of the RNAi agent comprises a nucleotide sequence of at least 19 contiguous nucleotides of UGUGAAGCGAAGUGCACACUU (SEQ ID NO: 25) and the sense strand comprises a nucleotide sequence of at least 19 contiguous nucleotides of GUGUGCACUUCGCUUCACA (SEQ ID
NO: 27).
In certain embodiments, the antisense strand of the RNAi agent comprises a nucleotide sequence of
ID NO: 1 (NC_003977.1). In certain embodiments, the RNAi agent targets nucleotides 1579-1597 or 1812-1831 of SEQ ID NO: 1 (NC_003977.1).
In certain embodiments, the antisense strand of the RNAi agent comprises a nucleotide sequence of at least 15 contiguous nucleotides of UGUGAAGCGAAGUGCACACUU (SEQ
ID NO:
25) or AGGUGAAAAAGUUGCAUGGUGUU (SEQ ID NO: 26). In certain embodiments, the antisense strand of the RNAi agent comprises a nucleotide sequence of at least 19 contiguous nucleotides of UGUGAAGCGAAGUGCACACUU (SEQ ID NO: 25) or AGGUGAAAAAGUUGCAUGGUGUU (SEQ ID NO: 26). In certain embodiments, the antisense strand of the RNAi agent comprises a nucleotide sequence of UGUGAAGCGAAGUGCACACUU
(SEQ ID NO: 25) or AGGUGAAAAAGUUGCAUGGUGUU (SEQ ID NO: 26).
In certain embodiments, the sense strand of the RNAi agent comprises a nucleotide sequence of at least 15 contiguous nucleotides of GUGUGCACUUCGCUUCACA (SEQ ID NO: 27) or CACCAUGCAACUUUUUCACCU (SEQ ID NO: 28). In certain embodiments, the sense strand of the RNAi agent comprises a nucleotide sequence of at least 19 contiguous nucleotides of GUGUGCACUUCGCUUCACA (SEQ ID NO: 27) or CACCAUGCAACUUUUUCACCU (SEQ ID
NO: 28). In certain embodiments, the sense strand of the RNAi agent comprises a nucleotide sequence of GUGUGCACUUCGCUUCACA (SEQ ID NO: 27) or CACCAUGCAACUUUUUCACCU (SEQ
ID NO: 28).
In certain embodiments, the antisense strand of the RNAi agent comprises a nucleotide sequence of at least 15 contiguous nucleotides of UGUGAAGCGAAGUGCACACUU (SEQ
ID NO:
25) and the sense strand comprises a nucleotide sequence of at least 15 contiguous nucleotides of GUGUGCACUUCGCUUCACA (SEQ ID NO: 27). In certain embodiments, the antisense strand of the RNAi agent comprises a nucleotide sequence of at least 19 contiguous nucleotides of UGUGAAGCGAAGUGCACACUU (SEQ ID NO: 25) and the sense strand comprises a nucleotide sequence of at least 19 contiguous nucleotides of GUGUGCACUUCGCUUCACA (SEQ ID
NO: 27).
In certain embodiments, the antisense strand of the RNAi agent comprises a nucleotide sequence of
8 UGUGAAGCGAAGUGCACACUU (SEQ ID NO: 25) and the sense strand comprises a nucleotide sequence of GUGUGCACUUCGCUUCACA (SEQ ID NO: 27).
In certain embodiments, the antisense strand of the RNAi agent comprises a nucleotide sequence of at least 15 contiguous nucleotides of AGGUGAAAAAGUUGCAUGGUGUU (SEQ
ID
NO: 26) and the sense strand of the RNAi agent comprises a nucleotide sequence of at least 15 contiguous nucleotides of CACCAUGCAACUUUUUCACCU (SEQ ID NO: 28). In certain embodiments, the antisense strand of the RNAi agent comprises a nucleotide sequence of at least 19 contiguous nucleotides of AGGUGAAAAAGUUGCAUGGUGUU (SEQ ID NO: 26) and the sense strand of the RNAi agent comprises a nucleotide sequence of at least 19 contiguous nucleotides of CACCAUGCAACUUUUUCACCU (SEQ ID NO: 28). In certain embodiments, the antisense strand of the RNAi agent comprises a nucleotide sequence of AGGUGAAAAAGUUGCAUGGUGUU
(SEQ ID NO: 26) and the sense strand of the RNAi agent comprises a nucleotide sequence of CACCAUGCAACUUUUUCACCU (SEQ ID NO: 28).
In certain embodiments of the regimen, substantially all of the nucleotides of said sense strand and substantially all of the nucleotides of said antisense strand are modified nucleotides, wherein said sense strand is conjugated to a ligand attached at the 3'-terminus. In certain embodiments, the ligand is one or more GalNAc derivatives attached through a monovalent linker, bivalent branched linker, or trivalent branched linker. In certain embodiments, the at least one of said modified nucleotides is selected from the group consisting of a deoxy-nucleotide, a 3'-terminal deoxy-thymine (dT) nucleotide, a 2'-0-methyl modified nucleotide, a 2'-fluoro modified nucleotide, a 2'-deoxy-modified nucleotide, a locked nucleotide, an unlocked nucleotide, a conformationally restricted nucleotide, a constrained ethyl nucleotide, an abasic nucleotide, a 2'-amino-modified nucleotide, a 2'-0-allyl-modified nucleotide, 2' -C-alkyl-modified nucleotide, 2' -hydroxly-modified nucleotide, a 2' -methoxyethyl modified nucleotide, a 2'-0-alkyl-modified nucleotide, a morpholino nucleotide, a phosphoramidate, a non-natural base comprising nucleotide, a tetrahydropyran modified nucleotide, a 1,5-anhydrohexitol modified nucleotide, a cyclohexenyl modified nucleotide, a nucleotide comprising a phosphorothioate group, a nucleotide comprising a methylphosphonate group, a nucleotide comprising a 5'-phosphate, and a nucleotide comprising a 5'-phosphate mimic.
In certain embodiments, at least one strand of the RNAi agent comprises a 3' overhang of at least 1 nucleotide. In certain embodiments, at least one strand if the RNAi agent comprises a 3' overhang of at least 2 nucleotides. In certain embodiments, the double-stranded region of the RNAi agent is 15-30 nucleotide pairs in length; 17-23 nucleotide pairs in length;
17-25 nucleotide pairs in length; 23-27 nucleotide pairs in length; 19-21 nucleotide pairs in length; 21-23 nucleotide pairs in length.
In certain embodiments, each strand of the RNAi agent has 15-30 nucleotides.
In certain embodiments, each strand of the RNAi agent has 19-30 nucleotides.
In certain embodiments, the ligand is
In certain embodiments, the antisense strand of the RNAi agent comprises a nucleotide sequence of at least 15 contiguous nucleotides of AGGUGAAAAAGUUGCAUGGUGUU (SEQ
ID
NO: 26) and the sense strand of the RNAi agent comprises a nucleotide sequence of at least 15 contiguous nucleotides of CACCAUGCAACUUUUUCACCU (SEQ ID NO: 28). In certain embodiments, the antisense strand of the RNAi agent comprises a nucleotide sequence of at least 19 contiguous nucleotides of AGGUGAAAAAGUUGCAUGGUGUU (SEQ ID NO: 26) and the sense strand of the RNAi agent comprises a nucleotide sequence of at least 19 contiguous nucleotides of CACCAUGCAACUUUUUCACCU (SEQ ID NO: 28). In certain embodiments, the antisense strand of the RNAi agent comprises a nucleotide sequence of AGGUGAAAAAGUUGCAUGGUGUU
(SEQ ID NO: 26) and the sense strand of the RNAi agent comprises a nucleotide sequence of CACCAUGCAACUUUUUCACCU (SEQ ID NO: 28).
In certain embodiments of the regimen, substantially all of the nucleotides of said sense strand and substantially all of the nucleotides of said antisense strand are modified nucleotides, wherein said sense strand is conjugated to a ligand attached at the 3'-terminus. In certain embodiments, the ligand is one or more GalNAc derivatives attached through a monovalent linker, bivalent branched linker, or trivalent branched linker. In certain embodiments, the at least one of said modified nucleotides is selected from the group consisting of a deoxy-nucleotide, a 3'-terminal deoxy-thymine (dT) nucleotide, a 2'-0-methyl modified nucleotide, a 2'-fluoro modified nucleotide, a 2'-deoxy-modified nucleotide, a locked nucleotide, an unlocked nucleotide, a conformationally restricted nucleotide, a constrained ethyl nucleotide, an abasic nucleotide, a 2'-amino-modified nucleotide, a 2'-0-allyl-modified nucleotide, 2' -C-alkyl-modified nucleotide, 2' -hydroxly-modified nucleotide, a 2' -methoxyethyl modified nucleotide, a 2'-0-alkyl-modified nucleotide, a morpholino nucleotide, a phosphoramidate, a non-natural base comprising nucleotide, a tetrahydropyran modified nucleotide, a 1,5-anhydrohexitol modified nucleotide, a cyclohexenyl modified nucleotide, a nucleotide comprising a phosphorothioate group, a nucleotide comprising a methylphosphonate group, a nucleotide comprising a 5'-phosphate, and a nucleotide comprising a 5'-phosphate mimic.
In certain embodiments, at least one strand of the RNAi agent comprises a 3' overhang of at least 1 nucleotide. In certain embodiments, at least one strand if the RNAi agent comprises a 3' overhang of at least 2 nucleotides. In certain embodiments, the double-stranded region of the RNAi agent is 15-30 nucleotide pairs in length; 17-23 nucleotide pairs in length;
17-25 nucleotide pairs in length; 23-27 nucleotide pairs in length; 19-21 nucleotide pairs in length; 21-23 nucleotide pairs in length.
In certain embodiments, each strand of the RNAi agent has 15-30 nucleotides.
In certain embodiments, each strand of the RNAi agent has 19-30 nucleotides.
In certain embodiments, the ligand is
9 HO 1:DEI
HO Of,-NN 0 AcHN
HO OH
HO
AcHN
O
HO H
HO
AcHN
and the RNAi agent is optionally conjugated to the ligand as shown in the following schematic 3' __________________________________________________ OH
s S.
HO PH
fLO
AcHN 0 Ho OH
(1)- H
N
AcHN 0 0 0' 0 HO PH
O
HO N
AcHN H H
wherein X is 0 or S.
In certain embodiments, the sense strand comprises the nucleotide sequence 5'-gsusguGfcAfCfUfucgcuucaca-3' (SEQ ID NO: 29) and the antisense strand comprises the nucleotide sequence 5'-usGfsugaAfgCfGfaaguGfcAfcacsusu-3' (SEQ ID NO: 30); or the sense strand comprises the nucleotide sequence 5'-csasccauGfcAfAfCfuuuuucaccu-3' (SEQ ID NO: 31) and the antisense strand comprises the nucleotide sequence 5'-asGfsgugAfaAfAfaguuGfcAfuggugsusu-3' (SEQ ID NO: 32), wherein a, c, and u are 2'-0-methyladenosine-3'-phosphate, 2'-0-methylcytidine-3'-phosphate, and 2'-0-methyluridine-3'-phosphate, respectively; as, cs, gs, and us are 2'-0-methyladenosine-3'- phosphorothioate, 2'-0-methylcytidine-3'-phosphorothioate, 2'-0-methylguanosine-3'- phosphorothioate, and 2'-0-methyluridine-3'-phosphorothioate, respectively; Af, Cf, Gf, and Uf are 2'-fluoroadenosine-3'-phosphate, 2'-fluorocytidine-3'-phosphate, 2'-fluoroguanosine-3'-phosphate, and 2'-fluorouridine-3'-phosphate, respectively;
and Gfs is 2'-fluoroguanosine-3'-phosphorothioate. In certain embodiments, the RNAi agent is AD-66810 or AD-66816.
In certain embodiments, the protein-based vaccine comprises epitopes present in at least 4, 5, 6, 7, 8, 9, or 10 genotypes of HBV.
In certain embodiments, the nucleic acid-based vaccine comprises epitopes present in at least 4, 5, 6, 7, 8, 9, or 10 genotypes of HBV.
The present invention further provides uses of the RNAi agents and vaccines provided herein for treatment of subjects having a hepatitis B virus infection based on the methods provided herein.
In certain embodiment, the RNAi agents and the HBV vaccines are used in the manufacture of medicaments for treatment of a subject with an HBV infection.
The present invention further provides kits comprising RNAi agents and vaccines provided herein and instructions providing treatment regimens for their use for treatment of subjects having a hepatitis B virus infection.
The present invention is further illustrated by the following detailed description and drawings.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 schematically depicts the structure of the approximately 3.2 kb double-stranded HBV genome. Replication of the HBV genome occurs through an RNA intermediate and produces 4 overlapping viral transcripts of about 3.5 kb, 2.4 kb, 2.1 kb, and 0.7 kb (termination sites indicated by arrows), and the common 3' end encoding seven viral proteins (pre-S1, pre-S2, S, P, X, pre-C, and C) that are translated across three reading frames.
Figures 2A-2E are graphs showing suppression of HBV by siRNA in a transgenic mouse model. The level of (2A) HBsAg, (2B) HBeAg, and (2C) HBV-DNA in serum of HBV1.3-xfs mice (n = 6 per group) after a single subcutaneous 3 mg/kg or 9 mg/kg dose of a control GalNAc-siRNA
(an siRNA that does not target HBV), AD-66816, or AD-66810. The level of (2D) total HBV RNA
and (2E) 3.5 kb HBV transcripts from liver lysates determined via RT-qPCR and normalized to expression of Glyceraldehyde 3-phosphate dehydrogenase (GAPDH).
Figure 3 is a schematic showing a dosing regimen for an experiment assaying the effect of pretreatment of HBV1.3-xfs mice with the nucleoside inhibitor, Entecavir, an HBV-shRNA, a control GalNAc-siRNA, AD-66816, or AD-66810 prior to administration of a therapeutic vaccine against HBV.
Figures 4A-4C are graphs showing the level of (4A) HBsAg, (4B) HBeAg, and (4C) HBV-DNA in serum of HBV1.3-xfs mice after treatment based on the dosing regimen provided in Figure 3.
Figures 5A-5F are graphs showing T cell immune response in the liver against peptides (5A) HBs(S208), (5B) HBc(C93), and (5C) MVA(B8R) in HBV1.3-xfs mice after treatment based on the dosing regimen provided in Figure 3. Figures 5D-5F show a reanalysis of the same data in Figures 5A-5C performed to accommodate for an insufficient exclusion of dead immune cells and shows T
cell immune response in the liver against peptides (5D) HBs(S208), (5E) HBc(C93), and (5F) MVA(B8R).
Figures 6A-6C show the level of HBV RNA and protein levels in liver cells in HBV1.3-xfs mice after treatment based on the dosing regimen provided in Figure 3. Figure 6A shows total HBV
RNA. Figure 6B shows HBV 3.5 kb transcript relative to GAPDH as determined by RT-qPCR.
Figure 6C shows the number of HBcAg positive cells per mm2 of liver section detected by immunohistochemical staining.
Figure 7 is a schematic showing a dosing regimen for the experiment assaying the effect of pretreatment of HBV1.3-xfs mice with control siRNA or AD-66816 prior to administration of a therapeutic vaccine against HBV.
Figures 8A-8C are graphs showing the level of (8A) HBsAg, (8B) HBeAg, and (8C) HBV-DNA in serum of HBV1.3-xfs mice after treatment based on the dosing regimen provided in Figure 7.
Figures 9A-9D are graphs showing T cell immune response in the liver against peptides (9A) HBs(S208), (9B) HBc(C93), (9C) HBc(Cpool) and (9D) MVA(B8R) in HBV1.3-xfs mice after treatment based on the dosing regimen provided in Figure 7.
Figures 10A-10C show the level of HBV RNA and protein levels in liver cells of HBV1.3-xfs mice after treatment based on the dosing regimen provided in Figure 7. Figure 10A shows total HBV
RNA. Figure 10B shows HBV 3.5 kb transcript relative to GAPDH as determined by RT-qPCR.
Figure 10C shows the number of HBcAg positive cells per mm2 of liver section detected by immunohistochemical staining.
Figures 11A and 11B are graphs showing the level of (11A) HBsAg and (11B) HBeAg in serum of individual HBV1.3-xfs mice at week 7 after the first vaccine dose after the 6 week regimen in the dosing regimen provided in Figure 7.
Figures 11C and 11D are graphs showing (11C) anti-HBs antibody response and (11D) T
cell immune response in the liver against HBs(S208) of individual HBV1.3-xfs mice at week 7 after the first vaccine dose after the 6 week regimen in the dosing regimen provided in Figure 7.
Figure 12 is a schematic showing a dosing regimen for the experiment assaying the effect of pretreatment of mice infected with an AAV vector encoding HBV with control siRNA or AD-66816 prior to administration of a therapeutic vaccine against HBV.
Figures 13A-13G are based on the dosing regimen provided in Figure 12. Figures 13A and 13B are graphs showing the level of (13A) HBsAg and (13B) HBeAg in serum of HBV-AAV mice (inset 13C is an exploded portion of the later time points in graph 13B).
Figure 13D shows the serum HBV DNA level at week 22. Figures 13D and 13E show the number of copies per liver cell of (13D) total HBV DNA and (13E) AAV-DNA at week 22. Figures 13F and 13G show the relative expression in liver of (13F) HBV 3.5 RNA relative to GAPDH RNA and (13G) total HBV RNA
relative to GAPDH RNA.
Figures 14A-14C are graphs showing (14A) anti-HBs antibody response throughout the course of the experiment and (14B) anti-HBe antibody response at day 116 of the experiment based on the dosing regimen provided in Figure 12. Figure 14C is an exploded portion of the later time points in graph 14B.
Figures 15A and 15B show (15A) ALT levels and (15B) body weights of the animals throughout the experiment based on the dosing regimen provided in Figure 12.
A formal sequence listing is provided herewith that forms part of the specification.
An Appendix A providing exemplary target sequences for siRNA targeting and iRNA agents is provided herewith and forms part of the specification.
DETAILED DESCRIPTION OF THE INVENTION
The present invention provides treatment regimens and methods of use of iRNA
agents which effect the RNA-induced silencing complex (RISC)-mediated cleavage of RNA
transcripts of one or more HBV genes (open reading frames/ transcripts) and hepatitis B vaccines to stimulate an immune response against one or more HBV proteins in the treatment of HBV infection.
The treatment regimens and methods preferably provide a functional cure within a defined period of time.
The following detailed description discloses how to make and use compositions containing iRNAs to inhibit the expression of an HBV gene as well as compositions, uses, and methods for treating subjects having diseases and disorders that would benefit from inhibition or reduction of the expression of an HBV gene.
I. Definitions In order that the present invention may be more readily understood, certain terms are first defined. In addition, it should be noted that whenever a value or range of values of a parameter are recited, it is intended that values and ranges intermediate to the recited values are also intended to be part of this invention.
The articles "a" and "an" are used herein to refer to one or to more than one (i.e., to at least one) of the grammatical object of the article. By way of example, "an element"
means one element or more than one element, e.g., a plurality of elements.
The term "including" is used herein to mean, and is used interchangeably with, the phrase "including but not limited to".
The term "or" is used herein to mean, and is used interchangeably with, the term "and/or,"
unless context clearly indicates otherwise.
The term "about" is used herein to mean within the typical ranges of tolerances in the art. For example, "about" can be understood as within 2 standard deviations from the mean. In certain embodiments, "about" means +/-10%. In certain embodiments, "about" means +/-5%. When about is present before a series of numbers or a range, it is understood that "about" can modify each of the numbers in the series or range.
The term "at least" prior to a number or series of numbers is understood to include the number adjacent to the term "at least", and all subsequent numbers or integers that could logically be included, as clear from context. For example, the number of nucleotides in a nucleic acid molecule must be an integer. For example, "at least 18 nucleotides of a 21 nucleotide nucleic acid molecule"
means that 18, 19, 20, or 21 nucleotides have the indicated property. When at least is present before a series of numbers or a range, it is understood that "at least" can modify each of the numbers in the series or range.
As used herein, "no more than" or "less than" is understood as the value adjacent to the phrase and logical lower values or integers, as logical from context, to zero.
For example, a duplex with an overhang of "no more than 2 nucleotides" has a 2, 1, or 0 nucleotide overhang. When "no more than" is present before a series of numbers or a range, it is understood that "no more than" can modify each of the numbers in the series or range. As used herein, ranges include both the upper and lower limit.
In the event of a conflict between a sequence and its indicated site on a transcript or other sequence, the nucleotide sequence recited in the specification takes precedence.
Various embodiments of the invention can be combined as determined appropriate by one of skill in the art.
As used herein, "Hepatitis B virus," used interchangeably with the term "HBV"
refers to the well-known non-cytopathic, liver-tropic DNA virus belonging to the Hepadnaviridae family.
The HBV genome is partially double-stranded, circular DNA with overlapping reading frames (see, e.g., Figure 1).
There are four transcripts (that may be referred to herein as "genes" or "open reading frames") based on size, encoded by the HBV genome. These contain open reading frames called C, X, P, and S. The core protein is coded for by gene C (HBcAg). Hepatitis B e antigen (HBeAg) is produced by proteolytic processing of the pre-core (pre-C) protein. The DNA
polymerase is encoded by gene P. Gene S is the gene that codes for the surface antigens (HBsAg). The HBsAg gene is one long open reading frame which contains three in frame "start" (ATG) codons resulting in polypeptides of three different sizes called large, middle, and small S antigens, pre-S1 +
pre-52 + S, pre-52 + S, or S. Surface antigens in addition to decorating the envelope of HBV, are also part of subviral particles, which are produced at large excess as compared to virion particles, and play a role in immune tolerance and in sequestering anti-HBsAg antibodies, thereby allowing for infectious particles to escape immune detection. The function of the non-structural protein coded for by gene X is not fully understood, but it plays a role in transcriptional transactivation and replication and is associated with the development of liver cancer. Exemplary protein sequences are provided in the attached sequence listing (see, e.g., SEQ ID NOs:1, 3, 16, and 20).
HBV is one of the few DNA viruses that utilize reverse transcriptase in the replication process which involves multiple stages including entry, uncoating, and transport of the virus genome to the nucleus. Initially, replication of the HBV genome involves the generation of an RNA intermediate that is then reverse transcribed to produce the DNA viral genome.
Upon infection of a cell with HBV, the viral genomic relaxed circular DNA
(rcDNA) is transported into the cell nucleus and converted into episomal covalently closed circular DNA
(cccDNA), which serves as the transcription template for the viral mRNAs.
After transcription and nuclear export, cytoplasmic viral pregenomic RNA (pgRNA) is assembled with HBV
polymerase and capsid proteins to form the nucleocapsid, inside which polymerase-catalyzed reverse transcription yields minus-strand DNA, which is subsequently copied into plus-strand DNA to form the progeny rcDNA genome. The mature nucleocapsids are then either packaged with viral envelope proteins to egress as virion particles or shuttled to the nucleus to amplify the cccDNA
reservoir through the intracellular cccDNA amplification pathway. cccDNA is an essential component of the HBV
replication cycle and is responsible for the establishment of infection and viral persistence.
HBV infection results in the production of two different particles: 1) the infectious HBV
virus itself (or Dane particle) which includes a viral capsid assembled from the HBcAg and is covered by an envelope consisting of a lipid membrane with HBV surface antigens, and 2) subviral particles (or SVPs) which contain the small and medium forms of the hepatitis B surface antigen HBsAg which are non-infectious. For each viral particle produced, over 10,000 SVPs are released into the blood. As such, SVPs (and the HBsAg protein they carry) represent the overwhelming majority of viral protein in the blood. HBV infected cells also secrete a soluble proteolytic product of the pre-core protein called the HBV e-antigen (HBeAg).
Eight genotypes of HBV, designated A to H, have been determined, and two additional genotypes I and J have been proposed, each having a distinct geographical distribution. The virus is non-cytopathic, with virus-specific cellular immunity being the main determinant for the outcome of exposure to HBV- acute infection with resolution of liver diseases with 6 months, or chronic HBV
infection that is frequently associated with progressive liver injury.
The term "HBV" includes any of the genotypes of HBV (A to J). The complete coding sequence of the reference sequence of the HBV genome may be found in for example, GenBank Accession Nos. GI:21326584 (SEQ ID NO:1) and GI:3582357 (SEQ ID NO:3).
Antisense sequences are provided in SEQ ID NO: 2 and 4, respectively. Amino acid sequences for the C, X, P, and S
proteins can be found, for example at NCBI Accession numbers YP_009173857.1 (C
protein);
YP_009173867.1 and BAA32912.1 (X protein); YP_009173866.1 and BAA32913.1 (P
protein); and YP_009173869.1, YP_009173870.1, YP_009173871.1, and BAA32914.1 (S protein) (SEQ ID NOs:
5-13) . Protein and DNA sequences from HBV genotype D, strain ayw are provided in SEQ ID NOs.:
14-17. Protein and DNA sequences from HBV genotype A, strain adw are provided in SEQ ID NOs.:
18-21.
Additional examples of HBV mRNA sequences are readily available using publicly available databases, e.g., GenBank, UniProt, and OMIM. The International Repository for Hepatitis B Virus Strain Data can be accessed at http://www.hpa-bioinformatics.org.uk/HepSEQ/main.php.
The term "HBV," as used herein, also refers to naturally occurring DNA
sequence variations of the HBV genome, i.e., genotypes A-J and variants thereof.
As used herein, "epitope" also referred to as "an antigenic determinant," or "determinant," is understood as the part of a protein antigen that is recognized by the immune system, specifically by antibodies, B cells, and/or T cells. Epitopes include conformational epitopes and linear epitopes.
Proteins share an epitope when they share an amino acid sequence of sufficient length or size and antigenicity to be recognized by an antibody, B cell, and/or T cell. T cell epitopes presented by MHC
class I molecules are typically peptides about 8 to 11 amino acids in length, whereas MHC class II
molecules present longer peptides about 13 to 17 amino acids in length.
Conformational epitopes are typically discontinuous and span a longer amino acid sequence.
As used herein, the term "nucelot(s)ide analog" or "reverse transcriptase inhibitor" is an inhibitor of DNA replication that is structurally similar to a nucleotide or nucleoside and specifically inhibits replication of the HBV cccDNA and does not significantly inhibit the replication of the host (e.g., human) DNA. Such inhibitors include Tenofovir disoproxil fumarate (TDF), Tenofovir alafenamide (TAF), Lamivudine, Adefovir dipivoxil, Entecavir (ETV), Telbivudine, AGX-1009, emtricitabine, clevudine, ritonavir, dipivoxil, lobucavir, famvir, FTC, N-Acetyl-Cysteine (NAC), PC1323, theradigm-HBV, thymosin-alpha, ganciclovir, besifovir (ANA-380/LB-80380), and tenofvir-exaliades (TLX/CMX157). In certain embodiments, the nucelot(s)ide analog is Entecavir (ETV).
Nucleot(s)ide analogs are commercially available from a number of sources and are used in the methods provided herein according to their label indication (e.g., typically orally administered at a specific dose) or as determined by a skilled practitioner in the treatment of HBV.
As used herein, "target sequence" refers to a contiguous portion of the nucleotide sequence of an mRNA molecule formed during the transcription of an HBV transcript, including mRNA that is a product of RNA processing of a primary transcription product. In one embodment, the target portion of the sequence will be at least long enough to serve as a substrate for iRNA-directed cleavage at or near that portion of the nucleotide sequence of an mRNA molecule formed during the transcription of an HBV transcript. In one embodiment, the target sequence is within the protein coding region of an HBV transcript.
The target sequence may be from about 9-36 nucleotides in length, e.g., about nucleotides in length. For example, the target sequence can be from about 15-30 nucleotides, 15-29, 15-28, 15-27, 15-26, 15-25, 15-24, 15-23, 15-22, 15-21, 15-20, 15-19, 15-18, 15-17, 18-30, 18-29, 18-28, 18-27, 18-26, 18-25, 18-24, 18-23, 18-22, 18-21, 18-20, 19-30, 19-29, 19-28, 19-27, 19-26, 19-25, 19-24, 19-23, 19-22, 19-21, 19-20, 20-30, 20-29, 20-28, 20-27, 20-26, 20-25, 20-24,20-23, 20-22, 20-21, 21-30, 21-29, 21-28, 21-27, 21-26, 21-25, 21-24, 21-23, or 21-22 nucleotides in length. Ranges and lengths intermediate to the above recited ranges and lengths are also contemplated to be part of the invention.
As used herein, the term "strand comprising a sequence" refers to an oligonucleotide comprising a chain of nucleotides that is described by the sequence referred to using the standard nucleotide nomenclature.
"G," "C," "A," "T," and "U" each generally stand for a nucleotide that contains guanine, cytosine, adenine, thymidine, and uracil as a base, respectively. However, it will be understood that the term "ribonucleotide" or "nucleotide" can also refer to a modified nucleotide, as further detailed below, or a surrogate replacement moiety. The skilled person is well aware that guanine, cytosine, adenine, and uracil can be replaced by other moieties without substantially altering the base pairing properties of an oligonucleotide comprising a nucleotide bearing such replacement moiety. For example, without limitation, a nucleotide comprising inosine as its base can base pair with nucleotides containing adenine, cytosine, or uracil. Hence, nucleotides containing uracil, guanine, or adenine can be replaced in the nucleotide sequences of dsRNA featured in the invention by a nucleotide containing, for example, inosine. In another example, adenine and cytosine anywhere in the oligonucleotide can be replaced with guanine and uracil, respectively to form G-U Wobble base pairing with the target mRNA. Sequences containing such replacement moieties are suitable for the compositions and methods featured in the invention.
As used herein, an "RNAi agent", an "iRNA agent", an "siRNA agent", and the like, is a double stranded RNA that preferably target regions in the HBV genome that are conserved across all serotypes of HBV and are preferably designed to inhibit all steps of the HBV
life cycle, e.g., replication, assembly, secretion of virus, and secretion of viral antigens, by inhibiting expression of more than one HBV transcript. In particular, since transcription of the HBV
genome results in polycistronic, overlapping RNAs, an RNAi agent for use in the invention targeting a single HBV
transcript preferably results in significant inhibition of expression of most or all HBV transcripts. All HBV transcripts are at least partly overlapping and share the same polyadenylation signal. Therefore, all viral transcripts have an identical 3-end and, thus, an RNAi agent of the invention targeting the X
gene will target all viral transcripts and should result in inhibition of not only X gene expression but also the expression of all other viral transcripts, including pregenomic RNA
(pgRNA). Furthermore, the RNAi agents of the invention have been designed to inhibit HBV viral replication by targeting pgRNA, HBV structural genes, polymerase, and the HBV X gene. In addition, they have been designed to mediate the silencing of SVP and other viral protiens that play a role in immune tolerance, thereby permitting a subject's immune system to detect and respond to the presence of viral antigens such that an immune response to control and to clear an HBV infection is mounted. Without intending to be limited by theory, it is believed that a combination or sub-combination of the foregoing properties and the specific target sites and/or the specific modifications in these RNAi agents confer to the RNAi agents of the invention improved efficacy, stability, safety, potency, and durability. Such agents are provided, for example, in PCT Publication Nos. WO
2016/077321, WO
2012/024170, WO 2017/027350, and WO 2013/003520, the entire contents of each of which is incorporated herein by reference. Exemplary target sites for RNAi agents and exemplary RNAi agents are provided in Appendix A, filed herewith, which forms a part of the specification. The term RNAi agents further includes shRNAs, e.g., adeno-associated virus (AAV) 8 vectors for delivery of an shRNA in an artificial mi(cro)RNA under a liver-specific promoter; optionally co-delivered a decoy ("TuD") directed against the shRNA sense strand to curb off-target gene regulation are provided in Michler et al., 2016 (EMBO Mol. Med., 8:1082-1098, incorporated herein by reference).
The majority of nucleotides of each strand of an iRNA agent may be ribonucleotides, but as described in detail herein, each or both strands can also include one or more non-ribonucleotides, e.g., a deoxyribonucleotide and/or a modified nucleotide. In addition, as used in this specification, an "RNAi agent" may include ribonucleotides with chemical modifications; an RNAi agent may include substantial modifications at multiple nucleotides.
As used herein, the term "modified nucleotide" refers to a nucleotide having, independently, a modified sugar moiety, a modified internucleotide linkage, and/or modified nucleobase. Thus, the term modified nucleotide encompasses substitutions, additions or removal of, e.g., a functional group or atom, to internucleoside linkages, sugar moieties, or nucleobases. The modifications suitable for use in the agents of the invention include all types of modifications disclosed herein or known in the art. Any such modifications, as used in a siRNA type molecule, are encompassed by "RNAi agent"
for the purposes of this specification and claims.
As used herein, a "therapeutic HBV vaccine," and the like, can be a peptide vaccine, a DNA
vaccine including a vector-based vaccine, or a cell-based vaccine that induces an immune response, preferably an effector T cell induced response, against one or more HBV
proteins. Preferably the vaccine is a multi-epitope vaccine that is cross-reactive with multiple HBV
serotypes, preferably all HBV serotypes. A number of therapeutic HBV vaccines are known in the art and are at various stages of pre-clinical and clinical development. Protein based vaccines include hepatitis B surface antigen (HBsAg) and core antigen (HBcAg) vaccines (e.g., Li et al., 2015, Vaccine.
33:4247-4254, incorporated herein by reference). Exemplary DNA vaccines include HB-110 (Genexine, Kim et al., 2008. Exp Mol Med. 40: 669-676.), pDPSC18 (PowderMed), INO-1800 (Inovio Pharmaceuticals), HBO2 VAC-AND (ANRS), and CVI-HBV-002 (CHA Vaccine Institute Co., Ltd.).
Exemplary protein based vaccines include Theravax/DV-601 (Dynavax Technologies Corp.), (Chongqing Jiachen Biotechnology Ltd.), and ABX 203 (ABIVAX S.A.). Exemplary cell based vaccines include HPDCs-T immune therapy (Sun Yat-Sen University). Combination vaccines and products are also known and include HepTcellTm (FP-02.2 vaccine (peptide) +
IC310 Adjuvant (a combination peptide-oligonucleotide adjuvant),(see U.S. Patent Publication Nos. 2013/0330382, 2012/0276138, and 2015/0216967, the entire contents of each of which is incorporated herein by reference)); GS-4774 (Gilead, a fusion protein S. core X vaccine + Tarmogen T
cell immune stimulator), pSG2.HBs/MVA.HBs (protein prime/viral vector boost, Oxxon Therapeutics), and a protein-prime/modified vaccinia virus Ankara vector-boost (HBsAg and HBsAg protein + HBcAg and HBsAg in MVA expression vector, Backes et al., 2016, Vaccine. 34:923-32, and W02017121791, both of which are incorporated herein by reference).
As used herein, the term "adjuvant" is understood to be an agent that promotes (e.g., enhances, accelerates, or prolongs) an immune response to an antigen with which it is administered to elicit long-term protective immunity. No substantial immune response is directed at the adjuvant itself. Adjuvants include, but are not limited to, pathogen components, particulate adjuvants, and combination adjuvants (see, e.g., www.niaid.nih.gov/research/vaccine-adjuvants-types). Pathogen components (e.g., monophosphoryl lipid A (MPL), poly(I:C), polyICLC adjuvant, CpG DNA, c-di-AMP, c-di-GMP, c-di-CMP; short, blunt-ended 5'-triphosphate dsRNA (3pRNA) RIG-1 ligand, and emulsions such as poly[di(sodiumcarboxylatoethylphenoxy)phosphazene] (PCEP)) can help trigger early non-specific, or innate, immune responses to vaccines by targeting various receptors inside or on the surface of innate immune cells. The innate immune system influences adaptive immune responses, which provide long-lasting protection against the pathogen that the vaccine targets. Particulate adjuvants (e.g., alum, virosomes, cytokines, e.g., IL-12) form very small particles that can stimulate the immune system and also may enhance delivery of antigen to immune cells.
Combination adjuvants (e.g., AS02, AS03, and AS04 (all GSK); MF59 (Novartis); ISCOMATRIX
(CSL
Limited); and IC31 (Altimmune) elicit multiple protective immune responses.
Adjuvants that have a modest effect when used alone may induce a more potent immune response when used together.
In preferred embodiments of the invention, adjuvants for use in the invention promote a humoral as well as a cellular immune response. For this, a balanced Th1/Th2 helper T cell response is desired to support neutralizing antibody responses as well as effector cytotoxic T cell responses.
Preferably the adjuvant provides a balanced Th1/Th2 response. In certain embodiments, the adjuvant is one or more of a polyI:C adjuvant, a polyICLC adjuvant, a CpG adjuvant, a STING agonist (a c-di-AMP adjuvant, a c-di-GMP adjuvant, or a c-di-CMP adjuvant), an ISCOMATRIX
adjuvant, a PCEP adjuvant, and a Rig-I-ligand adjuvant. In certain embodiments, the adjuvant is a polyI:C
adjuvant, a CpG adjuvant, a STING agonist, or a PCEP adjuvant. In certain embodiments, the adjuvant is not alum.
As used herein, an "immune stimulator" is an agent that stimulates an immune response that may or may not be administered independently of an antigen. Immune stimulators include, but are not limited to, pegylated interferon alfa 2a (PEG-IFN-alpha-2a), interferon alfa-2b, PEG-IFN-alpha-2b, interferon lambda a recombinant human interleukin-7, and a Toll-like receptor 3, 7, 8 or 9 (TLR3, TLR7, TLR8, TLR9) agonist, a viral entry inhibitor (e.g., Myrcludex), an oligonucleotide that inhibits the secretion or release of HBsAg (e.g., REP 9AC), a capsid inhibitor (e.g., Bay41-4109 and NVR-1221), a cccDNA inhibitor (e.g., IHVR-25). In certain embodiments, an immune stimulator can include a viral capsid, optionally an empty viral capsid, e.g., MVA capsid.
Immune stimulators can also include immune checkpoint regulators. Immune checkpoint regulators can be stimulatory or inhibitory. As used herein, immune checkpoint regulators potentiate an immune response. Immune checkpoint regulators include, but are not limited to, CTLA-4 inhibitors, such as ipilimumab, PD-1 inhibitors, such as Nivolumab, Pembrolizumab, and the BGB-A317 antibody. PD-Li inhibitors include atezolizumab, avelumab, and durvalumab, in addition to an affimer biotherapeutic.
As used herein, a "subject" is an animal, such as a mammal, including a primate (such as a human, a non-human primate, e.g., a monkey, and a chimpanzee), a non-primate (e.g., a mouse model or other animal model that can be infected with HBV). In an embodiment, the subject is a human, such as a human being treated or assessed for a disease, disorder, or condition that would benefit from reduction in HBV gene expression or replication. In certain embodiments, the subject has a chronic hepatitis B virus (HBV) infection. In certain embodiments, the subject has both a chronic hepatitis B
virus (HBV) infection and a hepatitis D virus (HDV) infection.
As used herein, the terms "treating" or "treatment" refer to a beneficial or desired result including, but not limited to, alleviation of one or more signs or symptoms in a subject with HBV
infection including, but not limited to, the presence of serum HBV DNA or liver HBV ccc DNA, the presence of serum or liver HBV antigen, e.g., HBsAg or HBeAg. Diagnostic criteria for HBV
infection are well known in the art. "Treatment" can also mean prolonging survival as compared to expected survival in the absence of treatment, or lower risk of HCC
development.
In certain embodiments, an HBV-associated disease is chronic hepatitis B
(CHB). In certain embodiments, subjects have been infected with HBV for at least five years. In certain embodiments, subjects have been infected with HBV for at least ten years. In certain embodiments, subjects became infected with HBV at birth. Subjects having chronic hepatitis B disease are immune tolerant, have an active chronic infection accompanied by necroinflammatory liver disease, have increased hepatocyte turn-over in the absence of detectable necroinflammation, or have an inactive chronic infection without any evidence of active disease, and they are also asymptomatic.
Subjects having chronic hepatitis B disease are HBsAg positive and have either high viremia (>104 HBV-DNA copies / ml blood) or low viremia (<103 HBV-DNA copies / ml blood). Patients with chronic active hepatitis, especially during the high replicative state, may have symptoms similar to those of acute hepatitis.
The persistence of HBV infection in CHB subjects is the result of ccc HBV DNA
persistence. In certain embodiments, a subject having CHB is HBeAg positive. In other embodiments, a subject having CHB is HBeAg negative.
In preferred embodiments, treatment of HBV infection results in a "functional cure" of hepatitis B. As used herein, the term "functional cure" is understood to be clearance of circulating HBsAg and is preferably accompanied by conversion to a status in which HBsAg antibodies become undetectable using a clinically relevant assay. For example, undetectable antibodies can include a signal lower than 10 mIU/m1 as measured by Chemiluminescent Microparticle Immunoassay (CMIA) or any other immunoassay, and may be called anti-HBs seroconversion.
Functional cure does not require clearance of all replicative forms of HBV (e.g., cccDNA from the liver). Anti-HBs seroconversion occurs spontaneously in about 0.2-1% of chronically infected patients per year.
However, even after anti-HBs seroconversion, low level persistence of HBV is observed for decades indicating that a functional rather than a complete cure occurs. Without being bound to mechanism, it is proposed that the immune system is able to keep HBV in check. A functional cure permits discontinuation of any treatment for the HBV infection. However, it is understood that a "functional cure" for HBV infection may not be sufficient to prevent or treat diseases or conditions that result from HBV infection, e.g., liver fibrosis, HCC, cirrhosis.
The term "lower" in the context of the level of HBV gene expression or HBV
replication in a subject, or a disease marker or symptom, refers to a statistically significant decrease in such level.
The decrease can be, for example, at least 70%, 75%, 80%, 85%, 90%, 95%, or more. In monitoring of HBV infection, a 10g10 scale is typically used to describe the level of antigenemia (e.g., HBsAg level in serum) or viremia (HBV DNA level in serum). It is understood that a 1 10g10 decrease is a 90% decrease (10% remaining), a 2 10g10 decrease is a 99% decrease (1%
remaining), etc. In certain embodiments, a disease marker is lowered to below the level of detection.
In certain embodiments, the expression of a disease marker is normalized, i.e., decreased to a level accepted as within the range of normal for an individual without such disorder, e.g., the level of .. a disease marker, such as, ALT or AST, is decreased to a level accepted as within the range of normal for an individual without such disorder. When the disease associated level is elevated from the normal level, the change is calculated from the upper level of normal (ULN).
When the disease associated level is decreased from the normal level, the change is calculated from the lower level of normal (LLN). The lowering is the percent difference in the change between the subject value and the normal value. For example, a normal AST level can be reported as 10 to 40 units per liter. If, prior to treatment, a subject has an AST level of 200 units per liter (i.e., 5 times the ULN, 160 units per liter above the upper level of normal) and, after treatment, the subject has an AST level of 120 units per liter (i.e., 3 times the ULN, 80 units per liter above the upper level of normal), the elevated AST would be lowered towards normal by 50% (80/160).
The term "inhibiting," as used herein, is used interchangeably with "reducing," "silencing,"
"downregulating", "suppressing", and other similar terms, and includes any level of inhibition.
Preferably inhibiting includes a statistically significant or clinically significant inhibition.
The phrase "inhibiting expression of an HBV gene" is intended to refer to knockdown of any HBV transcript (e.g., 3.5 kb, 2.4 kb, 2.1 kb, or 0.7 kb transcript) encoding one or more HBV viral proteins (such as, e.g., preS1/2-S, preS, S, P, X, preC, and C), as well as variants or mutants of an HBV gene.
"Inhibiting expression of an HBV gene" includes any significant level of inhibition of an HBV gene or transcript, e.g., at least partial suppression of the expression of an HBV gene S, P, X, or C, or any combination thereof, e.g., S, P, and C. The expression of the HBV
gene may be assessed based on the level, or the change in the level, of any variable associated with HBV gene expression, e.g., an HBV mRNA level, an HBV protein level, and/or an HBV cccDNA level.
This level may be assessed in an individual cell or in a group of cells, including, for example, a sample derived from a subject, e.g., levels may be monitored in serum.
In some embodiments of the methods of the invention, expression of an HBV gene is inhibited by at least 70%, 75%, 80%, 85%, 90%, 95%, or to below the level of detection of the assay.
In preferred embodiments, the inhibition of expression of an HBV gene results in a clinically relevant inhibition of the level of gene expression, e.g., sufficiently inhibited to permit an effective immune response to a vaccine against an HBV protein.
Inhibition of the expression of an HBV gene may be manifested by a reduction of the amount of RNA expressed by a first cell or group of cells (such cells may be present, for example, in a sample derived from a subject) in which an HBV gene is transcribed and which has or have been treated (e.g., by contacting the cell or cells with an RNAi agent of the invention, or by administering an RNAi agent of the invention to a subject in which the cells are or were present) such that the expression of an HBV gene is inhibited, as compared to a second cell or group of cells substantially identical to the first cell or group of cells but which has not or have not been so treated (control cell(s)). In preferred embodiments, the inhibition is assessed by the rtPCR method provided in Example 2 of PCT
Publication No. WO 2016/077321 (the entire contents of which are incorporated herein by reference), with in vitro assays being performed in an appropriately matched cell line with the duplex at a 10 nM
concentration, and expressing the level of mRNA in treated cells as a percentage of the level of mRNA in control cells, using the following formula:
(RNA in contd. c ¨ (RNA in treated celc) l -RNA in control cells Alternatively, inhibition of the expression of an HBV gene may be assessed in terms of a reduction of a parameter that is functionally linked to HBV gene expression, e.g., as described herein.
HBV gene silencing may be determined in any cell expressing an HBV gene, either constitutively or by genomic engineering, and by any assay known in the art.
Inhibition of the expression of an HBV protein may be manifested by a reduction in the level of an HBV protein that is expressed by a cell or group of cells (e.g., the level of protein expressed in a sample derived from a subject). As explained above, for the assessment of mRNA
suppression, the inhibition of protein expression levels in a treated cell or group of cells may similarly be expressed as a percentage of the level of protein in a control cell or group of cells or in serum.
A control cell or group of cells that may be used to assess the inhibition of the expression of an HBV gene includes a cell or group of cells that has not yet been contacted with an RNAi agent of .. the invention. For example, the control cell or group of cells may be derived from an individual subject (e.g., a human or animal subject) prior to treatment of the subject with an RNAi agent. In alternative embodiments, the level may be compared to an appropriate control sample, e.g., a known population control sample.
The level of HBV RNA that is expressed by a cell or group of cells, or the level of circulating HBV RNA, may be determined using any method known in the art for assessing mRNA expression, preferably using the rtPCR method provided in Example 2 of PCT Publication No.
WO
2016/077321,or Example 1 provided herein. In one embodiment, the level of expression of an HBV
gene (e.g., total HBV RNA, an HBV transcript, e.g., HBV 3.5 kb transcript) in a sample is determined by detecting a transcribed polynucleotide, or portion thereof, e.g., RNA of the HBV gene. RNA may .. be extracted from cells using RNA extraction techniques including, for example, using acid phenol/guanidine isothiocyanate extraction (RNAzol B; Biogenesis), RNeasy RNA
preparation kits (Qiagen0) or PAXgene (PreAnalytix, Switzerland). Typical assay formats utilizing ribonucleic acid hybridization include nuclear run-on assays, RT-PCR, RNase protection assays (Melton et al., Nuc.
Acids Res. 12:7035), northern blotting, in situ hybridization, and microarray analysis. Circulating HBV mRNA may be detected using methods the described in PCT Publication No. WO
2012/177906, the entire contents of which are hereby incorporated herein by reference.
In one embodiment, the level of expression of an HBV gene is determined using a nucleic acid probe. The term "probe", as used herein, refers to any molecule that is capable of selectively binding to a specific HBV gene. Probes can be synthesized by one of skill in the art, or derived from appropriate biological preparations. Probes may be specifically designed to be labeled. Examples of molecules that can be utilized as probes include, but are not limited to, RNA, DNA, proteins, antibodies, and organic molecules.
Isolated RNA can be used in hybridization or amplification assays that include, but are not limited to, Southern or northern analyses, polymerase chain reaction (PCR) analyses, and probe arrays. One method for the determination of mRNA levels involves contacting the isolated mRNA
with a nucleic acid molecule (probe) that can hybridize to an HBV mRNA. In one embodiment, the mRNA is immobilized on a solid surface and contacted with a probe, for example by running the isolated mRNA on an agarose gel and transferring the mRNA from the gel to a membrane, such as nitrocellulose. In an alternative embodiment, the probe(s) are immobilized on a solid surface and the mRNA is contacted with the probe(s), for example, in an Affymetrix gene chip array. A skilled artisan can readily adapt known mRNA detection methods for use in determining the level of an HBV
mRNA.
An alternative method for determining the level of expression of an HBV gene in a sample involves the process of nucleic acid amplification or reverse transcriptase (to prepare cDNA) of, for example mRNA in the sample, e.g., by RT-PCR (the experimental embodiment set forth in Mullis, .. 1987, US Patent No. 4,683,202), ligase chain reaction (Barany (1991) Proc.
Natl. Acad. Sci. USA
88:189-193), self sustained sequence replication (Guatelli et al. (1990) Proc.
Natl. Acad. Sci. USA
87:1874-1878), transcriptional amplification system (Kwoh et al. (1989) Proc.
Natl. Acad. Sci. USA
86:1173-1177), Q-Beta Replicase (Lizardi et al. (1988) Bio/Technology 6:1197), rolling circle replication (Lizardi et al., US Patent No. 5,854,033) or any other nucleic acid amplification method, followed by the detection of the amplified molecules using techniques well known to those of skill in the art. These detection schemes are especially useful for the detection of nucleic acid molecules if such molecules are present in very low numbers. In particular aspects of the invention, the level of expression of an HBV gene is determined by quantitative fluorogenic RT-PCR
(i.e., the TaqManTm System), e.g., using the method provided herein.
The expression levels of an HBV RNA may be monitored using a membrane blot (such as used in hybridization analysis such as northern, Southern, dot, and the like), or microwells, sample tubes, gels, beads, or fibers (or any solid support comprising bound nucleic acids). See U.S. Patent Nos. 5,770,722, 5,874,219, 5,744,305, 5,677,195, and 5,445,934, the entire contents of each of which are incorporated herein by reference. The determination of HBV expression level may also comprise using nucleic acid probes in solution.
In preferred embodiments, the level of RNA expression is assessed using real time PCR
(qPCR). The use of these methods is described and exemplified in the Examples presented herein.
The level of HBV protein expression may be determined using any method known in the art for the measurement of protein levels. Such methods include, for example, electrophoresis, capillary electrophoresis, high performance liquid chromatography (HPLC), thin layer chromatography (TLC), hyperdiffusion chromatography, fluid or gel precipiting reactions, absorption spectroscopy, a colorimetric assays, spectrophotometric assays, flow cytometry, immunodiffusion (single or double), immunoelectrophoresis, western blotting, radioimmunoassay (RIA), enzyme-linked immunosorbent assays (ELISAs), immunofluorescent assays, electrochemiluminescence assays, and the like.
In some embodiments, the efficacy of the methods of the invention can be monitored by detecting or monitoring a reduction in a symptom of an HBV infection. Symptoms may be assessed using any method known in the art.
As used herein, the term "Hepatitis B virus-associated disease" or "HBV-associated disease,"
is a disease or disorder that is caused by, or associated with HBV infection or replication. The term "HBV-associated disease" includes a disease, disorder, or condition that would benefit from reduction in HBV gene expression or replication. Non-limiting examples of HBV-associated diseases include, for example, hepatitis D virus infection,; hepatitis delta; chronic hepatitis B; liver fibrosis; end-stage liver disease; cryoglobulinemia; hepatocellular carcinoma.
The term "sample," as used herein, includes a collection of similar fluids, cells, or tissues isolated from a subject or prepared therefrom, as well as fluids, cells, or tissues present within a subject. Examples of biological fluids include blood, serum, plasma, immune cells, lymph, urine, saliva, and the like. Tissue samples may include samples from tissues, organs, or localized regions.
For example, samples may be derived from particular organs, parts of organs, or fluids or cells within those organs. In certain embodiments, samples may be derived from the liver (e.g., whole liver or certain segments of liver or certain types of cells in the liver, such as, e.g., hepatocytes, resident liver immune cells). In preferred embodiments, a "sample derived from a subject"
refers to blood drawn from the subject or plasma, serum, or selected cell pools derived therefrom (e.g., populations of immune cells). In further embodiments, a "sample derived from a subject"
refers to liver tissue (or subcomponents thereof) obtained from the subject.
As used herein, "coding sequence" is understood to refer to a DNA sequence that encodes for a specific amino acid sequence. In certain embodiments, the DNA sequence can be reverse transcribed from an RNA sequence. In certain embodiments, an iRNA, e.g., an shRNA, targets a coding sequence.
The terms, "suitable regulatory sequences," and the like, are used herein is to refer to nucleotide sequences located upstream (5' non-coding sequences), within, or downstream (3' non-coding sequences) of a coding sequence, and which influence the transcription, RNA processing or stability, or translation of the associated coding sequence. Regulatory sequences may include promoters, translation leader sequences, introns, and polyadenylation recognition sequences.
"Promoter" as used herein refers to a DNA sequence capable of controlling the expression of a coding sequence or functional RNA. In general, a coding sequence is located 3' to a promoter sequence. Promoters may be derived in their entirety from a native gene, or be composed of different elements derived from different promoters found in nature, or even comprise synthetic DNA
segments. A promoter may be selected to promote expression of a coding sequence in a particular cell type or at different stages of development, or in response to different environmental conditions. In certain embodiments, the promoter is a promoter that is active in liver, e.g., a liver-specific promoter.
Many promoter sequences are known in the art and selection of an appropriate promoter sequence for a specific context is within the ability of those of skill in the art.
The term "operably linked" refers to the association of nucleic acid sequences on a single nucleic acid fragment so that the function of one is affected by the other.
For example, a promoter is operably linked with a coding sequence when it is capable of affecting the expression of that coding sequence (i.e., the coding sequence is under the transcriptional control of the promoter).
The term "expression" as used herein refers to the transcription and stable accumulation of sense (mRNA) or antisense RNA, or an RNAi agent (e.g., an shRNA) derived from the nucleic acid fragment of the subject technology. "Over-expression" refers to the production of a gene product in transgenic or recombinant organisms that exceeds levels of production in normal or non-transformed organisms.
"Expression vector" or "expression construct," as used herein, refers to a nucleic acid in which a coding sequence is operably linked to a promoter sequence to permit expression of the coding sequence under the control of the promoter. Expression vectors include, but are not limited to, viral vectors or plasmid vectors. Methods for delivery of expression vectors into cells are known in the art.
Treatment Methods of the Invention The present invention provides treatment regimens and methods for the sequential use of an agent to reduce the expression of an HBV gene, e.g., iRNA agents which effect the RNA-induced silencing complex (RISC)-mediated cleavage of one or more HBV transcripts, and hepatitis B
vaccines to stimulate an immune response against one or more HBV proteins in the treatment of HBV
infection. The treatment regimens and methods preferably provide a functional cure of HBV within a defined period of time.
The treatment regimens and methods provided herein include the ordered administration of therapeutic agents to provide treatment, and preferably a functional cure, for HBV infection. The agents used in the methods are known in the art. However, the agents alone fail to consistently and durably decrease HBV disease burden, e.g., reducing HBsAg levels to below 2 10g10, preferably 1 log10 IU/ml or to below the level of detection, in most subjects.
Significantly reducing HBV disease burden, e.g., reducing HBsAg levels to below 2 10g10, preferably 1 10g10 IU/ml or to below the level of detection, will provide the opportunity of discontinuation of administration of therapeutic agents and provide a functional cure for HBV in a substantial number of subjects.
Without being bound by mechanism, it is proposed that the treatment regimens and methods provided herein, including administration of an iRNA agent targeted to HBV, substantially reduces HBV
antigens and nucleic acid for a sufficient magnitude and duration in a subject to allow an effective immune response induced by administration of multiple doses of a therapeutic vaccine. The regimens and methods, provided herein, consistently provide a substantial reduction of disease burden and a functional cure in a significant number of subjects, preferably at least 30%, 40%, 50%, 60%, or 70% of subjects.
A transgenic mouse model of HBV infection, HBV1.3 xfs was used to assess the combination therapy provided herein. Primary studies demonstrated the efficacy of two different chemically modified GalNAc- iRNA agents targeted to HBV (AD-66816 and AD-66810) to inhibit the level of HBsAg and HBeAg proteins, and HBV DNA in serum for at least 21 days with a single subcutaneous dose at 3 mg/kg or 9 mg/kg, with similar efficacy. No significant knockdown was observed with a non-HBV iRNA control (see Figure 2). Based on this result, the lower dose of 3 mg/kg was selected for combination therapy studies.
In the first combination therapy trial (see Figure 3), mice were pretreated with one of six treatment regimens (n= 6 per group):
(1) No pretreatment;
(2) Entecavir at 1 ig/m1 in water throughout the course of the study beginning on the first day of Week 0;
(3) A 3 mg/kg dose on the first day of Weeks 0, 4, 8, and 12 of the control iRNA agent.
(4) A single dose on the first day of Week 0 with an expression vector encoding an shRNA
targeted to HBV (HBV-shRNA) (Michler et al., 2016); or (5-6) A 3 mg/kg dose on the first day of Weeks 0, 4, 8, and 12 of AD-66816 or (generically, HBV-siRNA).
On the first day of Weeks 12 and 14, a mixture of recombinantly expressed yeast HBsAg (15 rig) and E. coli expressed HBcAg (15 rig) adjuvanted with 31.9 lig synthetic phosphorothioated CpGODN 1668 (CpG) and 25 lig polykli(sodiumcarboxylatoethyl-phenoxy)phosphazene] (PCEP) was subcutaneously administered to all mice as a protein prime vaccination (Backes, 2016).
On the first day of week 16, a mixture of modified vaccinia virus Ankara expressing HBsAg or HBcAg (5 x 107 particles of each virus) was subcutaneously administered to all mice as a boost vaccination (Backes, 2016).
Blood samples were obtained on the first days of Week 0, 2, 4, 8, 12, 16, and 17 and were assayed for levels of HBsAg, HBeAg, and HBV DNA. Results observed for HBsAg and HBeAg levels mice in groups 1, 2, and 3 (mock, Entecavir, control iRNA agent) were similar (Figure 4A and 4B). The HBV-shRNA or HBV-siRNAs alone caused a significant decrease in HBsAg, HBeAg, and HBV DNA in serum. The three dose prime-boost vaccination scheme resulted in a further decrease in HBsAg in all groups, and reduced the level of HBsAg in at least some animals in the HBV-shRNA
and HBV-siRNA groups to below the level of detection. However, vaccine treatment did not decrease HBeAg levels in any of the groups. HBV DNA levels were decreased to about the lower limit of quantitation with Entecavir alone so no effect of the three dose prime-boost vaccine could be detected (Figure 4C). Mock treatment and treatment with the HBV-shRNA, the HBV-siRNAs, and control siRNA all decreased HBV DNA levels, and the level of HBV-DNA was further decreased by the prime-boost vaccine in all groups. These data demonstrate that RNAi is superior to nucleot(s)ide analog therapy in reducing viral antigens. Also, the combination of RNAi and subsequent vaccination have a greater effect on HBsAg and HBV DNA levels than either agent alone.
On the final day of the experiment (the first day of week 17), mice were sacrificed and their livers were harvested. Intrahepatic CD8+ T cell responses were assessed for response to HBsAg, HBcAg, and the MVA virus particle using the method provided in Backes, 2016.
Mice treated with the HBV-shRNA or the HBV-siRNAs were able to generate a CD8+ immune response against the HBsAg and HBcAg (Figure 5A and 5B). No significant immune response against the HBV antigens was observed in the mock, Entecavir, or control siRNA groups. However, a similar immune response against the MVA virus was observed in all animals independent of pretreatment or viral antigen levels (Figure 5C) showing that vaccination had worked equally well in all animals, demonstrating the presence of a competent immune system. The data shown in Figure 5A-C were reanalyzed to accomodated for an insufficient exclusion of dead immune cells during the first analysis. The data obtained from the second analysis (shown in Figure 5 D-F) again shows that only the mice pretreated with the HBV-shRNA or the HBV-siRNAs were able to generate HBV-specific CD8+ T
cell responses after therapeutic vaccination, but that MVA-specific responses were not influenced by the pretreatment. The reduced variances in the second analysis are attributed to the more rigorous exclussion of dead cells. These data demonstrate that RNAi treatment, in contrast to the current standard of care treatment with a nucleoside analog, can restore HBV-specific T cell immunity and enable the induction of HBV-specific CD8 T cell responses after therapeutic vaccination.
Serum was also assessed for antibody immune response to HBV antigens. Although the vaccine was able to induce a T-cell immune response only in animals which had received HBV-siRNA or HBV-shRNA pretreatment, antibody responses against HBsAg and HBcAg were similar across all groups regardless of pretreatment at the time points evaluated until week 17. No HBeAg antibody responses could be detected. These data demonstrate that high HBV
antigen loads preferentially inhibit HBV-specific T cell, not B cell responses.
Livers were also assessed for the presence of HBV transcripts by RT-qPCR and normalized to the liver GAPDH transcript. Mice treated with the HBV-shRNA or the HBV-siRNAs demonstrated a significant decrease in HBV transcript levels (Figure 6A and 6B). No significant difference was observed between the mock and Entecavir or control siRNA groups. Liver sections were analysed by immunohistochemical stainings for expression of core antigen to assess the antiviral effect in the liver (Figure 6C). In animals that were not pretreated before vaccination, there were, on average, 83 hepatocytes per mm2 with cytoplasmic expression of HBc. This number was not significantly changed in animals that were pretreated with Entecavir or the control siRNA. However, the number of cytoplamic HBcAg positive cells was significantly reduced in AAV-shRNA or HBV
siRNA
pretreated animals. These data demonstrate that a combinatorial RNAi/vaccination therapy suppresses not only antigens in the serum, but also viral antigen expression in the liver.
Having demonstrated that suppression of expression of HBV antigens using shRNA
or siRNA is effective at potentiating an immune response to an HBV vaccine regimen, a study was designed to determine if the duration of HBV antigen suppression had an effect on the potentiation an HBV immune response. Using the HBV 1.3xfs mouse model, mice were treated for eight, six, or three weeks with HBV-siRNA AD-66816, or the control siRNA for 8 weeks, subcutaneously administered at 3 mg/kg/dose, followed by administration of the prime-boost vaccine regimen as set forth above, except 10 lig c-di-AMP was used as an adjuvant rather than PCEP +
CPG (n= 6 per 8 and 3 group, n = 6 for 6 week group) (see Figure 7).
A significant decrease in the levels of each of HBsAg, HBeAg, and HBV DNA was observed after the first administration of AD-66816 (Figures 8A-8C). A further significant decrease in HBsAg was observed after treatment with the vaccine boost with the greatest decrease observed in the 8 week pretreatment group to below the level of detection of the assay, representing a greater than 5 log10 decrease in HBsAg level in all treated animals. Immunization caused only slight further reductions (<0.5 10g10) of HBV DNA and no further reduction in HBeAg levels. These data demonstrate that efficacy of therapeutic vaccination correlates with duration of antigen suppression before start of vaccination. Reconstitution of HBV-specific CD8 T cell responses takes several weeks, with a 6 or preferably 8 week pretreatment resulting in more HBsAg knockdown than a 3 week pretreatment.
Similarly, T-cell responses against HBsAg and HBcAg in liver corresponded with the duration of HBV antigen knockdown, with longer duration of HBV antigen suppression resulting in greater T-cell responses (Figure 9A-9C). Similar responses to MVA virus antigens were observed across all groups independent of pretreatment (Figure 9D). Antibody responses were similar across all groups.
Livers were also assessed for the presence of HBV transcripts by RT-qPCR and normalized to the liver GAPDH transcript. Longer pretreatment durations trended to higher levels of HBV RNA
knockdown (Figure 10A and 10B).
Liver sections were also analysed by immunohistochemical staining for cytoplasmic expression of HBcAg to assess the antiviral effect of the treatment in the liver (Figure 10C). In animals pretreated with the control siRNA before vaccination, there were, on average, 172 hepatocytes per mm2which showed cytoplasmic expression of HBc. With longer duration of HBV
suppression before vaccination, there was a gradual decrease of cytoplasmic HBcAg positive hepatocytes with an average of only 12 cytoplasmic HBcAg positive hepatocytes per mm2in the 8 week pretreatment group. These data demonstrate that the increasing HBV-specific CD8+ T cell response observed with longer antigen suppression before vaccination led to decreased HBV antigen expression in the liver. To assess the durability of response, blood samples were collected from mice (n = 6) pretreated with the AD-66816 HBV-siRNA for six weeks at 2 and 3 weeks after administration of the boost vaccination. In three of the six mice, HBsAg levels continued to dropped to below the level of detection of the assay (Figure 11A and 11B).
Specifically, the three animals which had the highest HBsAg and HBeAg levels at start of vaccination (2, 4, and 5) did show a decline of antigen titers after vaccination, but rebounded with antigen titers towards the end of the experiment. In contrast, the three animals with the lowest antigen titers at start of vaccination (1, 3, and 6) showed a further decline of HBsAg to below the detection limit. These data demonstrate that a functional cure is possible using the treatment regimens provided herein.
These data also suggest that the antigen levels at start of vaccination can affect the response to therapeutic vaccination. Finally, without being bound by mechanism, these data suggest that the decline of antigen levels after therapeutic vaccination is mediated, at least in part, by CD8+ T cells. These data demonstrate that knockdown of circulating HBV antigens (e.g., HBsAg, HBcAg), but not inhibition of HBV DNA
replication alone, potentiates immune response to HBV therapeutic vaccine, e.g., a prime boost therapeutic vaccination regimen. That is, an immune response can be potentiated by pretreatment with an siRNA, but not with nucleot(s)ide inhibitors alone as the immune response is a CD8+ T-cell based immune response.
The magnitude and duration of knockdown required depends on, for example, the level of disease burden in the subject. The higher the level of circulating antigen, the greater the magnitude and duration of HBV antigen knockdown required to potentiate an immune response. Knockdown of HBsAg in serum should be at least 0.5 log 10 (IU/ml), preferably llog 10 (IU/ml), 1.5 log 10 (IU/ml), 2 log 10 (IU/ml), or more from the level in the subject prior to treatment with the therapeutic vaccine.
In certain embodiments, the level of serum HBsAg is no more than 2.5 log 10 (IU/ml), 2 log 10 (IU/ml), 1.5 log 10 (IU/ml) prior to vaccine administration.
Further, as demonstrated herein, a longer duration of HBV antigen knockdown trended towards a more robust immune response. Therefore, knockdown of serum HBsAg to a sufficiently low level for a duration of at least four weeks, six weeks, or eight weeks is preferred prior to administration of the vaccine.
A second series of experiments were designed to study the combination siRNA/vaccination treatment regimen in a mouse model of aquired HBV infection using an adeno-associated virus infection system. For these studies, wildtype C57/B16 mice (9 weeks of age) were injected i.v. with 2x101 genome equivalents of Adeno-Associated-Virus Serotype 8 (AAV8) carrying a 1.2-fold overlength HBV genome of genotype D (AAV-HBV1.2) (see, e.g., Yang, et al.
(2014) Cell and Mol Immunol 11:71). Starting 4 weeks after AAV-transduction (on day -28), animals were treated with three doses of either a control siRNA, or HBV siRNA (HBV AD-66816 or AD-66810) on days 0, 29, and 57, and subsequently half of the animals in each group were treated with a vaccine regimen consisting of prime protein vaccination with HBsAg, HbcAg, and 10 tig c-di-AMP
at days 57 and 70, and boosted with MVA-HBs and MVA-HBc at day 84. The treatment regimen is shown in Figure 12.
Following AAV-HBV1.2 transduction, HBsAg and HBeAg values rose to levels comparable to the levels seen in HBV transgenic mice (HBVxfs) (see, e.g., Figures 13A and 13B). Mice treated with the HBV siRNAs showed mean reductions of HBsAg levels of about 2 logio scales and of HBeAg levels greater than 1 logio scale such that HBsAg and HBeAg levels dropped to less than about 500 IU/per ml, whereas the control siRNA had no effect on antigen levels. Animals treated with one of the HBV siRNAs that did not receive the vaccine regimen showed slowly rebounding antigen levels after the last application of the siRNA. Antigenemia returned to baseline levels after 18 weeks.
The combination treatment with the HBV-siRNA and vaccine regimen resulted in a durable response with a decrease in HBsAg and HBeAg to below the limit of detection through the duration of the experiment. A decrease in HBsAg and HBeAg levels was observed prior to the administration of the MVA boost, suggesting that the protein vaccination may be sufficient to affect a cure. Both serum and liver HBV DNA and RNA were significantly decreased after combination treatment with the HBV-siRNA and vaccine regimen (Figures 13D-13H). This demonstrates, that RNAi-mediated suppression can strongly reduce antigen expression, but that treatment with the vaccine regimen extends the durability of response.
The vaccine regimen alone in animals that received the control siRNA produced a transient decline of antigen levels which rebounded towards the end of the experiment.
In contrast, all animals that received an HBV-siRNA and vaccination, HBsAg and HBeAg levels decreaased to below the detection limit after start of vaccination. Antigen levels remained largely undetectable at all through the last time point measured at least 22 weeks after the last siRNA
application (Figures 13A and 13B).
The durable loss of antigenemia in HBV siRNA pretreated animals, in contrast to the antigen rebound in control siRNA pretreated animals, further demonstrates that immune control was only achieved in animals which had lowered antigen titers before vaccination.
Coinciding with the loss of antigenemia, animals treated with HBV siRNA plus the vaccine regimen developed high titers of anti-HBs antibodies and resulted in anti-HBs and anti-HBe seroconversion in all vaccinated animals (Figure 14). siRNA-pretreated animals developed 10-fold higher and more constant anti-HBs titers and were able to completely and persistently clear serum HBsAg and HBeAg. Interestingly, 3/12 mice vaccinated after HBV siRNA treatment showed a transient drop in anti-HBe levels between week 15 and 22 resulting in a low-level relapse of HBeAg (Figure 13C) that was again controlled. Although anti-HBs antibodies could also be measured in animals that received the control siRNA plus the vaccine regimen, the levels were lower. Further, only animals that received HBV siRNA plus the vaccine regimen developed anti-HBe antibodies.
Taken together, functional cure was not achieved by the siRNA treatement regimen or the therapeutic vaccination regimen alone. However, the loss of antigenemia, as well as development of anti-HBs and anti-HBe antibodies, demonstrates that the combination HBV siRNA plus vaccine regimen can achieve a functional cure.
Throughout the experiment, ALT and body weight of the animals were monitored.
The loss of antigenemia concided with slight increases of ALT activity seen in treatment groups which had received HBV siRNA in conjunction with the vaccination regimen (Figure 15A).
These groups showed significant but mild increases (both p>0.05 or smaller by repeated measure two-way ANOVA; only comparing time points after start of vaccination) as compared to all other treatment groups that did not receive the combination HBVsiRNA-vaccine regimen. Without being bound by mechanism, it is suggested that the CD8+ T cells induced by the combinatorial HBV siRNA-vaccine regimen killed HBV-expressing hepatocytes resulting in elevated ALT.
The body weight of the animals was measured throughout the experiment to assess tolerability of the treatments. There was steady increases throughout the experiment independent of siRNA treatment. Animals that were vaccinated showed a slight and transient decrease (approximately 5%) of body weight after vaccination, but rebounded to normal levels within nine days, and subsequently gained weight comparable to the control groups (Figure 15B). Taken together, both, ALT activity and body weight data demonstrate that all examined treatments, including siRNA
only, vaccine only, as well as the combinatorial siRNA/vaccine regimen are well tolerated.
The number and timing of doses of siRNA to knockdown HBsAg level in serum depends, for example, on the specific agent used. Due to the duration and potency of the exemplary GalNAc siRNAs used in the methods herein and provided, for example, in Appendix A and in PCT Publication No. WO 2016/077321 (the entire contents of which are incorporated herein by reference), a single dose of siRNA may be sufficient to provide the level and duration of knockdown required prior to administration of the therapeutic vaccine. As shown in Figure 4, a single dose of an AAV vector encoded shRNA was sufficient to provide durable knockdown of HBV antigens and HBV DNA.
Those of skill in the art are able to monitor HBV disease status, e.g., by measuring HBsAg levels in blood, to determine the timing and level of siRNA and vaccine administration appropriate for a specific subject.
A number of therapeutic HBV vaccines are known in the art and discussed herein. In preferred embodiments, a prime-boost vaccination protocol, such as the protocol that is used herein, is preferred. However, the HBV antigen knockdown method provided herein can be used in combination with other therapeutic HBV vaccines known in the art, including those found to be insufficient when administered alone. Vaccinations include at least two doses of an antigen in protein or nucleic acid form. In certain embodiments, the vaccination includes three doses of a protein-based vaccine. In preferred embodiments, the methods include heterologous vaccine administration, i.e., at least one protein-based vaccine dose and at least one nucleic-acid based vaccine dose.
Exemplary embodiments of vaccines and dosing regimens are provided, for example, in PCT
Publication No.
WO 2017/121791, the entire contents of which are incorporated herein by reference.
The methods provided herein include the use of a nucleic acid-based vaccine comprising an expression vector construct encoding an HBcAg or an HBsAg, wherein the construct encodes a protein that shares an epitope with the protein-based vaccine. Therefore, it is clearly understood that neither the nucleic acid-based vaccine nor the protein-based vaccine are required to provide the full length protein. The nucleic acid-based vaccine and the protein-based vaccine are required to provide at least one shared epitope that is present in HBcAg or HBsAg, and does not require that the full length protein be provided. As noted above, epitopes may be relatively short, MHC class I molecules that are typically peptides about 8 to 11 amino acids in length, whereas MHC
class II molecules present longer peptides about 13 to 17 amino acids in length, with conformational epitopes being longer. However, it is understood that the use of protein antigens and coding sequences for protein antigens that encode multiple epitopes is preferred. Further, it is understood that the antigens present in the protein-based vaccine and encoded by the nucleic-acid based vaccine may or may not be identical. It is also obvious that antigens should also be selected for their immunogenicity. Such antigens are well known in the art.
In certain embodiments, the order of administration of the protein-based vaccine and the nucleic acid-based vaccine are reversed as compared to the order exemplified in the methods provided herein. That is, the nucleic acid-based vaccine is administered first and the protein-based vaccine is administered second. In certain embodiments, a total of three doses of vaccine are administered, two doses of the nucleic acid-based vaccine followed by a single dose of the protein-based vaccine. In alternative embodiments, a single dose of the nucleic acid-based vaccine is followed by two doses of a protein based vaccine. In other embodiments, one dose of each vaccine is administered.
In preferred embodiments, the prime-boost vaccination method includes the use of an adjuvant with protein antigens. Appropriate adjuvants for use in the methods promote a cell-based response to the antigens. Adjuvants preferably provide a balanced Th1/Th2 response.
The siRNA + vaccine methods provided herein can be used in combination with administration of nucleot(s)ide inhibitors which are the standard of care for treatment of HBV. In certain embodiments, subjects are treated with nucleot(s)ide inhibitors prior to treatment with the siRNA + vaccine treatment regimen. In certain embodiments, subjects are treated throughout the siRNA + vaccine treatment regimen with nucleot(s)ide inhibitors. In certain embodiments, the nucleot(s)ide inhibitor is dosed to reduce pre-existing inflammation associated with HBV infection prior to administration of the nucleic acid therapeutic targeted to HBV (e.g., siRNA, shRNA, antisense oligonucleotide).
In certain embodiments, subjects may be pretreated, or concurrently treated, with other agents used for the treatment of HBV. Such agents include, but are not limited to an immune stimulator (e.g., pegylated interferon alfa 2a (PEG-IFN-a2a), Interferon alfa-2b, a recombinant human interleukin-7, and aToll-like receptor 7 (TLR7) agonist), a viral entry inhibitor (e.g., Myrcludex), an oligonucleotide that inhibits the secretion or release of HbsAg (e.g., REP
9AC), a capsid inhibitor (e.g., Bay41-4109 and NVR-1221), a cccDNA inhibitor (e.g., IHVR-25), a Rig-I
ligand, or an immune checkpoint regulator. In certain embodiments, the immune stimulator is a Rig-I ligand or an immune checkpoint regulator. A functional cure includes a sustained period of at least 3 months, preferably 6 months of HBsAg below 50 IU/ml, or a detectable antibody response to HBsAg. In preferred embodiments, a functional cure includes both a sustained period of at least 3 months, preferably 6 months of HBsAg below 50 IU/ml and a detectable antibody response to HBsAg.
A. RNAi Agents For Use in the Methods of the Invention The present invention includes the use of iRNAs, which inhibit the expression of at least one HBV transcript, and preferably three or four HBV transcripts (open reading frames, sometimes referred to herein as genes). Due to the highly condensed structure of the HBV
genome, it is possible to design single iRNAs that will inhibit the expression of three or four HBV
transcripts (see Figure 1).
For the sake of simplicity, the text herein refers to "an HBV transcript" or "the HBV transcript." It is understood that preferred embodiments include inhibition of more than one HBV
transcript (or open .. reading frame), preferably at least three HBV transcripts (or open reading frames). Further, it is understood that there are eight HBV genotypes, and two proposed additional genotypes, that may further include mutations from published sequences. Therefore, certain iRNA
agents may inhibit different numbers of genes based on the specific genotype and subject infected with HBV.
In some embodiments, the iRNA agent includes double stranded ribonucleic acid (dsRNA) molecules for inhibiting the expression or decreasing the level of an HBV
transcript in a cell in a subject with an HBV infection. The dsRNA includes an antisense strand having a region of complementarity, which is complementary to at least a part of an mRNA formed in the expression of an HBV transcript. The region of complementarity is about 30 nucleotides or less in length (e.g., about 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, or 18 nucleotides or less in length). Upon contact with a cell expressing the HBV gene, the iRNA selectively inhibits the expression of at least one, preferably three or four HBV genes. In preferred embodiments, inhibition of expression is determined by the qPCR method in an appropriate cell line as provided in the examples. For in vitro assessment of activity, percent inhibition is determined using the methods provided in Example 2 of PCT Publication No.WO 2016/077321 at a single dose at a 10 nM duplex final concentration. For in vivo studies, the level after treatment can be compared to, for example, an appropriate historical control or a pooled population sample control to determine the level of reduction, e.g., when a baseline value is not available for the subject. An appropriate control must be carefully selected by one of skill in the art.
A dsRNA includes two RNA strands that are complementary and hybridize to form a duplex structure under conditions in which the dsRNA will be used. One strand of a dsRNA (the antisense strand) includes a region of complementarity that is substantially complementary, and generally fully complementary, to a target sequence. The target sequence can be derived from the sequence of an mRNA formed during the expression of an HBV gene. As multiple HBV genotypes are known, iRNA agents are preferably designed to inhibit expression of HBV genes across as many genotypes as possible. It is understood that an siRNA that is perfectly complementary to one or more HBV
genotypes will not be perfectly complementary to all genotypes. The other strand (the sense strand) includes a region that is complementary to the antisense strand, such that the two strands hybridize and form a duplex structure when combined under suitable conditions. As described elsewhere herein and as known in the art, the complementary sequences of a dsRNA can also be contained as self-.. complementary regions of a single nucleic acid molecule, as opposed to being on separate oligonucleotides.
Generally, the duplex structure is 15 and 30 base pairs in length, e.g., 15-29, 15-28, 15-27, 15-26, 15-25, 15-24, 15-23, 15-22, 15-21, 15-20, 15-19, 15-18, 15-17, 18-30, 18-29, 18-28, 18-27, 18-26, 18-25, 18-24, 18-23, 18-22, 18-21, 18-20, 19-30, 19-29, 19-28, 19-27, 19-26, 19-25, 19-24, 19-23, 19-22, 19-21, 19-20, 20-30, 20-29, 20-28, 20-27, 20-26, 20-25, 20-24, 20-23, 20-22, 20-21, 21-30, 21-29, 21-28, 21-27, 21-26, 21-25, 21-24, 21-23, or 21-22 base pairs in length.
Ranges and lengths intermediate to the above recited ranges and lengths are also contemplated to be part of the invention.
Similarly, the region of complementarity to the target sequence is 15 and 30 nucleotides in length, e.g., 15-29, 15-28, 15-27, 15-26, 15-25, 15-24, 15-23, 15-22, 15-21, 15-20, 15-19, 15-18, 15-17, 18-30, 18-29, 18-28, 18-27, 18-26, 18-25, 18-24, 18-23, 18-22, 18-21, 18-20, 19-30, 19-29, 19-28, 19-27, 19-26, 19-25, 19-24, 19-23, 19-22, 19-21, 19-20, 20-30, 20-29, 20-28, 20-27, 20-26, 20-25, 20-24,20-23, 20-22, 20-21, 21-30, 21-29, 21-28, 21-27, 21-26, 21-25, 21-24, 21-23, or 21-22 nucleotides in length. Ranges and lengths intermediate to the above recited ranges and lengths are also contemplated to be part of the invention.
In some embodiments, the dsRNA is about 15 to 20 nucleotides in length, or about 25 to 30 nucleotides in length. In general, the dsRNA is long enough to serve as a substrate for the Dicer enzyme. For example, it is well-known in the art that dsRNAs longer than about 21-23 nucleotides in length may serve as substrates for Dicer. As the ordinarily skilled person will also recognize, the region of an RNA targeted for cleavage will most often be part of a larger RNA
molecule, often an mRNA molecule. Where relevant, a "part" of an mRNA target is a contiguous sequence of an mRNA
target of sufficient length to allow it to be a substrate for RNAi-directed cleavage (i.e., cleavage through a RISC pathway).
One of skill in the art will also recognize that the duplex region is a primary functional portion of a dsRNA, e.g., a duplex region of about 9 to 36 base pairs, e.g., about 10-36, 11-36, 12-36, 13-36, 14-36, 15-36, 9-35, 10-35, 11-35, 12-35, 13-35, 14-35, 15-35, 9-34, 10-34, 11-34, 12-34, 13-34, 14-34, 15-34, 9-33, 10-33, 11-33, 12-33, 13-33, 14-33, 15-33, 9-32, 10-32, 11-32, 12-32, 13-32, 14-32, 15-32, 9-31, 10-31, 11-31, 12-31, 13-32, 14-31, 15-31, 15-30, 15-29, 15-28, 15-27, 15-26, 15-25, 15-24, 15-23, 15-22, 15-21, 15-20, 15-19, 15-18, 15-17, 18-30, 18-29, 18-28, 18-27, 18-26, 18-25, 18-24, 18-23, 18-22, 18-21, 18-20, 19-30, 19-29, 19-28, 19-27, 19-26, 19-25, 19-24, 19-23, 19-22, 19-21, 19-20, 20-30, 20-29, 20-28, 20-27, 20-26, 20-25, 20-24,20-23, 20-22, 20-21, 21-30, 21-29, 21-28, 21-27, 21-26, 21-25, 21-24, 21-23, or 21-22 base pairs. Thus, in one embodiment, to the extent that it becomes processed to a functional duplex, of e.g., 15-30 base pairs, that targets a desired RNA for cleavage, an RNA molecule or complex of RNA molecules having a duplex region greater than 30 base pairs is a dsRNA. Thus, an ordinarily skilled artisan will recognize that in one embodiment, a miRNA is a dsRNA. In another embodiment, a dsRNA is not a naturally occurring miRNA. In another embodiment, an iRNA agent useful to target HBV gene expression is not generated in the target cell by cleavage of a larger dsRNA.
The duplex region may be of any length that permits specific degradation of a desired target RNA through a RISC pathway, and may range from about 9 to 36 base pairs in length, e.g., about 15-30 base pairs in length, for example, about 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, or 36 base pairs in length, such as about 15-30, 15-29, 15-28, 15-27, 15-26, 15-25, 15-24, 15-23, 15-22, 15-21, 15-20, 15-19, 15-18, 15-17, 18-30, 18-29, 18-28, 18-27, 18-26, 18-25, 18-24, 18-23, 18-22, 18-21, 18-20, 19-30, 19-29, 19-28, 19-27, 19-26, 19-25, 19-24, 19-23, 19-22, 19-21, 19-20, 20-30, 20-29, 20-28, 20-27, 20-26, 20-25, 20-24,20-23, 20-22, 20-21, 21-30, 21-29, 21-28, 21-27, 21-26, 21-25, 21-24, 21-23, or 21-22 base pairs in length. Ranges and lengths intermediate to the above recited ranges and lengths are also contemplated to be part of the invention.
The two strands forming the duplex structure may be different portions of one larger RNA
molecule, or they may be separate RNA molecules. Where the two strands are part of one larger molecule, and therefore are connected by an uninterrupted chain of nucleotides between the 3'-end of one strand and the 5'-end of the respective other strand forming the duplex structure, the connecting RNA chain is referred to as a "hairpin loop." A hairpin loop can comprise at least one unpaired nucleotide. In some embodiments, the hairpin loop can comprise at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 20, at least 23 or more unpaired nucleotides.
In some embodiments, a dsRNA agent of the invention comprises a tetraloop. As used herein, "tetraloop" in the context of a dsRNA refers to a loop (a single stranded region) consisting of four nucleotides that forms a stable secondary structure that contributes to the stability of adjacent Watson-Crick hybridized nucleotides. Without being limited to theory, a tetraloop may stabilize an adjacent Watson-Crick base pair by stacking interactions. In addition, interactions among the four nucleotides in a tetraloop include, but are not limited to, non-Watson-Crick base pairing, stacking interactions, hydrogen bonding, and contact interactions (Cheong et al., Nature 1990 Aug 16;346(6285):680-2; Heus and Pardi, Science 1991 Jul 12;253(5016): 191-4). A
tetraloop confers an increase in the melting temperature (Tm) of an adjacent duplex that is higher than expected from a simple model loop sequence consisting of four random bases. For example, a tetraloop can confer a melting temperature of at least 55 C in 10mM NaHPO4 to a hairpin comprising a duplex of at least 2 base pairs in length. A tetraloop may contain ribonucleotides, deoxyribonucleotides, modified nucleotides, and combinations thereof. Examples of RNA tetraloops include the UNCG family of tetraloops (e.g., UUCG), the GNRA family of tetraloops (e.g., GAAA), and the CUUG tetraloop.
(Woese et al., Proc Natl Acad Sci U S A. 1990 Nov;87(21):8467-71 ; Antao et al., Nucleic Acids Res.
1991 Nov 11;19(21):5901-5). Examples of DNA tetraloops include the d(GNNA) family of tetraloops (e.g., d(GTTA), the d(GNRA)) family of tetraloops, the d(GNAB) family of tetraloops, the d(CNNG) family of tetraloops, the d(TNCG) family of tetraloops (e.g., d(TTCG)).
(Nakano et al. Biochemistry, 41(48), 14281 -14292, 2002; Shinji et al. Nippon Kagakkai Koen Yokoshu vol.78th; no.2; page.731 (2000).) In certain embodiments of the invention, tetraloop- and modified nucleotide-containing dsNAs are contemplated as described, e.g., as described in U.S. Patent Publication No. 2011/0288147, the entire contents of which are incorporated by reference herein. In certain such embodiments, a dsNA of the invention possesses a first strand and a second strand, where the first strand and the second strand form a duplex region of 19-25 nucleotides in length, wherein the first strand comprises a 3' region that extends beyond the first strand-second strand duplex region and comprises a tetraloop, and the dsNA comprises a discontinuity between the 3' terminus of the first strand and the 5' terminus of the second strand.
Optionally, the discontinuity is positioned at a projected Dicer cleavage site of the tetraloop-containing double stranded nucleic acid (dsNA). It is contemplated that, as for any of the other dupexed oligonucleotides of the invention, tetraloop-containing duplexes of the invention can possess any range of modifications disclosed herein or otherwise known in the art, including, e.g., 2'-0-methyl, 2'- fluoro, inverted base, GalNAc moieties, etc. Typically, every nucleotide on both strands of the tetraloop-containing dsNA is chemically modified if the tetraloop-containing dsNA is going to be delivered without using lipid nanoparticles or some other delivery method that protects the dsNA
from degradation during the delivery process. However, in certain embodiments, one or more nucleotides are not modified.
Where the two substantially complementary strands of a dsRNA are comprised by separate RNA molecules, those molecules need not, but can be covalently connected.
Where the two strands are connected covalently by means other than an uninterrupted chain of nucleotides between the 3'-end of one strand and the 5'-end of the respective other strand forming the duplex structure, the connecting structure is referred to as a "linker." The RNA strands may have the same or a different number of nucleotides. The maximum number of base pairs is the number of nucleotides in the shortest strand of the dsRNA minus any overhangs that are present in the duplex. In addition to the duplex structure, an RNAi may comprise one or more nucleotide overhangs.
A dsRNA as described herein can further include one or more single-stranded nucleotide overhangs e.g., 1, 2, 3, or 4 nucleotides. dsRNAs having at least one nucleotide overhang can have unexpectedly superior inhibitory properties relative to their blunt-ended counterparts. A nucleotide overhang can comprise or consist of a nucleotide/nucleoside analog, including a deoxynucleotide/nucleoside. The overhang(s) can be on the sense strand, the antisense strand or any combination thereof. Furthermore, the nucleotide(s) of an overhang can be present on the 5'-end, 3'-end or both ends of either an antisense or sense strand of a dsRNA. In certain embodiments, longer, extended overhangs are possible.
A dsRNA can be synthesized by standard methods known in the art. iRNA
compounds of the invention may be prepared using a two-step procedure. First, the individual strands of the double stranded RNA molecule are prepared separately. Then, the component strands are annealed. The individual strands of the siRNA compound can be prepared using solution-phase or solid-phase organic synthesis or both. In certain embodiments, the iRNA compound is produced from an expression vector delivered into a cell.
In one aspect, a dsRNA of the invention includes at least two nucleotide sequences, a sense sequence and an anti-sense sequence. The sense strand is selected from the group of sequences provided in any one of the Tables in Appendix A, and the corresponding antisense strand of the sense strand is selected from the group of sequences of any one of the Tables in Appendix A.
In some embodiments, the sense strand is selected from the group of sequences provided in any one of the Tables in Appendix A, and the corresponding antisense strand of the sense strand is .. selected from the group of sequences of any one of the Tables in Appendix A. In this aspect, one of the two sequences is complementary to the other of the two sequences, with one of the sequences being substantially complementary to a sequence of an mRNA generated in the expression of an HBV
gene. As such, in this aspect, a dsRNA will include two oligonucleotides, where one oligonucleotide is described as the sense strand in any one of the Tables in Appendix A and the second oligonucleotide is described as the corresponding antisense strand of the sense strand in any one of the Tables in Appendix A. In one embodiment, the substantially complementary sequences of the dsRNA
are contained on separate oligonucleotides. In another embodiment, the substantially complementary sequences of the dsRNA are contained on a single oligonucleotide.
It is understood that, although some of the sequences in the Tables in Appendix A are .. described as modified or conjugated sequences, the RNA of the iRNA of the invention e.g., a dsRNA
of the invention, may comprise any one of the sequences set forth in the Tables in Appendix A that is un-modified, unconjugated, or modified or conjugated differently than described therein. Additional target sites are provided, for example, in PCT Publication Nos. WO
2016/077321, WO 2012/024170, WO 2017/027350, and WO 2013/003520; and in Michler, 2016, the entire contents of wach of which are incorporated herein by reference.
The skilled person is well aware that dsRNAs having a duplex structure of about 20 to 23 base pairs, e.g., 21, base pairs have been hailed as particularly effective in inducing RNA interference (Elbashir et al., EMBO 2001, 20:6877-6888). However, others have found that shorter or longer RNA
duplex structures can also be effective (Chu and Rana (2007) RNA 14:1714-1719;
Kim et al. (2005) Nat Biotech 23:222-226). In the embodiments described above, by virtue of the nature of the oligonucleotide sequences provided in any one of the Tables in Appendix A, dsRNAs described herein can include at least one strand of a length of minimally 21 nucleotides. It can be reasonably expected that shorter duplexes having one of the sequences of any one of the Tables in Appendix A
minus only a few nucleotides on one or both ends can be similarly effective as compared to the dsRNAs described above. Hence, dsRNAs having a sequence of at least 15, 16, 17, 18, 19, 20, or more contiguous nucleotides derived from one of the sequences of any one of the Tables in Appendix A and differing in their ability to inhibit the expression of an HBV gene by not more than 5, 10, 15, 20, 25, or 30 % inhibition from a dsRNA comprising the full sequence.
An iRNA as described herein can contain one or more mismatches to the target sequence, or to one or more HBV target sequences due, e.g., to sequence variations among the HBV genotypes. In one embodiment, an iRNA as described herein contains no more than 3 mismatches. If the antisense strand of the iRNA contains mismatches to a target sequence, it is preferable that the area of mismatch is not located in the center of the region of complementarity. If the antisense strand of the iRNA
contains mismatches to the target sequence, it is preferable that the mismatch be restricted to be within the last 5 nucleotides from either the 5'- or 3'-end of the region of complementarity. For example, for a 23 nucleotide iRNA agent the strand which is complementary to a region of an HBV
gene, generally does not contain any mismatch within the central 13 nucleotides. The methods described herein or methods known in the art can be used to determine whether an iRNA containing a mismatch to a target sequence is effective in inhibiting the expression of an HBV gene. Consideration of the efficacy of iRNAs with mismatches in inhibiting expression of an HBV
gene is important, especially if the particular region of complementarity in an HBV gene is known to have polymorphic sequence variation within various genotypes and the population.
i. Modified iRNAs For Use in the Methods of the Invention In some embodiments, the RNA of the iRNA for use in the invention e.g., a dsRNA, is un-modified, and does not comprise, e.g., chemical modifications or conjugations known in the art and described herein, e.g., when produced from an expression vector. In other embodiments, the RNA of an iRNA of the invention, e.g., a dsRNA, is chemically modified to enhance stability or other beneficial characteristics. In certain embodiments of the invention, substantially all of the nucleotides of an iRNA of the invention are modified. In other embodiments of the invention, all of the nucleotides of an iRNA of the invention are modified. iRNAs of the invention in which "substantially all of the nucleotides are modified" are largely but not wholly modified and can include not more than 5, 4, 3, 2, or 1 unmodified nucleotides.
The nucleic acids featured in the invention can be synthesized or modified by methods well established in the art, such as those described in "Current protocols in nucleic acid chemistry,"
Beaucage, S.L. et al. (Edrs.), John Wiley & Sons, Inc., New York, NY, USA, which is incorporated herein by reference. Modifications include, for example, end modifications, e.g., 5'-end modifications (phosphorylation, conjugation, inverted linkages) or 3'-end modifications (conjugation, DNA nucleotides, inverted linkages, etc.); base modifications, e.g., replacement with stabilizing bases, destabilizing bases, or bases that base pair with an expanded repertoire of partners, removal of bases (abasic nucleotides), or conjugated bases; sugar modifications (e.g., at the 2'-position or 4'-position) or replacement of the sugar; or backbone modifications, including modification or replacement of the phosphodiester linkages. Specific examples of iRNA
compounds useful in the embodiments described herein include, but are not limited to RNAs containing modified backbones or no natural internucleoside linkages. RNAs having modified backbones include, among others, those that do not have a phosphorus atom in the backbone. For the purposes of this specification, and as sometimes referenced in the art, modified RNAs that do not have a phosphorus atom in their internucleoside backbone can also be considered to be oligonucleosides. In some embodiments, a modified iRNA will have a phosphorus atom in its internucleoside backbone.
Modified RNA backbones include, for example, phosphorothioates, chiral phosphorothioates, phosphorodithioates, phosphotriesters, aminoalkylphosphotriesters, methyl and other alkyl phosphonates including 3'-alkylene phosphonates and chiral phosphonates, phosphinates, phosphoramidates including 3'-amino phosphoramidate and aminoalkylphosphoramidates, thionophosphoramidates, thionoalkylphosphonates, thionoalkylphosphotriesters, and boranophosphates having normal 3' -5' linkages, 2' -5' -linked analogs of these, and those having inverted polarity wherein the adjacent pairs of nucleoside units are linked 3'-5' to 5'-3' or 2'-5' to 5'-2'. Various salts, mixed salts and free acid forms are also included.
Representative US patents that teach the preparation of the above phosphorus-containing linkages include, but are not limited to, US Patent Nos. 3,687,808; 4,469,863;
4,476,301; 5,023,243;
5,177,195; 5,188,897; 5,264,423; 5,276,019; 5,278,302; 5,286,717; 5,321,131;
5,399,676; 5,405,939;
5,453,496; 5,455,233; 5,466,677; 5,476,925; 5,519,126; 5,536,821; 5,541,316;
5,550,111; 5,563,253;
5,571,799; 5,587,361; 5,625,050; 6,028,188; 6,124,445; 6,160,109; 6,169,170;
6,172,209; 6, 239,265;
6,277,603; 6,326,199; 6,346,614; 6,444,423; 6,531,590; 6,534,639; 6,608,035;
6,683,167; 6,858,715;
6,867,294; 6,878,805; 7,015,315; 7,041,816; 7,273,933; 7,321,029; and US Pat RE39464, the entire contents of each of which are hereby incorporated herein by reference.
Modified RNA backbones that do not include a phosphorus atom therein have backbones that are formed by short chain alkyl or cycloalkyl internucleoside linkages, mixed heteroatoms and alkyl or cycloalkyl internucleoside linkages, or one or more short chain heteroatomic or heterocyclic internucleoside linkages. These include those having morpholino linkages (formed in part from the sugar portion of a nucleoside); siloxane backbones; sulfide, sulfoxide and sulfone backbones;
formacetyl and thioformacetyl backbones; methylene formacetyl and thioformacetyl backbones;
alkene containing backbones; sulfamate backbones; methyleneimino and methylenehydrazino backbones; sulfonate and sulfonamide backbones; amide backbones; and others having mixed N, 0, S
and CH2 component parts.
Representative US patents that teach the preparation of the above oligonucleosides include, but are not limited to, US Patent Nos. 5,034,506; 5,166,315; 5,185,444;
5,214,134; 5,216,141;
5,235,033; 5,64,562; 5,264,564; 5,405,938; 5,434,257; 5,466,677; 5,470,967;
5,489,677; 5,541,307;
5,561,225; 5,596,086; 5,602,240; 5,608,046; 5,610,289; 5,618,704; 5,623,070;
5,663,312; 5,633,360;
5,677,437; and, 5,677,439, the entire contents of each of which are hereby incorporated herein by reference.
In other embodiments, suitable RNA mimetics are contemplated for use in iRNAs, in which both the sugar and the internucleoside linkage, i.e., the backbone, of the nucleotide units are replaced with novel groups. The base units are maintained for hybridization with an appropriate nucleic acid target compound. One such oligomeric compound, an RNA mimetic that has been shown to have excellent hybridization properties, is referred to as a peptide nucleic acid (PNA). In PNA compounds, the sugar backbone of an RNA is replaced with an amide containing backbone, in particular an aminoethylglycine backbone. The nucleobases are retained and are bound directly or indirectly to aza nitrogen atoms of the amide portion of the backbone. Representative US patents that teach the preparation of PNA compounds include, but are not limited to, US Patent Nos.
5,539,082; 5,714,331;
and 5,719,262, the entire contents of each of which are hereby incorporated herein by reference.
Additional PNA compounds suitable for use in the iRNAs of the invention are described in, for example, in Nielsen et al., Science, 1991, 254, 1497-1500.
Some embodiments featured in the invention include RNAs with phosphorothioate backbones and oligonucleosides with heteroatom backbones, and in particular ¨CH2¨NH¨CH2-, --CH2¨N(CH3)-0¨CH24known as a methylene (methylimino) or MMI backbone], --CH2-0¨N(CH3)¨CH2--, --CH2¨
N(CH3)¨N(CH3)¨CH2¨and ¨N(CH3)¨CH2¨CH24wherein the native phosphodiester backbone is represented as ¨0¨P¨O¨CH2--] of the above-referenced US Patent No. 5,489,677, and the amide backbones of the above-referenced US Patent No. 5,602,240. In some embodiments, the RNAs featured herein have morpholino backbone structures of the above-referenced US
Patent No.
5,034,506.
Modified RNAs can also contain one or more substituted sugar moieties. The iRNAs, e.g., dsRNAs, featured herein can include one of the following at the 2'-position:
OH; F; 0-, S-, or N-alkyl; 0-, S-, or N-alkenyl; 0-, S- or N-alkynyl; or 0-alkyl-0-alkyl, wherein the alkyl, alkenyl and alkynyl can be substituted or unsubstituted Ci to Ci0 alkyl or C2 to Cio alkenyl and alkynyl.
Exemplary suitable modifications include ORCH2).0] .CH3, 0(CH2).110CH3, 0(CH2).NH2, 0(CH2) .CH3, 0(CH2).0NH2, and 0(CH2).0NRCH2).CH3)]2, where n and m are from 1 to about 10. In other embodiments, dsRNAs include one of the following at the 2' position: Ci to C10 lower alkyl, substituted lower alkyl, alkaryl, aralkyl, 0-alkaryl or 0-aralkyl, SH, SCH3, OCN, Cl, Br, CN, CF3, OCF3, SOCH3, 502CH3, 0NO2, NO2, N3, NH2, heterocycloalkyl, heterocycloalkaryl, aminoalkylamino, polyalkylamino, substituted silyl, an RNA cleaving group, a reporter group, an intercalator, a group for improving the pharmacokinetic properties of an iRNA, or a group for improving the pharmacodynamic properties of an iRNA, and other substituents having similar properties. In some embodiments, the modification includes a 2'-methoxyethoxy (2'-0-CH2CH2OCH3, also known as 2'-0-(2-methoxyethyl) or 2'-M0E) (Martin et al., Hely. Chim. Acta, 1995, 78:486-504) i.e., an alkoxy-alkoxy group. Another exemplary modification is 2' -dimethylaminooxyethoxy, i.e., a 0(CH2)20N(CH3)2 group, also known as 2'-DMA0E, as described in examples herein below, and 2'-dimethylaminoethoxyethoxy (also known in the art as 2'-0-dimethylaminoethoxyethyl or 2'-DMAEOE), i.e., 2'-O¨CH2-0¨CH2¨N(CH2)2.
Other modifications include 2' -methoxy (2'-OCH3), 2'-aminopropoxy (2'-OCH2CH2CH2NH2) and 2'-fluoro (2'-F). Similar modifications can also be made at other positions on the RNA of an iRNA, particularly the 3' position of the sugar on the 3' terminal nucleotide or in 2'-5' linked dsRNAs and the 5' position of 5' terminal nucleotide. iRNAs can also have sugar mimetics such as cyclobutyl moieties in place of the pentofuranosyl sugar.
Representative US patents that teach the preparation of such modified sugar structures include, but are not limited to, US Patent Nos.
4,981,957; 5,118,800; 5,319,080; 5,359,044; 5,393,878; 5,446,137; 5,466,786;
5,514,785; 5,519,134;
5,567,811; 5,576,427; 5,591,722; 5,597,909; 5,610,300; 5,627,053; 5,639,873;
5,646,265; 5,658,873;
5,670,633; and 5,700,920, certain of which are commonly owned with the instant application,. The entire contents of each of the foregoing are hereby incorporated herein by reference.
The RNA of an iRNA can also include nucleobase (often referred to in the art simply as "base") modifications or substitutions. As used herein, "unmodified" or "natural" nucleobases include the purine bases adenine (A) and guanine (G), and the pyrimidine bases thymine (T), cytosine (C) and uracil (U). Modified nucleobases include other synthetic and natural nucleobases such as deoxy-thymine (dT), 5-methylcytosine (5-me-C), 5-hydroxymethyl cytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-halouracil and cytosine, 5-propynyl uracil and cytosine, 6-azo uracil, cytosine and thymine, 5-uracil (pseudouracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl anal other 8-substituted adenines and guanines, 5-halo, particularly 5-bromo, 5-trifluoromethyl and other 5-substituted uracils and cytosines, 7-methylguanine and 7-methyladenine, 8-azaguanine and 8-azaadenine, 7-deazaguanine and 7-daazaadenine and 3-deazaguanine and 3-deazaadenine. Further nucleobases include those disclosed in US Patent No. 3,687,808, those disclosed in Modified Nucleosides in Biochemistry, Biotechnology and Medicine, Herdewijn, P. ed. Wiley-VCH, 2008; those disclosed in The Concise Encyclopedia Of Polymer Science And Engineering, pages 858-859, Kroschwitz, J.
L, ed. John Wiley & Sons, 1990, these disclosed by Englisch et al., Angewandte Chemie, International Edition, 1991, 30, 613, and those disclosed by Sanghvi, Y S., Chapter 15, dsRNA Research and Applications, pages 289-302, Crooke, S. T. and Lebleu, B., Ed., CRC Press, 1993. Certain of these nucleobases are particularly useful for increasing the binding affinity of the oligomeric compounds featured in the invention. These include 5-substituted pyrimidines, 6-azapyrimidines and N-2, N-6 and 0-6 substituted purines, including 2-aminopropyladenine, 5-propynyluracil and 5-propynylcytosine. 5-methylcytosine substitutions have been shown to increase nucleic acid duplex stability by 0.6-1.2 C
(Sanghvi, Y. S., Crooke, S. T. and Lebleu, B., Eds., dsRNA Research and Applications, CRC Press, Boca Raton, 1993, pp. 276-278) and are exemplary base substitutions, even more particularly when combined with 2'-0-methoxyethyl sugar modifications.
Representative US patents that teach the preparation of certain of the above noted modified nucleobases as well as other modified nucleobases include, but are not limited to, the above noted US
Patent Nos. 3,687,808, 4,845,205; 5,130,30; 5,134,066; 5,175,273; 5,367,066;
5,432,272; 5,457,187;
5,459,255; 5,484,908; 5,502,177; 5,525,711; 5,552,540; 5,587,469; 5,594,121, 5,596,091; 5,614,617;
5,681,941; 5,750,692; 6,015,886; 6,147,200; 6,166,197; 6,222,025; 6,235,887;
6,380,368; 6,528,640;
6,639,062; 6,617,438; 7,045,610; 7,427,672; and 7,495,088, the entire contents of each of which are hereby incorporated herein by reference.
The RNA of an iRNA can also be modified to include one or more locked nucleic acids (LNA). A locked nucleic acid is a nucleotide having a modified ribose moiety in which the ribose moiety comprises an extra bridge connecting the 2' and 4' carbons. This structure effectively "locks"
the ribose in the 3'-endo structural conformation. The addition of locked nucleic acids to siRNAs has been shown to increase siRNA stability in serum, and to reduce off-target effects (Elmen, J. et al., (2005) Nucleic Acids Research 33(1):439-447; Mook, OR. et al., (2007) Mol Canc Ther 6(3):833-843; Grunweller, A. et al., (2003) Nucleic Acids Research 31(12):3185-3193).
In some embodiments, the iRNA of the invention comprises one or more monomers that are UNA (unlocked nucleic acid) nucleotides. UNA is unlocked acyclic nucleic acid, wherein any of the bonds of the sugar has been removed, forming an unlocked "sugar" residue. In one example, UNA
also encompasses monomer with bonds between C1'-C4' have been removed (i.e.
the covalent carbon-oxygen-carbon bond between the Cl' and C4' carbons). In another example, the C2'-C3' bond (i.e. the covalent carbon-carbon bond between the C2' and C3' carbons) of the sugar has been removed (see Nuc. Acids Symp. Series, 52, 133-134 (2008) and Fluiter et al., Mol. Biosyst., 2009, 10, 1039 hereby incorporated by reference).
The RNA of an iRNA can also be modified to include one or more bicyclic sugar moities. A
"bicyclic sugar" is a furanosyl ring modified by the bridging of two atoms.
A"bicyclic nucleoside"("BNA") is a nucleoside having a sugar moiety comprising a bridge connecting two carbon atoms of the sugar ring, thereby forming a bicyclic ring system. In certain embodiments, the bridge connects the 4'-carbon and the 2'-carbon of the sugar ring. Thus, in some embodiments an agent of the invention may include one or more locked nucleic acids (LNA). A
locked nucleic acid is a nucleotide having a modified ribose moiety in which the ribose moiety comprises an extra bridge connecting the 2' and 4' carbons. In other words, an LNA is a nucleotide comprising a bicyclic sugar moiety comprising a 4'-CH2-0-2' bridge. This structure effectively "locks" the ribose in the 3'-endo structural conformation. The addition of locked nucleic acids to siRNAs has been shown to increase siRNA stability in serum, and to reduce off-target effects (Elmen, J. et al., (2005) Nucleic Acids Research 33(1):439-447; Mook, OR. Et al., (2007) Mol Canc Ther 6(3):833-843;
Grunweller, A. et al., (2003) Nucleic Acids Research 31(12):3185-3193). Examples of bicyclic nucleosides for use in the polynucleotides of the invention include without limitation nucleosides comprising a bridge between the 4' and the 2' ribosyl ring atoms. In certain embodiments, the antisense polynucleotide agents of the invention include one or more bicyclic nucleosides comprising a 4' to 2' bridge.
Examples of such 4' to 2' bridged bicyclic nucleosides, include but are not limited to 4'-(CH2)-0-2' (LNA); 4'-(CH2)¨S-2'; 4'-(CH2)2-0-2' (ENA); 4'-CH(CH3)-0-2' (also referred to as "constrained ethyl" or "cEt") and 4'-CH(CH2OCH3)-0-2' (and analogs thereof;
see, e.g., US Patent No. 7,399,845); 4'-C(CH3)(CH3)-0-2' (and analogs thereof; see e.g., US Patent No. 8,278,283); 4'-CH2¨N(OCH3)-2' (and analogs thereof; see e.g., US Patent No. 8,278,425); 4'-CH2-0¨N(CH3)-2' (see, e.g.,US20040171570); 4'-CH2¨N(R)-0-2', wherein R is H, C1-C12 alkyl, or a protecting group (see, e.g., US Patent No. 7,427,672); 4'-CH2¨C(H)(CH3)-2' (see, e.g., Chattopadhyaya et al., J. Org. Chem., 2009, 74, 118-134); and 4'-CH2¨C(=CH2)-2' (and analogs thereof;
see, e.g., US
Patent No. 8,278,426). The entire contents of each of the foregoing are hereby incorporated herein by reference.
Additional representative US patents and US patent publications that teach the preparation of locked nucleic acid nucleotides include, but are not limited to, the following: US Patent Nos.
6,268,490; 6,525,191; 6,670,461; 6,770,748; 6,794,499; 6,998,484; 7,053,207;
7,034,133;7,084,125;
7,399,845; 7,427,672; 7,569,686; 7,741,457; 8,022,193; 8,030,467; 8,278,425;
8,278,426; 8,278,283;
US 20080039618; and US 20090012281, the entire contents of each of which are hereby incorporated herein by reference.
Any of the foregoing bicyclic nucleosides can be prepared having one or more stereochemical sugar configurations including for example a-L-ribofuranose and I3-D-ribofuranose (see WO
99/14226).
The RNA of an iRNA can also be modified to include one or more constrained ethyl nucleotides. As used herein, a "constrained ethyl nucleotide" or "cEt" is a locked nucleic acid comprising a bicyclic sugar moiety comprising a 4'-CH(CH3)-0-2' bridge. In one embodiment, a constrained ethyl nucleotide is in the S conformation referred to herein as "S-cEt."
An iRNA of the invention may also include one or more "conformationally restricted nucleotides" ("CRN"). CRN are nucleotide analogs with a linker connecting the C2' and C4' carbons of ribose or the C3 and -05' carbons of ribose. CRN lock the ribose ring into a stable conformation and increase the hybridization affinity to mRNA. The linker is of sufficient length to place the oxygen in an optimal position for stability and affinity resulting in less ribose ring puckering.
Representative publications that teach the preparation of certain of the above noted CRN
include, but are not limited to, US 20130190383 and WO 2013036868, the entire contents of each of which are hereby incorporated herein by reference.
Potentially stabilizing modifications to the ends of RNA molecules can include N-(acetylaminocaproy1)-4-hydroxyprolinol (Hyp-C6-NHAc), N-(caproy1-4-hydroxyprolinol (Hyp-C6), N-(acetyl-4-hydroxyprolinol (Hyp-NHAc), thymidine-2'-0-deoxythymidine (ether), N-(aminocaproy1)-4-hydroxyprolinol (Hyp-C6-amino), 2-docosanoyl-uridine-3"-phosphate, inverted base dT(idT) and others. Disclosure of this modification can be found in WO
2011005861.
Other modifications of the nucleotides of an iRNA of the invention include a 5' phosphate or 5' phosphate mimic, e.g., a 5'-terminal phosphate or phosphate mimic on the antisense strand of an RNAi agent. Suitable phosphate mimics are disclosed in, for example U520120157511, the entire contents of which are incorporated herein by reference.
In certain specific embodiments, the RNAi agent for use in the methods of the invention is an agent selected from the group of agents listed in any one of the Tables in Appendix A. These agents may further comprise a ligand.
ii. iRNAs Conjugated to Ligands Another modification of the RNA of an iRNA of the invention involves chemically linking to the RNA one or more ligands, moieties or conjugates that enhance the activity, cellular distribution, or cellular uptake of the iRNA. Such moieties include but are not limited to lipid moieties such as a cholesterol moiety (Letsinger et al., Proc. Natl. Acid. Sci. USA, 1989, 86:
6553-6556), cholic acid (Manoharan et al., Biorg. Med. Chem. Let., 1994, 4:1053-1060), a thioether, e.g., beryl-S-tritylthiol (Manoharan et al., Ann. N.Y. Acad. Sci., 1992, 660:306-309; Manoharan et al., Biorg. Med. Chem.
Let., 1993, 3:2765-2770), a thiocholesterol (Oberhauser et al., Nucl. Acids Res., 1992, 20:533-538), an aliphatic chain, e.g., dodecandiol or undecyl residues (Saison-Behmoaras et al., EMBO J, 1991,
HO Of,-NN 0 AcHN
HO OH
HO
AcHN
O
HO H
HO
AcHN
and the RNAi agent is optionally conjugated to the ligand as shown in the following schematic 3' __________________________________________________ OH
s S.
HO PH
fLO
AcHN 0 Ho OH
(1)- H
N
AcHN 0 0 0' 0 HO PH
O
HO N
AcHN H H
wherein X is 0 or S.
In certain embodiments, the sense strand comprises the nucleotide sequence 5'-gsusguGfcAfCfUfucgcuucaca-3' (SEQ ID NO: 29) and the antisense strand comprises the nucleotide sequence 5'-usGfsugaAfgCfGfaaguGfcAfcacsusu-3' (SEQ ID NO: 30); or the sense strand comprises the nucleotide sequence 5'-csasccauGfcAfAfCfuuuuucaccu-3' (SEQ ID NO: 31) and the antisense strand comprises the nucleotide sequence 5'-asGfsgugAfaAfAfaguuGfcAfuggugsusu-3' (SEQ ID NO: 32), wherein a, c, and u are 2'-0-methyladenosine-3'-phosphate, 2'-0-methylcytidine-3'-phosphate, and 2'-0-methyluridine-3'-phosphate, respectively; as, cs, gs, and us are 2'-0-methyladenosine-3'- phosphorothioate, 2'-0-methylcytidine-3'-phosphorothioate, 2'-0-methylguanosine-3'- phosphorothioate, and 2'-0-methyluridine-3'-phosphorothioate, respectively; Af, Cf, Gf, and Uf are 2'-fluoroadenosine-3'-phosphate, 2'-fluorocytidine-3'-phosphate, 2'-fluoroguanosine-3'-phosphate, and 2'-fluorouridine-3'-phosphate, respectively;
and Gfs is 2'-fluoroguanosine-3'-phosphorothioate. In certain embodiments, the RNAi agent is AD-66810 or AD-66816.
In certain embodiments, the protein-based vaccine comprises epitopes present in at least 4, 5, 6, 7, 8, 9, or 10 genotypes of HBV.
In certain embodiments, the nucleic acid-based vaccine comprises epitopes present in at least 4, 5, 6, 7, 8, 9, or 10 genotypes of HBV.
The present invention further provides uses of the RNAi agents and vaccines provided herein for treatment of subjects having a hepatitis B virus infection based on the methods provided herein.
In certain embodiment, the RNAi agents and the HBV vaccines are used in the manufacture of medicaments for treatment of a subject with an HBV infection.
The present invention further provides kits comprising RNAi agents and vaccines provided herein and instructions providing treatment regimens for their use for treatment of subjects having a hepatitis B virus infection.
The present invention is further illustrated by the following detailed description and drawings.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 schematically depicts the structure of the approximately 3.2 kb double-stranded HBV genome. Replication of the HBV genome occurs through an RNA intermediate and produces 4 overlapping viral transcripts of about 3.5 kb, 2.4 kb, 2.1 kb, and 0.7 kb (termination sites indicated by arrows), and the common 3' end encoding seven viral proteins (pre-S1, pre-S2, S, P, X, pre-C, and C) that are translated across three reading frames.
Figures 2A-2E are graphs showing suppression of HBV by siRNA in a transgenic mouse model. The level of (2A) HBsAg, (2B) HBeAg, and (2C) HBV-DNA in serum of HBV1.3-xfs mice (n = 6 per group) after a single subcutaneous 3 mg/kg or 9 mg/kg dose of a control GalNAc-siRNA
(an siRNA that does not target HBV), AD-66816, or AD-66810. The level of (2D) total HBV RNA
and (2E) 3.5 kb HBV transcripts from liver lysates determined via RT-qPCR and normalized to expression of Glyceraldehyde 3-phosphate dehydrogenase (GAPDH).
Figure 3 is a schematic showing a dosing regimen for an experiment assaying the effect of pretreatment of HBV1.3-xfs mice with the nucleoside inhibitor, Entecavir, an HBV-shRNA, a control GalNAc-siRNA, AD-66816, or AD-66810 prior to administration of a therapeutic vaccine against HBV.
Figures 4A-4C are graphs showing the level of (4A) HBsAg, (4B) HBeAg, and (4C) HBV-DNA in serum of HBV1.3-xfs mice after treatment based on the dosing regimen provided in Figure 3.
Figures 5A-5F are graphs showing T cell immune response in the liver against peptides (5A) HBs(S208), (5B) HBc(C93), and (5C) MVA(B8R) in HBV1.3-xfs mice after treatment based on the dosing regimen provided in Figure 3. Figures 5D-5F show a reanalysis of the same data in Figures 5A-5C performed to accommodate for an insufficient exclusion of dead immune cells and shows T
cell immune response in the liver against peptides (5D) HBs(S208), (5E) HBc(C93), and (5F) MVA(B8R).
Figures 6A-6C show the level of HBV RNA and protein levels in liver cells in HBV1.3-xfs mice after treatment based on the dosing regimen provided in Figure 3. Figure 6A shows total HBV
RNA. Figure 6B shows HBV 3.5 kb transcript relative to GAPDH as determined by RT-qPCR.
Figure 6C shows the number of HBcAg positive cells per mm2 of liver section detected by immunohistochemical staining.
Figure 7 is a schematic showing a dosing regimen for the experiment assaying the effect of pretreatment of HBV1.3-xfs mice with control siRNA or AD-66816 prior to administration of a therapeutic vaccine against HBV.
Figures 8A-8C are graphs showing the level of (8A) HBsAg, (8B) HBeAg, and (8C) HBV-DNA in serum of HBV1.3-xfs mice after treatment based on the dosing regimen provided in Figure 7.
Figures 9A-9D are graphs showing T cell immune response in the liver against peptides (9A) HBs(S208), (9B) HBc(C93), (9C) HBc(Cpool) and (9D) MVA(B8R) in HBV1.3-xfs mice after treatment based on the dosing regimen provided in Figure 7.
Figures 10A-10C show the level of HBV RNA and protein levels in liver cells of HBV1.3-xfs mice after treatment based on the dosing regimen provided in Figure 7. Figure 10A shows total HBV
RNA. Figure 10B shows HBV 3.5 kb transcript relative to GAPDH as determined by RT-qPCR.
Figure 10C shows the number of HBcAg positive cells per mm2 of liver section detected by immunohistochemical staining.
Figures 11A and 11B are graphs showing the level of (11A) HBsAg and (11B) HBeAg in serum of individual HBV1.3-xfs mice at week 7 after the first vaccine dose after the 6 week regimen in the dosing regimen provided in Figure 7.
Figures 11C and 11D are graphs showing (11C) anti-HBs antibody response and (11D) T
cell immune response in the liver against HBs(S208) of individual HBV1.3-xfs mice at week 7 after the first vaccine dose after the 6 week regimen in the dosing regimen provided in Figure 7.
Figure 12 is a schematic showing a dosing regimen for the experiment assaying the effect of pretreatment of mice infected with an AAV vector encoding HBV with control siRNA or AD-66816 prior to administration of a therapeutic vaccine against HBV.
Figures 13A-13G are based on the dosing regimen provided in Figure 12. Figures 13A and 13B are graphs showing the level of (13A) HBsAg and (13B) HBeAg in serum of HBV-AAV mice (inset 13C is an exploded portion of the later time points in graph 13B).
Figure 13D shows the serum HBV DNA level at week 22. Figures 13D and 13E show the number of copies per liver cell of (13D) total HBV DNA and (13E) AAV-DNA at week 22. Figures 13F and 13G show the relative expression in liver of (13F) HBV 3.5 RNA relative to GAPDH RNA and (13G) total HBV RNA
relative to GAPDH RNA.
Figures 14A-14C are graphs showing (14A) anti-HBs antibody response throughout the course of the experiment and (14B) anti-HBe antibody response at day 116 of the experiment based on the dosing regimen provided in Figure 12. Figure 14C is an exploded portion of the later time points in graph 14B.
Figures 15A and 15B show (15A) ALT levels and (15B) body weights of the animals throughout the experiment based on the dosing regimen provided in Figure 12.
A formal sequence listing is provided herewith that forms part of the specification.
An Appendix A providing exemplary target sequences for siRNA targeting and iRNA agents is provided herewith and forms part of the specification.
DETAILED DESCRIPTION OF THE INVENTION
The present invention provides treatment regimens and methods of use of iRNA
agents which effect the RNA-induced silencing complex (RISC)-mediated cleavage of RNA
transcripts of one or more HBV genes (open reading frames/ transcripts) and hepatitis B vaccines to stimulate an immune response against one or more HBV proteins in the treatment of HBV infection.
The treatment regimens and methods preferably provide a functional cure within a defined period of time.
The following detailed description discloses how to make and use compositions containing iRNAs to inhibit the expression of an HBV gene as well as compositions, uses, and methods for treating subjects having diseases and disorders that would benefit from inhibition or reduction of the expression of an HBV gene.
I. Definitions In order that the present invention may be more readily understood, certain terms are first defined. In addition, it should be noted that whenever a value or range of values of a parameter are recited, it is intended that values and ranges intermediate to the recited values are also intended to be part of this invention.
The articles "a" and "an" are used herein to refer to one or to more than one (i.e., to at least one) of the grammatical object of the article. By way of example, "an element"
means one element or more than one element, e.g., a plurality of elements.
The term "including" is used herein to mean, and is used interchangeably with, the phrase "including but not limited to".
The term "or" is used herein to mean, and is used interchangeably with, the term "and/or,"
unless context clearly indicates otherwise.
The term "about" is used herein to mean within the typical ranges of tolerances in the art. For example, "about" can be understood as within 2 standard deviations from the mean. In certain embodiments, "about" means +/-10%. In certain embodiments, "about" means +/-5%. When about is present before a series of numbers or a range, it is understood that "about" can modify each of the numbers in the series or range.
The term "at least" prior to a number or series of numbers is understood to include the number adjacent to the term "at least", and all subsequent numbers or integers that could logically be included, as clear from context. For example, the number of nucleotides in a nucleic acid molecule must be an integer. For example, "at least 18 nucleotides of a 21 nucleotide nucleic acid molecule"
means that 18, 19, 20, or 21 nucleotides have the indicated property. When at least is present before a series of numbers or a range, it is understood that "at least" can modify each of the numbers in the series or range.
As used herein, "no more than" or "less than" is understood as the value adjacent to the phrase and logical lower values or integers, as logical from context, to zero.
For example, a duplex with an overhang of "no more than 2 nucleotides" has a 2, 1, or 0 nucleotide overhang. When "no more than" is present before a series of numbers or a range, it is understood that "no more than" can modify each of the numbers in the series or range. As used herein, ranges include both the upper and lower limit.
In the event of a conflict between a sequence and its indicated site on a transcript or other sequence, the nucleotide sequence recited in the specification takes precedence.
Various embodiments of the invention can be combined as determined appropriate by one of skill in the art.
As used herein, "Hepatitis B virus," used interchangeably with the term "HBV"
refers to the well-known non-cytopathic, liver-tropic DNA virus belonging to the Hepadnaviridae family.
The HBV genome is partially double-stranded, circular DNA with overlapping reading frames (see, e.g., Figure 1).
There are four transcripts (that may be referred to herein as "genes" or "open reading frames") based on size, encoded by the HBV genome. These contain open reading frames called C, X, P, and S. The core protein is coded for by gene C (HBcAg). Hepatitis B e antigen (HBeAg) is produced by proteolytic processing of the pre-core (pre-C) protein. The DNA
polymerase is encoded by gene P. Gene S is the gene that codes for the surface antigens (HBsAg). The HBsAg gene is one long open reading frame which contains three in frame "start" (ATG) codons resulting in polypeptides of three different sizes called large, middle, and small S antigens, pre-S1 +
pre-52 + S, pre-52 + S, or S. Surface antigens in addition to decorating the envelope of HBV, are also part of subviral particles, which are produced at large excess as compared to virion particles, and play a role in immune tolerance and in sequestering anti-HBsAg antibodies, thereby allowing for infectious particles to escape immune detection. The function of the non-structural protein coded for by gene X is not fully understood, but it plays a role in transcriptional transactivation and replication and is associated with the development of liver cancer. Exemplary protein sequences are provided in the attached sequence listing (see, e.g., SEQ ID NOs:1, 3, 16, and 20).
HBV is one of the few DNA viruses that utilize reverse transcriptase in the replication process which involves multiple stages including entry, uncoating, and transport of the virus genome to the nucleus. Initially, replication of the HBV genome involves the generation of an RNA intermediate that is then reverse transcribed to produce the DNA viral genome.
Upon infection of a cell with HBV, the viral genomic relaxed circular DNA
(rcDNA) is transported into the cell nucleus and converted into episomal covalently closed circular DNA
(cccDNA), which serves as the transcription template for the viral mRNAs.
After transcription and nuclear export, cytoplasmic viral pregenomic RNA (pgRNA) is assembled with HBV
polymerase and capsid proteins to form the nucleocapsid, inside which polymerase-catalyzed reverse transcription yields minus-strand DNA, which is subsequently copied into plus-strand DNA to form the progeny rcDNA genome. The mature nucleocapsids are then either packaged with viral envelope proteins to egress as virion particles or shuttled to the nucleus to amplify the cccDNA
reservoir through the intracellular cccDNA amplification pathway. cccDNA is an essential component of the HBV
replication cycle and is responsible for the establishment of infection and viral persistence.
HBV infection results in the production of two different particles: 1) the infectious HBV
virus itself (or Dane particle) which includes a viral capsid assembled from the HBcAg and is covered by an envelope consisting of a lipid membrane with HBV surface antigens, and 2) subviral particles (or SVPs) which contain the small and medium forms of the hepatitis B surface antigen HBsAg which are non-infectious. For each viral particle produced, over 10,000 SVPs are released into the blood. As such, SVPs (and the HBsAg protein they carry) represent the overwhelming majority of viral protein in the blood. HBV infected cells also secrete a soluble proteolytic product of the pre-core protein called the HBV e-antigen (HBeAg).
Eight genotypes of HBV, designated A to H, have been determined, and two additional genotypes I and J have been proposed, each having a distinct geographical distribution. The virus is non-cytopathic, with virus-specific cellular immunity being the main determinant for the outcome of exposure to HBV- acute infection with resolution of liver diseases with 6 months, or chronic HBV
infection that is frequently associated with progressive liver injury.
The term "HBV" includes any of the genotypes of HBV (A to J). The complete coding sequence of the reference sequence of the HBV genome may be found in for example, GenBank Accession Nos. GI:21326584 (SEQ ID NO:1) and GI:3582357 (SEQ ID NO:3).
Antisense sequences are provided in SEQ ID NO: 2 and 4, respectively. Amino acid sequences for the C, X, P, and S
proteins can be found, for example at NCBI Accession numbers YP_009173857.1 (C
protein);
YP_009173867.1 and BAA32912.1 (X protein); YP_009173866.1 and BAA32913.1 (P
protein); and YP_009173869.1, YP_009173870.1, YP_009173871.1, and BAA32914.1 (S protein) (SEQ ID NOs:
5-13) . Protein and DNA sequences from HBV genotype D, strain ayw are provided in SEQ ID NOs.:
14-17. Protein and DNA sequences from HBV genotype A, strain adw are provided in SEQ ID NOs.:
18-21.
Additional examples of HBV mRNA sequences are readily available using publicly available databases, e.g., GenBank, UniProt, and OMIM. The International Repository for Hepatitis B Virus Strain Data can be accessed at http://www.hpa-bioinformatics.org.uk/HepSEQ/main.php.
The term "HBV," as used herein, also refers to naturally occurring DNA
sequence variations of the HBV genome, i.e., genotypes A-J and variants thereof.
As used herein, "epitope" also referred to as "an antigenic determinant," or "determinant," is understood as the part of a protein antigen that is recognized by the immune system, specifically by antibodies, B cells, and/or T cells. Epitopes include conformational epitopes and linear epitopes.
Proteins share an epitope when they share an amino acid sequence of sufficient length or size and antigenicity to be recognized by an antibody, B cell, and/or T cell. T cell epitopes presented by MHC
class I molecules are typically peptides about 8 to 11 amino acids in length, whereas MHC class II
molecules present longer peptides about 13 to 17 amino acids in length.
Conformational epitopes are typically discontinuous and span a longer amino acid sequence.
As used herein, the term "nucelot(s)ide analog" or "reverse transcriptase inhibitor" is an inhibitor of DNA replication that is structurally similar to a nucleotide or nucleoside and specifically inhibits replication of the HBV cccDNA and does not significantly inhibit the replication of the host (e.g., human) DNA. Such inhibitors include Tenofovir disoproxil fumarate (TDF), Tenofovir alafenamide (TAF), Lamivudine, Adefovir dipivoxil, Entecavir (ETV), Telbivudine, AGX-1009, emtricitabine, clevudine, ritonavir, dipivoxil, lobucavir, famvir, FTC, N-Acetyl-Cysteine (NAC), PC1323, theradigm-HBV, thymosin-alpha, ganciclovir, besifovir (ANA-380/LB-80380), and tenofvir-exaliades (TLX/CMX157). In certain embodiments, the nucelot(s)ide analog is Entecavir (ETV).
Nucleot(s)ide analogs are commercially available from a number of sources and are used in the methods provided herein according to their label indication (e.g., typically orally administered at a specific dose) or as determined by a skilled practitioner in the treatment of HBV.
As used herein, "target sequence" refers to a contiguous portion of the nucleotide sequence of an mRNA molecule formed during the transcription of an HBV transcript, including mRNA that is a product of RNA processing of a primary transcription product. In one embodment, the target portion of the sequence will be at least long enough to serve as a substrate for iRNA-directed cleavage at or near that portion of the nucleotide sequence of an mRNA molecule formed during the transcription of an HBV transcript. In one embodiment, the target sequence is within the protein coding region of an HBV transcript.
The target sequence may be from about 9-36 nucleotides in length, e.g., about nucleotides in length. For example, the target sequence can be from about 15-30 nucleotides, 15-29, 15-28, 15-27, 15-26, 15-25, 15-24, 15-23, 15-22, 15-21, 15-20, 15-19, 15-18, 15-17, 18-30, 18-29, 18-28, 18-27, 18-26, 18-25, 18-24, 18-23, 18-22, 18-21, 18-20, 19-30, 19-29, 19-28, 19-27, 19-26, 19-25, 19-24, 19-23, 19-22, 19-21, 19-20, 20-30, 20-29, 20-28, 20-27, 20-26, 20-25, 20-24,20-23, 20-22, 20-21, 21-30, 21-29, 21-28, 21-27, 21-26, 21-25, 21-24, 21-23, or 21-22 nucleotides in length. Ranges and lengths intermediate to the above recited ranges and lengths are also contemplated to be part of the invention.
As used herein, the term "strand comprising a sequence" refers to an oligonucleotide comprising a chain of nucleotides that is described by the sequence referred to using the standard nucleotide nomenclature.
"G," "C," "A," "T," and "U" each generally stand for a nucleotide that contains guanine, cytosine, adenine, thymidine, and uracil as a base, respectively. However, it will be understood that the term "ribonucleotide" or "nucleotide" can also refer to a modified nucleotide, as further detailed below, or a surrogate replacement moiety. The skilled person is well aware that guanine, cytosine, adenine, and uracil can be replaced by other moieties without substantially altering the base pairing properties of an oligonucleotide comprising a nucleotide bearing such replacement moiety. For example, without limitation, a nucleotide comprising inosine as its base can base pair with nucleotides containing adenine, cytosine, or uracil. Hence, nucleotides containing uracil, guanine, or adenine can be replaced in the nucleotide sequences of dsRNA featured in the invention by a nucleotide containing, for example, inosine. In another example, adenine and cytosine anywhere in the oligonucleotide can be replaced with guanine and uracil, respectively to form G-U Wobble base pairing with the target mRNA. Sequences containing such replacement moieties are suitable for the compositions and methods featured in the invention.
As used herein, an "RNAi agent", an "iRNA agent", an "siRNA agent", and the like, is a double stranded RNA that preferably target regions in the HBV genome that are conserved across all serotypes of HBV and are preferably designed to inhibit all steps of the HBV
life cycle, e.g., replication, assembly, secretion of virus, and secretion of viral antigens, by inhibiting expression of more than one HBV transcript. In particular, since transcription of the HBV
genome results in polycistronic, overlapping RNAs, an RNAi agent for use in the invention targeting a single HBV
transcript preferably results in significant inhibition of expression of most or all HBV transcripts. All HBV transcripts are at least partly overlapping and share the same polyadenylation signal. Therefore, all viral transcripts have an identical 3-end and, thus, an RNAi agent of the invention targeting the X
gene will target all viral transcripts and should result in inhibition of not only X gene expression but also the expression of all other viral transcripts, including pregenomic RNA
(pgRNA). Furthermore, the RNAi agents of the invention have been designed to inhibit HBV viral replication by targeting pgRNA, HBV structural genes, polymerase, and the HBV X gene. In addition, they have been designed to mediate the silencing of SVP and other viral protiens that play a role in immune tolerance, thereby permitting a subject's immune system to detect and respond to the presence of viral antigens such that an immune response to control and to clear an HBV infection is mounted. Without intending to be limited by theory, it is believed that a combination or sub-combination of the foregoing properties and the specific target sites and/or the specific modifications in these RNAi agents confer to the RNAi agents of the invention improved efficacy, stability, safety, potency, and durability. Such agents are provided, for example, in PCT Publication Nos. WO
2016/077321, WO
2012/024170, WO 2017/027350, and WO 2013/003520, the entire contents of each of which is incorporated herein by reference. Exemplary target sites for RNAi agents and exemplary RNAi agents are provided in Appendix A, filed herewith, which forms a part of the specification. The term RNAi agents further includes shRNAs, e.g., adeno-associated virus (AAV) 8 vectors for delivery of an shRNA in an artificial mi(cro)RNA under a liver-specific promoter; optionally co-delivered a decoy ("TuD") directed against the shRNA sense strand to curb off-target gene regulation are provided in Michler et al., 2016 (EMBO Mol. Med., 8:1082-1098, incorporated herein by reference).
The majority of nucleotides of each strand of an iRNA agent may be ribonucleotides, but as described in detail herein, each or both strands can also include one or more non-ribonucleotides, e.g., a deoxyribonucleotide and/or a modified nucleotide. In addition, as used in this specification, an "RNAi agent" may include ribonucleotides with chemical modifications; an RNAi agent may include substantial modifications at multiple nucleotides.
As used herein, the term "modified nucleotide" refers to a nucleotide having, independently, a modified sugar moiety, a modified internucleotide linkage, and/or modified nucleobase. Thus, the term modified nucleotide encompasses substitutions, additions or removal of, e.g., a functional group or atom, to internucleoside linkages, sugar moieties, or nucleobases. The modifications suitable for use in the agents of the invention include all types of modifications disclosed herein or known in the art. Any such modifications, as used in a siRNA type molecule, are encompassed by "RNAi agent"
for the purposes of this specification and claims.
As used herein, a "therapeutic HBV vaccine," and the like, can be a peptide vaccine, a DNA
vaccine including a vector-based vaccine, or a cell-based vaccine that induces an immune response, preferably an effector T cell induced response, against one or more HBV
proteins. Preferably the vaccine is a multi-epitope vaccine that is cross-reactive with multiple HBV
serotypes, preferably all HBV serotypes. A number of therapeutic HBV vaccines are known in the art and are at various stages of pre-clinical and clinical development. Protein based vaccines include hepatitis B surface antigen (HBsAg) and core antigen (HBcAg) vaccines (e.g., Li et al., 2015, Vaccine.
33:4247-4254, incorporated herein by reference). Exemplary DNA vaccines include HB-110 (Genexine, Kim et al., 2008. Exp Mol Med. 40: 669-676.), pDPSC18 (PowderMed), INO-1800 (Inovio Pharmaceuticals), HBO2 VAC-AND (ANRS), and CVI-HBV-002 (CHA Vaccine Institute Co., Ltd.).
Exemplary protein based vaccines include Theravax/DV-601 (Dynavax Technologies Corp.), (Chongqing Jiachen Biotechnology Ltd.), and ABX 203 (ABIVAX S.A.). Exemplary cell based vaccines include HPDCs-T immune therapy (Sun Yat-Sen University). Combination vaccines and products are also known and include HepTcellTm (FP-02.2 vaccine (peptide) +
IC310 Adjuvant (a combination peptide-oligonucleotide adjuvant),(see U.S. Patent Publication Nos. 2013/0330382, 2012/0276138, and 2015/0216967, the entire contents of each of which is incorporated herein by reference)); GS-4774 (Gilead, a fusion protein S. core X vaccine + Tarmogen T
cell immune stimulator), pSG2.HBs/MVA.HBs (protein prime/viral vector boost, Oxxon Therapeutics), and a protein-prime/modified vaccinia virus Ankara vector-boost (HBsAg and HBsAg protein + HBcAg and HBsAg in MVA expression vector, Backes et al., 2016, Vaccine. 34:923-32, and W02017121791, both of which are incorporated herein by reference).
As used herein, the term "adjuvant" is understood to be an agent that promotes (e.g., enhances, accelerates, or prolongs) an immune response to an antigen with which it is administered to elicit long-term protective immunity. No substantial immune response is directed at the adjuvant itself. Adjuvants include, but are not limited to, pathogen components, particulate adjuvants, and combination adjuvants (see, e.g., www.niaid.nih.gov/research/vaccine-adjuvants-types). Pathogen components (e.g., monophosphoryl lipid A (MPL), poly(I:C), polyICLC adjuvant, CpG DNA, c-di-AMP, c-di-GMP, c-di-CMP; short, blunt-ended 5'-triphosphate dsRNA (3pRNA) RIG-1 ligand, and emulsions such as poly[di(sodiumcarboxylatoethylphenoxy)phosphazene] (PCEP)) can help trigger early non-specific, or innate, immune responses to vaccines by targeting various receptors inside or on the surface of innate immune cells. The innate immune system influences adaptive immune responses, which provide long-lasting protection against the pathogen that the vaccine targets. Particulate adjuvants (e.g., alum, virosomes, cytokines, e.g., IL-12) form very small particles that can stimulate the immune system and also may enhance delivery of antigen to immune cells.
Combination adjuvants (e.g., AS02, AS03, and AS04 (all GSK); MF59 (Novartis); ISCOMATRIX
(CSL
Limited); and IC31 (Altimmune) elicit multiple protective immune responses.
Adjuvants that have a modest effect when used alone may induce a more potent immune response when used together.
In preferred embodiments of the invention, adjuvants for use in the invention promote a humoral as well as a cellular immune response. For this, a balanced Th1/Th2 helper T cell response is desired to support neutralizing antibody responses as well as effector cytotoxic T cell responses.
Preferably the adjuvant provides a balanced Th1/Th2 response. In certain embodiments, the adjuvant is one or more of a polyI:C adjuvant, a polyICLC adjuvant, a CpG adjuvant, a STING agonist (a c-di-AMP adjuvant, a c-di-GMP adjuvant, or a c-di-CMP adjuvant), an ISCOMATRIX
adjuvant, a PCEP adjuvant, and a Rig-I-ligand adjuvant. In certain embodiments, the adjuvant is a polyI:C
adjuvant, a CpG adjuvant, a STING agonist, or a PCEP adjuvant. In certain embodiments, the adjuvant is not alum.
As used herein, an "immune stimulator" is an agent that stimulates an immune response that may or may not be administered independently of an antigen. Immune stimulators include, but are not limited to, pegylated interferon alfa 2a (PEG-IFN-alpha-2a), interferon alfa-2b, PEG-IFN-alpha-2b, interferon lambda a recombinant human interleukin-7, and a Toll-like receptor 3, 7, 8 or 9 (TLR3, TLR7, TLR8, TLR9) agonist, a viral entry inhibitor (e.g., Myrcludex), an oligonucleotide that inhibits the secretion or release of HBsAg (e.g., REP 9AC), a capsid inhibitor (e.g., Bay41-4109 and NVR-1221), a cccDNA inhibitor (e.g., IHVR-25). In certain embodiments, an immune stimulator can include a viral capsid, optionally an empty viral capsid, e.g., MVA capsid.
Immune stimulators can also include immune checkpoint regulators. Immune checkpoint regulators can be stimulatory or inhibitory. As used herein, immune checkpoint regulators potentiate an immune response. Immune checkpoint regulators include, but are not limited to, CTLA-4 inhibitors, such as ipilimumab, PD-1 inhibitors, such as Nivolumab, Pembrolizumab, and the BGB-A317 antibody. PD-Li inhibitors include atezolizumab, avelumab, and durvalumab, in addition to an affimer biotherapeutic.
As used herein, a "subject" is an animal, such as a mammal, including a primate (such as a human, a non-human primate, e.g., a monkey, and a chimpanzee), a non-primate (e.g., a mouse model or other animal model that can be infected with HBV). In an embodiment, the subject is a human, such as a human being treated or assessed for a disease, disorder, or condition that would benefit from reduction in HBV gene expression or replication. In certain embodiments, the subject has a chronic hepatitis B virus (HBV) infection. In certain embodiments, the subject has both a chronic hepatitis B
virus (HBV) infection and a hepatitis D virus (HDV) infection.
As used herein, the terms "treating" or "treatment" refer to a beneficial or desired result including, but not limited to, alleviation of one or more signs or symptoms in a subject with HBV
infection including, but not limited to, the presence of serum HBV DNA or liver HBV ccc DNA, the presence of serum or liver HBV antigen, e.g., HBsAg or HBeAg. Diagnostic criteria for HBV
infection are well known in the art. "Treatment" can also mean prolonging survival as compared to expected survival in the absence of treatment, or lower risk of HCC
development.
In certain embodiments, an HBV-associated disease is chronic hepatitis B
(CHB). In certain embodiments, subjects have been infected with HBV for at least five years. In certain embodiments, subjects have been infected with HBV for at least ten years. In certain embodiments, subjects became infected with HBV at birth. Subjects having chronic hepatitis B disease are immune tolerant, have an active chronic infection accompanied by necroinflammatory liver disease, have increased hepatocyte turn-over in the absence of detectable necroinflammation, or have an inactive chronic infection without any evidence of active disease, and they are also asymptomatic.
Subjects having chronic hepatitis B disease are HBsAg positive and have either high viremia (>104 HBV-DNA copies / ml blood) or low viremia (<103 HBV-DNA copies / ml blood). Patients with chronic active hepatitis, especially during the high replicative state, may have symptoms similar to those of acute hepatitis.
The persistence of HBV infection in CHB subjects is the result of ccc HBV DNA
persistence. In certain embodiments, a subject having CHB is HBeAg positive. In other embodiments, a subject having CHB is HBeAg negative.
In preferred embodiments, treatment of HBV infection results in a "functional cure" of hepatitis B. As used herein, the term "functional cure" is understood to be clearance of circulating HBsAg and is preferably accompanied by conversion to a status in which HBsAg antibodies become undetectable using a clinically relevant assay. For example, undetectable antibodies can include a signal lower than 10 mIU/m1 as measured by Chemiluminescent Microparticle Immunoassay (CMIA) or any other immunoassay, and may be called anti-HBs seroconversion.
Functional cure does not require clearance of all replicative forms of HBV (e.g., cccDNA from the liver). Anti-HBs seroconversion occurs spontaneously in about 0.2-1% of chronically infected patients per year.
However, even after anti-HBs seroconversion, low level persistence of HBV is observed for decades indicating that a functional rather than a complete cure occurs. Without being bound to mechanism, it is proposed that the immune system is able to keep HBV in check. A functional cure permits discontinuation of any treatment for the HBV infection. However, it is understood that a "functional cure" for HBV infection may not be sufficient to prevent or treat diseases or conditions that result from HBV infection, e.g., liver fibrosis, HCC, cirrhosis.
The term "lower" in the context of the level of HBV gene expression or HBV
replication in a subject, or a disease marker or symptom, refers to a statistically significant decrease in such level.
The decrease can be, for example, at least 70%, 75%, 80%, 85%, 90%, 95%, or more. In monitoring of HBV infection, a 10g10 scale is typically used to describe the level of antigenemia (e.g., HBsAg level in serum) or viremia (HBV DNA level in serum). It is understood that a 1 10g10 decrease is a 90% decrease (10% remaining), a 2 10g10 decrease is a 99% decrease (1%
remaining), etc. In certain embodiments, a disease marker is lowered to below the level of detection.
In certain embodiments, the expression of a disease marker is normalized, i.e., decreased to a level accepted as within the range of normal for an individual without such disorder, e.g., the level of .. a disease marker, such as, ALT or AST, is decreased to a level accepted as within the range of normal for an individual without such disorder. When the disease associated level is elevated from the normal level, the change is calculated from the upper level of normal (ULN).
When the disease associated level is decreased from the normal level, the change is calculated from the lower level of normal (LLN). The lowering is the percent difference in the change between the subject value and the normal value. For example, a normal AST level can be reported as 10 to 40 units per liter. If, prior to treatment, a subject has an AST level of 200 units per liter (i.e., 5 times the ULN, 160 units per liter above the upper level of normal) and, after treatment, the subject has an AST level of 120 units per liter (i.e., 3 times the ULN, 80 units per liter above the upper level of normal), the elevated AST would be lowered towards normal by 50% (80/160).
The term "inhibiting," as used herein, is used interchangeably with "reducing," "silencing,"
"downregulating", "suppressing", and other similar terms, and includes any level of inhibition.
Preferably inhibiting includes a statistically significant or clinically significant inhibition.
The phrase "inhibiting expression of an HBV gene" is intended to refer to knockdown of any HBV transcript (e.g., 3.5 kb, 2.4 kb, 2.1 kb, or 0.7 kb transcript) encoding one or more HBV viral proteins (such as, e.g., preS1/2-S, preS, S, P, X, preC, and C), as well as variants or mutants of an HBV gene.
"Inhibiting expression of an HBV gene" includes any significant level of inhibition of an HBV gene or transcript, e.g., at least partial suppression of the expression of an HBV gene S, P, X, or C, or any combination thereof, e.g., S, P, and C. The expression of the HBV
gene may be assessed based on the level, or the change in the level, of any variable associated with HBV gene expression, e.g., an HBV mRNA level, an HBV protein level, and/or an HBV cccDNA level.
This level may be assessed in an individual cell or in a group of cells, including, for example, a sample derived from a subject, e.g., levels may be monitored in serum.
In some embodiments of the methods of the invention, expression of an HBV gene is inhibited by at least 70%, 75%, 80%, 85%, 90%, 95%, or to below the level of detection of the assay.
In preferred embodiments, the inhibition of expression of an HBV gene results in a clinically relevant inhibition of the level of gene expression, e.g., sufficiently inhibited to permit an effective immune response to a vaccine against an HBV protein.
Inhibition of the expression of an HBV gene may be manifested by a reduction of the amount of RNA expressed by a first cell or group of cells (such cells may be present, for example, in a sample derived from a subject) in which an HBV gene is transcribed and which has or have been treated (e.g., by contacting the cell or cells with an RNAi agent of the invention, or by administering an RNAi agent of the invention to a subject in which the cells are or were present) such that the expression of an HBV gene is inhibited, as compared to a second cell or group of cells substantially identical to the first cell or group of cells but which has not or have not been so treated (control cell(s)). In preferred embodiments, the inhibition is assessed by the rtPCR method provided in Example 2 of PCT
Publication No. WO 2016/077321 (the entire contents of which are incorporated herein by reference), with in vitro assays being performed in an appropriately matched cell line with the duplex at a 10 nM
concentration, and expressing the level of mRNA in treated cells as a percentage of the level of mRNA in control cells, using the following formula:
(RNA in contd. c ¨ (RNA in treated celc) l -RNA in control cells Alternatively, inhibition of the expression of an HBV gene may be assessed in terms of a reduction of a parameter that is functionally linked to HBV gene expression, e.g., as described herein.
HBV gene silencing may be determined in any cell expressing an HBV gene, either constitutively or by genomic engineering, and by any assay known in the art.
Inhibition of the expression of an HBV protein may be manifested by a reduction in the level of an HBV protein that is expressed by a cell or group of cells (e.g., the level of protein expressed in a sample derived from a subject). As explained above, for the assessment of mRNA
suppression, the inhibition of protein expression levels in a treated cell or group of cells may similarly be expressed as a percentage of the level of protein in a control cell or group of cells or in serum.
A control cell or group of cells that may be used to assess the inhibition of the expression of an HBV gene includes a cell or group of cells that has not yet been contacted with an RNAi agent of .. the invention. For example, the control cell or group of cells may be derived from an individual subject (e.g., a human or animal subject) prior to treatment of the subject with an RNAi agent. In alternative embodiments, the level may be compared to an appropriate control sample, e.g., a known population control sample.
The level of HBV RNA that is expressed by a cell or group of cells, or the level of circulating HBV RNA, may be determined using any method known in the art for assessing mRNA expression, preferably using the rtPCR method provided in Example 2 of PCT Publication No.
WO
2016/077321,or Example 1 provided herein. In one embodiment, the level of expression of an HBV
gene (e.g., total HBV RNA, an HBV transcript, e.g., HBV 3.5 kb transcript) in a sample is determined by detecting a transcribed polynucleotide, or portion thereof, e.g., RNA of the HBV gene. RNA may .. be extracted from cells using RNA extraction techniques including, for example, using acid phenol/guanidine isothiocyanate extraction (RNAzol B; Biogenesis), RNeasy RNA
preparation kits (Qiagen0) or PAXgene (PreAnalytix, Switzerland). Typical assay formats utilizing ribonucleic acid hybridization include nuclear run-on assays, RT-PCR, RNase protection assays (Melton et al., Nuc.
Acids Res. 12:7035), northern blotting, in situ hybridization, and microarray analysis. Circulating HBV mRNA may be detected using methods the described in PCT Publication No. WO
2012/177906, the entire contents of which are hereby incorporated herein by reference.
In one embodiment, the level of expression of an HBV gene is determined using a nucleic acid probe. The term "probe", as used herein, refers to any molecule that is capable of selectively binding to a specific HBV gene. Probes can be synthesized by one of skill in the art, or derived from appropriate biological preparations. Probes may be specifically designed to be labeled. Examples of molecules that can be utilized as probes include, but are not limited to, RNA, DNA, proteins, antibodies, and organic molecules.
Isolated RNA can be used in hybridization or amplification assays that include, but are not limited to, Southern or northern analyses, polymerase chain reaction (PCR) analyses, and probe arrays. One method for the determination of mRNA levels involves contacting the isolated mRNA
with a nucleic acid molecule (probe) that can hybridize to an HBV mRNA. In one embodiment, the mRNA is immobilized on a solid surface and contacted with a probe, for example by running the isolated mRNA on an agarose gel and transferring the mRNA from the gel to a membrane, such as nitrocellulose. In an alternative embodiment, the probe(s) are immobilized on a solid surface and the mRNA is contacted with the probe(s), for example, in an Affymetrix gene chip array. A skilled artisan can readily adapt known mRNA detection methods for use in determining the level of an HBV
mRNA.
An alternative method for determining the level of expression of an HBV gene in a sample involves the process of nucleic acid amplification or reverse transcriptase (to prepare cDNA) of, for example mRNA in the sample, e.g., by RT-PCR (the experimental embodiment set forth in Mullis, .. 1987, US Patent No. 4,683,202), ligase chain reaction (Barany (1991) Proc.
Natl. Acad. Sci. USA
88:189-193), self sustained sequence replication (Guatelli et al. (1990) Proc.
Natl. Acad. Sci. USA
87:1874-1878), transcriptional amplification system (Kwoh et al. (1989) Proc.
Natl. Acad. Sci. USA
86:1173-1177), Q-Beta Replicase (Lizardi et al. (1988) Bio/Technology 6:1197), rolling circle replication (Lizardi et al., US Patent No. 5,854,033) or any other nucleic acid amplification method, followed by the detection of the amplified molecules using techniques well known to those of skill in the art. These detection schemes are especially useful for the detection of nucleic acid molecules if such molecules are present in very low numbers. In particular aspects of the invention, the level of expression of an HBV gene is determined by quantitative fluorogenic RT-PCR
(i.e., the TaqManTm System), e.g., using the method provided herein.
The expression levels of an HBV RNA may be monitored using a membrane blot (such as used in hybridization analysis such as northern, Southern, dot, and the like), or microwells, sample tubes, gels, beads, or fibers (or any solid support comprising bound nucleic acids). See U.S. Patent Nos. 5,770,722, 5,874,219, 5,744,305, 5,677,195, and 5,445,934, the entire contents of each of which are incorporated herein by reference. The determination of HBV expression level may also comprise using nucleic acid probes in solution.
In preferred embodiments, the level of RNA expression is assessed using real time PCR
(qPCR). The use of these methods is described and exemplified in the Examples presented herein.
The level of HBV protein expression may be determined using any method known in the art for the measurement of protein levels. Such methods include, for example, electrophoresis, capillary electrophoresis, high performance liquid chromatography (HPLC), thin layer chromatography (TLC), hyperdiffusion chromatography, fluid or gel precipiting reactions, absorption spectroscopy, a colorimetric assays, spectrophotometric assays, flow cytometry, immunodiffusion (single or double), immunoelectrophoresis, western blotting, radioimmunoassay (RIA), enzyme-linked immunosorbent assays (ELISAs), immunofluorescent assays, electrochemiluminescence assays, and the like.
In some embodiments, the efficacy of the methods of the invention can be monitored by detecting or monitoring a reduction in a symptom of an HBV infection. Symptoms may be assessed using any method known in the art.
As used herein, the term "Hepatitis B virus-associated disease" or "HBV-associated disease,"
is a disease or disorder that is caused by, or associated with HBV infection or replication. The term "HBV-associated disease" includes a disease, disorder, or condition that would benefit from reduction in HBV gene expression or replication. Non-limiting examples of HBV-associated diseases include, for example, hepatitis D virus infection,; hepatitis delta; chronic hepatitis B; liver fibrosis; end-stage liver disease; cryoglobulinemia; hepatocellular carcinoma.
The term "sample," as used herein, includes a collection of similar fluids, cells, or tissues isolated from a subject or prepared therefrom, as well as fluids, cells, or tissues present within a subject. Examples of biological fluids include blood, serum, plasma, immune cells, lymph, urine, saliva, and the like. Tissue samples may include samples from tissues, organs, or localized regions.
For example, samples may be derived from particular organs, parts of organs, or fluids or cells within those organs. In certain embodiments, samples may be derived from the liver (e.g., whole liver or certain segments of liver or certain types of cells in the liver, such as, e.g., hepatocytes, resident liver immune cells). In preferred embodiments, a "sample derived from a subject"
refers to blood drawn from the subject or plasma, serum, or selected cell pools derived therefrom (e.g., populations of immune cells). In further embodiments, a "sample derived from a subject"
refers to liver tissue (or subcomponents thereof) obtained from the subject.
As used herein, "coding sequence" is understood to refer to a DNA sequence that encodes for a specific amino acid sequence. In certain embodiments, the DNA sequence can be reverse transcribed from an RNA sequence. In certain embodiments, an iRNA, e.g., an shRNA, targets a coding sequence.
The terms, "suitable regulatory sequences," and the like, are used herein is to refer to nucleotide sequences located upstream (5' non-coding sequences), within, or downstream (3' non-coding sequences) of a coding sequence, and which influence the transcription, RNA processing or stability, or translation of the associated coding sequence. Regulatory sequences may include promoters, translation leader sequences, introns, and polyadenylation recognition sequences.
"Promoter" as used herein refers to a DNA sequence capable of controlling the expression of a coding sequence or functional RNA. In general, a coding sequence is located 3' to a promoter sequence. Promoters may be derived in their entirety from a native gene, or be composed of different elements derived from different promoters found in nature, or even comprise synthetic DNA
segments. A promoter may be selected to promote expression of a coding sequence in a particular cell type or at different stages of development, or in response to different environmental conditions. In certain embodiments, the promoter is a promoter that is active in liver, e.g., a liver-specific promoter.
Many promoter sequences are known in the art and selection of an appropriate promoter sequence for a specific context is within the ability of those of skill in the art.
The term "operably linked" refers to the association of nucleic acid sequences on a single nucleic acid fragment so that the function of one is affected by the other.
For example, a promoter is operably linked with a coding sequence when it is capable of affecting the expression of that coding sequence (i.e., the coding sequence is under the transcriptional control of the promoter).
The term "expression" as used herein refers to the transcription and stable accumulation of sense (mRNA) or antisense RNA, or an RNAi agent (e.g., an shRNA) derived from the nucleic acid fragment of the subject technology. "Over-expression" refers to the production of a gene product in transgenic or recombinant organisms that exceeds levels of production in normal or non-transformed organisms.
"Expression vector" or "expression construct," as used herein, refers to a nucleic acid in which a coding sequence is operably linked to a promoter sequence to permit expression of the coding sequence under the control of the promoter. Expression vectors include, but are not limited to, viral vectors or plasmid vectors. Methods for delivery of expression vectors into cells are known in the art.
Treatment Methods of the Invention The present invention provides treatment regimens and methods for the sequential use of an agent to reduce the expression of an HBV gene, e.g., iRNA agents which effect the RNA-induced silencing complex (RISC)-mediated cleavage of one or more HBV transcripts, and hepatitis B
vaccines to stimulate an immune response against one or more HBV proteins in the treatment of HBV
infection. The treatment regimens and methods preferably provide a functional cure of HBV within a defined period of time.
The treatment regimens and methods provided herein include the ordered administration of therapeutic agents to provide treatment, and preferably a functional cure, for HBV infection. The agents used in the methods are known in the art. However, the agents alone fail to consistently and durably decrease HBV disease burden, e.g., reducing HBsAg levels to below 2 10g10, preferably 1 log10 IU/ml or to below the level of detection, in most subjects.
Significantly reducing HBV disease burden, e.g., reducing HBsAg levels to below 2 10g10, preferably 1 10g10 IU/ml or to below the level of detection, will provide the opportunity of discontinuation of administration of therapeutic agents and provide a functional cure for HBV in a substantial number of subjects.
Without being bound by mechanism, it is proposed that the treatment regimens and methods provided herein, including administration of an iRNA agent targeted to HBV, substantially reduces HBV
antigens and nucleic acid for a sufficient magnitude and duration in a subject to allow an effective immune response induced by administration of multiple doses of a therapeutic vaccine. The regimens and methods, provided herein, consistently provide a substantial reduction of disease burden and a functional cure in a significant number of subjects, preferably at least 30%, 40%, 50%, 60%, or 70% of subjects.
A transgenic mouse model of HBV infection, HBV1.3 xfs was used to assess the combination therapy provided herein. Primary studies demonstrated the efficacy of two different chemically modified GalNAc- iRNA agents targeted to HBV (AD-66816 and AD-66810) to inhibit the level of HBsAg and HBeAg proteins, and HBV DNA in serum for at least 21 days with a single subcutaneous dose at 3 mg/kg or 9 mg/kg, with similar efficacy. No significant knockdown was observed with a non-HBV iRNA control (see Figure 2). Based on this result, the lower dose of 3 mg/kg was selected for combination therapy studies.
In the first combination therapy trial (see Figure 3), mice were pretreated with one of six treatment regimens (n= 6 per group):
(1) No pretreatment;
(2) Entecavir at 1 ig/m1 in water throughout the course of the study beginning on the first day of Week 0;
(3) A 3 mg/kg dose on the first day of Weeks 0, 4, 8, and 12 of the control iRNA agent.
(4) A single dose on the first day of Week 0 with an expression vector encoding an shRNA
targeted to HBV (HBV-shRNA) (Michler et al., 2016); or (5-6) A 3 mg/kg dose on the first day of Weeks 0, 4, 8, and 12 of AD-66816 or (generically, HBV-siRNA).
On the first day of Weeks 12 and 14, a mixture of recombinantly expressed yeast HBsAg (15 rig) and E. coli expressed HBcAg (15 rig) adjuvanted with 31.9 lig synthetic phosphorothioated CpGODN 1668 (CpG) and 25 lig polykli(sodiumcarboxylatoethyl-phenoxy)phosphazene] (PCEP) was subcutaneously administered to all mice as a protein prime vaccination (Backes, 2016).
On the first day of week 16, a mixture of modified vaccinia virus Ankara expressing HBsAg or HBcAg (5 x 107 particles of each virus) was subcutaneously administered to all mice as a boost vaccination (Backes, 2016).
Blood samples were obtained on the first days of Week 0, 2, 4, 8, 12, 16, and 17 and were assayed for levels of HBsAg, HBeAg, and HBV DNA. Results observed for HBsAg and HBeAg levels mice in groups 1, 2, and 3 (mock, Entecavir, control iRNA agent) were similar (Figure 4A and 4B). The HBV-shRNA or HBV-siRNAs alone caused a significant decrease in HBsAg, HBeAg, and HBV DNA in serum. The three dose prime-boost vaccination scheme resulted in a further decrease in HBsAg in all groups, and reduced the level of HBsAg in at least some animals in the HBV-shRNA
and HBV-siRNA groups to below the level of detection. However, vaccine treatment did not decrease HBeAg levels in any of the groups. HBV DNA levels were decreased to about the lower limit of quantitation with Entecavir alone so no effect of the three dose prime-boost vaccine could be detected (Figure 4C). Mock treatment and treatment with the HBV-shRNA, the HBV-siRNAs, and control siRNA all decreased HBV DNA levels, and the level of HBV-DNA was further decreased by the prime-boost vaccine in all groups. These data demonstrate that RNAi is superior to nucleot(s)ide analog therapy in reducing viral antigens. Also, the combination of RNAi and subsequent vaccination have a greater effect on HBsAg and HBV DNA levels than either agent alone.
On the final day of the experiment (the first day of week 17), mice were sacrificed and their livers were harvested. Intrahepatic CD8+ T cell responses were assessed for response to HBsAg, HBcAg, and the MVA virus particle using the method provided in Backes, 2016.
Mice treated with the HBV-shRNA or the HBV-siRNAs were able to generate a CD8+ immune response against the HBsAg and HBcAg (Figure 5A and 5B). No significant immune response against the HBV antigens was observed in the mock, Entecavir, or control siRNA groups. However, a similar immune response against the MVA virus was observed in all animals independent of pretreatment or viral antigen levels (Figure 5C) showing that vaccination had worked equally well in all animals, demonstrating the presence of a competent immune system. The data shown in Figure 5A-C were reanalyzed to accomodated for an insufficient exclusion of dead immune cells during the first analysis. The data obtained from the second analysis (shown in Figure 5 D-F) again shows that only the mice pretreated with the HBV-shRNA or the HBV-siRNAs were able to generate HBV-specific CD8+ T
cell responses after therapeutic vaccination, but that MVA-specific responses were not influenced by the pretreatment. The reduced variances in the second analysis are attributed to the more rigorous exclussion of dead cells. These data demonstrate that RNAi treatment, in contrast to the current standard of care treatment with a nucleoside analog, can restore HBV-specific T cell immunity and enable the induction of HBV-specific CD8 T cell responses after therapeutic vaccination.
Serum was also assessed for antibody immune response to HBV antigens. Although the vaccine was able to induce a T-cell immune response only in animals which had received HBV-siRNA or HBV-shRNA pretreatment, antibody responses against HBsAg and HBcAg were similar across all groups regardless of pretreatment at the time points evaluated until week 17. No HBeAg antibody responses could be detected. These data demonstrate that high HBV
antigen loads preferentially inhibit HBV-specific T cell, not B cell responses.
Livers were also assessed for the presence of HBV transcripts by RT-qPCR and normalized to the liver GAPDH transcript. Mice treated with the HBV-shRNA or the HBV-siRNAs demonstrated a significant decrease in HBV transcript levels (Figure 6A and 6B). No significant difference was observed between the mock and Entecavir or control siRNA groups. Liver sections were analysed by immunohistochemical stainings for expression of core antigen to assess the antiviral effect in the liver (Figure 6C). In animals that were not pretreated before vaccination, there were, on average, 83 hepatocytes per mm2 with cytoplasmic expression of HBc. This number was not significantly changed in animals that were pretreated with Entecavir or the control siRNA. However, the number of cytoplamic HBcAg positive cells was significantly reduced in AAV-shRNA or HBV
siRNA
pretreated animals. These data demonstrate that a combinatorial RNAi/vaccination therapy suppresses not only antigens in the serum, but also viral antigen expression in the liver.
Having demonstrated that suppression of expression of HBV antigens using shRNA
or siRNA is effective at potentiating an immune response to an HBV vaccine regimen, a study was designed to determine if the duration of HBV antigen suppression had an effect on the potentiation an HBV immune response. Using the HBV 1.3xfs mouse model, mice were treated for eight, six, or three weeks with HBV-siRNA AD-66816, or the control siRNA for 8 weeks, subcutaneously administered at 3 mg/kg/dose, followed by administration of the prime-boost vaccine regimen as set forth above, except 10 lig c-di-AMP was used as an adjuvant rather than PCEP +
CPG (n= 6 per 8 and 3 group, n = 6 for 6 week group) (see Figure 7).
A significant decrease in the levels of each of HBsAg, HBeAg, and HBV DNA was observed after the first administration of AD-66816 (Figures 8A-8C). A further significant decrease in HBsAg was observed after treatment with the vaccine boost with the greatest decrease observed in the 8 week pretreatment group to below the level of detection of the assay, representing a greater than 5 log10 decrease in HBsAg level in all treated animals. Immunization caused only slight further reductions (<0.5 10g10) of HBV DNA and no further reduction in HBeAg levels. These data demonstrate that efficacy of therapeutic vaccination correlates with duration of antigen suppression before start of vaccination. Reconstitution of HBV-specific CD8 T cell responses takes several weeks, with a 6 or preferably 8 week pretreatment resulting in more HBsAg knockdown than a 3 week pretreatment.
Similarly, T-cell responses against HBsAg and HBcAg in liver corresponded with the duration of HBV antigen knockdown, with longer duration of HBV antigen suppression resulting in greater T-cell responses (Figure 9A-9C). Similar responses to MVA virus antigens were observed across all groups independent of pretreatment (Figure 9D). Antibody responses were similar across all groups.
Livers were also assessed for the presence of HBV transcripts by RT-qPCR and normalized to the liver GAPDH transcript. Longer pretreatment durations trended to higher levels of HBV RNA
knockdown (Figure 10A and 10B).
Liver sections were also analysed by immunohistochemical staining for cytoplasmic expression of HBcAg to assess the antiviral effect of the treatment in the liver (Figure 10C). In animals pretreated with the control siRNA before vaccination, there were, on average, 172 hepatocytes per mm2which showed cytoplasmic expression of HBc. With longer duration of HBV
suppression before vaccination, there was a gradual decrease of cytoplasmic HBcAg positive hepatocytes with an average of only 12 cytoplasmic HBcAg positive hepatocytes per mm2in the 8 week pretreatment group. These data demonstrate that the increasing HBV-specific CD8+ T cell response observed with longer antigen suppression before vaccination led to decreased HBV antigen expression in the liver. To assess the durability of response, blood samples were collected from mice (n = 6) pretreated with the AD-66816 HBV-siRNA for six weeks at 2 and 3 weeks after administration of the boost vaccination. In three of the six mice, HBsAg levels continued to dropped to below the level of detection of the assay (Figure 11A and 11B).
Specifically, the three animals which had the highest HBsAg and HBeAg levels at start of vaccination (2, 4, and 5) did show a decline of antigen titers after vaccination, but rebounded with antigen titers towards the end of the experiment. In contrast, the three animals with the lowest antigen titers at start of vaccination (1, 3, and 6) showed a further decline of HBsAg to below the detection limit. These data demonstrate that a functional cure is possible using the treatment regimens provided herein.
These data also suggest that the antigen levels at start of vaccination can affect the response to therapeutic vaccination. Finally, without being bound by mechanism, these data suggest that the decline of antigen levels after therapeutic vaccination is mediated, at least in part, by CD8+ T cells. These data demonstrate that knockdown of circulating HBV antigens (e.g., HBsAg, HBcAg), but not inhibition of HBV DNA
replication alone, potentiates immune response to HBV therapeutic vaccine, e.g., a prime boost therapeutic vaccination regimen. That is, an immune response can be potentiated by pretreatment with an siRNA, but not with nucleot(s)ide inhibitors alone as the immune response is a CD8+ T-cell based immune response.
The magnitude and duration of knockdown required depends on, for example, the level of disease burden in the subject. The higher the level of circulating antigen, the greater the magnitude and duration of HBV antigen knockdown required to potentiate an immune response. Knockdown of HBsAg in serum should be at least 0.5 log 10 (IU/ml), preferably llog 10 (IU/ml), 1.5 log 10 (IU/ml), 2 log 10 (IU/ml), or more from the level in the subject prior to treatment with the therapeutic vaccine.
In certain embodiments, the level of serum HBsAg is no more than 2.5 log 10 (IU/ml), 2 log 10 (IU/ml), 1.5 log 10 (IU/ml) prior to vaccine administration.
Further, as demonstrated herein, a longer duration of HBV antigen knockdown trended towards a more robust immune response. Therefore, knockdown of serum HBsAg to a sufficiently low level for a duration of at least four weeks, six weeks, or eight weeks is preferred prior to administration of the vaccine.
A second series of experiments were designed to study the combination siRNA/vaccination treatment regimen in a mouse model of aquired HBV infection using an adeno-associated virus infection system. For these studies, wildtype C57/B16 mice (9 weeks of age) were injected i.v. with 2x101 genome equivalents of Adeno-Associated-Virus Serotype 8 (AAV8) carrying a 1.2-fold overlength HBV genome of genotype D (AAV-HBV1.2) (see, e.g., Yang, et al.
(2014) Cell and Mol Immunol 11:71). Starting 4 weeks after AAV-transduction (on day -28), animals were treated with three doses of either a control siRNA, or HBV siRNA (HBV AD-66816 or AD-66810) on days 0, 29, and 57, and subsequently half of the animals in each group were treated with a vaccine regimen consisting of prime protein vaccination with HBsAg, HbcAg, and 10 tig c-di-AMP
at days 57 and 70, and boosted with MVA-HBs and MVA-HBc at day 84. The treatment regimen is shown in Figure 12.
Following AAV-HBV1.2 transduction, HBsAg and HBeAg values rose to levels comparable to the levels seen in HBV transgenic mice (HBVxfs) (see, e.g., Figures 13A and 13B). Mice treated with the HBV siRNAs showed mean reductions of HBsAg levels of about 2 logio scales and of HBeAg levels greater than 1 logio scale such that HBsAg and HBeAg levels dropped to less than about 500 IU/per ml, whereas the control siRNA had no effect on antigen levels. Animals treated with one of the HBV siRNAs that did not receive the vaccine regimen showed slowly rebounding antigen levels after the last application of the siRNA. Antigenemia returned to baseline levels after 18 weeks.
The combination treatment with the HBV-siRNA and vaccine regimen resulted in a durable response with a decrease in HBsAg and HBeAg to below the limit of detection through the duration of the experiment. A decrease in HBsAg and HBeAg levels was observed prior to the administration of the MVA boost, suggesting that the protein vaccination may be sufficient to affect a cure. Both serum and liver HBV DNA and RNA were significantly decreased after combination treatment with the HBV-siRNA and vaccine regimen (Figures 13D-13H). This demonstrates, that RNAi-mediated suppression can strongly reduce antigen expression, but that treatment with the vaccine regimen extends the durability of response.
The vaccine regimen alone in animals that received the control siRNA produced a transient decline of antigen levels which rebounded towards the end of the experiment.
In contrast, all animals that received an HBV-siRNA and vaccination, HBsAg and HBeAg levels decreaased to below the detection limit after start of vaccination. Antigen levels remained largely undetectable at all through the last time point measured at least 22 weeks after the last siRNA
application (Figures 13A and 13B).
The durable loss of antigenemia in HBV siRNA pretreated animals, in contrast to the antigen rebound in control siRNA pretreated animals, further demonstrates that immune control was only achieved in animals which had lowered antigen titers before vaccination.
Coinciding with the loss of antigenemia, animals treated with HBV siRNA plus the vaccine regimen developed high titers of anti-HBs antibodies and resulted in anti-HBs and anti-HBe seroconversion in all vaccinated animals (Figure 14). siRNA-pretreated animals developed 10-fold higher and more constant anti-HBs titers and were able to completely and persistently clear serum HBsAg and HBeAg. Interestingly, 3/12 mice vaccinated after HBV siRNA treatment showed a transient drop in anti-HBe levels between week 15 and 22 resulting in a low-level relapse of HBeAg (Figure 13C) that was again controlled. Although anti-HBs antibodies could also be measured in animals that received the control siRNA plus the vaccine regimen, the levels were lower. Further, only animals that received HBV siRNA plus the vaccine regimen developed anti-HBe antibodies.
Taken together, functional cure was not achieved by the siRNA treatement regimen or the therapeutic vaccination regimen alone. However, the loss of antigenemia, as well as development of anti-HBs and anti-HBe antibodies, demonstrates that the combination HBV siRNA plus vaccine regimen can achieve a functional cure.
Throughout the experiment, ALT and body weight of the animals were monitored.
The loss of antigenemia concided with slight increases of ALT activity seen in treatment groups which had received HBV siRNA in conjunction with the vaccination regimen (Figure 15A).
These groups showed significant but mild increases (both p>0.05 or smaller by repeated measure two-way ANOVA; only comparing time points after start of vaccination) as compared to all other treatment groups that did not receive the combination HBVsiRNA-vaccine regimen. Without being bound by mechanism, it is suggested that the CD8+ T cells induced by the combinatorial HBV siRNA-vaccine regimen killed HBV-expressing hepatocytes resulting in elevated ALT.
The body weight of the animals was measured throughout the experiment to assess tolerability of the treatments. There was steady increases throughout the experiment independent of siRNA treatment. Animals that were vaccinated showed a slight and transient decrease (approximately 5%) of body weight after vaccination, but rebounded to normal levels within nine days, and subsequently gained weight comparable to the control groups (Figure 15B). Taken together, both, ALT activity and body weight data demonstrate that all examined treatments, including siRNA
only, vaccine only, as well as the combinatorial siRNA/vaccine regimen are well tolerated.
The number and timing of doses of siRNA to knockdown HBsAg level in serum depends, for example, on the specific agent used. Due to the duration and potency of the exemplary GalNAc siRNAs used in the methods herein and provided, for example, in Appendix A and in PCT Publication No. WO 2016/077321 (the entire contents of which are incorporated herein by reference), a single dose of siRNA may be sufficient to provide the level and duration of knockdown required prior to administration of the therapeutic vaccine. As shown in Figure 4, a single dose of an AAV vector encoded shRNA was sufficient to provide durable knockdown of HBV antigens and HBV DNA.
Those of skill in the art are able to monitor HBV disease status, e.g., by measuring HBsAg levels in blood, to determine the timing and level of siRNA and vaccine administration appropriate for a specific subject.
A number of therapeutic HBV vaccines are known in the art and discussed herein. In preferred embodiments, a prime-boost vaccination protocol, such as the protocol that is used herein, is preferred. However, the HBV antigen knockdown method provided herein can be used in combination with other therapeutic HBV vaccines known in the art, including those found to be insufficient when administered alone. Vaccinations include at least two doses of an antigen in protein or nucleic acid form. In certain embodiments, the vaccination includes three doses of a protein-based vaccine. In preferred embodiments, the methods include heterologous vaccine administration, i.e., at least one protein-based vaccine dose and at least one nucleic-acid based vaccine dose.
Exemplary embodiments of vaccines and dosing regimens are provided, for example, in PCT
Publication No.
WO 2017/121791, the entire contents of which are incorporated herein by reference.
The methods provided herein include the use of a nucleic acid-based vaccine comprising an expression vector construct encoding an HBcAg or an HBsAg, wherein the construct encodes a protein that shares an epitope with the protein-based vaccine. Therefore, it is clearly understood that neither the nucleic acid-based vaccine nor the protein-based vaccine are required to provide the full length protein. The nucleic acid-based vaccine and the protein-based vaccine are required to provide at least one shared epitope that is present in HBcAg or HBsAg, and does not require that the full length protein be provided. As noted above, epitopes may be relatively short, MHC class I molecules that are typically peptides about 8 to 11 amino acids in length, whereas MHC
class II molecules present longer peptides about 13 to 17 amino acids in length, with conformational epitopes being longer. However, it is understood that the use of protein antigens and coding sequences for protein antigens that encode multiple epitopes is preferred. Further, it is understood that the antigens present in the protein-based vaccine and encoded by the nucleic-acid based vaccine may or may not be identical. It is also obvious that antigens should also be selected for their immunogenicity. Such antigens are well known in the art.
In certain embodiments, the order of administration of the protein-based vaccine and the nucleic acid-based vaccine are reversed as compared to the order exemplified in the methods provided herein. That is, the nucleic acid-based vaccine is administered first and the protein-based vaccine is administered second. In certain embodiments, a total of three doses of vaccine are administered, two doses of the nucleic acid-based vaccine followed by a single dose of the protein-based vaccine. In alternative embodiments, a single dose of the nucleic acid-based vaccine is followed by two doses of a protein based vaccine. In other embodiments, one dose of each vaccine is administered.
In preferred embodiments, the prime-boost vaccination method includes the use of an adjuvant with protein antigens. Appropriate adjuvants for use in the methods promote a cell-based response to the antigens. Adjuvants preferably provide a balanced Th1/Th2 response.
The siRNA + vaccine methods provided herein can be used in combination with administration of nucleot(s)ide inhibitors which are the standard of care for treatment of HBV. In certain embodiments, subjects are treated with nucleot(s)ide inhibitors prior to treatment with the siRNA + vaccine treatment regimen. In certain embodiments, subjects are treated throughout the siRNA + vaccine treatment regimen with nucleot(s)ide inhibitors. In certain embodiments, the nucleot(s)ide inhibitor is dosed to reduce pre-existing inflammation associated with HBV infection prior to administration of the nucleic acid therapeutic targeted to HBV (e.g., siRNA, shRNA, antisense oligonucleotide).
In certain embodiments, subjects may be pretreated, or concurrently treated, with other agents used for the treatment of HBV. Such agents include, but are not limited to an immune stimulator (e.g., pegylated interferon alfa 2a (PEG-IFN-a2a), Interferon alfa-2b, a recombinant human interleukin-7, and aToll-like receptor 7 (TLR7) agonist), a viral entry inhibitor (e.g., Myrcludex), an oligonucleotide that inhibits the secretion or release of HbsAg (e.g., REP
9AC), a capsid inhibitor (e.g., Bay41-4109 and NVR-1221), a cccDNA inhibitor (e.g., IHVR-25), a Rig-I
ligand, or an immune checkpoint regulator. In certain embodiments, the immune stimulator is a Rig-I ligand or an immune checkpoint regulator. A functional cure includes a sustained period of at least 3 months, preferably 6 months of HBsAg below 50 IU/ml, or a detectable antibody response to HBsAg. In preferred embodiments, a functional cure includes both a sustained period of at least 3 months, preferably 6 months of HBsAg below 50 IU/ml and a detectable antibody response to HBsAg.
A. RNAi Agents For Use in the Methods of the Invention The present invention includes the use of iRNAs, which inhibit the expression of at least one HBV transcript, and preferably three or four HBV transcripts (open reading frames, sometimes referred to herein as genes). Due to the highly condensed structure of the HBV
genome, it is possible to design single iRNAs that will inhibit the expression of three or four HBV
transcripts (see Figure 1).
For the sake of simplicity, the text herein refers to "an HBV transcript" or "the HBV transcript." It is understood that preferred embodiments include inhibition of more than one HBV
transcript (or open .. reading frame), preferably at least three HBV transcripts (or open reading frames). Further, it is understood that there are eight HBV genotypes, and two proposed additional genotypes, that may further include mutations from published sequences. Therefore, certain iRNA
agents may inhibit different numbers of genes based on the specific genotype and subject infected with HBV.
In some embodiments, the iRNA agent includes double stranded ribonucleic acid (dsRNA) molecules for inhibiting the expression or decreasing the level of an HBV
transcript in a cell in a subject with an HBV infection. The dsRNA includes an antisense strand having a region of complementarity, which is complementary to at least a part of an mRNA formed in the expression of an HBV transcript. The region of complementarity is about 30 nucleotides or less in length (e.g., about 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, or 18 nucleotides or less in length). Upon contact with a cell expressing the HBV gene, the iRNA selectively inhibits the expression of at least one, preferably three or four HBV genes. In preferred embodiments, inhibition of expression is determined by the qPCR method in an appropriate cell line as provided in the examples. For in vitro assessment of activity, percent inhibition is determined using the methods provided in Example 2 of PCT Publication No.WO 2016/077321 at a single dose at a 10 nM duplex final concentration. For in vivo studies, the level after treatment can be compared to, for example, an appropriate historical control or a pooled population sample control to determine the level of reduction, e.g., when a baseline value is not available for the subject. An appropriate control must be carefully selected by one of skill in the art.
A dsRNA includes two RNA strands that are complementary and hybridize to form a duplex structure under conditions in which the dsRNA will be used. One strand of a dsRNA (the antisense strand) includes a region of complementarity that is substantially complementary, and generally fully complementary, to a target sequence. The target sequence can be derived from the sequence of an mRNA formed during the expression of an HBV gene. As multiple HBV genotypes are known, iRNA agents are preferably designed to inhibit expression of HBV genes across as many genotypes as possible. It is understood that an siRNA that is perfectly complementary to one or more HBV
genotypes will not be perfectly complementary to all genotypes. The other strand (the sense strand) includes a region that is complementary to the antisense strand, such that the two strands hybridize and form a duplex structure when combined under suitable conditions. As described elsewhere herein and as known in the art, the complementary sequences of a dsRNA can also be contained as self-.. complementary regions of a single nucleic acid molecule, as opposed to being on separate oligonucleotides.
Generally, the duplex structure is 15 and 30 base pairs in length, e.g., 15-29, 15-28, 15-27, 15-26, 15-25, 15-24, 15-23, 15-22, 15-21, 15-20, 15-19, 15-18, 15-17, 18-30, 18-29, 18-28, 18-27, 18-26, 18-25, 18-24, 18-23, 18-22, 18-21, 18-20, 19-30, 19-29, 19-28, 19-27, 19-26, 19-25, 19-24, 19-23, 19-22, 19-21, 19-20, 20-30, 20-29, 20-28, 20-27, 20-26, 20-25, 20-24, 20-23, 20-22, 20-21, 21-30, 21-29, 21-28, 21-27, 21-26, 21-25, 21-24, 21-23, or 21-22 base pairs in length.
Ranges and lengths intermediate to the above recited ranges and lengths are also contemplated to be part of the invention.
Similarly, the region of complementarity to the target sequence is 15 and 30 nucleotides in length, e.g., 15-29, 15-28, 15-27, 15-26, 15-25, 15-24, 15-23, 15-22, 15-21, 15-20, 15-19, 15-18, 15-17, 18-30, 18-29, 18-28, 18-27, 18-26, 18-25, 18-24, 18-23, 18-22, 18-21, 18-20, 19-30, 19-29, 19-28, 19-27, 19-26, 19-25, 19-24, 19-23, 19-22, 19-21, 19-20, 20-30, 20-29, 20-28, 20-27, 20-26, 20-25, 20-24,20-23, 20-22, 20-21, 21-30, 21-29, 21-28, 21-27, 21-26, 21-25, 21-24, 21-23, or 21-22 nucleotides in length. Ranges and lengths intermediate to the above recited ranges and lengths are also contemplated to be part of the invention.
In some embodiments, the dsRNA is about 15 to 20 nucleotides in length, or about 25 to 30 nucleotides in length. In general, the dsRNA is long enough to serve as a substrate for the Dicer enzyme. For example, it is well-known in the art that dsRNAs longer than about 21-23 nucleotides in length may serve as substrates for Dicer. As the ordinarily skilled person will also recognize, the region of an RNA targeted for cleavage will most often be part of a larger RNA
molecule, often an mRNA molecule. Where relevant, a "part" of an mRNA target is a contiguous sequence of an mRNA
target of sufficient length to allow it to be a substrate for RNAi-directed cleavage (i.e., cleavage through a RISC pathway).
One of skill in the art will also recognize that the duplex region is a primary functional portion of a dsRNA, e.g., a duplex region of about 9 to 36 base pairs, e.g., about 10-36, 11-36, 12-36, 13-36, 14-36, 15-36, 9-35, 10-35, 11-35, 12-35, 13-35, 14-35, 15-35, 9-34, 10-34, 11-34, 12-34, 13-34, 14-34, 15-34, 9-33, 10-33, 11-33, 12-33, 13-33, 14-33, 15-33, 9-32, 10-32, 11-32, 12-32, 13-32, 14-32, 15-32, 9-31, 10-31, 11-31, 12-31, 13-32, 14-31, 15-31, 15-30, 15-29, 15-28, 15-27, 15-26, 15-25, 15-24, 15-23, 15-22, 15-21, 15-20, 15-19, 15-18, 15-17, 18-30, 18-29, 18-28, 18-27, 18-26, 18-25, 18-24, 18-23, 18-22, 18-21, 18-20, 19-30, 19-29, 19-28, 19-27, 19-26, 19-25, 19-24, 19-23, 19-22, 19-21, 19-20, 20-30, 20-29, 20-28, 20-27, 20-26, 20-25, 20-24,20-23, 20-22, 20-21, 21-30, 21-29, 21-28, 21-27, 21-26, 21-25, 21-24, 21-23, or 21-22 base pairs. Thus, in one embodiment, to the extent that it becomes processed to a functional duplex, of e.g., 15-30 base pairs, that targets a desired RNA for cleavage, an RNA molecule or complex of RNA molecules having a duplex region greater than 30 base pairs is a dsRNA. Thus, an ordinarily skilled artisan will recognize that in one embodiment, a miRNA is a dsRNA. In another embodiment, a dsRNA is not a naturally occurring miRNA. In another embodiment, an iRNA agent useful to target HBV gene expression is not generated in the target cell by cleavage of a larger dsRNA.
The duplex region may be of any length that permits specific degradation of a desired target RNA through a RISC pathway, and may range from about 9 to 36 base pairs in length, e.g., about 15-30 base pairs in length, for example, about 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, or 36 base pairs in length, such as about 15-30, 15-29, 15-28, 15-27, 15-26, 15-25, 15-24, 15-23, 15-22, 15-21, 15-20, 15-19, 15-18, 15-17, 18-30, 18-29, 18-28, 18-27, 18-26, 18-25, 18-24, 18-23, 18-22, 18-21, 18-20, 19-30, 19-29, 19-28, 19-27, 19-26, 19-25, 19-24, 19-23, 19-22, 19-21, 19-20, 20-30, 20-29, 20-28, 20-27, 20-26, 20-25, 20-24,20-23, 20-22, 20-21, 21-30, 21-29, 21-28, 21-27, 21-26, 21-25, 21-24, 21-23, or 21-22 base pairs in length. Ranges and lengths intermediate to the above recited ranges and lengths are also contemplated to be part of the invention.
The two strands forming the duplex structure may be different portions of one larger RNA
molecule, or they may be separate RNA molecules. Where the two strands are part of one larger molecule, and therefore are connected by an uninterrupted chain of nucleotides between the 3'-end of one strand and the 5'-end of the respective other strand forming the duplex structure, the connecting RNA chain is referred to as a "hairpin loop." A hairpin loop can comprise at least one unpaired nucleotide. In some embodiments, the hairpin loop can comprise at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 20, at least 23 or more unpaired nucleotides.
In some embodiments, a dsRNA agent of the invention comprises a tetraloop. As used herein, "tetraloop" in the context of a dsRNA refers to a loop (a single stranded region) consisting of four nucleotides that forms a stable secondary structure that contributes to the stability of adjacent Watson-Crick hybridized nucleotides. Without being limited to theory, a tetraloop may stabilize an adjacent Watson-Crick base pair by stacking interactions. In addition, interactions among the four nucleotides in a tetraloop include, but are not limited to, non-Watson-Crick base pairing, stacking interactions, hydrogen bonding, and contact interactions (Cheong et al., Nature 1990 Aug 16;346(6285):680-2; Heus and Pardi, Science 1991 Jul 12;253(5016): 191-4). A
tetraloop confers an increase in the melting temperature (Tm) of an adjacent duplex that is higher than expected from a simple model loop sequence consisting of four random bases. For example, a tetraloop can confer a melting temperature of at least 55 C in 10mM NaHPO4 to a hairpin comprising a duplex of at least 2 base pairs in length. A tetraloop may contain ribonucleotides, deoxyribonucleotides, modified nucleotides, and combinations thereof. Examples of RNA tetraloops include the UNCG family of tetraloops (e.g., UUCG), the GNRA family of tetraloops (e.g., GAAA), and the CUUG tetraloop.
(Woese et al., Proc Natl Acad Sci U S A. 1990 Nov;87(21):8467-71 ; Antao et al., Nucleic Acids Res.
1991 Nov 11;19(21):5901-5). Examples of DNA tetraloops include the d(GNNA) family of tetraloops (e.g., d(GTTA), the d(GNRA)) family of tetraloops, the d(GNAB) family of tetraloops, the d(CNNG) family of tetraloops, the d(TNCG) family of tetraloops (e.g., d(TTCG)).
(Nakano et al. Biochemistry, 41(48), 14281 -14292, 2002; Shinji et al. Nippon Kagakkai Koen Yokoshu vol.78th; no.2; page.731 (2000).) In certain embodiments of the invention, tetraloop- and modified nucleotide-containing dsNAs are contemplated as described, e.g., as described in U.S. Patent Publication No. 2011/0288147, the entire contents of which are incorporated by reference herein. In certain such embodiments, a dsNA of the invention possesses a first strand and a second strand, where the first strand and the second strand form a duplex region of 19-25 nucleotides in length, wherein the first strand comprises a 3' region that extends beyond the first strand-second strand duplex region and comprises a tetraloop, and the dsNA comprises a discontinuity between the 3' terminus of the first strand and the 5' terminus of the second strand.
Optionally, the discontinuity is positioned at a projected Dicer cleavage site of the tetraloop-containing double stranded nucleic acid (dsNA). It is contemplated that, as for any of the other dupexed oligonucleotides of the invention, tetraloop-containing duplexes of the invention can possess any range of modifications disclosed herein or otherwise known in the art, including, e.g., 2'-0-methyl, 2'- fluoro, inverted base, GalNAc moieties, etc. Typically, every nucleotide on both strands of the tetraloop-containing dsNA is chemically modified if the tetraloop-containing dsNA is going to be delivered without using lipid nanoparticles or some other delivery method that protects the dsNA
from degradation during the delivery process. However, in certain embodiments, one or more nucleotides are not modified.
Where the two substantially complementary strands of a dsRNA are comprised by separate RNA molecules, those molecules need not, but can be covalently connected.
Where the two strands are connected covalently by means other than an uninterrupted chain of nucleotides between the 3'-end of one strand and the 5'-end of the respective other strand forming the duplex structure, the connecting structure is referred to as a "linker." The RNA strands may have the same or a different number of nucleotides. The maximum number of base pairs is the number of nucleotides in the shortest strand of the dsRNA minus any overhangs that are present in the duplex. In addition to the duplex structure, an RNAi may comprise one or more nucleotide overhangs.
A dsRNA as described herein can further include one or more single-stranded nucleotide overhangs e.g., 1, 2, 3, or 4 nucleotides. dsRNAs having at least one nucleotide overhang can have unexpectedly superior inhibitory properties relative to their blunt-ended counterparts. A nucleotide overhang can comprise or consist of a nucleotide/nucleoside analog, including a deoxynucleotide/nucleoside. The overhang(s) can be on the sense strand, the antisense strand or any combination thereof. Furthermore, the nucleotide(s) of an overhang can be present on the 5'-end, 3'-end or both ends of either an antisense or sense strand of a dsRNA. In certain embodiments, longer, extended overhangs are possible.
A dsRNA can be synthesized by standard methods known in the art. iRNA
compounds of the invention may be prepared using a two-step procedure. First, the individual strands of the double stranded RNA molecule are prepared separately. Then, the component strands are annealed. The individual strands of the siRNA compound can be prepared using solution-phase or solid-phase organic synthesis or both. In certain embodiments, the iRNA compound is produced from an expression vector delivered into a cell.
In one aspect, a dsRNA of the invention includes at least two nucleotide sequences, a sense sequence and an anti-sense sequence. The sense strand is selected from the group of sequences provided in any one of the Tables in Appendix A, and the corresponding antisense strand of the sense strand is selected from the group of sequences of any one of the Tables in Appendix A.
In some embodiments, the sense strand is selected from the group of sequences provided in any one of the Tables in Appendix A, and the corresponding antisense strand of the sense strand is .. selected from the group of sequences of any one of the Tables in Appendix A. In this aspect, one of the two sequences is complementary to the other of the two sequences, with one of the sequences being substantially complementary to a sequence of an mRNA generated in the expression of an HBV
gene. As such, in this aspect, a dsRNA will include two oligonucleotides, where one oligonucleotide is described as the sense strand in any one of the Tables in Appendix A and the second oligonucleotide is described as the corresponding antisense strand of the sense strand in any one of the Tables in Appendix A. In one embodiment, the substantially complementary sequences of the dsRNA
are contained on separate oligonucleotides. In another embodiment, the substantially complementary sequences of the dsRNA are contained on a single oligonucleotide.
It is understood that, although some of the sequences in the Tables in Appendix A are .. described as modified or conjugated sequences, the RNA of the iRNA of the invention e.g., a dsRNA
of the invention, may comprise any one of the sequences set forth in the Tables in Appendix A that is un-modified, unconjugated, or modified or conjugated differently than described therein. Additional target sites are provided, for example, in PCT Publication Nos. WO
2016/077321, WO 2012/024170, WO 2017/027350, and WO 2013/003520; and in Michler, 2016, the entire contents of wach of which are incorporated herein by reference.
The skilled person is well aware that dsRNAs having a duplex structure of about 20 to 23 base pairs, e.g., 21, base pairs have been hailed as particularly effective in inducing RNA interference (Elbashir et al., EMBO 2001, 20:6877-6888). However, others have found that shorter or longer RNA
duplex structures can also be effective (Chu and Rana (2007) RNA 14:1714-1719;
Kim et al. (2005) Nat Biotech 23:222-226). In the embodiments described above, by virtue of the nature of the oligonucleotide sequences provided in any one of the Tables in Appendix A, dsRNAs described herein can include at least one strand of a length of minimally 21 nucleotides. It can be reasonably expected that shorter duplexes having one of the sequences of any one of the Tables in Appendix A
minus only a few nucleotides on one or both ends can be similarly effective as compared to the dsRNAs described above. Hence, dsRNAs having a sequence of at least 15, 16, 17, 18, 19, 20, or more contiguous nucleotides derived from one of the sequences of any one of the Tables in Appendix A and differing in their ability to inhibit the expression of an HBV gene by not more than 5, 10, 15, 20, 25, or 30 % inhibition from a dsRNA comprising the full sequence.
An iRNA as described herein can contain one or more mismatches to the target sequence, or to one or more HBV target sequences due, e.g., to sequence variations among the HBV genotypes. In one embodiment, an iRNA as described herein contains no more than 3 mismatches. If the antisense strand of the iRNA contains mismatches to a target sequence, it is preferable that the area of mismatch is not located in the center of the region of complementarity. If the antisense strand of the iRNA
contains mismatches to the target sequence, it is preferable that the mismatch be restricted to be within the last 5 nucleotides from either the 5'- or 3'-end of the region of complementarity. For example, for a 23 nucleotide iRNA agent the strand which is complementary to a region of an HBV
gene, generally does not contain any mismatch within the central 13 nucleotides. The methods described herein or methods known in the art can be used to determine whether an iRNA containing a mismatch to a target sequence is effective in inhibiting the expression of an HBV gene. Consideration of the efficacy of iRNAs with mismatches in inhibiting expression of an HBV
gene is important, especially if the particular region of complementarity in an HBV gene is known to have polymorphic sequence variation within various genotypes and the population.
i. Modified iRNAs For Use in the Methods of the Invention In some embodiments, the RNA of the iRNA for use in the invention e.g., a dsRNA, is un-modified, and does not comprise, e.g., chemical modifications or conjugations known in the art and described herein, e.g., when produced from an expression vector. In other embodiments, the RNA of an iRNA of the invention, e.g., a dsRNA, is chemically modified to enhance stability or other beneficial characteristics. In certain embodiments of the invention, substantially all of the nucleotides of an iRNA of the invention are modified. In other embodiments of the invention, all of the nucleotides of an iRNA of the invention are modified. iRNAs of the invention in which "substantially all of the nucleotides are modified" are largely but not wholly modified and can include not more than 5, 4, 3, 2, or 1 unmodified nucleotides.
The nucleic acids featured in the invention can be synthesized or modified by methods well established in the art, such as those described in "Current protocols in nucleic acid chemistry,"
Beaucage, S.L. et al. (Edrs.), John Wiley & Sons, Inc., New York, NY, USA, which is incorporated herein by reference. Modifications include, for example, end modifications, e.g., 5'-end modifications (phosphorylation, conjugation, inverted linkages) or 3'-end modifications (conjugation, DNA nucleotides, inverted linkages, etc.); base modifications, e.g., replacement with stabilizing bases, destabilizing bases, or bases that base pair with an expanded repertoire of partners, removal of bases (abasic nucleotides), or conjugated bases; sugar modifications (e.g., at the 2'-position or 4'-position) or replacement of the sugar; or backbone modifications, including modification or replacement of the phosphodiester linkages. Specific examples of iRNA
compounds useful in the embodiments described herein include, but are not limited to RNAs containing modified backbones or no natural internucleoside linkages. RNAs having modified backbones include, among others, those that do not have a phosphorus atom in the backbone. For the purposes of this specification, and as sometimes referenced in the art, modified RNAs that do not have a phosphorus atom in their internucleoside backbone can also be considered to be oligonucleosides. In some embodiments, a modified iRNA will have a phosphorus atom in its internucleoside backbone.
Modified RNA backbones include, for example, phosphorothioates, chiral phosphorothioates, phosphorodithioates, phosphotriesters, aminoalkylphosphotriesters, methyl and other alkyl phosphonates including 3'-alkylene phosphonates and chiral phosphonates, phosphinates, phosphoramidates including 3'-amino phosphoramidate and aminoalkylphosphoramidates, thionophosphoramidates, thionoalkylphosphonates, thionoalkylphosphotriesters, and boranophosphates having normal 3' -5' linkages, 2' -5' -linked analogs of these, and those having inverted polarity wherein the adjacent pairs of nucleoside units are linked 3'-5' to 5'-3' or 2'-5' to 5'-2'. Various salts, mixed salts and free acid forms are also included.
Representative US patents that teach the preparation of the above phosphorus-containing linkages include, but are not limited to, US Patent Nos. 3,687,808; 4,469,863;
4,476,301; 5,023,243;
5,177,195; 5,188,897; 5,264,423; 5,276,019; 5,278,302; 5,286,717; 5,321,131;
5,399,676; 5,405,939;
5,453,496; 5,455,233; 5,466,677; 5,476,925; 5,519,126; 5,536,821; 5,541,316;
5,550,111; 5,563,253;
5,571,799; 5,587,361; 5,625,050; 6,028,188; 6,124,445; 6,160,109; 6,169,170;
6,172,209; 6, 239,265;
6,277,603; 6,326,199; 6,346,614; 6,444,423; 6,531,590; 6,534,639; 6,608,035;
6,683,167; 6,858,715;
6,867,294; 6,878,805; 7,015,315; 7,041,816; 7,273,933; 7,321,029; and US Pat RE39464, the entire contents of each of which are hereby incorporated herein by reference.
Modified RNA backbones that do not include a phosphorus atom therein have backbones that are formed by short chain alkyl or cycloalkyl internucleoside linkages, mixed heteroatoms and alkyl or cycloalkyl internucleoside linkages, or one or more short chain heteroatomic or heterocyclic internucleoside linkages. These include those having morpholino linkages (formed in part from the sugar portion of a nucleoside); siloxane backbones; sulfide, sulfoxide and sulfone backbones;
formacetyl and thioformacetyl backbones; methylene formacetyl and thioformacetyl backbones;
alkene containing backbones; sulfamate backbones; methyleneimino and methylenehydrazino backbones; sulfonate and sulfonamide backbones; amide backbones; and others having mixed N, 0, S
and CH2 component parts.
Representative US patents that teach the preparation of the above oligonucleosides include, but are not limited to, US Patent Nos. 5,034,506; 5,166,315; 5,185,444;
5,214,134; 5,216,141;
5,235,033; 5,64,562; 5,264,564; 5,405,938; 5,434,257; 5,466,677; 5,470,967;
5,489,677; 5,541,307;
5,561,225; 5,596,086; 5,602,240; 5,608,046; 5,610,289; 5,618,704; 5,623,070;
5,663,312; 5,633,360;
5,677,437; and, 5,677,439, the entire contents of each of which are hereby incorporated herein by reference.
In other embodiments, suitable RNA mimetics are contemplated for use in iRNAs, in which both the sugar and the internucleoside linkage, i.e., the backbone, of the nucleotide units are replaced with novel groups. The base units are maintained for hybridization with an appropriate nucleic acid target compound. One such oligomeric compound, an RNA mimetic that has been shown to have excellent hybridization properties, is referred to as a peptide nucleic acid (PNA). In PNA compounds, the sugar backbone of an RNA is replaced with an amide containing backbone, in particular an aminoethylglycine backbone. The nucleobases are retained and are bound directly or indirectly to aza nitrogen atoms of the amide portion of the backbone. Representative US patents that teach the preparation of PNA compounds include, but are not limited to, US Patent Nos.
5,539,082; 5,714,331;
and 5,719,262, the entire contents of each of which are hereby incorporated herein by reference.
Additional PNA compounds suitable for use in the iRNAs of the invention are described in, for example, in Nielsen et al., Science, 1991, 254, 1497-1500.
Some embodiments featured in the invention include RNAs with phosphorothioate backbones and oligonucleosides with heteroatom backbones, and in particular ¨CH2¨NH¨CH2-, --CH2¨N(CH3)-0¨CH24known as a methylene (methylimino) or MMI backbone], --CH2-0¨N(CH3)¨CH2--, --CH2¨
N(CH3)¨N(CH3)¨CH2¨and ¨N(CH3)¨CH2¨CH24wherein the native phosphodiester backbone is represented as ¨0¨P¨O¨CH2--] of the above-referenced US Patent No. 5,489,677, and the amide backbones of the above-referenced US Patent No. 5,602,240. In some embodiments, the RNAs featured herein have morpholino backbone structures of the above-referenced US
Patent No.
5,034,506.
Modified RNAs can also contain one or more substituted sugar moieties. The iRNAs, e.g., dsRNAs, featured herein can include one of the following at the 2'-position:
OH; F; 0-, S-, or N-alkyl; 0-, S-, or N-alkenyl; 0-, S- or N-alkynyl; or 0-alkyl-0-alkyl, wherein the alkyl, alkenyl and alkynyl can be substituted or unsubstituted Ci to Ci0 alkyl or C2 to Cio alkenyl and alkynyl.
Exemplary suitable modifications include ORCH2).0] .CH3, 0(CH2).110CH3, 0(CH2).NH2, 0(CH2) .CH3, 0(CH2).0NH2, and 0(CH2).0NRCH2).CH3)]2, where n and m are from 1 to about 10. In other embodiments, dsRNAs include one of the following at the 2' position: Ci to C10 lower alkyl, substituted lower alkyl, alkaryl, aralkyl, 0-alkaryl or 0-aralkyl, SH, SCH3, OCN, Cl, Br, CN, CF3, OCF3, SOCH3, 502CH3, 0NO2, NO2, N3, NH2, heterocycloalkyl, heterocycloalkaryl, aminoalkylamino, polyalkylamino, substituted silyl, an RNA cleaving group, a reporter group, an intercalator, a group for improving the pharmacokinetic properties of an iRNA, or a group for improving the pharmacodynamic properties of an iRNA, and other substituents having similar properties. In some embodiments, the modification includes a 2'-methoxyethoxy (2'-0-CH2CH2OCH3, also known as 2'-0-(2-methoxyethyl) or 2'-M0E) (Martin et al., Hely. Chim. Acta, 1995, 78:486-504) i.e., an alkoxy-alkoxy group. Another exemplary modification is 2' -dimethylaminooxyethoxy, i.e., a 0(CH2)20N(CH3)2 group, also known as 2'-DMA0E, as described in examples herein below, and 2'-dimethylaminoethoxyethoxy (also known in the art as 2'-0-dimethylaminoethoxyethyl or 2'-DMAEOE), i.e., 2'-O¨CH2-0¨CH2¨N(CH2)2.
Other modifications include 2' -methoxy (2'-OCH3), 2'-aminopropoxy (2'-OCH2CH2CH2NH2) and 2'-fluoro (2'-F). Similar modifications can also be made at other positions on the RNA of an iRNA, particularly the 3' position of the sugar on the 3' terminal nucleotide or in 2'-5' linked dsRNAs and the 5' position of 5' terminal nucleotide. iRNAs can also have sugar mimetics such as cyclobutyl moieties in place of the pentofuranosyl sugar.
Representative US patents that teach the preparation of such modified sugar structures include, but are not limited to, US Patent Nos.
4,981,957; 5,118,800; 5,319,080; 5,359,044; 5,393,878; 5,446,137; 5,466,786;
5,514,785; 5,519,134;
5,567,811; 5,576,427; 5,591,722; 5,597,909; 5,610,300; 5,627,053; 5,639,873;
5,646,265; 5,658,873;
5,670,633; and 5,700,920, certain of which are commonly owned with the instant application,. The entire contents of each of the foregoing are hereby incorporated herein by reference.
The RNA of an iRNA can also include nucleobase (often referred to in the art simply as "base") modifications or substitutions. As used herein, "unmodified" or "natural" nucleobases include the purine bases adenine (A) and guanine (G), and the pyrimidine bases thymine (T), cytosine (C) and uracil (U). Modified nucleobases include other synthetic and natural nucleobases such as deoxy-thymine (dT), 5-methylcytosine (5-me-C), 5-hydroxymethyl cytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-halouracil and cytosine, 5-propynyl uracil and cytosine, 6-azo uracil, cytosine and thymine, 5-uracil (pseudouracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl anal other 8-substituted adenines and guanines, 5-halo, particularly 5-bromo, 5-trifluoromethyl and other 5-substituted uracils and cytosines, 7-methylguanine and 7-methyladenine, 8-azaguanine and 8-azaadenine, 7-deazaguanine and 7-daazaadenine and 3-deazaguanine and 3-deazaadenine. Further nucleobases include those disclosed in US Patent No. 3,687,808, those disclosed in Modified Nucleosides in Biochemistry, Biotechnology and Medicine, Herdewijn, P. ed. Wiley-VCH, 2008; those disclosed in The Concise Encyclopedia Of Polymer Science And Engineering, pages 858-859, Kroschwitz, J.
L, ed. John Wiley & Sons, 1990, these disclosed by Englisch et al., Angewandte Chemie, International Edition, 1991, 30, 613, and those disclosed by Sanghvi, Y S., Chapter 15, dsRNA Research and Applications, pages 289-302, Crooke, S. T. and Lebleu, B., Ed., CRC Press, 1993. Certain of these nucleobases are particularly useful for increasing the binding affinity of the oligomeric compounds featured in the invention. These include 5-substituted pyrimidines, 6-azapyrimidines and N-2, N-6 and 0-6 substituted purines, including 2-aminopropyladenine, 5-propynyluracil and 5-propynylcytosine. 5-methylcytosine substitutions have been shown to increase nucleic acid duplex stability by 0.6-1.2 C
(Sanghvi, Y. S., Crooke, S. T. and Lebleu, B., Eds., dsRNA Research and Applications, CRC Press, Boca Raton, 1993, pp. 276-278) and are exemplary base substitutions, even more particularly when combined with 2'-0-methoxyethyl sugar modifications.
Representative US patents that teach the preparation of certain of the above noted modified nucleobases as well as other modified nucleobases include, but are not limited to, the above noted US
Patent Nos. 3,687,808, 4,845,205; 5,130,30; 5,134,066; 5,175,273; 5,367,066;
5,432,272; 5,457,187;
5,459,255; 5,484,908; 5,502,177; 5,525,711; 5,552,540; 5,587,469; 5,594,121, 5,596,091; 5,614,617;
5,681,941; 5,750,692; 6,015,886; 6,147,200; 6,166,197; 6,222,025; 6,235,887;
6,380,368; 6,528,640;
6,639,062; 6,617,438; 7,045,610; 7,427,672; and 7,495,088, the entire contents of each of which are hereby incorporated herein by reference.
The RNA of an iRNA can also be modified to include one or more locked nucleic acids (LNA). A locked nucleic acid is a nucleotide having a modified ribose moiety in which the ribose moiety comprises an extra bridge connecting the 2' and 4' carbons. This structure effectively "locks"
the ribose in the 3'-endo structural conformation. The addition of locked nucleic acids to siRNAs has been shown to increase siRNA stability in serum, and to reduce off-target effects (Elmen, J. et al., (2005) Nucleic Acids Research 33(1):439-447; Mook, OR. et al., (2007) Mol Canc Ther 6(3):833-843; Grunweller, A. et al., (2003) Nucleic Acids Research 31(12):3185-3193).
In some embodiments, the iRNA of the invention comprises one or more monomers that are UNA (unlocked nucleic acid) nucleotides. UNA is unlocked acyclic nucleic acid, wherein any of the bonds of the sugar has been removed, forming an unlocked "sugar" residue. In one example, UNA
also encompasses monomer with bonds between C1'-C4' have been removed (i.e.
the covalent carbon-oxygen-carbon bond between the Cl' and C4' carbons). In another example, the C2'-C3' bond (i.e. the covalent carbon-carbon bond between the C2' and C3' carbons) of the sugar has been removed (see Nuc. Acids Symp. Series, 52, 133-134 (2008) and Fluiter et al., Mol. Biosyst., 2009, 10, 1039 hereby incorporated by reference).
The RNA of an iRNA can also be modified to include one or more bicyclic sugar moities. A
"bicyclic sugar" is a furanosyl ring modified by the bridging of two atoms.
A"bicyclic nucleoside"("BNA") is a nucleoside having a sugar moiety comprising a bridge connecting two carbon atoms of the sugar ring, thereby forming a bicyclic ring system. In certain embodiments, the bridge connects the 4'-carbon and the 2'-carbon of the sugar ring. Thus, in some embodiments an agent of the invention may include one or more locked nucleic acids (LNA). A
locked nucleic acid is a nucleotide having a modified ribose moiety in which the ribose moiety comprises an extra bridge connecting the 2' and 4' carbons. In other words, an LNA is a nucleotide comprising a bicyclic sugar moiety comprising a 4'-CH2-0-2' bridge. This structure effectively "locks" the ribose in the 3'-endo structural conformation. The addition of locked nucleic acids to siRNAs has been shown to increase siRNA stability in serum, and to reduce off-target effects (Elmen, J. et al., (2005) Nucleic Acids Research 33(1):439-447; Mook, OR. Et al., (2007) Mol Canc Ther 6(3):833-843;
Grunweller, A. et al., (2003) Nucleic Acids Research 31(12):3185-3193). Examples of bicyclic nucleosides for use in the polynucleotides of the invention include without limitation nucleosides comprising a bridge between the 4' and the 2' ribosyl ring atoms. In certain embodiments, the antisense polynucleotide agents of the invention include one or more bicyclic nucleosides comprising a 4' to 2' bridge.
Examples of such 4' to 2' bridged bicyclic nucleosides, include but are not limited to 4'-(CH2)-0-2' (LNA); 4'-(CH2)¨S-2'; 4'-(CH2)2-0-2' (ENA); 4'-CH(CH3)-0-2' (also referred to as "constrained ethyl" or "cEt") and 4'-CH(CH2OCH3)-0-2' (and analogs thereof;
see, e.g., US Patent No. 7,399,845); 4'-C(CH3)(CH3)-0-2' (and analogs thereof; see e.g., US Patent No. 8,278,283); 4'-CH2¨N(OCH3)-2' (and analogs thereof; see e.g., US Patent No. 8,278,425); 4'-CH2-0¨N(CH3)-2' (see, e.g.,US20040171570); 4'-CH2¨N(R)-0-2', wherein R is H, C1-C12 alkyl, or a protecting group (see, e.g., US Patent No. 7,427,672); 4'-CH2¨C(H)(CH3)-2' (see, e.g., Chattopadhyaya et al., J. Org. Chem., 2009, 74, 118-134); and 4'-CH2¨C(=CH2)-2' (and analogs thereof;
see, e.g., US
Patent No. 8,278,426). The entire contents of each of the foregoing are hereby incorporated herein by reference.
Additional representative US patents and US patent publications that teach the preparation of locked nucleic acid nucleotides include, but are not limited to, the following: US Patent Nos.
6,268,490; 6,525,191; 6,670,461; 6,770,748; 6,794,499; 6,998,484; 7,053,207;
7,034,133;7,084,125;
7,399,845; 7,427,672; 7,569,686; 7,741,457; 8,022,193; 8,030,467; 8,278,425;
8,278,426; 8,278,283;
US 20080039618; and US 20090012281, the entire contents of each of which are hereby incorporated herein by reference.
Any of the foregoing bicyclic nucleosides can be prepared having one or more stereochemical sugar configurations including for example a-L-ribofuranose and I3-D-ribofuranose (see WO
99/14226).
The RNA of an iRNA can also be modified to include one or more constrained ethyl nucleotides. As used herein, a "constrained ethyl nucleotide" or "cEt" is a locked nucleic acid comprising a bicyclic sugar moiety comprising a 4'-CH(CH3)-0-2' bridge. In one embodiment, a constrained ethyl nucleotide is in the S conformation referred to herein as "S-cEt."
An iRNA of the invention may also include one or more "conformationally restricted nucleotides" ("CRN"). CRN are nucleotide analogs with a linker connecting the C2' and C4' carbons of ribose or the C3 and -05' carbons of ribose. CRN lock the ribose ring into a stable conformation and increase the hybridization affinity to mRNA. The linker is of sufficient length to place the oxygen in an optimal position for stability and affinity resulting in less ribose ring puckering.
Representative publications that teach the preparation of certain of the above noted CRN
include, but are not limited to, US 20130190383 and WO 2013036868, the entire contents of each of which are hereby incorporated herein by reference.
Potentially stabilizing modifications to the ends of RNA molecules can include N-(acetylaminocaproy1)-4-hydroxyprolinol (Hyp-C6-NHAc), N-(caproy1-4-hydroxyprolinol (Hyp-C6), N-(acetyl-4-hydroxyprolinol (Hyp-NHAc), thymidine-2'-0-deoxythymidine (ether), N-(aminocaproy1)-4-hydroxyprolinol (Hyp-C6-amino), 2-docosanoyl-uridine-3"-phosphate, inverted base dT(idT) and others. Disclosure of this modification can be found in WO
2011005861.
Other modifications of the nucleotides of an iRNA of the invention include a 5' phosphate or 5' phosphate mimic, e.g., a 5'-terminal phosphate or phosphate mimic on the antisense strand of an RNAi agent. Suitable phosphate mimics are disclosed in, for example U520120157511, the entire contents of which are incorporated herein by reference.
In certain specific embodiments, the RNAi agent for use in the methods of the invention is an agent selected from the group of agents listed in any one of the Tables in Appendix A. These agents may further comprise a ligand.
ii. iRNAs Conjugated to Ligands Another modification of the RNA of an iRNA of the invention involves chemically linking to the RNA one or more ligands, moieties or conjugates that enhance the activity, cellular distribution, or cellular uptake of the iRNA. Such moieties include but are not limited to lipid moieties such as a cholesterol moiety (Letsinger et al., Proc. Natl. Acid. Sci. USA, 1989, 86:
6553-6556), cholic acid (Manoharan et al., Biorg. Med. Chem. Let., 1994, 4:1053-1060), a thioether, e.g., beryl-S-tritylthiol (Manoharan et al., Ann. N.Y. Acad. Sci., 1992, 660:306-309; Manoharan et al., Biorg. Med. Chem.
Let., 1993, 3:2765-2770), a thiocholesterol (Oberhauser et al., Nucl. Acids Res., 1992, 20:533-538), an aliphatic chain, e.g., dodecandiol or undecyl residues (Saison-Behmoaras et al., EMBO J, 1991,
10:1111-1118; Kabanov et al., FEBS Lett., 1990, 259:327-330; Svinarchuk et al., Biochimie, 1993, 75:49-54), a phospholipid, e.g., di-hexadecyl-rac-glycerol or triethyl-ammonium 1,2-di-O-hexadecyl-rac-glycero-3-phosphonate (Manoharan et al., Tetrahedron Lett., 1995, 36:3651-3654; Shea et al., Nucl. Acids Res., 1990, 18:3777-3783), a polyamine or a polyethylene glycol chain (Manoharan et al., Nucleosides & Nucleotides, 1995, 14:969-973), or adamantane acetic acid (Manoharan et al., Tetrahedron Lett., 1995, 36:3651-3654), a palmityl moiety (Mishra et al., Biochim. Biophys. Acta, 1995, 1264:229-237), or an octadecylamine or hexylamino-carbonyloxycholesterol moiety (Crooke et al., J. Pharmacol. Exp. Ther., 1996, 277:923-937).
In one embodiment, a ligand alters the distribution, targeting, or lifetime of an iRNA agent into which it is incorporated. In preferred embodiments a ligand provides an enhanced affinity for a selected target, e.g., molecule, cell or cell type, compartment, e.g., a cellular or organ compartment, tissue, organ or region of the body, as, e.g., compared to a species absent such a ligand. Preferred ligands will not take part in duplex pairing in a duplexed nucleic acid.
Ligands can include a naturally occurring substance, such as a protein (e.g., human serum albumin (HSA), low-density lipoprotein (LDL), or globulin); carbohydrate (e.g., a dextran, pullulan, chitin, chitosan, inulin, cyclodextrin, N-acetylgalactosamine, or hyaluronic acid); or a lipid. The ligand can also be a recombinant or synthetic molecule, such as a synthetic polymer, e.g., a synthetic polyamino acid. Examples of polyamino acids include polyamino acid is a polylysine (PLL), poly L-aspartic acid, poly L-glutamic acid, styrene-maleic acid anhydride copolymer, poly(L-lactide-co-glycolied) copolymer, divinyl ether-maleic anhydride copolymer, N-(2-hydroxypropyl)methacrylamide copolymer (HMPA), polyethylene glycol (PEG), polyvinyl alcohol (PVA), polyurethane, poly(2-ethylacryllic acid), N-isopropylacrylamide polymers, or polyphosphazine. Example of polyamines include: polyethylenimine, polylysine (PLL), spermine, spermidine, polyamine, pseudopeptide-polyamine, peptidomimetic polyamine, dendrimer polyamine, arginine, amidine, protamine, cationic lipid, cationic porphyrin, quaternary salt of a polyamine, or an alpha helical peptide.
Ligands can also include targeting groups, e.g., a cell or tissue targeting agent, e.g., a lectin, glycoprotein, lipid, or protein, e.g., an antibody, that binds to a specified cell type such as a kidney cell. A targeting group can be a thyrotropin, melanotropin, lectin, glycoprotein, surfactant protein A, Mucin carbohydrate, multivalent lactose, monovalent or multivalent galactose, N-acetyl-galactosamine, N-acetyl-gulucoseamine multivalent mannose, multivalent fucose, glycosylated polyaminoacids, transferrin, bisphosphonate, polyglutamate, polyaspartate, a lipid, cholesterol, a steroid, bile acid, folate, vitamin B12, vitamin A, biotin, or an RGD peptide or RGD peptide mimetic.
In certain embodiments, ligands include monovalent or multivalent galactose.
In certain embodiments, ligands include cholesterol.
Other examples of ligands include dyes, intercalating agents (e.g. acridines), cross-linkers (e.g. psoralene, mitomycin C), porphyrins (TPPC4, texaphyrin, Sapphyrin), polycyclic aromatic hydrocarbons (e.g., phenazine, dihydrophenazine), artificial endonucleases (e.g. EDTA), lipophilic molecules, e.g., cholesterol, cholic acid, adamantane acetic acid, 1-pyrene butyric acid, dihydrotestosterone, 1,3-Bis-0(hexadecyl)glycerol, geranyloxyhexyl group, hexadecylglycerol, borneol, menthol, 1,3-propanediol, heptadecyl group, palmitic acid, myristic acid,03-(oleoyl)lithocholic acid, 03-(oleoyl)cholenic acid, dimethoxytrityl, or phenoxazine)and peptide conjugates (e.g., antennapedia peptide, Tat peptide), alkylating agents, phosphate, amino, mercapto, PEG (e.g., PEG-40K), MPEG, [MPEG12, polyamino, alkyl, substituted alkyl, radiolabeled markers, enzymes, haptens (e.g. biotin), transport/absorption facilitators (e.g., aspirin, vitamin E, folic acid), synthetic ribonucleases (e.g., imidazole, bisimidazole, histamine, imidazole clusters, acridine-imidazole conjugates, Eu3+ complexes of tetraazamacrocycles), dinitrophenyl, HRP, or AP.
Ligands can be proteins, e.g., glycoproteins, or peptides, e.g., molecules having a specific affinity for a co-ligand, or antibodies e.g., an antibody, that binds to a specified cell type such as a hepatic cell. Ligands can also include hormones and hormone receptors. They can also include non-peptidic species, such as lipids, lectins, carbohydrates, vitamins, cofactors, multivalent lactose, monovalent or multivalent galactose, N-acetyl-galactosamine, N-acetyl-gulucosamine multivalent mannose, or multivalent fucose. The ligand can be, for example, a lipopolysaccharide, an activator of p38 MAP kinase, or an activator of NF-KB.
The ligand can be a substance, e.g., a drug, which can increase the uptake of the iRNA agent into the cell, for example, by disrupting the cell's cytoskeleton, e.g., by disrupting the cell's microtubules, microfilaments, or intermediate filaments. The drug can be, for example, taxon, vincristine, vinblastine, cytochalasin, nocodazole, japlakinolide, latrunculin A, phalloidin, swinholide A, indanocine, or myoservin.
In some embodiments, a ligand attached to an iRNA as described herein acts as a pharmacokinetic modulator (PK modulator). PK modulators include lipophiles, bile acids, steroids, phospholipid analogues, peptides, protein binding agents, PEG, vitamins etc.
Exemplary PK
modulators include, but are not limited to, cholesterol, fatty acids, cholic acid, lithocholic acid, dialkylglycerides, diacylglyceride, phospholipids, sphingolipids, naproxen, ibuprofen, vitamin E, biotin etc. Oligonucleotides that comprise a number of phosphorothioate linkages are also known to bind to serum protein, thus short oligonucleotides, e.g., oligonucleotides of about 5 bases, 10 bases, 15 bases or 20 bases, comprising multiple of phosphorothioate linkages in the backbone are also amenable to the present invention as ligands (e.g. as PK modulating ligands).
In addition, aptamers that bind serum components (e.g. serum proteins) are also suitable for use as PK modulating ligands in the embodiments described herein.
Ligand-conjugated oligonucleotides of the invention may be synthesized by the use of an oligonucleotide that bears a pendant reactive functionality, such as that derived from the attachment of a linking molecule onto the oligonucleotide (described below). This reactive oligonucleotide may be reacted directly with commercially-available ligands, ligands that are synthesized bearing any of a variety of protecting groups, or ligands that have a linking moiety attached thereto.
The oligonucleotides used in the conjugates of the present invention may be conveniently and routinely made through the well-known technique of solid-phase synthesis.
Equipment for such synthesis is sold by several vendors including, for example, Applied Biosystems (Foster City, Calif.).
Any other means for such synthesis known in the art may additionally or alternatively be employed. It is also known to use similar techniques to prepare other oligonucleotides, such as the phosphorothioates and alkylated derivatives.
In the ligand-conjugated oligonucleotides and ligand-molecule bearing sequence-specific linked nucleosides of the present invention, the oligonucleotides and oligonucleosides may be assembled on a suitable DNA synthesizer utilizing standard nucleotide or nucleoside precursors, or nucleotide or nucleoside conjugate precursors that already bear the linking moiety, ligand-nucleotide or nucleoside-conjugate precursors that already bear the ligand molecule, or non-nucleoside ligand-bearing building blocks.
When using nucleotide-conjugate precursors that already bear a linking moiety, the synthesis of the sequence-specific linked nucleosides is typically completed, and the ligand molecule is then .. reacted with the linking moiety to form the ligand-conjugated oligonucleotide. In some embodiments, the oligonucleotides or linked nucleosides of the present invention are synthesized by an automated synthesizer using phosphoramidites derived from ligand-nucleoside conjugates in addition to the standard phosphoramidites and non-standard phosphoramidites that are commercially available and routinely used in oligonucleotide synthesis.
1. Lipid Conjugates In one embodiment, the ligand or conjugate is a lipid or lipid-based molecule.
Such a lipid or lipid-based molecule preferably binds a serum protein, e.g., human serum albumin (HSA). An HSA
binding ligand allows for distribution of the conjugate to a target tissue, e.g., a non-kidney target tissue of the body. For example, the target tissue can be the liver, including parenchymal cells of the liver. Other molecules that can bind HSA can also be used as ligands. For example, naproxen or aspirin can be used. A lipid or lipid-based ligand can (a) increase resistance to degradation of the conjugate, (b) increase targeting or transport into a target cell or cell membrane, or (c) can be used to adjust binding to a serum protein, e.g., HSA.
A lipid based ligand can be used to inhibit, e.g., control the binding of the conjugate to a target tissue. For example, a lipid or lipid-based ligand that binds to HSA
more strongly will be less likely to be targeted to the kidney and therefore less likely to be cleared from the body. A lipid or lipid-based ligand that binds to HSA less strongly can be used to target the conjugate to the kidney.
In a preferred embodiment, the lipid based ligand binds HSA. Preferably, it binds HSA with a sufficient affinity such that the conjugate will be preferably distributed to a non-kidney tissue.
However, it is preferred that the affinity not be so strong that the HSA-ligand binding cannot be reversed.
In another preferred embodiment, the lipid based ligand binds HSA weakly or not at all, such that the conjugate will be preferably distributed to the kidney. Other moieties that target to kidney cells can also be used in place of or in addition to the lipid based ligand.
In another aspect, the ligand is a moiety, e.g., a vitamin, which is taken up by a target cell, e.g., a proliferating cell. These are particularly useful for treating disorders characterized by unwanted cell proliferation, e.g., of the malignant or non-malignant type, e.g., cancer cells.
Exemplary vitamins include vitamin A, E, and K. Other exemplary vitamins include are B vitamin, e.g., folic acid, B12, riboflavin, biotin, pyridoxal or other vitamins or nutrients taken up by target cells such as liver cells. Also included are HSA and low density lipoprotein (LDL).
2. Cell Permeation Agents In another aspect, the ligand is a cell-permeation agent, preferably a helical cell-permeation agent. Preferably, the agent is amphipathic. An exemplary agent is a peptide such as tat or antennopedia. If the agent is a peptide, it can be modified, including a peptidylmimetic, invertomers, non-peptide or pseudo-peptide linkages, and use of D-amino acids. The helical agent is preferably an alpha-helical agent, which preferably has a lipophilic and a lipophobic phase.
The ligand can be a peptide or peptidomimetic. A peptidomimetic (also referred to herein as an oligopeptidomimetic) is a molecule capable of folding into a defined three-dimensional structure similar to a natural peptide. The attachment of peptide and peptidomimetics to iRNA agents can affect pharmacokinetic distribution of the iRNA, such as by enhancing cellular recognition and absorption. The peptide or peptidomimetic moiety can be about 5-50 amino acids long, e.g., about 5, 10, 15, 20, 25, 30, 35, 40, 45, or 50 amino acids long.
A peptide or peptidomimetic can be, for example, a cell permeation peptide, cationic peptide, amphipathic peptide, or hydrophobic peptide (e.g., consisting primarily of Tyr, Trp or Phe). The peptide moiety can be a dendrimer peptide, constrained peptide or crosslinked peptide. In another alternative, the peptide moiety can include a hydrophobic membrane translocation sequence (MTS).
An exemplary hydrophobic MTS-containing peptide is RFGF having the amino acid sequence AAVALLPAVLLALLAP (SEQ ID NO: 33). An RFGF analogue (e.g., amino acid sequence AALLPVLLAAP (SEQ ID NO: 34) containing a hydrophobic MTS can also be a targeting moiety.
The peptide moiety can be a "delivery" peptide, which can carry large polar molecules including peptides, oligonucleotides, and protein across cell membranes. For example, sequences from the HIV
Tat protein (GRKKRRQRRRPPQ (SEQ ID NO: 35) and the Drosophila Antennapedia protein (RQIKIWFQNRRMKWKK (SEQ ID NO: 36) have been found to be capable of functioning as delivery peptides. A peptide or peptidomimetic can be encoded by a random sequence of DNA, such as a peptide identified from a phage-display library, or one-bead-one-compound (OBOC) combinatorial library (Lam et al., Nature, 354:82-84, 1991). Examples of a peptide or peptidomimetic tethered to a dsRNA agent via an incorporated monomer unit for cell targeting purposes is an arginine-glycine-aspartic acid (RGD)-peptide, or RGD mimic. A
peptide moiety can range in length from about 5 amino acids to about 40 amino acids. The peptide moieties can have a structural modification, such as to increase stability or direct conformational properties. Any of the structural modifications described below can be utilized.
An RGD peptide for use in the compositions and methods of the invention may be linear or cyclic, and may be modified, e.g., glycosylated or methylated, to facilitate targeting to a specific tissue(s). RGD-containing peptides and peptidiomimemtics may include D-amino acids, as well as synthetic RGD mimics. In addition to RGD, one can use other moieties that target the integrin ligand.
Preferred conjugates of this ligand target PECAM-1 or VEGF.
A "cell permeation peptide" is capable of permeating a cell, e.g., a microbial cell, such as a bacterial or fungal cell, or a mammalian cell, such as a human cell. A
microbial cell-permeating peptide can be, for example, an a-helical linear peptide (e.g., LL-37 or Ceropin P1), a disulfide bond-containing peptide (e.g., a -defensin, I3-defensin or bactenecin), or a peptide containing only one or two dominating amino acids (e.g., PR-39 or indolicidin). A cell permeation peptide can also include a nuclear localization signal (NLS). For example, a cell permeation peptide can be a bipartite amphipathic peptide, such as MPG, which is derived from the fusion peptide domain of HIV-1 gp41 and the NLS of SV40 large T antigen (Simeoni et al., Nucl. Acids Res. 31:2717-2724, 2003).
3. Carbohydrate Conjugates In some embodiments of the compositions and methods of the invention, an iRNA
oligonucleotide further comprises a carbohydrate. The carbohydrate conjugated iRNA are advantageous for the in vivo delivery of nucleic acids, as well as compositions suitable for in vivo therapeutic use, as described herein. As used herein, "carbohydrate" refers to a compound which is either a carbohydrate per se made up of one or more monosaccharide units having at least 6 carbon atoms (which can be linear, branched or cyclic) with an oxygen, nitrogen or sulfur atom bonded to each carbon atom; or a compound having as a part thereof a carbohydrate moiety made up of one or more monosaccharide units each having at least six carbon atoms (which can be linear, branched or cyclic), with an oxygen, nitrogen or sulfur atom bonded to each carbon atom.
Representative carbohydrates include the sugars (mono-, di-, tri- and oligosaccharides containing from about 4, 5, 6, 7, 8, or 9 monosaccharide units), and polysaccharides such as starches, glycogen, cellulose and polysaccharide gums. Specific monosaccharides include C5 and above (e.g., C5, C6, C7, or C8) sugars; di- and trisaccharides include sugars having two or three monosaccharide units (e.g., C5, C6, C7, or C8).
In one embodiment, a carbohydrate conjugate for use in the compositions and methods of the invention is a monosaccharide. In another embodiment, a carbohydrate conjugate for use in the compositions and methods of the invention is selected from the group consisting of:
OH
H0.7...._.
HOOr.1\1,N 0 AcHN 0 HO OH
0, HO 0,(N,N1.0õ7"Nj AcHN 0 0 ICI
O
HO H
AcHN H H
0 Formula II, HO HO
HOT
HO HO H
HO1......\H
0, 0õ,...^Ø---...õ0õ..,..,,N_I---,....,0õ,...-i'l HO HO HO CY
HOFic¨;......j4 0c)õ.0 ,N4 H Formula III, OH
HO....\.....
HO 0()0 OH NHAc \----\
HO....\.... N-HO 0()0 NHAc Formula IV, OH
HO,.....\.....
NHAc OH
H
H4HO 00.,¨/-0 NHAc Formula V, HO OH
HO,...4.D...\ H
OrN
\
N
HO OHHAc 0 HO.-41\O1 NH/
NHAc 0 Formula VI, HO OH
HO OH NHAc HOO,3 NHAc Ho oH
HO....\.C.)....) NHAc Formula VII, Bz2?_Boz Bz0 i-----\
Bz0 __ B.z0.0Bz 0 OAc f -0 Bz0 0 (Dlq,Formula VIII, HC OH
.T...........\/
HO
H
NNy0 AcHN H 0 OH
HO
HO O ..:) N
.\/ 0 c H
NO
AcHN H T 0 OH
HO
0 oi___LI
HO-NO
HO
AcHN H Formula IX, O
HO H
HO 0c)ONO
AcHN H
OH
Ho e (=) _c._2.\/
HO 0c)ON
AcHN H
OH
) HO
0c),ON,0 HO
AcHN H Formula X, Fi'03 H0(3)--\ - ?-1 H
___________ HO_- -' ) (1)Po; 1 ...__Ot_Ho HO \ - H
HO------\1 0 e H c O ' ¨
0.,..,..--Ø-"-..-ON 0 H Formula XI, O PcT3 cHo HO
HO
H H
P63 01,-NN) !_?..._____!H 0 c...)._\
HO
HO 1Z) H H
pr_ OrNN1Ø-,,µ,,, _C2._:....OH 0 0 e HO
0...................,...r.NNO
H H
0 Formula XII, .,r.(2.....\/0.,)i-,.. ----...--._ _ENI
_ ir \
AcHN H 0 HO 0,=c H
m---......----.....----.....N 0.-----...----v AcHN
0 ,----HOv_OH 0 H 0 HO.,01¨NmNJLO---AcHN H Formula XIII, HO H
..:7-.._?.._\
HO\ 1.3H.f....... HO o 0 AcHN
0 0 0 -).L NH
HO
AcHN /\)LN/\/sr H
0 Formula XIV, HO\ __. H
HO ----r-?-o 0 HOµ 1_)_HT...... AcHN
0 0 0 =)NH
HO
AcHN
H
0 Formula XV, HOµ _... H
H 0 -----r I-2--o 0 HO (:__Ir....-1_,....\ AcHN
u 0 0 .LNH
HO
H
0 Formula XVI, OH
HO 1:2 "----___7...\0 HO ).L
HOHO 0 0 ...r...... 0 -1\1H
HO
H
0 Formula XVII, OH
OH
H0 ,r2\0 HO
'NH
HO
HO
0 Formula XVIII, ()H
OH H 1-1¨C-3--T9.-o 0 HO HO
II
HO
0 Formula XIX, H0j-- OH
HO
HO
HO
0 Formula XX, HO OH
HO
HO
HO
HO
0.LNPrPI
0 Formula XXI, HO:-.\ 10H
HO
HO
HO
0)LN'Pri 0 Formula XXII.
In one embodiment, the monosaccharide is an N-acetylgalactosamine, such as HO OH
HO _-7O( 0 AcHN
HO OH
HO
AcHN
O
HO H
HOONNO
AcHN
0 Formula II.
Another representative carbohydrate conjugate for use in the embodiments described herein includes, but is not limited to, H cp..c.TOH
HO
AcHN
H /OH 0 o HO
AcHN H H
X0, H /OH
L
HO
AcHN N
jcis(:0,Lo 0 (Formula XXIII), when one of X or Y is an oligonucleotide, the other is a hydrogen.
In certain embodiments of the invention, the GalNAc or GalNAc derivative is attached to an iRNA agent of the invention via a monovalent linker. In some embodiments, the GalNAc or GalNAc derivative is attached to an iRNA agent of the invention via a bivalent linker. In yet other embodiments of the invention, the GalNAc or GalNAc derivative is attached to an iRNA agent of the invention via a trivalent linker.
In one embodiment, the double stranded RNAi agents of the invention comprise one GalNAc or GalNAc derivative attached to the iRNA agent. In another embodiment, the double stranded RNAi agents of the invention comprise a plurality (e.g., 2, 3, 4, 5, or 6) GalNAc or GalNAc derivatives, each independently attached to a plurality of nucleotides of the double stranded RNAi agent through a plurality of monovalent linkers.
In some embodiments, for example, when the two strands of an iRNA agent of the invention are part of one larger molecule connected by an uninterrupted chain of nucleotides between the 3'-end of one strand and the 5'-end of the respective other strand forming a hairpin loop comprising, a plurality of unpaired nucleotides, each unpaired nucleotide within the hairpin loop may independently comprise a GalNAc or GalNAc derivative attached via a monovalent linker. The hairpin loop may also be formed by an extended overhang in one strand of the duplex.
In some embodiments, the carbohydrate conjugate further comprises one or more additional ligands as described above, such as, but not limited to, a PK modulator or a cell permeation peptide.
Additional carbohydrate conjugates suitable for use in the present invention include those described in WO 2014179620 and WO 2014179627, the entire contents of each of which are incorporated herein by reference.
4. Linkers In some embodiments, the conjugate or ligand described herein can be attached to an iRNA
oligonucleotide with various linkers that can be cleavable or non-cleavable.
The term "linker" or "linking group" means an organic moiety that connects two parts of a compound, e.g., covalently attaches two parts of a compound. Linkers typically comprise a direct bond or an atom such as oxygen or sulfur, a unit such as NR8, C(0), C(0)NH, SO, SO2, SO2NH or a chain of atoms, such as, but not limited to, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, arylalkyl, arylalkenyl, arylalkynyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, heterocyclylalkyl, heterocyclylalkenyl, heterocyclylalkynyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, cycloalkenyl, alkylarylalkyl, alkylarylalkenyl, alkylarylalkynyl, alkenylarylalkyl, alkenylarylalkenyl, alkenylarylalkynyl, alkynylarylalkyl, alkynylarylalkenyl, alkynylarylalkynyl, alkylheteroarylalkyl, alkylheteroarylalkenyl, alkylheteroarylalkynyl, alkenylheteroarylalkyl, alkenylheteroarylalkenyl, alkenylheteroarylalkynyl, alkynylheteroarylalkyl, alkynylheteroarylalkenyl, alkynylheteroarylalkynyl, alkylheterocyclylalkyl, alkylheterocyclylalkenyl, alkylhererocyclylalkynyl, alkenylheterocyclylalkyl, alkenylheterocyclylalkenyl, alkenylheterocyclylalkynyl, alkynylheterocyclylalkyl, alkynylheterocyclylalkenyl, alkynylheterocyclylalkynyl, alkylaryl, alkenylaryl, alkynylaryl, alkylheteroaryl, alkenylheteroaryl, alkynylhereroaryl, which one or more methylenes can be interrupted or terminated by 0, S, S(0), SO2, N(R8), C(0), substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocyclic; where R8 is hydrogen, acyl, aliphatic or substituted aliphatic. In one embodiment, the linker is about 1-24 atoms, 2-24, 3-24, 4-24, 5-24, 6-24, 6-18, 7-18, 8-18 atoms, 7-17, 8-17, 6-16, 7-16, or 8-16 atoms.
A cleavable linking group is one which is sufficiently stable outside the cell, but which upon entry into a target cell is cleaved to release the two parts the linker is holding together. In a preferred embodiment, the cleavable linking group is cleaved at least about 10 times, 20, times, 30 times, 40 times, 50 times, 60 times, 70 times, 80 times, 90 times or more, or at least about 100 times faster in a target cell or under a first reference condition (which can, e.g., be selected to mimic or represent intracellular conditions) than in the blood of a subject, or under a second reference condition (which can, e.g., be selected to mimic or represent conditions found in the blood or serum).
Cleavable linking groups are susceptible to cleavage agents, e.g., pH, redox potential or the presence of degradative molecules. Generally, cleavage agents are more prevalent or found at higher levels or activities inside cells than in serum or blood. Examples of such degradative agents include:
redox agents which are selected for particular substrates or which have no substrate specificity, including, e.g., oxidative or reductive enzymes or reductive agents such as mercaptans, present in cells, that can degrade a redox cleavable linking group by reduction;
esterases; endosomes or agents that can create an acidic environment, e.g., those that result in a pH of five or lower; enzymes that can hydrolyze or degrade an acid cleavable linking group by acting as a general acid, peptidases (which can be substrate specific), and phosphatases.
A cleavable linkage group, such as a disulfide bond can be susceptible to pH.
The pH of human serum is 7.4, while the average intracellular pH is slightly lower, ranging from about 7.1-7.3.
Endosomes have a more acidic pH, in the range of 5.5-6.0, and lysosomes have an even more acidic pH at around 5Ø Some linkers will have a cleavable linking group that is cleaved at a preferred pH, thereby releasing a cationic lipid from the ligand inside the cell, or into the desired compartment of the cell.
A linker can include a cleavable linking group that is cleavable by a particular enzyme. The type of cleavable linking group incorporated into a linker can depend on the cell to be targeted. For example, a liver-targeting ligand can be linked to a cationic lipid through a linker that includes an ester group. Liver cells are rich in esterases, and therefore the linker will be cleaved more efficiently in liver cells than in cell types that are not esterase-rich. Other cell-types rich in esterases include cells of the lung, renal cortex, and testis.
Linkers that contain peptide bonds can be used when targeting cell types rich in peptidases, such as liver cells and synoviocytes.
In general, the suitability of a candidate cleavable linking group can be evaluated by testing the ability of a degradative agent (or condition) to cleave the candidate linking group. It will also be desirable to also test the candidate cleavable linking group for the ability to resist cleavage in the blood or when in contact with other non-target tissue. Thus, one can determine the relative susceptibility to cleavage between a first and a second condition, where the first is selected to be indicative of cleavage in a target cell and the second is selected to be indicative of cleavage in other tissues or biological fluids, e.g., blood or serum. The evaluations can be carried out in cell free systems, in cells, in cell culture, in organ or tissue culture, or in whole animals. It can be useful to make initial evaluations in cell-free or culture conditions and to confirm by further evaluations in whole animals. In preferred embodiments, useful candidate compounds are cleaved at least about 2, 4, 10, 20, 30, 40, 50, 60, 70, 80, 90, or about 100 times faster in the cell (or under in vitro conditions selected to mimic intracellular conditions) as compared to blood or serum (or under in vitro conditions selected to mimic extracellular conditions).
a. Redox cleavable linking groups In one embodiment, a cleavable linking group is a redox cleavable linking group that is cleaved upon reduction or oxidation. An example of reductively cleavable linking group is a disulphide linking group (-S-S-). To determine if a candidate cleavable linking group is a suitable "reductively cleavable linking group," or for example is suitable for use with a particular iRNA
moiety and particular targeting agent one can look to methods described herein. For example, a candidate can be evaluated by incubation with dithiothreitol (DTT), or other reducing agent using reagents know in the art, which mimic the rate of cleavage which would be observed in a cell, e.g., a target cell. The candidates can also be evaluated under conditions which are selected to mimic blood or serum conditions. In one, candidate compounds are cleaved by at most about 10% in the blood. In other embodiments, useful candidate compounds are degraded at least about 2, 4, 10, 20, 30, 40, 50, 60, 70, 80, 90, or about 100 times faster in the cell (or under in vitro conditions selected to mimic intracellular conditions) as compared to blood (or under in vitro conditions selected to mimic extracellular conditions). The rate of cleavage of candidate compounds can be determined using standard enzyme kinetics assays under conditions chosen to mimic intracellular media and compared to conditions chosen to mimic extracellular media.
b. Phosphate-based cleavable linking groups In another embodiment, a cleavable linker comprises a phosphate-based cleavable linking group. A phosphate-based cleavable linking group is cleaved by agents that degrade or hydrolyze the phosphate group. An example of an agent that cleaves phosphate groups in cells are enzymes such as phosphatases in cells. Examples of phosphate-based linking groups are -0-P(0)(ORk)-0-, -0-P(S)(0Rk)-0-, -0-P(S)(SRk)-0-, -S-P(0)(0Rk)-0-, -0-P(0)(0Rk)-S-, -S-P(0)(0Rk)-S-, -0-P(S)(ORk)-S-, -S-P(S)(ORk)-0-, -0-P(0)(Rk)-0-, -0-P(S)(Rk)-0-, -S-P(0)(Rk)-0-, -S-P(S)(Rk)-0-, -S-P(0)(Rk)-S-, -0-P(S)( Rk)-S-. Preferred embodiments are -0-P(0)(OH)-0-, -0-P(S)(OH)-0-, -0-P(S)(SH)-0-, -S-P(0)(OH)-0-, -0-P(0)(OH)-S-, -S-P(0)(OH)-S-, -0-P(S)(OH)-S-, -S-P(S)(OH)-0-, -0-P(0)(H)-0-, -0-P(S)(H)-0-, -S-P(0)(H)-0, -S-P(S)(H)-0-, -S-P(0)(H)-S-, -0-P(S)(H)-S-. A
preferred embodiment is -0-P(0)(OH)-0-. These candidates can be evaluated using methods analogous to those described above.
c. Acid cleavable linking groups In another embodiment, a cleavable linker comprises an acid cleavable linking group. An acid cleavable linking group is a linking group that is cleaved under acidic conditions. In preferred embodiments acid cleavable linking groups are cleaved in an acidic environment with a pH of about 6.5 or lower (e.g., about 6.0, 5.75, 5.5, 5.25, 5.0, or lower), or by agents such as enzymes that can act as a general acid. In a cell, specific low pH organelles, such as endosomes and lysosomes can provide a cleaving environment for acid cleavable linking groups. Examples of acid cleavable linking groups include but are not limited to hydrazones, esters, and esters of amino acids.
Acid cleavable groups can have the general formula -C=NN-, C(0)0, or -0C(0). A preferred embodiment is when the carbon attached to the oxygen of the ester (the alkoxy group) is an aryl group, substituted alkyl group, or tertiary alkyl group such as dimethyl pentyl or t-butyl. These candidates can be evaluated using methods analogous to those described above.
d. Ester-based linking groups In another embodiment, a cleavable linker comprises an ester-based cleavable linking group.
An ester-based cleavable linking group is cleaved by enzymes such as esterases and amidases in cells.
Examples of ester-based cleavable linking groups include but are not limited to esters of alkylene, alkenylene and alkynylene groups. Ester cleavable linking groups have the general formula -C(0)0-, or -0C(0)-. These candidates can be evaluated using methods analogous to those described above.
e. Peptide-based cleaving groups In yet another embodiment, a cleavable linker comprises a peptide-based cleavable linking group. A peptide-based cleavable linking group is cleaved by enzymes such as peptidases and proteases in cells. Peptide-based cleavable linking groups are peptide bonds formed between amino acids to yield oligopeptides (e.g., dipeptides, tripeptides etc.) and polypeptides. Peptide-based cleavable groups do not include the amide group (-C(0)NH-). The amide group can be formed between any alkylene, alkenylene or alkynelene. A peptide bond is a special type of amide bond formed between amino acids to yield peptides and proteins. The peptide based cleavage group is generally limited to the peptide bond (i.e., the amide bond) formed between amino acids yielding peptides and proteins and does not include the entire amide functional group.
Peptide-based cleavable linking groups have the general formula ¨ NHCHRAC(0)NHCHRBC(0)-, where RA and RB are the R groups of the two adjacent amino acids. These candidates can be evaluated using methods analogous to those described above.
In one embodiment, an iRNA of the invention is conjugated to a carbohydrate through a linker. Non-limiting examples of iRNA carbohydrate conjugates with linkers of the compositions and methods of the invention include, but are not limited to, OH /OH
HO
AcHN II HO.to cH OH 0 HO ----4===\, AcHN
cH OH
HO
AcHN
0 (Formula XXIV), HO\ OH
HO Nõ^õ,,N 0 HO, AcHN 0 HO OH 0, AcHN 0 0 .CY
O
HO H
HOONNO
AcHN 0 (Formula XXV), HO OH
H
...c N 0 N....,..õ---,..õ y 1.,...
AcHN H 0 X-01_ HO OH
HO---r--P-_\/(k N
c ---.,-.---....-----....---NON()1 1 \ O
AcHN H x 0 y H 00 r HO OH
HO ,, ,_,NNADJ y = 1-15 AcHN H (Formula XXVI), ON__T, H
N
HO0"...---..---"....- y \
AcHN H 0 X-R
HO OH 0 H 0 H N"
HO N N TO- N,Ir}l N (CD,4(nr N
AcHN
H 0 ,/ 0 H x 0 Y
HO OH
LA._:.,)._, m N A0,- y = 1-15 HO __/ ./
AcHN H
(Formula XXVII), HO eOH 0 H
0,1---. ... _ N 0 HO N __ __ __ y \ X-Ot AcHN H 0 H ,O-Y
HO OH N
H H N,Lo HO N NyO-N,..irHS¨S
AcHN 0 Y
H 0 0 x HO OH x = 0-30 k-, 0 H 0 y= 1-15 1---N m N Acy-HO
AcHN H
(Formula XXVIII), __O/ H
01-..N---..õ---....õ---...- N yO\
HO X-R
AcHN H 0 HO OH
H H -(--z 0 -)240 HO AcHN NH N y0,---N....rrHS¨S
Y
0 0 x HO eOH x = 0-30 _________________ ,, 0 H 0 y= 1-15 k-,.)1.--N m NAG-- z = 1-20 HO--' AcHN H
(Formula XXIX), ?.s.\/ H
0-) i\J- Ny HO X-R
AcHN H 0 0, NH
H 0 ,,O-Y
HO OH N ' HO N N ...1 T0,4-1H0,/).r,,S¨S
AcHN x`' z 0 Y
0 r HOZ H x = 1-30 0 y = 1-15 HO 0,---------1 L- ri....----....---------- NAcy--1 z = 1-20 AcHN H
(Formula XXX), and HO-7-2-\=CLN y )._____. HO H X-0%
AcHN H 0 Y
H H N.4,-...yAo HO 0 N7.N, 0-N--_,H0.%)Ø.S----S(HThf AcHN II Y
H N 0 i.-- 0 x z 0 HO eOH x = 1-30 = 1-15 HO INM N(`O' z =
AcHN H
(Formula XXXI), when one of X or Y is an oligonucleotide, the other is a hydrogen.
In certain embodiments of the compositions and methods of the invention, a ligand is one or more "GalNAc" (N-acetylgalactosamine) derivatives attached through a bivalent or trivalent branched linker.
In one embodiment, a dsRNA of the invention is conjugated to a bivalent or trivalent branched linker selected from the group of structures shown in any of formula (XXXII) - (XXXV):
Formula XXXII Formula XXXIII
.4. p2A_Q2A_R2A 1_2A 1-2A_L2A jp3A_Q3A_ 3A R3A1__T3A_L3A
q 41/' JUN. N q 1.,p2B_Q2B_R2B i2B -1-2B_L2B I\ p3B_Q3B_R3B I_3B T3B_L3B
q q p5A-Q5A-R5A i_q5AT5A-L5A
p4A_Q4A_R4A 1 zi6, T4A_L4A
H:
q p4B_Q4B_R4B 1_q4B -1-4B_L4B
1 pl5cp_5;5_cQ_R5BR5B 1_q5B
5_c1-5B_L5B
q 5T C-L5C
;
Formula XXXIV Formula XXXV
wherein:
q2A, q2B, q3A, q3B, q4A, q4B, q5A, q5B and q5C represent independently for each occurrence 0-20 and wherein the repeating unit can be the same or different;
p2A, p2B, p3A, p3B , p4A, p4B, p5A, p5B , p5C, T2A, T2B, T3A, T3B, T4A, T4B, T4A, T5B, I,-.-,5C
are each independently for each occurrence absent, CO, NH, 0, S, OC(0), NHC(0), CH2, CH2NH or CH20;
Q2A, Q2B, Q3A, Q3B, Q4A, Q4B, Q5A, Q5B, .-.5C
l,2 are independently for each occurrence absent, alkylene, substituted alkylene wherin one or more methylenes can be interrupted or terminated by one or more of 0, S, S(0), SO2, N(RN), C(R')=C(R"), CEC or C(0);
R2A, R2B, R3A, R3B, R4A, R4B, R5A, R5B, R5c are each independently for each occurrence absent, NH, 0, HO¨L
S, CH, C(0)0, C(0)NH, NHCH(Ra)C(0), -C(0)-CH(Ra)-NH-, CO, CH=N-0, 0 S¨S
)_N ,N),,,, J. <¨s H , ,,r-r'r/ \S" or heterocyclyl;
L2A, L2B, L3A, L3B, L4A, L4B, L5A, L5B and L5c represent the ligand; i.e. each independently for each occurrence a monosaccharide (such as GalNAc), disaccharide, trisaccharide, tetrasaccharide, oligosaccharide, or polysaccharide; andle is H or amino acid side chain.Trivalent conjugating GalNAc derivatives are particularly useful for use with RNAi agents for inhibiting the expression of a target gene, such as those of formula (XXXV):
Formula XXXV
p5A_Q5A_R5A i_T5A_L5A
'1111j-VE q5A
I p5B_Q5B_R5B 1_1-5B_L5B
q5B
Ip5C_Q5C_R5C 1771-5C_L5C
, wherein L5A, L5B and L5c represent a monosaccharide, such as GalNAc derivative.
Examples of suitable bivalent and trivalent branched linker groups conjugating GalNAc derivatives include, but are not limited to, the structures recited above as formulas II, VII, XI, X, and XIII.
Representative US patents that teach the preparation of RNA conjugates include, but are not limited to, US Patent Nos. 4,828,979; 4,948,882; 5,218,105; 5,525,465;
5,541,313; 5,545,730;
5,552,538; 5,578,717, 5,580,731; 5,591,584; 5,109,124; 5,118,802; 5,138,045;
5,414,077; 5,486,603;
5,512,439; 5,578,718; 5,608,046; 4,587,044; 4,605,735; 4,667,025; 4,762,779;
4,789,737; 4,824,941;
4,835,263; 4,876,335; 4,904,582; 4,958,013; 5,082,830; 5,112,963; 5,214,136;
5,082,830; 5,112,963;
5,214,136; 5,245,022; 5,254,469; 5,258,506; 5,262,536; 5,272,250; 5,292,873;
5,317,098; 5,371,241, 5,391,723; 5,416,203, 5,451,463; 5,510,475; 5,512,667; 5,514,785; 5,565,552;
5,567,810; 5,574,142;
5,585,481; 5,587,371; 5,595,726; 5,597,696; 5,599,923; 5,599,928 and 5,688,941; 6,294,664;
6,320,017; 6,576,752; 6,783,931; 6,900,297; 7,037,646; 8,106,022, the entire contents of each of which are hereby incorporated herein by reference.
It is not necessary for all positions in a given compound to be uniformly modified, and in fact more than one of the aforementioned modifications can be incorporated in a single compound or even at a single nucleoside within an iRNA. The present invention also includes iRNA compounds that are chimeric compounds.
"Chimeric" iRNA compounds or "chimeras," in the context of this invention, are iRNA
compounds, preferably dsRNAs, which contain two or more chemically distinct regions, each made up of at least one monomer unit, i.e., a nucleotide in the case of a dsRNA
compound. These iRNAs typically contain at least one region wherein the RNA is modified so as to confer upon the iRNA
increased resistance to nuclease degradation, increased cellular uptake, or increased binding affinity for the target nucleic acid. An additional region of the iRNA can serve as a substrate for enzymes capable of cleaving RNa:DNA or RNA:RNA hybrids. By way of example, RNase H is a cellular endonuclease which cleaves the RNa strand of an RNA:DNA duplex. Activation of RNase H, therefore, results in cleavage of the RNA target, thereby greatly enhancing the efficiency of iRNA
inhibition of gene expression. Consequently, comparable results can often be obtained with shorter iRNAs when chimeric dsRNAs are used, compared to phosphorothioate deoxy dsRNAs hybridizing to the same target region. Cleavage of the RNA target can be routinely detected by gel electrophoresis and, if necessary, associated nucleic acid hybridization techniques known in the art.
In certain instances, the RNA of an iRNA can be modified by a non-ligand group. A number of non-ligand molecules have been conjugated to iRNAs in order to enhance the activity, cellular distribution or cellular uptake of the iRNA, and procedures for performing such conjugations are available in the scientific literature. Such non-ligand moieties have included lipid moieties, such as cholesterol (Kubo, T. et al., Biochem. Biophys. Res. Comm., 2007, 365(1):54-61; Letsinger et al., Proc. Natl. Acad. Sci. USA, 1989, 86:6553), cholic acid (Manoharan et al., Bioorg. Med. Chem. Lett., 1994, 4:1053), a thioether, e.g., hexyl-S-tritylthiol (Manoharan et al., Ann.
N.Y. Acad. Sci., 1992, 660:306; Manoharan et al., Bioorg. Med. Chem. Let., 1993, 3:2765), a thiocholesterol (Oberhauser et al., Nucl. Acids Res., 1992, 20:533), an aliphatic chain, e.g., dodecandiol or undecyl residues (Saison-Behmoaras et al., EMBO J., 1991, 10:111; Kabanov et al., FEBS Lett., 1990, 259:327; Svinarchuk et al., Biochimie, 1993, 75:49), a phospholipid, e.g., di-hexadecyl-rac-glycerol or triethylammonium 1,2-di-O-hexadecyl-rac-glycero-3-H-phosphonate (Manoharan et al., Tetrahedron Lett., 1995, 36:3651;
Shea et al., Nucl. Acids Res., 1990, 18:3777), a polyamine or a polyethylene glycol chain (Manoharan et al., Nucleosides & Nucleotides, 1995, 14:969), or adamantane acetic acid (Manoharan et al., Tetrahedron Lett., 1995, 36:3651), a palmityl moiety (Mishra et al., Biochim.
Biophys. Acta, 1995, 1264:229), or an octadecylamine or hexylamino-carbonyl-oxycholesterol moiety (Crooke et al., J.
Pharmacol. Exp. Ther., 1996, 277:923). Representative United States patents that teach the preparation of such RNA conjugates have been listed above. Typical conjugation protocols involve the synthesis of an RNAs bearing an aminolinker at one or more positions of the sequence. The amino group is then reacted with the molecule being conjugated using appropriate coupling or activating reagents. The conjugation reaction can be performed either with the RNA still bound to the solid support or following cleavage of the RNA, in solution phase. Purification of the RNA conjugate by HPLC typically affords the pure conjugate.
iii. Delivery of an iRNA of the Invention The delivery of an iRNA of the invention to a cell e.g., a cell within a subject, such as a human subject infected with HBV can be achieved in a number of different ways.
Delivery may also be performed directly by administering a composition comprising an iRNA, e.g., a dsRNA, to a subject. Alternatively, in vivo delivery may be performed indirectly by administering one or more vectors that encode and direct the expression of the iRNA. These alternatives are discussed further below.
In general, any method of delivering a nucleic acid molecule (in vitro or in vivo) can be adapted for use with an iRNA of the invention (see e.g., Akhtar S. and Julian RL. (1992) Trends Cell.
Biol. 2(5):139-144 and W09402595, which are incorporated herein by reference in their entireties).
For in vivo delivery, factors to consider in order to deliver an iRNA molecule include, for example, biological stability of the delivered molecule, prevention of non-specific effects, and accumulation of the delivered molecule in the target tissue. For administering an iRNA
systemically for the treatment of a disease, the RNA can be modified or alternatively delivered using a drug delivery system; both methods act to prevent the rapid degradation of the dsRNA by endo- and exo-nucleases in vivo.
Modification of the RNA or the pharmaceutical carrier can also permit targeting of the iRNA
composition to the target tissue and avoid undesirable off-target effects.
iRNA molecules can be modified by chemical conjugation to lipophilic groups such as cholesterol to enhance cellular uptake and prevent degradation. In an alternative embodiment, the iRNA can be delivered using drug delivery systems such as a nanoparticle, a dendrimer, a polymer, liposomes, or a cationic delivery system. Positively charged cationic delivery systems facilitate binding of an iRNA molecule (negatively charged) and also enhance interactions at the negatively charged cell membrane to permit efficient uptake of an iRNA by the cell. Cationic lipids, dendrimers, or polymers can either be bound to an iRNA, or induced to form a vesicle or micelle (see e.g., Kim SH., et al (2008) Journal of Controlled Release 129(2):107-116) that encases an iRNA. The formation of vesicles or micelles further prevents degradation of the iRNA when administered systemically.
Methods for making and administering cationic- iRNA complexes are well within the abilities of one skilled in the art (see e.g., Sorensen, DR., et al (2003) J. Mol. Biol 327:761-766; Verma, UN., et al (2003) Clin. Cancer Res.
9:1291-1300; Arnold, AS et al (2007) J. Hypertens. 25:197-205, which are incorporated herein by reference in their entirety). Some non-limiting examples of drug delivery systems useful for systemic delivery of iRNAs include DOTAP (Sorensen, DR., et al (2003), supra; Verma, UN., et al (2003), supra), Oligofectamine, "solid nucleic acid lipid particles" (Zimmermann, TS., et al (2006) Nature 441:111-114), cardiolipin (Chien, PY., et al (2005) Cancer Gene Ther. 12:321-328; Pal, A., et al (2005) Int J. Oncol. 26:1087-1091), polyethyleneimine (Bonnet ME., et al (2008) Phann. Res. Aug 16 Epub ahead of print; Aigner, A. (2006) J. Biomed. Biotechnol. 71659), Arg-Gly-Asp (RGD) peptides (Liu, S. (2006) Mol. Pharm. 3:472-487), and polyamidoamines (Tomalia, DA., et al (2007) Biochem. Soc. Trans. 35:61-67; Yoo, H., et al (1999) Pharm. Res. 16:1799-1804). In some embodiments, an iRNA forms a complex with cyclodextrin for systemic administration. Methods for administration and pharmaceutical compositions of iRNAs and cyclodextrins can be found in US
Patent No. 7,427,605, which is herein incorporated by reference in its entirety. In certain embodiments, the iRNA agents can be administered with amphipathic peptides to facilitate pH-dependent endosomal escape (see, e.g., Bartz et al., 2011. Biochem. J. 435:475-87, incorporated herein by reference) 1. Vector encoded iRNAs for use in the Invention iRNA targeting an HBV gene can be expressed from transcription units inserted into DNA or RNA vectors (see, e.g., Couture, A, et al., TIG. (1996), 12:5-10; Skillern, A., et al., WO 00/22113, WO 00/22114, and US Patent No. 6,054,299). Exemplary expression vectors for expression of shRNA targeted to HBV are provided in Michler et al., 2016 which discloses adeno-associated virus (AAV) 8 vectors for delivery included (i) embedded the shRNA in an artificial mi(cro)RNA under a liver-specific promoter; (ii) co-expressed Argonaute-2, a rate limiting cellular factor whose saturation with excess RNAi triggers can be toxic; or (iii) co-delivered a decoy ("TuD") directed against the shRNA sense strand to curb off-target gene regulation. The plasmids expressing shRNAs shHBV4 to 7 that were used in the cell culture studies were cloned by direct insertion of the respective shRNA-encoding oligonucleotides into a self-complementary AAV vector plasmid previously reported by Grimm et al, 2006 (Nature 441: 537 ¨ 541), containing an H1 promoter followed by two BbsI sites for oligonucleotide insertion as well as an RSV promoter. Such constructs can also be used for the expression of vaccine antigens if appropriately sized for the expression vector.
Expression can be transient (on the order of days to weeks) or sustained (weeks to months, or longer), depending upon the specific construct used and the target tissue or cell type. These transgenes can be introduced as a linear construct, a circular plasmid, or a viral vector, which can be an integrating or non-integrating vector. The transgene can also be constructed to permit it to be inherited as an extrachromosomal plasmid (Gassmann, et al., Proc. Natl. Acad.
Sci. USA (1995) 92:1292).
The individual strand or strands of an iRNA can be transcribed from a promoter on an expression vector. Where two separate strands are to be expressed to generate, for example, a dsRNA, two separate expression vectors can be co-introduced (e.g., by transfection or infection) into a target cell. Alternatively each individual strand of a dsRNA can be transcribed by promoters both of which are located on the same expression plasmid. In one embodiment, a dsRNA
is expressed as inverted repeat polynucleotides joined by a linker polynucleotide sequence such that the dsRNA has a stem and loop structure.
iRNA expression vectors are generally DNA plasmids or viral vectors.
Expression vectors compatible with eukaryotic cells, preferably those compatible with vertebrate cells, can be used to produce recombinant constructs for the expression of an iRNA as described herein. Eukaryotic cell expression vectors are well known in the art and are available from a number of commercial sources.
Typically, such vectors are provided containing convenient restriction sites for insertion of the desired nucleic acid segment. Delivery of iRNA expressing vectors can be systemic, such as by subcutaneous, intravenous, or intramuscular administration. Such vectors can also be used for expression of viral antigens from nucleic acid-based vaccines.
Viral vector systems which can be utilized with the methods and compositions described herein include, but are not limited to, (a) adenovirus vectors; (b) retrovirus vectors, including but not limited to lentiviral vectors, moloney murine leukemia virus, etc.; (c) adeno-associated virus vectors;
(d) herpes simplex virus vectors; (e) SV 40 vectors; (f) polyoma virus vectors; (g) papilloma virus vectors; (h) picornavirus vectors; (i) pox virus vectors such as an orthopox, e.g., vaccinia virus vectors including modified vaccinia virus Ankara vector or avipox, e.g. canary pox or fowl pox; and (j) a helper-dependent or gutless adenovirus. Replication-defective viruses can also be advantageous.
Different vectors will or will not become incorporated into the cells' genome.
The constructs can include viral sequences for transfection, if desired. Alternatively, the construct can be incorporated into vectors capable of episomal replication, e.g. EPV and EBV vectors.
Constructs for the recombinant expression of an iRNA or HBV antigen will generally require regulatory elements, e.g., promoters, enhancers, etc., to ensure the expression of the iRNA in target cells. Other aspects to consider for vectors and constructs are further described below.
Such constructs and vectors can also be used for the expression of vaccine antigens if appropriately sized for the expression vector. Such limitations are well understood by those of skill in the art.
B. Therapeutic HBV Vaccines For Use in the Mehods of the Invention Therapeutic HBV vaccines for use in the regimens and methods of the invention can be a peptide vaccine, a DNA vaccine including a vector-based vaccine, or cell-based vaccine that induces an immune response, preferably an effector T cell induced response, against one or more HBV
proteins. Preferably the vaccine is a multi-epitope vaccine that is cross-reactive with multiple HBV
serotypes, preferably all HBV serotypes.
A therapeutic vaccine is designed to activate the patient's immune system to recognize and control or eliminate an already established pathogen infection. This is clearly distinct from a prophylactic vaccination which is designed to promote rapid antibody-mediated neutralization of an invading pathogen. Control and elimination of persistent viruses such as hepatitis, herpes, or papilloma viruses requires multi-specific and poly-functional effector T cell responses. These T cell responses are ideally directed against continuously expressed viral antigens to keep the pathogen in check. Therapeutic vaccines are under development for a number of chronic infections. Hepatitis B
virus infection is a candidate for treatment by therapeutic vaccination since a spontaneous, immune-mediated recovery of chronic hepatitis B and an elimination of the virus has been observed in very rare cases.
Robust T cell responses seem to be essential to achieve HBV cure. While HBV-specific CD4+ and CD8+ T cell responses are readily detectable in patients resolving HBV infection, HBV-specific T cells are scarce and functionally impaired in chronic hepatitis B
most likely due to high amounts of circulating viral HBeAg and HBsAg. T cells eliminate HBV infected cells by their cytotoxic activity but also control HBV gene expression and replication in a non-cytolytic fashion.
To overcome immune tolerance in chronic hepatitis B different approaches have been investigated in preclinical models using DNA or peptide vaccines, or vector-or cell-based vaccines to induce an effector T cell response. Multi-epitope therapeutic vaccine candidates that cover sufficient different HBV genotypes and most frequent HLA types have been developed.
Although proper peptide presentation was demonstrated, immunogenicity was limited and the approach was not translated into the clinics. A non-exhaustive list is provided in the table below.
Therapeutic HBV Vaccine Tables Vaccine Name Proteins/ coding Vaccine type/ Results available Sponsor Development Clinical Trial References oe sequences Composition Stage Reference No. (the entire contents of each of which are incorporated herein by reference) HB-110 HBsAgõ HBcAg, 3 Plasmid based Study completed, Genexine Phase I NCT01813487 Kim et al., 2008. Exp Mol human IL-12 DNA vaccine results not reported NCT01641536 Med. 40: 669-676 cs, cs, HB-100 pGX10 S 5 Plasmid based Yang et al., 2006. Gene +pGX10 S1/52/X DNA vaccine ¨4 Therapy. 13:1110-1117 +pGX10 core antigens + human +pGX10 Pol IL-12 +pGX10 hIL-ppdpSC18 DNA vaccine Study completed, PowderMed Phase I NCT00277576 adjuvanted with results not reported particle mediated epidermal delivery oe INO-1800 HbsAg, HBcAg DNA plasmid Recruiting Inovio Phase I NCT02431312 -a 5 oe Pharmaceuticals cr ME1 27037625v.1 HB02 VAC- HB preS/S pCMV-S2.S DNA Well tolerated; No ANRS
Phase I/II NCT00536627 Mancini ¨ Bourgine et al., ADN vaccine; CMV change in relapse 2006. Vaccine 24:4482- 0 promoter, plasmid rate in HBV treated oe vector patients or decrease in virological breakthrough CVI-HBV-002 HbsAg DNA+ L-pampo Recruiting CHA Vaccine Phase I/II NCT02693652 Institute Co., Ltd.
Theravax (DV- HBsAg, HBcAg Protein + adjuvant Well tolerated;
Dynavax Phase Ib NCT01023230 601) anti-viral response Technologies cs, observed in all Corp.
patients HepTcellTm IC310 adjuvanted Recruiting Altimmune, Phase I NCT02496897 US 20130330382 peptide Inc.
HBsAg/HBcAg HBsAg protein Research Li et al., 2015, Vaccine.
HBcAg 33:4247-4254 GS-4774 Fusion protein Protein + Phase II naïve Gilead Phase II NCT01943799 Gaggar et al., 2014.
HBsAg, HBcAg, Tamogen T cell group ongoing; no NCT01779505 Vaccine. 32:4925-4931.
HBxAg stimulator significant viral oe decrease in oe treatment-ME1 27037625v.1 experience patients EPA-44 Multi-peptide Some Chongqing Phase II NCT00869778 0 vaccine seroconversion J aichen observed in all Biotechnology, groups, no Ltd.
statistical analysis ABX 203 HBsAg, HBcAg HBsAg, HBcAg Ongoing ABIVAX S.A.
Phase II/III NCT02249988 pSG2.HBs/ Protein prime- Well tolerated, but Oxxon Phase ha ISRCTN Cavenaugh et al., 2011.
MVA.HBs viral vector boost did not control Therapeutics 67270384 PLoS ONE 6: e14626.
HBV infection HBsAg, HBcAg Adjuvanted Research Backes, 2016, Vaccine;
protein prime-OC cs, viral vector boost ME1 27037625v.1 Existing prophylactic vaccines have been used to restore HBV-specific immunity in chronically infected patients, but have failed to provide a functional cure.
These subviral particle-based vaccines were able to reduce HBV replication in animal models of chronic hepadnaviral infection, but have not been successful in patients with chronic hepatitis B.
An antigen-antibody (HBsAg-HBIG) immunogenic complex therapeutic vaccine candidate with alum as adjuvant first showed promising results in a double-blind, placebo controlled, phase IIb clinical trial, but results of a phase III clinical trial including 450 patients were disappointing. This is most likely due to the fact that subviral particle vaccines with alum-based adjuvants are designed as prophylactic vaccines and preferentially induce antibodies but not cytotoxic T cell responses that would be required for therapeutic efficacy.
Alternatively, DNA vaccines encoding HBV envelope proteins were designed to induce HBV-specific T cells but also had limited success. Since DNA-based vaccines hardly induce antibody responses, they failed to achieve HBeAg or HBsAg seroconversion. An alternative DNA prime, poxvirus-boost vaccine encompassing the HBV preS/S region encoding for the HBV
envelope .. proteins showed promising results in chimpanzees, but also failed in a clinical phase Ha trial neither inducing sustained T cell responses nor reducing viremia in chronic HBV
carriers. They may have failed to induce T cell help or broad enough, multi-specific immune responses.
Any vaccines known in the art can be used in the methods and regimens provided herein.
Preferred embodiments include the prime-boost vaccination scheme with protein antigens administered twice and a nucleic acid vaccine administered once as provided in the Examples and provided in PCT Publication No. WO 2017/121791 (the entire contents of which are incorporated herein by reference). As discussed above, the sequence of the protein antigen in the vaccine and the amino acid sequence encoded by nucleic acid-based vaccine need not be identical. They simply must share at least one epitope, preferably multiple epitopes, so that the sequential administration of the vaccines has the desired prime-boost effect. Further, as discussed herein, in preferred embodiments, the treatment regimen provided herein would provide a treatment regimen effective across multiple, if not all, HBV serotypes. Therefore, it is understood that the antigen delivered to the subject may not have antigen sequences identical to the antigens expressed by the HBV virus that infected the subject.
It is known in the art that some portions of HBV antigens are the main targets of antibodies generated during the initial immune response to infection with HBV known as determinants. For example the HBsAg includes the "a" determinant epitope that is located at amino acids 124 to 147 within the major hydrophilic region (MHR, amino acids 100 to 169) of the 226 amino acid S gene (SEQ ID NO: 8 or 22). This "a" determinant is one of the main targets of anti-HBs antibodies during the course of the initial immune response in acute hepatitis B. In certain embodiments, an immunogenic fragment of HBsAg comprises compared to the full length protein at least amino acids 99 to 168 corresponding to the amino acid positons of the small envelope protein (SEQ ID NO: 23) (see, e.g., Lada et al., J. Virol.(2006) 80:2968-2975, the entire contents of which are incorporated herein by reference).
Similarly, determinants have been identified in HBcAg (see, e.g., Salfeld et al., J. Virol.
(1989) 63:798-808, the entire contents of which are incorporated herein by reference). The full-length core protein is 183 amino acids in length and consists of an assembly domain (amino acids 1 to 149) and a nucleic acid-binding domain (amino acids 150 to 183). Three distinct major determinants have been characterized. The single conformational determinant responsible for HBc antigenicity in the assembled core (HBc) and a linear HBe-related determinant (HBel) were both mapped to an overlapping hydrophilic sequence around amino acid 80; a second HBe determinant (HBe2) was assigned to a location in the vicinity of amino acid 138 but found to require for its antigenicity the intramolecular participation of the extended sequence between amino acids 10 and 140. Typically, such an immunogenic fragment comprises, compared to the full length core protein, at least amino acids 18 to 143 corresponding to the sequence positions set forth in SEQ ID
NO: 24. Analogous sequences can be identified in SEQ ID NO: 10.
In preferred embodiments, the vaccines include an amino acid sequence or encode an amino acid sequence that includes at least one determinant of HBsAg or HBcAg.
Specifically, in certain embodiments, a vaccine targeted to HBsAg includes at least the amino acid sequence of amino acids 127 to 147 of HBsAg, e.g., includes at least amino acids 99 to 168 of the amino acid sequence of the small envelope protein (SEQ ID NO: 23). In certain embodiments, a vaccine targeted to a hydrophilic sequence at least around amino acid 80 of HBcAg or an amino acid sequence at least around amino acid 138, e.g., at least a 40 amino acid portion, at least a 50 amino acid portion, at least a 60 amino acid portion, at least a 70 amino acid portion, at least an 80 amino acid portion, at least a 90 amino acid portion, or at least a 100 amino acid portion of SEQ ID NO: 43 including amino acid 80 or amino acid 138, or a coding sequence therefor. In preferred embodiments, the antigen amino sequence of the antigen targeted to HBcAg includes at least 20 amino acids N-terminal and C-terminal to amino acid 80 or 138 of SEQ ID NO: 24. In certain embodiments, a vaccine targeted to HBcAg includes at least the amino acid sequence of amino acids 10 to 140 or 18 to 143 of HBsAg.
In certain embodiments, the vaccine may comprise the entire amino acid sequence or encode the entire amino acid sequence of any one or more of SEQ ID NO: 22, 23, or 24.
It is understood that there are multiple serotypes of HBV with different nucleic acid sequences that encode different amino acid sequences. Therefore, it is understood that the amino acid sequence of a protein-based vaccine or the amino acid sequence encoded by a nucleic acid-based vaccine may not be 100% identical to the sequences provided in the SEQ ID NOs.
In certain embodiments of the invention, the the amino acid sequence of a protein-based vaccine or the amino acid sequence encoded by a nucleic acid-based vaccine is at least 90%
identical, at least 91%
identical, at least 92% identical, at least 93% identical, at least 94%
identical, at least 95% identical, at least 96% identical, at least 97% identical, or at least 98% identical to the portion of SEQ ID NO: 22, 23, or 24. Additional exemplary HBsAg and HBcAg amino acid sequenences are provided in the sequence listing. Alignment methods to identify appropriate sequences corresponding to the HBsAg and HBcAg determinants in the sequences indicated above are known in the art.
The vaccine preferably comprises MVA viruses in a concentration range of 104 to 109 tissue-culture infectious dose (TCID)50/ml, preferably in a concentration range of 105 to 5x108TCID50/ml, more preferably in a concentration range of 106 to 108 TCID50/ml, and most preferably in a concentration range of 107 to 108 TCID50/ml.
A preferred vaccination dose for humans comprises 106 to 109 TCID50, most preferably a dose of 106 TCID50 or 107 TCID50 or 108 TCID50.
The preferred methods of the invention include administration of both a protein-based vaccine and a nucleic acid-based vaccine. However, other methods include administration of only protein antigens. Less preferred embodiments include administration of only nucleic acids encoding antigens.
i. Adjuvants As used herein "adjuvant" is understood as an agent that promotes (e.g., enhances, accelerates, or prolongs) an immune response to an antigen with which it is administered to elicit long-term protective immunity. No substantial immune response is directed at the adjuvant itself.
Adjuvants include, but are not limited to, pathogen components, particulate adjuvants, and combination adjuvants (see, e.g., www.niaid.nih.gov/research/vaccine-adjuvants-types). Pathogen components (e.g., monophosphoryl lipid A (MPL), poly(I:C), CpG DNA, emulsions such as poly[di(sodiumcarboxylatoethylphenoxy)phosphazene] (PCEP)) can help trigger early non-specific, or innate, immune responses to vaccines by targeting various receptors inside or on the surface of innate immune cells. The innate immune system influences adaptive immune responses, which provide long-lasting protection against the pathogen that the vaccine targets.
Particulate adjuvants (e.g., alum, virosomes, cytokines, e.g., IL-12) form very small particles that can stimulate the immune system and also may enhance delivery of antigen to immune cells. Combination adjuvants (e.g., AS02, AS03 and AS04 (GSK); MF59 (Novartis); and IC31 (Altimmune) elicit multiple protective immune responses. Adjuvants that have a modest effect when used alone may induce a more potent immune response when used together. In certain embodiments, preferred adjuvants include c-di-AMP, c-di-GMP, c-di-CMP, PolyICLC, CpG, ISCOMATRIX , AS02, AS03, AS04, or a RIG-I
ligand such as 5' 3P-RNA. In certain embodiments, a viral capsid, with or without a nucleic acid expressing an HBV antigen can be used as an adjuvant. For example, a vaccine that preferentially .. stimulates T cells such as an MVA-only or a DNA prime, MVA boost or an adenovirus vector prime-MVA boost can be used in the methods of the invention.
In preferred embodiments of the invention, adjuvants for use in the invention promote a humoral and a cellular immune response as discussed above. In certain embodiments, adjuvants provide a balanced Th1/Th2 response.
ii. Non-adjuvant immune stimulators and additional agents Methods of the invention can further include administration of additional agents used in the treatment of HBV or to stimulate an immune response. Such agents can include an immune stimulator (e.g., pegylated interferon alfa 2a (PEG-IFN-a2a), Interferon alfa-2b, a recombinant human interleukin-7, and aToll-like receptor 3, 7, 8, or 9 (TLR3, TLR7, TLR8, or TLR9) agonist), a viral entry inhibitor (e.g., Myrcludex), an oligonucleotide that inhibits the secretion or release of HBsAg (e.g., REP 9AC), a capsid inhibitor (e.g., Bay41-4109 and NVR-1221), a cccDNA
inhibitor (e.g., IHVR-25), a Rig-I-ligand, a STING agonist, an antibody based immune therapy against HBV (mono-, bi-, or trispecific antibody against HBV), or an immune checkpoint regulator.
Such agents are known in the art.
C. Nucleotide and Nucleoside Analogs For Use in the Methods of the Invention Nucleotide and nucleoside analogs are considered to be the standard of care for HBV
infection as they are generally considered safe and inexpensive. However, nucleotide and nucleoside analogs cannot cure HBV infection, may cause the development of resistance, and must be taken indefinitely. Nucleotide analog and nucleoside analogs include, but are not limited to, Tenofovir disoproxil fumarate (TDF), Tenofovir alafenamide, Lamivudine, Adefovir dipivoxil, Entecavir (ETV), Telbivudine, AGX-1009, emtricitabine, clevudine, ritonavir, dipivoxil, lobucavir, famvir, FTC, N-Acetyl-Cysteine (NAC), PC1323, theradigm-HBV, thymosin-alpha, ganciclovir, Besifovir (ANA-380/LB-80380), and Tenofvir-Exalidex (TXL/CMX157) . In certain embodiments, the nucelot(s)ide analog is Entecavir (ETV) or Tenofovir or a derivative thereof.
In certain embodiments, the nucleot(s)ide analog is not Lamivudine. Nucleot(s)ide analogs are commercially available from a number of sources and are used in the methods provided herein according to their label indication (e.g., typically orally administered at a specific dose) or as determined by a skilled practitioner in the treatment of HBV.
III. Antisense Oligonucleotides Targeting HBV
The present invention includes the use of iRNAs which promote cleavage of at least one HBV
transcript, and preferably three or four HBV transcripts. Antisense oligonucleotides can similarly be used to promote cleavage of at least one HBV transcript, preferably three or four HBV transcripts, in the methods of the invention provided here. Exemplary antisense oligonucleotides targeted to HBV
are provided, for example, in U.S. Patent Publication Nos. 2013/0035366, 2012/0207709, and 2004/0127446, the contents of each of which is incorporated by reference herein in its entirety.
It is understood by those of skill in the art that conjugates, linkers, and formulations for the delivery of siRNAs as provided above can be used for the formulation and delivery of antisense oligonucleotide therapeutic agents to subjects.
IV. Pharmaceutical Compositions of the Invention The present invention also includes pharmaceutical compositions and formulations which include the iRNAs or vaccines for use in the invention. It is understood that approved therapeutic agents are formulated and administered by the route indicated on their package instructions.
In some embodiments, provided herein are pharmaceutical compositions containing an iRNA
or a vaccine, as described herein, and a pharmaceutically acceptable carrier.
The pharmaceutical compositions containing the iRNA or vaccine are useful for treating subject with an HBV infection.
Such pharmaceutical compositions are formulated based on the mode of delivery, e.g., for systemic administration via parenteral delivery, e.g., by subcutaneous (SC), intramuscular (IM), or intravenous (IV) delivery.
The pharmaceutical RNAi compositions for use in the invention may be administered in dosages sufficient to significantly reduce the level of at least one HBV
transcript. In general, a suitable dose of an iRNA of the invention will be in the range of about 0.001 to about 200.0 milligrams per kilogram body weight of the recipient per day, generally in the range of about 1 to 50 mg per kilogram body weight per day. Typically, a suitable dose of an iRNA of the invention will be in the range of about 0.1 mg/kg to about 5.0 mg/kg, preferably about 0.3 mg/kg and about 3.0 mg/kg.
A repeat-dose regimen may include administration of a therapeutic amount of iRNA on a regular basis, such as every other week or once a year. In certain embodiments, the iRNA is administered about once per month to about once per quarter (i.e., about once every three months). In preferred embodiments, the RNAi agent is administered subcutaneously.
Formulation and dosing of the vaccine will depend on the nature of the vaccine administered.
In a protein prime-expression vector boost vaccination strategy, the protein-based priming vaccines are administered about 2, 3, or 4 weeks apart with the expression vector vaccine boost being administered about 2, 3, or 4 weeks after the second protein-based vaccine dose. In certain embodiments, it is about two weeks between the first and second doses of the protein-based vaccine.
In certain embodiments, it is about two weeks between the second dose of the protein based vaccine and the DNA expression vector vaccine boost. In certain embodiments, the prime and boost vaccinations are administered by routes independently selected from intramuscularly, intradermally, or subcutaneously.
The pharmaceutical nucleic acid-based vaccines for use in the invention may be administered in dosages sufficient to promote an immune response, as either a prime agent or a boost agent. The amount of nucleic acid-based vaccine to be administered will depend, for example, on the design of the vaccine. As the regimens provided herein can include the use of existing nucleic acid-based vaccines, knowledge regarding appropriate dosages based on therapeutic efficacy and safety should be based on the specific agent used.
The pharmaceutical protein-based vaccines for use in the invention may be administered in dosages sufficient to promote an immune response, as either a prime or a boost agent. The amount of protein-based vaccine to be administered will depend, for example, on the adjuvant used. Protein-based vaccines can be dosed, for example, at about 5-100 mg/kg/dose, about 10-50 mg/kg/dose, or about 20-40 mg/kg/dose. As the regimens provided herein can include the use of existing protein-based vaccines, knowledge regarding appropriate dosages based on therapeutic efficacy and safety should be based on the specific agent used.
After an initial treatment regimen, the treatments can be administered on a less frequent basis.
In preferred embodiments, the treatment regimens and methods provided herein result in a functional cure allowing for discontinuation of treatment after completion of the regimen or after diagnostic criteria indicate a functional cure, e.g., decreased HBsAg levels preferably to below the level of detection of the methods provided herein and a detectable immune response to HBsAg.
The skilled artisan will appreciate that certain factors can influence the dosage and timing required to effectively treat a subject, including but not limited to the severity of the disease or disorder, previous treatments, the general health or age of the subject, and other diseases present.
Moreover, treatment of a subject with a therapeutically effective amount of a composition can include a single treatment or a series of treatments. Estimates of effective dosages and in vivo half-lives for the individual therapeutic agent used in the methods and regimens invention can be made using conventional methodologies or on the basis of in vivo testing using an appropriate animal model, as described elsewhere herein and known in the art.
A. iRNA Formulations Comprising Membranous Molecular Assemblies An iRNA for use in the compositions and methods of the invention can be formulated for delivery in a membranous molecular assembly, e.g., a liposome or a micelle. As used herein, the term "liposome" refers to a vesicle composed of amphiphilic lipids arranged in at least one bilayer, e.g., one bilayer or a plurality of bilayers. Liposomes include unilamellar and multilamellar vesicles that have a membrane formed from a lipophilic material and an aqueous interior. The aqueous portion contains the iRNA composition. The lipophilic material isolates the aqueous interior from an aqueous exterior, which typically does not include the iRNA composition, although in some examples, it may.
Liposomes are useful for the transfer and delivery of active ingredients to the site of action. Because the liposomal membrane is structurally similar to biological membranes, when liposomes are applied to a tissue, the liposomal bilayer fuses with bilayer of the cellular membranes. As the merging of the liposome and cell progresses, the internal aqueous contents that include the iRNA are delivered into the cell where the iRNA can specifically bind to a target RNA and can mediate iRNA. In some cases the liposomes are also specifically targeted, e.g., to direct the iRNA to particular cell types.
A liposome containing an iRNA agent can be prepared by a variety of methods.
In one example, the lipid component of a liposome is dissolved in a detergent so that micelles are formed with the lipid component. For example, the lipid component can be an amphipathic cationic lipid or lipid conjugate. The detergent can have a high critical micelle concentration and may be nonionic.
Exemplary detergents include cholate, CHAPS, octylglucoside, deoxycholate, and lauroyl sarcosine.
The iRNA agent preparation is then added to the micelles that include the lipid component. The cationic groups on the lipid interact with the iRNA agent and condense around the iRNA agent to form a liposome. After condensation, the detergent is removed, e.g., by dialysis, to yield a liposomal preparation of the iRNA agent.
If necessary a carrier compound that assists in condensation can be added during the condensation reaction, e.g., by controlled addition. For example, the carrier compound can be a polymer other than a nucleic acid (e.g., spermine or spermidine). pH can also adjusted to favor condensation.
Methods for producing stable polynucleotide delivery vehicles, which incorporate a polynucleotide/cationic lipid complex as structural components of the delivery vehicle, are further described in, e.g., WO 9637194, the entire contents of which are incorporated herein by reference.
Liposome formation can also include one or more aspects of exemplary methods described in Felgner, P. L. et al., Proc. Natl. Acad. Sci., USA 8:7413-7417, 1987; US Patent No.
4,897,355; US Patent No.
5,171,678; Bangham, et al. M. Mol. Biol. 23:238, 1965; Olson, et al. Biochim.
Biophys. Acta 557:9, 1979; Szoka, et al. Proc. Natl. Acad. Sci. USA 75: 4194, 1978; Mayhew, et al.
Biochim. Biophys. Acta 775:169, 1984; Kim, et al. Biochim. Biophys. Acta 728:339, 1983; and Fukunaga, et al. Endocrinol.
115:757, 1984. Commonly used techniques for preparing lipid aggregates of appropriate size for use as delivery vehicles include sonication and freeze-thaw plus extrusion (see, e.g., Mayer, et al.
Biochim. Biophys. Acta 858:161, 1986). Microfluidization can be used when consistently small (50 to 200 nm) and relatively uniform aggregates are desired (Mayhew, et al. Biochim.
Biophys. Acta 775:169, 1984). These methods are readily adapted to packaging iRNA agent preparations into liposomes.
Liposomes fall into two broad classes. Cationic liposomes are positively charged liposomes which interact with the negatively charged nucleic acid molecules to form a stable complex. The positively charged nucleic acid/liposome complex binds to the negatively charged cell surface and is internalized in an endosome. Due to the acidic pH within the endosome, the liposomes are ruptured, releasing their contents into the cell cytoplasm (Wang et al., Biochem.
Biophys. Res. Commun., 1987, 147, 980-985).
Liposomes which are pH-sensitive or negatively-charged, entrap nucleic acids rather than complex with it. Since both the nucleic acid and the lipid are similarly charged, repulsion rather than complex formation occurs. Nevertheless, some nucleic acid is entrapped within the aqueous interior of these liposomes. pH-sensitive liposomes have been used to deliver nucleic acids encoding the thymidine kinase gene to cell monolayers in culture. Expression of the exogenous gene was detected in the target cells (Zhou et al., Journal of Controlled Release, 1992, 19, 269-274).
One major type of liposomal composition includes phospholipids other than naturally-derived phosphatidylcholine. Neutral liposome compositions, for example, can be formed from dimyristoyl phosphatidylcholine (DMPC) or dipalmitoyl phosphatidylcholine (DPPC). Anionic liposome compositions generally are formed from dimyristoyl phosphatidylglycerol, while anionic fusogenic liposomes are formed primarily from dioleoyl phosphatidylethanolamine (DOPE).
Another type of liposomal composition is formed from phosphatidylcholine (PC) such as, for example, soybean PC
and egg PC. Another type is formed from mixtures of phospholipid or phosphatidylcholine or cholesterol.
Examples of other methods to introduce liposomes into cells in vitro and in vivo include US
Patent Nos. 5,283,185 and 5,171,678; WO 94/00569; WO 93/24640; WO 91/16024;
Felgner, J. Biol.
Chem. 269:2550, 1994; Nabel, Proc. Natl. Acad. Sci. USA 90:11307, 1993; Nabel, Human Gene Ther.
3:649, 1992; Gershon, Biochem. 32:7143, 1993; and Strauss EMBO / 11:417, 1992.
Non-ionic liposomal systems have also been examined to determine their utility in the delivery of drugs to the skin, in particular systems comprising non-ionic surfactant and cholesterol.
Non-ionic liposomal formulations comprising NovasomeTm I (glyceryl dilaurate/cholesterol/polyoxyethylene-10-stearyl ether) and NovasomeTm II
(glyceryl distearate/cholesterol/polyoxyethylene-10-stearyl ether) were used to deliver cyclosporin-A into the dermis of mouse skin. Results indicated that such non-ionic liposomal systems were effective in facilitating the deposition of cyclosporine A into different layers of the skin (Hu et al. S.T.P.Phanna.
Sci., 1994, 4(6) 466).
Liposomes also include "sterically stabilized" liposomes, a term which, as used herein, refers to liposomes comprising one or more specialized lipids that, when incorporated into liposomes, result in enhanced circulation lifetimes relative to liposomes lacking such specialized lipids. Examples of sterically stabilized liposomes are those in which part of the vesicle-forming lipid portion of the liposome (A) comprises one or more glycolipids, such as monosialoganglioside Gmi, or (B) is derivatized with one or more hydrophilic polymers, such as a polyethylene glycol (PEG) moiety.
While not wishing to be bound by any particular theory, it is thought in the art that, at least for sterically stabilized liposomes containing gangliosides, sphingomyelin, or PEG-derivatized lipids, the enhanced circulation half-life of these sterically stabilized liposomes derives from a reduced uptake into cells of the reticuloendothelial system (RES) (Allen et al., FEBS
Letters, 1987, 223, 42; Wu et al., Cancer Research, 1993, 53, 3765).
Various liposomes comprising one or more glycolipids are known in the art.
Papahadjopoulos et al. (Ann. N.Y. Acad. Sci., 1987, 507, 64) reported the ability of monosialoganglioside Gmi, galactocerebroside sulfate and phosphatidylinositol to improve blood half-lives of liposomes. These findings were expounded upon by Gabizon et al. (Proc. Natl. Acad. Sci. USA, 1988, 85, 6949). US
Patent No. 4,837,028 and WO 88/04924, both to Allen et al., disclose liposomes comprising (1) sphingomyelin and (2) the ganglioside Gmi or a galactocerebroside sulfate ester. US Patent No.
5,543,152 discloses liposomes comprising sphingomyelin. Liposomes comprising 1,2-sn-dimyristoylphosphatidylcholine are disclosed in WO 9713499 (Lim et al).
Cationic liposomes possess the advantage of being able to fuse to the cell membrane. Non-cationic liposomes, although not able to fuse as efficiently with the plasma membrane, are taken up by macrophages in vivo and can be used to deliver iRNA agents to macrophages.
Further advantages of liposomes include: liposomes obtained from natural phospholipids are biocompatible and biodegradable; liposomes can incorporate a wide range of water and lipid soluble drugs; liposomes can protect encapsulated iRNA agents in their internal compartments from metabolism and degradation (Rosoff, in "Pharmaceutical Dosage Forms,"
Lieberman, Rieger and Banker (Eds.), 1988, volume 1, p. 245). Important considerations in the preparation of liposome formulations are the lipid surface charge, vesicle size and the aqueous volume of the liposomes.
A positively charged synthetic cationic lipid, N41-(2,3-dioleyloxy)propy1]-N,N,N-trimethylammonium chloride (DOTMA) can be used to form small liposomes that interact spontaneously with nucleic acid to form lipid-nucleic acid complexes which are capable of fusing with the negatively charged lipids of the cell membranes of tissue culture cells, resulting in delivery of iRNA agent (see, e.g., Felgner, P. L. et al., Proc. Natl. Acad. Sci., USA
8:7413-7417, 1987 and US
Patent No. 4,897,355 for a description of DOTMA and its use with DNA).
A DOTMA analogue, 1,2-bis(oleoyloxy)-3-(trimethylammonia)propane (DOTAP) can be used in combination with a phospholipid to form DNA-complexing vesicles.
LipofectinTM Bethesda Research Laboratories, Gaithersburg, Md.) is an effective agent for the delivery of highly anionic nucleic acids into living tissue culture cells that comprise positively charged DOTMA liposomes which interact spontaneously with negatively charged polynucleotides to form complexes. When enough positively charged liposomes are used, the net charge on the resulting complexes is also positive. Positively charged complexes prepared in this way spontaneously attach to negatively charged cell surfaces, fuse with the plasma membrane, and efficiently deliver functional nucleic acids into, for example, tissue culture cells. Another commercially available cationic lipid, 1,2-bis(oleoyloxy)-3,3-(trimethylammonia)propane ("DOTAP") (Boehringer Mannheim, Indianapolis, Indiana) differs from DOTMA in that the oleoyl moieties are linked by ester, rather than ether linkages.
Other reported cationic lipid compounds include those that have been conjugated to a variety of moieties including, for example, carboxyspermine which has been conjugated to one of two types of lipids and includes compounds such as 5-carboxyspermylglycine dioctaoleoylamide ("DOGS") (TransfectamTm, Promega, Madison, Wisconsin) and dipalmitoylphosphatidylethanolamine 5-carboxyspermyl-amide ("DPPES") (see, e.g., US Patent No. 5,171,678).
Another cationic lipid conjugate includes derivatization of the lipid with cholesterol ("DC-Chol") which has been formulated into liposomes in combination with DOPE (See, Gao, X. and Huang, L., Biochim. Biophys. Res. Commun. 179:280, 1991). Lipopolylysine, made by conjugating polylysine to DOPE, has been reported to be effective for transfection in the presence of serum (Zhou, X. et al., Biochim. Biophys. Acta 1065:8, 1991). For certain cell lines, these liposomes containing conjugated cationic lipids, are said to exhibit lower toxicity and provide more efficient transfection than the DOTMA-containing compositions. Other commercially available cationic lipid products include DMRIE and DMRIE-HP (Vical, La Jolla, California) and Lipofectamine (DOSPA) (Life Technology, Inc., Gaithersburg, Maryland). Other cationic lipids suitable for the delivery of oligonucleotides are described in WO 98/39359 and WO 96/37194.
Liposomal formulations are particularly suited for topical administration.
Liposomes present several advantages over other formulations. Such advantages include reduced side effects related to high systemic absorption of the administered drug, increased accumulation of the administered drug at the desired target, and the ability to administer iRNA agent into the skin. In some implementations, liposomes are used for delivering iRNA agent to epidermal cells and also to enhance the penetration of iRNA agent into dermal tissues, e.g., into skin. For example, the liposomes can be applied topically. Topical delivery of drugs formulated as liposomes to the skin has been documented (see, e.g., Weiner et al., Journal of Drug Targeting, 1992, vol. 2,405-410 and du Plessis et al., Antiviral Research, 18, 1992, 259-265; Mannino, R. J. and Fould-Fogerite, S., Biotechniques 6:682-690, 1988;
Itani, T. et al. Gene 56:267-276. 1987; Nicolau, C. et al. Meth. Enz. 149:157-176, 1987; Straubinger, R. M. and Papahadjopoulos, D. Meth. Enz. 101:512-527, 1983; Wang, C. Y. and Huang, L., Proc.
Natl. Acad. Sci. USA 84:7851-7855, 1987).
Liposomes that include iRNA can be made highly deformable. Such deformability can enable the liposomes to penetrate through pore that are smaller than the average radius of the liposome. For example, transfersomes are a type of deformable liposomes. Transferosomes can be made by adding surface edge activators, usually surfactants, to a standard liposomal composition. Transfersomes that include iRNA agent can be delivered, for example, subcutaneously by infection in order to deliver iRNA agent to keratinocytes in the skin. In order to cross intact mammalian skin, lipid vesicles must pass through a series of fine pores, each with a diameter less than 50 nm, under the influence of a suitable transdermal gradient. In addition, due to the lipid properties, these transferosomes can be self-optimizing (adaptive to the shape of pores, e.g., in the skin), self-repairing, and can frequently reach their targets without fragmenting, and often self-loading.
Other formulations amenable to the present invention are described in WO
2008042973.
Surfactants find wide application in formulations such as emulsions (including microemulsions) and liposomes. The most common way of classifying and ranking the properties of the many different types of surfactants, both natural and synthetic, is by the use of the hydrophile/lipophile balance (HLB). The nature of the hydrophilic group (also known as the "head") provides the most useful means for categorizing the different surfactants used in formulations (Rieger, in "Pharmaceutical Dosage Forms", Marcel Dekker, Inc., New York, N.Y., 1988, p. 285).
If the surfactant molecule is not ionized, it is classified as a nonionic surfactant. Nonionic surfactants find wide application in pharmaceutical and cosmetic products and are usable over a wide range of pH values. In general their HLB values range from 2 to about 18 depending on their structure. Nonionic surfactants include nonionic esters such as ethylene glycol esters, propylene glycol esters, glyceryl esters, polyglyceryl esters, sorbitan esters, sucrose esters, and ethoxylated esters. Nonionic alkanolamides and ethers such as fatty alcohol ethoxylates, propoxylated alcohols, and ethoxylated/propoxylated block polymers are also included in this class.
The polyoxyethylene surfactants are the most popular members of the nonionic surfactant class.
If the surfactant molecule carries a negative charge when it is dissolved or dispersed in water, the surfactant is classified as anionic. Anionic surfactants include carboxylates such as soaps, acyl lactylates, acyl amides of amino acids, esters of sulfuric acid such as alkyl sulfates and ethoxylated alkyl sulfates, sulfonates such as alkyl benzene sulfonates, acyl isethionates, acyl taurates and sulfosuccinates, and phosphates. The most important members of the anionic surfactant class are the alkyl sulfates and the soaps.
If the surfactant molecule carries a positive charge when it is dissolved or dispersed in water, the surfactant is classified as cationic. Cationic surfactants include quaternary ammonium salts and ethoxylated amines. The quaternary ammonium salts are the most used members of this class.
If the surfactant molecule has the ability to carry either a positive or negative charge, the surfactant is classified as amphoteric. Amphoteric surfactants include acrylic acid derivatives, substituted alkylamides, N-alkylbetaines and phosphatides.
The use of surfactants in drug products, formulations and in emulsions has been reviewed (Rieger, in "Pharmaceutical Dosage Forms", Marcel Dekker, Inc., New York, N.Y., 1988, p. 285).
The iRNA for use in the methods of the invention can also be provided as micellar formulations. "Micelles" are defined herein as a particular type of molecular assembly in which amphipathic molecules are arranged in a spherical structure such that all the hydrophobic portions of the molecules are directed inward, leaving the hydrophilic portions in contact with the surrounding aqueous phase. The converse arrangement exists if the environment is hydrophobic.
B. Lipid particles iRNAs, e.g., dsRNAs of in the invention may be fully encapsulated in a lipid formulation, e.g., a LNP, or other nucleic acid-lipid particle. Expression vectors or RNAs containing coding sequences for viral antigens under the control of an appropriate promoter can be formulated in lipid particles for delivery.
As used herein, the term "LNP" refers to a stable nucleic acid-lipid particle.
LNPs typically contain a cationic lipid, a non-cationic lipid, and a lipid that prevents aggregation of the particle (e.g., a PEG-lipid conjugate). LNPs are extremely useful for systemic applications, as they exhibit extended circulation lifetimes following intravenous (i.v.) injection and accumulate at distal sites (e.g., sites physically separated from the administration site). LNPs include "pSPLP,"
which include an encapsulated condensing agent-nucleic acid complex as set forth in WO 0003683.
The particles of the present invention typically have a mean diameter of about 50 nm to about 150 nm, more typically about 60 nm to about 130 nm, more typically about 70 nm to about 110 nm, most typically about 70 nm to about 90 nm, and are substantially nontoxic. In addition, the nucleic acids when present in the nucleic acid- lipid particles of the present invention are resistant in aqueous solution to degradation with a nuclease. Nucleic acid-lipid particles and their method of preparation are disclosed in, e.g., US
Patent Nos. 5,976,567; 5,981,501; 6,534,484; 6,586,410; and 6,815,432;
US20100324120 and WO
9640964.
In some embodiments, the lipid to drug ratio (mass/mass ratio) (e.g., lipid to dsRNA ratio) will be in the range of from about 1:1 to about 50:1, from about 1:1 to about 25:1, from about 3:1 to about 15:1, from about 4:1 to about 10:1, from about 5:1 to about 9:1, or about 6:1 to about 9:1.
Ranges intermediate to the above recited ranges are also contemplated to be part of the invention.
The cationic lipid can be, for example, N,N-dioleyl-N,N-dimethylammonium chloride (DODAC), N,N-distearyl-N,N-dimethylammonium bromide (DDAB), N-(I -(2,3-dioleoyloxy)propy1)-N,N,N-trimethylammonium chloride (DOTAP), N-(I -(2,3-dioleyloxy)propy1)-N,N,N-trimethylammonium chloride (DOTMA), N,N-dimethy1-2,3-dioleyloxy)propylamine (DODMA), 1,2-DiLinoleyloxy-N,N-dimethylaminopropane (DLinDMA),1,2-Dilinolenyloxy-N,N-dimethylaminopropane (DLenDMA), 1,2-Dilinoleylcarbamoyloxy-3-dimethylaminopropane (DLin-C-DAP), 1,2-Dilinoleyoxy-3-(dimethylamino)acetoxypropane (Dlin-DAC), 1,2-Dilinoleyoxy-3-morpholinopropane (DLin-MA), 1,2-Dilinoleoy1-3-dimethylaminopropane (DLinDaP), 1,2-Dilinoleylthio-3-dimethylaminopropane (DLin-S-DMA), 1-linoleoy1-2-linoleyloxy-dimethylaminopropane (DLin-2-DMAP), 1,2-Dilinoleyloxy-3-trimethylaminopropane chloride salt (DLin-TMA.C1), 1,2-Dilinoleoy1-3-trimethylaminopropane chloride salt (DLin-TAP.C1), 1,2-Dilinoleyloxy-3-(N-methylpiperazino)propane (DLin-MPz), or 3-(N,N-Dilinoleylamino)-1,2-propanediol (DLinAP), 3-(N,N-Dioleylamino)-1,2-propanedio (DOAP), 1,2-Dilinoleyloxo-3-(2-N,N-dimethylamino)ethoxypropane (DLin-EG-DMA),1,2-Dilinolenyloxy-N,N-dimethylaminopropane (DLinDMA), 2,2-Dilinoley1-4-dimethylaminomethy141,3]-dioxolane (DLin-K-DMA) or analogs thereof, (3aR,55,6aS)-N,N-dimethy1-2,2-di((9Z,12Z)-octadeca-9,12-dienyl)tetrahydro-3aH-cyclopent4d][1,3]dioxo1-5-amine (ALN100), (6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-y1 4-(dimethylamino)butanoate (MC3), 1,1'-(2-(4-(2-((2-(bis(2-hydroxydodecyl)amino)ethyl)(2-hydroxydodecyl)amino)ethyl)piperazin-1-yl)ethylazanediy1)didodecan-2-ol (Tech G1), or a mixture thereof. The cationic lipid can comprise from about 20 mol % to about 50 mol %
or about 40 mol %
of the total lipid present in the particle. In other embodiments, the compound 2,2-Dilinoley1-4-dimethylaminoethy141,3]-dioxolane can be used to prepare lipid-siRNA
nanoparticles.
In some embodiments, the lipid-siRNA particle includes 40% 2, 2-Dilinoley1-4-dimethylaminoethy141,3]-dioxolane: 10% DSPC: 40% Cholesterol: 10% PEG-C-DOMG
(mole percent) with a particle size of 63.0 20 nm and a 0.027 siRNA/Lipid Ratio.
The ionizable/non-cationic lipid can be an anionic lipid or a neutral lipid including, but not limited to, distearoylphosphatidylcholine (DSPC), dioleoylphosphatidylcholine (DOPC), dipalmitoylphosphatidylcholine (DPPC), dioleoylphosphatidylglycerol (DOPG), dipalmitoylphosphatidylglycerol (DPPG), dioleoyl-phosphatidylethanolamine (DOPE), palmitoyloleoylphosphatidylcholine (POPC), palmitoyloleoylphosphatidylethanolamine (POPE), dioleoyl- phosphatidylethanolamine 4-(N-maleimidomethyl)-cyclohexane-1-carboxylate (DOPE-mal), dipalmitoyl phosphatidyl ethanolamine (DPPE), dimyristoylphosphoethanolamine (DMPE), distearoyl-phosphatidyl-ethanolamine (DSPE), 16-0-monomethyl PE, 16-0-dimethyl PE, 18-1 -trans PE, 1 -stearoy1-2-oleoyl- phosphatidyethanolamine (SOPE), cholesterol, or a mixture thereof. The non-cationic lipid can be from about 5 mol % to about 90 mol %, about 10 mol %, or about 58 mol %
if cholesterol is included, of the total lipid present in the particle.
The conjugated lipid that inhibits aggregation of particles can be, for example, a polyethyleneglycol (PEG)-lipid including, without limitation, a PEG-diacylglycerol (DAG), a PEG-dialkyloxypropyl (DAA), a PEG-phospholipid, a PEG-ceramide (Cer), or a mixture thereof. The PEG-DAA conjugate can be, for example, a PEG-dilauryloxypropyl (Ci2), a PEG-dimyristyloxypropyl (Ci4), a PEG-dipalmityloxypropyl (Ci6), or a PEG-distearyloxypropyl (C]8). The conjugated lipid that prevents aggregation of particles can be from 0 mol % to about 20 mol % or about 2 mol % of the total lipid present in the particle.
In some embodiments, the nucleic acid-lipid particle further includes cholesterol at, e.g., about 10 mol % to about 60 mol % or about 48 mol % of the total lipid present in the particle.
In one embodiment, the lipidoid ND98=4HC1 (MW 1487) (see US20090023673, which is incorporated herein by reference), Cholesterol (Sigma-Aldrich), and PEG-Ceramide C16 (Avanti Polar Lipids) can be used to prepare lipid-dsRNA nanoparticles (i.e., LNP01 particles). Stock solutions of each in ethanol can be prepared as follows: ND98, 133 mg/ml;
Cholesterol, 25 mg/ml, PEG-Ceramide C16, 100 mg/ml. The ND98, Cholesterol, and PEG-Ceramide C16 stock solutions can then be combined in a, e.g., 42:48:10 molar ratio. The combined lipid solution can be mixed with aqueous dsRNA (e.g., in sodium acetate pH 5) such that the final ethanol concentration is about 35-45% and the final sodium acetate concentration is about 100-300 mM. Lipid-dsRNA
nanoparticles typically form spontaneously upon mixing. Depending on the desired particle size distribution, the resultant nanoparticle mixture can be extruded through a polycarbonate membrane (e.g., 100 nm cut-off) using, for example, a thermobarrel extruder, such as Lipex Extruder (Northern Lipids, Inc). In some cases, the extrusion step can be omitted. Ethanol removal and simultaneous buffer exchange can be accomplished by, for example, dialysis or tangential flow filtration. Buffer can be exchanged with, for example, phosphate buffered saline (PBS) at about pH 7, e.g., about pH
6.9, about pH 7.0, about pH 7.1, about pH 7.2, about pH 7.3, or about pH 7.4.
N)NNNNrN
NO iCeN
ND98 Isomer I
Formula 1 LNP01 formulations are described, e.g., in WO 2008042973, which is hereby incorporated by reference.
Additional exemplary lipid-dsRNA formulations are described in Table 1.
Table 1 cationic lipid/non-cationic Ionizable/Cationic Lipid lipid/cholesterol/PEG-lipid conjugate Lipid:siRNA ratio DLinDMA/DPPC/Cholesterol/PEG-cDMA
SNALP- 1,2-Dilinolenyloxy-N,N-(57.1/7.1/34.4/1.4) 1 dimethylaminopropane (DLinDMA) lipid:siRNA ¨ 7:1 XTC/DPPC/Cholesterol/PEG-cDMA
2,2-Dilinoley1-4-dimethylaminoethy141,3]-2-XTC 57.1/7.1/34.4/1.4 dioxolane (XTC) lipid:siRNA ¨ 7:1 XTC/DSPC/Cholesterol/PEG-DMG
2,2-Dilinoley1-4-dimethylaminoethy141,3]-LNP05 57.5/7.5/31.5/3.5 dioxolane (XTC) lipid:siRNA ¨ 6:1 XTC/DSPC/Cholesterol/PEG-DMG
2,2-Dilinoley1-4-dimethylaminoethy141,3]-LNP06 57.5/7.5/31.5/3.5 dioxolane (XTC) lipid:siRNA ¨ 11:1 XTC/DSPC/Cholesterol/PEG-DMG
2,2-Dilinoley1-4-dimethylaminoethy141,3]-LNP07 60/7.5/31/1.5, dioxolane (XTC) lipid:siRNA ¨ 6:1 XTC/DSPC/Cholesterol/PEG-DMG
2,2-Dilinoley1-4-dimethylaminoethy141,3]-LNP08 60/7.5/31/1.5, dioxolane (XTC) lipid:siRNA ¨ 11:1 XTC/DSPC/Cholesterol/PEG-DMG
2,2-Dilinoley1-4-dimethylaminoethy141,3]-LNP09 50/10/38.5/1.5 dioxolane (XTC) Lipid:siRNA 10:1 (3aR,55,6aS)-N,N-dimethy1-2,2-di((9Z,12Z)-octadeca-9,12- ALN100/DSPC/Cholesterol/PEG-DMG
LNP10 dienyl)tetrahydro-3aH- 50/10/38.5/1.5 cyclopenta[d][1,3]dioxo1-5-amine Lipid:siRNA 10:1 (ALN100) (6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31- MC-3/DSPC/Cholesterol/PEG-DMG
LNP11 tetraen-19-y1 4-(dimethylamino)butanoate 50/10/38.5/1.5 (MC3) Lipid:siRNA 10:1 1,1'-(2-(4-(2-((2-(bis(2- Tech Gl/DSPC/Cholesterol/PEG-DMG
hydroxydodecyl)amino)ethyl)(2- 50/10/38.5/1.5 hydroxydodecyl)amino)ethyl)piperazin-1- Lipid:siRNA 10:1 yl)ethylazanediy1)didodecan-2-ol (Tech Gl) XTC/DSPC/Chol/PEG-DMG
LNP13 XTC 50/10/38.5/1.5 Lipid:siRNA: 33:1 MC3/DSPC/Chol/PEG-DMG
Lipid:siRNA: 11:1 MC3/DSPC/Chol/PEG-DSG/Ga1NAc-PEG-DSG
50/10/35/4.5/0.5 Lipid:siRNA: 11:1 MC3/DSPC/Chol/PEG-DMG
LNP16 MC3 50/10/38.5/1.5 Lipid:siRNA: 7:1 MC3/DSPC/Chol/PEG-DSG
LNP17 MC3 50/10/38.5/1.5 Lipid:siRNA: 10:1 MC3/DSPC/Chol/PEG-DMG
LNP18 MC3 50/10/38.5/1.5 Lipid:siRNA: 12:1 MC3/DSPC/Chol/PEG-DMG
Lipid:siRNA: 8:1 MC3/DSPC/Chol/PEG-DPG
LNP20 MC3 50/10/38.5/1.5 Lipid:siRNA: 10:1 C12-200/DSPC/Chol/PEG-DSG
LNP21 C12-200 50/10/38.5/1.5 Lipid:siRNA: 7:1 XTC/DSPC/Chol/PEG-DSG
LNP22 XTC 50/10/38.5/1.5 Lipid:siRNA: 10:1 DSPC: distearoylphosphatidylcholine DPPC: dipalmitoylphosphatidylcholine PEG-DMG: PEG-didimyristoyl glycerol (C14-PEG, or PEG-C14) (PEG with avg mol wt of 2000) PEG-DSG: PEG-distyryl glycerol (C18-PEG, or PEG-C18) (PEG with avg mol wt of 2000) PEG-cDMA: PEG-carbamoy1-1,2-dimyristyloxypropylamine (PEG with avg mol wt of 2000) SNALP (1,2-Dilinolenyloxy-N,N-dimethylaminopropane (DLinDMA)) comprising formulations are described in International Publication No. WO 2009/127060, filed April 15, 2009, which is hereby incorporated by reference.
XTC comprising formulations are described in PCT Publication No. WO
2010/088537, the entire contents of which are hereby incorporated herein by reference.
MC3 comprising formulations are described, e.g., in U.S. Publication No.
2010/0324120, the entire contents of which are hereby incorporated by reference.
ALNY-100 comprising formulations are described in PCT Publication No. WO
2010/054406, the entire contents of which are hereby incorporated herein by reference.
C12-200 comprising formulations are described in PCT Publication No. WO
2010/129709, the entire contents of which are hereby incorporated herein by reference.
Compositions and formulations for oral administration include powders or granules, microparticulates, nanoparticulates, suspensions or solutions in water or non-aqueous media, capsules, gel capsules, sachets, tablets or minitablets. Thickeners, flavoring agents, diluents, emulsifiers, dispersing aids or binders can be desirable. In some embodiments, oral formulations are those in which dsRNAs featured in the invention are administered in conjunction with one or more penetration enhancer surfactants and chelators. Suitable surfactants include fatty acids or esters or salts thereof, bile acids or salts thereof. Suitable bile acids/salts include chenodeoxycholic acid (CDCA) and ursodeoxychenodeoxycholic acid (UDCA), cholic acid, dehydrocholic acid, deoxycholic acid, glucholic acid, glycholic acid, glycodeoxycholic acid, taurocholic acid, taurodeoxycholic acid, sodium tauro-24,25-dihydro-fusidate and sodium glycodihydrofusidate. Suitable fatty acids include arachidonic acid, undecanoic acid, oleic acid, lauric acid, caprylic acid, capric acid, myristic acid, palmitic acid, stearic acid, linoleic acid, linolenic acid, dicaprate, tricaprate, monoolein, dilaurin, glyceryl 1-monocaprate, 1-dodecylazacycloheptan-2-one, an acylcarnitine, an acylcholine, or a monoglyceride, a diglyceride or a pharmaceutically acceptable salt thereof (e.g., sodium). In some embodiments, combinations of penetration enhancers are used, for example, fatty acids/salts in combination with bile acids/salts. One exemplary combination is the sodium salt of lauric acid, capric acid and UDCA. Further penetration enhancers include polyoxyethylene-9-lauryl ether, polyoxyethylene-20-cetyl ether. DsRNAs featured in the invention can be delivered orally, in granular form including sprayed dried particles, or complexed to form micro or nanoparticles. DsRNA
complexing agents include poly-amino acids; polyimines; polyacrylates;
polyalkylacrylates, polyoxethanes, polyalkylcyanoacrylates; cationized gelatins, albumins, starches, acrylates, polyethyleneglycols (PEG) and starches; polyalkylcyanoacrylates; DEAE-derivatized polyimines, pollulans, celluloses and starches. Suitable complexing agents include chitosan, N-trimethylchitosan, poly-L-lysine, polyhistidine, polyornithine, polyspermines, protamine, polyvinylpyridine, polythiodiethylaminomethylethylene P(TDAE), polyaminostyrene (e.g., p-amino), poly(methylcyanoacrylate), poly(ethylcyanoacrylate), poly(butylcyanoacrylate), poly(isobutylcyanoacrylate), poly(isohexylcynaoacrylate), DEAE-methacrylate, DEAE-hexylacrylate, DEAE-acrylamide, DEAE-albumin and DEAE-dextran, polymethylacrylate, polyhexylacrylate, poly(D,L-lactic acid), poly(DL-lactic-co-glycolic acid (PLGA), alginate, and polyethyleneglycol (PEG). Oral formulations for dsRNAs and their preparation are described in detail in US Patent Nos.
6,887,906 and 6,747,014, and US 20030027780, each of which is incorporated herein by reference.
Pharmaceutical compositions of the present invention include, but are not limited to, solutions, emulsions, and liposome-containing formulations. These compositions can be generated from a variety of components that include, but are not limited to, preformed liquids, self-emulsifying solids and self-emulsifying semisolids. Particularly preferred are formulations that target the liver when treating hepatic disorders such as hepatic carcinoma.
The pharmaceutical formulations of the present invention, which can conveniently be presented in unit dosage form, can be prepared according to conventional techniques well known in the pharmaceutical industry. Such techniques include the step of bringing into association the active ingredients with the pharmaceutical carrier(s) or excipient(s). In general, the formulations are prepared by uniformly and intimately bringing into association the active ingredients with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product.
V. Uses of the Methods of the Invention The invention sets forth various methods and treatment regimens. It is understood that the methods can be provided as uses of the RNAi agents and vaccines provided herein. That is, the invention provides a) an RNAi agent that targets at least three HBV transcripts, wherein the RNAi agent comprises a sense strand and an antisense strand;
b) a protein-based vaccine comprising an HBV core antigen (HBcAg) and an HBV
surface antigen (HBsAg); and c) a nucleic acid-based vaccine comprising an expression vector construct encoding an HBcAg or an HBsAg, wherein the construct encodes a protein that shares an epitope with the protein-based vaccine; thereby treating the subject for use in methods of treating a subject having a hepatitis B infection.
The uses include all of the variations and exemplary RNAi agents, protein-based vaccines, and nucleic acid-based vaccines provided herein.
VI. Kits for Practicing the Methods of the Invention The invention sets forth various methods, treatment regimensm and uses of agents for the treatment of a subject having a hepatitis B infection. It is understood that agents for practicing the methods of the invention can be prepared based in the disclosure provided herein. Such a kit would include, a) an RNAi agent that targets at least three HBV transcripts, wherein the RNAi agent comprises a sense strand and an antisense strand;
b) a protein-based vaccine comprising an HBV core antigen (HBcAg) and an HBV
surface antigen (HBsAg);
c) a nucleic acid-based vaccine comprising an expression vector construct encoding an HBcAg or an HBsAg, wherein the construct encodes a protein that shares an epitope with the protein-based vaccine; thereby treating the subject; and d) instructions for use in methods of treating a subject having a hepatitis B
infection.
The uses include all of the variations and exemplary RNAi agents, protein-based vaccines, and nucleic acid-based vaccines provided herein. The components of the kit may be provided together, e.g., in a box. In certain embodiments, the components of the invention may be provided separately, e.g., due to different storage requirements, but be provided for use together, e.g., based on .. package instructions for use.
This invention is further illustrated by the following examples which should not be construed as limiting. The entire contents of all references, patents and published patent applications cited .. throughout this application, as well as the Figures, Appendix A, and the Sequence Listing, are hereby incorporated herein by reference.
EXAMPLES
.. Example 1. Materials and methods Exemplaiy iRNAs Exemplary iRNA target sites and unmodified and modified siRNA sequences are provided in the tables in Appendix A.
The chemically modified HBV-siRNA duplexes used in the experiments below have the .. following sequences:
Unmodified sequences:
DuplexID Sense Sequence Unmodified (5' to 3') SEQ Antisense Sequence Umodified (5' to 3') SEQ
ID:
ID:
Modified sequences:
DuplexID SEQ Antisense Sequence Modified (5' to 3') SEQ
Sense Sequence Modified (5' to 3') ID:
ID:
AD-66810 gsusguGfcAfCfUfucgcuucacaL96 37 usGfsugaAfgCfGfaaguGfcAfcacsusu 30 AD-66816 csasccauGfcAfAfCfuuuuucaccuL96 38 asGfsgugAfaAfAfaguuGfcAfuggugsusu Abbreviations for nucleotide monomers in modified nucleic acid sequences are provided in Table 1 of Appendix A.
The target site of AD-66810 is GTGTGCACTTCGCTTCACA (SEQ ID NO: 39) which is nucleotides 1579-1597 of NC_003977.1 (SEQ ID NO: 1).
The target site of AD-66816 is CACCATGCAACTTTTTCACCT (SEQ ID NO: 40) which is nucleotides 1812-1832 of NC_003977.1 (SEQ ID NO: 1).
Cell Culture Evaluation of HBV-siRNA
hNTCP-expressing HepG2 cells were infected (100 multiplicity of infection (MOI)) HBV
particles/cell (subtype ayw)) in duplicate. At day 4 after infection, cells were trypsinized and reseeded into multiwell plates and transfected with control or HBV-siRNAs AD-66810 (having the chemical modifications shown in the table above and sense and antisense sequences as set forth in SEQ ID NOs: 37 and 30, respectively) or AD-66816 (having the chemical modifications shown in the table above and sense and antisense sequences as set forth in SEQ ID NOs: 38 and 32, respectively) each delivered at 100 nM, 10 nM, or 1 nM using Lipofectamine RNAiMax.
Supernatant was harvested at days 3, 6, 10, 13, and 17 after reseeding and HBeAg and HBsAg levels were determined relative to non-transfected control. HBsAg and HBeAg levels were determined using a chemiluminescent microparticle immunoassay (CMIA) measured in an Abbott Architect immunoassay analyzer (Abbott Laboratories, Abbott Park, IL, USA).
Mice, siRNA Administration, and Vaccinations HBV-transgenic mice (StrainHBV1.3xfs (HBV genotype D, subtype ayw)), were derived from in-house breeding under specific pathogen-free conditions following institutional guidelines.
For siRNA administration, mice were subcutaneously administered a 3 mg/kg or 9 mg/kg dose of control siRNA or HBV-siRNA (modified AD-66810 or modified AD-66816);
or intravenously administered by tail vein injection 1 x 10" AAV particles for expression of the HBV-shRNA as indicated in the Figures and Examples below.
For protein vaccinations, mice were immunized subcutaneously with recombinant yeast HBsAg and Escherichia coli HBcAg (APP Latvijas Biomedicinas, Riga, Latvia) mixed with 31.91 lig of synthetic phosphorothioated CpG ODN 1668 and 25 lig poly[di(sodiumcarboxylatoethyl-phenoxy)phosphazene] (PCEP) in 50 I.L1 PBS.
Recombinant MVA were generated by homologous recombination and host range selection as described previously (Staib et al., 2003. Biotechniques. 34:694-700). The entire HBcAg (genotype D, subtype ayw) and HBsAg open reading frames (genotype A, subtype ayw or adw) were cloned into MVA transfer plasmids pIIIAHR-PH5 or pIIIAHR-P7.5, thereby placing the HBV
proteins under the control of the early/late Vaccinia virus-specific promoters PH5 (HBcAg ayw /HBsAg ayw/HBsAg adw) or P7.5 (HBsAg ayw). After construction of each virus, gene expression, sequence of inserted DNA, and viral purity were verified. For generation of vaccine preparations, MVA were routinely propagated in CEF, purified by ultracentrifugation through sucrose, reconstituted in 1 mM Tris-HC1 pH 9.0 and titrated following standard methodology (Staib et al., 2004.
Methods Mol Biol. 269:77-.. 100). For MVA vaccination, mice were vaccinated intraperitoneally with 1 x 108 infectious units of respective recombinant MVA in 500 I.L1 PBS.
Specific dosing regimens are provided in the Examples below and in Figures 3, 7, and 12.
Serological analysis Serum levels of HBsAg and HBeAg were determined in 1:33 dilutions; and anti-HBs levels were determined in a 1:100 dilution using chemiluminescent microparticle immunoassay (CMIA) measured in an Abbott Architect immunoassay analyzer (Abbott Laboratories, Abbott Park, IL, USA).
Quantification of serum HBV titers by real-time polymerase chain reaction and determination of HBV
DNA levels in serum was performed as described in Untergasser et al., 2006 (Hepatology. 43:539-47). The amount of HBV DNA was normalized to DNA level prior to treatment.
Levels of anti-HBc antibodies were determined in 1:20 dilution using the Enzgnost anti-HBc monoclonal test on the BEPIII platform (Both Siemens Healthcare, Eschborn, Germany). If a sample was measured outside the linear range, higher or lower dilutions were used as appropiate.
Quantification of serum HBV titers by real-time polymerase chain reaction and determination of HBV DNA levels in serum was performed as described in Untergasser et al., 2006 (Hepatology.
43:539-47). The amount of HBV DNA was normalized to DNA level prior to treatment.
ALT activity was measured at the day of bleeding in a 1:4 dilution in phosphate buffered saline (PBS) using the Reflotron GPT/ALT test (Roche Diagnostics, Mannheim, Germany).
Lymphocyte stimulation assay Liver-associated lymphocytes (LAL) were isolated as described in Stross et al., 2012 (Hepatology 56:873-83) and stimulated with H2-kb-or H-2Db-restricted peptides (see Backes, 2016) for 12 hours in the presence of 1 mg/ml Brefeldin A (Sigma-Aldrich, Tauflcirchen,Germany). Cells were live/dead-stained with ethidium monoazidebromide (Invitrogen , Karlsruhe, Germany) and blocked with anti-CD16/CD32-Fc-Block (BD Biosciences, Heidelberg, Germany).
Surface markers were stained with PB-conjugated anti-CD8-alpha and PE-conjugated anti-CD4 (eBiosciences, Eching, Germany). Intracellular cytokine staining (ICS) was performed with FITC anti-IFN-gamma (XMG1.2), PE-Cy7 anti-TNF-alpha and APC anti-IL-2 (eBiosciences, Ech-ing, Germany) using the Cytofix/Cytoperm kit (BD Biosciences, Heidelberg, Germany) according to the manufacturer's recommendations. The same data were analyzed twice, the second time with a more rigorous exclusion of dead cells.
Immunohistochemical stainings for HBc-expressing hepatocytes Livers were harvested, fixed in 4% paraformaldehyde, and paraffin-embedded.
The liver was sectioned (2 [tin) and sections were stained with rabbit anti-HBcAg as the primary antibody (Diagnostic Biosystems, Pleasanton, CA; #RP 017; 1:50 dilution; retrieval at 100 C for 30 min with EDTA) and a horseradish peroxide coupled secondary antibody. Incubation in Ventana buffer and staining were performed on a NEXES immunohistochemistry robot (Ventana Instruments) using an IVIEW DAB Detection Kit (Ventana Instruments) or on a Bond MAX (Leica Biosystems). For analysis, slides were scanned using a SCN 400 slide scanner and positive cells were counted using the integrated Tissue AT software (both Leica Biosystems).
HBV transcripts from liver lysate For analysis of HBV RNA from liver lysate, RNA was extracted from 30 mg liver tissue with the RNeasy mini kit (Qiagen) and cDNA was synthesized with the Superscript III
kit (Thermo Fisher Scientific). HBV transcripts were amplified with primers specific for only the 3.5 kb transcripts (forward primer 5'- GAGTGTGGATTCGCACTCC-3' (SEQ ID NO: 41); reverese primer 5'-GAGGCGAGGGAGTTCTTCT-3' (SEQ ID NO: 42)), or with primers binding to the common 3 end of all HBV transcripts (forward primer 5'- TCACCAGCACCATGCAAC-3' (SEQ ID NO:
43);
reverse primer 5'- AAGCCACCCAAGGCACAG-3' (SEQ ID NO: 44)) (Denaturation: 95 C
5 min;
Amplification: 95 C 3s, 60 C 30s (40 cycles)) (Yan et al., 2012). Results were normalised to murine GAPDH expression (forward primer 5'- ACCAACTGCTTAGCCC-3' (SEQ ID NO: 45);
reverse primer 5'- CCACGACGGACACATT-3' (SEQ ID NO: 46)) (Denaturation: 95 C 5 min;
Amplification: 95 C 15s, 60C 10s, 72 C 25s (45 cycles)). All PCR reactions were performed on a LightCycler 480 (Roche Diagnostics).
AAV-HBV mouse model For the AAV mouse model, wildtype C57/B16 mice (9 weeks of age; 6 animals per treatment group) were injected i.v. with 2x101 genome equivalents (geq) of Adeno-Associated-Virus Serotype 8 (AAV8) carrying a 1.2-fold overlength HBV genome of genotype D (AAV-HBV1.2) (day -28) (see, e.g., Yang, et al. (2014) Cell and Mol Immunol 11:71) . Starting 4 weeks after AAV-transduction (day 0), animals were treated with 3 injections (3 mg/kg bw, n=12 per group) of either a control siRNA, or HBV siRNA (AD-66816 or AD-66810) (days 0, 29, and 57). Each siRNA
treatment group was divided into two groups (n = 6 per group) to be not treated or treated with the vaccine regimen consisting of recombinant HBsAg, HBcAg (15 tig of each) and 10 tig c-di-AMP
given at day 57 and 70 and boosted with MVA-HBs and MVA-HBc (5x107 geq of each) at day 84. A
schematic showing the treatment regimen is provided in Figure 12.
Example 2¨ Evaluation of HBV-siRNA in HepG2-NTCP Cell Culture and Dose Finding Experiments in HBVxfs Mice Anti-HBV siRNAs were evaluated for efficient knockdown of HBV antigens and DNA
in an in vitro infection model using HBV-infected HepG2-NTCP cells treated with 1 nM, 10 nM, or 100 nM of one of modified AD-66810 or modified AD-66816 HBV-siRNA, or a control siRNA as provided above. Supernatants were collected at days 3, 6, 10, 13, and 17 days after siRNA treatment and assayed for HBeAg and HBsAg levels as compared to untransfected control.
Both HBV-siRNAs were demonstrated to effectively knockdown expression of both HBeAg and HBsAg with the highest levels of knockdown observed at days 13 and 17. No significant knockdown was observed with the control siRNA. These data demonstrate that the AD-66810 or AD-66816 HBV-siRNAs are effective at knocking down expression of HBV antigens in a sustained manner in an in vitro system of HBV
infection.
The HBV and control siRNAs were then tested in the HBVxfs transgenic model of chronic hepatitis B. The HBVxfs mice include an integrated HBV genome that is expressed under the control of a liver-specific promoter. At about 10 weeks of age, mice were administered a 3 or 9 mg/kg dose of one of AD-66810 or AD-66816 HBV-siRNA or a control siRNA (n = 6 per group).
Blood samples were collected at days 6, 13, and 21 after siRNA treatment and serum was prepared. HBeAg, HBsAg, and HBV DNA levels in serum (Figures 2A-2C) were determined as provided above.
Further, RNA
was isolated from liver and total HBV RNA and HBV 3.5 kB transcript levels were detected using the method of Yan, 2012 and normalized to GAPDH expression (Figures 2D and 2E).
Both of the HBV-siRNAs at both doses were demonstrated to effectively knockdown expression of HBsAg and HBeAg and to decrease HBV DNA levels in serum as compared to control levels (see Figures 2A-2C). Futher, total liver HBV RNA relative to GAPDH DNA
and 3.5 kb HBV
RNA relative to GAPDH RNA levels were strongly decreased by both doses of the HBV siRNAs as compared to control levels (Figures 2D and 2E). Based on these results, the 3 mg/kg dose was selected for use in further experiments.
Example 3 ¨ Comparison of Reducing Antigen Load with siRNA to Nucleot(s)ide Analogs Prior to Therapeutic Vaccine Administration in an HBV Transgenic Mouse Model Having demonstrated that siRNA targeted to HBV can effectively knockdown expression of HBsAg and HBeAg and decrease HBV DNA levels in serum in the HBVxfs mouse model, the effect of treatment of mice with the nucleoside analog Entecavir or HBV-siRNA prior to therapeutic vaccine administration using a prime-boost regimen was tested. The treatment scheme is shown in Figure 3.
Mice were pretreated with one of six treatment regimens prior to vaccination using a prime-boost regimen (n= 6 per group):
(1) No pretreatment;
(2) Entecavir at 1 lig/m1 in water throughout the course of the study beginning on the first day of Week 0 (expected dose of about 4 mg/day based on calculations provided in Liitgehetmann et al., 2011, Gastroenterology.140:2074-83);
(3) A 3 mg/kg dose on the first day of Weeks 0, 4, 8, and 12 of the control iRNA agent.
(4) A single dose on the first day of Week 0 with an expression vector encoding an shRNA
targeted to HBV (HBV-shRNA) (Michler et al., 2016); or (5-6) A 3 mg/kg dose on the first day of Weeks 0, 4, 8, and 12 of modified AD-66816 or modified AD-86610 (generically HBV-siRNA).
On the first day of Weeks 12 and 14, a mixture of recombinantly expressed yeast HBsAg (15 rig) and E. coli expressed HBcAg (15 rig) adjuvanted with 31.9 lig synthetic phosphorothioated CpGODN 1668 (CpG) and 25 lig polykli(sodiumcarboxylatoethyl-phenoxy)phosphazene] (PCEP) was subcutaneously administered to all mice as a protein-prime vaccination (Backes, 2016).
On the first day of week 16, a mixture of modified vaccinia viruses Ankara expressing HBsAg or HBcAg (5 x 107 particles of each virus) was subcutaneously administered to all mice as a boost vaccination (Backes, 2016).
Blood samples were obtained on the first days of Week 0, 2, 4, 8, 12, 16, and 17 and serum samples prepared therefrom were assayed for levels of HBsAg, HBeAg, and HBV
DNA. Results are shown in Figure 4.
HBsAg and HBeAg levels mice in groups 1, 2, and 3 (mock, Entecavir, control iRNA agent) were similar. The HBV-shRNA or HBV-siRNAs (AD-66816 or AD-86610) alone caused a significant decrease in HBsAg, HBeAg, and HBV DNA in serum (Figures 4A-4C).
The three dose prime-boost vaccination scheme resulted in a further decrease in HBsAg in all groups, and reduced the level of HBsAg in at least some animals in the HBV-shRNA and HBV-siRNA
groups to below the level of detection. However, vaccine treatment did not decrease HBeAg levels in any of the groups. Without being bound by mechanism, it is proposed that the decrease in HBsAg, but not HBeAg, results from the immune response induced by the vaccine against the s antigen, but not the e antigen, which is produced by proteolytic processing of the C protein (see Figure 5 discussed below).
HBV DNA levels were decreased to about the lower limit of quantitation with Entecavir alone so no effect of the three dose prime-boost vaccine could be detected (Figure 4C). Mock treatment and treatment with the HBV-shRNA, the HBV-siRNAs, and control siRNA all decreased HBV DNA
levels and the level of HBV-DNA was further decreased by the prime-boost vaccine in all groups. It is unclear why the mock treatment and control siRNA decreased HBV DNA levels in this experiment.
No decrease in HBV DNA was observed in response to treatment with control siRNA in other experiments (see, e.g., Figures 2C and 8C). These data demonstrate that RNAi is superior to nucleot(s)ide analog therapy in reducing viral antigens. Also, RNAi and subsequent vaccination have a combined effect on HBsAg and HBV DNA levels greater than either agent alone.
On the final day of the experiment (first day of Week 17), mice were sacrificed and their livers harvested. Liver associated lymphocytes were isolated from liver and after peptide stimulation CD8+ T cell responses measured via intracellular cytokine staining.
Specifically, intrahepatic CD8+
T cell responses were assessed for response to HBsAg, HBcAg, and the MVA virus particle using the method provided in Backes, 2016. The data were analyzed twice using two different thresholds for the exclusion of dead immune cells as the exclusion of dead immune cells in the first analysis provided in Figures 5A-5C was determined to be insufficient. The second analysis is presented in Figures 5D-5F. The second analysis confirmed the conclusions from the first analysis.
Mice pretreated with the HBV-shRNA or the HBV-siRNAs before vaccination were able to generate a CD8+ T cell immune response against the HBsAg and HBcAg (Figures 5A, 5B, 5D, and 5E) indicating that cytotoxic T cells able to clear HBV infection are induced when HBV antigen levels are suppressed prior to vaccination. No significant CD8+ T cell immune response against the HBV antigens was observed in the mock, Entecavir, or control siRNA groups. A
significant and similar CD8+ T cell immune response against the MVA virus in all animals, independent of pretreatment or viral antigen levels, demonstrated that vaccination had worked equally well in all animals and was not influenced by HBV antigen levels, thereby demonstrating the presence of a competent immune system (Figures 5C and 5F). No significant differences in antibody production were observed between mock treated animals and any of the other groups indicating that high HBV
antigen levels may induce T cell tolerance.
These data demonstrate that RNAi treatment, in contrast to the current standard of care treatment with a nucleoside analog, can restore HBV-specific T cell immunity in the liver and enable the induction of HBV-specific CD8+ T cell responses after therapeutic vaccination. A robust CD8+
effector T cell response has been associated with viral clearance and functional cure (see, e.g., Thimme et al., 2003. J. Virol. 77:68-76, and Backes et al., 2016. Vaccine.
34:923-932).
RNA was also isolated from liver and total HBV RNA and HBV 3.5 kB transcript levels were detected using the method of Yan, 2012 and normalized to GAPDH expression.
Treatment of mice with HBV-siRNA or HBV-shRNA prior to vaccine administration resulted in a significant decrease in HBV total RNA and HBV 3.5 kb transcript as compared to the mock treated control (Figures 6A and 6B). No significant change in HBV total RNA and HBV 3.5 kb transcript was observed in the mice treated with Entecavir or the control siRNA prior to vaccination as compared to the mock treated control. These data demonstrate that both HBV siRNAs and the shRNA, in contrast to the control and Entecavir groups, successfully led to a decrease in HBV transcript levels.
Further, expression of HBV antigens in the liver was analyzed by immunohistochemical staining for HBc of liver sections and counting of HBc positive cells per mm2 (Figure 6C). Only groups of animals pre-treated with HBV siRNA or shRNA, but not Entecavir or the control siRNA, showed reduced HBc expression following vaccination.
Throughout the experiment, body weight and ALT levels were monitored. No significant differences were observed in any of the treatment groups as compared to mock treated control.
Example 4 ¨ Evaluation of the Effect of Duration of HBV Antigen Knockdown on Response to Immunization in an HBV Transgenic Mouse Model Having demonstrated that suppression of expression of HBV antigens using shRNA
or siRNA
is effective at potentiating an immune response to an HBV vaccine regimen, a study was designed to determine if the length of time of HBV antigen suppression had an effect on potentiation of an HBV
immune response. A treatment scheme is shown in Figure 7.
Using the HBV1.3xfs mouse model, mice were treated for eight, six, or three weeks with HBV-siRNA AD-66816 (modified) or the control siRNA for 8 weeks, administered subcutaneously at 3 mg/kg/dose. siRNA administration was followed by administration of the prime-boost vaccine regimen as set forth above with the exception that c-di-AMP was used as an adjuvant with protein administration rather than PCEP + CPG (n= 6 per group). Therefore, mice in the 8 week group (n =
6) received three doses of siRNA with the third dose being administered on the first day of vaccine administration. The mice in the 6 week group (n = 12) received two doses of siRNA with the second dose being administered two weeks prior to the first day of vaccine administration. Finally, the mice in the 3 week group (n = 6) received one dose of siRNA with the dose being administered three weeks prior to the first day of vaccine administration.
Blood samples were collected on the first day of -8 weeks, -6 weeks, -4 weeks, -2 weeks, 0 weeks, 2 weeks, 4 weeks, and 6 weeks, before (negative numbers) and after the first dose of vaccine administration on the first day of Week 0. Serum was prepared and HBsAg, HBeAg, and HBV DNA
levels were assessed as provided above.
A significant decrease in each HBsAg, HBeAg, and HBV DNA was observed after the first administration of AD-66816 (Figures 8A-8C). A further significant decrease in HBsAg was observed after treatment with the vaccine boost, with the greatest decrease observed in the 8 week pretreatment group to below the level of detection of the assay, representing a greater than 5 10g10 decrease in HBsAg level in all treated animals. Immunization caused only slight further reductions (<0.5 10g10) of HBV DNA which had been significantly decreased by the siRNA treatment. No further decrease in HBeAg levels was observed in response to the vaccination regimen.
These data demonstrate that efficacy of therapeutic vaccination correlates with duration of antigen suppression before start of vaccination. Reconstitution of HBV-specific CD8+ T cell responses takes several weeks, with a 6 or preferably 8 week pretreatment rather than a 3 week pretreatment.
On the final day of the experiment, on the first day of Week 6 after the start of immunization, mice were sacrificed and their livers harvested for six mice from each group.
Liver associated lymphocytes were isolated and a lymphocyte stimulation assay was performed as provided above.
Specifically, intrahepatic CD8+ T cell responses were assessed for response to HBsAg, HBcAg, and the MVA virus particle using the method provided in Backes, 2016. T-cell responses against HBsAg and HBcAg in liver corresponded with the duration of HBV antigen knockdown, with a trend of higher levels of immune response observed with longer duration of HBV antigen resulting in greater T-cell response (see Figures 9A-9C). Similar responses to MVA virus antigens were observed across all groups, independent of pretreatment, showing that vaccination had worked equally well in all animals and was not influenced by HBV antigen levels demonstrating the presence of a competent immune system (Figure 9D). No significant differences in antibody production were observed between control siRNA treated animals and any of the other groups. This demonstrates, that reconstitution of HBV-specific CD8+ T cell responses does not occur immediately, with stronger responses seen after therapeutic vaccination if animals had lowered HBV
antigen titers for at least 6 or 8 weeks compared to only 3 weeks. It further confirms the previous finding that, in contrast to T cell responses, B cell immunity does not seem to be significant influenced by HBV
antigen titers.
RNA was also isolated from liver and total HBV RNA and HBV 3.5 lcB transcript levels were detected using the method of Yan, 2012 and normalized to GAPDH expression.
Treatment of mice with HBV-siRNA AD-66816 prior to vaccine administration resulted in a significant decrease in HBV
total RNA and HBV 3.5 kb transcript in liver lysates as compared to the control siRNA treated control (Figures 10A and 10B). Further, HBV antigen expression in the liver was analyzed by immunohistochemical staning and counting of HBc positive cells per mm2 (Figure 10C). Correlating the observed increase in HBV-specific CD8 responses with increased duration of siRNA pretreatment, decreased numbers of HBc expressing cells where observed in the liver. These results demonstrate that the CD8+ T cell responses did prevent antigen expression in the liver..
To assess the durability of response, blood samples were collected from mice pretreated with the AD-66816 HBV-siRNA using the six week treatment regimen at 2 and 3 weeks after administration of the boost vaccination (Figures 11A-11D). In three of the six mice, HBsAg levels continued to drop to below the level of detection of the assay (Figure 11A).
No similar decrease in HBeAg levels were observed during the course of the experiment (Figure 11B).
These data show that the maximum effect by the siRNA-vaccination combinatorial therapy provided herein is later than 1 week after the MVA vaccination, which was chosen as termination time point to best asses CD8+ T
cell responses. Anti-HBs antibody response (Figure 11C) and T cell immune response in the liver against HBs(5208) (Figure 11D) at week 7 after the first vaccine dose after the 6 week regimen in the dosing regimen. The antibody response varied among animals.
These data demonstrate that a functional cure is possible using the treatment regimens provided herein. Further, these data suggest that a lower HBsAg and HBeAg burden can result in a greater level of immune clearance of HB antigens and potentiate an immune response, at least within the short time course of the experiment.
Throughout the experiment, body weight and ALT levels were monitored. No significant differences were observed in any of the treatment groups as compared to mock treated control.
Example 5 ¨ Evaluation of the Effect of Duration of HBV Antigen Knockdown on Response to Immunization in an AAV-HBV Mouse Model Having demonstrated the efficacy of the siRNA-vaccine combination treatment regimen in a transgenic mouse model, an AAV-HBV infection mouse model was used to study the efficacy of the treatment regimen in acquired infection model (see, e.g., Yang, et al. (2014) Cell Mol Immunol
In one embodiment, a ligand alters the distribution, targeting, or lifetime of an iRNA agent into which it is incorporated. In preferred embodiments a ligand provides an enhanced affinity for a selected target, e.g., molecule, cell or cell type, compartment, e.g., a cellular or organ compartment, tissue, organ or region of the body, as, e.g., compared to a species absent such a ligand. Preferred ligands will not take part in duplex pairing in a duplexed nucleic acid.
Ligands can include a naturally occurring substance, such as a protein (e.g., human serum albumin (HSA), low-density lipoprotein (LDL), or globulin); carbohydrate (e.g., a dextran, pullulan, chitin, chitosan, inulin, cyclodextrin, N-acetylgalactosamine, or hyaluronic acid); or a lipid. The ligand can also be a recombinant or synthetic molecule, such as a synthetic polymer, e.g., a synthetic polyamino acid. Examples of polyamino acids include polyamino acid is a polylysine (PLL), poly L-aspartic acid, poly L-glutamic acid, styrene-maleic acid anhydride copolymer, poly(L-lactide-co-glycolied) copolymer, divinyl ether-maleic anhydride copolymer, N-(2-hydroxypropyl)methacrylamide copolymer (HMPA), polyethylene glycol (PEG), polyvinyl alcohol (PVA), polyurethane, poly(2-ethylacryllic acid), N-isopropylacrylamide polymers, or polyphosphazine. Example of polyamines include: polyethylenimine, polylysine (PLL), spermine, spermidine, polyamine, pseudopeptide-polyamine, peptidomimetic polyamine, dendrimer polyamine, arginine, amidine, protamine, cationic lipid, cationic porphyrin, quaternary salt of a polyamine, or an alpha helical peptide.
Ligands can also include targeting groups, e.g., a cell or tissue targeting agent, e.g., a lectin, glycoprotein, lipid, or protein, e.g., an antibody, that binds to a specified cell type such as a kidney cell. A targeting group can be a thyrotropin, melanotropin, lectin, glycoprotein, surfactant protein A, Mucin carbohydrate, multivalent lactose, monovalent or multivalent galactose, N-acetyl-galactosamine, N-acetyl-gulucoseamine multivalent mannose, multivalent fucose, glycosylated polyaminoacids, transferrin, bisphosphonate, polyglutamate, polyaspartate, a lipid, cholesterol, a steroid, bile acid, folate, vitamin B12, vitamin A, biotin, or an RGD peptide or RGD peptide mimetic.
In certain embodiments, ligands include monovalent or multivalent galactose.
In certain embodiments, ligands include cholesterol.
Other examples of ligands include dyes, intercalating agents (e.g. acridines), cross-linkers (e.g. psoralene, mitomycin C), porphyrins (TPPC4, texaphyrin, Sapphyrin), polycyclic aromatic hydrocarbons (e.g., phenazine, dihydrophenazine), artificial endonucleases (e.g. EDTA), lipophilic molecules, e.g., cholesterol, cholic acid, adamantane acetic acid, 1-pyrene butyric acid, dihydrotestosterone, 1,3-Bis-0(hexadecyl)glycerol, geranyloxyhexyl group, hexadecylglycerol, borneol, menthol, 1,3-propanediol, heptadecyl group, palmitic acid, myristic acid,03-(oleoyl)lithocholic acid, 03-(oleoyl)cholenic acid, dimethoxytrityl, or phenoxazine)and peptide conjugates (e.g., antennapedia peptide, Tat peptide), alkylating agents, phosphate, amino, mercapto, PEG (e.g., PEG-40K), MPEG, [MPEG12, polyamino, alkyl, substituted alkyl, radiolabeled markers, enzymes, haptens (e.g. biotin), transport/absorption facilitators (e.g., aspirin, vitamin E, folic acid), synthetic ribonucleases (e.g., imidazole, bisimidazole, histamine, imidazole clusters, acridine-imidazole conjugates, Eu3+ complexes of tetraazamacrocycles), dinitrophenyl, HRP, or AP.
Ligands can be proteins, e.g., glycoproteins, or peptides, e.g., molecules having a specific affinity for a co-ligand, or antibodies e.g., an antibody, that binds to a specified cell type such as a hepatic cell. Ligands can also include hormones and hormone receptors. They can also include non-peptidic species, such as lipids, lectins, carbohydrates, vitamins, cofactors, multivalent lactose, monovalent or multivalent galactose, N-acetyl-galactosamine, N-acetyl-gulucosamine multivalent mannose, or multivalent fucose. The ligand can be, for example, a lipopolysaccharide, an activator of p38 MAP kinase, or an activator of NF-KB.
The ligand can be a substance, e.g., a drug, which can increase the uptake of the iRNA agent into the cell, for example, by disrupting the cell's cytoskeleton, e.g., by disrupting the cell's microtubules, microfilaments, or intermediate filaments. The drug can be, for example, taxon, vincristine, vinblastine, cytochalasin, nocodazole, japlakinolide, latrunculin A, phalloidin, swinholide A, indanocine, or myoservin.
In some embodiments, a ligand attached to an iRNA as described herein acts as a pharmacokinetic modulator (PK modulator). PK modulators include lipophiles, bile acids, steroids, phospholipid analogues, peptides, protein binding agents, PEG, vitamins etc.
Exemplary PK
modulators include, but are not limited to, cholesterol, fatty acids, cholic acid, lithocholic acid, dialkylglycerides, diacylglyceride, phospholipids, sphingolipids, naproxen, ibuprofen, vitamin E, biotin etc. Oligonucleotides that comprise a number of phosphorothioate linkages are also known to bind to serum protein, thus short oligonucleotides, e.g., oligonucleotides of about 5 bases, 10 bases, 15 bases or 20 bases, comprising multiple of phosphorothioate linkages in the backbone are also amenable to the present invention as ligands (e.g. as PK modulating ligands).
In addition, aptamers that bind serum components (e.g. serum proteins) are also suitable for use as PK modulating ligands in the embodiments described herein.
Ligand-conjugated oligonucleotides of the invention may be synthesized by the use of an oligonucleotide that bears a pendant reactive functionality, such as that derived from the attachment of a linking molecule onto the oligonucleotide (described below). This reactive oligonucleotide may be reacted directly with commercially-available ligands, ligands that are synthesized bearing any of a variety of protecting groups, or ligands that have a linking moiety attached thereto.
The oligonucleotides used in the conjugates of the present invention may be conveniently and routinely made through the well-known technique of solid-phase synthesis.
Equipment for such synthesis is sold by several vendors including, for example, Applied Biosystems (Foster City, Calif.).
Any other means for such synthesis known in the art may additionally or alternatively be employed. It is also known to use similar techniques to prepare other oligonucleotides, such as the phosphorothioates and alkylated derivatives.
In the ligand-conjugated oligonucleotides and ligand-molecule bearing sequence-specific linked nucleosides of the present invention, the oligonucleotides and oligonucleosides may be assembled on a suitable DNA synthesizer utilizing standard nucleotide or nucleoside precursors, or nucleotide or nucleoside conjugate precursors that already bear the linking moiety, ligand-nucleotide or nucleoside-conjugate precursors that already bear the ligand molecule, or non-nucleoside ligand-bearing building blocks.
When using nucleotide-conjugate precursors that already bear a linking moiety, the synthesis of the sequence-specific linked nucleosides is typically completed, and the ligand molecule is then .. reacted with the linking moiety to form the ligand-conjugated oligonucleotide. In some embodiments, the oligonucleotides or linked nucleosides of the present invention are synthesized by an automated synthesizer using phosphoramidites derived from ligand-nucleoside conjugates in addition to the standard phosphoramidites and non-standard phosphoramidites that are commercially available and routinely used in oligonucleotide synthesis.
1. Lipid Conjugates In one embodiment, the ligand or conjugate is a lipid or lipid-based molecule.
Such a lipid or lipid-based molecule preferably binds a serum protein, e.g., human serum albumin (HSA). An HSA
binding ligand allows for distribution of the conjugate to a target tissue, e.g., a non-kidney target tissue of the body. For example, the target tissue can be the liver, including parenchymal cells of the liver. Other molecules that can bind HSA can also be used as ligands. For example, naproxen or aspirin can be used. A lipid or lipid-based ligand can (a) increase resistance to degradation of the conjugate, (b) increase targeting or transport into a target cell or cell membrane, or (c) can be used to adjust binding to a serum protein, e.g., HSA.
A lipid based ligand can be used to inhibit, e.g., control the binding of the conjugate to a target tissue. For example, a lipid or lipid-based ligand that binds to HSA
more strongly will be less likely to be targeted to the kidney and therefore less likely to be cleared from the body. A lipid or lipid-based ligand that binds to HSA less strongly can be used to target the conjugate to the kidney.
In a preferred embodiment, the lipid based ligand binds HSA. Preferably, it binds HSA with a sufficient affinity such that the conjugate will be preferably distributed to a non-kidney tissue.
However, it is preferred that the affinity not be so strong that the HSA-ligand binding cannot be reversed.
In another preferred embodiment, the lipid based ligand binds HSA weakly or not at all, such that the conjugate will be preferably distributed to the kidney. Other moieties that target to kidney cells can also be used in place of or in addition to the lipid based ligand.
In another aspect, the ligand is a moiety, e.g., a vitamin, which is taken up by a target cell, e.g., a proliferating cell. These are particularly useful for treating disorders characterized by unwanted cell proliferation, e.g., of the malignant or non-malignant type, e.g., cancer cells.
Exemplary vitamins include vitamin A, E, and K. Other exemplary vitamins include are B vitamin, e.g., folic acid, B12, riboflavin, biotin, pyridoxal or other vitamins or nutrients taken up by target cells such as liver cells. Also included are HSA and low density lipoprotein (LDL).
2. Cell Permeation Agents In another aspect, the ligand is a cell-permeation agent, preferably a helical cell-permeation agent. Preferably, the agent is amphipathic. An exemplary agent is a peptide such as tat or antennopedia. If the agent is a peptide, it can be modified, including a peptidylmimetic, invertomers, non-peptide or pseudo-peptide linkages, and use of D-amino acids. The helical agent is preferably an alpha-helical agent, which preferably has a lipophilic and a lipophobic phase.
The ligand can be a peptide or peptidomimetic. A peptidomimetic (also referred to herein as an oligopeptidomimetic) is a molecule capable of folding into a defined three-dimensional structure similar to a natural peptide. The attachment of peptide and peptidomimetics to iRNA agents can affect pharmacokinetic distribution of the iRNA, such as by enhancing cellular recognition and absorption. The peptide or peptidomimetic moiety can be about 5-50 amino acids long, e.g., about 5, 10, 15, 20, 25, 30, 35, 40, 45, or 50 amino acids long.
A peptide or peptidomimetic can be, for example, a cell permeation peptide, cationic peptide, amphipathic peptide, or hydrophobic peptide (e.g., consisting primarily of Tyr, Trp or Phe). The peptide moiety can be a dendrimer peptide, constrained peptide or crosslinked peptide. In another alternative, the peptide moiety can include a hydrophobic membrane translocation sequence (MTS).
An exemplary hydrophobic MTS-containing peptide is RFGF having the amino acid sequence AAVALLPAVLLALLAP (SEQ ID NO: 33). An RFGF analogue (e.g., amino acid sequence AALLPVLLAAP (SEQ ID NO: 34) containing a hydrophobic MTS can also be a targeting moiety.
The peptide moiety can be a "delivery" peptide, which can carry large polar molecules including peptides, oligonucleotides, and protein across cell membranes. For example, sequences from the HIV
Tat protein (GRKKRRQRRRPPQ (SEQ ID NO: 35) and the Drosophila Antennapedia protein (RQIKIWFQNRRMKWKK (SEQ ID NO: 36) have been found to be capable of functioning as delivery peptides. A peptide or peptidomimetic can be encoded by a random sequence of DNA, such as a peptide identified from a phage-display library, or one-bead-one-compound (OBOC) combinatorial library (Lam et al., Nature, 354:82-84, 1991). Examples of a peptide or peptidomimetic tethered to a dsRNA agent via an incorporated monomer unit for cell targeting purposes is an arginine-glycine-aspartic acid (RGD)-peptide, or RGD mimic. A
peptide moiety can range in length from about 5 amino acids to about 40 amino acids. The peptide moieties can have a structural modification, such as to increase stability or direct conformational properties. Any of the structural modifications described below can be utilized.
An RGD peptide for use in the compositions and methods of the invention may be linear or cyclic, and may be modified, e.g., glycosylated or methylated, to facilitate targeting to a specific tissue(s). RGD-containing peptides and peptidiomimemtics may include D-amino acids, as well as synthetic RGD mimics. In addition to RGD, one can use other moieties that target the integrin ligand.
Preferred conjugates of this ligand target PECAM-1 or VEGF.
A "cell permeation peptide" is capable of permeating a cell, e.g., a microbial cell, such as a bacterial or fungal cell, or a mammalian cell, such as a human cell. A
microbial cell-permeating peptide can be, for example, an a-helical linear peptide (e.g., LL-37 or Ceropin P1), a disulfide bond-containing peptide (e.g., a -defensin, I3-defensin or bactenecin), or a peptide containing only one or two dominating amino acids (e.g., PR-39 or indolicidin). A cell permeation peptide can also include a nuclear localization signal (NLS). For example, a cell permeation peptide can be a bipartite amphipathic peptide, such as MPG, which is derived from the fusion peptide domain of HIV-1 gp41 and the NLS of SV40 large T antigen (Simeoni et al., Nucl. Acids Res. 31:2717-2724, 2003).
3. Carbohydrate Conjugates In some embodiments of the compositions and methods of the invention, an iRNA
oligonucleotide further comprises a carbohydrate. The carbohydrate conjugated iRNA are advantageous for the in vivo delivery of nucleic acids, as well as compositions suitable for in vivo therapeutic use, as described herein. As used herein, "carbohydrate" refers to a compound which is either a carbohydrate per se made up of one or more monosaccharide units having at least 6 carbon atoms (which can be linear, branched or cyclic) with an oxygen, nitrogen or sulfur atom bonded to each carbon atom; or a compound having as a part thereof a carbohydrate moiety made up of one or more monosaccharide units each having at least six carbon atoms (which can be linear, branched or cyclic), with an oxygen, nitrogen or sulfur atom bonded to each carbon atom.
Representative carbohydrates include the sugars (mono-, di-, tri- and oligosaccharides containing from about 4, 5, 6, 7, 8, or 9 monosaccharide units), and polysaccharides such as starches, glycogen, cellulose and polysaccharide gums. Specific monosaccharides include C5 and above (e.g., C5, C6, C7, or C8) sugars; di- and trisaccharides include sugars having two or three monosaccharide units (e.g., C5, C6, C7, or C8).
In one embodiment, a carbohydrate conjugate for use in the compositions and methods of the invention is a monosaccharide. In another embodiment, a carbohydrate conjugate for use in the compositions and methods of the invention is selected from the group consisting of:
OH
H0.7...._.
HOOr.1\1,N 0 AcHN 0 HO OH
0, HO 0,(N,N1.0õ7"Nj AcHN 0 0 ICI
O
HO H
AcHN H H
0 Formula II, HO HO
HOT
HO HO H
HO1......\H
0, 0õ,...^Ø---...õ0õ..,..,,N_I---,....,0õ,...-i'l HO HO HO CY
HOFic¨;......j4 0c)õ.0 ,N4 H Formula III, OH
HO....\.....
HO 0()0 OH NHAc \----\
HO....\.... N-HO 0()0 NHAc Formula IV, OH
HO,.....\.....
NHAc OH
H
H4HO 00.,¨/-0 NHAc Formula V, HO OH
HO,...4.D...\ H
OrN
\
N
HO OHHAc 0 HO.-41\O1 NH/
NHAc 0 Formula VI, HO OH
HO OH NHAc HOO,3 NHAc Ho oH
HO....\.C.)....) NHAc Formula VII, Bz2?_Boz Bz0 i-----\
Bz0 __ B.z0.0Bz 0 OAc f -0 Bz0 0 (Dlq,Formula VIII, HC OH
.T...........\/
HO
H
NNy0 AcHN H 0 OH
HO
HO O ..:) N
.\/ 0 c H
NO
AcHN H T 0 OH
HO
0 oi___LI
HO-NO
HO
AcHN H Formula IX, O
HO H
HO 0c)ONO
AcHN H
OH
Ho e (=) _c._2.\/
HO 0c)ON
AcHN H
OH
) HO
0c),ON,0 HO
AcHN H Formula X, Fi'03 H0(3)--\ - ?-1 H
___________ HO_- -' ) (1)Po; 1 ...__Ot_Ho HO \ - H
HO------\1 0 e H c O ' ¨
0.,..,..--Ø-"-..-ON 0 H Formula XI, O PcT3 cHo HO
HO
H H
P63 01,-NN) !_?..._____!H 0 c...)._\
HO
HO 1Z) H H
pr_ OrNN1Ø-,,µ,,, _C2._:....OH 0 0 e HO
0...................,...r.NNO
H H
0 Formula XII, .,r.(2.....\/0.,)i-,.. ----...--._ _ENI
_ ir \
AcHN H 0 HO 0,=c H
m---......----.....----.....N 0.-----...----v AcHN
0 ,----HOv_OH 0 H 0 HO.,01¨NmNJLO---AcHN H Formula XIII, HO H
..:7-.._?.._\
HO\ 1.3H.f....... HO o 0 AcHN
0 0 0 -).L NH
HO
AcHN /\)LN/\/sr H
0 Formula XIV, HO\ __. H
HO ----r-?-o 0 HOµ 1_)_HT...... AcHN
0 0 0 =)NH
HO
AcHN
H
0 Formula XV, HOµ _... H
H 0 -----r I-2--o 0 HO (:__Ir....-1_,....\ AcHN
u 0 0 .LNH
HO
H
0 Formula XVI, OH
HO 1:2 "----___7...\0 HO ).L
HOHO 0 0 ...r...... 0 -1\1H
HO
H
0 Formula XVII, OH
OH
H0 ,r2\0 HO
'NH
HO
HO
0 Formula XVIII, ()H
OH H 1-1¨C-3--T9.-o 0 HO HO
II
HO
0 Formula XIX, H0j-- OH
HO
HO
HO
0 Formula XX, HO OH
HO
HO
HO
HO
0.LNPrPI
0 Formula XXI, HO:-.\ 10H
HO
HO
HO
0)LN'Pri 0 Formula XXII.
In one embodiment, the monosaccharide is an N-acetylgalactosamine, such as HO OH
HO _-7O( 0 AcHN
HO OH
HO
AcHN
O
HO H
HOONNO
AcHN
0 Formula II.
Another representative carbohydrate conjugate for use in the embodiments described herein includes, but is not limited to, H cp..c.TOH
HO
AcHN
H /OH 0 o HO
AcHN H H
X0, H /OH
L
HO
AcHN N
jcis(:0,Lo 0 (Formula XXIII), when one of X or Y is an oligonucleotide, the other is a hydrogen.
In certain embodiments of the invention, the GalNAc or GalNAc derivative is attached to an iRNA agent of the invention via a monovalent linker. In some embodiments, the GalNAc or GalNAc derivative is attached to an iRNA agent of the invention via a bivalent linker. In yet other embodiments of the invention, the GalNAc or GalNAc derivative is attached to an iRNA agent of the invention via a trivalent linker.
In one embodiment, the double stranded RNAi agents of the invention comprise one GalNAc or GalNAc derivative attached to the iRNA agent. In another embodiment, the double stranded RNAi agents of the invention comprise a plurality (e.g., 2, 3, 4, 5, or 6) GalNAc or GalNAc derivatives, each independently attached to a plurality of nucleotides of the double stranded RNAi agent through a plurality of monovalent linkers.
In some embodiments, for example, when the two strands of an iRNA agent of the invention are part of one larger molecule connected by an uninterrupted chain of nucleotides between the 3'-end of one strand and the 5'-end of the respective other strand forming a hairpin loop comprising, a plurality of unpaired nucleotides, each unpaired nucleotide within the hairpin loop may independently comprise a GalNAc or GalNAc derivative attached via a monovalent linker. The hairpin loop may also be formed by an extended overhang in one strand of the duplex.
In some embodiments, the carbohydrate conjugate further comprises one or more additional ligands as described above, such as, but not limited to, a PK modulator or a cell permeation peptide.
Additional carbohydrate conjugates suitable for use in the present invention include those described in WO 2014179620 and WO 2014179627, the entire contents of each of which are incorporated herein by reference.
4. Linkers In some embodiments, the conjugate or ligand described herein can be attached to an iRNA
oligonucleotide with various linkers that can be cleavable or non-cleavable.
The term "linker" or "linking group" means an organic moiety that connects two parts of a compound, e.g., covalently attaches two parts of a compound. Linkers typically comprise a direct bond or an atom such as oxygen or sulfur, a unit such as NR8, C(0), C(0)NH, SO, SO2, SO2NH or a chain of atoms, such as, but not limited to, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, arylalkyl, arylalkenyl, arylalkynyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, heterocyclylalkyl, heterocyclylalkenyl, heterocyclylalkynyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, cycloalkenyl, alkylarylalkyl, alkylarylalkenyl, alkylarylalkynyl, alkenylarylalkyl, alkenylarylalkenyl, alkenylarylalkynyl, alkynylarylalkyl, alkynylarylalkenyl, alkynylarylalkynyl, alkylheteroarylalkyl, alkylheteroarylalkenyl, alkylheteroarylalkynyl, alkenylheteroarylalkyl, alkenylheteroarylalkenyl, alkenylheteroarylalkynyl, alkynylheteroarylalkyl, alkynylheteroarylalkenyl, alkynylheteroarylalkynyl, alkylheterocyclylalkyl, alkylheterocyclylalkenyl, alkylhererocyclylalkynyl, alkenylheterocyclylalkyl, alkenylheterocyclylalkenyl, alkenylheterocyclylalkynyl, alkynylheterocyclylalkyl, alkynylheterocyclylalkenyl, alkynylheterocyclylalkynyl, alkylaryl, alkenylaryl, alkynylaryl, alkylheteroaryl, alkenylheteroaryl, alkynylhereroaryl, which one or more methylenes can be interrupted or terminated by 0, S, S(0), SO2, N(R8), C(0), substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocyclic; where R8 is hydrogen, acyl, aliphatic or substituted aliphatic. In one embodiment, the linker is about 1-24 atoms, 2-24, 3-24, 4-24, 5-24, 6-24, 6-18, 7-18, 8-18 atoms, 7-17, 8-17, 6-16, 7-16, or 8-16 atoms.
A cleavable linking group is one which is sufficiently stable outside the cell, but which upon entry into a target cell is cleaved to release the two parts the linker is holding together. In a preferred embodiment, the cleavable linking group is cleaved at least about 10 times, 20, times, 30 times, 40 times, 50 times, 60 times, 70 times, 80 times, 90 times or more, or at least about 100 times faster in a target cell or under a first reference condition (which can, e.g., be selected to mimic or represent intracellular conditions) than in the blood of a subject, or under a second reference condition (which can, e.g., be selected to mimic or represent conditions found in the blood or serum).
Cleavable linking groups are susceptible to cleavage agents, e.g., pH, redox potential or the presence of degradative molecules. Generally, cleavage agents are more prevalent or found at higher levels or activities inside cells than in serum or blood. Examples of such degradative agents include:
redox agents which are selected for particular substrates or which have no substrate specificity, including, e.g., oxidative or reductive enzymes or reductive agents such as mercaptans, present in cells, that can degrade a redox cleavable linking group by reduction;
esterases; endosomes or agents that can create an acidic environment, e.g., those that result in a pH of five or lower; enzymes that can hydrolyze or degrade an acid cleavable linking group by acting as a general acid, peptidases (which can be substrate specific), and phosphatases.
A cleavable linkage group, such as a disulfide bond can be susceptible to pH.
The pH of human serum is 7.4, while the average intracellular pH is slightly lower, ranging from about 7.1-7.3.
Endosomes have a more acidic pH, in the range of 5.5-6.0, and lysosomes have an even more acidic pH at around 5Ø Some linkers will have a cleavable linking group that is cleaved at a preferred pH, thereby releasing a cationic lipid from the ligand inside the cell, or into the desired compartment of the cell.
A linker can include a cleavable linking group that is cleavable by a particular enzyme. The type of cleavable linking group incorporated into a linker can depend on the cell to be targeted. For example, a liver-targeting ligand can be linked to a cationic lipid through a linker that includes an ester group. Liver cells are rich in esterases, and therefore the linker will be cleaved more efficiently in liver cells than in cell types that are not esterase-rich. Other cell-types rich in esterases include cells of the lung, renal cortex, and testis.
Linkers that contain peptide bonds can be used when targeting cell types rich in peptidases, such as liver cells and synoviocytes.
In general, the suitability of a candidate cleavable linking group can be evaluated by testing the ability of a degradative agent (or condition) to cleave the candidate linking group. It will also be desirable to also test the candidate cleavable linking group for the ability to resist cleavage in the blood or when in contact with other non-target tissue. Thus, one can determine the relative susceptibility to cleavage between a first and a second condition, where the first is selected to be indicative of cleavage in a target cell and the second is selected to be indicative of cleavage in other tissues or biological fluids, e.g., blood or serum. The evaluations can be carried out in cell free systems, in cells, in cell culture, in organ or tissue culture, or in whole animals. It can be useful to make initial evaluations in cell-free or culture conditions and to confirm by further evaluations in whole animals. In preferred embodiments, useful candidate compounds are cleaved at least about 2, 4, 10, 20, 30, 40, 50, 60, 70, 80, 90, or about 100 times faster in the cell (or under in vitro conditions selected to mimic intracellular conditions) as compared to blood or serum (or under in vitro conditions selected to mimic extracellular conditions).
a. Redox cleavable linking groups In one embodiment, a cleavable linking group is a redox cleavable linking group that is cleaved upon reduction or oxidation. An example of reductively cleavable linking group is a disulphide linking group (-S-S-). To determine if a candidate cleavable linking group is a suitable "reductively cleavable linking group," or for example is suitable for use with a particular iRNA
moiety and particular targeting agent one can look to methods described herein. For example, a candidate can be evaluated by incubation with dithiothreitol (DTT), or other reducing agent using reagents know in the art, which mimic the rate of cleavage which would be observed in a cell, e.g., a target cell. The candidates can also be evaluated under conditions which are selected to mimic blood or serum conditions. In one, candidate compounds are cleaved by at most about 10% in the blood. In other embodiments, useful candidate compounds are degraded at least about 2, 4, 10, 20, 30, 40, 50, 60, 70, 80, 90, or about 100 times faster in the cell (or under in vitro conditions selected to mimic intracellular conditions) as compared to blood (or under in vitro conditions selected to mimic extracellular conditions). The rate of cleavage of candidate compounds can be determined using standard enzyme kinetics assays under conditions chosen to mimic intracellular media and compared to conditions chosen to mimic extracellular media.
b. Phosphate-based cleavable linking groups In another embodiment, a cleavable linker comprises a phosphate-based cleavable linking group. A phosphate-based cleavable linking group is cleaved by agents that degrade or hydrolyze the phosphate group. An example of an agent that cleaves phosphate groups in cells are enzymes such as phosphatases in cells. Examples of phosphate-based linking groups are -0-P(0)(ORk)-0-, -0-P(S)(0Rk)-0-, -0-P(S)(SRk)-0-, -S-P(0)(0Rk)-0-, -0-P(0)(0Rk)-S-, -S-P(0)(0Rk)-S-, -0-P(S)(ORk)-S-, -S-P(S)(ORk)-0-, -0-P(0)(Rk)-0-, -0-P(S)(Rk)-0-, -S-P(0)(Rk)-0-, -S-P(S)(Rk)-0-, -S-P(0)(Rk)-S-, -0-P(S)( Rk)-S-. Preferred embodiments are -0-P(0)(OH)-0-, -0-P(S)(OH)-0-, -0-P(S)(SH)-0-, -S-P(0)(OH)-0-, -0-P(0)(OH)-S-, -S-P(0)(OH)-S-, -0-P(S)(OH)-S-, -S-P(S)(OH)-0-, -0-P(0)(H)-0-, -0-P(S)(H)-0-, -S-P(0)(H)-0, -S-P(S)(H)-0-, -S-P(0)(H)-S-, -0-P(S)(H)-S-. A
preferred embodiment is -0-P(0)(OH)-0-. These candidates can be evaluated using methods analogous to those described above.
c. Acid cleavable linking groups In another embodiment, a cleavable linker comprises an acid cleavable linking group. An acid cleavable linking group is a linking group that is cleaved under acidic conditions. In preferred embodiments acid cleavable linking groups are cleaved in an acidic environment with a pH of about 6.5 or lower (e.g., about 6.0, 5.75, 5.5, 5.25, 5.0, or lower), or by agents such as enzymes that can act as a general acid. In a cell, specific low pH organelles, such as endosomes and lysosomes can provide a cleaving environment for acid cleavable linking groups. Examples of acid cleavable linking groups include but are not limited to hydrazones, esters, and esters of amino acids.
Acid cleavable groups can have the general formula -C=NN-, C(0)0, or -0C(0). A preferred embodiment is when the carbon attached to the oxygen of the ester (the alkoxy group) is an aryl group, substituted alkyl group, or tertiary alkyl group such as dimethyl pentyl or t-butyl. These candidates can be evaluated using methods analogous to those described above.
d. Ester-based linking groups In another embodiment, a cleavable linker comprises an ester-based cleavable linking group.
An ester-based cleavable linking group is cleaved by enzymes such as esterases and amidases in cells.
Examples of ester-based cleavable linking groups include but are not limited to esters of alkylene, alkenylene and alkynylene groups. Ester cleavable linking groups have the general formula -C(0)0-, or -0C(0)-. These candidates can be evaluated using methods analogous to those described above.
e. Peptide-based cleaving groups In yet another embodiment, a cleavable linker comprises a peptide-based cleavable linking group. A peptide-based cleavable linking group is cleaved by enzymes such as peptidases and proteases in cells. Peptide-based cleavable linking groups are peptide bonds formed between amino acids to yield oligopeptides (e.g., dipeptides, tripeptides etc.) and polypeptides. Peptide-based cleavable groups do not include the amide group (-C(0)NH-). The amide group can be formed between any alkylene, alkenylene or alkynelene. A peptide bond is a special type of amide bond formed between amino acids to yield peptides and proteins. The peptide based cleavage group is generally limited to the peptide bond (i.e., the amide bond) formed between amino acids yielding peptides and proteins and does not include the entire amide functional group.
Peptide-based cleavable linking groups have the general formula ¨ NHCHRAC(0)NHCHRBC(0)-, where RA and RB are the R groups of the two adjacent amino acids. These candidates can be evaluated using methods analogous to those described above.
In one embodiment, an iRNA of the invention is conjugated to a carbohydrate through a linker. Non-limiting examples of iRNA carbohydrate conjugates with linkers of the compositions and methods of the invention include, but are not limited to, OH /OH
HO
AcHN II HO.to cH OH 0 HO ----4===\, AcHN
cH OH
HO
AcHN
0 (Formula XXIV), HO\ OH
HO Nõ^õ,,N 0 HO, AcHN 0 HO OH 0, AcHN 0 0 .CY
O
HO H
HOONNO
AcHN 0 (Formula XXV), HO OH
H
...c N 0 N....,..õ---,..õ y 1.,...
AcHN H 0 X-01_ HO OH
HO---r--P-_\/(k N
c ---.,-.---....-----....---NON()1 1 \ O
AcHN H x 0 y H 00 r HO OH
HO ,, ,_,NNADJ y = 1-15 AcHN H (Formula XXVI), ON__T, H
N
HO0"...---..---"....- y \
AcHN H 0 X-R
HO OH 0 H 0 H N"
HO N N TO- N,Ir}l N (CD,4(nr N
AcHN
H 0 ,/ 0 H x 0 Y
HO OH
LA._:.,)._, m N A0,- y = 1-15 HO __/ ./
AcHN H
(Formula XXVII), HO eOH 0 H
0,1---. ... _ N 0 HO N __ __ __ y \ X-Ot AcHN H 0 H ,O-Y
HO OH N
H H N,Lo HO N NyO-N,..irHS¨S
AcHN 0 Y
H 0 0 x HO OH x = 0-30 k-, 0 H 0 y= 1-15 1---N m N Acy-HO
AcHN H
(Formula XXVIII), __O/ H
01-..N---..õ---....õ---...- N yO\
HO X-R
AcHN H 0 HO OH
H H -(--z 0 -)240 HO AcHN NH N y0,---N....rrHS¨S
Y
0 0 x HO eOH x = 0-30 _________________ ,, 0 H 0 y= 1-15 k-,.)1.--N m NAG-- z = 1-20 HO--' AcHN H
(Formula XXIX), ?.s.\/ H
0-) i\J- Ny HO X-R
AcHN H 0 0, NH
H 0 ,,O-Y
HO OH N ' HO N N ...1 T0,4-1H0,/).r,,S¨S
AcHN x`' z 0 Y
0 r HOZ H x = 1-30 0 y = 1-15 HO 0,---------1 L- ri....----....---------- NAcy--1 z = 1-20 AcHN H
(Formula XXX), and HO-7-2-\=CLN y )._____. HO H X-0%
AcHN H 0 Y
H H N.4,-...yAo HO 0 N7.N, 0-N--_,H0.%)Ø.S----S(HThf AcHN II Y
H N 0 i.-- 0 x z 0 HO eOH x = 1-30 = 1-15 HO INM N(`O' z =
AcHN H
(Formula XXXI), when one of X or Y is an oligonucleotide, the other is a hydrogen.
In certain embodiments of the compositions and methods of the invention, a ligand is one or more "GalNAc" (N-acetylgalactosamine) derivatives attached through a bivalent or trivalent branched linker.
In one embodiment, a dsRNA of the invention is conjugated to a bivalent or trivalent branched linker selected from the group of structures shown in any of formula (XXXII) - (XXXV):
Formula XXXII Formula XXXIII
.4. p2A_Q2A_R2A 1_2A 1-2A_L2A jp3A_Q3A_ 3A R3A1__T3A_L3A
q 41/' JUN. N q 1.,p2B_Q2B_R2B i2B -1-2B_L2B I\ p3B_Q3B_R3B I_3B T3B_L3B
q q p5A-Q5A-R5A i_q5AT5A-L5A
p4A_Q4A_R4A 1 zi6, T4A_L4A
H:
q p4B_Q4B_R4B 1_q4B -1-4B_L4B
1 pl5cp_5;5_cQ_R5BR5B 1_q5B
5_c1-5B_L5B
q 5T C-L5C
;
Formula XXXIV Formula XXXV
wherein:
q2A, q2B, q3A, q3B, q4A, q4B, q5A, q5B and q5C represent independently for each occurrence 0-20 and wherein the repeating unit can be the same or different;
p2A, p2B, p3A, p3B , p4A, p4B, p5A, p5B , p5C, T2A, T2B, T3A, T3B, T4A, T4B, T4A, T5B, I,-.-,5C
are each independently for each occurrence absent, CO, NH, 0, S, OC(0), NHC(0), CH2, CH2NH or CH20;
Q2A, Q2B, Q3A, Q3B, Q4A, Q4B, Q5A, Q5B, .-.5C
l,2 are independently for each occurrence absent, alkylene, substituted alkylene wherin one or more methylenes can be interrupted or terminated by one or more of 0, S, S(0), SO2, N(RN), C(R')=C(R"), CEC or C(0);
R2A, R2B, R3A, R3B, R4A, R4B, R5A, R5B, R5c are each independently for each occurrence absent, NH, 0, HO¨L
S, CH, C(0)0, C(0)NH, NHCH(Ra)C(0), -C(0)-CH(Ra)-NH-, CO, CH=N-0, 0 S¨S
)_N ,N),,,, J. <¨s H , ,,r-r'r/ \S" or heterocyclyl;
L2A, L2B, L3A, L3B, L4A, L4B, L5A, L5B and L5c represent the ligand; i.e. each independently for each occurrence a monosaccharide (such as GalNAc), disaccharide, trisaccharide, tetrasaccharide, oligosaccharide, or polysaccharide; andle is H or amino acid side chain.Trivalent conjugating GalNAc derivatives are particularly useful for use with RNAi agents for inhibiting the expression of a target gene, such as those of formula (XXXV):
Formula XXXV
p5A_Q5A_R5A i_T5A_L5A
'1111j-VE q5A
I p5B_Q5B_R5B 1_1-5B_L5B
q5B
Ip5C_Q5C_R5C 1771-5C_L5C
, wherein L5A, L5B and L5c represent a monosaccharide, such as GalNAc derivative.
Examples of suitable bivalent and trivalent branched linker groups conjugating GalNAc derivatives include, but are not limited to, the structures recited above as formulas II, VII, XI, X, and XIII.
Representative US patents that teach the preparation of RNA conjugates include, but are not limited to, US Patent Nos. 4,828,979; 4,948,882; 5,218,105; 5,525,465;
5,541,313; 5,545,730;
5,552,538; 5,578,717, 5,580,731; 5,591,584; 5,109,124; 5,118,802; 5,138,045;
5,414,077; 5,486,603;
5,512,439; 5,578,718; 5,608,046; 4,587,044; 4,605,735; 4,667,025; 4,762,779;
4,789,737; 4,824,941;
4,835,263; 4,876,335; 4,904,582; 4,958,013; 5,082,830; 5,112,963; 5,214,136;
5,082,830; 5,112,963;
5,214,136; 5,245,022; 5,254,469; 5,258,506; 5,262,536; 5,272,250; 5,292,873;
5,317,098; 5,371,241, 5,391,723; 5,416,203, 5,451,463; 5,510,475; 5,512,667; 5,514,785; 5,565,552;
5,567,810; 5,574,142;
5,585,481; 5,587,371; 5,595,726; 5,597,696; 5,599,923; 5,599,928 and 5,688,941; 6,294,664;
6,320,017; 6,576,752; 6,783,931; 6,900,297; 7,037,646; 8,106,022, the entire contents of each of which are hereby incorporated herein by reference.
It is not necessary for all positions in a given compound to be uniformly modified, and in fact more than one of the aforementioned modifications can be incorporated in a single compound or even at a single nucleoside within an iRNA. The present invention also includes iRNA compounds that are chimeric compounds.
"Chimeric" iRNA compounds or "chimeras," in the context of this invention, are iRNA
compounds, preferably dsRNAs, which contain two or more chemically distinct regions, each made up of at least one monomer unit, i.e., a nucleotide in the case of a dsRNA
compound. These iRNAs typically contain at least one region wherein the RNA is modified so as to confer upon the iRNA
increased resistance to nuclease degradation, increased cellular uptake, or increased binding affinity for the target nucleic acid. An additional region of the iRNA can serve as a substrate for enzymes capable of cleaving RNa:DNA or RNA:RNA hybrids. By way of example, RNase H is a cellular endonuclease which cleaves the RNa strand of an RNA:DNA duplex. Activation of RNase H, therefore, results in cleavage of the RNA target, thereby greatly enhancing the efficiency of iRNA
inhibition of gene expression. Consequently, comparable results can often be obtained with shorter iRNAs when chimeric dsRNAs are used, compared to phosphorothioate deoxy dsRNAs hybridizing to the same target region. Cleavage of the RNA target can be routinely detected by gel electrophoresis and, if necessary, associated nucleic acid hybridization techniques known in the art.
In certain instances, the RNA of an iRNA can be modified by a non-ligand group. A number of non-ligand molecules have been conjugated to iRNAs in order to enhance the activity, cellular distribution or cellular uptake of the iRNA, and procedures for performing such conjugations are available in the scientific literature. Such non-ligand moieties have included lipid moieties, such as cholesterol (Kubo, T. et al., Biochem. Biophys. Res. Comm., 2007, 365(1):54-61; Letsinger et al., Proc. Natl. Acad. Sci. USA, 1989, 86:6553), cholic acid (Manoharan et al., Bioorg. Med. Chem. Lett., 1994, 4:1053), a thioether, e.g., hexyl-S-tritylthiol (Manoharan et al., Ann.
N.Y. Acad. Sci., 1992, 660:306; Manoharan et al., Bioorg. Med. Chem. Let., 1993, 3:2765), a thiocholesterol (Oberhauser et al., Nucl. Acids Res., 1992, 20:533), an aliphatic chain, e.g., dodecandiol or undecyl residues (Saison-Behmoaras et al., EMBO J., 1991, 10:111; Kabanov et al., FEBS Lett., 1990, 259:327; Svinarchuk et al., Biochimie, 1993, 75:49), a phospholipid, e.g., di-hexadecyl-rac-glycerol or triethylammonium 1,2-di-O-hexadecyl-rac-glycero-3-H-phosphonate (Manoharan et al., Tetrahedron Lett., 1995, 36:3651;
Shea et al., Nucl. Acids Res., 1990, 18:3777), a polyamine or a polyethylene glycol chain (Manoharan et al., Nucleosides & Nucleotides, 1995, 14:969), or adamantane acetic acid (Manoharan et al., Tetrahedron Lett., 1995, 36:3651), a palmityl moiety (Mishra et al., Biochim.
Biophys. Acta, 1995, 1264:229), or an octadecylamine or hexylamino-carbonyl-oxycholesterol moiety (Crooke et al., J.
Pharmacol. Exp. Ther., 1996, 277:923). Representative United States patents that teach the preparation of such RNA conjugates have been listed above. Typical conjugation protocols involve the synthesis of an RNAs bearing an aminolinker at one or more positions of the sequence. The amino group is then reacted with the molecule being conjugated using appropriate coupling or activating reagents. The conjugation reaction can be performed either with the RNA still bound to the solid support or following cleavage of the RNA, in solution phase. Purification of the RNA conjugate by HPLC typically affords the pure conjugate.
iii. Delivery of an iRNA of the Invention The delivery of an iRNA of the invention to a cell e.g., a cell within a subject, such as a human subject infected with HBV can be achieved in a number of different ways.
Delivery may also be performed directly by administering a composition comprising an iRNA, e.g., a dsRNA, to a subject. Alternatively, in vivo delivery may be performed indirectly by administering one or more vectors that encode and direct the expression of the iRNA. These alternatives are discussed further below.
In general, any method of delivering a nucleic acid molecule (in vitro or in vivo) can be adapted for use with an iRNA of the invention (see e.g., Akhtar S. and Julian RL. (1992) Trends Cell.
Biol. 2(5):139-144 and W09402595, which are incorporated herein by reference in their entireties).
For in vivo delivery, factors to consider in order to deliver an iRNA molecule include, for example, biological stability of the delivered molecule, prevention of non-specific effects, and accumulation of the delivered molecule in the target tissue. For administering an iRNA
systemically for the treatment of a disease, the RNA can be modified or alternatively delivered using a drug delivery system; both methods act to prevent the rapid degradation of the dsRNA by endo- and exo-nucleases in vivo.
Modification of the RNA or the pharmaceutical carrier can also permit targeting of the iRNA
composition to the target tissue and avoid undesirable off-target effects.
iRNA molecules can be modified by chemical conjugation to lipophilic groups such as cholesterol to enhance cellular uptake and prevent degradation. In an alternative embodiment, the iRNA can be delivered using drug delivery systems such as a nanoparticle, a dendrimer, a polymer, liposomes, or a cationic delivery system. Positively charged cationic delivery systems facilitate binding of an iRNA molecule (negatively charged) and also enhance interactions at the negatively charged cell membrane to permit efficient uptake of an iRNA by the cell. Cationic lipids, dendrimers, or polymers can either be bound to an iRNA, or induced to form a vesicle or micelle (see e.g., Kim SH., et al (2008) Journal of Controlled Release 129(2):107-116) that encases an iRNA. The formation of vesicles or micelles further prevents degradation of the iRNA when administered systemically.
Methods for making and administering cationic- iRNA complexes are well within the abilities of one skilled in the art (see e.g., Sorensen, DR., et al (2003) J. Mol. Biol 327:761-766; Verma, UN., et al (2003) Clin. Cancer Res.
9:1291-1300; Arnold, AS et al (2007) J. Hypertens. 25:197-205, which are incorporated herein by reference in their entirety). Some non-limiting examples of drug delivery systems useful for systemic delivery of iRNAs include DOTAP (Sorensen, DR., et al (2003), supra; Verma, UN., et al (2003), supra), Oligofectamine, "solid nucleic acid lipid particles" (Zimmermann, TS., et al (2006) Nature 441:111-114), cardiolipin (Chien, PY., et al (2005) Cancer Gene Ther. 12:321-328; Pal, A., et al (2005) Int J. Oncol. 26:1087-1091), polyethyleneimine (Bonnet ME., et al (2008) Phann. Res. Aug 16 Epub ahead of print; Aigner, A. (2006) J. Biomed. Biotechnol. 71659), Arg-Gly-Asp (RGD) peptides (Liu, S. (2006) Mol. Pharm. 3:472-487), and polyamidoamines (Tomalia, DA., et al (2007) Biochem. Soc. Trans. 35:61-67; Yoo, H., et al (1999) Pharm. Res. 16:1799-1804). In some embodiments, an iRNA forms a complex with cyclodextrin for systemic administration. Methods for administration and pharmaceutical compositions of iRNAs and cyclodextrins can be found in US
Patent No. 7,427,605, which is herein incorporated by reference in its entirety. In certain embodiments, the iRNA agents can be administered with amphipathic peptides to facilitate pH-dependent endosomal escape (see, e.g., Bartz et al., 2011. Biochem. J. 435:475-87, incorporated herein by reference) 1. Vector encoded iRNAs for use in the Invention iRNA targeting an HBV gene can be expressed from transcription units inserted into DNA or RNA vectors (see, e.g., Couture, A, et al., TIG. (1996), 12:5-10; Skillern, A., et al., WO 00/22113, WO 00/22114, and US Patent No. 6,054,299). Exemplary expression vectors for expression of shRNA targeted to HBV are provided in Michler et al., 2016 which discloses adeno-associated virus (AAV) 8 vectors for delivery included (i) embedded the shRNA in an artificial mi(cro)RNA under a liver-specific promoter; (ii) co-expressed Argonaute-2, a rate limiting cellular factor whose saturation with excess RNAi triggers can be toxic; or (iii) co-delivered a decoy ("TuD") directed against the shRNA sense strand to curb off-target gene regulation. The plasmids expressing shRNAs shHBV4 to 7 that were used in the cell culture studies were cloned by direct insertion of the respective shRNA-encoding oligonucleotides into a self-complementary AAV vector plasmid previously reported by Grimm et al, 2006 (Nature 441: 537 ¨ 541), containing an H1 promoter followed by two BbsI sites for oligonucleotide insertion as well as an RSV promoter. Such constructs can also be used for the expression of vaccine antigens if appropriately sized for the expression vector.
Expression can be transient (on the order of days to weeks) or sustained (weeks to months, or longer), depending upon the specific construct used and the target tissue or cell type. These transgenes can be introduced as a linear construct, a circular plasmid, or a viral vector, which can be an integrating or non-integrating vector. The transgene can also be constructed to permit it to be inherited as an extrachromosomal plasmid (Gassmann, et al., Proc. Natl. Acad.
Sci. USA (1995) 92:1292).
The individual strand or strands of an iRNA can be transcribed from a promoter on an expression vector. Where two separate strands are to be expressed to generate, for example, a dsRNA, two separate expression vectors can be co-introduced (e.g., by transfection or infection) into a target cell. Alternatively each individual strand of a dsRNA can be transcribed by promoters both of which are located on the same expression plasmid. In one embodiment, a dsRNA
is expressed as inverted repeat polynucleotides joined by a linker polynucleotide sequence such that the dsRNA has a stem and loop structure.
iRNA expression vectors are generally DNA plasmids or viral vectors.
Expression vectors compatible with eukaryotic cells, preferably those compatible with vertebrate cells, can be used to produce recombinant constructs for the expression of an iRNA as described herein. Eukaryotic cell expression vectors are well known in the art and are available from a number of commercial sources.
Typically, such vectors are provided containing convenient restriction sites for insertion of the desired nucleic acid segment. Delivery of iRNA expressing vectors can be systemic, such as by subcutaneous, intravenous, or intramuscular administration. Such vectors can also be used for expression of viral antigens from nucleic acid-based vaccines.
Viral vector systems which can be utilized with the methods and compositions described herein include, but are not limited to, (a) adenovirus vectors; (b) retrovirus vectors, including but not limited to lentiviral vectors, moloney murine leukemia virus, etc.; (c) adeno-associated virus vectors;
(d) herpes simplex virus vectors; (e) SV 40 vectors; (f) polyoma virus vectors; (g) papilloma virus vectors; (h) picornavirus vectors; (i) pox virus vectors such as an orthopox, e.g., vaccinia virus vectors including modified vaccinia virus Ankara vector or avipox, e.g. canary pox or fowl pox; and (j) a helper-dependent or gutless adenovirus. Replication-defective viruses can also be advantageous.
Different vectors will or will not become incorporated into the cells' genome.
The constructs can include viral sequences for transfection, if desired. Alternatively, the construct can be incorporated into vectors capable of episomal replication, e.g. EPV and EBV vectors.
Constructs for the recombinant expression of an iRNA or HBV antigen will generally require regulatory elements, e.g., promoters, enhancers, etc., to ensure the expression of the iRNA in target cells. Other aspects to consider for vectors and constructs are further described below.
Such constructs and vectors can also be used for the expression of vaccine antigens if appropriately sized for the expression vector. Such limitations are well understood by those of skill in the art.
B. Therapeutic HBV Vaccines For Use in the Mehods of the Invention Therapeutic HBV vaccines for use in the regimens and methods of the invention can be a peptide vaccine, a DNA vaccine including a vector-based vaccine, or cell-based vaccine that induces an immune response, preferably an effector T cell induced response, against one or more HBV
proteins. Preferably the vaccine is a multi-epitope vaccine that is cross-reactive with multiple HBV
serotypes, preferably all HBV serotypes.
A therapeutic vaccine is designed to activate the patient's immune system to recognize and control or eliminate an already established pathogen infection. This is clearly distinct from a prophylactic vaccination which is designed to promote rapid antibody-mediated neutralization of an invading pathogen. Control and elimination of persistent viruses such as hepatitis, herpes, or papilloma viruses requires multi-specific and poly-functional effector T cell responses. These T cell responses are ideally directed against continuously expressed viral antigens to keep the pathogen in check. Therapeutic vaccines are under development for a number of chronic infections. Hepatitis B
virus infection is a candidate for treatment by therapeutic vaccination since a spontaneous, immune-mediated recovery of chronic hepatitis B and an elimination of the virus has been observed in very rare cases.
Robust T cell responses seem to be essential to achieve HBV cure. While HBV-specific CD4+ and CD8+ T cell responses are readily detectable in patients resolving HBV infection, HBV-specific T cells are scarce and functionally impaired in chronic hepatitis B
most likely due to high amounts of circulating viral HBeAg and HBsAg. T cells eliminate HBV infected cells by their cytotoxic activity but also control HBV gene expression and replication in a non-cytolytic fashion.
To overcome immune tolerance in chronic hepatitis B different approaches have been investigated in preclinical models using DNA or peptide vaccines, or vector-or cell-based vaccines to induce an effector T cell response. Multi-epitope therapeutic vaccine candidates that cover sufficient different HBV genotypes and most frequent HLA types have been developed.
Although proper peptide presentation was demonstrated, immunogenicity was limited and the approach was not translated into the clinics. A non-exhaustive list is provided in the table below.
Therapeutic HBV Vaccine Tables Vaccine Name Proteins/ coding Vaccine type/ Results available Sponsor Development Clinical Trial References oe sequences Composition Stage Reference No. (the entire contents of each of which are incorporated herein by reference) HB-110 HBsAgõ HBcAg, 3 Plasmid based Study completed, Genexine Phase I NCT01813487 Kim et al., 2008. Exp Mol human IL-12 DNA vaccine results not reported NCT01641536 Med. 40: 669-676 cs, cs, HB-100 pGX10 S 5 Plasmid based Yang et al., 2006. Gene +pGX10 S1/52/X DNA vaccine ¨4 Therapy. 13:1110-1117 +pGX10 core antigens + human +pGX10 Pol IL-12 +pGX10 hIL-ppdpSC18 DNA vaccine Study completed, PowderMed Phase I NCT00277576 adjuvanted with results not reported particle mediated epidermal delivery oe INO-1800 HbsAg, HBcAg DNA plasmid Recruiting Inovio Phase I NCT02431312 -a 5 oe Pharmaceuticals cr ME1 27037625v.1 HB02 VAC- HB preS/S pCMV-S2.S DNA Well tolerated; No ANRS
Phase I/II NCT00536627 Mancini ¨ Bourgine et al., ADN vaccine; CMV change in relapse 2006. Vaccine 24:4482- 0 promoter, plasmid rate in HBV treated oe vector patients or decrease in virological breakthrough CVI-HBV-002 HbsAg DNA+ L-pampo Recruiting CHA Vaccine Phase I/II NCT02693652 Institute Co., Ltd.
Theravax (DV- HBsAg, HBcAg Protein + adjuvant Well tolerated;
Dynavax Phase Ib NCT01023230 601) anti-viral response Technologies cs, observed in all Corp.
patients HepTcellTm IC310 adjuvanted Recruiting Altimmune, Phase I NCT02496897 US 20130330382 peptide Inc.
HBsAg/HBcAg HBsAg protein Research Li et al., 2015, Vaccine.
HBcAg 33:4247-4254 GS-4774 Fusion protein Protein + Phase II naïve Gilead Phase II NCT01943799 Gaggar et al., 2014.
HBsAg, HBcAg, Tamogen T cell group ongoing; no NCT01779505 Vaccine. 32:4925-4931.
HBxAg stimulator significant viral oe decrease in oe treatment-ME1 27037625v.1 experience patients EPA-44 Multi-peptide Some Chongqing Phase II NCT00869778 0 vaccine seroconversion J aichen observed in all Biotechnology, groups, no Ltd.
statistical analysis ABX 203 HBsAg, HBcAg HBsAg, HBcAg Ongoing ABIVAX S.A.
Phase II/III NCT02249988 pSG2.HBs/ Protein prime- Well tolerated, but Oxxon Phase ha ISRCTN Cavenaugh et al., 2011.
MVA.HBs viral vector boost did not control Therapeutics 67270384 PLoS ONE 6: e14626.
HBV infection HBsAg, HBcAg Adjuvanted Research Backes, 2016, Vaccine;
protein prime-OC cs, viral vector boost ME1 27037625v.1 Existing prophylactic vaccines have been used to restore HBV-specific immunity in chronically infected patients, but have failed to provide a functional cure.
These subviral particle-based vaccines were able to reduce HBV replication in animal models of chronic hepadnaviral infection, but have not been successful in patients with chronic hepatitis B.
An antigen-antibody (HBsAg-HBIG) immunogenic complex therapeutic vaccine candidate with alum as adjuvant first showed promising results in a double-blind, placebo controlled, phase IIb clinical trial, but results of a phase III clinical trial including 450 patients were disappointing. This is most likely due to the fact that subviral particle vaccines with alum-based adjuvants are designed as prophylactic vaccines and preferentially induce antibodies but not cytotoxic T cell responses that would be required for therapeutic efficacy.
Alternatively, DNA vaccines encoding HBV envelope proteins were designed to induce HBV-specific T cells but also had limited success. Since DNA-based vaccines hardly induce antibody responses, they failed to achieve HBeAg or HBsAg seroconversion. An alternative DNA prime, poxvirus-boost vaccine encompassing the HBV preS/S region encoding for the HBV
envelope .. proteins showed promising results in chimpanzees, but also failed in a clinical phase Ha trial neither inducing sustained T cell responses nor reducing viremia in chronic HBV
carriers. They may have failed to induce T cell help or broad enough, multi-specific immune responses.
Any vaccines known in the art can be used in the methods and regimens provided herein.
Preferred embodiments include the prime-boost vaccination scheme with protein antigens administered twice and a nucleic acid vaccine administered once as provided in the Examples and provided in PCT Publication No. WO 2017/121791 (the entire contents of which are incorporated herein by reference). As discussed above, the sequence of the protein antigen in the vaccine and the amino acid sequence encoded by nucleic acid-based vaccine need not be identical. They simply must share at least one epitope, preferably multiple epitopes, so that the sequential administration of the vaccines has the desired prime-boost effect. Further, as discussed herein, in preferred embodiments, the treatment regimen provided herein would provide a treatment regimen effective across multiple, if not all, HBV serotypes. Therefore, it is understood that the antigen delivered to the subject may not have antigen sequences identical to the antigens expressed by the HBV virus that infected the subject.
It is known in the art that some portions of HBV antigens are the main targets of antibodies generated during the initial immune response to infection with HBV known as determinants. For example the HBsAg includes the "a" determinant epitope that is located at amino acids 124 to 147 within the major hydrophilic region (MHR, amino acids 100 to 169) of the 226 amino acid S gene (SEQ ID NO: 8 or 22). This "a" determinant is one of the main targets of anti-HBs antibodies during the course of the initial immune response in acute hepatitis B. In certain embodiments, an immunogenic fragment of HBsAg comprises compared to the full length protein at least amino acids 99 to 168 corresponding to the amino acid positons of the small envelope protein (SEQ ID NO: 23) (see, e.g., Lada et al., J. Virol.(2006) 80:2968-2975, the entire contents of which are incorporated herein by reference).
Similarly, determinants have been identified in HBcAg (see, e.g., Salfeld et al., J. Virol.
(1989) 63:798-808, the entire contents of which are incorporated herein by reference). The full-length core protein is 183 amino acids in length and consists of an assembly domain (amino acids 1 to 149) and a nucleic acid-binding domain (amino acids 150 to 183). Three distinct major determinants have been characterized. The single conformational determinant responsible for HBc antigenicity in the assembled core (HBc) and a linear HBe-related determinant (HBel) were both mapped to an overlapping hydrophilic sequence around amino acid 80; a second HBe determinant (HBe2) was assigned to a location in the vicinity of amino acid 138 but found to require for its antigenicity the intramolecular participation of the extended sequence between amino acids 10 and 140. Typically, such an immunogenic fragment comprises, compared to the full length core protein, at least amino acids 18 to 143 corresponding to the sequence positions set forth in SEQ ID
NO: 24. Analogous sequences can be identified in SEQ ID NO: 10.
In preferred embodiments, the vaccines include an amino acid sequence or encode an amino acid sequence that includes at least one determinant of HBsAg or HBcAg.
Specifically, in certain embodiments, a vaccine targeted to HBsAg includes at least the amino acid sequence of amino acids 127 to 147 of HBsAg, e.g., includes at least amino acids 99 to 168 of the amino acid sequence of the small envelope protein (SEQ ID NO: 23). In certain embodiments, a vaccine targeted to a hydrophilic sequence at least around amino acid 80 of HBcAg or an amino acid sequence at least around amino acid 138, e.g., at least a 40 amino acid portion, at least a 50 amino acid portion, at least a 60 amino acid portion, at least a 70 amino acid portion, at least an 80 amino acid portion, at least a 90 amino acid portion, or at least a 100 amino acid portion of SEQ ID NO: 43 including amino acid 80 or amino acid 138, or a coding sequence therefor. In preferred embodiments, the antigen amino sequence of the antigen targeted to HBcAg includes at least 20 amino acids N-terminal and C-terminal to amino acid 80 or 138 of SEQ ID NO: 24. In certain embodiments, a vaccine targeted to HBcAg includes at least the amino acid sequence of amino acids 10 to 140 or 18 to 143 of HBsAg.
In certain embodiments, the vaccine may comprise the entire amino acid sequence or encode the entire amino acid sequence of any one or more of SEQ ID NO: 22, 23, or 24.
It is understood that there are multiple serotypes of HBV with different nucleic acid sequences that encode different amino acid sequences. Therefore, it is understood that the amino acid sequence of a protein-based vaccine or the amino acid sequence encoded by a nucleic acid-based vaccine may not be 100% identical to the sequences provided in the SEQ ID NOs.
In certain embodiments of the invention, the the amino acid sequence of a protein-based vaccine or the amino acid sequence encoded by a nucleic acid-based vaccine is at least 90%
identical, at least 91%
identical, at least 92% identical, at least 93% identical, at least 94%
identical, at least 95% identical, at least 96% identical, at least 97% identical, or at least 98% identical to the portion of SEQ ID NO: 22, 23, or 24. Additional exemplary HBsAg and HBcAg amino acid sequenences are provided in the sequence listing. Alignment methods to identify appropriate sequences corresponding to the HBsAg and HBcAg determinants in the sequences indicated above are known in the art.
The vaccine preferably comprises MVA viruses in a concentration range of 104 to 109 tissue-culture infectious dose (TCID)50/ml, preferably in a concentration range of 105 to 5x108TCID50/ml, more preferably in a concentration range of 106 to 108 TCID50/ml, and most preferably in a concentration range of 107 to 108 TCID50/ml.
A preferred vaccination dose for humans comprises 106 to 109 TCID50, most preferably a dose of 106 TCID50 or 107 TCID50 or 108 TCID50.
The preferred methods of the invention include administration of both a protein-based vaccine and a nucleic acid-based vaccine. However, other methods include administration of only protein antigens. Less preferred embodiments include administration of only nucleic acids encoding antigens.
i. Adjuvants As used herein "adjuvant" is understood as an agent that promotes (e.g., enhances, accelerates, or prolongs) an immune response to an antigen with which it is administered to elicit long-term protective immunity. No substantial immune response is directed at the adjuvant itself.
Adjuvants include, but are not limited to, pathogen components, particulate adjuvants, and combination adjuvants (see, e.g., www.niaid.nih.gov/research/vaccine-adjuvants-types). Pathogen components (e.g., monophosphoryl lipid A (MPL), poly(I:C), CpG DNA, emulsions such as poly[di(sodiumcarboxylatoethylphenoxy)phosphazene] (PCEP)) can help trigger early non-specific, or innate, immune responses to vaccines by targeting various receptors inside or on the surface of innate immune cells. The innate immune system influences adaptive immune responses, which provide long-lasting protection against the pathogen that the vaccine targets.
Particulate adjuvants (e.g., alum, virosomes, cytokines, e.g., IL-12) form very small particles that can stimulate the immune system and also may enhance delivery of antigen to immune cells. Combination adjuvants (e.g., AS02, AS03 and AS04 (GSK); MF59 (Novartis); and IC31 (Altimmune) elicit multiple protective immune responses. Adjuvants that have a modest effect when used alone may induce a more potent immune response when used together. In certain embodiments, preferred adjuvants include c-di-AMP, c-di-GMP, c-di-CMP, PolyICLC, CpG, ISCOMATRIX , AS02, AS03, AS04, or a RIG-I
ligand such as 5' 3P-RNA. In certain embodiments, a viral capsid, with or without a nucleic acid expressing an HBV antigen can be used as an adjuvant. For example, a vaccine that preferentially .. stimulates T cells such as an MVA-only or a DNA prime, MVA boost or an adenovirus vector prime-MVA boost can be used in the methods of the invention.
In preferred embodiments of the invention, adjuvants for use in the invention promote a humoral and a cellular immune response as discussed above. In certain embodiments, adjuvants provide a balanced Th1/Th2 response.
ii. Non-adjuvant immune stimulators and additional agents Methods of the invention can further include administration of additional agents used in the treatment of HBV or to stimulate an immune response. Such agents can include an immune stimulator (e.g., pegylated interferon alfa 2a (PEG-IFN-a2a), Interferon alfa-2b, a recombinant human interleukin-7, and aToll-like receptor 3, 7, 8, or 9 (TLR3, TLR7, TLR8, or TLR9) agonist), a viral entry inhibitor (e.g., Myrcludex), an oligonucleotide that inhibits the secretion or release of HBsAg (e.g., REP 9AC), a capsid inhibitor (e.g., Bay41-4109 and NVR-1221), a cccDNA
inhibitor (e.g., IHVR-25), a Rig-I-ligand, a STING agonist, an antibody based immune therapy against HBV (mono-, bi-, or trispecific antibody against HBV), or an immune checkpoint regulator.
Such agents are known in the art.
C. Nucleotide and Nucleoside Analogs For Use in the Methods of the Invention Nucleotide and nucleoside analogs are considered to be the standard of care for HBV
infection as they are generally considered safe and inexpensive. However, nucleotide and nucleoside analogs cannot cure HBV infection, may cause the development of resistance, and must be taken indefinitely. Nucleotide analog and nucleoside analogs include, but are not limited to, Tenofovir disoproxil fumarate (TDF), Tenofovir alafenamide, Lamivudine, Adefovir dipivoxil, Entecavir (ETV), Telbivudine, AGX-1009, emtricitabine, clevudine, ritonavir, dipivoxil, lobucavir, famvir, FTC, N-Acetyl-Cysteine (NAC), PC1323, theradigm-HBV, thymosin-alpha, ganciclovir, Besifovir (ANA-380/LB-80380), and Tenofvir-Exalidex (TXL/CMX157) . In certain embodiments, the nucelot(s)ide analog is Entecavir (ETV) or Tenofovir or a derivative thereof.
In certain embodiments, the nucleot(s)ide analog is not Lamivudine. Nucleot(s)ide analogs are commercially available from a number of sources and are used in the methods provided herein according to their label indication (e.g., typically orally administered at a specific dose) or as determined by a skilled practitioner in the treatment of HBV.
III. Antisense Oligonucleotides Targeting HBV
The present invention includes the use of iRNAs which promote cleavage of at least one HBV
transcript, and preferably three or four HBV transcripts. Antisense oligonucleotides can similarly be used to promote cleavage of at least one HBV transcript, preferably three or four HBV transcripts, in the methods of the invention provided here. Exemplary antisense oligonucleotides targeted to HBV
are provided, for example, in U.S. Patent Publication Nos. 2013/0035366, 2012/0207709, and 2004/0127446, the contents of each of which is incorporated by reference herein in its entirety.
It is understood by those of skill in the art that conjugates, linkers, and formulations for the delivery of siRNAs as provided above can be used for the formulation and delivery of antisense oligonucleotide therapeutic agents to subjects.
IV. Pharmaceutical Compositions of the Invention The present invention also includes pharmaceutical compositions and formulations which include the iRNAs or vaccines for use in the invention. It is understood that approved therapeutic agents are formulated and administered by the route indicated on their package instructions.
In some embodiments, provided herein are pharmaceutical compositions containing an iRNA
or a vaccine, as described herein, and a pharmaceutically acceptable carrier.
The pharmaceutical compositions containing the iRNA or vaccine are useful for treating subject with an HBV infection.
Such pharmaceutical compositions are formulated based on the mode of delivery, e.g., for systemic administration via parenteral delivery, e.g., by subcutaneous (SC), intramuscular (IM), or intravenous (IV) delivery.
The pharmaceutical RNAi compositions for use in the invention may be administered in dosages sufficient to significantly reduce the level of at least one HBV
transcript. In general, a suitable dose of an iRNA of the invention will be in the range of about 0.001 to about 200.0 milligrams per kilogram body weight of the recipient per day, generally in the range of about 1 to 50 mg per kilogram body weight per day. Typically, a suitable dose of an iRNA of the invention will be in the range of about 0.1 mg/kg to about 5.0 mg/kg, preferably about 0.3 mg/kg and about 3.0 mg/kg.
A repeat-dose regimen may include administration of a therapeutic amount of iRNA on a regular basis, such as every other week or once a year. In certain embodiments, the iRNA is administered about once per month to about once per quarter (i.e., about once every three months). In preferred embodiments, the RNAi agent is administered subcutaneously.
Formulation and dosing of the vaccine will depend on the nature of the vaccine administered.
In a protein prime-expression vector boost vaccination strategy, the protein-based priming vaccines are administered about 2, 3, or 4 weeks apart with the expression vector vaccine boost being administered about 2, 3, or 4 weeks after the second protein-based vaccine dose. In certain embodiments, it is about two weeks between the first and second doses of the protein-based vaccine.
In certain embodiments, it is about two weeks between the second dose of the protein based vaccine and the DNA expression vector vaccine boost. In certain embodiments, the prime and boost vaccinations are administered by routes independently selected from intramuscularly, intradermally, or subcutaneously.
The pharmaceutical nucleic acid-based vaccines for use in the invention may be administered in dosages sufficient to promote an immune response, as either a prime agent or a boost agent. The amount of nucleic acid-based vaccine to be administered will depend, for example, on the design of the vaccine. As the regimens provided herein can include the use of existing nucleic acid-based vaccines, knowledge regarding appropriate dosages based on therapeutic efficacy and safety should be based on the specific agent used.
The pharmaceutical protein-based vaccines for use in the invention may be administered in dosages sufficient to promote an immune response, as either a prime or a boost agent. The amount of protein-based vaccine to be administered will depend, for example, on the adjuvant used. Protein-based vaccines can be dosed, for example, at about 5-100 mg/kg/dose, about 10-50 mg/kg/dose, or about 20-40 mg/kg/dose. As the regimens provided herein can include the use of existing protein-based vaccines, knowledge regarding appropriate dosages based on therapeutic efficacy and safety should be based on the specific agent used.
After an initial treatment regimen, the treatments can be administered on a less frequent basis.
In preferred embodiments, the treatment regimens and methods provided herein result in a functional cure allowing for discontinuation of treatment after completion of the regimen or after diagnostic criteria indicate a functional cure, e.g., decreased HBsAg levels preferably to below the level of detection of the methods provided herein and a detectable immune response to HBsAg.
The skilled artisan will appreciate that certain factors can influence the dosage and timing required to effectively treat a subject, including but not limited to the severity of the disease or disorder, previous treatments, the general health or age of the subject, and other diseases present.
Moreover, treatment of a subject with a therapeutically effective amount of a composition can include a single treatment or a series of treatments. Estimates of effective dosages and in vivo half-lives for the individual therapeutic agent used in the methods and regimens invention can be made using conventional methodologies or on the basis of in vivo testing using an appropriate animal model, as described elsewhere herein and known in the art.
A. iRNA Formulations Comprising Membranous Molecular Assemblies An iRNA for use in the compositions and methods of the invention can be formulated for delivery in a membranous molecular assembly, e.g., a liposome or a micelle. As used herein, the term "liposome" refers to a vesicle composed of amphiphilic lipids arranged in at least one bilayer, e.g., one bilayer or a plurality of bilayers. Liposomes include unilamellar and multilamellar vesicles that have a membrane formed from a lipophilic material and an aqueous interior. The aqueous portion contains the iRNA composition. The lipophilic material isolates the aqueous interior from an aqueous exterior, which typically does not include the iRNA composition, although in some examples, it may.
Liposomes are useful for the transfer and delivery of active ingredients to the site of action. Because the liposomal membrane is structurally similar to biological membranes, when liposomes are applied to a tissue, the liposomal bilayer fuses with bilayer of the cellular membranes. As the merging of the liposome and cell progresses, the internal aqueous contents that include the iRNA are delivered into the cell where the iRNA can specifically bind to a target RNA and can mediate iRNA. In some cases the liposomes are also specifically targeted, e.g., to direct the iRNA to particular cell types.
A liposome containing an iRNA agent can be prepared by a variety of methods.
In one example, the lipid component of a liposome is dissolved in a detergent so that micelles are formed with the lipid component. For example, the lipid component can be an amphipathic cationic lipid or lipid conjugate. The detergent can have a high critical micelle concentration and may be nonionic.
Exemplary detergents include cholate, CHAPS, octylglucoside, deoxycholate, and lauroyl sarcosine.
The iRNA agent preparation is then added to the micelles that include the lipid component. The cationic groups on the lipid interact with the iRNA agent and condense around the iRNA agent to form a liposome. After condensation, the detergent is removed, e.g., by dialysis, to yield a liposomal preparation of the iRNA agent.
If necessary a carrier compound that assists in condensation can be added during the condensation reaction, e.g., by controlled addition. For example, the carrier compound can be a polymer other than a nucleic acid (e.g., spermine or spermidine). pH can also adjusted to favor condensation.
Methods for producing stable polynucleotide delivery vehicles, which incorporate a polynucleotide/cationic lipid complex as structural components of the delivery vehicle, are further described in, e.g., WO 9637194, the entire contents of which are incorporated herein by reference.
Liposome formation can also include one or more aspects of exemplary methods described in Felgner, P. L. et al., Proc. Natl. Acad. Sci., USA 8:7413-7417, 1987; US Patent No.
4,897,355; US Patent No.
5,171,678; Bangham, et al. M. Mol. Biol. 23:238, 1965; Olson, et al. Biochim.
Biophys. Acta 557:9, 1979; Szoka, et al. Proc. Natl. Acad. Sci. USA 75: 4194, 1978; Mayhew, et al.
Biochim. Biophys. Acta 775:169, 1984; Kim, et al. Biochim. Biophys. Acta 728:339, 1983; and Fukunaga, et al. Endocrinol.
115:757, 1984. Commonly used techniques for preparing lipid aggregates of appropriate size for use as delivery vehicles include sonication and freeze-thaw plus extrusion (see, e.g., Mayer, et al.
Biochim. Biophys. Acta 858:161, 1986). Microfluidization can be used when consistently small (50 to 200 nm) and relatively uniform aggregates are desired (Mayhew, et al. Biochim.
Biophys. Acta 775:169, 1984). These methods are readily adapted to packaging iRNA agent preparations into liposomes.
Liposomes fall into two broad classes. Cationic liposomes are positively charged liposomes which interact with the negatively charged nucleic acid molecules to form a stable complex. The positively charged nucleic acid/liposome complex binds to the negatively charged cell surface and is internalized in an endosome. Due to the acidic pH within the endosome, the liposomes are ruptured, releasing their contents into the cell cytoplasm (Wang et al., Biochem.
Biophys. Res. Commun., 1987, 147, 980-985).
Liposomes which are pH-sensitive or negatively-charged, entrap nucleic acids rather than complex with it. Since both the nucleic acid and the lipid are similarly charged, repulsion rather than complex formation occurs. Nevertheless, some nucleic acid is entrapped within the aqueous interior of these liposomes. pH-sensitive liposomes have been used to deliver nucleic acids encoding the thymidine kinase gene to cell monolayers in culture. Expression of the exogenous gene was detected in the target cells (Zhou et al., Journal of Controlled Release, 1992, 19, 269-274).
One major type of liposomal composition includes phospholipids other than naturally-derived phosphatidylcholine. Neutral liposome compositions, for example, can be formed from dimyristoyl phosphatidylcholine (DMPC) or dipalmitoyl phosphatidylcholine (DPPC). Anionic liposome compositions generally are formed from dimyristoyl phosphatidylglycerol, while anionic fusogenic liposomes are formed primarily from dioleoyl phosphatidylethanolamine (DOPE).
Another type of liposomal composition is formed from phosphatidylcholine (PC) such as, for example, soybean PC
and egg PC. Another type is formed from mixtures of phospholipid or phosphatidylcholine or cholesterol.
Examples of other methods to introduce liposomes into cells in vitro and in vivo include US
Patent Nos. 5,283,185 and 5,171,678; WO 94/00569; WO 93/24640; WO 91/16024;
Felgner, J. Biol.
Chem. 269:2550, 1994; Nabel, Proc. Natl. Acad. Sci. USA 90:11307, 1993; Nabel, Human Gene Ther.
3:649, 1992; Gershon, Biochem. 32:7143, 1993; and Strauss EMBO / 11:417, 1992.
Non-ionic liposomal systems have also been examined to determine their utility in the delivery of drugs to the skin, in particular systems comprising non-ionic surfactant and cholesterol.
Non-ionic liposomal formulations comprising NovasomeTm I (glyceryl dilaurate/cholesterol/polyoxyethylene-10-stearyl ether) and NovasomeTm II
(glyceryl distearate/cholesterol/polyoxyethylene-10-stearyl ether) were used to deliver cyclosporin-A into the dermis of mouse skin. Results indicated that such non-ionic liposomal systems were effective in facilitating the deposition of cyclosporine A into different layers of the skin (Hu et al. S.T.P.Phanna.
Sci., 1994, 4(6) 466).
Liposomes also include "sterically stabilized" liposomes, a term which, as used herein, refers to liposomes comprising one or more specialized lipids that, when incorporated into liposomes, result in enhanced circulation lifetimes relative to liposomes lacking such specialized lipids. Examples of sterically stabilized liposomes are those in which part of the vesicle-forming lipid portion of the liposome (A) comprises one or more glycolipids, such as monosialoganglioside Gmi, or (B) is derivatized with one or more hydrophilic polymers, such as a polyethylene glycol (PEG) moiety.
While not wishing to be bound by any particular theory, it is thought in the art that, at least for sterically stabilized liposomes containing gangliosides, sphingomyelin, or PEG-derivatized lipids, the enhanced circulation half-life of these sterically stabilized liposomes derives from a reduced uptake into cells of the reticuloendothelial system (RES) (Allen et al., FEBS
Letters, 1987, 223, 42; Wu et al., Cancer Research, 1993, 53, 3765).
Various liposomes comprising one or more glycolipids are known in the art.
Papahadjopoulos et al. (Ann. N.Y. Acad. Sci., 1987, 507, 64) reported the ability of monosialoganglioside Gmi, galactocerebroside sulfate and phosphatidylinositol to improve blood half-lives of liposomes. These findings were expounded upon by Gabizon et al. (Proc. Natl. Acad. Sci. USA, 1988, 85, 6949). US
Patent No. 4,837,028 and WO 88/04924, both to Allen et al., disclose liposomes comprising (1) sphingomyelin and (2) the ganglioside Gmi or a galactocerebroside sulfate ester. US Patent No.
5,543,152 discloses liposomes comprising sphingomyelin. Liposomes comprising 1,2-sn-dimyristoylphosphatidylcholine are disclosed in WO 9713499 (Lim et al).
Cationic liposomes possess the advantage of being able to fuse to the cell membrane. Non-cationic liposomes, although not able to fuse as efficiently with the plasma membrane, are taken up by macrophages in vivo and can be used to deliver iRNA agents to macrophages.
Further advantages of liposomes include: liposomes obtained from natural phospholipids are biocompatible and biodegradable; liposomes can incorporate a wide range of water and lipid soluble drugs; liposomes can protect encapsulated iRNA agents in their internal compartments from metabolism and degradation (Rosoff, in "Pharmaceutical Dosage Forms,"
Lieberman, Rieger and Banker (Eds.), 1988, volume 1, p. 245). Important considerations in the preparation of liposome formulations are the lipid surface charge, vesicle size and the aqueous volume of the liposomes.
A positively charged synthetic cationic lipid, N41-(2,3-dioleyloxy)propy1]-N,N,N-trimethylammonium chloride (DOTMA) can be used to form small liposomes that interact spontaneously with nucleic acid to form lipid-nucleic acid complexes which are capable of fusing with the negatively charged lipids of the cell membranes of tissue culture cells, resulting in delivery of iRNA agent (see, e.g., Felgner, P. L. et al., Proc. Natl. Acad. Sci., USA
8:7413-7417, 1987 and US
Patent No. 4,897,355 for a description of DOTMA and its use with DNA).
A DOTMA analogue, 1,2-bis(oleoyloxy)-3-(trimethylammonia)propane (DOTAP) can be used in combination with a phospholipid to form DNA-complexing vesicles.
LipofectinTM Bethesda Research Laboratories, Gaithersburg, Md.) is an effective agent for the delivery of highly anionic nucleic acids into living tissue culture cells that comprise positively charged DOTMA liposomes which interact spontaneously with negatively charged polynucleotides to form complexes. When enough positively charged liposomes are used, the net charge on the resulting complexes is also positive. Positively charged complexes prepared in this way spontaneously attach to negatively charged cell surfaces, fuse with the plasma membrane, and efficiently deliver functional nucleic acids into, for example, tissue culture cells. Another commercially available cationic lipid, 1,2-bis(oleoyloxy)-3,3-(trimethylammonia)propane ("DOTAP") (Boehringer Mannheim, Indianapolis, Indiana) differs from DOTMA in that the oleoyl moieties are linked by ester, rather than ether linkages.
Other reported cationic lipid compounds include those that have been conjugated to a variety of moieties including, for example, carboxyspermine which has been conjugated to one of two types of lipids and includes compounds such as 5-carboxyspermylglycine dioctaoleoylamide ("DOGS") (TransfectamTm, Promega, Madison, Wisconsin) and dipalmitoylphosphatidylethanolamine 5-carboxyspermyl-amide ("DPPES") (see, e.g., US Patent No. 5,171,678).
Another cationic lipid conjugate includes derivatization of the lipid with cholesterol ("DC-Chol") which has been formulated into liposomes in combination with DOPE (See, Gao, X. and Huang, L., Biochim. Biophys. Res. Commun. 179:280, 1991). Lipopolylysine, made by conjugating polylysine to DOPE, has been reported to be effective for transfection in the presence of serum (Zhou, X. et al., Biochim. Biophys. Acta 1065:8, 1991). For certain cell lines, these liposomes containing conjugated cationic lipids, are said to exhibit lower toxicity and provide more efficient transfection than the DOTMA-containing compositions. Other commercially available cationic lipid products include DMRIE and DMRIE-HP (Vical, La Jolla, California) and Lipofectamine (DOSPA) (Life Technology, Inc., Gaithersburg, Maryland). Other cationic lipids suitable for the delivery of oligonucleotides are described in WO 98/39359 and WO 96/37194.
Liposomal formulations are particularly suited for topical administration.
Liposomes present several advantages over other formulations. Such advantages include reduced side effects related to high systemic absorption of the administered drug, increased accumulation of the administered drug at the desired target, and the ability to administer iRNA agent into the skin. In some implementations, liposomes are used for delivering iRNA agent to epidermal cells and also to enhance the penetration of iRNA agent into dermal tissues, e.g., into skin. For example, the liposomes can be applied topically. Topical delivery of drugs formulated as liposomes to the skin has been documented (see, e.g., Weiner et al., Journal of Drug Targeting, 1992, vol. 2,405-410 and du Plessis et al., Antiviral Research, 18, 1992, 259-265; Mannino, R. J. and Fould-Fogerite, S., Biotechniques 6:682-690, 1988;
Itani, T. et al. Gene 56:267-276. 1987; Nicolau, C. et al. Meth. Enz. 149:157-176, 1987; Straubinger, R. M. and Papahadjopoulos, D. Meth. Enz. 101:512-527, 1983; Wang, C. Y. and Huang, L., Proc.
Natl. Acad. Sci. USA 84:7851-7855, 1987).
Liposomes that include iRNA can be made highly deformable. Such deformability can enable the liposomes to penetrate through pore that are smaller than the average radius of the liposome. For example, transfersomes are a type of deformable liposomes. Transferosomes can be made by adding surface edge activators, usually surfactants, to a standard liposomal composition. Transfersomes that include iRNA agent can be delivered, for example, subcutaneously by infection in order to deliver iRNA agent to keratinocytes in the skin. In order to cross intact mammalian skin, lipid vesicles must pass through a series of fine pores, each with a diameter less than 50 nm, under the influence of a suitable transdermal gradient. In addition, due to the lipid properties, these transferosomes can be self-optimizing (adaptive to the shape of pores, e.g., in the skin), self-repairing, and can frequently reach their targets without fragmenting, and often self-loading.
Other formulations amenable to the present invention are described in WO
2008042973.
Surfactants find wide application in formulations such as emulsions (including microemulsions) and liposomes. The most common way of classifying and ranking the properties of the many different types of surfactants, both natural and synthetic, is by the use of the hydrophile/lipophile balance (HLB). The nature of the hydrophilic group (also known as the "head") provides the most useful means for categorizing the different surfactants used in formulations (Rieger, in "Pharmaceutical Dosage Forms", Marcel Dekker, Inc., New York, N.Y., 1988, p. 285).
If the surfactant molecule is not ionized, it is classified as a nonionic surfactant. Nonionic surfactants find wide application in pharmaceutical and cosmetic products and are usable over a wide range of pH values. In general their HLB values range from 2 to about 18 depending on their structure. Nonionic surfactants include nonionic esters such as ethylene glycol esters, propylene glycol esters, glyceryl esters, polyglyceryl esters, sorbitan esters, sucrose esters, and ethoxylated esters. Nonionic alkanolamides and ethers such as fatty alcohol ethoxylates, propoxylated alcohols, and ethoxylated/propoxylated block polymers are also included in this class.
The polyoxyethylene surfactants are the most popular members of the nonionic surfactant class.
If the surfactant molecule carries a negative charge when it is dissolved or dispersed in water, the surfactant is classified as anionic. Anionic surfactants include carboxylates such as soaps, acyl lactylates, acyl amides of amino acids, esters of sulfuric acid such as alkyl sulfates and ethoxylated alkyl sulfates, sulfonates such as alkyl benzene sulfonates, acyl isethionates, acyl taurates and sulfosuccinates, and phosphates. The most important members of the anionic surfactant class are the alkyl sulfates and the soaps.
If the surfactant molecule carries a positive charge when it is dissolved or dispersed in water, the surfactant is classified as cationic. Cationic surfactants include quaternary ammonium salts and ethoxylated amines. The quaternary ammonium salts are the most used members of this class.
If the surfactant molecule has the ability to carry either a positive or negative charge, the surfactant is classified as amphoteric. Amphoteric surfactants include acrylic acid derivatives, substituted alkylamides, N-alkylbetaines and phosphatides.
The use of surfactants in drug products, formulations and in emulsions has been reviewed (Rieger, in "Pharmaceutical Dosage Forms", Marcel Dekker, Inc., New York, N.Y., 1988, p. 285).
The iRNA for use in the methods of the invention can also be provided as micellar formulations. "Micelles" are defined herein as a particular type of molecular assembly in which amphipathic molecules are arranged in a spherical structure such that all the hydrophobic portions of the molecules are directed inward, leaving the hydrophilic portions in contact with the surrounding aqueous phase. The converse arrangement exists if the environment is hydrophobic.
B. Lipid particles iRNAs, e.g., dsRNAs of in the invention may be fully encapsulated in a lipid formulation, e.g., a LNP, or other nucleic acid-lipid particle. Expression vectors or RNAs containing coding sequences for viral antigens under the control of an appropriate promoter can be formulated in lipid particles for delivery.
As used herein, the term "LNP" refers to a stable nucleic acid-lipid particle.
LNPs typically contain a cationic lipid, a non-cationic lipid, and a lipid that prevents aggregation of the particle (e.g., a PEG-lipid conjugate). LNPs are extremely useful for systemic applications, as they exhibit extended circulation lifetimes following intravenous (i.v.) injection and accumulate at distal sites (e.g., sites physically separated from the administration site). LNPs include "pSPLP,"
which include an encapsulated condensing agent-nucleic acid complex as set forth in WO 0003683.
The particles of the present invention typically have a mean diameter of about 50 nm to about 150 nm, more typically about 60 nm to about 130 nm, more typically about 70 nm to about 110 nm, most typically about 70 nm to about 90 nm, and are substantially nontoxic. In addition, the nucleic acids when present in the nucleic acid- lipid particles of the present invention are resistant in aqueous solution to degradation with a nuclease. Nucleic acid-lipid particles and their method of preparation are disclosed in, e.g., US
Patent Nos. 5,976,567; 5,981,501; 6,534,484; 6,586,410; and 6,815,432;
US20100324120 and WO
9640964.
In some embodiments, the lipid to drug ratio (mass/mass ratio) (e.g., lipid to dsRNA ratio) will be in the range of from about 1:1 to about 50:1, from about 1:1 to about 25:1, from about 3:1 to about 15:1, from about 4:1 to about 10:1, from about 5:1 to about 9:1, or about 6:1 to about 9:1.
Ranges intermediate to the above recited ranges are also contemplated to be part of the invention.
The cationic lipid can be, for example, N,N-dioleyl-N,N-dimethylammonium chloride (DODAC), N,N-distearyl-N,N-dimethylammonium bromide (DDAB), N-(I -(2,3-dioleoyloxy)propy1)-N,N,N-trimethylammonium chloride (DOTAP), N-(I -(2,3-dioleyloxy)propy1)-N,N,N-trimethylammonium chloride (DOTMA), N,N-dimethy1-2,3-dioleyloxy)propylamine (DODMA), 1,2-DiLinoleyloxy-N,N-dimethylaminopropane (DLinDMA),1,2-Dilinolenyloxy-N,N-dimethylaminopropane (DLenDMA), 1,2-Dilinoleylcarbamoyloxy-3-dimethylaminopropane (DLin-C-DAP), 1,2-Dilinoleyoxy-3-(dimethylamino)acetoxypropane (Dlin-DAC), 1,2-Dilinoleyoxy-3-morpholinopropane (DLin-MA), 1,2-Dilinoleoy1-3-dimethylaminopropane (DLinDaP), 1,2-Dilinoleylthio-3-dimethylaminopropane (DLin-S-DMA), 1-linoleoy1-2-linoleyloxy-dimethylaminopropane (DLin-2-DMAP), 1,2-Dilinoleyloxy-3-trimethylaminopropane chloride salt (DLin-TMA.C1), 1,2-Dilinoleoy1-3-trimethylaminopropane chloride salt (DLin-TAP.C1), 1,2-Dilinoleyloxy-3-(N-methylpiperazino)propane (DLin-MPz), or 3-(N,N-Dilinoleylamino)-1,2-propanediol (DLinAP), 3-(N,N-Dioleylamino)-1,2-propanedio (DOAP), 1,2-Dilinoleyloxo-3-(2-N,N-dimethylamino)ethoxypropane (DLin-EG-DMA),1,2-Dilinolenyloxy-N,N-dimethylaminopropane (DLinDMA), 2,2-Dilinoley1-4-dimethylaminomethy141,3]-dioxolane (DLin-K-DMA) or analogs thereof, (3aR,55,6aS)-N,N-dimethy1-2,2-di((9Z,12Z)-octadeca-9,12-dienyl)tetrahydro-3aH-cyclopent4d][1,3]dioxo1-5-amine (ALN100), (6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-y1 4-(dimethylamino)butanoate (MC3), 1,1'-(2-(4-(2-((2-(bis(2-hydroxydodecyl)amino)ethyl)(2-hydroxydodecyl)amino)ethyl)piperazin-1-yl)ethylazanediy1)didodecan-2-ol (Tech G1), or a mixture thereof. The cationic lipid can comprise from about 20 mol % to about 50 mol %
or about 40 mol %
of the total lipid present in the particle. In other embodiments, the compound 2,2-Dilinoley1-4-dimethylaminoethy141,3]-dioxolane can be used to prepare lipid-siRNA
nanoparticles.
In some embodiments, the lipid-siRNA particle includes 40% 2, 2-Dilinoley1-4-dimethylaminoethy141,3]-dioxolane: 10% DSPC: 40% Cholesterol: 10% PEG-C-DOMG
(mole percent) with a particle size of 63.0 20 nm and a 0.027 siRNA/Lipid Ratio.
The ionizable/non-cationic lipid can be an anionic lipid or a neutral lipid including, but not limited to, distearoylphosphatidylcholine (DSPC), dioleoylphosphatidylcholine (DOPC), dipalmitoylphosphatidylcholine (DPPC), dioleoylphosphatidylglycerol (DOPG), dipalmitoylphosphatidylglycerol (DPPG), dioleoyl-phosphatidylethanolamine (DOPE), palmitoyloleoylphosphatidylcholine (POPC), palmitoyloleoylphosphatidylethanolamine (POPE), dioleoyl- phosphatidylethanolamine 4-(N-maleimidomethyl)-cyclohexane-1-carboxylate (DOPE-mal), dipalmitoyl phosphatidyl ethanolamine (DPPE), dimyristoylphosphoethanolamine (DMPE), distearoyl-phosphatidyl-ethanolamine (DSPE), 16-0-monomethyl PE, 16-0-dimethyl PE, 18-1 -trans PE, 1 -stearoy1-2-oleoyl- phosphatidyethanolamine (SOPE), cholesterol, or a mixture thereof. The non-cationic lipid can be from about 5 mol % to about 90 mol %, about 10 mol %, or about 58 mol %
if cholesterol is included, of the total lipid present in the particle.
The conjugated lipid that inhibits aggregation of particles can be, for example, a polyethyleneglycol (PEG)-lipid including, without limitation, a PEG-diacylglycerol (DAG), a PEG-dialkyloxypropyl (DAA), a PEG-phospholipid, a PEG-ceramide (Cer), or a mixture thereof. The PEG-DAA conjugate can be, for example, a PEG-dilauryloxypropyl (Ci2), a PEG-dimyristyloxypropyl (Ci4), a PEG-dipalmityloxypropyl (Ci6), or a PEG-distearyloxypropyl (C]8). The conjugated lipid that prevents aggregation of particles can be from 0 mol % to about 20 mol % or about 2 mol % of the total lipid present in the particle.
In some embodiments, the nucleic acid-lipid particle further includes cholesterol at, e.g., about 10 mol % to about 60 mol % or about 48 mol % of the total lipid present in the particle.
In one embodiment, the lipidoid ND98=4HC1 (MW 1487) (see US20090023673, which is incorporated herein by reference), Cholesterol (Sigma-Aldrich), and PEG-Ceramide C16 (Avanti Polar Lipids) can be used to prepare lipid-dsRNA nanoparticles (i.e., LNP01 particles). Stock solutions of each in ethanol can be prepared as follows: ND98, 133 mg/ml;
Cholesterol, 25 mg/ml, PEG-Ceramide C16, 100 mg/ml. The ND98, Cholesterol, and PEG-Ceramide C16 stock solutions can then be combined in a, e.g., 42:48:10 molar ratio. The combined lipid solution can be mixed with aqueous dsRNA (e.g., in sodium acetate pH 5) such that the final ethanol concentration is about 35-45% and the final sodium acetate concentration is about 100-300 mM. Lipid-dsRNA
nanoparticles typically form spontaneously upon mixing. Depending on the desired particle size distribution, the resultant nanoparticle mixture can be extruded through a polycarbonate membrane (e.g., 100 nm cut-off) using, for example, a thermobarrel extruder, such as Lipex Extruder (Northern Lipids, Inc). In some cases, the extrusion step can be omitted. Ethanol removal and simultaneous buffer exchange can be accomplished by, for example, dialysis or tangential flow filtration. Buffer can be exchanged with, for example, phosphate buffered saline (PBS) at about pH 7, e.g., about pH
6.9, about pH 7.0, about pH 7.1, about pH 7.2, about pH 7.3, or about pH 7.4.
N)NNNNrN
NO iCeN
ND98 Isomer I
Formula 1 LNP01 formulations are described, e.g., in WO 2008042973, which is hereby incorporated by reference.
Additional exemplary lipid-dsRNA formulations are described in Table 1.
Table 1 cationic lipid/non-cationic Ionizable/Cationic Lipid lipid/cholesterol/PEG-lipid conjugate Lipid:siRNA ratio DLinDMA/DPPC/Cholesterol/PEG-cDMA
SNALP- 1,2-Dilinolenyloxy-N,N-(57.1/7.1/34.4/1.4) 1 dimethylaminopropane (DLinDMA) lipid:siRNA ¨ 7:1 XTC/DPPC/Cholesterol/PEG-cDMA
2,2-Dilinoley1-4-dimethylaminoethy141,3]-2-XTC 57.1/7.1/34.4/1.4 dioxolane (XTC) lipid:siRNA ¨ 7:1 XTC/DSPC/Cholesterol/PEG-DMG
2,2-Dilinoley1-4-dimethylaminoethy141,3]-LNP05 57.5/7.5/31.5/3.5 dioxolane (XTC) lipid:siRNA ¨ 6:1 XTC/DSPC/Cholesterol/PEG-DMG
2,2-Dilinoley1-4-dimethylaminoethy141,3]-LNP06 57.5/7.5/31.5/3.5 dioxolane (XTC) lipid:siRNA ¨ 11:1 XTC/DSPC/Cholesterol/PEG-DMG
2,2-Dilinoley1-4-dimethylaminoethy141,3]-LNP07 60/7.5/31/1.5, dioxolane (XTC) lipid:siRNA ¨ 6:1 XTC/DSPC/Cholesterol/PEG-DMG
2,2-Dilinoley1-4-dimethylaminoethy141,3]-LNP08 60/7.5/31/1.5, dioxolane (XTC) lipid:siRNA ¨ 11:1 XTC/DSPC/Cholesterol/PEG-DMG
2,2-Dilinoley1-4-dimethylaminoethy141,3]-LNP09 50/10/38.5/1.5 dioxolane (XTC) Lipid:siRNA 10:1 (3aR,55,6aS)-N,N-dimethy1-2,2-di((9Z,12Z)-octadeca-9,12- ALN100/DSPC/Cholesterol/PEG-DMG
LNP10 dienyl)tetrahydro-3aH- 50/10/38.5/1.5 cyclopenta[d][1,3]dioxo1-5-amine Lipid:siRNA 10:1 (ALN100) (6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31- MC-3/DSPC/Cholesterol/PEG-DMG
LNP11 tetraen-19-y1 4-(dimethylamino)butanoate 50/10/38.5/1.5 (MC3) Lipid:siRNA 10:1 1,1'-(2-(4-(2-((2-(bis(2- Tech Gl/DSPC/Cholesterol/PEG-DMG
hydroxydodecyl)amino)ethyl)(2- 50/10/38.5/1.5 hydroxydodecyl)amino)ethyl)piperazin-1- Lipid:siRNA 10:1 yl)ethylazanediy1)didodecan-2-ol (Tech Gl) XTC/DSPC/Chol/PEG-DMG
LNP13 XTC 50/10/38.5/1.5 Lipid:siRNA: 33:1 MC3/DSPC/Chol/PEG-DMG
Lipid:siRNA: 11:1 MC3/DSPC/Chol/PEG-DSG/Ga1NAc-PEG-DSG
50/10/35/4.5/0.5 Lipid:siRNA: 11:1 MC3/DSPC/Chol/PEG-DMG
LNP16 MC3 50/10/38.5/1.5 Lipid:siRNA: 7:1 MC3/DSPC/Chol/PEG-DSG
LNP17 MC3 50/10/38.5/1.5 Lipid:siRNA: 10:1 MC3/DSPC/Chol/PEG-DMG
LNP18 MC3 50/10/38.5/1.5 Lipid:siRNA: 12:1 MC3/DSPC/Chol/PEG-DMG
Lipid:siRNA: 8:1 MC3/DSPC/Chol/PEG-DPG
LNP20 MC3 50/10/38.5/1.5 Lipid:siRNA: 10:1 C12-200/DSPC/Chol/PEG-DSG
LNP21 C12-200 50/10/38.5/1.5 Lipid:siRNA: 7:1 XTC/DSPC/Chol/PEG-DSG
LNP22 XTC 50/10/38.5/1.5 Lipid:siRNA: 10:1 DSPC: distearoylphosphatidylcholine DPPC: dipalmitoylphosphatidylcholine PEG-DMG: PEG-didimyristoyl glycerol (C14-PEG, or PEG-C14) (PEG with avg mol wt of 2000) PEG-DSG: PEG-distyryl glycerol (C18-PEG, or PEG-C18) (PEG with avg mol wt of 2000) PEG-cDMA: PEG-carbamoy1-1,2-dimyristyloxypropylamine (PEG with avg mol wt of 2000) SNALP (1,2-Dilinolenyloxy-N,N-dimethylaminopropane (DLinDMA)) comprising formulations are described in International Publication No. WO 2009/127060, filed April 15, 2009, which is hereby incorporated by reference.
XTC comprising formulations are described in PCT Publication No. WO
2010/088537, the entire contents of which are hereby incorporated herein by reference.
MC3 comprising formulations are described, e.g., in U.S. Publication No.
2010/0324120, the entire contents of which are hereby incorporated by reference.
ALNY-100 comprising formulations are described in PCT Publication No. WO
2010/054406, the entire contents of which are hereby incorporated herein by reference.
C12-200 comprising formulations are described in PCT Publication No. WO
2010/129709, the entire contents of which are hereby incorporated herein by reference.
Compositions and formulations for oral administration include powders or granules, microparticulates, nanoparticulates, suspensions or solutions in water or non-aqueous media, capsules, gel capsules, sachets, tablets or minitablets. Thickeners, flavoring agents, diluents, emulsifiers, dispersing aids or binders can be desirable. In some embodiments, oral formulations are those in which dsRNAs featured in the invention are administered in conjunction with one or more penetration enhancer surfactants and chelators. Suitable surfactants include fatty acids or esters or salts thereof, bile acids or salts thereof. Suitable bile acids/salts include chenodeoxycholic acid (CDCA) and ursodeoxychenodeoxycholic acid (UDCA), cholic acid, dehydrocholic acid, deoxycholic acid, glucholic acid, glycholic acid, glycodeoxycholic acid, taurocholic acid, taurodeoxycholic acid, sodium tauro-24,25-dihydro-fusidate and sodium glycodihydrofusidate. Suitable fatty acids include arachidonic acid, undecanoic acid, oleic acid, lauric acid, caprylic acid, capric acid, myristic acid, palmitic acid, stearic acid, linoleic acid, linolenic acid, dicaprate, tricaprate, monoolein, dilaurin, glyceryl 1-monocaprate, 1-dodecylazacycloheptan-2-one, an acylcarnitine, an acylcholine, or a monoglyceride, a diglyceride or a pharmaceutically acceptable salt thereof (e.g., sodium). In some embodiments, combinations of penetration enhancers are used, for example, fatty acids/salts in combination with bile acids/salts. One exemplary combination is the sodium salt of lauric acid, capric acid and UDCA. Further penetration enhancers include polyoxyethylene-9-lauryl ether, polyoxyethylene-20-cetyl ether. DsRNAs featured in the invention can be delivered orally, in granular form including sprayed dried particles, or complexed to form micro or nanoparticles. DsRNA
complexing agents include poly-amino acids; polyimines; polyacrylates;
polyalkylacrylates, polyoxethanes, polyalkylcyanoacrylates; cationized gelatins, albumins, starches, acrylates, polyethyleneglycols (PEG) and starches; polyalkylcyanoacrylates; DEAE-derivatized polyimines, pollulans, celluloses and starches. Suitable complexing agents include chitosan, N-trimethylchitosan, poly-L-lysine, polyhistidine, polyornithine, polyspermines, protamine, polyvinylpyridine, polythiodiethylaminomethylethylene P(TDAE), polyaminostyrene (e.g., p-amino), poly(methylcyanoacrylate), poly(ethylcyanoacrylate), poly(butylcyanoacrylate), poly(isobutylcyanoacrylate), poly(isohexylcynaoacrylate), DEAE-methacrylate, DEAE-hexylacrylate, DEAE-acrylamide, DEAE-albumin and DEAE-dextran, polymethylacrylate, polyhexylacrylate, poly(D,L-lactic acid), poly(DL-lactic-co-glycolic acid (PLGA), alginate, and polyethyleneglycol (PEG). Oral formulations for dsRNAs and their preparation are described in detail in US Patent Nos.
6,887,906 and 6,747,014, and US 20030027780, each of which is incorporated herein by reference.
Pharmaceutical compositions of the present invention include, but are not limited to, solutions, emulsions, and liposome-containing formulations. These compositions can be generated from a variety of components that include, but are not limited to, preformed liquids, self-emulsifying solids and self-emulsifying semisolids. Particularly preferred are formulations that target the liver when treating hepatic disorders such as hepatic carcinoma.
The pharmaceutical formulations of the present invention, which can conveniently be presented in unit dosage form, can be prepared according to conventional techniques well known in the pharmaceutical industry. Such techniques include the step of bringing into association the active ingredients with the pharmaceutical carrier(s) or excipient(s). In general, the formulations are prepared by uniformly and intimately bringing into association the active ingredients with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product.
V. Uses of the Methods of the Invention The invention sets forth various methods and treatment regimens. It is understood that the methods can be provided as uses of the RNAi agents and vaccines provided herein. That is, the invention provides a) an RNAi agent that targets at least three HBV transcripts, wherein the RNAi agent comprises a sense strand and an antisense strand;
b) a protein-based vaccine comprising an HBV core antigen (HBcAg) and an HBV
surface antigen (HBsAg); and c) a nucleic acid-based vaccine comprising an expression vector construct encoding an HBcAg or an HBsAg, wherein the construct encodes a protein that shares an epitope with the protein-based vaccine; thereby treating the subject for use in methods of treating a subject having a hepatitis B infection.
The uses include all of the variations and exemplary RNAi agents, protein-based vaccines, and nucleic acid-based vaccines provided herein.
VI. Kits for Practicing the Methods of the Invention The invention sets forth various methods, treatment regimensm and uses of agents for the treatment of a subject having a hepatitis B infection. It is understood that agents for practicing the methods of the invention can be prepared based in the disclosure provided herein. Such a kit would include, a) an RNAi agent that targets at least three HBV transcripts, wherein the RNAi agent comprises a sense strand and an antisense strand;
b) a protein-based vaccine comprising an HBV core antigen (HBcAg) and an HBV
surface antigen (HBsAg);
c) a nucleic acid-based vaccine comprising an expression vector construct encoding an HBcAg or an HBsAg, wherein the construct encodes a protein that shares an epitope with the protein-based vaccine; thereby treating the subject; and d) instructions for use in methods of treating a subject having a hepatitis B
infection.
The uses include all of the variations and exemplary RNAi agents, protein-based vaccines, and nucleic acid-based vaccines provided herein. The components of the kit may be provided together, e.g., in a box. In certain embodiments, the components of the invention may be provided separately, e.g., due to different storage requirements, but be provided for use together, e.g., based on .. package instructions for use.
This invention is further illustrated by the following examples which should not be construed as limiting. The entire contents of all references, patents and published patent applications cited .. throughout this application, as well as the Figures, Appendix A, and the Sequence Listing, are hereby incorporated herein by reference.
EXAMPLES
.. Example 1. Materials and methods Exemplaiy iRNAs Exemplary iRNA target sites and unmodified and modified siRNA sequences are provided in the tables in Appendix A.
The chemically modified HBV-siRNA duplexes used in the experiments below have the .. following sequences:
Unmodified sequences:
DuplexID Sense Sequence Unmodified (5' to 3') SEQ Antisense Sequence Umodified (5' to 3') SEQ
ID:
ID:
Modified sequences:
DuplexID SEQ Antisense Sequence Modified (5' to 3') SEQ
Sense Sequence Modified (5' to 3') ID:
ID:
AD-66810 gsusguGfcAfCfUfucgcuucacaL96 37 usGfsugaAfgCfGfaaguGfcAfcacsusu 30 AD-66816 csasccauGfcAfAfCfuuuuucaccuL96 38 asGfsgugAfaAfAfaguuGfcAfuggugsusu Abbreviations for nucleotide monomers in modified nucleic acid sequences are provided in Table 1 of Appendix A.
The target site of AD-66810 is GTGTGCACTTCGCTTCACA (SEQ ID NO: 39) which is nucleotides 1579-1597 of NC_003977.1 (SEQ ID NO: 1).
The target site of AD-66816 is CACCATGCAACTTTTTCACCT (SEQ ID NO: 40) which is nucleotides 1812-1832 of NC_003977.1 (SEQ ID NO: 1).
Cell Culture Evaluation of HBV-siRNA
hNTCP-expressing HepG2 cells were infected (100 multiplicity of infection (MOI)) HBV
particles/cell (subtype ayw)) in duplicate. At day 4 after infection, cells were trypsinized and reseeded into multiwell plates and transfected with control or HBV-siRNAs AD-66810 (having the chemical modifications shown in the table above and sense and antisense sequences as set forth in SEQ ID NOs: 37 and 30, respectively) or AD-66816 (having the chemical modifications shown in the table above and sense and antisense sequences as set forth in SEQ ID NOs: 38 and 32, respectively) each delivered at 100 nM, 10 nM, or 1 nM using Lipofectamine RNAiMax.
Supernatant was harvested at days 3, 6, 10, 13, and 17 after reseeding and HBeAg and HBsAg levels were determined relative to non-transfected control. HBsAg and HBeAg levels were determined using a chemiluminescent microparticle immunoassay (CMIA) measured in an Abbott Architect immunoassay analyzer (Abbott Laboratories, Abbott Park, IL, USA).
Mice, siRNA Administration, and Vaccinations HBV-transgenic mice (StrainHBV1.3xfs (HBV genotype D, subtype ayw)), were derived from in-house breeding under specific pathogen-free conditions following institutional guidelines.
For siRNA administration, mice were subcutaneously administered a 3 mg/kg or 9 mg/kg dose of control siRNA or HBV-siRNA (modified AD-66810 or modified AD-66816);
or intravenously administered by tail vein injection 1 x 10" AAV particles for expression of the HBV-shRNA as indicated in the Figures and Examples below.
For protein vaccinations, mice were immunized subcutaneously with recombinant yeast HBsAg and Escherichia coli HBcAg (APP Latvijas Biomedicinas, Riga, Latvia) mixed with 31.91 lig of synthetic phosphorothioated CpG ODN 1668 and 25 lig poly[di(sodiumcarboxylatoethyl-phenoxy)phosphazene] (PCEP) in 50 I.L1 PBS.
Recombinant MVA were generated by homologous recombination and host range selection as described previously (Staib et al., 2003. Biotechniques. 34:694-700). The entire HBcAg (genotype D, subtype ayw) and HBsAg open reading frames (genotype A, subtype ayw or adw) were cloned into MVA transfer plasmids pIIIAHR-PH5 or pIIIAHR-P7.5, thereby placing the HBV
proteins under the control of the early/late Vaccinia virus-specific promoters PH5 (HBcAg ayw /HBsAg ayw/HBsAg adw) or P7.5 (HBsAg ayw). After construction of each virus, gene expression, sequence of inserted DNA, and viral purity were verified. For generation of vaccine preparations, MVA were routinely propagated in CEF, purified by ultracentrifugation through sucrose, reconstituted in 1 mM Tris-HC1 pH 9.0 and titrated following standard methodology (Staib et al., 2004.
Methods Mol Biol. 269:77-.. 100). For MVA vaccination, mice were vaccinated intraperitoneally with 1 x 108 infectious units of respective recombinant MVA in 500 I.L1 PBS.
Specific dosing regimens are provided in the Examples below and in Figures 3, 7, and 12.
Serological analysis Serum levels of HBsAg and HBeAg were determined in 1:33 dilutions; and anti-HBs levels were determined in a 1:100 dilution using chemiluminescent microparticle immunoassay (CMIA) measured in an Abbott Architect immunoassay analyzer (Abbott Laboratories, Abbott Park, IL, USA).
Quantification of serum HBV titers by real-time polymerase chain reaction and determination of HBV
DNA levels in serum was performed as described in Untergasser et al., 2006 (Hepatology. 43:539-47). The amount of HBV DNA was normalized to DNA level prior to treatment.
Levels of anti-HBc antibodies were determined in 1:20 dilution using the Enzgnost anti-HBc monoclonal test on the BEPIII platform (Both Siemens Healthcare, Eschborn, Germany). If a sample was measured outside the linear range, higher or lower dilutions were used as appropiate.
Quantification of serum HBV titers by real-time polymerase chain reaction and determination of HBV DNA levels in serum was performed as described in Untergasser et al., 2006 (Hepatology.
43:539-47). The amount of HBV DNA was normalized to DNA level prior to treatment.
ALT activity was measured at the day of bleeding in a 1:4 dilution in phosphate buffered saline (PBS) using the Reflotron GPT/ALT test (Roche Diagnostics, Mannheim, Germany).
Lymphocyte stimulation assay Liver-associated lymphocytes (LAL) were isolated as described in Stross et al., 2012 (Hepatology 56:873-83) and stimulated with H2-kb-or H-2Db-restricted peptides (see Backes, 2016) for 12 hours in the presence of 1 mg/ml Brefeldin A (Sigma-Aldrich, Tauflcirchen,Germany). Cells were live/dead-stained with ethidium monoazidebromide (Invitrogen , Karlsruhe, Germany) and blocked with anti-CD16/CD32-Fc-Block (BD Biosciences, Heidelberg, Germany).
Surface markers were stained with PB-conjugated anti-CD8-alpha and PE-conjugated anti-CD4 (eBiosciences, Eching, Germany). Intracellular cytokine staining (ICS) was performed with FITC anti-IFN-gamma (XMG1.2), PE-Cy7 anti-TNF-alpha and APC anti-IL-2 (eBiosciences, Ech-ing, Germany) using the Cytofix/Cytoperm kit (BD Biosciences, Heidelberg, Germany) according to the manufacturer's recommendations. The same data were analyzed twice, the second time with a more rigorous exclusion of dead cells.
Immunohistochemical stainings for HBc-expressing hepatocytes Livers were harvested, fixed in 4% paraformaldehyde, and paraffin-embedded.
The liver was sectioned (2 [tin) and sections were stained with rabbit anti-HBcAg as the primary antibody (Diagnostic Biosystems, Pleasanton, CA; #RP 017; 1:50 dilution; retrieval at 100 C for 30 min with EDTA) and a horseradish peroxide coupled secondary antibody. Incubation in Ventana buffer and staining were performed on a NEXES immunohistochemistry robot (Ventana Instruments) using an IVIEW DAB Detection Kit (Ventana Instruments) or on a Bond MAX (Leica Biosystems). For analysis, slides were scanned using a SCN 400 slide scanner and positive cells were counted using the integrated Tissue AT software (both Leica Biosystems).
HBV transcripts from liver lysate For analysis of HBV RNA from liver lysate, RNA was extracted from 30 mg liver tissue with the RNeasy mini kit (Qiagen) and cDNA was synthesized with the Superscript III
kit (Thermo Fisher Scientific). HBV transcripts were amplified with primers specific for only the 3.5 kb transcripts (forward primer 5'- GAGTGTGGATTCGCACTCC-3' (SEQ ID NO: 41); reverese primer 5'-GAGGCGAGGGAGTTCTTCT-3' (SEQ ID NO: 42)), or with primers binding to the common 3 end of all HBV transcripts (forward primer 5'- TCACCAGCACCATGCAAC-3' (SEQ ID NO:
43);
reverse primer 5'- AAGCCACCCAAGGCACAG-3' (SEQ ID NO: 44)) (Denaturation: 95 C
5 min;
Amplification: 95 C 3s, 60 C 30s (40 cycles)) (Yan et al., 2012). Results were normalised to murine GAPDH expression (forward primer 5'- ACCAACTGCTTAGCCC-3' (SEQ ID NO: 45);
reverse primer 5'- CCACGACGGACACATT-3' (SEQ ID NO: 46)) (Denaturation: 95 C 5 min;
Amplification: 95 C 15s, 60C 10s, 72 C 25s (45 cycles)). All PCR reactions were performed on a LightCycler 480 (Roche Diagnostics).
AAV-HBV mouse model For the AAV mouse model, wildtype C57/B16 mice (9 weeks of age; 6 animals per treatment group) were injected i.v. with 2x101 genome equivalents (geq) of Adeno-Associated-Virus Serotype 8 (AAV8) carrying a 1.2-fold overlength HBV genome of genotype D (AAV-HBV1.2) (day -28) (see, e.g., Yang, et al. (2014) Cell and Mol Immunol 11:71) . Starting 4 weeks after AAV-transduction (day 0), animals were treated with 3 injections (3 mg/kg bw, n=12 per group) of either a control siRNA, or HBV siRNA (AD-66816 or AD-66810) (days 0, 29, and 57). Each siRNA
treatment group was divided into two groups (n = 6 per group) to be not treated or treated with the vaccine regimen consisting of recombinant HBsAg, HBcAg (15 tig of each) and 10 tig c-di-AMP
given at day 57 and 70 and boosted with MVA-HBs and MVA-HBc (5x107 geq of each) at day 84. A
schematic showing the treatment regimen is provided in Figure 12.
Example 2¨ Evaluation of HBV-siRNA in HepG2-NTCP Cell Culture and Dose Finding Experiments in HBVxfs Mice Anti-HBV siRNAs were evaluated for efficient knockdown of HBV antigens and DNA
in an in vitro infection model using HBV-infected HepG2-NTCP cells treated with 1 nM, 10 nM, or 100 nM of one of modified AD-66810 or modified AD-66816 HBV-siRNA, or a control siRNA as provided above. Supernatants were collected at days 3, 6, 10, 13, and 17 days after siRNA treatment and assayed for HBeAg and HBsAg levels as compared to untransfected control.
Both HBV-siRNAs were demonstrated to effectively knockdown expression of both HBeAg and HBsAg with the highest levels of knockdown observed at days 13 and 17. No significant knockdown was observed with the control siRNA. These data demonstrate that the AD-66810 or AD-66816 HBV-siRNAs are effective at knocking down expression of HBV antigens in a sustained manner in an in vitro system of HBV
infection.
The HBV and control siRNAs were then tested in the HBVxfs transgenic model of chronic hepatitis B. The HBVxfs mice include an integrated HBV genome that is expressed under the control of a liver-specific promoter. At about 10 weeks of age, mice were administered a 3 or 9 mg/kg dose of one of AD-66810 or AD-66816 HBV-siRNA or a control siRNA (n = 6 per group).
Blood samples were collected at days 6, 13, and 21 after siRNA treatment and serum was prepared. HBeAg, HBsAg, and HBV DNA levels in serum (Figures 2A-2C) were determined as provided above.
Further, RNA
was isolated from liver and total HBV RNA and HBV 3.5 kB transcript levels were detected using the method of Yan, 2012 and normalized to GAPDH expression (Figures 2D and 2E).
Both of the HBV-siRNAs at both doses were demonstrated to effectively knockdown expression of HBsAg and HBeAg and to decrease HBV DNA levels in serum as compared to control levels (see Figures 2A-2C). Futher, total liver HBV RNA relative to GAPDH DNA
and 3.5 kb HBV
RNA relative to GAPDH RNA levels were strongly decreased by both doses of the HBV siRNAs as compared to control levels (Figures 2D and 2E). Based on these results, the 3 mg/kg dose was selected for use in further experiments.
Example 3 ¨ Comparison of Reducing Antigen Load with siRNA to Nucleot(s)ide Analogs Prior to Therapeutic Vaccine Administration in an HBV Transgenic Mouse Model Having demonstrated that siRNA targeted to HBV can effectively knockdown expression of HBsAg and HBeAg and decrease HBV DNA levels in serum in the HBVxfs mouse model, the effect of treatment of mice with the nucleoside analog Entecavir or HBV-siRNA prior to therapeutic vaccine administration using a prime-boost regimen was tested. The treatment scheme is shown in Figure 3.
Mice were pretreated with one of six treatment regimens prior to vaccination using a prime-boost regimen (n= 6 per group):
(1) No pretreatment;
(2) Entecavir at 1 lig/m1 in water throughout the course of the study beginning on the first day of Week 0 (expected dose of about 4 mg/day based on calculations provided in Liitgehetmann et al., 2011, Gastroenterology.140:2074-83);
(3) A 3 mg/kg dose on the first day of Weeks 0, 4, 8, and 12 of the control iRNA agent.
(4) A single dose on the first day of Week 0 with an expression vector encoding an shRNA
targeted to HBV (HBV-shRNA) (Michler et al., 2016); or (5-6) A 3 mg/kg dose on the first day of Weeks 0, 4, 8, and 12 of modified AD-66816 or modified AD-86610 (generically HBV-siRNA).
On the first day of Weeks 12 and 14, a mixture of recombinantly expressed yeast HBsAg (15 rig) and E. coli expressed HBcAg (15 rig) adjuvanted with 31.9 lig synthetic phosphorothioated CpGODN 1668 (CpG) and 25 lig polykli(sodiumcarboxylatoethyl-phenoxy)phosphazene] (PCEP) was subcutaneously administered to all mice as a protein-prime vaccination (Backes, 2016).
On the first day of week 16, a mixture of modified vaccinia viruses Ankara expressing HBsAg or HBcAg (5 x 107 particles of each virus) was subcutaneously administered to all mice as a boost vaccination (Backes, 2016).
Blood samples were obtained on the first days of Week 0, 2, 4, 8, 12, 16, and 17 and serum samples prepared therefrom were assayed for levels of HBsAg, HBeAg, and HBV
DNA. Results are shown in Figure 4.
HBsAg and HBeAg levels mice in groups 1, 2, and 3 (mock, Entecavir, control iRNA agent) were similar. The HBV-shRNA or HBV-siRNAs (AD-66816 or AD-86610) alone caused a significant decrease in HBsAg, HBeAg, and HBV DNA in serum (Figures 4A-4C).
The three dose prime-boost vaccination scheme resulted in a further decrease in HBsAg in all groups, and reduced the level of HBsAg in at least some animals in the HBV-shRNA and HBV-siRNA
groups to below the level of detection. However, vaccine treatment did not decrease HBeAg levels in any of the groups. Without being bound by mechanism, it is proposed that the decrease in HBsAg, but not HBeAg, results from the immune response induced by the vaccine against the s antigen, but not the e antigen, which is produced by proteolytic processing of the C protein (see Figure 5 discussed below).
HBV DNA levels were decreased to about the lower limit of quantitation with Entecavir alone so no effect of the three dose prime-boost vaccine could be detected (Figure 4C). Mock treatment and treatment with the HBV-shRNA, the HBV-siRNAs, and control siRNA all decreased HBV DNA
levels and the level of HBV-DNA was further decreased by the prime-boost vaccine in all groups. It is unclear why the mock treatment and control siRNA decreased HBV DNA levels in this experiment.
No decrease in HBV DNA was observed in response to treatment with control siRNA in other experiments (see, e.g., Figures 2C and 8C). These data demonstrate that RNAi is superior to nucleot(s)ide analog therapy in reducing viral antigens. Also, RNAi and subsequent vaccination have a combined effect on HBsAg and HBV DNA levels greater than either agent alone.
On the final day of the experiment (first day of Week 17), mice were sacrificed and their livers harvested. Liver associated lymphocytes were isolated from liver and after peptide stimulation CD8+ T cell responses measured via intracellular cytokine staining.
Specifically, intrahepatic CD8+
T cell responses were assessed for response to HBsAg, HBcAg, and the MVA virus particle using the method provided in Backes, 2016. The data were analyzed twice using two different thresholds for the exclusion of dead immune cells as the exclusion of dead immune cells in the first analysis provided in Figures 5A-5C was determined to be insufficient. The second analysis is presented in Figures 5D-5F. The second analysis confirmed the conclusions from the first analysis.
Mice pretreated with the HBV-shRNA or the HBV-siRNAs before vaccination were able to generate a CD8+ T cell immune response against the HBsAg and HBcAg (Figures 5A, 5B, 5D, and 5E) indicating that cytotoxic T cells able to clear HBV infection are induced when HBV antigen levels are suppressed prior to vaccination. No significant CD8+ T cell immune response against the HBV antigens was observed in the mock, Entecavir, or control siRNA groups. A
significant and similar CD8+ T cell immune response against the MVA virus in all animals, independent of pretreatment or viral antigen levels, demonstrated that vaccination had worked equally well in all animals and was not influenced by HBV antigen levels, thereby demonstrating the presence of a competent immune system (Figures 5C and 5F). No significant differences in antibody production were observed between mock treated animals and any of the other groups indicating that high HBV
antigen levels may induce T cell tolerance.
These data demonstrate that RNAi treatment, in contrast to the current standard of care treatment with a nucleoside analog, can restore HBV-specific T cell immunity in the liver and enable the induction of HBV-specific CD8+ T cell responses after therapeutic vaccination. A robust CD8+
effector T cell response has been associated with viral clearance and functional cure (see, e.g., Thimme et al., 2003. J. Virol. 77:68-76, and Backes et al., 2016. Vaccine.
34:923-932).
RNA was also isolated from liver and total HBV RNA and HBV 3.5 kB transcript levels were detected using the method of Yan, 2012 and normalized to GAPDH expression.
Treatment of mice with HBV-siRNA or HBV-shRNA prior to vaccine administration resulted in a significant decrease in HBV total RNA and HBV 3.5 kb transcript as compared to the mock treated control (Figures 6A and 6B). No significant change in HBV total RNA and HBV 3.5 kb transcript was observed in the mice treated with Entecavir or the control siRNA prior to vaccination as compared to the mock treated control. These data demonstrate that both HBV siRNAs and the shRNA, in contrast to the control and Entecavir groups, successfully led to a decrease in HBV transcript levels.
Further, expression of HBV antigens in the liver was analyzed by immunohistochemical staining for HBc of liver sections and counting of HBc positive cells per mm2 (Figure 6C). Only groups of animals pre-treated with HBV siRNA or shRNA, but not Entecavir or the control siRNA, showed reduced HBc expression following vaccination.
Throughout the experiment, body weight and ALT levels were monitored. No significant differences were observed in any of the treatment groups as compared to mock treated control.
Example 4 ¨ Evaluation of the Effect of Duration of HBV Antigen Knockdown on Response to Immunization in an HBV Transgenic Mouse Model Having demonstrated that suppression of expression of HBV antigens using shRNA
or siRNA
is effective at potentiating an immune response to an HBV vaccine regimen, a study was designed to determine if the length of time of HBV antigen suppression had an effect on potentiation of an HBV
immune response. A treatment scheme is shown in Figure 7.
Using the HBV1.3xfs mouse model, mice were treated for eight, six, or three weeks with HBV-siRNA AD-66816 (modified) or the control siRNA for 8 weeks, administered subcutaneously at 3 mg/kg/dose. siRNA administration was followed by administration of the prime-boost vaccine regimen as set forth above with the exception that c-di-AMP was used as an adjuvant with protein administration rather than PCEP + CPG (n= 6 per group). Therefore, mice in the 8 week group (n =
6) received three doses of siRNA with the third dose being administered on the first day of vaccine administration. The mice in the 6 week group (n = 12) received two doses of siRNA with the second dose being administered two weeks prior to the first day of vaccine administration. Finally, the mice in the 3 week group (n = 6) received one dose of siRNA with the dose being administered three weeks prior to the first day of vaccine administration.
Blood samples were collected on the first day of -8 weeks, -6 weeks, -4 weeks, -2 weeks, 0 weeks, 2 weeks, 4 weeks, and 6 weeks, before (negative numbers) and after the first dose of vaccine administration on the first day of Week 0. Serum was prepared and HBsAg, HBeAg, and HBV DNA
levels were assessed as provided above.
A significant decrease in each HBsAg, HBeAg, and HBV DNA was observed after the first administration of AD-66816 (Figures 8A-8C). A further significant decrease in HBsAg was observed after treatment with the vaccine boost, with the greatest decrease observed in the 8 week pretreatment group to below the level of detection of the assay, representing a greater than 5 10g10 decrease in HBsAg level in all treated animals. Immunization caused only slight further reductions (<0.5 10g10) of HBV DNA which had been significantly decreased by the siRNA treatment. No further decrease in HBeAg levels was observed in response to the vaccination regimen.
These data demonstrate that efficacy of therapeutic vaccination correlates with duration of antigen suppression before start of vaccination. Reconstitution of HBV-specific CD8+ T cell responses takes several weeks, with a 6 or preferably 8 week pretreatment rather than a 3 week pretreatment.
On the final day of the experiment, on the first day of Week 6 after the start of immunization, mice were sacrificed and their livers harvested for six mice from each group.
Liver associated lymphocytes were isolated and a lymphocyte stimulation assay was performed as provided above.
Specifically, intrahepatic CD8+ T cell responses were assessed for response to HBsAg, HBcAg, and the MVA virus particle using the method provided in Backes, 2016. T-cell responses against HBsAg and HBcAg in liver corresponded with the duration of HBV antigen knockdown, with a trend of higher levels of immune response observed with longer duration of HBV antigen resulting in greater T-cell response (see Figures 9A-9C). Similar responses to MVA virus antigens were observed across all groups, independent of pretreatment, showing that vaccination had worked equally well in all animals and was not influenced by HBV antigen levels demonstrating the presence of a competent immune system (Figure 9D). No significant differences in antibody production were observed between control siRNA treated animals and any of the other groups. This demonstrates, that reconstitution of HBV-specific CD8+ T cell responses does not occur immediately, with stronger responses seen after therapeutic vaccination if animals had lowered HBV
antigen titers for at least 6 or 8 weeks compared to only 3 weeks. It further confirms the previous finding that, in contrast to T cell responses, B cell immunity does not seem to be significant influenced by HBV
antigen titers.
RNA was also isolated from liver and total HBV RNA and HBV 3.5 lcB transcript levels were detected using the method of Yan, 2012 and normalized to GAPDH expression.
Treatment of mice with HBV-siRNA AD-66816 prior to vaccine administration resulted in a significant decrease in HBV
total RNA and HBV 3.5 kb transcript in liver lysates as compared to the control siRNA treated control (Figures 10A and 10B). Further, HBV antigen expression in the liver was analyzed by immunohistochemical staning and counting of HBc positive cells per mm2 (Figure 10C). Correlating the observed increase in HBV-specific CD8 responses with increased duration of siRNA pretreatment, decreased numbers of HBc expressing cells where observed in the liver. These results demonstrate that the CD8+ T cell responses did prevent antigen expression in the liver..
To assess the durability of response, blood samples were collected from mice pretreated with the AD-66816 HBV-siRNA using the six week treatment regimen at 2 and 3 weeks after administration of the boost vaccination (Figures 11A-11D). In three of the six mice, HBsAg levels continued to drop to below the level of detection of the assay (Figure 11A).
No similar decrease in HBeAg levels were observed during the course of the experiment (Figure 11B).
These data show that the maximum effect by the siRNA-vaccination combinatorial therapy provided herein is later than 1 week after the MVA vaccination, which was chosen as termination time point to best asses CD8+ T
cell responses. Anti-HBs antibody response (Figure 11C) and T cell immune response in the liver against HBs(5208) (Figure 11D) at week 7 after the first vaccine dose after the 6 week regimen in the dosing regimen. The antibody response varied among animals.
These data demonstrate that a functional cure is possible using the treatment regimens provided herein. Further, these data suggest that a lower HBsAg and HBeAg burden can result in a greater level of immune clearance of HB antigens and potentiate an immune response, at least within the short time course of the experiment.
Throughout the experiment, body weight and ALT levels were monitored. No significant differences were observed in any of the treatment groups as compared to mock treated control.
Example 5 ¨ Evaluation of the Effect of Duration of HBV Antigen Knockdown on Response to Immunization in an AAV-HBV Mouse Model Having demonstrated the efficacy of the siRNA-vaccine combination treatment regimen in a transgenic mouse model, an AAV-HBV infection mouse model was used to study the efficacy of the treatment regimen in acquired infection model (see, e.g., Yang, et al. (2014) Cell Mol Immunol
11:71). This mouse model exhibits sustained HBV viremia after infection with a recombinant adeno-associated virus (AAV) carrying a replicable HBV genome.
There are a number of differences between the HBV-transgenic and AAV-HBV mouse models. The HBV transgenic mice can express HBV antigens essentially from birth, whereas the AAV-HBV model allows for the introduction of the HBV genome at a later time in the life of the mice. This may have an effect on immune tolerance. Further, the HBV transgenic mice carry the transgene in every cell of the body, providing the possibility of "leaky"
extrahepatic expression.
Although the AAV8 serotype could infect cells outside of the liver, it has a strong liver tropism.
Moreover, it is not possible to clear an HBV infection in a transgenic mouse.
When a transgenic HBV expressing liver cell is killed, it is replaced by a new HBV expressing cell. In the infection model, if the infected cells are killed, the newly dividing cells are not infected at the time of cell division.
Nine week old C57/B16 mice were infected with AAV-HBV (- 28 days). Mice were then treated with one of control siRNA, or one of two HBV-siRNAs, modified AD-66816 or modified AD-66810 at 3 mg/kg administered subcutaneously on days 0, 29, and 57 (i.e., 0 weeks, 4 weeks, 8 weeks) (n=12 per group). Each siRNA treatment group was divided into two groups (n=6 per group). One group was treated with the HBV vaccine protocol (protein prime on days 57 and 70, and MVA boost on day 84, i.e., weeks 8, 10, and 12, respectively) and one group was not. A
schematic showing the dosing regimen is provided in Figure 12. Mice were monitored throughout the experiment for serum HBsAg, HBeAg, anti-HBs antibodies, body weight, and ALT. Anti-HBe antibody levels were also periodically tested.
Figures 13A and 13B show an increase in HBsAg and HBeAg levels comparable to that seen in transgenic mice within two weeks of transduction with the AAV-HBV virus.
Mice treated only with the control siRNA replicated HBV for greater than 8 months at levels comparable to chronically infected humans (HBsAg levels around 2,000 IU/ml, HBV viremia 106107 IU/ml).
HBV siRNAs AD-66816 and AD-66810 reduced HBsAg by 2 and 2.5 logio, respectively, and HBeAg by >1 logio.
The effect persisted for at least 4 weeks after stopping siRNA treatment before antigenemia slowly rebounded to baseline levels after 18 weeks (Figures 13A and13B).
Intrahepatic HBV DNA (Figure 13D) and AAV DNA (Figure 13E) levels were determined at week 22 by qPCR as described above. The relative expression in liver of HBV
3.5 RNA relative to GAPDH RNA (Figure 13F) and total HBV RNA relative to GAPDH RNA (Figure 13G) were determined using rtPCR. Mice treated with the combined siRNA-vaccine protocol demonstrated a significant decrease in total HBV DNA and AAV DNA as compared to untreated control or siRNA or vaccine treatement alone at the 22 week time point (Figures 13D and 13E).
Notably, total HBV DNA
levels dropped to less than one copy per cell as a result of the combination treatment (Figure 13D).
Mice treated with the combined siRNA-vaccine protocol also demonstrated a significant decrease level of HBV 3.5 kb RNA expression relative to GAPDH RNA expression as compared to all other treatment regimens (Figure 13F). A significant decrease in total HBV RNA
relative to GAPDH RNA
expression was observed as compared to treatment with vaccine or siRNA alone (Figure 13G). These data suggest that a short course of administration of siRNA alone or a therapeutic vaccine against HBV is insufficient to durably suppress HBV infection. Immune mediated control of HBV after siRNA knockdown of HBV expression is long lasting. At 22 weeks after the last siRNA dose, the .. effect of the siRNA was waning as seen in the groups which had only received the HBV siRNAs without vaccination. Mice treated with the siRNA-vaccine protocol maintained HBV DNA and RNA
suppression long after the end of siRNA administration.
No immune responses were observed in these fully immune competent mice under siRNA
treatment alone, but vaccine treatment resulted in anti-HBs seroconversion in all vaccinated animals (Figures 14A and 14B). siRNA-pretreated animals, however, developed 10-fold higher and more constant anti-HBs titers and were able to completely and persistently clear serum HBsAg and HBeAg.
In contrast, anti-HBe seroconversion was only observed in antimals pretreated with HBV siRNAs.
Interestingly, three of the 12 mice vaccinated after HBV siRNA treatment showed a transient relapse of HBeAg between week 15 and 22 co-inciding with decreased levels of anti-HBe (Figure 13C).
Without being bound by mechanism, it is proposed that theHBeAg relapse was controlled by a memory immune response induced by the vaccine. Taken together, suppression of HBV antigen expression by an siRNA in combination with a heterologous prime-boost vaccine is sufficient to break immune tolerance to HBV antigens. The sequential therapy achieved long-term functional cure in a mouse model of persistent HBV infection without causing significant liver damage.
Figures 14A and 14B show that animals treated with HBV siRNA plus the vaccine regimen developed high titers of anti-HBs antibodies and anti-HBe antibodies. The level of anti-HBs antibodies continued to increase after the last vaccine dose. Although anti-HBs antibodies could also be measured in animals that received the control siRNA plus the vaccine regimen, the levels were significantly lower. Further, only animals that received HBV siRNA plus the vaccine regimen developed anti-HBe antibodies and achieved anti-HBe seroconversion. The combinatorial therapy using siRNA and vaccine appeared to be well tolerated. All mice equally gained weight and only a mild ALT elevation (<2-fold upper limit of normal) was observed (Figures 15A
and 15B). The loss of antigenemia concided with slight increases of ALT activity seen in treatment groups which had received HBV siRNA in conjunction with the vaccination regimen (Figure 15A).
These groups showed significant but mild increases (both p>0.05 or smaller by repeated measure two-way ANOVA; only comparing time points after start of vaccination) as compared to all other treatment groups that did not receive the combination HBVsiRNA-vaccine regimen. There was a steady increase in body weight in all animals throughout the experiment independent of siRNA treatment.
Animals that were vaccinated showed a slight and transient decrease (approximately 5%) of body weight after vaccination, but rebounded to normal levels within nine days and subsequently gained weight comparable to the control groups (Figure 15B).
Without being bound by mechanism, the data provided herein strongly suggest that the high level of HBV antigen expression routinely detected as circulating HBsAg and HBeAg prevents HBV-specific CD8+ T cell responses, which has far reaching consequences for future immune therapy of chronic hepatitis B. Using 2 different mouse models for chronic hepatitis B, it is proposed that HBV-specific immunomodulation can be reverted by suppressing HBV protein expression in hepatocytes using an RNAi-based therapy. Such reduction of HBV antigens by RNAi, in contrast to standard-of-care nucleo(t)side analogues, allows for induction of strong HBV-specific CD8+
T cell responses by therapeutic vaccination that are required for control of HBV infection.
APPENDIX A
Table 1. Abbreviations of nucleotide monomers used in nucleic acid sequence representation. It will be understood that, unless otherwise indicated, these monomers, when present in an oligonucleotide, are mutually linked by 5'-3'-phosphodiester bonds.
Abbreviation Nucleotide(s) A Adenosine-3'-phosphate Af 2'-fluoroadenosine-3' -phosphate Afs 2'-fluoroadenosine-3'-phosphorothioate As adenosine-3' -phosphorothioate cytidine-3' -phosphate Cf 2'-fluorocytidine-3' -phosphate Cfs 2'-fluorocytidine-3'-phosphorothioate Cs cytidine-3'-phosphorothioate guanosine-3'-phosphate Gf 2'-fluoroguanosine-3' -phosphate Gfs 2'-fluoroguanosine-3'-phosphorothioate Gs guanosine-3'-phosphorothioate 5'-methyluridine-3' -phosphate Tf 2'-fluoro-5-methyluridine-3' -phosphate Tfs 2'-fluoro-5-methyluridine-3'-phosphorothioate Ts 5-methyluridine-3'-phosphorothioate Uridine-3'-phosphate Uf 2'-fluorouridine-3' -phosphate Ufs 2'-fluorouridine -3'-phosphorothioate Us uridine -3' -phosphorothioate any nucleotide (G, A, C, T or U) a 2'-0-methyladenosine-3' -phosphate as 2'-0-methyladenosine-3'- phosphorothioate 2'-0-methylcytidine-3'-phosphate cs 2'-0-methylcytidine-3'- phosphorothioate 2'-0-methylguanosine-3'-phosphate gs 2'-0-methylguanosine-3'- phosphorothioate 2'-0-methyl-5-methyluridine-3' -phosphate ts 2'-0-methyl-5-methyluridine-3'-phosphorothioate 2'-0-methyluridine-3'-phosphate us 2'-0-methyluridine-3'-phosphorothioate phosphorothioate linkage Abbreviation Nucleotide(s) L96 N-Itris(Ga1NAc-alkyl)-amidodecanoy1)]-4-hydroxyprolinol Hyp-(GalNAc-alky1)3 (dT) T -deoxythymidine-3 -phosphate Y34 2-hydroxymethyl-tetrahydrofurane-4-methoxy-3-phosphate (abasic 2'-0Me furanose) Y44 2-hydroxymethyl-tetrahydrofurane-5-phosphate (Agn) Adenosine-glycol nucleic acid (GNA) (Tgn) Thymidine-glycol nucleic acid (GNA) S-Isomer (Cgn) Cytidine-glycol nucleic acid (GNA) P Phosphate VP Vinyl-phosphate Table 2. Exemplary Unmodified Sense and Antisense Strand Sequences of HBV
dsRNAs (Activity data available in W02016/077321, incorporated herein by reference) n.) o 1-, oe Duplex Sense Oligo SEQ Antisense SEQ ID Position in Sense Sequence (5' to 3') Antisense Sequence (5' to 3') vD
Name Name ID NO Oligo Name NO: NC_003977.1 vi 1-, c:
263 731_753 vi 264 373_395 265 250_272 266 250_272 267 250_272 268 250_272 252_274 P
270 250_272 c, 271 250_272 272 250_272 .
c, 273 250_272 , ,-, UGAGAGAAGUCCACCACGA 274 254_276 , c, .3 275 250_272 252_274 277 250_272 278 250_272 279 250_272 280 250_272 Iv n 252_274 1-3 282 250_272 cp n.) 283 250_272 o 1-, oe 284 250_272 t..) oe UGAGAGAAGUCCACCACGA 285 254_276 1-, c:
286 250_272 ME1 27037625v.1 Duplex Sense Oligo SEQ Antisense SEQ ID Position in Sense Sequence (5' to 3') Antisense Sequence (5' to 3') Name Name ID NO Oligo Name NO: NC_003977.1 UGAGAGAAGUCCACCACGAUU 287 252_274 0 n.) UGAGAGAAGUCCACCACGAGUCU 288 250_272 oe UGAGAGAAGUCCACCACGAGUCU 289 250_272 vi UGAGAGAAGUCCACCACGAGUCU 290 250_272 c:
vi UGAGAGAAGUCCACCACGAGUCU 291 250_272 UGAGAGAAGUCCACCACGAGUCU 292 250_272 UGAGAGAAGUCCACCACGAGUCU 293 250_272 UGAGAGAAGUCCACCACGAGUCU 294 250_272 UGAGAGAAGUCCACCACGAGUCU 295 250_272 UGAGAGAAGUCCACCACGAGUCU 296 250_272 UGAGAGAAGUCCACCACGAGUCU 297 250_272 Q
UGAGAGAAGUCCACCACGAGUCU 298 250_272 u, UGAGAGAAGUCCACCACGAGUCU 299 250_272 .
'-c->
.
UGAGAGAAGTCCACCACGAGUCU 300 250_272 " , ' AD -63975 A-127915 ACUCGUGGUGGACUUCTCUCA
301 250_272 , .
, UGAGAGAAGUCCACCACGAGUCU 302 250_272 ' .3 UGAGAGAAGUCCACCACGAGUCU 303 250_272 UGAGAGAAGUCCACCACGAGUCU 304 250_272 UGAGAGAAGUCCACCACGAGUCU 305 250_272 UGAGAGAAGUCCACCACGAGUCU 306 250_272 UGAGAGAAGUCCACCACGAGUCU 307 250_272 UGAGAGAAGUCCACCACGAGUCU 308 250_272 Iv n UGAGAGAAGUCCACCACGAGUCU 309 250_272 cp AAAUUGAGAGAAGUCCACCACGA 310 254_276 n.) 1¨, AAAUUGAGAGAAGUCCACCACGA 311 254_276 0 e AAAUUGAGAGAAGUCCACCACGA 312 254_276 n.) oe 1¨, AAAUUGAGAGAAGUCCACC 313 258_280 cr ME1 27037625v.1 Duplex Sense Oligo SEQ Antisense SEQ ID Position in Sense Sequence (5' to 3') Antisense Sequence (5' to 3') Name Name ID NO Oligo Name NO: NC_003977.1 314 254_276 0 n.) 256_278 1--, oe 316 254_276 1--, vi 317 254_276 1--, c:
vi 318 254_276 256_278 320 254_276 256_278 322 254_276 323 254_276 AAAUUGAGAGAAGUCCACC 324 258_280 Q
325 254_276 u, 256_278 .
'-c->
.
t.) AD-64003 A-127964 GUGGUGGACUUCUCUCAAUUU 111 A-127956 AAAUUGAGAGAAGUCCACCACGA 327 254_276 " , ' AD-64004 A-127955 GUGGUGGACUUCUCUCAAUUU 112 A-127972 AAAUUGAGAGAAGUCCACCACGA
328 254_276 , .
, 329 254_276 .3 330 254_276 331 254_276 332 254_276 333 254_276 334 254_276 335 254_276 Iv n 336 254_276 cp 337 254_276 n.) 1--, 338 254_276 0 e 339 254_276 n.) oe 1--, 340 254_276 1--, cr ME1 27037625v.1 Duplex Sense Oligo SEQ Antisense SEQ ID Position in Sense Sequence (5' to 3') Antisense Sequence (5' to 3') Name Name ID NO Oligo Name NO: NC_003977.1 341 254_276 0 n.) 342 254_276 1--, oe 343 254_276 1--, vi 344 254_276 1--, c:
vi 345 254_276 346 254_276 347 254_276 348 254_276 349 254_276 350 254_276 351 254_276 Q
256_278 u, 353 254_276 .
'-c->
.
w AD-64272 A-128001 GUGCACUUCGCUUCACCUCUG 138 A-128002 CAGAGGUGAAGCGAAGUGCACAC
354 1577_1599 " , ' AD-64274 A-128363 GUUGACAAAAAUCCUCACAAU 139 A-128364 AUUGUGAGGAUUUUUGUCAACAA
355 215_237 , .
, 356 214_236 ' .3 357 256_278 358 2259_2281 359 2259_2281 360 1857_1879 361 1255_1277 362 375_397 Iv n 363 1545_1567 cp 364 1831_1853 n.) 1--, 365 245_267 0 e 366 1256_1278 n.) oe 1--, 367 207_229 1--, cr ME1 27037625v.1 Duplex Sense Oligo SEQ Antisense SEQ ID Position in Sense Sequence (5' to 3') Antisense Sequence (5' to 3') Name Name ID NO Oligo Name NO: NC_003977.1 UAGAAGAACCAACAAGAAGAUGA 368 426_448 0 n.) AUUUUUGUCAACAAGAAAAACCC 369 206_228 1--, oe UAACAAGAGAUGAUUAGGCAGAG 370 1829_1851 1--, vi UACUCUGUGGUAUUGUGAGGAUU 371 226_248 1--, c:
vi UUGAGGAUUUUUGUCAACAAGAA 372 212_234 AGGCAGAGGUGAAAAAGUUGCAU 373 1814_1836 UAUGCUGUAGCUCUUGUUCCCAA 374 2828_2850 AAUUGAGAGAAGUCCACCAGCAG 375 253_275 UAAGAUGAGGCAUAGCAGCAGGA 376 411_433 AACGCCGCAGACACAUCCAACGA 377 370_392 UAGGCAUAGCAGCAGGAUGAAGA 378 405_427 Q
UAGGAUUUUUGUCAACAAGAAAA 379 210_232 u, UAAUACCACAUCAUCCAUAUAAC 380 734_756 .
'-c->
.
-i. AD -64303 A-128429 UUCAUCCUGCUGCUAUGCCUC 165 A-128430 GAGGCAUAGCAGCAGGAUGAAGA 381 405_427 " , ' AD -64304 A-128443 GUGCACUUCGCUUCACCUCUA
382 1577_1599 , .
, UAUUGUGAGGAUUUUUGUCAACA 383 216_238 ' .3 UAAGGCACAGCUUGGAGGCUUGA 384 1864_1886 UAUAGCAGCAGGAUGAAGAGGAA 385 401_423 AAGAUGAGGCAUAGCAGCAGGAU 386 410_432 AGAAGAACCAACAAGAAGAUGAG 387 425_447 UAGAUGAGAAGGCACAGACGGGG 388 1547_1569 AGAACCAACAAGAAGAUGAGGCA 389 422_444 Iv n UAAGAUAGGGGCAUUUGGUGGUC 390 2298_2320 cp AGUAUGGAUCGGCAGAGGAGCCA 391 1250_1272 n.) 1--, AUUGUGAGGAUUUUUGUCAACAA 392 215_237 0 e UUGUGAGGAUUUUUGUCAACAAG 393 214_236 n.) oe 1--, UAAAAUUGAGAGAAGUCCACCAC 394 256_278 1--, cr ME1 27037625v.1 Duplex Sense Oligo SEQ Antisense SEQ ID Position in Sense Sequence (5' to 3') Antisense Sequence (5' to 3') Name Name ID NO Oligo Name NO: NC_003977.1 395 2259_2281 0 n.) 396 2259_2281 1--, oe 397 1857_1879 1--, vi 398 1255_1277 1--, c:
vi 399 731_753 400 375_397 401 1545_1567 402 1831_1853 403 245_267 404 1256_1278 405 426_448 Q
406 263_285 u, 407 250_272 .
'-c->
.
(.., AD-64332 A-128001 GUGCACUUCGCUUCACCUCUG 192 A-128485 CAGAGGUGAAGCGAAGUGCACAC 408 1577_1599 " , ' AD-64333 A-128367 GUUUUUCUUGUUGACAAAAAU 193 A-128448 AUUUUUGUCAACAAGAAAAACCC
409 206_228 , .
, 410 1829_1851 .3 411 226_248 412 212_234 413 254_276 414 1814_1836 415 2828_2850 416 424_446 Iv n 417 411_433 cp 418 370_392 n.) 1--, 419 405_427 0 e 420 210_232 n.) oe 1--, 421 373_395 1--, cr ME1 27037625v.1 Duplex Sense Oligo SEQ Antisense SEQ ID Position in Sense Sequence (5' to 3') Antisense Sequence (5' to 3') Name Name ID NO Oligo Name NO: NC_003977.1 422 734_756 0 n.) 423 405_427 oe 424 1577_1599 vi 425 216_238 c:
vi 426 1174_1196 427 1174_1196 428 1864_1886 429 401_423 430 410_432 431 425_447 432 1547_1569 Q
433 422_444 u, 434 2298_2320 .
'-c->
.
cs, AD-64360 A-128433 GCUCCUCUGCCGAUCCAUACU 219 A-128482 AGUAUGGAUCGGCAGAGGAGCCA 435 1250_1272 " , ' AD-64700 A-129379 ACUCGUGGUGTACUUCUCUCA 220 A-127906 UGAGAGAAGUCCACCACGAGUCU
436 250_272 , .
, 437 250_272 ' .3 438 250_272 439 250_272 440 250_272 441 250_272 442 250_272 443 250_272 Iv n 444 250_272 cp 445 250_272 n.) 1¨, 446 250_272 0 e 447 250_272 n.) oe 1¨, 448 250_272 cr ME1 27037625v.1 Duplex Sense Oligo SEQ Antisense SEQ ID Position in Sense Sequence (5' to 3') Antisense Sequence (5' to 3') Name Name ID NO Oligo Name NO: NC_003977.1 UGAGAGAAGTCCACCACGAGUCU 449 250_272 0 n.) UGAGAGAAGTCCACCACGAGUCU 450 250_272 1--, oe UGAGAGAAGTCCACCACGAGUCU 451 250_272 1--, vi UGAGAGAAGUCCACCACGAGUCU 452 250_272 1--, c:
vi UGAGAGAAGUCCACCACGAGUCU 453 250_272 UGAGAGAAGUCCACCACGAGUCU 454 250_272 UGAGAGAAGTCCACCACGAGUCU 455 250_272 UGAGAGAAGTCCACCACGAGUCU 456 250_272 UGAGAGAAGTCCACCACGAGUCU 457 250_272 UGAGAGAAGUCCACCACGAGUCU 458 250_272 UGAGAGAAGUCCACCACGAGUCU 459 250_272 Q
UGAGAGAAGTCCACCACGAGUCU 460 250_272 u, UGAGAGAAGUCCACCACGAGUCU 461 250_272 .
'-c->
.
---.1 AD -64727 A-129384 ACUCGUGGTGGACUUCACUCA
462 250_272 " , ' AD -64728 A-129376 ACUCGUGGUGGACUUCACUCA
463 250_272 , .
, UGAGAGAAGUCCACCACGAGUCU 464 250_272 ' .3 UGAGAGAAGTCCACCACGAGUCU 465 250_272 UGAGAGAAGTCCACCACGAGUCU 466 250_272 UGAGAGAAGUCCACCACGAGUCU 467 250_272 UGAGAGAAGTCCACCACGAGUCU 468 250_272 UGAGAGAAGUCCACCACGAGUCU 469 250_272 UGAGAGAAGTCCACCACGAGUCU 470 250_272 Iv n UGAGAGAAGTCCACCACGAGUCU 471 250_272 cp UGAGAGAAGTCCACCACGAGUCU 472 250_272 n.) 1--, UGAGAGAAGUCCACCACGAGUCU 473 250_272 0 e UGAGAGAAGUCCACCACGAGUCU 474 250_272 n.) oe 1--, UGAGAGAAGTCCACCACGAGUCU 475 250_272 1--, cr ME1 27037625v.1 Duplex Sense Oligo SEQ Antisense SEQ ID Position in Sense Sequence (5' to 3') Antisense Sequence (5' to 3') Name Name ID NO Oligo Name NO: NC_003977.1 476 250_272 0 n.) o 477 250_272 oe 478 250_272 un 1¨, c:
u, Table 3. Exemplary Modified Sense and Antisense Strand Sequences of HBV dsRNAs (Activity data available in W02016/077321, incorporated herein by reference) SEQ
SEQ
Duplex Sense Oligo Antisense Sense Sequence (5' to 3') ID
Antisense Sequence (5 to 3') ID
Name Name Oligo Name NO:
NO:
AD-61522 A-123463 AfsgsUfuAfuAfuGfGfAfuGfaUfgUfgGfuAfL96 479 A-123464 usAfscCfaCfaUfcAfuccAfuAfuAfaCfusgsa 694 P
AD-61547 A-123487 GfsgsAfuGfuGfuCfUfGfcGfgCfgUfuUfuAfL96 480 A-123488 usAfsaAfaCfgCfcGfcagAfcAfcAfuCfcsasg 695 u, 696 .
cc AD-63939 A-127909 ascsucGfuGfgUfGfGfaCfuucUfcucaL96 usGfsaGfaGfaAfgUfccaCfcAfcGfaGfuscsu 697 , , AD-63940 A-127917 ascsucguggugdGacuuc(Tgn)cucaL96 usGfsaGfaGfaAfgUfccaCfcAfcGfaGfuscsu 698 , , AD-63941 A-127905 AfscsUfcGfuGfgUfGfGfaCfuUfcUfcUfcAfL96 484 A-127925 usGfsaGfagaAfguccaCfcAfcgaGfuscsu 699 .
.3 AD-63942 A-127933 uscsGfuGfgUfGfGfaCfuUfcUfcUfcAfL96 485 A-127934 usGfsaGfaGfaAfgUfccaCfcAfcGfasgsu 700 AD-63943 A-127944 ascsucGfuGfguGfGfaCfuucucucaL96 486 A-127942 usGfsAfgaGfaAfgUfccaCfcAfcGfaguscsu 701 AD-63945 A-127910 ascsucguGfgUfGfGfaCfuucUfcucaL96 usGfsaGfaGfaAfgUfccaCfcAfcGfaGfuscsu 702 AD-63946 A-127918 ascsucguGfgUfGfGfacuuCfucucaL96 usGfsaGfaGfaAfgUfccaCfcAfcGfaGfuscsu 703 AD-63947 A-127905 AfscsUfcGfuGfgUfGfGfaCfuUfcUfcUfcAfL96 489 A-127926 usGfsaGfagaagUfccaCfcAfcgaGfuscsu 704 IV
AD-63948 A-127935 gsusGfgUfGfGfaCfuUfcUfcUfcAfL96 490 A-127936 usGfsaGfaGfaAfgUfccaCfcAfcsgsa 705 n AD-63949 A-127944 ascsucGfuGfguGfGfaCfuucucucaL96 usGfsaGfaGfaAfgUfccaCfcAfcGfaGfuscsu 706 cp AD-63950 A-127900 Y44UfcGfuGfgUfgGfaCfuUfcUfcUfcAfusuY44 492 A-127901 usGfsasGfaGfaAfgUfcCfaCfcAfcGfausu 707 n.) o 1¨, AD-63951 A-127911 ascsucguGfgUfGfGfaCfuucucucaL96 usGfsaGfaGfaAfgUfccaCfcAfcGfaGfuscsu 708 0 e AD-63952 A-127905 AfscsUfcGfuGfgUfGfGfaCfuUfcUfcUfcAfL96 494 A-127919 usGfsaGfaGfaagUfccaCfcAfcGfaGfuscsu 709 n.) oe 1¨, AD-63953 A-127905 AfscsUfcGfuGfgUfGfGfaCfuUfcUfcUfcAfL96 495 A-127927 usGfsagagaAfgUfccaCfcAfcgaguscsu 710 cr ME1 27037625v.1 SEQ
SEQ
Duplex Sense Oligo Antisense Sense Sequence (5' to 3') ID
Antisense Sequence (5 to 3') ID
Name Name Oligo Name NO:
NO: 0 n.) AD-63955 A-127945 ascsucgugguGfGfacuucucucaL96 496 A-127940 usGfsAfgAfgAfaGfuccaCfCfaCfgAfguscsu 711 1¨, oe AD-63956 A-127902 Y44uscsGfuGfgUfgGfaCfuUfcUfcUfcAfY44 497 A-127903 usGfsaGfaGfaAfgUfcCfaCfcAfcGfasusu 712 un AD-63957 A-127912 ascsucguGfgUfGfGfacuucucucaL96 498 A-127906 usGfsaGfaGfaAfgUfccaCfcAfcGfaGfuscsu 713 cA
un AD-63958 A-127905 AfscsUfcGfuGfgUfGfGfaCfuUfcUfcUfcAfL96 499 A-127920 usGfsagaGfaAfgUfccaCfcAfcgaGfuscsu 714 AD-63959 A-127905 AfscsUfcGfuGfgUfGfGfaCfuUfcUfcUfcAfL96 500 A-127928 usGfsaGfagaAfguccaCfcAfcgaguscsu 715 AD-63960 A-126619 usasUfuUfCfCfuAfgGfgUfaCfaAfL96 501 A-127938 PusGfsaGfaGfaAfgUfccaCfcAfcsgsa 716 AD-63961 A-127945 ascsucgugguGfGfacuucucucaL96 502 A-127942 usGfsAfgaGfaAfgUfccaCfcAfcGfaguscsu 717 AD-63962 A-127902 Y44uscsGfuGfgUfgGfaCfuUfcUfcUfcAfY44 503 A-127904 PusGfsaGfaGfaAfgUfcCfaCfcAfcGfasusu 718 AD-63963 A-127913 ascsucguggUfgGfacuucucucaL96 504 A-127906 usGfsaGfaGfaAfgUfccaCfcAfcGfaGfuscsu 719 AD-63964 A-127905 AfscsUfcGfuGfgUfGfGfaCfuUfcUfcUfcAfL96 505 A-127921 usGfsaGfaGfaAfgUfccaCfcAfcgaguscsu 720 P
AD-63965 A-127905 AfscsUfcGfuGfgUfGfGfaCfuUfcUfcUfcAfL96 506 A-127929 usGfsagaGfaaGfuccaCfcAfcgaguscsu 721 .
L.
u9 AD-63966 A-127939 ascsUfcGfugguGfGfaCfuuCfuCfucaL96 507 A-127940 usGfsAfgAfgAfaGfuccaCfCfaCfgAfguscsu 722 ..' s:) AD-63967 A-127945 ascsucgugguGfGfacuucucucaL96 508 A-127906 usGfsaGfaGfaAfgUfccaCfcAfcGfaGfuscsu 723 , AD-63968 A-127905 AfscsUfcGfuGfgUfGfGfaCfuUfcUfcUfcAfL96 509 A-127906 usGfsaGfaGfaAfgUfccaCfcAfcGfaGfuscsu 724 .
, , AD-63968 A-127905 AfscsUfcGfuGfgUfGfGfaCfuUfcUfcUfcAfL96 510 A-127906 usGfsaGfaGfaAfgUfccaCfcAfcGfaGfuscsu 725 , .3 AD-63968 A-127905 AfscsUfcGfuGfgUfGfGfaCfuUfcUfcUfcAfL96 511 A-127906 usGfsaGfaGfaAfgUfccaCfcAfcGfaGfuscsu 726 AD-63969 A-127914 ascsucguggugGfacuucucucaL96 512 A-127906 usGfsaGfaGfaAfgUfccaCfcAfcGfaGfuscsu 727 AD-63970 A-127905 AfscsUfcGfuGfgUfGfGfaCfuUfcUfcUfcAfL96 513 A-127922 usGfsagaGfaagUfccaCfcAfcgaGfuscsu 728 AD-63971 A-127905 AfscsUfcGfuGfgUfGfGfaCfuUfcUfcUfcAfL96 514 A-127930 usGfsagaGfaaguccaCfcAfcgaguscsu 729 AD-63972 A-127941 ascsUfcGfuGfguGfGfaCfuuCfuCfucaL96 515 A-127942 usGfsAfgaGfaAfgUfccaCfcAfcGfaguscsu 730 AD-63973 A-127946 ascsucguggudGdGacuucucucaL96 516 A-127947 usdGsaGfaGfaAfgdTccadCcAfcGfaguscsu 731 IV
n AD-63975 A-127915 ascsucguggUfgGfacuuc(Tgn)cucaL96 517 A-127906 usGfsaGfaGfaAfgUfccaCfcAfcGfaGfuscsu 732 1-3 AD-63976 A-127905 AfscsUfcGfuGfgUfGfGfaCfuUfcUfcUfcAfL96 518 A-127923 usGfsagaGfaAfgUfccaCfcAfcgaguscsu 733 cp n.) o AD-63977 A-127917 ascsucguggugdGacuuc(Tgn)cucaL96 519 A-127931 usdGsagagaaguccadCcacgaguscsu 734 oe AD-63978 A-127943 ascsUfcGfuGfguGfGfaCfuUfcUfcUfcaL96 520 A-127906 usGfsaGfaGfaAfgUfccaCfcAfcGfaGfuscsu 735 n.) oe 1¨, AD-63979 A-127908 ascsucGfuGfgUfGfGfaCfuucUfcucAfL96 521 A-127906 usGfsaGfaGfaAfgUfccaCfcAfcGfaGfuscsu 736 cA
ME1 27037625v.1 SEQ
SEQ
Duplex Sense Oligo Antisense Sense Sequence (5' to 3') ID
Antisense Sequence (5 to 3') ID
Name Name Oligo Name NO:
NO: 0 n.) AD-63980 A-127916 ascsucguggugGfacuuc(Tgn)cucaL96 522 A-127906 usGfsaGfaGfaAfgUfccaCfcAfcGfaGfuscsu 737 1¨, oe AD-63981 A-127905 AfscsUfcGfuGfgUfGfGfaCfuUfcUfcUfcAfL96 523 A-127924 usGfsaGfagaAfgUfccaCfcAfcgaGfuscsu 738 un AD-63982 A-127917 ascsucguggugdGacuuc(Tgn)cucaL96 524 A-127932 PusdGsagagaaguccadCcacgaguscsu 739 cA
un AD-63983 A-127944 ascsucGfuGfguGfGfaCfuucucucaL96 525 A-127940 usGfsAfgAfgAfaGfuccaCfCfaCfgAfguscsu 740 AD-63985 A-127961 gsusggugGfaCfUfUfcUfcucAfauuuL96 526 A-127956 asAfsaUfuGfaGfaGfaagUfcCfaCfcAfcsgsa 741 AD-63986 A-127969 gsusggugGfaCfUfUfcucuCfaauuuL96 527 A-127956 asAfsaUfuGfaGfaGfaagUfcCfaCfcAfcsgsa 742 AD-63987 A-127955 GfsusGfgUfgGfaCfUfUfcUfcUfcAfaUfuUfL96 528 A-127977 asAfsaUfugagaGfaagUfcCfaccAfcsgsa 743 AD-63988 A-127986 usgsGfaCfUfUfcUfcUfcAfaUfuUfL96 529 A-127987 asAfsaUfuGfaGfaGfaagUfcCfascsc 744 AD-63989 A-127996 gsusgguggacUfUfcucucaauuuL96 530 A-127992 asAfsAfUfuGfaGfaGfaagUfcCfaCfcacsgsa 745 AD-63990 A-127950 Y44GfgUfgGfaCfuUfcUfcUfcAfaUfuUfusuY44 531 A-127951 asAfsasUfuGfaGfaGfaAfgUfcCfaCfcusu 746 P
AD-63991 A-127962 gsusggugGfaCfUfUfcUfcucaauuuL96 532 A-127956 asAfsaUfuGfaGfaGfaagUfcCfaCfcAfcsgsa 747 .
L.
u9 AD-63992 A-127955 GfsusGfgUfgGfaCfUfUfcUfcUfcAfaUfuUfL96 533 A-127970 asAfsaUfuGfagaGfaagUfcCfaCfcAfcsgsa 748 ..' .
.
AD-63993 A-127955 GfsusGfgUfgGfaCfUfUfcUfcUfcAfaUfuUfL96 534 A-127978 asAfsauugaGfaGfaagUfcCfaccacsgsa 749 , AD-63994 A-127984 gsgUfgGfaCfUfUfcUfcUfcAfaUfuUfL96 535 A-127988 PasAfsaUfuGfaGfaGfaagUfcCfaCfcsasc 750 .
, , AD-63995 A-127996 gsusgguggacUfUfcucucaauuuL96 536 A-127993 asAfsAfuuGfaGfaGfaagUfCfcaCfcacsgsa 751 , .3 AD-63996 A-127952 Y44gsgsUfgGfaCfuUfcUfcUfcAfaUfuUfY44 537 A-127953 asAfsaUfuGfaGfaGfaAfgUfcCfaCfcsusu 752 AD-63997 A-127963 gsusggugGfaCfUfUfcucucaauuuL96 538 A-127956 asAfsaUfuGfaGfaGfaagUfcCfaCfcAfcsgsa 753 AD-63999 A-127955 GfsusGfgUfgGfaCfUfUfcUfcUfcAfaUfuUfL96 539 A-127979 asAfsaUfugaGfagaagUfcCfaccacsgsa 754 AD-64000 A-127986 usgsGfaCfUfUfcUfcUfcAfaUfuUfL96 540 A-127989 PasAfsaUfuGfaGfaGfaagUfcCfascsc 755 AD-64001 A-127996 gsusgguggacUfUfcucucaauuuL96 541 A-127994 asAfsAfUfuGfaGfaGfaagUfCfcaCfcacsgsa 756 AD-64002 A-127952 Y44gsgsUfgGfaCfuUfcUfcUfcAfaUfuUfY44 542 A-127954 PasAfsaUfuGfaGfaGfaAfgUfcCfaCfcsusu 757 IV
n AD-64003 A-127964 gsusgguggaCfuUfcucucaauuuL96 543 A-127956 asAfsaUfuGfaGfaGfaagUfcCfaCfcAfcsgsa 758 1-3 AD-64004 A-127955 GfsusGfgUfgGfaCfUfUfcUfcUfcAfaUfuUfL96 544 A-127972 asAfsaUfuGfaGfaGfaagUfcCfaccacsgsa 759 cp n.) o AD-64005 A-127955 GfsusGfgUfgGfaCfUfUfcUfcUfcAfaUfuUfL96 545 A-127980 asAfsauuGfagAfgaagUfcCfaccacsgsa 760 oe AD-64006 A-127990 gsusGfgugGfaCfUfUfcUfcUfcAfaUfuuL96 546 A-127991 asAfsaUfuGfaGfaGfaagUfcCfaCfcacsgsa 761 n.) oe 1¨, AD-64007 A-127996 gsusgguggacUfUfcucucaauuuL96 547 A-127995 asAfsAfUfugaGfaGfaagUfCfcaCfcacsgsa 762 cA
ME1 27037625v.1 SEQ
SEQ
Duplex Sense Oligo Antisense Sense Sequence (5' to 3') ID
Antisense Sequence (5 to 3') ID
Name Name Oligo Name NO:
NO: 0 n.) GfsusGfgUfgGfaCfUfUfcUfcUfcAfaUfuUfL96 548 A-127956 asAfs aUfuGfaGfaGfaagUfcCfaCfcAfc sg s a 763 o 1¨, oe GfsusGfgUfgGfaCfUfUfcUfcUfcAfaUfuUfL96 549 A-127956 asAfs aUfuGfaGfaGfaagUfcCfaCfcAfc sg s a 764 un AD -64009 A-127965 gsusgguggacuUfcucucaauuuL96 550 A-127956 asAfs aUfuGfaGfaGfaagUfcCfaCfcAfc sg s a cA
un GfsusGfgUfgGfaCfUfUfcUfcUfcAfaUfuUfL96 551 A-127973 asAfs auuGfagaGfaagUfcCfaccAfc sg s a 766 GfsusGfgUfgGfaCfUfUfcUfcUfcAfaUfuUfL96 552 A-127981 asAfs auuGfagagaagUfcCfacc acsg s a 767 gsusGfgugGfaCfUfUfcUfcUfcAfaUfuuL96 553 A-127992 asAfsAfUfuGfaGfaGfaagUfcCfaCfcacs gs a 768 gsusgguggacdTdTcucucaauuuL96 554 A-127998 asdAsAfuugaGfaGfaagdTdCc aCfc ac sg s a 769 Y44GfsusGfgUfgGfaCfUfUfcUfcUfcAfaUfuUfL96 555 A-127958 P asAfs aUfuGfaGfaGfaagUfcCfaCfcAfcs gs a 770 gsusgguggaCfuUfcucuc(Agn)auuuL96 556 A-127956 asAfs aUfuGfaGfaGfaagUfcCfaCfcAfc sg s a 771 GfsusGfgUfgGfaCfUfUfcUfcUfcAfaUfuUfL96 557 A-127974 asAfs auuGfaGfaGfaagUfcCfacc ac sgs a 772 P
gsusgguggacudTcucuc(Agn)auuuL96 558 A-127982 asdAsauugagagaagdTccaccacsgsa 773 .
L.
u9 gsusGfgugGfaCfUfUfcUfcUfcAfaUfuuL96 559 A-127993 asAfsAfuuGfaGfaGfaagUfCfc aCfc ac sg s a 774 ..' .
.
. AD -64019 A-127959 gsusggUfgGfaCfUfUfcUfcucAfauuUfL96 560 A-127956 asAfs aUfuGfaGfaGfaagUfcCfaCfcAfc sg s a 775 , gsusgguggacuUfcucuc(Agn)auuuL96 561 A-127956 asAfs aUfuGfaGfaGfaagUfcCfaCfcAfc sg s a 776 .
, , GfsusGfgUfgGfaCfUfUfcUfcUfcAfaUfuUfL96 562 A-127975 asAfs aUfug aGfaGfaagUfcCfaccAfc sg s a 777 , .3 gsusgguggacudTcucuc(Agn)auuuL96 563 A-127983 PasdAsauugagagaagdTccaccacsgsa 778 gsusGfgugGfaCfUfUfcUfcUfcAfaUfuuL96 564 A-127994 asAfsAfUfuGfaGfaGfaagUfCfcaCfc ac sg s a 779 gsusggUfgGfaCfUfUfcUfcucAfauuuL96 565 A-127956 asAfs aUfuGfaGfaGfaagUfcCfaCfcAfc sg s a 780 gsusgguggacudTcucuc(Agn)auuuL96 566 A-127956 asAfs aUfuGfaGfaGfaagUfcCfaCfcAfc sg s a 781 GfsusGfgUfgGfaCfUfUfcUfcUfcAfaUfuUfL96 567 A-127976 asAfsaUfugaGfagaagUfcCfaccAfcsgsa 782 gsgUfgGfaCfUfUfcUfcUfcAfaUfuUfL96 568 A-127985 asAfsaUfuGfaGfaGfaagUfcCfaCfcsasc 783 IV
n gsusGfgugGfaCfUfUfcUfcUfcAfaUfuuL96 569 A-127995 asAfsAfUfugaGfaGfaagUfCfc aCfc ac sg s a 784 1-3 GfsusGfcAfcUfuCfGfCfuUfcAfcCfuCfuGfL96 570 A-128002 csAfsgAfgGfuGfaAfgcgAfaGfuGfcAfcsasc 785 cp n.) o GfsusUfgAfcAfaAfAfAfuCfcUfcAfcAfaUfL96 571 A-128364 asUfsuGfuGfaGfgAfuuuUfuGfuCfaAfcs as a 786 oe UfsgsUfuGfaCfaAfAfAfaUfcCfuCfaCfaAfL96 572 A-128378 usUfsgUfgAfgGfaUfuuuUfgUfcAfaCfas as g 787 n.) oe 1¨, GfsgsUfgGfaCfuUfCfUfcUfcAfaUfuUfuAfL96 573 A-128394 usAfsaAfaUfuGfaGfagaAfgUfcCfaCfcsasc 788 cA
ME1 27037625v.1 SEQ
SEQ
Duplex Sense Oligo Antisense Sense Sequence (5' to 3') ID
Antisense Sequence (5 to 3') ID
Name Name Oligo Name NO:
NO: 0 n.) AD-64277 A-128407 UfscsUfuUfuGfgAfGfUfgUfgGfaUfuCfgAfL96 574 A-128408 usCfsgAfaUfcCfaCfacuCfcAfaAfaGfasc s a 789 o 1¨, oe AD-64277 A-128407 UfscsUfuUfuGfgAfGfUfgUfgGfaUfuCfgAfL96 575 A-128408 usCfsgAfaUfcCfaCfacuCfcAfaAfaGfasc s a un AD-64278 A-128423 AfscsUfgUfuCfaAfGfCfcUfcCfaAfgCfuAfL96 576 A-128424 usAfsgCfuUfgGfaGfgcuUfgAfaCfaAfgsasc 791 cA
un AD-64279 A-128435 UfscsUfgCfcGfaUfCfCfaUfaCfuGfcGfgAfL96 577 A-128436 usCfscGfcAfgUfaUfggaUfcGfgCfaGfasgsg 792 AD-64280 A-128379 AfsusGfuGfuCfuGfCfGfgCfgUfuUfuAfuAfL96 578 A-128380 usAfsuAfaAfaCfgCfcgcAfgAfcAfcAfuscsc 793 AD-64281 A-128395 CfscsCfcGfuCfuGfUfGfcCfuUfcUfcAfuAfL96 579 A-128396 usAfsuGfaGfaAfgGfcacAfgAfcGfgGfgsasg 794 AD-64282 A-128409 GfscsCfuAfaUfcAfUfCfuCfuUfgUfuCfaUfL96 580 A-128410 asUfsgAfaCfaAfgAfgauGfaUfuAfgCfgsasg 795 AD-64283 A-128425 UfscsUfaGfaCfuCfGfUfgGfuGfgAfcUfuCfL96 581 A-128426 gsAfsaGfuCfcAfcCfacgAfgUfcUfaGfascsu 796 AD-64284 A-128437 CfsusGfcCfgAfuCfCfAfuAfcUfgCfgGfaAfL96 582 A-128438 usUfscCfgCfaGfuAfuggAfuCfgGfcAfgsasg 797 AD-64285 A-128365 UfsusUfuUfcUfuGfUfUfgAfcAfaAfaAfuAfL96 583 A-128366 usAfsuUfuUfuGfuCfaacAfaGfaAfaAfascsc 798 P
AD-64286 A-128381 AfsusCfuUfcUfuGfUfUfgGfuUfcUfuCfuAfL96 584 A-128382 usAfsgAfaGfaAfcCfaacAfaGfaAfgAfusg s a 799 .
L.
u9 AD-64289 A-128367 GfsusUfuUfuCfuUfGfUfuGfaCfaAfaAfaUfL96 585 A-128368 asUfsuUfuUfgUfcAfacaAfgAfaAfaAfcscsc 800 ..' .
.
AD-64290 A-128383 CfsusGfcCfuAfaUfCfAfuCfuCfuUfgUfuAfL96 586 A-128384 usAfsaCfaAfgAfgAfugaUfuAfgGfcAfgsasg 801 , AD-64291 A-128399 UfscsCfuCfaCfaAfUfAfcCfaCfaGfaGfuAfL96 587 A-128400 usAfscUfcUfgUfgGfuauUfgUfgAfgGfasusu 802 .
, , AD-64292 A-128413 CfsusUfgUfuGfaCfAfAfaAfaUfcCfuCfaAfL96 588 A-128414 usUfsgAfgGfaUfuUfuugUfcAfaCfaAfgs as a 803 , o .3 AD-64293 A-128439 GfscsAfaCfuUfuUfUfCfaCfcUfcUfgCfcUfL96 589 A-128440 asGfsgCfaGfaGfgUfgaaAfaAfgUfuGfcsasu 804 AD-64294 A-128369 GfsgsGfaAfcAfaGfAfGfcUfaCfaGfcAfuAfL96 590 A-128370 usAfsuGfcUfgUfaGfcucUfuGfuUfcCfc s as a AD-64295 A-128385 CfsgsUfgGfuGfgAfC11JfuCfuCfuCfaAfuUfL96 591 A-128386 asAfsuUfgAfgAfgAfaguCfcAfcCfaGfcs as g AD-64297 A-128415 CfsusGfcUfgCfuAfUfGfcCfuCfaUfcUfuAfL96 592 A-128416 usAfs aGfaUfgAfgGfcauAfgCfaGfcAfg sg s a AD-64298 A-128427 GfsusUfgGfaUfgUfG11JfcUfgCfgGfcGfuUfL96 593 A-128428 asAfscGfcCfgCfaGfacaCfaUfcCfaAfc sg s a AD-64299 A-128441 UfsusCfaUfcCfuGfCfUfgCfuAfuGfcCfuAfL96 594 A-128442 usAfsgGfcAfuAfgCfagcAfgGfaUfgAfasg s a n AD-64300 A-128371 UfsusCfuUfgUfuGfAfCfaAfaAfaUfcCfuAfL96 595 A-128372 usAfsgGfaUfuUfuUfgucAfaCfaAfgAfas as a AD-64302 A-128417 UfsasUfaUfgGfaUfGfAfuGfuGfgUfaUfuAfL96 596 A-128418 usAfsaUfaCfcAfcAfucaUfcCfaUfaUfasasc 811 cp n.) o AD-64303 A-128429 UfsusCfaUfcCfuGfC11JfgCfuAfuGfcCfuCfL96 597 A-128430 g sAfsgGfcAfuAfgCfagcAfgGfaUfgAfasg s a oe AD-64304 A-128443 GfsusGfcAfcUfuCfGfCfuUfcAfcCfuCfuAfL96 598 A-128444 usAfsgAfgGfuGfaAfgcgAfaGfuGfcAfcsasc 813 n.) oe 1¨, AD-64305 A-128373 UfsusGfaCfaAfaAfAfUfcCfuCfaCfaAfuAfL96 599 A-128374 usAfsuUfgUfgAfgGfauuUfuUfgUfcAfasc s a 814 cA
ME1 27037625v.1 SEQ
SEQ
Duplex Sense Oligo Antisense Sense Sequence (5' to 3') ID
Antisense Sequence (5 to 3') ID
Name Name Oligo Name NO:
NO: 0 n.) AD-64307 A-128403 AfsasGfcCfuCfcAfAfGfcUfgUfgCfcUfuAfL96 600 A-128404 usAfs aGfgCfaCfaGfcuuGfgAfgGfcUfusg s a 1¨, oe AD-64308 A-128419 CfscsUfcUfuCfaUfCfCfuGfcUfgCfuAfuAfL96 601 A-128420 usAfsuAfgCfaGfcAfgg aUfgAfaGfaGfg s as a un AD-64309 A-128431 CfscsUfgCfuGfcUfAfUfgCfcUfcAfuCfuUfL96 602 A-128432 asAfsgAfuGfaGfgCfauaGfcAfgCfaGfgsasu 817 cA
un AD-64310 A-128375 CfsasUfcUfuCfuUfGfUfuGfgUfuCfuUfcUfL96 603 A-128376 asGfs aAfgAfaCfcAfac aAfgAfaGfaUfg s as g AD-64311 A-128391 CfscsGfuCfuGfuGfCfCfuUfcUfcAfuCfuAfL96 604 A-128392 usAfsgAfuGfaGfaAfggcAfcAfgAfcGfgsgsg 819 AD-64312 A-128405 CfscsUfcAfuCfuUfCfUfuGfuUfgGfuUfcUfL96 605 A-128406 asGfs aAfcCfaAfcAfag aAfgAfuGfaGfg sc s a AD-64313 A-128421 CfscsAfcCfaAfaUfGfCfcCfcUfaUfcUfuAfL96 606 A-128422 usAfsaGfaUfaGfgGfgcaUfuUfgGfuGfgsusc 821 AD-64314 A-128433 GfscsUfcCfuCfuGfCfCfgAfuCfcAfuAfcUfL96 607 A-128434 asGfsuAfuGfgAfuCfggcAfgAfgGfaGfc scs a AD-64315 A-128363 GfsusUfgAfcAfaAfAfAfuCfcUfcAfcAfaUfL96 608 A-128445 P asUfsuGfuGfaGfgAfuuuUfuGfuCfaAfc s as a 823 AD-64316 A-128377 UfsgsUfuGfaCfaAfAfAfaUfcCfuCfaCfaAfL96 PusUfsgUfgAfgGfaUfuuuUfgUfcAfaCfas as g 824 P
AD-64317 A-128393 GfsgsUfgGfaCfuUfCfUfcUfcAfaUfuUfuAfL96 610 A-128461 Pus Afs aAfaUfuGfaGfag aAfgUfcCfaCfc s asc 825 .
L.
u9 AD-64318 A-128407 UfscsUfuUfuGfgAfGfUfgUfgGfaUfuCfgAfL96 PusCfsgAfaUfcCfaCfacuCfcAfaAfaGfasc s a 826 ..' .
.
w AD-64319 A-128423 AfscsUfgUfuCfaAfGfCfcUfcCfaAfgCfuAfL96 612 A-128477 Pus AfsgCfuUfgGfaGfgcuUfgAfaCfaAfgs asc 827 , AD-64320 A-128435 UfscsUfgCfcGfaUfCfCfaUfaCfuGfcGfgAfL96 613 A-128483 PusCfscGfcAfgUfaUfggaUfcGfgCfaGfasgsg 828 .
, , AD-64321 A-123463 AfsgsUfuAfuAfuGfGfAfuGfaUfgUfgGfuAfL96 614 A-128446 Pus AfscCfaCfaUfcAfuccAfuAfuAfaCfus gs a 829 , .3 AD-64322 A-128379 AfsusGfuGfuCfuGfCfGfgCfgUfuUfuAfuAfL96 615 A-128454 Pus AfsuAfaAfaCfgCfcgcAfgAfcAfcAfuscsc 830 AD-64323 A-128395 CfscsCfcGfuCfuG11JfGfcCfuUfcUfcAfuAfL96 616 A-128462 Pus AfsuGfaGfaAfgGfcacAfgAfcGfgGfg s asg 831 AD-64324 A-128409 GfscsCfuAfaUfcAfUfCfuCfuUfgUfuCfaUfL96 617 A-128470 PasUfsgAfaCfaAfgAfgauGfaUfuAfgCfgsasg 832 AD-64325 A-128425 UfscsUfaGfaCfuCfGfUfgGfuGfgAfcUfuCfL96 618 A-128478 PgsAfsaGfuCfcAfcCfacgAfgUfcUfaGfascsu 833 AD-64326 A-128437 CfsusGfcCfgAfuCfCfAfuAfcUfgCfgGfaAfL96 619 A-128484 PusUfscCfgCfaGfuAfuggAfuCfgGfcAfgsasg 834 AD-64328 A-128381 AfsusCfuUfcUfuGfUfUfgGfuUfcUfuCfuAfL96 620 A-128455 Pus AfsgAfaGfaAfcCfaacAfaGfaAfgAfusg s a 835 IV
n AD-64330 A-128411 UfsusCfuCfuCfaAfUfUfuUfcUfaGfgGfgAfL96 621 A-128471 PusCfscCfcUfaGfaAfaauUfgAfgAfgAfasgsu 836 1-3 AD-64331 A-127905 AfscsUfcGfuGfgUfGfGfaCfuUfcUfcUfcAfL96 622 A-127907 PusGfsaGfaGfaAfgUfccaCfcAfcGfaGfuscsu 837 cp n.) o AD-64332 A-128001 GfsusGfcAfcUfuCfGfCfuUfcAfcCfuCfuGfL96 623 A-128485 PcsAfsgAfgGfuGfaAfgcgAfaGfuGfcAfcsasc 838 oe AD-64333 A-128367 GfsusUfuUfuCfuUfGfUfuGfaCfaAfaAfaUfL96 624 A-128448 PasUfsuUfuUfgUfcAfacaAfgAfaAfaAfcscsc 839 n.) oe 1¨, AD-64334 A-128383 CfsusGfcCfuAfaUfCfAfuCfuCfuUfgUfuAfL96 625 A-128456 Pus Afs aCfaAfgAfgAfugaUfuAfgGfcAfg s as g 840 cA
ME1 27037625v.1 SEQ
SEQ
Duplex Sense Oligo Antisense Sense Sequence (5' to 3') ID
Antisense Sequence (5 to 3') ID
Name Name Oligo Name NO:
NO: 0 n.) AD-64335 A-128399 UfscsCfuCfaCfaAfUfAfcCfaCfaGfaGfuAfL96 626 A-128464 Pus AfscUfcUfgUfgGfuauUfgUfgAfgGfasusu 841 1¨, oe AD-64336 A-128413 CfsusUfgUfuGfaCfAfAfaAfaUfcCfuCfaAfL96 627 A-128472 PusUfsgAfgGfaUfuUfuugUfcAfaCfaAfg s as a 842 un AD-64337 A-127955 GfsusGfgUfgGfaCfUfUfcUfcUfcAfaUfuUfL96 628 A-127958 P asAfs aUfuGfaGfaGfaagUfcCfaCfcAfcs gs a 843 cA
un AD-64338 A-128439 GfscsAfaCfuUfuUfUfCfaCfcUfcUfgCfcUfL96 629 A-128486 PasGfsgCfaGfaGfgUfgaaAfaAfgUfuGfcsasu 844 AD-64339 A-128369 GfsgsGfaAfcAfaGfAfGfcUfaCfaGfcAfuAfL96 630 A-128449 Pus AfsuGfcUfgUfaGfcucUfuGfuUfcCfc s as a 845 AD-64341 A-128401 UfscsAfuCfuUfcUfUfGfuUfgGfuUfcUfuAfL96 631 A-128465 Pus Afs aGfaAfcCfaAfcaaGfaAfgAfuGfasg sg 846 AD-64342 A-128415 CfsusGfcUfgCfuA11JfGfcCfuCfaUfcUfuAfL96 632 A-128473 Pus Afs aGfaUfgAfgGfcauAfgCfaGfcAfg sg s a 847 AD-64343 A-128427 GfsusUfgGfaUfgUfG11JfcUfgCfgGfcGfuUfL96 633 A-128479 P asAfscGfcCfgCfaGfacaCfaUfcCfaAfcs g s a AD-64344 A-128441 UfsusCfaUfcCfuGfCfUfgCfuAfuGfcCfuAfL96 634 A-128487 Pus AfsgGfcAfuAfgCfagcAfgGfaUfgAfas gs a 849 AD-64345 A-128371 UfsusCfuUfgUfuGfAfCfaAfaAfaUfcCfuAfL96 635 A-128450 Pus AfsgGfaUfuUfuUfgucAfaCfaAfgAfas as a 850 P
AD-64347 A-123487 GfsgsAfuGfuGfuCfUfGfcGfgCfgUfuUfuAfL96 636 A-128466 Pus Afs aAfaCfgCfcGfcagAfcAfcAfuCfc s asg 851 .
L.
u9 AD-64348 A-128417 UfsasUfaUfgGfaUfGfAfuGfuGfgUfaUfuAfL96 637 A-128474 Pus Afs aUfaCfcAfcAfucaUfcCfaUfaUfas asc 852 ..' .
.
AD-64349 A-128429 UfsusCfaUfcCfuGfC11JfgCfuAfuGfcCfuCfL96 638 A-128480 Pgs AfsgGfcAfuAfgCfagcAfgGfaUfgAfas gs a 853 , AD-64350 A-128443 GfsusGfcAfcUfuCfGfCfuUfcAfcCfuCfuAfL96 639 A-128488 Pus AfsgAfgGfuGfaAfgcgAfaGfuGfcAfc s asc 854 .
, , AD-64351 A-128373 UfsusGfaCfaAfaAfAfUfcCfuCfaCfaAfuAfL96 640 A-128451 Pus AfsuUfgUfgAfgGfauuUfuUfgUfcAfasc s a 855 .3 AD-64352 A-128389 CfscsAfaGfuGfuUfUfGfcUfgAfcGfcAfaAfL96 641 A-128459 PusUfsuGfcGfuCfaGfc aaAfcAfcUfuGfg scs a 856 AD-64352 A-128389 CfscsAfaGfuGfuUfUfGfcUfgAfcGfcAfaAfL96 642 A-128459 PusUfsuGfcGfuCfaGfc aaAfcAfcUfuGfg scs a 857 AD-64353 A-128403 AfsasGfcCfuCfcAfAfGfcUfgUfgCfcUfuAfL96 643 A-128467 Pus Afs aGfgCfaCfaGfcuuGfgAfgGfcUfusg s a 858 AD-64354 A-128419 CfscsUfcUfuCfaUfCfCfuGfcUfgCfuAfuAfL96 644 A-128475 Pus AfsuAfgCfaGfcAfggaUfgAfaGfaGfg s as a 859 AD-64355 A-128431 CfscsUfgCfuGfcUfAfUfgCfcUfcAfuCfuUfL96 645 A-128481 PasAfsgAfuGfaGfgCfauaGfcAfgCfaGfgsasu 860 AD-64356 A-128375 CfsasUfcUfuCfuUfGfUfuGfgUfuCfuUfcUfL96 646 A-128452 PasGfsaAfgAfaCfcAfacaAfgAfaGfaUfgsasg 861 IV
n AD-64357 A-128391 CfscsGfuCfuGfuGfCfCfuUfcUfcAfuCfuAfL96 647 A-128460 Pus AfsgAfuGfaGfaAfggcAfcAfgAfcGfg sg sg 862 1-3 AD-64358 A-128405 CfscsUfcAfuCfuUfCfUfuGfuUfgGfuUfcUfL96 648 A-128468 P asGfs aAfcCfaAfcAfag aAfgAfuGfaGfg scs a 863 cp n.) o AD-64359 A-128421 CfscsAfcCfaAfaUfGfCfcCfcUfaUfcUfuAfL96 649 A-128476 Pus Afs aGfaUfaGfgGfgc aUfuUfgGfuGfgsusc 864 oe AD-64360 A-128433 GfscsUfcCfuCfuGfCfCfgAfuCfcAfuAfcUfL96 asGfsuAfuGfgAfuCfggcAfgAfgGfaGfc scs a 865 n.) oe 1¨, AD-64700 A-129379 ascsucguggugdTacuu(Cgn)ucucaL96 651 A-127906 usGfsaGfaGfaAfgUfccaCfcAfcGfaGfuscsu 866 cA
ME1 27037625v.1 SEQ
SEQ
Duplex Sense Oligo Antisense Sense Sequence (5' to 3') ID
Antisense Sequence (5 to 3') ID
Name Name Oligo Name NO:
NO: 0 n.) AD-64701 A-127905 AfscsUfcGfuGfgUfGfGfaCfuUfcUfcUfcAfL96 652 A-129387 PusgsagagaagdTccadCcacgaguscsu 867 o 1¨, oe AD-64702 A-127905 AfscsUfcGfuGfgUfGfGfaCfuUfcUfcUfcAfL96 653 A-129395 usGsagadGaaguccaCcacgaguscsu 868 un AD-64703 A-129376 ascsucguggugdGacuucdAcucaL96 654 A-129385 usdGsagagaagdTccadCcacgaguscsu 869 cA
un AD-64704 A-129381 ascsucguggdTgdTacuucdAcucaL96 655 A-129389 usdGsagadGaaguccadCcacgaguscsu 870 AD-64705 A-129380 ascsucguggugdTacuucdAcucaL96 656 A-127906 usGfsaGfaGfaAfgUfccaCfcAfcGfaGfuscsu 871 AD-64706 A-127905 AfscsUfcGfuGfgUfGfGfaCfuUfcUfcUfcAfL96 657 A-129388 usdGsadGagaaguccadCcacgaguscsu 872 AD-64707 A-127905 AfscsUfcGfuGfgUfGfGfaCfuUfcUfcUfcAfL96 658 A-129396 usgsagadGaagdTccadCcacgaguscsu 873 AD-64708 A-129382 ascsucguggdTgdGacuuc(Tgn)cucaL96 659 A-129385 usdGsagagaagdTccadCcacgaguscsu 874 AD-64709 A-129373 ascsucguggugdGacuu(Cgn)ucucaL96 660 A-129391 usdGsagadGaagdTccadCcacgaguscsu 875 AD-64710 A-129373 ascsucguggugdGacuu(Cgn)ucucaL96 usGfsaGfaGfaAfgUfccaCfcAfcGfaGfuscsu 876 P
AD-64711 A-129381 ascsucguggdTgdTacuucdAcucaL96 usGfsaGfaGfaAfgUfccaCfcAfcGfaGfuscsu 877 .
L.
u9 AD-64712 A-127905 AfscsUfcGfuGfgUfGfGfaCfuUfcUfcUfcAfL96 663 A-129389 usdGsagadGaaguccadCcacgaguscsu 878 ..' .
.
AD-64713 A-127905 AfscsUfcGfuGfgUfGfGfaCfuUfcUfcUfcAfL96 664 A-129397 PusgsagadGaagdTccadCcacgaguscsu 879 , AD-64714 A-129384 ascsucguggdTgdGacuucdAcucaL96 665 A-129385 usdGsagagaagdTccadCcacgaguscsu 880 .
, , AD-64715 A-129376 ascsucguggugdGacuucdAcucaL96 666 A-129391 usdGsagadGaagdTccadCcacgaguscsu 881 , .3 AD-64716 A-129374 ascsucguggugdGacuucu(Cgn)ucaL96 usGfsaGfaGfaAfgUfccaCfcAfcGfaGfuscsu 882 AD-64717 A-129382 ascsucguggdTgdGacuuc(Tgn)cucaL96 usGfsaGfaGfaAfgUfccaCfcAfcGfaGfuscsu 883 AD-64718 A-127905 AfscsUfcGfuGfgUfGfGfaCfuUfcUfcUfcAfL96 669 A-129390 usdGsagagadAguccadCcacgaguscsu 884 AD-64719 A-127917 ascsucguggugdGacuuc(Tgn)cucaL96 670 A-129385 usdGsagagaagdTccadCcacgaguscsu 885 AD-64720 A-129381 ascsucguggdTgdTacuucdAcucaL96 671 A-129385 usdGsagagaagdTccadCcacgaguscsu 886 AD-64721 A-129382 ascsucguggdTgdGacuuc(Tgn)cucaL96 672 A-129391 usdGsagadGaagdTccadCcacgaguscsu 887 IV
n AD-64722 A-129375 ascsucguggugdGacuucY34cucaL96 usGfsaGfaGfaAfgUfccaCfcAfcGfaGfuscsu 888 1-3 AD-64723 A-129383 ascsucguggugdGdAcuuc(Tgn)cucaL96 usGfsaGfaGfaAfgUfccaCfcAfcGfaGfuscsu 889 cp n.) o AD-64725 A-127917 ascsucguggugdGacuuc(Tgn)cucaL96 675 A-129398 PusdGsagagaagdTccadCcacgaguscsu 890 oe AD-64726 A-129373 ascsucguggugdGacuu(Cgn)ucucaL96 676 A-129389 usdGsagadGaaguccadCcacgaguscsu 891 n.) oe 1¨, AD-64727 A-129384 ascsucguggdTgdGacuucdAcucaL96 677 A-129391 usdGsagadGaagdTccadCcacgaguscsu 892 cA
ME1 27037625v.1 SEQ
SEQ
Duplex Sense Oligo Antisense Sense Sequence (5' to 3') ID
Antisense Sequence (5' to 3') ID
Name Name Oligo Name NO:
NO: 0 n.) AD-64728 A-129376 ascsucguggugdGacuucdAcucaL96 678 A-127906 usGfsaGfaGfaAfgUfccaCfcAfcGfaGfuscsu 893 o 1¨, oe AD-64729 A-129384 ascsucguggdTgdGacuucdAcucaL96 679 A-127906 usGfsaGfaGfaAfgUfccaCfcAfcGfaGfuscsu 894 un AD-64730 A-127905 AfscsUfcGfuGfgUfGfGfaCfuUfcUfcUfcAfL96 680 A-129392 usGsagagaagdTccadCcacgaguscsu 895 cA
un AD-64731 A-129399 Y34ascsucguggugdGacuuc(Tgn)cucaL96 681 A-129385 usdGsagagaagdTccadCcacgaguscsu 896 AD-64732 A-129376 ascsucguggugdGacuucdAcucaL96 682 A-129389 usdGsagadGaaguccadCcacgaguscsu 897 AD-64733 A-129381 ascsucguggdTgdTacuucdAcucaL96 683 A-129391 usdGsagadGaagdTccadCcacgaguscsu 898 AD-64734 A-129377 ascsucguggugdGacuucdCcucaL96 684 A-127906 usGfsaGfaGfaAfgUfccaCfcAfcGfaGfuscsu 899 AD-64735 A-127905 AfscsUfcGfuGfgUfGfGfaCfuUfcUfcUfcAfL96 685 A-129385 usdGsagagaagdTccadCcacgaguscsu 900 AD-64736 A-127905 AfscsUfcGfuGfgUfGfGfaCfuUfcUfcUfcAfL96 686 A-129393 usdGsagagaagdTccaCcacgaguscsu 901 AD-64737 A-129399 Y34ascsucguggugdGacuuc(Tgn)cucaL96 687 A-129398 PusdGsagagaagdTccadCcacgaguscsu 902 P
AD-64738 A-129382 ascsucguggdTgdGacuuc(Tgn)cucaL96 688 A-129389 usdGsagadGaaguccadCcacgaguscsu 903 .
L.
u9 AD-64739 A-129378 ascsucguggugdGacuucdGcucaL96 689 A-127906 usGfsaGfaGfaAfgUfccaCfcAfcGfaGfuscsu 904 ..' .
.
AD-64740 A-127905 AfscsUfcGfuGfgUfGfGfaCfuUfcUfcUfcAfL96 690 A-129386 usgsagagaagdTccadCcacgaguscsu 905 , AD-64741 A-127905 AfscsUfcGfuGfgUfGfGfaCfuUfcUfcUfcAfL96 691 A-129394 usGsagagaagdTccaCcacgaguscsu 906 .
, , AD-64742 A-129373 ascsucguggugdGacuu(Cgn)ucucaL96 692 A-129385 usdGsagagaagdTccadCcacgaguscsu 907 , o .3 AD-64743 A-129384 ascsucguggdTgdGacuucdAcucaL96 693 A-129389 usdGsagadGaaguccadCcacgaguscsu 908 Table 4. Unmodified Sense and Antisense Strand Sequences of HBV dsRNAs (Activity data available in W02016/077321, incorporated herein by reference) Iv SEQ
SEQ n ,-i Duplex ID Sense Sequence (5' to 3') ID Antisense Sequence (5' to 3') ID
NO:
NO: cp n.) o oe CB
n.) oe 1¨, cA
ME1 27037625v.1 SEQ
SEQ
Duplex ID Sense Sequence (5' to 3') ID Antisense Sequence (5' to 3') ID
NO:
NO: 0 t..) cio vD
u, u, P
.
.
.
.
, .
, , , .
.3 od n cp t..) o -a-, w cio cr ME1 27037625v.1 Table 5. Exemplary Modified Sense and Antisense Strand Sequences of HBV dsRNAs (Activity data available in W02016/077321, incorporated herein by reference) t.) o 1¨, oe SEQ
SEQ 1¨
DuplexID Sense Sequence (5' to 3') ID Antisense Sequence (5' to 3') ID vi 1¨, NO:
NO: c7, u, AD-65369 uscsguGfgUfGfGfacuuCfUfcucaL96 967 PusGfsagaGfaAfGfuccaCfcAfcgasusu 996 AD-65381 uscsguGfgUfGfGfacuucucucaL96 968 PusGfsagaGfaAfGfuccaCfcAfcgasusu 997 AD-63962 Y44uscsGfuGfgUfgGfaCfuUfcUfcUfcAfY44 969 PusGfsaGfaGfaAfgUfcCfaCfcAfcGfasusu 998 AD-65561 uscsguGfgUfGfGfacuuCfUfcucaL96 971 UfsGfsagaGfaAfGfuccaCfcAfcgasusu 1000 AD-65566 uscsguGfgUfGfGfacuucucucaL96 972 UfsGfsagaGfaAfGfuccaCfcAfcgasusu 1001 AD-63944 Y44ucGuGGuGGAcuucucucAusuY44 973 UfGfagAfgAfAfGUfccaCfCAfcgAusu 1002 P
AfscsUfcGfuGfgUfGfGfaCfuUfcUfcUfcAfL96 974 usGfsaGfaGfaAfgUfccaCfcAfcGfaGfuscsu 1003 u9 ..' . AD-65406 uscsguGfgUfGfGfacuuCfUfcucaL96 975 usGfsagaGfaAfGfuccaCfcAfcgasusu 1004 .
oc ,, AD-65396 ascsucguGfgUfGfGfacuucucucaL96 976 usGfsagaGfaaguccaCfcAfcgagususu 1005 ,9 , AD-65427 gsusgcacUfuCfGfCfuucaccucuaL96 977 PusAfsgagGfugaagegAfaGfugcacsusu 1006 , , AD-65573 gsusgcacUfuCfGfCfuucaCfCfucuaL96 978 UfsAfsgagGfuGfAfagegAfaGfugcacsasc 1007 .3 AD-65432 gscsacUfucGfCfuucacCfucuaL96 979 PusAfsgagGfuGfAfagegAfaGfugcsasc 1008 GfsusGfcAfcUfuCfGfCfuUfcAfcCfuCfuGfL96 980 PcsAfsgAfgGfuGfaAfgcgAfaGfuGfcAfcsasc 1009 AfsusGfuGfuCfuGfCfGfgCfgUfuUfuAfuAfL96 981 PusAfsuAfaAfaCfgCfcgcAfgAfcAfcAfuscsc 1010 GfsusGfcAfcUfuCfGfCfuUfcAfcCfuCfuGfL96 982 csAfsgAfgGfuGfaAfgcgAfaGfuGfcAfcsasc 1011 AD-65583 gscsacuucgdCuucac(Cgn)ucuaL96 983 usdAsgagdGugaagcgdAagugcsusu 1012 Iv AD-63994 gsgsUfgGfaCfUfUfcUfcUfcAfaUfuUfL96 984 PasAfsaUfuGfaGfaGfaagUfcCfaCfcsasc 1013 n ,-i AD-65370 csgsugguGfgAfCfUfucucUfCfaauuL96 985 asAfsuugAfgAfGfaaguCfcAfccagcsasg 1014 cp t.) AD-65265 gsusggugGfaCfUfUfcUfcucaauuuL96 986 asAfsaUfugagaGfaagUfcCfaccAfcsgsa 1015 =
1¨, oe AD-65407 csgsugguGfgAfCfUfucucUfCfaauuL96 987 asAfsuugAfgAfgAfaguCfcAfccagcsasg 1016 'a t.) AD-64027 gsgsUfgGfaCfUfUfcUfcUfcAfaUfuUfL96 988 asAfsaUfuGfaGfaGfaagUfcCfaCfcsasc 1017 oe 1¨, 1¨, AD-65266 gsusggugGfaCfUfUfcucuCfaauuuL96 989 asAfsaUfugagaGfaagUfcCfaccAfcsgsa 1018 cr ME1 27037625v.1 SEQ
SEQ
DuplexID Sense Sequence (5' to 3') ID Antisense Sequence (5' to 3') ID
NO:
NO: 0 n.) AD-65389 usgsgudGgucdTucucuaaauuL96 990 asdAsuugagagdAagudCcaccasusu 1019 =
1¨, oe AD-64008 GfsusGfgUfgGfaCfUfUfcUfcUfcAfaUfuUfL96 991 asAfsaUfuGfaGfaGfaagUfcCfaCfcAfcsgsa 1020 AD-65377 csgsuggudGgucdTucucuaaauuL96 992 asdAsuugagagdAagudCcaccagcsusu 1021 vi 1¨, c:
vi AD-65409 gsgsuggaCfuUfCfUfcucaAfUfuuuaL96 993 PusAfsaaaUfuGfAfgagaAfgUfccaccsasc 1022 AD-65403 gsgsuggaCfuUfCfUfcucaAfUfuuuaL96 994 usAfsaaaUfuGfAfgagaAfgUfccaccsasc 1023 AD-65385 usgsgacuacdTcucaaauuuaL96 995 usdAsaaauugadGagadAguccasusu 1024 Table 6. Exemplary Unmodified Sense and Antisense Strand Sequences of HBV
dsRNAs (Activity data available in W02016/077321, incorporated herein by reference) P
SEQ
u, ID Antisense SEQ ID .
-f5 Duplex ID Sense ID Sense Sequence Unmodified (5' to 3') NO:
ID Antisense Sequence Unmodified (5' to 3') NO: " , , , UGAGAGAAGUCCACCACGAUU 1036 .
, .3 1-d UAGAGGUGAAGCGAAGUGCACUU 1040 n ,-i UAGAGGUGAAGCGAAGUGCACUU 1041 cp t.) o 1¨
oe AAUUGAGAGAAGUCCACCAGCAG 1042 'a t.) oe 1¨
AAUUGAGAGAAGUCCACCAGCUU 1043 cr ME1 27037625v.1 SEQ
ID Antisense SEQ ID
Duplex ID Sense ID Sense Sequence Unmodified (5' to 3') NO:
ID Antisense Sequence Unmodified (5' to 3') NO: 0 n.) o 1¨, UAAAAUUGAGAGAAGUCCACCAC 1044 oe 1¨, vo un 1¨, UAAAAUUGAGAGAAGUCCACCAC 1045 c:
un Table 7. Exemplary Modified Sense and Antisense Strand Sequences of HBV dsRNAs (Activity data available in W02016/077321, incorporated herein by reference) P
SEQ
SEQ
Antisense 2 Duplex ID Sense ID Sense Sequence (5 to 3' ID ) ID
Antisense Sequence (5' to 3') ID .
u, NO:
NO: .
AD-65381 A-130366 uscsguGfgUfGfGfacuucucucaL96 1047 A-131904 PusGfsagaGfaAfGfuccaCfcAfcgasusu 1058 , , , AD-66019 A-130366 uscsguGfgUfGfGfacuucucucaL96 1048 A-131904 VPusGfsagaGfaAfGfuccaCfcAfcgasusu .3 AD-65375 A-130366 uscsguGfgUfGfGfacuucucucaL96 1049 A-130364 usGfsagaGfaAfGfuccaCfcAfcgasusu 1060 AD-65427 A-130441 gsusgcacUfuCfGfCfuucaccucuaL96 1050 A-131905 PusAfsgagGfugaagcgAfaGfugcacsusu 1061 AD-66110 A-130441 gsusgcacUfuCfGfCfuucaccucuaL96 1051 A-131905 VPusAfsgagGfugaagcgAfaGfugcacsusu 1062 IV
AD-65421 A-130441 gsusgcacUfuCfGfCfuucaccucuaL96 1052 A-130442 us Afs gagGfugaagcgAfaGfugc ac susu 1063 n c 4 AD-65407 A-130371 csgsugguGfgAfCfUfucucUfCfaauuL96 1053 A-130372 as AfsuugAfgAfgAfaguCfcAfccagc s as g 1064 n.) o 1¨, oe AD-65377 A-130384 csgsuggudGgucdTucucuaaauuL96 1054 A-130748 asdAsuugagagdAagudCcaccagcsusu 1065 n.) oe 1¨, 1¨, cr ME1 27037625v.1 SEQ SEQ
AMisense Duplex ID Sense ID Sense Sequence (5' to 3') ID
Antisense Sequence (5' to 3') ID
ID
NO:
NO: 0 n.) AD-65409 A-130388 gsgsuggaCfuUfCfUfcucaAfUfuuuaL96 1055 A-131906 PusAfs aaaUfuGfAfgagaAfgUfcc aces as c 1066 oe 1¨, o vi AD-66111 A-130388 gsgsuggaCfuUfCfUfcucaAfUfuuuaL96 1056 A-131906 VPusAfsaaaUfuGfAfgagaAfgUfccaccsasc 1067 o vi AD-65403 A-130388 gsgsuggaCfuUfCfUfcucaAfUfuuuaL96 1057 A-130389 us AfsaaaUfuGfAfg ag aAfgUfccaccsasc 1068 Table 8. Exemplary Unmodified Sense and Antisense Strand Sequences of HBV
dsRNAs (Activity data available in W02016/077321, incorporated herein by reference) P
SEQ
SEQ .
Sense Oligo Antisense .
DuplexID Sense Sequence (5' to 3') ID Antisense Sequence (5' to 3') ID u, Name OligoName .
NO:
NO: .
AGAGGUGAAGCGAAGUGCACACG 1115 ' , , UCAGAGGUGAAGCGAAGUGCACA 1116 , , .
UAGGUGAAGCGAAGUGCACACGG 1117 ' IV
1123 n cp UGACGUGCAGAGGUGAAGCGAAG 1125 n.) o 1¨, oe k .., UAUGAGAAGGCACAGACGGGGAG 1127 c'e 1¨, 1¨, UAGAUGAGAAGGCACAGACGGGG 1128 cr ME1 27037625v.1 SEQ
SEQ
Sense Oligo Antisense DuplexID Sense Sequence (5' to 3') ID
Antisense Sequence (5 to 3') ID
Name OligoName NO:
NO: 0 n.) UAAAAAGUUGCAUGGUGCUGGUG 1129 o 1-, oe vi c:
vi UCCAAGAGUCCUCUUAUGUAAGA 1139 .
u, UAAGAGUCCUCUUAUGUAAGACC 1140 .
t.) AD-61561 A-123523 ACUUCAAAGACUGUUUGUUUA 1095 A-123524 , AAACAAACAGUCUUUGAAGUAUG 1142 .
, , , AACAAACAGUCUUUGAAGUAUGC 1143 .
.3 1149 Iv n 1151 cp n.) o -,-:--, 1153 n.) oe 1-, cr ME1 27037625v.1 SEQ
SEQ
Sense Oligo Antisense DuplexID Sense Sequence (5' to 3') ID
Antisense Sequence (5' to 3') ID
Name OligoName NO:
NO: 0 n.) AGUACAAAGACCUUUAAUCUAAU 1155 o oe o vi o vi Table 9. Exemplary Unmodified Sense and Antisense Strand Sequences of HBV
dsRNAs (Activity data available in W02016/077321, incorporated herein by reference) P
.
Sense SEQ Antisense u, SEQ ID
..' Duplex ID Oligo Sense Sequence (5 to 3') ID Oligo Antisense Sequence (5' to 3') .
NO:
w Name NO: Name ."
, AD-65776 A-131859 UfsgsUfgCfaCfuUfCfGfcUfuCfaCfcUfcUfL96 1161 A-131860 as Gfs aGfgUfgAfaGfcgaAfgUfgCfaCfasc sg 1207 ' , , AD-65782 A-131877 UfsgsCfaCfuUfcGfCfUfuCfaCfcUfcUfgAfL96 1162 A-131878 usCfs aGfaGfgUfgAfageGfaAfgUfgCfascs a 1208 2 AD-65792 A-131865 GfsusGfuGfcAfcUfUfCfgCfuUfcAfcCfuAfL96 1163 A-131866 usAfsgGfuGfaAfgCfgaaGfuGfcAfcAfcsgsg 1209 AD-65781 A-131861 CfsgsUfgUfgCfaCfUfUfcGfcUfuCfaCfcUfL96 1164 A-131862 as GfsgUfgAfaGfc GfaagUfgCfaCfaCfgsgsu 1210 AD-64304 A-128443 GfsusGfcAfcUfuCfGfCfuUfcAfcCfuCfuAfL96 1165 A-128444 usAfsgAfgGfuGfaAfgcgAfaGfuGfcAfcsasc 1211 AD-65771 A-131857 CfscsGfuGfuGfcAfCfUfuCfgCfuUfcAfcAfL96 1166 A-131858 us GfsuGfaAfgCfgAfaguGfcAfcAfcGfgsusc 1212 AD-65758 A-131867 CfsasCfuUfcGfcUfUfCfaCfcUfcUfgCfaAfL96 1167 A-131868 usUfsgCfaGfaGfgUfgaaGfcGfaAfgUfgsc s a 1213 AD-65777 A-131875 AfscsUfuCfgCfuUfCfAfcCfuCfuGfcAfcAfL96 1168 A-131876 us GfsuGfcAfgAfgGfugaAfgCfgAfaGfusgsc 1214 Iv n 1-i AD-61567 A-123525 GfsgsCfuGfuAfgGfCfAfuAfaAfuUfgGfuAfL96 1169 A-123526 usAfscCfaAfuUfuAfugcCfuAfcAfgCfcsusc 1215 cp AD-65772 A-131873 UfsusCfgCfuUfcAfCfCfuCfuGfcAfcGfuAfL96 1170 A-131874 usAfscGfuGfcAfgAfgguGfaAfgCfgAfasgsu 1216 t.) o 1-, AD-65767 A-131871 UfscsGfcUfuCfaCfCfUfcUfgCfaCfgUfcAfL96 1171 A-131872 us Gfs aCfgUfgCfaGfaggUfgAfaGfcGfas asg 1217 0 e AD-65763 A-131869 CfsusUfcGfcUfuCfAfCfcUfcUfgCfaCfgUfL96 1172 A-131870 asCfsgUfgCfaGfaGfgugAfaGfcGfaAfgsusg 1218 t.) oe 1-, AD-64281 A-128395 CfscsCfcGfuCfuGfUfGfcCfuUfcUfcAfuAfL96 1173 A-128396 usAfsuGfaGfaAfgGfcacAfgAfcGfgGfgsasg 1219 cr ME1 27037625v.1 Sense SEQ Antisense SE Q ID
Duplex ID Oligo Sense Sequence (5' to 3') ID Oligo Antisense Sequence (5' to 3') NO:
Name NO: Name t.) o AD-64311 A-128391 CfscsGfuCfuGfuGfCfCfuUfcUfcAfuCfuAfL96 1174 A-128392 usAfsgAfuGfaGfaAfggcAfcAfgAfcGfgsgsg 1220 oe AD-65790 A-131837 CfscsAfgCfaCfcAfUfGfcAfaCfuUfuUfuAfL96 1175 A-131838 usAfsaAfaAfgUfuGfcauGfgUfgCfuGfgsusg 1221 vi AD-65761 A-131841 CfsasCfcAfgCfaCfCfAfuGfcAfaCfuUfuUfL96 1176 A-131842 asAfsaAfgUfuGfcAfuggUfgCfuGfgUfgscsg 1222 c:
vi AD-65786 A-131849 CfsasCfcAfuGfcAfAfCfuUfuUfuCfaCfcUfL96 1177 A-131850 as GfsgUfgAfaAfaAfguuGfcAfuGfgUfgscsu 1223 AD-65785 A-131835 CfsasAfuGfuCfaAfCfGfaCfcGfaCfcUfuAfL96 1178 A-131836 usAfs aGfgUfc GfgUfcguUfgAfcAfuUfgscs a 1224 AD-65787 A-131863 CfsgsCfuUfcAfcCfUfCfuGfcAfcGfuCfgAfL96 1179 A-131864 usCfsgAfc GfuGfcAfgagGfuGfaAfgCfgs as a 1225 AD-65770 A-131845 AfscsCfuUfgAfgGfCfAfuAfcUfuCfaAfaGfL96 1180 A-131846 csUfsuUfgAfaGfuAfugcCfuCfaAfgGfuscsg 1226 AD-65766 A-131843 CfscsGfaCfcUfuGfAfGfgCfaUfaCfuUfcAfL96 1181 A-131844 us Gfs aAfgUfaUfgCfcucAfaGfgUfcGfgsusc 1227 AD-61555 A-123521 GfsasCfcUfuGfaGfGfCfaUfaCfuUfcAfaAfL96 1182 A-123522 usUfsuGfaAfgUfaUfgccUfcAfaGfgUfcsgsg 1228 AD-65762 A-131855 AfscsCfgAfcCfuUfGfAfgGfcAfuAfcUfuAfL96 1183 A-131856 usAfsaGfuAfuGfcCfucaAfgGfuCfgGfuscsg 1229 P
AD-65755 A-131827 UfscsGfcAfuGfgAfGfAfcCfaCfcGfuGfaAfL96 1184 A-131828 usUfscAfcGfgUfgGfucuCfcAfuGfcGfascsg 1230 2 AD-65788 A-131811 UfsusAfcAfuAfaGfAfGfgAfcUfcUfuGfgAfL96 1185 A-131812 usCfscAfaGfaGfuCfcucUfuAfuGfuAfasgs a 1231 ..'.
-I" AD-65768 A-131803 UfscsUfuAfcAfuAfAfGfaGfgAfcUfcUfuAfL96 1186 A-131804 usAfsaGfaGfuCfcUfcuuAfuGfuAfaGfascsc 1232 , AD-61561 A-123523 Afsc sUfuCfaAfaGfAfCfuGfuUfuGfuUfuAfL96 1187 A-123524 usAfsaAfcAfaAfcAfgucUfuUfgAfaGfusasu 1233 , AD-65764 A-131801 UfsasCfuUfcAfaAfGfAfcUfgUfuUfgUfuUfL96 1188 A-131802 asAfsaCfaAfaCfaGfucuUfuGfaAfgUfasusg 1234 2 AD-65753 A-131799 AfsusAfcUfuCfaAfAfGfaCfuGfuUfuGfuUfL96 1189 A-131800 asAfscAfaAfcAfgUfcuuUfgAfaGfuAfusgsc 1235 AD-65765 A-131817 UfsusGfuUfuAfaAfGfAfcUfgGfgAfgGfaAfL96 1190 A-131818 usUfscCfuCfcCfaGfucuUfuAfaAfcAfasasc 1236 AD-65769 A-131819 GfscsAfuAfcUfuCfAfAfaGfaCfuGfuUfuAfL96 1191 A-131820 usAfsaAfcAfgUfcUfuugAfaGfuAfuGfcscsu 1237 AD-65759 A-131815 CfsasAfaGfaCfuGfUfUfuGfuUfuAfaAfgAfL96 1192 A-131816 usCfsuUfuAfaAfcAfaacAfgUfcUfuUfgs as a 1238 AD-65774 A-131831 AfsgsAfcUfgUfuUfGfUfuUfaAfaGfaCfuAfL96 1193 A-131832 usAfsgUfcUfuUfaAfacaAfaCfaGfuCfususu 1239 Iv AD-65778 A-131807 GfsusUfuGfuUfuAfAfAfgAfcUfgGfgAfgAfL96 1194 A-131808 usCfsuCfcCfaGfuCfuuuAfaAfcAfaAfcsasg 1240 n AD-65773 A-131805 GfsgsGfgGfaGfgAfGfAfuUfaGfaUfuAfaAfL96 1195 A-131806 usUfsuAfaUfcUfaAfucuCfcUfcCfcCfc sas a 1241 cp AD-65789 A-131825 GfsgsGfgAfgGfaGfAfUfuAfgAfuUfaAfaGfL96 1196 A-131826 c sUfsuUfaAfuCfuAfaucUfcCfuCfcCfc sc s a 1242 t.) o 1¨, AD-65783 A-131809 GfsusUfgGfgGfgAfGfGfaGfaUfuAfgAfuUfL96 1197 A-131810 asAfsuCfuAfaUfcUfccuCfcCfcCfaAfcsusc 1243 0 e AD-65754 A-131813 UfsusGfgGfgGfaGfGfAfgAfuUfaGfaUfuAfL96 1198 A-131814 usAfsaUfcUfaAfuCfuccUfcCfcCfcAfascsu 1244 t.) oe 1¨, AD-65779 A-131821 GfsgsGfaGfgAfgAfUfUfaGfaUfuAfaAfgAfL96 1199 A-131822 usCfsuUfuAfaUfcUfaauCfuCfcUfcCfcscsc 1245 cr ME1 27037625v.1 Sense SEQ Antisense SEQ ID
Duplex ID Oligo Sense Sequence (5' to 3') ID
Oligo Antisense Sequence (5' to 3') NO:
Name NO: Name t..) o AD-65791 A-131851 UfsusAfgAfuUfaAfAfGfgUfcUfuUfgUfaAfL96 1200 A-131852 usUfsaCfaAfaGfaCfcuuUfaAfuCfuAfasusc 1246 oe AD-65760 A-131829 UfsasGfaUfuAfaAfGfGfuCfuUfuGfuAfcUfL96 1201 A-131830 asGfsuAfcAfaAfgAfccuUfuAfaUfcUfasasu 1247 yD
vi AD-65784 A-131823 AfsusUfaGfaUfuAfAfAfgGfuCfuUfuGfuAfL96 1202 A-131824 usAfscAfaAfgAfcCfuuuAfaUfcUfaAfuscsu 1248 c:
vi AD-65757 A-131853 GfsasGfgAfgAfuUfAfGfaUfuAfaAfgGfuAfL96 1203 A-131854 usAfscCfuUfuAfaUfcuaAfuCfuCfcUfcscsc 1249 AD-65775 A-131847 GfsgsAfcUfcUfuGfGfAfcUfcUfcUfgCfaAfL96 1204 A-131848 usUfsgCfaGfaGfaGfuccAfaGfaGfuCfcsusc 1250 AD-65780 A-131833 AfscsUfcUfuGfgAfCfUfcUfcUfgCfaAfuAfL96 1205 A-131834 usAfsuUfgCfaGfaGfaguCfcAfaGfaGfuscsc 1251 AD-65756 A-131839 AfsgsAfuUfaAfaGfGfUfcUfuUfgUfaCfuAfL96 1206 A-131840 usAfsgUfaCfaAfaGfaccUfuUfaAfuCfusasa 1252 Table 10. Exemplary Unmodified HBV X ORF Sense and Antisense Sequences.
(Activity data available in W02016/077321, incorporated herein by P
reference) u9 ..' DuplexID Sense Sequence Unmodified (5' to 3') SEQ ID NO:
Antisense Sequence Umodified (5' to 3') SEQ ID NO:
.
, , .3 AGAGGUGAAGCGAAGUGCACAUU 1268 Iv n AAAAGUUGCAUGGUGCUGGUGUU 1270 cp t..) o 1¨, AGGUGAAAAAGUUGCAUGGUGUU 1271 oe -a-, t.., AGGUGAAAAAGUUGCAUGGUGUU 1272 c'e 1¨, 1¨, c:
ME1 27037625v.1 Table 11. Exemplary Modified HBV X ORF Sense and Antisense Sequences.
(Activity data available in W02016/077321, incorporated herein by reference) t.) o 1¨, oe 1¨, DuplexID SEQ ID Antisense Sequence Modified (5' to 3') SEQ ID
u, Sense Sequence Modified (5' to 3') ,.., NO:
NO: c7, u, AD-66808 gsuscuGfuGfCfCfuucucaucuaL96 1273 usAfsgauGfaGfAfaggcAfcAfgacsusu 1283 AD-66809 gsuscuGfuGfCfCfuucucaucuaL96 1274 UfsAfsgauGfaGfAfaggcAfcAfgacsusu 1284 AD-66810 gsusguGfcAfCfUfucgcuucacaL96 1275 usGfsugaAfgCfGfaaguGfcAfcacsusu 1285 AD-66811 gsusguGfcAfCfUfucgcuucacaL96 1276 UfsGfsugaAfgCfGfaaguGfcAfcacsusu 1286 AD-66812 usgsugcaCfuUfCfGfcuucaccucuL96 1277 asGfsaggUfgAfAfgcgaAfgUfgcacasusu 1287 P
AD-66813 usgsugcaCfuUfCfGfcuucaccucuL96 1278 AfsGfsaggUfgAfAfgcgaAfgUfgcacasusu 1288 .
u9 AD-66814 csasccagCfaCfCfAfugcaacuuuuL96 1279 asAfsaagUfuGfCfauggUfgCfuggugsusu 1289 ..' cs, AD-66815 csasccagCfaCfCfAfugcaacuuuuL96 1280 AfsAfsaagUfuGfCfauggUfgCfuggugsusu 1290 " , AD-66816 csasccauGfcAfAfCfuuuuucaccuL96 1281 asGfsgugAfaAfAfaguuGfcAfuggugsusu 1291 , , , AD-66817 csasccauGfcAfAfCfuuuuucaccuL96 1282 AfsGfsgugAfaAfAfaguuGfcAfuggugsusu 1292 .3 Iv n ,¨i cp t.., =
oe -c-:--, t.., oe c7, ME1 27037625v.1 Table 12: HBV Target Sequences, noting target sites on Accession No. X02763.1.
(Activity data and exemplary chemical modifications available at W02012/024170, incorporated herein by reference) Target Sequence Target Site SEQ ID NO:
Target Sequence Target Site SEQ ID NO:
Target Sequence Target Site SEQ ID NO:
Table 13. Various HBV siNA sense and antisense sequences corresponding to the identified target sequences in Table la. (Activity data and exemplary chemical modifications available at W02012/024170, incorporated herein by reference) E. S Q ID SEQ ID
Target Site Sense Sequence Anti sense Sequence NO: NO:
E. S Q ID SEQ
ID
Target Site Sense Sequence Antisense Sequence NO: NO:
E. S Q ID SEQ
ID
Target Site Sense Sequence Antisense Sequence NO: NO:
EQUIVALENTS
Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments and methods described herein. Such equivalents are intended to be encompassed by the scope of the following claims.
There are a number of differences between the HBV-transgenic and AAV-HBV mouse models. The HBV transgenic mice can express HBV antigens essentially from birth, whereas the AAV-HBV model allows for the introduction of the HBV genome at a later time in the life of the mice. This may have an effect on immune tolerance. Further, the HBV transgenic mice carry the transgene in every cell of the body, providing the possibility of "leaky"
extrahepatic expression.
Although the AAV8 serotype could infect cells outside of the liver, it has a strong liver tropism.
Moreover, it is not possible to clear an HBV infection in a transgenic mouse.
When a transgenic HBV expressing liver cell is killed, it is replaced by a new HBV expressing cell. In the infection model, if the infected cells are killed, the newly dividing cells are not infected at the time of cell division.
Nine week old C57/B16 mice were infected with AAV-HBV (- 28 days). Mice were then treated with one of control siRNA, or one of two HBV-siRNAs, modified AD-66816 or modified AD-66810 at 3 mg/kg administered subcutaneously on days 0, 29, and 57 (i.e., 0 weeks, 4 weeks, 8 weeks) (n=12 per group). Each siRNA treatment group was divided into two groups (n=6 per group). One group was treated with the HBV vaccine protocol (protein prime on days 57 and 70, and MVA boost on day 84, i.e., weeks 8, 10, and 12, respectively) and one group was not. A
schematic showing the dosing regimen is provided in Figure 12. Mice were monitored throughout the experiment for serum HBsAg, HBeAg, anti-HBs antibodies, body weight, and ALT. Anti-HBe antibody levels were also periodically tested.
Figures 13A and 13B show an increase in HBsAg and HBeAg levels comparable to that seen in transgenic mice within two weeks of transduction with the AAV-HBV virus.
Mice treated only with the control siRNA replicated HBV for greater than 8 months at levels comparable to chronically infected humans (HBsAg levels around 2,000 IU/ml, HBV viremia 106107 IU/ml).
HBV siRNAs AD-66816 and AD-66810 reduced HBsAg by 2 and 2.5 logio, respectively, and HBeAg by >1 logio.
The effect persisted for at least 4 weeks after stopping siRNA treatment before antigenemia slowly rebounded to baseline levels after 18 weeks (Figures 13A and13B).
Intrahepatic HBV DNA (Figure 13D) and AAV DNA (Figure 13E) levels were determined at week 22 by qPCR as described above. The relative expression in liver of HBV
3.5 RNA relative to GAPDH RNA (Figure 13F) and total HBV RNA relative to GAPDH RNA (Figure 13G) were determined using rtPCR. Mice treated with the combined siRNA-vaccine protocol demonstrated a significant decrease in total HBV DNA and AAV DNA as compared to untreated control or siRNA or vaccine treatement alone at the 22 week time point (Figures 13D and 13E).
Notably, total HBV DNA
levels dropped to less than one copy per cell as a result of the combination treatment (Figure 13D).
Mice treated with the combined siRNA-vaccine protocol also demonstrated a significant decrease level of HBV 3.5 kb RNA expression relative to GAPDH RNA expression as compared to all other treatment regimens (Figure 13F). A significant decrease in total HBV RNA
relative to GAPDH RNA
expression was observed as compared to treatment with vaccine or siRNA alone (Figure 13G). These data suggest that a short course of administration of siRNA alone or a therapeutic vaccine against HBV is insufficient to durably suppress HBV infection. Immune mediated control of HBV after siRNA knockdown of HBV expression is long lasting. At 22 weeks after the last siRNA dose, the .. effect of the siRNA was waning as seen in the groups which had only received the HBV siRNAs without vaccination. Mice treated with the siRNA-vaccine protocol maintained HBV DNA and RNA
suppression long after the end of siRNA administration.
No immune responses were observed in these fully immune competent mice under siRNA
treatment alone, but vaccine treatment resulted in anti-HBs seroconversion in all vaccinated animals (Figures 14A and 14B). siRNA-pretreated animals, however, developed 10-fold higher and more constant anti-HBs titers and were able to completely and persistently clear serum HBsAg and HBeAg.
In contrast, anti-HBe seroconversion was only observed in antimals pretreated with HBV siRNAs.
Interestingly, three of the 12 mice vaccinated after HBV siRNA treatment showed a transient relapse of HBeAg between week 15 and 22 co-inciding with decreased levels of anti-HBe (Figure 13C).
Without being bound by mechanism, it is proposed that theHBeAg relapse was controlled by a memory immune response induced by the vaccine. Taken together, suppression of HBV antigen expression by an siRNA in combination with a heterologous prime-boost vaccine is sufficient to break immune tolerance to HBV antigens. The sequential therapy achieved long-term functional cure in a mouse model of persistent HBV infection without causing significant liver damage.
Figures 14A and 14B show that animals treated with HBV siRNA plus the vaccine regimen developed high titers of anti-HBs antibodies and anti-HBe antibodies. The level of anti-HBs antibodies continued to increase after the last vaccine dose. Although anti-HBs antibodies could also be measured in animals that received the control siRNA plus the vaccine regimen, the levels were significantly lower. Further, only animals that received HBV siRNA plus the vaccine regimen developed anti-HBe antibodies and achieved anti-HBe seroconversion. The combinatorial therapy using siRNA and vaccine appeared to be well tolerated. All mice equally gained weight and only a mild ALT elevation (<2-fold upper limit of normal) was observed (Figures 15A
and 15B). The loss of antigenemia concided with slight increases of ALT activity seen in treatment groups which had received HBV siRNA in conjunction with the vaccination regimen (Figure 15A).
These groups showed significant but mild increases (both p>0.05 or smaller by repeated measure two-way ANOVA; only comparing time points after start of vaccination) as compared to all other treatment groups that did not receive the combination HBVsiRNA-vaccine regimen. There was a steady increase in body weight in all animals throughout the experiment independent of siRNA treatment.
Animals that were vaccinated showed a slight and transient decrease (approximately 5%) of body weight after vaccination, but rebounded to normal levels within nine days and subsequently gained weight comparable to the control groups (Figure 15B).
Without being bound by mechanism, the data provided herein strongly suggest that the high level of HBV antigen expression routinely detected as circulating HBsAg and HBeAg prevents HBV-specific CD8+ T cell responses, which has far reaching consequences for future immune therapy of chronic hepatitis B. Using 2 different mouse models for chronic hepatitis B, it is proposed that HBV-specific immunomodulation can be reverted by suppressing HBV protein expression in hepatocytes using an RNAi-based therapy. Such reduction of HBV antigens by RNAi, in contrast to standard-of-care nucleo(t)side analogues, allows for induction of strong HBV-specific CD8+
T cell responses by therapeutic vaccination that are required for control of HBV infection.
APPENDIX A
Table 1. Abbreviations of nucleotide monomers used in nucleic acid sequence representation. It will be understood that, unless otherwise indicated, these monomers, when present in an oligonucleotide, are mutually linked by 5'-3'-phosphodiester bonds.
Abbreviation Nucleotide(s) A Adenosine-3'-phosphate Af 2'-fluoroadenosine-3' -phosphate Afs 2'-fluoroadenosine-3'-phosphorothioate As adenosine-3' -phosphorothioate cytidine-3' -phosphate Cf 2'-fluorocytidine-3' -phosphate Cfs 2'-fluorocytidine-3'-phosphorothioate Cs cytidine-3'-phosphorothioate guanosine-3'-phosphate Gf 2'-fluoroguanosine-3' -phosphate Gfs 2'-fluoroguanosine-3'-phosphorothioate Gs guanosine-3'-phosphorothioate 5'-methyluridine-3' -phosphate Tf 2'-fluoro-5-methyluridine-3' -phosphate Tfs 2'-fluoro-5-methyluridine-3'-phosphorothioate Ts 5-methyluridine-3'-phosphorothioate Uridine-3'-phosphate Uf 2'-fluorouridine-3' -phosphate Ufs 2'-fluorouridine -3'-phosphorothioate Us uridine -3' -phosphorothioate any nucleotide (G, A, C, T or U) a 2'-0-methyladenosine-3' -phosphate as 2'-0-methyladenosine-3'- phosphorothioate 2'-0-methylcytidine-3'-phosphate cs 2'-0-methylcytidine-3'- phosphorothioate 2'-0-methylguanosine-3'-phosphate gs 2'-0-methylguanosine-3'- phosphorothioate 2'-0-methyl-5-methyluridine-3' -phosphate ts 2'-0-methyl-5-methyluridine-3'-phosphorothioate 2'-0-methyluridine-3'-phosphate us 2'-0-methyluridine-3'-phosphorothioate phosphorothioate linkage Abbreviation Nucleotide(s) L96 N-Itris(Ga1NAc-alkyl)-amidodecanoy1)]-4-hydroxyprolinol Hyp-(GalNAc-alky1)3 (dT) T -deoxythymidine-3 -phosphate Y34 2-hydroxymethyl-tetrahydrofurane-4-methoxy-3-phosphate (abasic 2'-0Me furanose) Y44 2-hydroxymethyl-tetrahydrofurane-5-phosphate (Agn) Adenosine-glycol nucleic acid (GNA) (Tgn) Thymidine-glycol nucleic acid (GNA) S-Isomer (Cgn) Cytidine-glycol nucleic acid (GNA) P Phosphate VP Vinyl-phosphate Table 2. Exemplary Unmodified Sense and Antisense Strand Sequences of HBV
dsRNAs (Activity data available in W02016/077321, incorporated herein by reference) n.) o 1-, oe Duplex Sense Oligo SEQ Antisense SEQ ID Position in Sense Sequence (5' to 3') Antisense Sequence (5' to 3') vD
Name Name ID NO Oligo Name NO: NC_003977.1 vi 1-, c:
263 731_753 vi 264 373_395 265 250_272 266 250_272 267 250_272 268 250_272 252_274 P
270 250_272 c, 271 250_272 272 250_272 .
c, 273 250_272 , ,-, UGAGAGAAGUCCACCACGA 274 254_276 , c, .3 275 250_272 252_274 277 250_272 278 250_272 279 250_272 280 250_272 Iv n 252_274 1-3 282 250_272 cp n.) 283 250_272 o 1-, oe 284 250_272 t..) oe UGAGAGAAGUCCACCACGA 285 254_276 1-, c:
286 250_272 ME1 27037625v.1 Duplex Sense Oligo SEQ Antisense SEQ ID Position in Sense Sequence (5' to 3') Antisense Sequence (5' to 3') Name Name ID NO Oligo Name NO: NC_003977.1 UGAGAGAAGUCCACCACGAUU 287 252_274 0 n.) UGAGAGAAGUCCACCACGAGUCU 288 250_272 oe UGAGAGAAGUCCACCACGAGUCU 289 250_272 vi UGAGAGAAGUCCACCACGAGUCU 290 250_272 c:
vi UGAGAGAAGUCCACCACGAGUCU 291 250_272 UGAGAGAAGUCCACCACGAGUCU 292 250_272 UGAGAGAAGUCCACCACGAGUCU 293 250_272 UGAGAGAAGUCCACCACGAGUCU 294 250_272 UGAGAGAAGUCCACCACGAGUCU 295 250_272 UGAGAGAAGUCCACCACGAGUCU 296 250_272 UGAGAGAAGUCCACCACGAGUCU 297 250_272 Q
UGAGAGAAGUCCACCACGAGUCU 298 250_272 u, UGAGAGAAGUCCACCACGAGUCU 299 250_272 .
'-c->
.
UGAGAGAAGTCCACCACGAGUCU 300 250_272 " , ' AD -63975 A-127915 ACUCGUGGUGGACUUCTCUCA
301 250_272 , .
, UGAGAGAAGUCCACCACGAGUCU 302 250_272 ' .3 UGAGAGAAGUCCACCACGAGUCU 303 250_272 UGAGAGAAGUCCACCACGAGUCU 304 250_272 UGAGAGAAGUCCACCACGAGUCU 305 250_272 UGAGAGAAGUCCACCACGAGUCU 306 250_272 UGAGAGAAGUCCACCACGAGUCU 307 250_272 UGAGAGAAGUCCACCACGAGUCU 308 250_272 Iv n UGAGAGAAGUCCACCACGAGUCU 309 250_272 cp AAAUUGAGAGAAGUCCACCACGA 310 254_276 n.) 1¨, AAAUUGAGAGAAGUCCACCACGA 311 254_276 0 e AAAUUGAGAGAAGUCCACCACGA 312 254_276 n.) oe 1¨, AAAUUGAGAGAAGUCCACC 313 258_280 cr ME1 27037625v.1 Duplex Sense Oligo SEQ Antisense SEQ ID Position in Sense Sequence (5' to 3') Antisense Sequence (5' to 3') Name Name ID NO Oligo Name NO: NC_003977.1 314 254_276 0 n.) 256_278 1--, oe 316 254_276 1--, vi 317 254_276 1--, c:
vi 318 254_276 256_278 320 254_276 256_278 322 254_276 323 254_276 AAAUUGAGAGAAGUCCACC 324 258_280 Q
325 254_276 u, 256_278 .
'-c->
.
t.) AD-64003 A-127964 GUGGUGGACUUCUCUCAAUUU 111 A-127956 AAAUUGAGAGAAGUCCACCACGA 327 254_276 " , ' AD-64004 A-127955 GUGGUGGACUUCUCUCAAUUU 112 A-127972 AAAUUGAGAGAAGUCCACCACGA
328 254_276 , .
, 329 254_276 .3 330 254_276 331 254_276 332 254_276 333 254_276 334 254_276 335 254_276 Iv n 336 254_276 cp 337 254_276 n.) 1--, 338 254_276 0 e 339 254_276 n.) oe 1--, 340 254_276 1--, cr ME1 27037625v.1 Duplex Sense Oligo SEQ Antisense SEQ ID Position in Sense Sequence (5' to 3') Antisense Sequence (5' to 3') Name Name ID NO Oligo Name NO: NC_003977.1 341 254_276 0 n.) 342 254_276 1--, oe 343 254_276 1--, vi 344 254_276 1--, c:
vi 345 254_276 346 254_276 347 254_276 348 254_276 349 254_276 350 254_276 351 254_276 Q
256_278 u, 353 254_276 .
'-c->
.
w AD-64272 A-128001 GUGCACUUCGCUUCACCUCUG 138 A-128002 CAGAGGUGAAGCGAAGUGCACAC
354 1577_1599 " , ' AD-64274 A-128363 GUUGACAAAAAUCCUCACAAU 139 A-128364 AUUGUGAGGAUUUUUGUCAACAA
355 215_237 , .
, 356 214_236 ' .3 357 256_278 358 2259_2281 359 2259_2281 360 1857_1879 361 1255_1277 362 375_397 Iv n 363 1545_1567 cp 364 1831_1853 n.) 1--, 365 245_267 0 e 366 1256_1278 n.) oe 1--, 367 207_229 1--, cr ME1 27037625v.1 Duplex Sense Oligo SEQ Antisense SEQ ID Position in Sense Sequence (5' to 3') Antisense Sequence (5' to 3') Name Name ID NO Oligo Name NO: NC_003977.1 UAGAAGAACCAACAAGAAGAUGA 368 426_448 0 n.) AUUUUUGUCAACAAGAAAAACCC 369 206_228 1--, oe UAACAAGAGAUGAUUAGGCAGAG 370 1829_1851 1--, vi UACUCUGUGGUAUUGUGAGGAUU 371 226_248 1--, c:
vi UUGAGGAUUUUUGUCAACAAGAA 372 212_234 AGGCAGAGGUGAAAAAGUUGCAU 373 1814_1836 UAUGCUGUAGCUCUUGUUCCCAA 374 2828_2850 AAUUGAGAGAAGUCCACCAGCAG 375 253_275 UAAGAUGAGGCAUAGCAGCAGGA 376 411_433 AACGCCGCAGACACAUCCAACGA 377 370_392 UAGGCAUAGCAGCAGGAUGAAGA 378 405_427 Q
UAGGAUUUUUGUCAACAAGAAAA 379 210_232 u, UAAUACCACAUCAUCCAUAUAAC 380 734_756 .
'-c->
.
-i. AD -64303 A-128429 UUCAUCCUGCUGCUAUGCCUC 165 A-128430 GAGGCAUAGCAGCAGGAUGAAGA 381 405_427 " , ' AD -64304 A-128443 GUGCACUUCGCUUCACCUCUA
382 1577_1599 , .
, UAUUGUGAGGAUUUUUGUCAACA 383 216_238 ' .3 UAAGGCACAGCUUGGAGGCUUGA 384 1864_1886 UAUAGCAGCAGGAUGAAGAGGAA 385 401_423 AAGAUGAGGCAUAGCAGCAGGAU 386 410_432 AGAAGAACCAACAAGAAGAUGAG 387 425_447 UAGAUGAGAAGGCACAGACGGGG 388 1547_1569 AGAACCAACAAGAAGAUGAGGCA 389 422_444 Iv n UAAGAUAGGGGCAUUUGGUGGUC 390 2298_2320 cp AGUAUGGAUCGGCAGAGGAGCCA 391 1250_1272 n.) 1--, AUUGUGAGGAUUUUUGUCAACAA 392 215_237 0 e UUGUGAGGAUUUUUGUCAACAAG 393 214_236 n.) oe 1--, UAAAAUUGAGAGAAGUCCACCAC 394 256_278 1--, cr ME1 27037625v.1 Duplex Sense Oligo SEQ Antisense SEQ ID Position in Sense Sequence (5' to 3') Antisense Sequence (5' to 3') Name Name ID NO Oligo Name NO: NC_003977.1 395 2259_2281 0 n.) 396 2259_2281 1--, oe 397 1857_1879 1--, vi 398 1255_1277 1--, c:
vi 399 731_753 400 375_397 401 1545_1567 402 1831_1853 403 245_267 404 1256_1278 405 426_448 Q
406 263_285 u, 407 250_272 .
'-c->
.
(.., AD-64332 A-128001 GUGCACUUCGCUUCACCUCUG 192 A-128485 CAGAGGUGAAGCGAAGUGCACAC 408 1577_1599 " , ' AD-64333 A-128367 GUUUUUCUUGUUGACAAAAAU 193 A-128448 AUUUUUGUCAACAAGAAAAACCC
409 206_228 , .
, 410 1829_1851 .3 411 226_248 412 212_234 413 254_276 414 1814_1836 415 2828_2850 416 424_446 Iv n 417 411_433 cp 418 370_392 n.) 1--, 419 405_427 0 e 420 210_232 n.) oe 1--, 421 373_395 1--, cr ME1 27037625v.1 Duplex Sense Oligo SEQ Antisense SEQ ID Position in Sense Sequence (5' to 3') Antisense Sequence (5' to 3') Name Name ID NO Oligo Name NO: NC_003977.1 422 734_756 0 n.) 423 405_427 oe 424 1577_1599 vi 425 216_238 c:
vi 426 1174_1196 427 1174_1196 428 1864_1886 429 401_423 430 410_432 431 425_447 432 1547_1569 Q
433 422_444 u, 434 2298_2320 .
'-c->
.
cs, AD-64360 A-128433 GCUCCUCUGCCGAUCCAUACU 219 A-128482 AGUAUGGAUCGGCAGAGGAGCCA 435 1250_1272 " , ' AD-64700 A-129379 ACUCGUGGUGTACUUCUCUCA 220 A-127906 UGAGAGAAGUCCACCACGAGUCU
436 250_272 , .
, 437 250_272 ' .3 438 250_272 439 250_272 440 250_272 441 250_272 442 250_272 443 250_272 Iv n 444 250_272 cp 445 250_272 n.) 1¨, 446 250_272 0 e 447 250_272 n.) oe 1¨, 448 250_272 cr ME1 27037625v.1 Duplex Sense Oligo SEQ Antisense SEQ ID Position in Sense Sequence (5' to 3') Antisense Sequence (5' to 3') Name Name ID NO Oligo Name NO: NC_003977.1 UGAGAGAAGTCCACCACGAGUCU 449 250_272 0 n.) UGAGAGAAGTCCACCACGAGUCU 450 250_272 1--, oe UGAGAGAAGTCCACCACGAGUCU 451 250_272 1--, vi UGAGAGAAGUCCACCACGAGUCU 452 250_272 1--, c:
vi UGAGAGAAGUCCACCACGAGUCU 453 250_272 UGAGAGAAGUCCACCACGAGUCU 454 250_272 UGAGAGAAGTCCACCACGAGUCU 455 250_272 UGAGAGAAGTCCACCACGAGUCU 456 250_272 UGAGAGAAGTCCACCACGAGUCU 457 250_272 UGAGAGAAGUCCACCACGAGUCU 458 250_272 UGAGAGAAGUCCACCACGAGUCU 459 250_272 Q
UGAGAGAAGTCCACCACGAGUCU 460 250_272 u, UGAGAGAAGUCCACCACGAGUCU 461 250_272 .
'-c->
.
---.1 AD -64727 A-129384 ACUCGUGGTGGACUUCACUCA
462 250_272 " , ' AD -64728 A-129376 ACUCGUGGUGGACUUCACUCA
463 250_272 , .
, UGAGAGAAGUCCACCACGAGUCU 464 250_272 ' .3 UGAGAGAAGTCCACCACGAGUCU 465 250_272 UGAGAGAAGTCCACCACGAGUCU 466 250_272 UGAGAGAAGUCCACCACGAGUCU 467 250_272 UGAGAGAAGTCCACCACGAGUCU 468 250_272 UGAGAGAAGUCCACCACGAGUCU 469 250_272 UGAGAGAAGTCCACCACGAGUCU 470 250_272 Iv n UGAGAGAAGTCCACCACGAGUCU 471 250_272 cp UGAGAGAAGTCCACCACGAGUCU 472 250_272 n.) 1--, UGAGAGAAGUCCACCACGAGUCU 473 250_272 0 e UGAGAGAAGUCCACCACGAGUCU 474 250_272 n.) oe 1--, UGAGAGAAGTCCACCACGAGUCU 475 250_272 1--, cr ME1 27037625v.1 Duplex Sense Oligo SEQ Antisense SEQ ID Position in Sense Sequence (5' to 3') Antisense Sequence (5' to 3') Name Name ID NO Oligo Name NO: NC_003977.1 476 250_272 0 n.) o 477 250_272 oe 478 250_272 un 1¨, c:
u, Table 3. Exemplary Modified Sense and Antisense Strand Sequences of HBV dsRNAs (Activity data available in W02016/077321, incorporated herein by reference) SEQ
SEQ
Duplex Sense Oligo Antisense Sense Sequence (5' to 3') ID
Antisense Sequence (5 to 3') ID
Name Name Oligo Name NO:
NO:
AD-61522 A-123463 AfsgsUfuAfuAfuGfGfAfuGfaUfgUfgGfuAfL96 479 A-123464 usAfscCfaCfaUfcAfuccAfuAfuAfaCfusgsa 694 P
AD-61547 A-123487 GfsgsAfuGfuGfuCfUfGfcGfgCfgUfuUfuAfL96 480 A-123488 usAfsaAfaCfgCfcGfcagAfcAfcAfuCfcsasg 695 u, 696 .
cc AD-63939 A-127909 ascsucGfuGfgUfGfGfaCfuucUfcucaL96 usGfsaGfaGfaAfgUfccaCfcAfcGfaGfuscsu 697 , , AD-63940 A-127917 ascsucguggugdGacuuc(Tgn)cucaL96 usGfsaGfaGfaAfgUfccaCfcAfcGfaGfuscsu 698 , , AD-63941 A-127905 AfscsUfcGfuGfgUfGfGfaCfuUfcUfcUfcAfL96 484 A-127925 usGfsaGfagaAfguccaCfcAfcgaGfuscsu 699 .
.3 AD-63942 A-127933 uscsGfuGfgUfGfGfaCfuUfcUfcUfcAfL96 485 A-127934 usGfsaGfaGfaAfgUfccaCfcAfcGfasgsu 700 AD-63943 A-127944 ascsucGfuGfguGfGfaCfuucucucaL96 486 A-127942 usGfsAfgaGfaAfgUfccaCfcAfcGfaguscsu 701 AD-63945 A-127910 ascsucguGfgUfGfGfaCfuucUfcucaL96 usGfsaGfaGfaAfgUfccaCfcAfcGfaGfuscsu 702 AD-63946 A-127918 ascsucguGfgUfGfGfacuuCfucucaL96 usGfsaGfaGfaAfgUfccaCfcAfcGfaGfuscsu 703 AD-63947 A-127905 AfscsUfcGfuGfgUfGfGfaCfuUfcUfcUfcAfL96 489 A-127926 usGfsaGfagaagUfccaCfcAfcgaGfuscsu 704 IV
AD-63948 A-127935 gsusGfgUfGfGfaCfuUfcUfcUfcAfL96 490 A-127936 usGfsaGfaGfaAfgUfccaCfcAfcsgsa 705 n AD-63949 A-127944 ascsucGfuGfguGfGfaCfuucucucaL96 usGfsaGfaGfaAfgUfccaCfcAfcGfaGfuscsu 706 cp AD-63950 A-127900 Y44UfcGfuGfgUfgGfaCfuUfcUfcUfcAfusuY44 492 A-127901 usGfsasGfaGfaAfgUfcCfaCfcAfcGfausu 707 n.) o 1¨, AD-63951 A-127911 ascsucguGfgUfGfGfaCfuucucucaL96 usGfsaGfaGfaAfgUfccaCfcAfcGfaGfuscsu 708 0 e AD-63952 A-127905 AfscsUfcGfuGfgUfGfGfaCfuUfcUfcUfcAfL96 494 A-127919 usGfsaGfaGfaagUfccaCfcAfcGfaGfuscsu 709 n.) oe 1¨, AD-63953 A-127905 AfscsUfcGfuGfgUfGfGfaCfuUfcUfcUfcAfL96 495 A-127927 usGfsagagaAfgUfccaCfcAfcgaguscsu 710 cr ME1 27037625v.1 SEQ
SEQ
Duplex Sense Oligo Antisense Sense Sequence (5' to 3') ID
Antisense Sequence (5 to 3') ID
Name Name Oligo Name NO:
NO: 0 n.) AD-63955 A-127945 ascsucgugguGfGfacuucucucaL96 496 A-127940 usGfsAfgAfgAfaGfuccaCfCfaCfgAfguscsu 711 1¨, oe AD-63956 A-127902 Y44uscsGfuGfgUfgGfaCfuUfcUfcUfcAfY44 497 A-127903 usGfsaGfaGfaAfgUfcCfaCfcAfcGfasusu 712 un AD-63957 A-127912 ascsucguGfgUfGfGfacuucucucaL96 498 A-127906 usGfsaGfaGfaAfgUfccaCfcAfcGfaGfuscsu 713 cA
un AD-63958 A-127905 AfscsUfcGfuGfgUfGfGfaCfuUfcUfcUfcAfL96 499 A-127920 usGfsagaGfaAfgUfccaCfcAfcgaGfuscsu 714 AD-63959 A-127905 AfscsUfcGfuGfgUfGfGfaCfuUfcUfcUfcAfL96 500 A-127928 usGfsaGfagaAfguccaCfcAfcgaguscsu 715 AD-63960 A-126619 usasUfuUfCfCfuAfgGfgUfaCfaAfL96 501 A-127938 PusGfsaGfaGfaAfgUfccaCfcAfcsgsa 716 AD-63961 A-127945 ascsucgugguGfGfacuucucucaL96 502 A-127942 usGfsAfgaGfaAfgUfccaCfcAfcGfaguscsu 717 AD-63962 A-127902 Y44uscsGfuGfgUfgGfaCfuUfcUfcUfcAfY44 503 A-127904 PusGfsaGfaGfaAfgUfcCfaCfcAfcGfasusu 718 AD-63963 A-127913 ascsucguggUfgGfacuucucucaL96 504 A-127906 usGfsaGfaGfaAfgUfccaCfcAfcGfaGfuscsu 719 AD-63964 A-127905 AfscsUfcGfuGfgUfGfGfaCfuUfcUfcUfcAfL96 505 A-127921 usGfsaGfaGfaAfgUfccaCfcAfcgaguscsu 720 P
AD-63965 A-127905 AfscsUfcGfuGfgUfGfGfaCfuUfcUfcUfcAfL96 506 A-127929 usGfsagaGfaaGfuccaCfcAfcgaguscsu 721 .
L.
u9 AD-63966 A-127939 ascsUfcGfugguGfGfaCfuuCfuCfucaL96 507 A-127940 usGfsAfgAfgAfaGfuccaCfCfaCfgAfguscsu 722 ..' s:) AD-63967 A-127945 ascsucgugguGfGfacuucucucaL96 508 A-127906 usGfsaGfaGfaAfgUfccaCfcAfcGfaGfuscsu 723 , AD-63968 A-127905 AfscsUfcGfuGfgUfGfGfaCfuUfcUfcUfcAfL96 509 A-127906 usGfsaGfaGfaAfgUfccaCfcAfcGfaGfuscsu 724 .
, , AD-63968 A-127905 AfscsUfcGfuGfgUfGfGfaCfuUfcUfcUfcAfL96 510 A-127906 usGfsaGfaGfaAfgUfccaCfcAfcGfaGfuscsu 725 , .3 AD-63968 A-127905 AfscsUfcGfuGfgUfGfGfaCfuUfcUfcUfcAfL96 511 A-127906 usGfsaGfaGfaAfgUfccaCfcAfcGfaGfuscsu 726 AD-63969 A-127914 ascsucguggugGfacuucucucaL96 512 A-127906 usGfsaGfaGfaAfgUfccaCfcAfcGfaGfuscsu 727 AD-63970 A-127905 AfscsUfcGfuGfgUfGfGfaCfuUfcUfcUfcAfL96 513 A-127922 usGfsagaGfaagUfccaCfcAfcgaGfuscsu 728 AD-63971 A-127905 AfscsUfcGfuGfgUfGfGfaCfuUfcUfcUfcAfL96 514 A-127930 usGfsagaGfaaguccaCfcAfcgaguscsu 729 AD-63972 A-127941 ascsUfcGfuGfguGfGfaCfuuCfuCfucaL96 515 A-127942 usGfsAfgaGfaAfgUfccaCfcAfcGfaguscsu 730 AD-63973 A-127946 ascsucguggudGdGacuucucucaL96 516 A-127947 usdGsaGfaGfaAfgdTccadCcAfcGfaguscsu 731 IV
n AD-63975 A-127915 ascsucguggUfgGfacuuc(Tgn)cucaL96 517 A-127906 usGfsaGfaGfaAfgUfccaCfcAfcGfaGfuscsu 732 1-3 AD-63976 A-127905 AfscsUfcGfuGfgUfGfGfaCfuUfcUfcUfcAfL96 518 A-127923 usGfsagaGfaAfgUfccaCfcAfcgaguscsu 733 cp n.) o AD-63977 A-127917 ascsucguggugdGacuuc(Tgn)cucaL96 519 A-127931 usdGsagagaaguccadCcacgaguscsu 734 oe AD-63978 A-127943 ascsUfcGfuGfguGfGfaCfuUfcUfcUfcaL96 520 A-127906 usGfsaGfaGfaAfgUfccaCfcAfcGfaGfuscsu 735 n.) oe 1¨, AD-63979 A-127908 ascsucGfuGfgUfGfGfaCfuucUfcucAfL96 521 A-127906 usGfsaGfaGfaAfgUfccaCfcAfcGfaGfuscsu 736 cA
ME1 27037625v.1 SEQ
SEQ
Duplex Sense Oligo Antisense Sense Sequence (5' to 3') ID
Antisense Sequence (5 to 3') ID
Name Name Oligo Name NO:
NO: 0 n.) AD-63980 A-127916 ascsucguggugGfacuuc(Tgn)cucaL96 522 A-127906 usGfsaGfaGfaAfgUfccaCfcAfcGfaGfuscsu 737 1¨, oe AD-63981 A-127905 AfscsUfcGfuGfgUfGfGfaCfuUfcUfcUfcAfL96 523 A-127924 usGfsaGfagaAfgUfccaCfcAfcgaGfuscsu 738 un AD-63982 A-127917 ascsucguggugdGacuuc(Tgn)cucaL96 524 A-127932 PusdGsagagaaguccadCcacgaguscsu 739 cA
un AD-63983 A-127944 ascsucGfuGfguGfGfaCfuucucucaL96 525 A-127940 usGfsAfgAfgAfaGfuccaCfCfaCfgAfguscsu 740 AD-63985 A-127961 gsusggugGfaCfUfUfcUfcucAfauuuL96 526 A-127956 asAfsaUfuGfaGfaGfaagUfcCfaCfcAfcsgsa 741 AD-63986 A-127969 gsusggugGfaCfUfUfcucuCfaauuuL96 527 A-127956 asAfsaUfuGfaGfaGfaagUfcCfaCfcAfcsgsa 742 AD-63987 A-127955 GfsusGfgUfgGfaCfUfUfcUfcUfcAfaUfuUfL96 528 A-127977 asAfsaUfugagaGfaagUfcCfaccAfcsgsa 743 AD-63988 A-127986 usgsGfaCfUfUfcUfcUfcAfaUfuUfL96 529 A-127987 asAfsaUfuGfaGfaGfaagUfcCfascsc 744 AD-63989 A-127996 gsusgguggacUfUfcucucaauuuL96 530 A-127992 asAfsAfUfuGfaGfaGfaagUfcCfaCfcacsgsa 745 AD-63990 A-127950 Y44GfgUfgGfaCfuUfcUfcUfcAfaUfuUfusuY44 531 A-127951 asAfsasUfuGfaGfaGfaAfgUfcCfaCfcusu 746 P
AD-63991 A-127962 gsusggugGfaCfUfUfcUfcucaauuuL96 532 A-127956 asAfsaUfuGfaGfaGfaagUfcCfaCfcAfcsgsa 747 .
L.
u9 AD-63992 A-127955 GfsusGfgUfgGfaCfUfUfcUfcUfcAfaUfuUfL96 533 A-127970 asAfsaUfuGfagaGfaagUfcCfaCfcAfcsgsa 748 ..' .
.
AD-63993 A-127955 GfsusGfgUfgGfaCfUfUfcUfcUfcAfaUfuUfL96 534 A-127978 asAfsauugaGfaGfaagUfcCfaccacsgsa 749 , AD-63994 A-127984 gsgUfgGfaCfUfUfcUfcUfcAfaUfuUfL96 535 A-127988 PasAfsaUfuGfaGfaGfaagUfcCfaCfcsasc 750 .
, , AD-63995 A-127996 gsusgguggacUfUfcucucaauuuL96 536 A-127993 asAfsAfuuGfaGfaGfaagUfCfcaCfcacsgsa 751 , .3 AD-63996 A-127952 Y44gsgsUfgGfaCfuUfcUfcUfcAfaUfuUfY44 537 A-127953 asAfsaUfuGfaGfaGfaAfgUfcCfaCfcsusu 752 AD-63997 A-127963 gsusggugGfaCfUfUfcucucaauuuL96 538 A-127956 asAfsaUfuGfaGfaGfaagUfcCfaCfcAfcsgsa 753 AD-63999 A-127955 GfsusGfgUfgGfaCfUfUfcUfcUfcAfaUfuUfL96 539 A-127979 asAfsaUfugaGfagaagUfcCfaccacsgsa 754 AD-64000 A-127986 usgsGfaCfUfUfcUfcUfcAfaUfuUfL96 540 A-127989 PasAfsaUfuGfaGfaGfaagUfcCfascsc 755 AD-64001 A-127996 gsusgguggacUfUfcucucaauuuL96 541 A-127994 asAfsAfUfuGfaGfaGfaagUfCfcaCfcacsgsa 756 AD-64002 A-127952 Y44gsgsUfgGfaCfuUfcUfcUfcAfaUfuUfY44 542 A-127954 PasAfsaUfuGfaGfaGfaAfgUfcCfaCfcsusu 757 IV
n AD-64003 A-127964 gsusgguggaCfuUfcucucaauuuL96 543 A-127956 asAfsaUfuGfaGfaGfaagUfcCfaCfcAfcsgsa 758 1-3 AD-64004 A-127955 GfsusGfgUfgGfaCfUfUfcUfcUfcAfaUfuUfL96 544 A-127972 asAfsaUfuGfaGfaGfaagUfcCfaccacsgsa 759 cp n.) o AD-64005 A-127955 GfsusGfgUfgGfaCfUfUfcUfcUfcAfaUfuUfL96 545 A-127980 asAfsauuGfagAfgaagUfcCfaccacsgsa 760 oe AD-64006 A-127990 gsusGfgugGfaCfUfUfcUfcUfcAfaUfuuL96 546 A-127991 asAfsaUfuGfaGfaGfaagUfcCfaCfcacsgsa 761 n.) oe 1¨, AD-64007 A-127996 gsusgguggacUfUfcucucaauuuL96 547 A-127995 asAfsAfUfugaGfaGfaagUfCfcaCfcacsgsa 762 cA
ME1 27037625v.1 SEQ
SEQ
Duplex Sense Oligo Antisense Sense Sequence (5' to 3') ID
Antisense Sequence (5 to 3') ID
Name Name Oligo Name NO:
NO: 0 n.) GfsusGfgUfgGfaCfUfUfcUfcUfcAfaUfuUfL96 548 A-127956 asAfs aUfuGfaGfaGfaagUfcCfaCfcAfc sg s a 763 o 1¨, oe GfsusGfgUfgGfaCfUfUfcUfcUfcAfaUfuUfL96 549 A-127956 asAfs aUfuGfaGfaGfaagUfcCfaCfcAfc sg s a 764 un AD -64009 A-127965 gsusgguggacuUfcucucaauuuL96 550 A-127956 asAfs aUfuGfaGfaGfaagUfcCfaCfcAfc sg s a cA
un GfsusGfgUfgGfaCfUfUfcUfcUfcAfaUfuUfL96 551 A-127973 asAfs auuGfagaGfaagUfcCfaccAfc sg s a 766 GfsusGfgUfgGfaCfUfUfcUfcUfcAfaUfuUfL96 552 A-127981 asAfs auuGfagagaagUfcCfacc acsg s a 767 gsusGfgugGfaCfUfUfcUfcUfcAfaUfuuL96 553 A-127992 asAfsAfUfuGfaGfaGfaagUfcCfaCfcacs gs a 768 gsusgguggacdTdTcucucaauuuL96 554 A-127998 asdAsAfuugaGfaGfaagdTdCc aCfc ac sg s a 769 Y44GfsusGfgUfgGfaCfUfUfcUfcUfcAfaUfuUfL96 555 A-127958 P asAfs aUfuGfaGfaGfaagUfcCfaCfcAfcs gs a 770 gsusgguggaCfuUfcucuc(Agn)auuuL96 556 A-127956 asAfs aUfuGfaGfaGfaagUfcCfaCfcAfc sg s a 771 GfsusGfgUfgGfaCfUfUfcUfcUfcAfaUfuUfL96 557 A-127974 asAfs auuGfaGfaGfaagUfcCfacc ac sgs a 772 P
gsusgguggacudTcucuc(Agn)auuuL96 558 A-127982 asdAsauugagagaagdTccaccacsgsa 773 .
L.
u9 gsusGfgugGfaCfUfUfcUfcUfcAfaUfuuL96 559 A-127993 asAfsAfuuGfaGfaGfaagUfCfc aCfc ac sg s a 774 ..' .
.
. AD -64019 A-127959 gsusggUfgGfaCfUfUfcUfcucAfauuUfL96 560 A-127956 asAfs aUfuGfaGfaGfaagUfcCfaCfcAfc sg s a 775 , gsusgguggacuUfcucuc(Agn)auuuL96 561 A-127956 asAfs aUfuGfaGfaGfaagUfcCfaCfcAfc sg s a 776 .
, , GfsusGfgUfgGfaCfUfUfcUfcUfcAfaUfuUfL96 562 A-127975 asAfs aUfug aGfaGfaagUfcCfaccAfc sg s a 777 , .3 gsusgguggacudTcucuc(Agn)auuuL96 563 A-127983 PasdAsauugagagaagdTccaccacsgsa 778 gsusGfgugGfaCfUfUfcUfcUfcAfaUfuuL96 564 A-127994 asAfsAfUfuGfaGfaGfaagUfCfcaCfc ac sg s a 779 gsusggUfgGfaCfUfUfcUfcucAfauuuL96 565 A-127956 asAfs aUfuGfaGfaGfaagUfcCfaCfcAfc sg s a 780 gsusgguggacudTcucuc(Agn)auuuL96 566 A-127956 asAfs aUfuGfaGfaGfaagUfcCfaCfcAfc sg s a 781 GfsusGfgUfgGfaCfUfUfcUfcUfcAfaUfuUfL96 567 A-127976 asAfsaUfugaGfagaagUfcCfaccAfcsgsa 782 gsgUfgGfaCfUfUfcUfcUfcAfaUfuUfL96 568 A-127985 asAfsaUfuGfaGfaGfaagUfcCfaCfcsasc 783 IV
n gsusGfgugGfaCfUfUfcUfcUfcAfaUfuuL96 569 A-127995 asAfsAfUfugaGfaGfaagUfCfc aCfc ac sg s a 784 1-3 GfsusGfcAfcUfuCfGfCfuUfcAfcCfuCfuGfL96 570 A-128002 csAfsgAfgGfuGfaAfgcgAfaGfuGfcAfcsasc 785 cp n.) o GfsusUfgAfcAfaAfAfAfuCfcUfcAfcAfaUfL96 571 A-128364 asUfsuGfuGfaGfgAfuuuUfuGfuCfaAfcs as a 786 oe UfsgsUfuGfaCfaAfAfAfaUfcCfuCfaCfaAfL96 572 A-128378 usUfsgUfgAfgGfaUfuuuUfgUfcAfaCfas as g 787 n.) oe 1¨, GfsgsUfgGfaCfuUfCfUfcUfcAfaUfuUfuAfL96 573 A-128394 usAfsaAfaUfuGfaGfagaAfgUfcCfaCfcsasc 788 cA
ME1 27037625v.1 SEQ
SEQ
Duplex Sense Oligo Antisense Sense Sequence (5' to 3') ID
Antisense Sequence (5 to 3') ID
Name Name Oligo Name NO:
NO: 0 n.) AD-64277 A-128407 UfscsUfuUfuGfgAfGfUfgUfgGfaUfuCfgAfL96 574 A-128408 usCfsgAfaUfcCfaCfacuCfcAfaAfaGfasc s a 789 o 1¨, oe AD-64277 A-128407 UfscsUfuUfuGfgAfGfUfgUfgGfaUfuCfgAfL96 575 A-128408 usCfsgAfaUfcCfaCfacuCfcAfaAfaGfasc s a un AD-64278 A-128423 AfscsUfgUfuCfaAfGfCfcUfcCfaAfgCfuAfL96 576 A-128424 usAfsgCfuUfgGfaGfgcuUfgAfaCfaAfgsasc 791 cA
un AD-64279 A-128435 UfscsUfgCfcGfaUfCfCfaUfaCfuGfcGfgAfL96 577 A-128436 usCfscGfcAfgUfaUfggaUfcGfgCfaGfasgsg 792 AD-64280 A-128379 AfsusGfuGfuCfuGfCfGfgCfgUfuUfuAfuAfL96 578 A-128380 usAfsuAfaAfaCfgCfcgcAfgAfcAfcAfuscsc 793 AD-64281 A-128395 CfscsCfcGfuCfuGfUfGfcCfuUfcUfcAfuAfL96 579 A-128396 usAfsuGfaGfaAfgGfcacAfgAfcGfgGfgsasg 794 AD-64282 A-128409 GfscsCfuAfaUfcAfUfCfuCfuUfgUfuCfaUfL96 580 A-128410 asUfsgAfaCfaAfgAfgauGfaUfuAfgCfgsasg 795 AD-64283 A-128425 UfscsUfaGfaCfuCfGfUfgGfuGfgAfcUfuCfL96 581 A-128426 gsAfsaGfuCfcAfcCfacgAfgUfcUfaGfascsu 796 AD-64284 A-128437 CfsusGfcCfgAfuCfCfAfuAfcUfgCfgGfaAfL96 582 A-128438 usUfscCfgCfaGfuAfuggAfuCfgGfcAfgsasg 797 AD-64285 A-128365 UfsusUfuUfcUfuGfUfUfgAfcAfaAfaAfuAfL96 583 A-128366 usAfsuUfuUfuGfuCfaacAfaGfaAfaAfascsc 798 P
AD-64286 A-128381 AfsusCfuUfcUfuGfUfUfgGfuUfcUfuCfuAfL96 584 A-128382 usAfsgAfaGfaAfcCfaacAfaGfaAfgAfusg s a 799 .
L.
u9 AD-64289 A-128367 GfsusUfuUfuCfuUfGfUfuGfaCfaAfaAfaUfL96 585 A-128368 asUfsuUfuUfgUfcAfacaAfgAfaAfaAfcscsc 800 ..' .
.
AD-64290 A-128383 CfsusGfcCfuAfaUfCfAfuCfuCfuUfgUfuAfL96 586 A-128384 usAfsaCfaAfgAfgAfugaUfuAfgGfcAfgsasg 801 , AD-64291 A-128399 UfscsCfuCfaCfaAfUfAfcCfaCfaGfaGfuAfL96 587 A-128400 usAfscUfcUfgUfgGfuauUfgUfgAfgGfasusu 802 .
, , AD-64292 A-128413 CfsusUfgUfuGfaCfAfAfaAfaUfcCfuCfaAfL96 588 A-128414 usUfsgAfgGfaUfuUfuugUfcAfaCfaAfgs as a 803 , o .3 AD-64293 A-128439 GfscsAfaCfuUfuUfUfCfaCfcUfcUfgCfcUfL96 589 A-128440 asGfsgCfaGfaGfgUfgaaAfaAfgUfuGfcsasu 804 AD-64294 A-128369 GfsgsGfaAfcAfaGfAfGfcUfaCfaGfcAfuAfL96 590 A-128370 usAfsuGfcUfgUfaGfcucUfuGfuUfcCfc s as a AD-64295 A-128385 CfsgsUfgGfuGfgAfC11JfuCfuCfuCfaAfuUfL96 591 A-128386 asAfsuUfgAfgAfgAfaguCfcAfcCfaGfcs as g AD-64297 A-128415 CfsusGfcUfgCfuAfUfGfcCfuCfaUfcUfuAfL96 592 A-128416 usAfs aGfaUfgAfgGfcauAfgCfaGfcAfg sg s a AD-64298 A-128427 GfsusUfgGfaUfgUfG11JfcUfgCfgGfcGfuUfL96 593 A-128428 asAfscGfcCfgCfaGfacaCfaUfcCfaAfc sg s a AD-64299 A-128441 UfsusCfaUfcCfuGfCfUfgCfuAfuGfcCfuAfL96 594 A-128442 usAfsgGfcAfuAfgCfagcAfgGfaUfgAfasg s a n AD-64300 A-128371 UfsusCfuUfgUfuGfAfCfaAfaAfaUfcCfuAfL96 595 A-128372 usAfsgGfaUfuUfuUfgucAfaCfaAfgAfas as a AD-64302 A-128417 UfsasUfaUfgGfaUfGfAfuGfuGfgUfaUfuAfL96 596 A-128418 usAfsaUfaCfcAfcAfucaUfcCfaUfaUfasasc 811 cp n.) o AD-64303 A-128429 UfsusCfaUfcCfuGfC11JfgCfuAfuGfcCfuCfL96 597 A-128430 g sAfsgGfcAfuAfgCfagcAfgGfaUfgAfasg s a oe AD-64304 A-128443 GfsusGfcAfcUfuCfGfCfuUfcAfcCfuCfuAfL96 598 A-128444 usAfsgAfgGfuGfaAfgcgAfaGfuGfcAfcsasc 813 n.) oe 1¨, AD-64305 A-128373 UfsusGfaCfaAfaAfAfUfcCfuCfaCfaAfuAfL96 599 A-128374 usAfsuUfgUfgAfgGfauuUfuUfgUfcAfasc s a 814 cA
ME1 27037625v.1 SEQ
SEQ
Duplex Sense Oligo Antisense Sense Sequence (5' to 3') ID
Antisense Sequence (5 to 3') ID
Name Name Oligo Name NO:
NO: 0 n.) AD-64307 A-128403 AfsasGfcCfuCfcAfAfGfcUfgUfgCfcUfuAfL96 600 A-128404 usAfs aGfgCfaCfaGfcuuGfgAfgGfcUfusg s a 1¨, oe AD-64308 A-128419 CfscsUfcUfuCfaUfCfCfuGfcUfgCfuAfuAfL96 601 A-128420 usAfsuAfgCfaGfcAfgg aUfgAfaGfaGfg s as a un AD-64309 A-128431 CfscsUfgCfuGfcUfAfUfgCfcUfcAfuCfuUfL96 602 A-128432 asAfsgAfuGfaGfgCfauaGfcAfgCfaGfgsasu 817 cA
un AD-64310 A-128375 CfsasUfcUfuCfuUfGfUfuGfgUfuCfuUfcUfL96 603 A-128376 asGfs aAfgAfaCfcAfac aAfgAfaGfaUfg s as g AD-64311 A-128391 CfscsGfuCfuGfuGfCfCfuUfcUfcAfuCfuAfL96 604 A-128392 usAfsgAfuGfaGfaAfggcAfcAfgAfcGfgsgsg 819 AD-64312 A-128405 CfscsUfcAfuCfuUfCfUfuGfuUfgGfuUfcUfL96 605 A-128406 asGfs aAfcCfaAfcAfag aAfgAfuGfaGfg sc s a AD-64313 A-128421 CfscsAfcCfaAfaUfGfCfcCfcUfaUfcUfuAfL96 606 A-128422 usAfsaGfaUfaGfgGfgcaUfuUfgGfuGfgsusc 821 AD-64314 A-128433 GfscsUfcCfuCfuGfCfCfgAfuCfcAfuAfcUfL96 607 A-128434 asGfsuAfuGfgAfuCfggcAfgAfgGfaGfc scs a AD-64315 A-128363 GfsusUfgAfcAfaAfAfAfuCfcUfcAfcAfaUfL96 608 A-128445 P asUfsuGfuGfaGfgAfuuuUfuGfuCfaAfc s as a 823 AD-64316 A-128377 UfsgsUfuGfaCfaAfAfAfaUfcCfuCfaCfaAfL96 PusUfsgUfgAfgGfaUfuuuUfgUfcAfaCfas as g 824 P
AD-64317 A-128393 GfsgsUfgGfaCfuUfCfUfcUfcAfaUfuUfuAfL96 610 A-128461 Pus Afs aAfaUfuGfaGfag aAfgUfcCfaCfc s asc 825 .
L.
u9 AD-64318 A-128407 UfscsUfuUfuGfgAfGfUfgUfgGfaUfuCfgAfL96 PusCfsgAfaUfcCfaCfacuCfcAfaAfaGfasc s a 826 ..' .
.
w AD-64319 A-128423 AfscsUfgUfuCfaAfGfCfcUfcCfaAfgCfuAfL96 612 A-128477 Pus AfsgCfuUfgGfaGfgcuUfgAfaCfaAfgs asc 827 , AD-64320 A-128435 UfscsUfgCfcGfaUfCfCfaUfaCfuGfcGfgAfL96 613 A-128483 PusCfscGfcAfgUfaUfggaUfcGfgCfaGfasgsg 828 .
, , AD-64321 A-123463 AfsgsUfuAfuAfuGfGfAfuGfaUfgUfgGfuAfL96 614 A-128446 Pus AfscCfaCfaUfcAfuccAfuAfuAfaCfus gs a 829 , .3 AD-64322 A-128379 AfsusGfuGfuCfuGfCfGfgCfgUfuUfuAfuAfL96 615 A-128454 Pus AfsuAfaAfaCfgCfcgcAfgAfcAfcAfuscsc 830 AD-64323 A-128395 CfscsCfcGfuCfuG11JfGfcCfuUfcUfcAfuAfL96 616 A-128462 Pus AfsuGfaGfaAfgGfcacAfgAfcGfgGfg s asg 831 AD-64324 A-128409 GfscsCfuAfaUfcAfUfCfuCfuUfgUfuCfaUfL96 617 A-128470 PasUfsgAfaCfaAfgAfgauGfaUfuAfgCfgsasg 832 AD-64325 A-128425 UfscsUfaGfaCfuCfGfUfgGfuGfgAfcUfuCfL96 618 A-128478 PgsAfsaGfuCfcAfcCfacgAfgUfcUfaGfascsu 833 AD-64326 A-128437 CfsusGfcCfgAfuCfCfAfuAfcUfgCfgGfaAfL96 619 A-128484 PusUfscCfgCfaGfuAfuggAfuCfgGfcAfgsasg 834 AD-64328 A-128381 AfsusCfuUfcUfuGfUfUfgGfuUfcUfuCfuAfL96 620 A-128455 Pus AfsgAfaGfaAfcCfaacAfaGfaAfgAfusg s a 835 IV
n AD-64330 A-128411 UfsusCfuCfuCfaAfUfUfuUfcUfaGfgGfgAfL96 621 A-128471 PusCfscCfcUfaGfaAfaauUfgAfgAfgAfasgsu 836 1-3 AD-64331 A-127905 AfscsUfcGfuGfgUfGfGfaCfuUfcUfcUfcAfL96 622 A-127907 PusGfsaGfaGfaAfgUfccaCfcAfcGfaGfuscsu 837 cp n.) o AD-64332 A-128001 GfsusGfcAfcUfuCfGfCfuUfcAfcCfuCfuGfL96 623 A-128485 PcsAfsgAfgGfuGfaAfgcgAfaGfuGfcAfcsasc 838 oe AD-64333 A-128367 GfsusUfuUfuCfuUfGfUfuGfaCfaAfaAfaUfL96 624 A-128448 PasUfsuUfuUfgUfcAfacaAfgAfaAfaAfcscsc 839 n.) oe 1¨, AD-64334 A-128383 CfsusGfcCfuAfaUfCfAfuCfuCfuUfgUfuAfL96 625 A-128456 Pus Afs aCfaAfgAfgAfugaUfuAfgGfcAfg s as g 840 cA
ME1 27037625v.1 SEQ
SEQ
Duplex Sense Oligo Antisense Sense Sequence (5' to 3') ID
Antisense Sequence (5 to 3') ID
Name Name Oligo Name NO:
NO: 0 n.) AD-64335 A-128399 UfscsCfuCfaCfaAfUfAfcCfaCfaGfaGfuAfL96 626 A-128464 Pus AfscUfcUfgUfgGfuauUfgUfgAfgGfasusu 841 1¨, oe AD-64336 A-128413 CfsusUfgUfuGfaCfAfAfaAfaUfcCfuCfaAfL96 627 A-128472 PusUfsgAfgGfaUfuUfuugUfcAfaCfaAfg s as a 842 un AD-64337 A-127955 GfsusGfgUfgGfaCfUfUfcUfcUfcAfaUfuUfL96 628 A-127958 P asAfs aUfuGfaGfaGfaagUfcCfaCfcAfcs gs a 843 cA
un AD-64338 A-128439 GfscsAfaCfuUfuUfUfCfaCfcUfcUfgCfcUfL96 629 A-128486 PasGfsgCfaGfaGfgUfgaaAfaAfgUfuGfcsasu 844 AD-64339 A-128369 GfsgsGfaAfcAfaGfAfGfcUfaCfaGfcAfuAfL96 630 A-128449 Pus AfsuGfcUfgUfaGfcucUfuGfuUfcCfc s as a 845 AD-64341 A-128401 UfscsAfuCfuUfcUfUfGfuUfgGfuUfcUfuAfL96 631 A-128465 Pus Afs aGfaAfcCfaAfcaaGfaAfgAfuGfasg sg 846 AD-64342 A-128415 CfsusGfcUfgCfuA11JfGfcCfuCfaUfcUfuAfL96 632 A-128473 Pus Afs aGfaUfgAfgGfcauAfgCfaGfcAfg sg s a 847 AD-64343 A-128427 GfsusUfgGfaUfgUfG11JfcUfgCfgGfcGfuUfL96 633 A-128479 P asAfscGfcCfgCfaGfacaCfaUfcCfaAfcs g s a AD-64344 A-128441 UfsusCfaUfcCfuGfCfUfgCfuAfuGfcCfuAfL96 634 A-128487 Pus AfsgGfcAfuAfgCfagcAfgGfaUfgAfas gs a 849 AD-64345 A-128371 UfsusCfuUfgUfuGfAfCfaAfaAfaUfcCfuAfL96 635 A-128450 Pus AfsgGfaUfuUfuUfgucAfaCfaAfgAfas as a 850 P
AD-64347 A-123487 GfsgsAfuGfuGfuCfUfGfcGfgCfgUfuUfuAfL96 636 A-128466 Pus Afs aAfaCfgCfcGfcagAfcAfcAfuCfc s asg 851 .
L.
u9 AD-64348 A-128417 UfsasUfaUfgGfaUfGfAfuGfuGfgUfaUfuAfL96 637 A-128474 Pus Afs aUfaCfcAfcAfucaUfcCfaUfaUfas asc 852 ..' .
.
AD-64349 A-128429 UfsusCfaUfcCfuGfC11JfgCfuAfuGfcCfuCfL96 638 A-128480 Pgs AfsgGfcAfuAfgCfagcAfgGfaUfgAfas gs a 853 , AD-64350 A-128443 GfsusGfcAfcUfuCfGfCfuUfcAfcCfuCfuAfL96 639 A-128488 Pus AfsgAfgGfuGfaAfgcgAfaGfuGfcAfc s asc 854 .
, , AD-64351 A-128373 UfsusGfaCfaAfaAfAfUfcCfuCfaCfaAfuAfL96 640 A-128451 Pus AfsuUfgUfgAfgGfauuUfuUfgUfcAfasc s a 855 .3 AD-64352 A-128389 CfscsAfaGfuGfuUfUfGfcUfgAfcGfcAfaAfL96 641 A-128459 PusUfsuGfcGfuCfaGfc aaAfcAfcUfuGfg scs a 856 AD-64352 A-128389 CfscsAfaGfuGfuUfUfGfcUfgAfcGfcAfaAfL96 642 A-128459 PusUfsuGfcGfuCfaGfc aaAfcAfcUfuGfg scs a 857 AD-64353 A-128403 AfsasGfcCfuCfcAfAfGfcUfgUfgCfcUfuAfL96 643 A-128467 Pus Afs aGfgCfaCfaGfcuuGfgAfgGfcUfusg s a 858 AD-64354 A-128419 CfscsUfcUfuCfaUfCfCfuGfcUfgCfuAfuAfL96 644 A-128475 Pus AfsuAfgCfaGfcAfggaUfgAfaGfaGfg s as a 859 AD-64355 A-128431 CfscsUfgCfuGfcUfAfUfgCfcUfcAfuCfuUfL96 645 A-128481 PasAfsgAfuGfaGfgCfauaGfcAfgCfaGfgsasu 860 AD-64356 A-128375 CfsasUfcUfuCfuUfGfUfuGfgUfuCfuUfcUfL96 646 A-128452 PasGfsaAfgAfaCfcAfacaAfgAfaGfaUfgsasg 861 IV
n AD-64357 A-128391 CfscsGfuCfuGfuGfCfCfuUfcUfcAfuCfuAfL96 647 A-128460 Pus AfsgAfuGfaGfaAfggcAfcAfgAfcGfg sg sg 862 1-3 AD-64358 A-128405 CfscsUfcAfuCfuUfCfUfuGfuUfgGfuUfcUfL96 648 A-128468 P asGfs aAfcCfaAfcAfag aAfgAfuGfaGfg scs a 863 cp n.) o AD-64359 A-128421 CfscsAfcCfaAfaUfGfCfcCfcUfaUfcUfuAfL96 649 A-128476 Pus Afs aGfaUfaGfgGfgc aUfuUfgGfuGfgsusc 864 oe AD-64360 A-128433 GfscsUfcCfuCfuGfCfCfgAfuCfcAfuAfcUfL96 asGfsuAfuGfgAfuCfggcAfgAfgGfaGfc scs a 865 n.) oe 1¨, AD-64700 A-129379 ascsucguggugdTacuu(Cgn)ucucaL96 651 A-127906 usGfsaGfaGfaAfgUfccaCfcAfcGfaGfuscsu 866 cA
ME1 27037625v.1 SEQ
SEQ
Duplex Sense Oligo Antisense Sense Sequence (5' to 3') ID
Antisense Sequence (5 to 3') ID
Name Name Oligo Name NO:
NO: 0 n.) AD-64701 A-127905 AfscsUfcGfuGfgUfGfGfaCfuUfcUfcUfcAfL96 652 A-129387 PusgsagagaagdTccadCcacgaguscsu 867 o 1¨, oe AD-64702 A-127905 AfscsUfcGfuGfgUfGfGfaCfuUfcUfcUfcAfL96 653 A-129395 usGsagadGaaguccaCcacgaguscsu 868 un AD-64703 A-129376 ascsucguggugdGacuucdAcucaL96 654 A-129385 usdGsagagaagdTccadCcacgaguscsu 869 cA
un AD-64704 A-129381 ascsucguggdTgdTacuucdAcucaL96 655 A-129389 usdGsagadGaaguccadCcacgaguscsu 870 AD-64705 A-129380 ascsucguggugdTacuucdAcucaL96 656 A-127906 usGfsaGfaGfaAfgUfccaCfcAfcGfaGfuscsu 871 AD-64706 A-127905 AfscsUfcGfuGfgUfGfGfaCfuUfcUfcUfcAfL96 657 A-129388 usdGsadGagaaguccadCcacgaguscsu 872 AD-64707 A-127905 AfscsUfcGfuGfgUfGfGfaCfuUfcUfcUfcAfL96 658 A-129396 usgsagadGaagdTccadCcacgaguscsu 873 AD-64708 A-129382 ascsucguggdTgdGacuuc(Tgn)cucaL96 659 A-129385 usdGsagagaagdTccadCcacgaguscsu 874 AD-64709 A-129373 ascsucguggugdGacuu(Cgn)ucucaL96 660 A-129391 usdGsagadGaagdTccadCcacgaguscsu 875 AD-64710 A-129373 ascsucguggugdGacuu(Cgn)ucucaL96 usGfsaGfaGfaAfgUfccaCfcAfcGfaGfuscsu 876 P
AD-64711 A-129381 ascsucguggdTgdTacuucdAcucaL96 usGfsaGfaGfaAfgUfccaCfcAfcGfaGfuscsu 877 .
L.
u9 AD-64712 A-127905 AfscsUfcGfuGfgUfGfGfaCfuUfcUfcUfcAfL96 663 A-129389 usdGsagadGaaguccadCcacgaguscsu 878 ..' .
.
AD-64713 A-127905 AfscsUfcGfuGfgUfGfGfaCfuUfcUfcUfcAfL96 664 A-129397 PusgsagadGaagdTccadCcacgaguscsu 879 , AD-64714 A-129384 ascsucguggdTgdGacuucdAcucaL96 665 A-129385 usdGsagagaagdTccadCcacgaguscsu 880 .
, , AD-64715 A-129376 ascsucguggugdGacuucdAcucaL96 666 A-129391 usdGsagadGaagdTccadCcacgaguscsu 881 , .3 AD-64716 A-129374 ascsucguggugdGacuucu(Cgn)ucaL96 usGfsaGfaGfaAfgUfccaCfcAfcGfaGfuscsu 882 AD-64717 A-129382 ascsucguggdTgdGacuuc(Tgn)cucaL96 usGfsaGfaGfaAfgUfccaCfcAfcGfaGfuscsu 883 AD-64718 A-127905 AfscsUfcGfuGfgUfGfGfaCfuUfcUfcUfcAfL96 669 A-129390 usdGsagagadAguccadCcacgaguscsu 884 AD-64719 A-127917 ascsucguggugdGacuuc(Tgn)cucaL96 670 A-129385 usdGsagagaagdTccadCcacgaguscsu 885 AD-64720 A-129381 ascsucguggdTgdTacuucdAcucaL96 671 A-129385 usdGsagagaagdTccadCcacgaguscsu 886 AD-64721 A-129382 ascsucguggdTgdGacuuc(Tgn)cucaL96 672 A-129391 usdGsagadGaagdTccadCcacgaguscsu 887 IV
n AD-64722 A-129375 ascsucguggugdGacuucY34cucaL96 usGfsaGfaGfaAfgUfccaCfcAfcGfaGfuscsu 888 1-3 AD-64723 A-129383 ascsucguggugdGdAcuuc(Tgn)cucaL96 usGfsaGfaGfaAfgUfccaCfcAfcGfaGfuscsu 889 cp n.) o AD-64725 A-127917 ascsucguggugdGacuuc(Tgn)cucaL96 675 A-129398 PusdGsagagaagdTccadCcacgaguscsu 890 oe AD-64726 A-129373 ascsucguggugdGacuu(Cgn)ucucaL96 676 A-129389 usdGsagadGaaguccadCcacgaguscsu 891 n.) oe 1¨, AD-64727 A-129384 ascsucguggdTgdGacuucdAcucaL96 677 A-129391 usdGsagadGaagdTccadCcacgaguscsu 892 cA
ME1 27037625v.1 SEQ
SEQ
Duplex Sense Oligo Antisense Sense Sequence (5' to 3') ID
Antisense Sequence (5' to 3') ID
Name Name Oligo Name NO:
NO: 0 n.) AD-64728 A-129376 ascsucguggugdGacuucdAcucaL96 678 A-127906 usGfsaGfaGfaAfgUfccaCfcAfcGfaGfuscsu 893 o 1¨, oe AD-64729 A-129384 ascsucguggdTgdGacuucdAcucaL96 679 A-127906 usGfsaGfaGfaAfgUfccaCfcAfcGfaGfuscsu 894 un AD-64730 A-127905 AfscsUfcGfuGfgUfGfGfaCfuUfcUfcUfcAfL96 680 A-129392 usGsagagaagdTccadCcacgaguscsu 895 cA
un AD-64731 A-129399 Y34ascsucguggugdGacuuc(Tgn)cucaL96 681 A-129385 usdGsagagaagdTccadCcacgaguscsu 896 AD-64732 A-129376 ascsucguggugdGacuucdAcucaL96 682 A-129389 usdGsagadGaaguccadCcacgaguscsu 897 AD-64733 A-129381 ascsucguggdTgdTacuucdAcucaL96 683 A-129391 usdGsagadGaagdTccadCcacgaguscsu 898 AD-64734 A-129377 ascsucguggugdGacuucdCcucaL96 684 A-127906 usGfsaGfaGfaAfgUfccaCfcAfcGfaGfuscsu 899 AD-64735 A-127905 AfscsUfcGfuGfgUfGfGfaCfuUfcUfcUfcAfL96 685 A-129385 usdGsagagaagdTccadCcacgaguscsu 900 AD-64736 A-127905 AfscsUfcGfuGfgUfGfGfaCfuUfcUfcUfcAfL96 686 A-129393 usdGsagagaagdTccaCcacgaguscsu 901 AD-64737 A-129399 Y34ascsucguggugdGacuuc(Tgn)cucaL96 687 A-129398 PusdGsagagaagdTccadCcacgaguscsu 902 P
AD-64738 A-129382 ascsucguggdTgdGacuuc(Tgn)cucaL96 688 A-129389 usdGsagadGaaguccadCcacgaguscsu 903 .
L.
u9 AD-64739 A-129378 ascsucguggugdGacuucdGcucaL96 689 A-127906 usGfsaGfaGfaAfgUfccaCfcAfcGfaGfuscsu 904 ..' .
.
AD-64740 A-127905 AfscsUfcGfuGfgUfGfGfaCfuUfcUfcUfcAfL96 690 A-129386 usgsagagaagdTccadCcacgaguscsu 905 , AD-64741 A-127905 AfscsUfcGfuGfgUfGfGfaCfuUfcUfcUfcAfL96 691 A-129394 usGsagagaagdTccaCcacgaguscsu 906 .
, , AD-64742 A-129373 ascsucguggugdGacuu(Cgn)ucucaL96 692 A-129385 usdGsagagaagdTccadCcacgaguscsu 907 , o .3 AD-64743 A-129384 ascsucguggdTgdGacuucdAcucaL96 693 A-129389 usdGsagadGaaguccadCcacgaguscsu 908 Table 4. Unmodified Sense and Antisense Strand Sequences of HBV dsRNAs (Activity data available in W02016/077321, incorporated herein by reference) Iv SEQ
SEQ n ,-i Duplex ID Sense Sequence (5' to 3') ID Antisense Sequence (5' to 3') ID
NO:
NO: cp n.) o oe CB
n.) oe 1¨, cA
ME1 27037625v.1 SEQ
SEQ
Duplex ID Sense Sequence (5' to 3') ID Antisense Sequence (5' to 3') ID
NO:
NO: 0 t..) cio vD
u, u, P
.
.
.
.
, .
, , , .
.3 od n cp t..) o -a-, w cio cr ME1 27037625v.1 Table 5. Exemplary Modified Sense and Antisense Strand Sequences of HBV dsRNAs (Activity data available in W02016/077321, incorporated herein by reference) t.) o 1¨, oe SEQ
SEQ 1¨
DuplexID Sense Sequence (5' to 3') ID Antisense Sequence (5' to 3') ID vi 1¨, NO:
NO: c7, u, AD-65369 uscsguGfgUfGfGfacuuCfUfcucaL96 967 PusGfsagaGfaAfGfuccaCfcAfcgasusu 996 AD-65381 uscsguGfgUfGfGfacuucucucaL96 968 PusGfsagaGfaAfGfuccaCfcAfcgasusu 997 AD-63962 Y44uscsGfuGfgUfgGfaCfuUfcUfcUfcAfY44 969 PusGfsaGfaGfaAfgUfcCfaCfcAfcGfasusu 998 AD-65561 uscsguGfgUfGfGfacuuCfUfcucaL96 971 UfsGfsagaGfaAfGfuccaCfcAfcgasusu 1000 AD-65566 uscsguGfgUfGfGfacuucucucaL96 972 UfsGfsagaGfaAfGfuccaCfcAfcgasusu 1001 AD-63944 Y44ucGuGGuGGAcuucucucAusuY44 973 UfGfagAfgAfAfGUfccaCfCAfcgAusu 1002 P
AfscsUfcGfuGfgUfGfGfaCfuUfcUfcUfcAfL96 974 usGfsaGfaGfaAfgUfccaCfcAfcGfaGfuscsu 1003 u9 ..' . AD-65406 uscsguGfgUfGfGfacuuCfUfcucaL96 975 usGfsagaGfaAfGfuccaCfcAfcgasusu 1004 .
oc ,, AD-65396 ascsucguGfgUfGfGfacuucucucaL96 976 usGfsagaGfaaguccaCfcAfcgagususu 1005 ,9 , AD-65427 gsusgcacUfuCfGfCfuucaccucuaL96 977 PusAfsgagGfugaagegAfaGfugcacsusu 1006 , , AD-65573 gsusgcacUfuCfGfCfuucaCfCfucuaL96 978 UfsAfsgagGfuGfAfagegAfaGfugcacsasc 1007 .3 AD-65432 gscsacUfucGfCfuucacCfucuaL96 979 PusAfsgagGfuGfAfagegAfaGfugcsasc 1008 GfsusGfcAfcUfuCfGfCfuUfcAfcCfuCfuGfL96 980 PcsAfsgAfgGfuGfaAfgcgAfaGfuGfcAfcsasc 1009 AfsusGfuGfuCfuGfCfGfgCfgUfuUfuAfuAfL96 981 PusAfsuAfaAfaCfgCfcgcAfgAfcAfcAfuscsc 1010 GfsusGfcAfcUfuCfGfCfuUfcAfcCfuCfuGfL96 982 csAfsgAfgGfuGfaAfgcgAfaGfuGfcAfcsasc 1011 AD-65583 gscsacuucgdCuucac(Cgn)ucuaL96 983 usdAsgagdGugaagcgdAagugcsusu 1012 Iv AD-63994 gsgsUfgGfaCfUfUfcUfcUfcAfaUfuUfL96 984 PasAfsaUfuGfaGfaGfaagUfcCfaCfcsasc 1013 n ,-i AD-65370 csgsugguGfgAfCfUfucucUfCfaauuL96 985 asAfsuugAfgAfGfaaguCfcAfccagcsasg 1014 cp t.) AD-65265 gsusggugGfaCfUfUfcUfcucaauuuL96 986 asAfsaUfugagaGfaagUfcCfaccAfcsgsa 1015 =
1¨, oe AD-65407 csgsugguGfgAfCfUfucucUfCfaauuL96 987 asAfsuugAfgAfgAfaguCfcAfccagcsasg 1016 'a t.) AD-64027 gsgsUfgGfaCfUfUfcUfcUfcAfaUfuUfL96 988 asAfsaUfuGfaGfaGfaagUfcCfaCfcsasc 1017 oe 1¨, 1¨, AD-65266 gsusggugGfaCfUfUfcucuCfaauuuL96 989 asAfsaUfugagaGfaagUfcCfaccAfcsgsa 1018 cr ME1 27037625v.1 SEQ
SEQ
DuplexID Sense Sequence (5' to 3') ID Antisense Sequence (5' to 3') ID
NO:
NO: 0 n.) AD-65389 usgsgudGgucdTucucuaaauuL96 990 asdAsuugagagdAagudCcaccasusu 1019 =
1¨, oe AD-64008 GfsusGfgUfgGfaCfUfUfcUfcUfcAfaUfuUfL96 991 asAfsaUfuGfaGfaGfaagUfcCfaCfcAfcsgsa 1020 AD-65377 csgsuggudGgucdTucucuaaauuL96 992 asdAsuugagagdAagudCcaccagcsusu 1021 vi 1¨, c:
vi AD-65409 gsgsuggaCfuUfCfUfcucaAfUfuuuaL96 993 PusAfsaaaUfuGfAfgagaAfgUfccaccsasc 1022 AD-65403 gsgsuggaCfuUfCfUfcucaAfUfuuuaL96 994 usAfsaaaUfuGfAfgagaAfgUfccaccsasc 1023 AD-65385 usgsgacuacdTcucaaauuuaL96 995 usdAsaaauugadGagadAguccasusu 1024 Table 6. Exemplary Unmodified Sense and Antisense Strand Sequences of HBV
dsRNAs (Activity data available in W02016/077321, incorporated herein by reference) P
SEQ
u, ID Antisense SEQ ID .
-f5 Duplex ID Sense ID Sense Sequence Unmodified (5' to 3') NO:
ID Antisense Sequence Unmodified (5' to 3') NO: " , , , UGAGAGAAGUCCACCACGAUU 1036 .
, .3 1-d UAGAGGUGAAGCGAAGUGCACUU 1040 n ,-i UAGAGGUGAAGCGAAGUGCACUU 1041 cp t.) o 1¨
oe AAUUGAGAGAAGUCCACCAGCAG 1042 'a t.) oe 1¨
AAUUGAGAGAAGUCCACCAGCUU 1043 cr ME1 27037625v.1 SEQ
ID Antisense SEQ ID
Duplex ID Sense ID Sense Sequence Unmodified (5' to 3') NO:
ID Antisense Sequence Unmodified (5' to 3') NO: 0 n.) o 1¨, UAAAAUUGAGAGAAGUCCACCAC 1044 oe 1¨, vo un 1¨, UAAAAUUGAGAGAAGUCCACCAC 1045 c:
un Table 7. Exemplary Modified Sense and Antisense Strand Sequences of HBV dsRNAs (Activity data available in W02016/077321, incorporated herein by reference) P
SEQ
SEQ
Antisense 2 Duplex ID Sense ID Sense Sequence (5 to 3' ID ) ID
Antisense Sequence (5' to 3') ID .
u, NO:
NO: .
AD-65381 A-130366 uscsguGfgUfGfGfacuucucucaL96 1047 A-131904 PusGfsagaGfaAfGfuccaCfcAfcgasusu 1058 , , , AD-66019 A-130366 uscsguGfgUfGfGfacuucucucaL96 1048 A-131904 VPusGfsagaGfaAfGfuccaCfcAfcgasusu .3 AD-65375 A-130366 uscsguGfgUfGfGfacuucucucaL96 1049 A-130364 usGfsagaGfaAfGfuccaCfcAfcgasusu 1060 AD-65427 A-130441 gsusgcacUfuCfGfCfuucaccucuaL96 1050 A-131905 PusAfsgagGfugaagcgAfaGfugcacsusu 1061 AD-66110 A-130441 gsusgcacUfuCfGfCfuucaccucuaL96 1051 A-131905 VPusAfsgagGfugaagcgAfaGfugcacsusu 1062 IV
AD-65421 A-130441 gsusgcacUfuCfGfCfuucaccucuaL96 1052 A-130442 us Afs gagGfugaagcgAfaGfugc ac susu 1063 n c 4 AD-65407 A-130371 csgsugguGfgAfCfUfucucUfCfaauuL96 1053 A-130372 as AfsuugAfgAfgAfaguCfcAfccagc s as g 1064 n.) o 1¨, oe AD-65377 A-130384 csgsuggudGgucdTucucuaaauuL96 1054 A-130748 asdAsuugagagdAagudCcaccagcsusu 1065 n.) oe 1¨, 1¨, cr ME1 27037625v.1 SEQ SEQ
AMisense Duplex ID Sense ID Sense Sequence (5' to 3') ID
Antisense Sequence (5' to 3') ID
ID
NO:
NO: 0 n.) AD-65409 A-130388 gsgsuggaCfuUfCfUfcucaAfUfuuuaL96 1055 A-131906 PusAfs aaaUfuGfAfgagaAfgUfcc aces as c 1066 oe 1¨, o vi AD-66111 A-130388 gsgsuggaCfuUfCfUfcucaAfUfuuuaL96 1056 A-131906 VPusAfsaaaUfuGfAfgagaAfgUfccaccsasc 1067 o vi AD-65403 A-130388 gsgsuggaCfuUfCfUfcucaAfUfuuuaL96 1057 A-130389 us AfsaaaUfuGfAfg ag aAfgUfccaccsasc 1068 Table 8. Exemplary Unmodified Sense and Antisense Strand Sequences of HBV
dsRNAs (Activity data available in W02016/077321, incorporated herein by reference) P
SEQ
SEQ .
Sense Oligo Antisense .
DuplexID Sense Sequence (5' to 3') ID Antisense Sequence (5' to 3') ID u, Name OligoName .
NO:
NO: .
AGAGGUGAAGCGAAGUGCACACG 1115 ' , , UCAGAGGUGAAGCGAAGUGCACA 1116 , , .
UAGGUGAAGCGAAGUGCACACGG 1117 ' IV
1123 n cp UGACGUGCAGAGGUGAAGCGAAG 1125 n.) o 1¨, oe k .., UAUGAGAAGGCACAGACGGGGAG 1127 c'e 1¨, 1¨, UAGAUGAGAAGGCACAGACGGGG 1128 cr ME1 27037625v.1 SEQ
SEQ
Sense Oligo Antisense DuplexID Sense Sequence (5' to 3') ID
Antisense Sequence (5 to 3') ID
Name OligoName NO:
NO: 0 n.) UAAAAAGUUGCAUGGUGCUGGUG 1129 o 1-, oe vi c:
vi UCCAAGAGUCCUCUUAUGUAAGA 1139 .
u, UAAGAGUCCUCUUAUGUAAGACC 1140 .
t.) AD-61561 A-123523 ACUUCAAAGACUGUUUGUUUA 1095 A-123524 , AAACAAACAGUCUUUGAAGUAUG 1142 .
, , , AACAAACAGUCUUUGAAGUAUGC 1143 .
.3 1149 Iv n 1151 cp n.) o -,-:--, 1153 n.) oe 1-, cr ME1 27037625v.1 SEQ
SEQ
Sense Oligo Antisense DuplexID Sense Sequence (5' to 3') ID
Antisense Sequence (5' to 3') ID
Name OligoName NO:
NO: 0 n.) AGUACAAAGACCUUUAAUCUAAU 1155 o oe o vi o vi Table 9. Exemplary Unmodified Sense and Antisense Strand Sequences of HBV
dsRNAs (Activity data available in W02016/077321, incorporated herein by reference) P
.
Sense SEQ Antisense u, SEQ ID
..' Duplex ID Oligo Sense Sequence (5 to 3') ID Oligo Antisense Sequence (5' to 3') .
NO:
w Name NO: Name ."
, AD-65776 A-131859 UfsgsUfgCfaCfuUfCfGfcUfuCfaCfcUfcUfL96 1161 A-131860 as Gfs aGfgUfgAfaGfcgaAfgUfgCfaCfasc sg 1207 ' , , AD-65782 A-131877 UfsgsCfaCfuUfcGfCfUfuCfaCfcUfcUfgAfL96 1162 A-131878 usCfs aGfaGfgUfgAfageGfaAfgUfgCfascs a 1208 2 AD-65792 A-131865 GfsusGfuGfcAfcUfUfCfgCfuUfcAfcCfuAfL96 1163 A-131866 usAfsgGfuGfaAfgCfgaaGfuGfcAfcAfcsgsg 1209 AD-65781 A-131861 CfsgsUfgUfgCfaCfUfUfcGfcUfuCfaCfcUfL96 1164 A-131862 as GfsgUfgAfaGfc GfaagUfgCfaCfaCfgsgsu 1210 AD-64304 A-128443 GfsusGfcAfcUfuCfGfCfuUfcAfcCfuCfuAfL96 1165 A-128444 usAfsgAfgGfuGfaAfgcgAfaGfuGfcAfcsasc 1211 AD-65771 A-131857 CfscsGfuGfuGfcAfCfUfuCfgCfuUfcAfcAfL96 1166 A-131858 us GfsuGfaAfgCfgAfaguGfcAfcAfcGfgsusc 1212 AD-65758 A-131867 CfsasCfuUfcGfcUfUfCfaCfcUfcUfgCfaAfL96 1167 A-131868 usUfsgCfaGfaGfgUfgaaGfcGfaAfgUfgsc s a 1213 AD-65777 A-131875 AfscsUfuCfgCfuUfCfAfcCfuCfuGfcAfcAfL96 1168 A-131876 us GfsuGfcAfgAfgGfugaAfgCfgAfaGfusgsc 1214 Iv n 1-i AD-61567 A-123525 GfsgsCfuGfuAfgGfCfAfuAfaAfuUfgGfuAfL96 1169 A-123526 usAfscCfaAfuUfuAfugcCfuAfcAfgCfcsusc 1215 cp AD-65772 A-131873 UfsusCfgCfuUfcAfCfCfuCfuGfcAfcGfuAfL96 1170 A-131874 usAfscGfuGfcAfgAfgguGfaAfgCfgAfasgsu 1216 t.) o 1-, AD-65767 A-131871 UfscsGfcUfuCfaCfCfUfcUfgCfaCfgUfcAfL96 1171 A-131872 us Gfs aCfgUfgCfaGfaggUfgAfaGfcGfas asg 1217 0 e AD-65763 A-131869 CfsusUfcGfcUfuCfAfCfcUfcUfgCfaCfgUfL96 1172 A-131870 asCfsgUfgCfaGfaGfgugAfaGfcGfaAfgsusg 1218 t.) oe 1-, AD-64281 A-128395 CfscsCfcGfuCfuGfUfGfcCfuUfcUfcAfuAfL96 1173 A-128396 usAfsuGfaGfaAfgGfcacAfgAfcGfgGfgsasg 1219 cr ME1 27037625v.1 Sense SEQ Antisense SE Q ID
Duplex ID Oligo Sense Sequence (5' to 3') ID Oligo Antisense Sequence (5' to 3') NO:
Name NO: Name t.) o AD-64311 A-128391 CfscsGfuCfuGfuGfCfCfuUfcUfcAfuCfuAfL96 1174 A-128392 usAfsgAfuGfaGfaAfggcAfcAfgAfcGfgsgsg 1220 oe AD-65790 A-131837 CfscsAfgCfaCfcAfUfGfcAfaCfuUfuUfuAfL96 1175 A-131838 usAfsaAfaAfgUfuGfcauGfgUfgCfuGfgsusg 1221 vi AD-65761 A-131841 CfsasCfcAfgCfaCfCfAfuGfcAfaCfuUfuUfL96 1176 A-131842 asAfsaAfgUfuGfcAfuggUfgCfuGfgUfgscsg 1222 c:
vi AD-65786 A-131849 CfsasCfcAfuGfcAfAfCfuUfuUfuCfaCfcUfL96 1177 A-131850 as GfsgUfgAfaAfaAfguuGfcAfuGfgUfgscsu 1223 AD-65785 A-131835 CfsasAfuGfuCfaAfCfGfaCfcGfaCfcUfuAfL96 1178 A-131836 usAfs aGfgUfc GfgUfcguUfgAfcAfuUfgscs a 1224 AD-65787 A-131863 CfsgsCfuUfcAfcCfUfCfuGfcAfcGfuCfgAfL96 1179 A-131864 usCfsgAfc GfuGfcAfgagGfuGfaAfgCfgs as a 1225 AD-65770 A-131845 AfscsCfuUfgAfgGfCfAfuAfcUfuCfaAfaGfL96 1180 A-131846 csUfsuUfgAfaGfuAfugcCfuCfaAfgGfuscsg 1226 AD-65766 A-131843 CfscsGfaCfcUfuGfAfGfgCfaUfaCfuUfcAfL96 1181 A-131844 us Gfs aAfgUfaUfgCfcucAfaGfgUfcGfgsusc 1227 AD-61555 A-123521 GfsasCfcUfuGfaGfGfCfaUfaCfuUfcAfaAfL96 1182 A-123522 usUfsuGfaAfgUfaUfgccUfcAfaGfgUfcsgsg 1228 AD-65762 A-131855 AfscsCfgAfcCfuUfGfAfgGfcAfuAfcUfuAfL96 1183 A-131856 usAfsaGfuAfuGfcCfucaAfgGfuCfgGfuscsg 1229 P
AD-65755 A-131827 UfscsGfcAfuGfgAfGfAfcCfaCfcGfuGfaAfL96 1184 A-131828 usUfscAfcGfgUfgGfucuCfcAfuGfcGfascsg 1230 2 AD-65788 A-131811 UfsusAfcAfuAfaGfAfGfgAfcUfcUfuGfgAfL96 1185 A-131812 usCfscAfaGfaGfuCfcucUfuAfuGfuAfasgs a 1231 ..'.
-I" AD-65768 A-131803 UfscsUfuAfcAfuAfAfGfaGfgAfcUfcUfuAfL96 1186 A-131804 usAfsaGfaGfuCfcUfcuuAfuGfuAfaGfascsc 1232 , AD-61561 A-123523 Afsc sUfuCfaAfaGfAfCfuGfuUfuGfuUfuAfL96 1187 A-123524 usAfsaAfcAfaAfcAfgucUfuUfgAfaGfusasu 1233 , AD-65764 A-131801 UfsasCfuUfcAfaAfGfAfcUfgUfuUfgUfuUfL96 1188 A-131802 asAfsaCfaAfaCfaGfucuUfuGfaAfgUfasusg 1234 2 AD-65753 A-131799 AfsusAfcUfuCfaAfAfGfaCfuGfuUfuGfuUfL96 1189 A-131800 asAfscAfaAfcAfgUfcuuUfgAfaGfuAfusgsc 1235 AD-65765 A-131817 UfsusGfuUfuAfaAfGfAfcUfgGfgAfgGfaAfL96 1190 A-131818 usUfscCfuCfcCfaGfucuUfuAfaAfcAfasasc 1236 AD-65769 A-131819 GfscsAfuAfcUfuCfAfAfaGfaCfuGfuUfuAfL96 1191 A-131820 usAfsaAfcAfgUfcUfuugAfaGfuAfuGfcscsu 1237 AD-65759 A-131815 CfsasAfaGfaCfuGfUfUfuGfuUfuAfaAfgAfL96 1192 A-131816 usCfsuUfuAfaAfcAfaacAfgUfcUfuUfgs as a 1238 AD-65774 A-131831 AfsgsAfcUfgUfuUfGfUfuUfaAfaGfaCfuAfL96 1193 A-131832 usAfsgUfcUfuUfaAfacaAfaCfaGfuCfususu 1239 Iv AD-65778 A-131807 GfsusUfuGfuUfuAfAfAfgAfcUfgGfgAfgAfL96 1194 A-131808 usCfsuCfcCfaGfuCfuuuAfaAfcAfaAfcsasg 1240 n AD-65773 A-131805 GfsgsGfgGfaGfgAfGfAfuUfaGfaUfuAfaAfL96 1195 A-131806 usUfsuAfaUfcUfaAfucuCfcUfcCfcCfc sas a 1241 cp AD-65789 A-131825 GfsgsGfgAfgGfaGfAfUfuAfgAfuUfaAfaGfL96 1196 A-131826 c sUfsuUfaAfuCfuAfaucUfcCfuCfcCfc sc s a 1242 t.) o 1¨, AD-65783 A-131809 GfsusUfgGfgGfgAfGfGfaGfaUfuAfgAfuUfL96 1197 A-131810 asAfsuCfuAfaUfcUfccuCfcCfcCfaAfcsusc 1243 0 e AD-65754 A-131813 UfsusGfgGfgGfaGfGfAfgAfuUfaGfaUfuAfL96 1198 A-131814 usAfsaUfcUfaAfuCfuccUfcCfcCfcAfascsu 1244 t.) oe 1¨, AD-65779 A-131821 GfsgsGfaGfgAfgAfUfUfaGfaUfuAfaAfgAfL96 1199 A-131822 usCfsuUfuAfaUfcUfaauCfuCfcUfcCfcscsc 1245 cr ME1 27037625v.1 Sense SEQ Antisense SEQ ID
Duplex ID Oligo Sense Sequence (5' to 3') ID
Oligo Antisense Sequence (5' to 3') NO:
Name NO: Name t..) o AD-65791 A-131851 UfsusAfgAfuUfaAfAfGfgUfcUfuUfgUfaAfL96 1200 A-131852 usUfsaCfaAfaGfaCfcuuUfaAfuCfuAfasusc 1246 oe AD-65760 A-131829 UfsasGfaUfuAfaAfGfGfuCfuUfuGfuAfcUfL96 1201 A-131830 asGfsuAfcAfaAfgAfccuUfuAfaUfcUfasasu 1247 yD
vi AD-65784 A-131823 AfsusUfaGfaUfuAfAfAfgGfuCfuUfuGfuAfL96 1202 A-131824 usAfscAfaAfgAfcCfuuuAfaUfcUfaAfuscsu 1248 c:
vi AD-65757 A-131853 GfsasGfgAfgAfuUfAfGfaUfuAfaAfgGfuAfL96 1203 A-131854 usAfscCfuUfuAfaUfcuaAfuCfuCfcUfcscsc 1249 AD-65775 A-131847 GfsgsAfcUfcUfuGfGfAfcUfcUfcUfgCfaAfL96 1204 A-131848 usUfsgCfaGfaGfaGfuccAfaGfaGfuCfcsusc 1250 AD-65780 A-131833 AfscsUfcUfuGfgAfCfUfcUfcUfgCfaAfuAfL96 1205 A-131834 usAfsuUfgCfaGfaGfaguCfcAfaGfaGfuscsc 1251 AD-65756 A-131839 AfsgsAfuUfaAfaGfGfUfcUfuUfgUfaCfuAfL96 1206 A-131840 usAfsgUfaCfaAfaGfaccUfuUfaAfuCfusasa 1252 Table 10. Exemplary Unmodified HBV X ORF Sense and Antisense Sequences.
(Activity data available in W02016/077321, incorporated herein by P
reference) u9 ..' DuplexID Sense Sequence Unmodified (5' to 3') SEQ ID NO:
Antisense Sequence Umodified (5' to 3') SEQ ID NO:
.
, , .3 AGAGGUGAAGCGAAGUGCACAUU 1268 Iv n AAAAGUUGCAUGGUGCUGGUGUU 1270 cp t..) o 1¨, AGGUGAAAAAGUUGCAUGGUGUU 1271 oe -a-, t.., AGGUGAAAAAGUUGCAUGGUGUU 1272 c'e 1¨, 1¨, c:
ME1 27037625v.1 Table 11. Exemplary Modified HBV X ORF Sense and Antisense Sequences.
(Activity data available in W02016/077321, incorporated herein by reference) t.) o 1¨, oe 1¨, DuplexID SEQ ID Antisense Sequence Modified (5' to 3') SEQ ID
u, Sense Sequence Modified (5' to 3') ,.., NO:
NO: c7, u, AD-66808 gsuscuGfuGfCfCfuucucaucuaL96 1273 usAfsgauGfaGfAfaggcAfcAfgacsusu 1283 AD-66809 gsuscuGfuGfCfCfuucucaucuaL96 1274 UfsAfsgauGfaGfAfaggcAfcAfgacsusu 1284 AD-66810 gsusguGfcAfCfUfucgcuucacaL96 1275 usGfsugaAfgCfGfaaguGfcAfcacsusu 1285 AD-66811 gsusguGfcAfCfUfucgcuucacaL96 1276 UfsGfsugaAfgCfGfaaguGfcAfcacsusu 1286 AD-66812 usgsugcaCfuUfCfGfcuucaccucuL96 1277 asGfsaggUfgAfAfgcgaAfgUfgcacasusu 1287 P
AD-66813 usgsugcaCfuUfCfGfcuucaccucuL96 1278 AfsGfsaggUfgAfAfgcgaAfgUfgcacasusu 1288 .
u9 AD-66814 csasccagCfaCfCfAfugcaacuuuuL96 1279 asAfsaagUfuGfCfauggUfgCfuggugsusu 1289 ..' cs, AD-66815 csasccagCfaCfCfAfugcaacuuuuL96 1280 AfsAfsaagUfuGfCfauggUfgCfuggugsusu 1290 " , AD-66816 csasccauGfcAfAfCfuuuuucaccuL96 1281 asGfsgugAfaAfAfaguuGfcAfuggugsusu 1291 , , , AD-66817 csasccauGfcAfAfCfuuuuucaccuL96 1282 AfsGfsgugAfaAfAfaguuGfcAfuggugsusu 1292 .3 Iv n ,¨i cp t.., =
oe -c-:--, t.., oe c7, ME1 27037625v.1 Table 12: HBV Target Sequences, noting target sites on Accession No. X02763.1.
(Activity data and exemplary chemical modifications available at W02012/024170, incorporated herein by reference) Target Sequence Target Site SEQ ID NO:
Target Sequence Target Site SEQ ID NO:
Target Sequence Target Site SEQ ID NO:
Table 13. Various HBV siNA sense and antisense sequences corresponding to the identified target sequences in Table la. (Activity data and exemplary chemical modifications available at W02012/024170, incorporated herein by reference) E. S Q ID SEQ ID
Target Site Sense Sequence Anti sense Sequence NO: NO:
E. S Q ID SEQ
ID
Target Site Sense Sequence Antisense Sequence NO: NO:
E. S Q ID SEQ
ID
Target Site Sense Sequence Antisense Sequence NO: NO:
EQUIVALENTS
Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments and methods described herein. Such equivalents are intended to be encompassed by the scope of the following claims.
Claims (112)
1. An RNAi agent and an HBV vaccine comprising a protein-based vaccine and a nucleic acid-based vaccine for use in treatment of hepatitis B virus (HBV) infection or a method for treating a subject having an HBV infection, comprising sequentially administering to the subject having an HBV infection:
a) an RNAi agent that inhibits expression of at least three HBV transcripts, wherein the RNAi agent comprises a sense strand and an antisense strand forming a double stranded region;
b) a protein-based vaccine comprising a first HBV core antigen (HBcAg) polypeptide, or immunogenic fragment thereof, and a first HBV surface antigen (HBsAg) polypeptide, or immunogenic fragment thereof; and c) a nucleic acid-based vaccine comprising an expression vector construct encoding a second HBcAg polypeptide, or immunogenic fragment thereof, and/or a second HBsAg polypeptide, or immunogenic fragment thereof, wherein the second HBcAg polypeptide, or immunogenic fragment thereof, and/or the second HBsAg polypeptide, or immunogenic fragment thereof, shares at least one epitope with at least one of the first HBcAg polypeptide, or immunogenic fragment thereof, and/or the first HBsAg polypeptide, or immunogenic fragment thereof; thereby treating the subject.
a) an RNAi agent that inhibits expression of at least three HBV transcripts, wherein the RNAi agent comprises a sense strand and an antisense strand forming a double stranded region;
b) a protein-based vaccine comprising a first HBV core antigen (HBcAg) polypeptide, or immunogenic fragment thereof, and a first HBV surface antigen (HBsAg) polypeptide, or immunogenic fragment thereof; and c) a nucleic acid-based vaccine comprising an expression vector construct encoding a second HBcAg polypeptide, or immunogenic fragment thereof, and/or a second HBsAg polypeptide, or immunogenic fragment thereof, wherein the second HBcAg polypeptide, or immunogenic fragment thereof, and/or the second HBsAg polypeptide, or immunogenic fragment thereof, shares at least one epitope with at least one of the first HBcAg polypeptide, or immunogenic fragment thereof, and/or the first HBsAg polypeptide, or immunogenic fragment thereof; thereby treating the subject.
2. The use or method of claim 1, wherein the RNAi agent comprises at least one modified nucleotide.
3. The use or method of claim 1 or 2, wherein the nucleic acid-based vaccine comprises an expression vector construct encoding the second HBcAg polypeptide, or immunogenic fragment thereof, and the second HBsAg polypeptide, or immunogenic fragment thereof. .
4. The use or method of any of claims 1-3, wherein at least two doses of the RNAi agent are administered to the subject.
5. The use or method of any of claims 1-4, wherein the RNAi agent is administered to the subject such that the level of HBsAg in the serum of the subject is decreased by at least 0.5 log 10 IU/ml.
6. The use or method of any of claims 1-5, wherein the level of HBsAg in the serum of the subject is decreased by at least a 0.5 log10 IU/ml prior to administration of a first dose of the protein based vaccine.
7. The use or method of any of claims 1-6, wherein the level of HBsAg in the serum of the subject is decreased by at least a 1 log10 IU/ml prior to administration of a first dose of the protein based vaccine.
8. The use or method of any of claims 1-7, wherein the level of HBsAg in the serum of the subject is decreased by at least a 2 log 10 IU/ml prior to administration of a first dose of the protein based vaccine.
9. The use or method of any of claims 1-8, wherein the level of HBeAg in the serum of the subject is decreased by at least a 1 log 10 IU/ml prior to administration of a first dose of the protein based vaccine.
10. The use or method of any of claims 1-9, wherein the level of HBsAg in the serum of the subject is decreased by at least a 2 log 10 IU/ml and the the level of HBeAg in the serum of the subject is decreased by at least a 1 log 10 IU/ml prior to administration of a first dose of the protein based vaccine.
11. The use or method of any one of claims 1-10, wherein the subject has a serum HBsAg level of 500 IU/ml or less after administration of the RNAi agent and prior to administration of a first dose of the protein based vaccine.
12. The use or method of any one of claims 1-10, wherein the subject has a serum HBsAg level of 200 IU/ml or less after administration of the RNAi agent and prior to administration of a first dose of the protein based vaccine.
13. The use or method of any one of claims 1-10, wherein the subject has a serum HBsAg level of 100 IU/ml or less after administration of the RNAi agent and prior to administration of a first dose of the protein based vaccine.
14. The use or method of any one of claims 1-13, wherein the subject has a serum HBeAg level of 500 IU/ml or less after administration of the RNAi agent and prior to administration of a first dose of the protein based vaccine.
15. The use or method of any one of claims 1-13, wherein the subject has a serum HBeAg level of HBeAg level to 200 IU/ml or less after administration of the RNAi agent and prior to administration of a first dose of the protein based vaccine.
16. The use or method of any one of claims 1-13, wherein the subject has a serum HBeAg level of HBeAg level to 100 IU/ml or less after administration of the RNAi agent and prior to administration of a first dose of the protein based vaccine.
17. The use or method of any one of claims 1-16, wherein the subject has a serum HBsAg level of 500 IU/ml or less and a serum HBeAg level of 500 IU/ml or less after administration of the RNAi agent and prior to administration of a first dose of the protein based vaccine.
18. The use or method of any one of claims 1-16, wherein the subject has a serum HBsAg level of 200 IU/ml or less and a serum HBeAg level of 200 IU/ml or less after administration of the RNAi agent and prior to administration of a first dose of the protein based vaccine.
19. The use or method of any one of claims 1-16, wherein the subject has a serum HBsAg level of 100 IU/ml or less and a serum HBeAg level of 100 IU/ml or less after administration of the RNAi agent and prior to administration of a first dose of the protein based vaccine.
20. The use or method of any of claims 1-19, wherein a dose of the RNAi agent is administered to the subject no more than once per week.
21. The use or method of any of claims 1-19, wherein a dose of the RNAi agent is administered to the subject no more than once every four weeks.
22. The use or method of any one of claims 1-21, wherein the RNAi agent is administered to the subject at a dose of 0.01 mg/kg to 10 mg/kg; or 0.5 mg/kg to 50 mg/kg; or 10 mg/kg to 30 mg/kg.
23. The use or method of of any one of claims 1-21, wherein the RNAi agent is administered to the subject at a dose selected from the group consisting of 0.5 mg/kg, 1 mg/kg, 1.5 mg/kg, 3 mg/kg, mg/kg, 10 mg/kg, and 30 mg/kg.
24. The use or method of any of claims 1-23, wherein the first HBcAg polypeptide, or immunogenic fragment thereof, comprises at least one HBcAg determinant and the first HBsAg polypeptide, or immunogenic fragment thereof, comprises at least one HBsAg determinant.
25. The use or method of any one of claims 1-24, wherein the second HBcAg polypeptide, or immunogenic fragment thereof, comprises at least one HBcAg determinant and the second HBsAg polypeptide, or immunogenic fragment thereof, comprises at least one HBsAg determinant.
26. The use or method of claim 24 or 25, wherein the first and/or second HBsAg determinant comprises an amino acid sequence at least 90% identical to amino acids 124 to 147 of SEQ ID NO:
22.
22.
27. The use or method of claim 24 or 25, wherein the first and/or second HBsAg determinant comprises an amino acid sequence at least 90% identical to amino acids 99 to 168 of SEQ ID NO: 23.
28. The use or method of claim 24 or 25, wherein the first and/or second HBcAg determinant comprises an amino acid sequence comprising amino acid residue 80 of SEQ ID
NO: 24.
NO: 24.
29. The use or method of claim 28, wherein the sequence comprising amino acid 80 of SEQ
ID NO: 24 comprises an amino acid sequence at lest 90% identical to at least amino acids 70 to 90 of SEQ ID NO: 24.
ID NO: 24 comprises an amino acid sequence at lest 90% identical to at least amino acids 70 to 90 of SEQ ID NO: 24.
30. The use or method of claim 28, wherein the first and/or second HBcAg determinant comprises an amino acid sequence comprising amino acid residue 138 of SEQ ID
NO: 24.
NO: 24.
31. The use or method of claim 28, wherein the sequence comprising amino acid 80 of SEQ
ID NO: 14 comprises an amino acid sequence at lest 90% identical to at least amino acids 128 to 143 of SEQ ID NO: 24.
ID NO: 14 comprises an amino acid sequence at lest 90% identical to at least amino acids 128 to 143 of SEQ ID NO: 24.
32. The use or method of any of claims 28 or 31, wherein the first and/or second HBcAg determinant comprises an amino acid sequence at least 90% identical to at least 40, 50, 60, 70, 80, 90, or 100 contiguous amino acids of SEQ ID NO: 24.
33. The use or method of claim 25, wherein the determinant of HBcAg comprises a sequence at least 90% identical to amino acids 18 to 143 of SEQ ID NO: 24.
34. The use or method of any one of claims 1-33, wherein the a dose of the protein-based vaccine administered to the subject comprises about 0.1 lig to about 1.0 mg of the first HBcAg polypeptide, or immunogenic fragment thereof, and a dose of about 0.1 lig to about 1.0 mg of the first HBsAg polypeptide, or immunogenic fragment thereof.
35. The use or method of any of claims 1-34, wherein the first HBcAg polypeptide, or immunogenic fragment thereof, and the first HBsAg polypeptide, or immunogenic fragment thereof, are present in a single protein-based vaccine formulation.
36. The use or method of any of claims 1-35, wherein the protein-based vaccine further comprises an adjuvant.
37. The use or method of claim 36, wherein the adjuvant stimulates a balanced Th1/Th2 response.
38. The use or method of claim 36, wherein the adjuvant is selected from the group consisting of monophosphoryl lipid A (MPL), poly(I:C), polyICLC adjuvant, CpG
DNA, polyICLC
adjuvant ,a STING agonist, c-di-AMP, c-di-GMP, c-di-CMP; short, blunt-ended 5'-triphosphate dsRNA (3pRNA) Rig-Iligand, poly[di(sodiumcarboxylatoethylphenoxy)phosphazene]
(PCEP)), alum, virosomes, cytokines, IL-12, AS02, AS03, AS04, MF59, ISCOMATRIX®, IC31®, or Rig-I ligand.
DNA, polyICLC
adjuvant ,a STING agonist, c-di-AMP, c-di-GMP, c-di-CMP; short, blunt-ended 5'-triphosphate dsRNA (3pRNA) Rig-Iligand, poly[di(sodiumcarboxylatoethylphenoxy)phosphazene]
(PCEP)), alum, virosomes, cytokines, IL-12, AS02, AS03, AS04, MF59, ISCOMATRIX®, IC31®, or Rig-I ligand.
39. The use or method of claim 36, wherein the adjuvant is selected from the group consisting of a polyI:C adjuvant, a CpG adjuvant, a STING agonist, or a PCEP
adjuvant.
adjuvant.
40. The use or method of any of claims 1-39, wherein a dose of the protein based vaccine is administered to the subject at least two times.
41. The use or method of claim 40, wherein a dose of the protein-based vaccine is administered to the subject no more than once every two weeks.
42. The use or method of any of claims 1-41, wherein a dose of the protein-based vaccine is administered to the subject no sooner than the day on which a final dose of the RNAi agent has been administered to the subject.
43. The use or method of claim 42, wherein a dose of the protein-based vaccine is administered to the subject on the same day as a final dose of the RNAi agent has been administered to the subject.
44. The use or method of any of claims 1-42, wherein the a dose of the protein-based vaccine is administered to the subject no later than one month after a final dose of the RNAi agent has been administered to the subject.
45. The use or method of any of claims 1-42, wherein a dose of the protein-based vaccine is administered to the subject no later than three months after a final dose of the RNAi agent has been administered to the subject.
46. The use or method of any of claims 1-45, wherein the level of HBsAg in the serum of the subject is determined after administration of at least one dose of the RNAi agent and prior to administration of the protein based vaccine.
47. The use or method of any of claims 1-45, wherein the level of HBeAg in the serum of the subject is determined after administration of at least one dose of the RNAi agent and prior to administration of the protein based vaccine.
48. The use or method of any of claims 1-45, wherein the level of HBsAg and the level of HBeAg in the serum of the subject are determined after administration of at least one dose of the RNAi agent and prior to administration of the protein based vaccine.
49. The use or method of any of claims 1-45, wherein the nucleic acid-based vaccine comprises at least one expression vector construct encoding the second HBcAg polypeptide, or immunogenic fragment thereof, and the second HBsAg polypeptide, or immunogenic fragment thereof.
50. The use or method of claim 49, wherein the at least one expression construct comprises a promoter that promotes expression of the second HBcAg polypeptide, or immunogenic fragment thereof, and the second HBsAg polypeptide, or immunogenic fragment thereof.
51. The use or method of claim 49, wherein the at least one expression construct comprises a first and second promoter, the first promoter promoting expression of the second HBcAg polypeptide, or immunogenic fragment thereof, and the second promoter promoting expression of the second HBsAg polypeptide, or immunogenic fragment thereof.
52. The use or method of claim 50 or 51 wherein at least one the promoters is selected from the group consisting of a respiratory syncytial virus (RSV) promoter, a cytomegalovirus (CMV) promoter, a PH5 promoter, and an H1 promoter.
53. The use or method of any of claims 1-52, wherein the expression construct comprises a viral vector.
54. The use or method of claim 53, wherein the viral vector is selected from the group consosting of an adenovirus vector; a retrovirus vector, a lentiviral vector, a moloney murine leukemia virus vector,an adeno- associated virus vector; a herpes simplex virus vector; a SV 40 vector; a polyoma virus vector; a papilloma virus vector; a picornavirus vector; a pox virus vector, an orthopox virus vector, a vaccinia virus vector, a modified vaccinia virus Ankara (MVA) vector, an avipox vector, a canary pox vector, a fowl pox vector, and an Epstein Barr virus vector.
55. The use or method of claim 53, wherein the viral vector is an MVA vector.
56. The use or method of any one of claims 1-55, wherein a dose of the nucleic acid-based vaccine administered to the subject comprises a tissue-culture infectious dose (TCID50) of 106 to 1010 TCID50; or 106 to 109 TCID50; or 106 to 108 TCID50.
57. The use or method of any of claims 1-56, wherein a dose of the nucleic acid-based vaccine is administered to the subject no sooner than two weeks after administration of a final dose of the protein-based vaccine is administered to the subject.
58. The use or method of any of claims 1-57, wherein the level of HBsAg in the serum of the subject after administration of at least one dose of the RNAi agent is determined prior to administration of a dose of the nucleic acid-based vaccine.
59. The use or method of any of claims 1-58, wherein a first dose of the nucleic acid-based vaccine is administered to the subject when the level of HBsAg in the serum of the subject is further decreasd to at least 0.5 log 10 IU/ml following administration of at least one dose of the protein-based vaccine.
60. The use or method of any of claims 1-59, wherein a single dose of the nucleic-acid based vaccine is administered to the subject.
61. The use or method of any of claims 1-60, further comprising administering a nucleot(s)ide analog to the subject.
62. The use or method of claim 61, wherein at least one dose of the nucleot(s)ide analog is administered to the subject prior to administration of the RNAi agent to the subject; or multiple doses of the nucleot(s)ide analog are administered to the subject.
63. The use or method of claim 61 or 62, wherein the nucleot(s)ide analog is selected from the group consisting of Tenofovir disoproxil fumarate (TDF), Tenofovir alafenamide (TAF), Lamivudine, Adefovir dipivoxil, Entecavir (ETV), Telbivudine, AGX-1009, emtricitabine, clevudine, ritonavir, dipivoxil, lobucavir, famvir, FTC, N-Acetyl-Cysteine (NAC), PC1323, theradigm-HBV, thymosin-alpha, and ganciclovir, besifovir (ANA-380/LB-80380), and tenofvir-exaliades (TLX/CMX157).
64. The use or method of any one of claims 1-63, wherein the level of serum HBsAg in the subject is below 3000 IU/ml, 4000 IU/ml, or 5000 IU/ml prior to administration of the RNAi agent.
65. The use or method of any of claims 1-64, wherein the level of serum HBsAg in the subject is decreased to below the level of detection using a clinical assay for at least six months after the end of the dose of the nucleic acid-based vaccine.
66. The use or method of any of claims 1-64, wherein the level of serum HBeAg in the subject is decreased to below the level of detection using a clinical assay for at least six months after the end of the dose of the nucleic acid-based vaccine.
67. The use or method of any of claims 1-64, wherein the level of serum HBsAg and HBeAg in the subject are decreased to below the level of detection using a clinical assay for at least six months after the end of the dose of the nucleic acid-based vaccine.
68. The use or method of any of claims 1-67, further comprising administering an immune stimulator to the subject.
69. The use or method of claim 68, wherein immune stimulator is selected from the group consisting of pegylated interferon alfa 2a (PEG-IFN-alpha-2a), Interferon alfa-2b, PEG-IFN-alpha-2b, Interferon lambda a recombinant human interleukin-7, and a Toll-like receptor 3, 7, 8 or 9 (TLR3, TLR7, TLR8, TLR9) agonist, a viral entry inhibitor, Myrcludex, an oligonucleotide that inhibits the secretion or release of HBsAg, REP 9AC, a capsid inhibitor, Bay41-4109, NVR-1221, a cccDNA
inhibitor, IHVR-25) a viral capsid, an MVA capsid, an immune checkpoint regulator, an CTLA-4 inhibitor, ipilimumab, a PD-1 inhibitor, Nivolumab, Pembrolizumab, BGB-A317 antibody, a PD-L1 inhibitor, atezolizumab, avelumab, durvalumab, and an affimer biotherapeutic.
inhibitor, IHVR-25) a viral capsid, an MVA capsid, an immune checkpoint regulator, an CTLA-4 inhibitor, ipilimumab, a PD-1 inhibitor, Nivolumab, Pembrolizumab, BGB-A317 antibody, a PD-L1 inhibitor, atezolizumab, avelumab, durvalumab, and an affimer biotherapeutic.
70. The use or method of any one of claims 1-69, wherein the subject is human.
71. The use or method of any of claims 1-70, wherein the RNAi agent inhibits expression of four HBV transcripts.
72. The use or method of any of claims 1-70, wherein the RNAi agent inhibits expression of at least three HBV transcripts.
73. The use or method of any of claims 1-72, wherein the RNAi agent is selected from any one of the iRNA agents in Appendix A.
74. The use or method of claim 73, wherein the RNAi agent is selected from any one of the RNAi agents in Tables 2-11 in Appendix A.
75. The use or method of any of claims 1-74, wherein the RNAi agent targets at least 15 contiguous nucleotides of nucleotides 1579-1597, 206-228, 207-229, 210-232, 212-234, 214-236, 215-237, 216-238, 226-248, 245-267, 250-272, 252-274, 253-275, 254-276, 256-278, 258-280, 263-285, 370-392, 373-395, 375-397, 401-423, 405-427, 410-432, 411-433, 422-444, 424-446, 425-447, 426-448, 731-753, 734-756, 1174-1196, 1250-1272, 1255-1277, 1256-1278, 1545-1567, 1547-1569, 1551-1571, 1577-1597, 1580-1598, 1806-1825, 1812-1831, 1814-1836, 1829-1851, 1831-1853, 1857-1879, 1864-1886, 2259-2281, 2298-2320, or 2828-2850 of SEQ ID NO: 1 (NC_003977.1).
76. The use or method of any of claims 1-75, wherein the RNAi agent targets at least 15 contiguous nucleotides of nucleotides 1579-1597 or 1812-1831 of SEQ ID NO: 1 (NC_003977.1).
77. The use or method of any of claims 1-75, wherein the RNAi agent targets nucleotides 1579-1597 or 1812-1831 of SEQ ID NO: 1 (NC_003977.1).
78. The use or method of claim 75, wherein the antisense strand of the RNAi agent comprises at least 15 contiguous nucleotides of the nucleotide sequence of 5'-UGUGAAGCGAAGUGCACACUU-3' (SEQ ID NO: 25) or 5'-AGGUGAAAAAGUUGCAUGGUGUU-3' (SEQ ID NO: 26).
79. The use or method of claim 75, wherein the antisense strand of the RNAi agent comprises at least 19 contiguous nucleotides of the nucleotide sequence of 5'-UGUGAAGCGAAGUGCACACUU-3' (SEQ ID NO: 25) or 5'-AGGUGAAAAAGUUGCAUGGUGUU-3' (SEQ ID NO: 26).
80. The use or method of claim 75, wherein the antisense strand of the RNAi agent comprises the nucleotide sequence of 5'-UGUGAAGCGAAGUGCACACUU-3' (SEQ ID NO: 25) or 5'-AGGUGAAAAAGUUGCAUGGUGUU-3' (SEQ ID NO: 26).
81. The use or method of any of claims 75-80, wherein the sense strand of the RNAi agent comprises at least 15 contiguous nucleotides of the nucleotide sequence of 5'-GUGUGCACUUCGCUUCACA-3' (SEQ ID NO: 27) or 5'-CACCAUGCAACUUUUUCACCU-3' (SEQ ID NO: 28).
82. The use or method of any of claims 75-80, wherein the sense strand of the RNAi agent comprises at least 19 contiguous nucleotides of the nucleotide sequence of 5'-GUGUGCACUUCGCUUCACA-3' (SEQ ID NO: 27) or 5'-CACCAUGCAACUUUUUCACCU-3' (SEQ ID NO: 28).
83. The use or method of any of claims 75-80, wherein the sense strand of the RNAi agent comprises the nucleotide sequence of 5'-GUGUGCACUUCGCUUCACA-3' (SEQ ID NO: 27) or 5'-CACCAUGCAACUUUUUCACCU-3' (SEQ ID NO: 28).
84. The use or method of any of claims 75-77, wherein the antisense strand of the RNAi agent comprises at least 15 contiguous nucleotides of the nucleotide sequence of 5'-UGUGAAGCGAAGUGCACACUU-3' (SEQ ID NO: 25) and the sense strand comprises at least 15 contiguous nucleotides of the nucleotide sequence of 5'-GUGUGCACUUCGCUUCACA-3' (SEQ ID
NO: 27).
NO: 27).
85. The use or method of any of claims 75-77, wherein the antisense strand of the RNAi agent comprises at least 19 contiguous nucleotides of the nucleotide sequence of 5'-UGUGAAGCGAAGUGCACACUU-3' (SEQ ID NO: 25) and the sense strand comprises at least 19 contiguous nucleotides of the nucleotide sequence of 5'-GUGUGCACUUCGCUUCACA-3' (SEQ ID
NO: 27).
NO: 27).
86. The use or method of any of claims 75-77, wherein the antisense strand of the RNAi agent comprises the nucleotide sequence of 5'-UGUGAAGCGAAGUGCACACUU-3' (SEQ ID
NO:
25) and the sense strand comprises the nucleotide sequence of 5'-GUGUGCACUUCGCUUCACA-3' (SEQ ID NO: 27).
NO:
25) and the sense strand comprises the nucleotide sequence of 5'-GUGUGCACUUCGCUUCACA-3' (SEQ ID NO: 27).
87. The use or method of any of claims 75-77, wherein the antisense strand of the RNAi agent comprises at least 15 contiguous nucleotides of the nucleotide sequence of 5'-AGGUGAAAAAGUUGCAUGGUGUU-3' (SEQ ID NO: 26) and the sense strand of the RNAi agent comprises at least 15 contiguous nucleotides of the nucleotide sequence of 5'-CACCAUGCAACUUUUUCACCU-3' (SEQ ID NO: 28).
88. The use or method of any of claims 75-77, wherein the antisense strand of the RNAi agent comprises a at least 19 contiguous nucleotides of the nucleotide sequence of 5'-AGGUGAAAAAGUUGCAUGGUGUU-3' (SEQ ID NO: 26) and the sense strand of the RNAi agent comprises at least 19 contiguous nucleotides of the nucleotide sequence of 5'-CACCAUGCAACUUUUUCACCU-3' (SEQ ID NO: 28).
89. The use or method of any of claims 75-77, wherein the antisense strand of the RNAi agent comprises the nucleotide sequence of 5' -AGGUGAAAAAGUUGCAUGGUGUU-3' (SEQ
ID
NO: 26) and the sense strand of the RNAi agent comprises the nucleotide sequence of 5'-CACCAUGCAACUUUUUCACCU-3' (SEQ ID NO: 28).
ID
NO: 26) and the sense strand of the RNAi agent comprises the nucleotide sequence of 5'-CACCAUGCAACUUUUUCACCU-3' (SEQ ID NO: 28).
90. The use or method of any of claims 1-89, wherein substantially all of the nucleotides of said sense strand and substantially all of the nucleotides of said antisense strand are modified nucleotides, wherein said sense strand is conjugated to a ligand attached at the 3' -terminus.
91. The use or method of claim 90, wherein the ligand is one or more GalNAc derivatives attached through a monovalent linker, bivalent branched linker, or trivalent branched linker.
92. The use or method of claim 91, wherein at least one of said modified nucleotides is selected from the group consisting of a deoxy-nucleotide, a 3' -terminal deoxy-thymine (dT) nucleotide, a 2'-O-methyl modified nucleotide, a 2'-fluoro modified nucleotide, a 2'-deoxy-modified nucleotide, a locked nucleotide, an unlocked nucleotide, a conformationally restricted nucleotide, a constrained ethyl nucleotide, an abasic nucleotide, a 2'-amino-modified nucleotide, a 2' -O-allyl-modified nucleotide, 2' -C-alkyl-modified nucleotide, 2' -hydroxly-modified nucleotide, a 2' -methoxyethyl modified nucleotide, a 2' -O-alkyl-modified nucleotide, a morpholino nucleotide, a phosphoramidate, a non-natural base comprising nucleotide, a tetrahydropyran modified nucleotide, a 1,5-anhydrohexitol modified nucleotide, a cyclohexenyl modified nucleotide, a nucleotide comprising a phosphorothioate group, a nucleotide comprising a methylphosphonate group, a nucleotide comprising a 5'-phosphate, and a nucleotide comprising a 5'-phosphate mimic.
93. The use or method of any of claims 1-92, wherein at least one strand of the RNAi agent comprises a 3' overhang of at least 1 nucleotide.
94. The use or method of any of claims 1-92, wherein at least one strand if the RNAi agent comprises a 3' overhang of at least 2 nucleotides.
95. The use or method of any of claims 1-92, wherein the double-stranded region of the RNAi agent is 15-30 nucleotide pairs in length.
96. The use or method of any of claims 1-92, wherein the double-stranded region of the RNAi agent is 17-23 nucleotide pairs in length.
97. The use or method of any of claims 1-92, wherein the double-stranded region of the RNAi agent is 17-25 nucleotide pairs in length.
98. The use or method of any of claims 1-92, wherein the double-stranded region of the RNAi agent is 23-27 nucleotide pairs in length.
99. The use or method of any of claims 1-92, wherein the double-stranded region of the RNAi agent is 19-21 nucleotide pairs in length.
100. The use or method of any of claims 1-92, wherein the double-stranded region of the RNAi agent is 21-23 nucleotide pairs in length.
101. The use or method of any of claims 1-92, wherein each strand of the RNAi agent has 15-30 nucleotides.
102. The use or method of any of claims 1-92, wherein each strand of the RNAi agent has 19-30 nucleotides.
103. The use or method of claim 90, wherein the ligand is
104. The use or method of claim 90, wherein the RNAi agent is conjugated to the ligand as shown in the following schematic wherein X is O or S.
105. The use or method of any of claims 1-75 wherein the RNAi agent is AD-66810 or AD-66816.
106. The use or method of any of claims 1-105, wherein the first HBcAg polypeptide, or immunogenic fragment thereof, and/or the first HBsAg polypeptide, or immunogenic fragment thereof, comprise at least one determinant present in at least four genotypes of HBV.
107. The use or method of any of claims 1-105, wherein the first HBcAg polypeptide, or immunogenic fragment thereof, and/or the first HBsAg polypeptide, or immunogenic fragment thereof, comprise at least one determinant present in at least six genotypes of HBV.
108. The use or method of any of claims 1-105, wherein the first HBcAg polypeptide, or immunogenic fragment thereof, and/or the first HBsAg polypeptide, or immunogenic fragment thereof, comprise at least one determinant present in at least seven genotypes of HBV.
109. The use or method of any of claims 1-108, wherein the second HBcAg polypeptide, or immunogenic fragment thereof, and/or the second HBsAg polypeptide, or immunogenic fragment thereof, comprise at least one determinant present in at least four genotypes of HBV.
110. The use or method of any of claims 1-108, wherein the second HBcAg polypeptide, or immunogenic fragment thereof, and/or the second HBsAg polypeptide, or immunogenic fragment thereof, comprise at least one determinant present in at least six genotypes of HBV.
111. The use or method of any of claims 1-108, wherein the second HBcAg polypeptide, or immunogenic fragment thereof, and/or the second HBsAg polypeptide, or immunogenic fragment thereof, comprise at least one determinant present in at least seven genotypes of HBV.
112. A kit for treating a subject having an HBV infection, the kit comprising:
a) an RNAi agent that inhibits expression of at least three HBV transcripts, wherein the RNAi agent comprises a sense strand and an antisense strand forming a double stranded region;
b) a protein-based vaccine comprising a first HBV core antigen (HBcAg) polypeptide, or immunogenic fragment thereof, and a first HBV surface antigen (HBsAg) polypeptide, or immunogenic fragment thereof; and c) a nucleic acid-based vaccine comprising an expression vector construct encoding a second HBcAg polypeptide, or immunogenic fragment thereof, and/or a second HBsAg polypeptide, or immunogenic fragment thereof, wherein the second HBcAg polypeptide, or immunogenic fragment thereof, and/or the second HBsAg polypeptide, or immunogenic fragment thereof, shares at least one epitope with at least one of the first HBcAg polypeptide, or immunogenic fragment thereof, and/or the first HBsAg polypeptide, or immunogenic fragment thereof; and d) instructions for use according to the uses or methods of any one of claims 1-111.
a) an RNAi agent that inhibits expression of at least three HBV transcripts, wherein the RNAi agent comprises a sense strand and an antisense strand forming a double stranded region;
b) a protein-based vaccine comprising a first HBV core antigen (HBcAg) polypeptide, or immunogenic fragment thereof, and a first HBV surface antigen (HBsAg) polypeptide, or immunogenic fragment thereof; and c) a nucleic acid-based vaccine comprising an expression vector construct encoding a second HBcAg polypeptide, or immunogenic fragment thereof, and/or a second HBsAg polypeptide, or immunogenic fragment thereof, wherein the second HBcAg polypeptide, or immunogenic fragment thereof, and/or the second HBsAg polypeptide, or immunogenic fragment thereof, shares at least one epitope with at least one of the first HBcAg polypeptide, or immunogenic fragment thereof, and/or the first HBsAg polypeptide, or immunogenic fragment thereof; and d) instructions for use according to the uses or methods of any one of claims 1-111.
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762486618P | 2017-04-18 | 2017-04-18 | |
US62/486,618 | 2017-04-18 | ||
US201762553358P | 2017-09-01 | 2017-09-01 | |
US62/553,358 | 2017-09-01 | ||
US201862646978P | 2018-03-23 | 2018-03-23 | |
US62/646,978 | 2018-03-23 | ||
US201862655862P | 2018-04-11 | 2018-04-11 | |
US62/655,862 | 2018-04-11 | ||
PCT/US2018/028116 WO2018195165A1 (en) | 2017-04-18 | 2018-04-18 | Methods for the treatment of subjects having a hepatitis b virus (hbv) infection |
Publications (1)
Publication Number | Publication Date |
---|---|
CA3059446A1 true CA3059446A1 (en) | 2018-10-25 |
Family
ID=62111274
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA3059446A Pending CA3059446A1 (en) | 2017-04-18 | 2018-04-18 | Methods for the treatment of subjects having a hepatitis b virus (hbv) infection |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP3612219A1 (en) |
KR (1) | KR20200015895A (en) |
CN (1) | CN110913898B (en) |
AU (1) | AU2018254437A1 (en) |
BR (1) | BR112019021852A2 (en) |
CA (1) | CA3059446A1 (en) |
MA (1) | MA50278A (en) |
PH (1) | PH12019550220A1 (en) |
SG (1) | SG11201909572QA (en) |
TW (1) | TWI801377B (en) |
WO (1) | WO2018195165A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113398261A (en) * | 2021-07-16 | 2021-09-17 | 山西医科大学 | Application of poly-sarcosine in preparing biological preparation for improving HBsAg positive mother infant hepatitis B vaccine response level |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JOP20200092A1 (en) | 2014-11-10 | 2017-06-16 | Alnylam Pharmaceuticals Inc | HEPATITIS B VIRUS (HBV) iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
SG11201909433XA (en) * | 2017-04-11 | 2019-11-28 | Arbutus Biopharma Corp | Targeted compositions |
WO2018222910A1 (en) * | 2017-05-31 | 2018-12-06 | Arbutus Biopharma Corporation | Therapeutic compositions and methods for treating hepatitis b |
SG11202100715WA (en) | 2018-08-13 | 2021-02-25 | Alnylam Pharmaceuticals Inc | HEPATITIS B VIRUS (HBV) dsRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF |
AU2019406186A1 (en) | 2018-12-20 | 2021-07-15 | Praxis Precision Medicines, Inc. | Compositions and methods for the treatment of KCNT1 related disorders |
TW202039000A (en) * | 2018-12-20 | 2020-11-01 | 瑞士商休曼斯生物醫藥公司 | Combination hbv therapy |
JP2022516041A (en) * | 2018-12-24 | 2022-02-24 | 遠大賽威信生命科学(南京)有限公司 | Drug preparation for treating hepatitis B, its manufacturing method and use |
US20220339281A1 (en) * | 2019-03-05 | 2022-10-27 | GalxoSmithKline Biologicals SA | Hepatitis b immunisation regimen and compositions |
CN114126628A (en) * | 2019-05-13 | 2022-03-01 | 维尔生物科技有限公司 | Compositions and methods for treating Hepatitis B Virus (HBV) infection |
JP2022534080A (en) * | 2019-05-23 | 2022-07-27 | シァメン・ユニヴァーシティ | Novel anti-hepatitis B virus antibody and use thereof |
CN114340663A (en) * | 2019-06-18 | 2022-04-12 | 爱尔兰詹森科学公司 | Combination of Hepatitis B Virus (HBV) vaccine and HBV-targeted RNAi |
US20220305117A1 (en) * | 2019-06-18 | 2022-09-29 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and hbv-targeting rnai |
WO2021061807A1 (en) * | 2019-09-23 | 2021-04-01 | Ascendo Biotechnology, Inc. | Biodegradable nanocomplex vaccines, methods for suppression of hepapitis b virus replication and hepapitis b virus surface antigen secretion |
EP4036111A4 (en) * | 2019-09-27 | 2023-10-25 | Fujirebio Inc. | Immunoassay for hepatitis b virus core-related antigen and kit therefor |
WO2021107097A1 (en) * | 2019-11-28 | 2021-06-03 | 株式会社ボナック | Nucleic acid molecule for hepatitis b treatment use |
US20230220386A1 (en) * | 2019-12-06 | 2023-07-13 | Medshine Discovery Inc. | Sirna conjugate, double-stranded sirna conjugate, salt thereof and application thereof |
CN113637706A (en) * | 2020-05-11 | 2021-11-12 | 复旦大学 | Establishment method and application of hepatitis B virus recombinant cccDNA mouse model |
EP4150089A1 (en) | 2020-05-15 | 2023-03-22 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of retinoschisin 1 (rs1) |
WO2021231673A1 (en) | 2020-05-15 | 2021-11-18 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of leucine rich repeat kinase 2 (lrrk2) |
WO2021231692A1 (en) | 2020-05-15 | 2021-11-18 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of otoferlin (otof) |
WO2021231680A1 (en) | 2020-05-15 | 2021-11-18 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of methyl-cpg binding protein 2 (mecp2) |
EP4150077A1 (en) | 2020-05-15 | 2023-03-22 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of transmembrane channel-like protein 1 (tmc1) |
EP4150078A1 (en) | 2020-05-15 | 2023-03-22 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of argininosuccinate lyase (asl) |
EP4150087A1 (en) | 2020-05-15 | 2023-03-22 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of gap junction protein beta 2 (gjb2) |
WO2021231675A1 (en) | 2020-05-15 | 2021-11-18 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of argininosuccinate synthetase (ass1) |
AR122534A1 (en) | 2020-06-03 | 2022-09-21 | Triplet Therapeutics Inc | METHODS FOR THE TREATMENT OF NUCLEOTIDE REPEAT EXPANSION DISORDERS ASSOCIATED WITH MSH3 ACTIVITY |
WO2021249352A1 (en) | 2020-06-10 | 2021-12-16 | 正大天晴药业集团股份有限公司 | Conjugate of double-stranded sirna analogue |
IL299771A (en) | 2020-07-10 | 2023-03-01 | Inst Nat Sante Rech Med | Methods and compositions for treating epilepsy |
CN114507663A (en) * | 2020-11-16 | 2022-05-17 | 浙江柏拉阿图医药科技有限公司 | Oligonucleotide and application thereof in resisting hepatitis B virus and hepatitis D virus |
EP4341405A1 (en) | 2021-05-20 | 2024-03-27 | Korro Bio, Inc. | Methods and compositions for adar-mediated editing |
WO2022256283A2 (en) | 2021-06-01 | 2022-12-08 | Korro Bio, Inc. | Methods for restoring protein function using adar |
WO2023278410A1 (en) | 2021-06-29 | 2023-01-05 | Korro Bio, Inc. | Methods and compositions for adar-mediated editing |
US20230194709A9 (en) | 2021-06-29 | 2023-06-22 | Seagate Technology Llc | Range information detection using coherent pulse sets with selected waveform characteristics |
CA3234835A1 (en) | 2021-10-22 | 2023-04-27 | Korro Bio, Inc. | Methods and compositions for disrupting nrf2-keap1 protein interaction by adar mediated rna editing |
WO2023155909A1 (en) * | 2022-02-18 | 2023-08-24 | 南京明德新药研发有限公司 | Ribavirin analog and use thereof as embedding group |
Family Cites Families (233)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US564562A (en) | 1896-07-21 | Joseph p | ||
US513030A (en) | 1894-01-16 | Machine for waxing or coating paper | ||
US3687808A (en) | 1969-08-14 | 1972-08-29 | Univ Leland Stanford Junior | Synthetic polynucleotides |
US4469863A (en) | 1980-11-12 | 1984-09-04 | Ts O Paul O P | Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof |
US5023243A (en) | 1981-10-23 | 1991-06-11 | Molecular Biosystems, Inc. | Oligonucleotide therapeutic agent and method of making same |
US4476301A (en) | 1982-04-29 | 1984-10-09 | Centre National De La Recherche Scientifique | Oligonucleotides, a process for preparing the same and their application as mediators of the action of interferon |
JPS5927900A (en) | 1982-08-09 | 1984-02-14 | Wakunaga Seiyaku Kk | Oligonucleotide derivative and its preparation |
FR2540122B1 (en) | 1983-01-27 | 1985-11-29 | Centre Nat Rech Scient | NOVEL COMPOUNDS COMPRISING A SEQUENCE OF OLIGONUCLEOTIDE LINKED TO AN INTERCALATION AGENT, THEIR SYNTHESIS PROCESS AND THEIR APPLICATION |
US4605735A (en) | 1983-02-14 | 1986-08-12 | Wakunaga Seiyaku Kabushiki Kaisha | Oligonucleotide derivatives |
US4948882A (en) | 1983-02-22 | 1990-08-14 | Syngene, Inc. | Single-stranded labelled oligonucleotides, reactive monomers and methods of synthesis |
US4824941A (en) | 1983-03-10 | 1989-04-25 | Julian Gordon | Specific antibody to the native form of 2'5'-oligonucleotides, the method of preparation and the use as reagents in immunoassays or for binding 2'5'-oligonucleotides in biological systems |
US4587044A (en) | 1983-09-01 | 1986-05-06 | The Johns Hopkins University | Linkage of proteins to nucleic acids |
US5118800A (en) | 1983-12-20 | 1992-06-02 | California Institute Of Technology | Oligonucleotides possessing a primary amino group in the terminal nucleotide |
US5118802A (en) | 1983-12-20 | 1992-06-02 | California Institute Of Technology | DNA-reporter conjugates linked via the 2' or 5'-primary amino group of the 5'-terminal nucleoside |
US5550111A (en) | 1984-07-11 | 1996-08-27 | Temple University-Of The Commonwealth System Of Higher Education | Dual action 2',5'-oligoadenylate antiviral derivatives and uses thereof |
FR2567892B1 (en) | 1984-07-19 | 1989-02-17 | Centre Nat Rech Scient | NOVEL OLIGONUCLEOTIDES, THEIR PREPARATION PROCESS AND THEIR APPLICATIONS AS MEDIATORS IN DEVELOPING THE EFFECTS OF INTERFERONS |
US5258506A (en) | 1984-10-16 | 1993-11-02 | Chiron Corporation | Photolabile reagents for incorporation into oligonucleotide chains |
US5430136A (en) | 1984-10-16 | 1995-07-04 | Chiron Corporation | Oligonucleotides having selectably cleavable and/or abasic sites |
US5367066A (en) | 1984-10-16 | 1994-11-22 | Chiron Corporation | Oligonucleotides with selectably cleavable and/or abasic sites |
US4828979A (en) | 1984-11-08 | 1989-05-09 | Life Technologies, Inc. | Nucleotide analogs for nucleic acid labeling and detection |
US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
FR2575751B1 (en) | 1985-01-08 | 1987-04-03 | Pasteur Institut | NOVEL ADENOSINE DERIVATIVE NUCLEOSIDES, THEIR PREPARATION AND THEIR BIOLOGICAL APPLICATIONS |
US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
US5235033A (en) | 1985-03-15 | 1993-08-10 | Anti-Gene Development Group | Alpha-morpholino ribonucleoside derivatives and polymers thereof |
US5405938A (en) | 1989-12-20 | 1995-04-11 | Anti-Gene Development Group | Sequence-specific binding polymers for duplex nucleic acids |
US5166315A (en) | 1989-12-20 | 1992-11-24 | Anti-Gene Development Group | Sequence-specific binding polymers for duplex nucleic acids |
US5185444A (en) | 1985-03-15 | 1993-02-09 | Anti-Gene Deveopment Group | Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4762779A (en) | 1985-06-13 | 1988-08-09 | Amgen Inc. | Compositions and methods for functionalizing nucleic acids |
US5317098A (en) | 1986-03-17 | 1994-05-31 | Hiroaki Shizuya | Non-radioisotope tagging of fragments |
JPS638396A (en) | 1986-06-30 | 1988-01-14 | Wakunaga Pharmaceut Co Ltd | Poly-labeled oligonucleotide derivative |
US4920016A (en) | 1986-12-24 | 1990-04-24 | Linear Technology, Inc. | Liposomes with enhanced circulation time |
US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5276019A (en) | 1987-03-25 | 1994-01-04 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibitors for replication of retroviruses and for the expression of oncogene products |
US5264423A (en) | 1987-03-25 | 1993-11-23 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibitors for replication of retroviruses and for the expression of oncogene products |
US4904582A (en) | 1987-06-11 | 1990-02-27 | Synthetic Genetics | Novel amphiphilic nucleic acid conjugates |
DE3851889T2 (en) | 1987-06-24 | 1995-04-13 | Florey Howard Inst | NUCLEOSIDE DERIVATIVES. |
US5585481A (en) | 1987-09-21 | 1996-12-17 | Gen-Probe Incorporated | Linking reagents for nucleotide probes |
US5188897A (en) | 1987-10-22 | 1993-02-23 | Temple University Of The Commonwealth System Of Higher Education | Encapsulated 2',5'-phosphorothioate oligoadenylates |
US4924624A (en) | 1987-10-22 | 1990-05-15 | Temple University-Of The Commonwealth System Of Higher Education | 2,',5'-phosphorothioate oligoadenylates and plant antiviral uses thereof |
US5525465A (en) | 1987-10-28 | 1996-06-11 | Howard Florey Institute Of Experimental Physiology And Medicine | Oligonucleotide-polyamide conjugates and methods of production and applications of the same |
DE3738460A1 (en) | 1987-11-12 | 1989-05-24 | Max Planck Gesellschaft | MODIFIED OLIGONUCLEOTIDS |
US5082830A (en) | 1988-02-26 | 1992-01-21 | Enzo Biochem, Inc. | End labeled nucleotide probe |
EP0406309A4 (en) | 1988-03-25 | 1992-08-19 | The University Of Virginia Alumni Patents Foundation | Oligonucleotide n-alkylphosphoramidates |
US5278302A (en) | 1988-05-26 | 1994-01-11 | University Patents, Inc. | Polynucleotide phosphorodithioates |
US5109124A (en) | 1988-06-01 | 1992-04-28 | Biogen, Inc. | Nucleic acid probe linked to a label having a terminal cysteine |
US5216141A (en) | 1988-06-06 | 1993-06-01 | Benner Steven A | Oligonucleotide analogs containing sulfur linkages |
US5175273A (en) | 1988-07-01 | 1992-12-29 | Genentech, Inc. | Nucleic acid intercalating agents |
US5262536A (en) | 1988-09-15 | 1993-11-16 | E. I. Du Pont De Nemours And Company | Reagents for the preparation of 5'-tagged oligonucleotides |
US5512439A (en) | 1988-11-21 | 1996-04-30 | Dynal As | Oligonucleotide-linked magnetic particles and uses thereof |
US5599923A (en) | 1989-03-06 | 1997-02-04 | Board Of Regents, University Of Tx | Texaphyrin metal complexes having improved functionalization |
US5457183A (en) | 1989-03-06 | 1995-10-10 | Board Of Regents, The University Of Texas System | Hydroxylated texaphyrins |
FR2645866B1 (en) | 1989-04-17 | 1991-07-05 | Centre Nat Rech Scient | NEW LIPOPOLYAMINES, THEIR PREPARATION AND THEIR USE |
US5391723A (en) | 1989-05-31 | 1995-02-21 | Neorx Corporation | Oligonucleotide conjugates |
US4958013A (en) | 1989-06-06 | 1990-09-18 | Northwestern University | Cholesteryl modified oligonucleotides |
US5744101A (en) | 1989-06-07 | 1998-04-28 | Affymax Technologies N.V. | Photolabile nucleoside protecting groups |
US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
US5451463A (en) | 1989-08-28 | 1995-09-19 | Clontech Laboratories, Inc. | Non-nucleoside 1,3-diol reagents for labeling synthetic oligonucleotides |
US5134066A (en) | 1989-08-29 | 1992-07-28 | Monsanto Company | Improved probes using nucleosides containing 3-dezauracil analogs |
US5254469A (en) | 1989-09-12 | 1993-10-19 | Eastman Kodak Company | Oligonucleotide-enzyme conjugate that can be used as a probe in hybridization assays and polymerase chain reaction procedures |
US5591722A (en) | 1989-09-15 | 1997-01-07 | Southern Research Institute | 2'-deoxy-4'-thioribonucleosides and their antiviral activity |
US5399676A (en) | 1989-10-23 | 1995-03-21 | Gilead Sciences | Oligonucleotides with inverted polarity |
US5264564A (en) | 1989-10-24 | 1993-11-23 | Gilead Sciences | Oligonucleotide analogs with novel linkages |
EP0942000B1 (en) | 1989-10-24 | 2004-06-23 | Isis Pharmaceuticals, Inc. | 2'-Modified oligonucleotides |
US5292873A (en) | 1989-11-29 | 1994-03-08 | The Research Foundation Of State University Of New York | Nucleic acids labeled with naphthoquinone probe |
US5177198A (en) | 1989-11-30 | 1993-01-05 | University Of N.C. At Chapel Hill | Process for preparing oligoribonucleoside and oligodeoxyribonucleoside boranophosphates |
CA2029273A1 (en) | 1989-12-04 | 1991-06-05 | Christine L. Brakel | Modified nucleotide compounds |
US5486603A (en) | 1990-01-08 | 1996-01-23 | Gilead Sciences, Inc. | Oligonucleotide having enhanced binding affinity |
US5459255A (en) | 1990-01-11 | 1995-10-17 | Isis Pharmaceuticals, Inc. | N-2 substituted purines |
US6783931B1 (en) | 1990-01-11 | 2004-08-31 | Isis Pharmaceuticals, Inc. | Amine-derivatized nucleosides and oligonucleosides |
US5670633A (en) | 1990-01-11 | 1997-09-23 | Isis Pharmaceuticals, Inc. | Sugar modified oligonucleotides that detect and modulate gene expression |
US5587361A (en) | 1991-10-15 | 1996-12-24 | Isis Pharmaceuticals, Inc. | Oligonucleotides having phosphorothioate linkages of high chiral purity |
US5578718A (en) | 1990-01-11 | 1996-11-26 | Isis Pharmaceuticals, Inc. | Thiol-derivatized nucleosides |
US5587470A (en) | 1990-01-11 | 1996-12-24 | Isis Pharmaceuticals, Inc. | 3-deazapurines |
US7037646B1 (en) | 1990-01-11 | 2006-05-02 | Isis Pharmaceuticals, Inc. | Amine-derivatized nucleosides and oligonucleosides |
US5646265A (en) | 1990-01-11 | 1997-07-08 | Isis Pharmceuticals, Inc. | Process for the preparation of 2'-O-alkyl purine phosphoramidites |
US5681941A (en) | 1990-01-11 | 1997-10-28 | Isis Pharmaceuticals, Inc. | Substituted purines and oligonucleotide cross-linking |
WO1991013080A1 (en) | 1990-02-20 | 1991-09-05 | Gilead Sciences, Inc. | Pseudonucleosides and pseudonucleotides and their polymers |
US5214136A (en) | 1990-02-20 | 1993-05-25 | Gilead Sciences, Inc. | Anthraquinone-derivatives oligonucleotides |
US5321131A (en) | 1990-03-08 | 1994-06-14 | Hybridon, Inc. | Site-specific functionalization of oligodeoxynucleotides for non-radioactive labelling |
US5470967A (en) | 1990-04-10 | 1995-11-28 | The Dupont Merck Pharmaceutical Company | Oligonucleotide analogs with sulfamate linkages |
US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
GB9009980D0 (en) | 1990-05-03 | 1990-06-27 | Amersham Int Plc | Phosphoramidite derivatives,their preparation and the use thereof in the incorporation of reporter groups on synthetic oligonucleotides |
DK0455905T3 (en) | 1990-05-11 | 1998-12-07 | Microprobe Corp | Dipsticks for nucleic acid hybridization assays and method for covalent immobilization of oligonucleotides |
ATE154246T1 (en) | 1990-07-27 | 1997-06-15 | Isis Pharmaceuticals Inc | NUCLEASE RESISTANT PYRIMIDINE MODIFIED OLIGONUCLEOTIDES THAT DETECTE AND MODULATE GENE EXPRESSION |
US5608046A (en) | 1990-07-27 | 1997-03-04 | Isis Pharmaceuticals, Inc. | Conjugated 4'-desmethyl nucleoside analog compounds |
US5489677A (en) | 1990-07-27 | 1996-02-06 | Isis Pharmaceuticals, Inc. | Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms |
US5618704A (en) | 1990-07-27 | 1997-04-08 | Isis Pharmacueticals, Inc. | Backbone-modified oligonucleotide analogs and preparation thereof through radical coupling |
US5138045A (en) | 1990-07-27 | 1992-08-11 | Isis Pharmaceuticals | Polyamine conjugated oligonucleotides |
US5541307A (en) | 1990-07-27 | 1996-07-30 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogs and solid phase synthesis thereof |
US5218105A (en) | 1990-07-27 | 1993-06-08 | Isis Pharmaceuticals | Polyamine conjugated oligonucleotides |
US5688941A (en) | 1990-07-27 | 1997-11-18 | Isis Pharmaceuticals, Inc. | Methods of making conjugated 4' desmethyl nucleoside analog compounds |
US5623070A (en) | 1990-07-27 | 1997-04-22 | Isis Pharmaceuticals, Inc. | Heteroatomic oligonucleoside linkages |
US5677437A (en) | 1990-07-27 | 1997-10-14 | Isis Pharmaceuticals, Inc. | Heteroatomic oligonucleoside linkages |
US5602240A (en) | 1990-07-27 | 1997-02-11 | Ciba Geigy Ag. | Backbone modified oligonucleotide analogs |
US5610289A (en) | 1990-07-27 | 1997-03-11 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogues |
US5245022A (en) | 1990-08-03 | 1993-09-14 | Sterling Drug, Inc. | Exonuclease resistant terminally substituted oligonucleotides |
WO1992002534A2 (en) | 1990-08-03 | 1992-02-20 | Sterling Drug, Inc. | Compounds and methods for inhibiting gene expression |
US5512667A (en) | 1990-08-28 | 1996-04-30 | Reed; Michael W. | Trifunctional intermediates for preparing 3'-tailed oligonucleotides |
US5214134A (en) | 1990-09-12 | 1993-05-25 | Sterling Winthrop Inc. | Process of linking nucleosides with a siloxane bridge |
US5561225A (en) | 1990-09-19 | 1996-10-01 | Southern Research Institute | Polynucleotide analogs containing sulfonate and sulfonamide internucleoside linkages |
WO1992005186A1 (en) | 1990-09-20 | 1992-04-02 | Gilead Sciences | Modified internucleoside linkages |
US5432272A (en) | 1990-10-09 | 1995-07-11 | Benner; Steven A. | Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases |
KR930702373A (en) | 1990-11-08 | 1993-09-08 | 안토니 제이. 페이네 | Addition of Multiple Reporter Groups to Synthetic Oligonucleotides |
GB9100304D0 (en) | 1991-01-08 | 1991-02-20 | Ici Plc | Compound |
US7015315B1 (en) | 1991-12-24 | 2006-03-21 | Isis Pharmaceuticals, Inc. | Gapped oligonucleotides |
US5539082A (en) | 1993-04-26 | 1996-07-23 | Nielsen; Peter E. | Peptide nucleic acids |
US5714331A (en) | 1991-05-24 | 1998-02-03 | Buchardt, Deceased; Ole | Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility |
US5719262A (en) | 1993-11-22 | 1998-02-17 | Buchardt, Deceased; Ole | Peptide nucleic acids having amino acid side chains |
US5371241A (en) | 1991-07-19 | 1994-12-06 | Pharmacia P-L Biochemicals Inc. | Fluorescein labelled phosphoramidites |
US5571799A (en) | 1991-08-12 | 1996-11-05 | Basco, Ltd. | (2'-5') oligoadenylate analogues useful as inhibitors of host-v5.-graft response |
US5283185A (en) | 1991-08-28 | 1994-02-01 | University Of Tennessee Research Corporation | Method for delivering nucleic acids into cells |
EP0538194B1 (en) | 1991-10-17 | 1997-06-04 | Novartis AG | Bicyclic nucleosides, oligonucleotides, their method of preparation and intermediates therein |
US5594121A (en) | 1991-11-07 | 1997-01-14 | Gilead Sciences, Inc. | Enhanced triple-helix and double-helix formation with oligomers containing modified purines |
CA2124087C (en) | 1991-11-22 | 2002-10-01 | James L. Winkler | Combinatorial strategies for polymer synthesis |
US5484908A (en) | 1991-11-26 | 1996-01-16 | Gilead Sciences, Inc. | Oligonucleotides containing 5-propynyl pyrimidines |
US6235887B1 (en) | 1991-11-26 | 2001-05-22 | Isis Pharmaceuticals, Inc. | Enhanced triple-helix and double-helix formation directed by oligonucleotides containing modified pyrimidines |
US5359044A (en) | 1991-12-13 | 1994-10-25 | Isis Pharmaceuticals | Cyclobutyl oligonucleotide surrogates |
EP1695979B1 (en) | 1991-12-24 | 2011-07-06 | Isis Pharmaceuticals, Inc. | Gapped modified oligonucleotides |
US6277603B1 (en) | 1991-12-24 | 2001-08-21 | Isis Pharmaceuticals, Inc. | PNA-DNA-PNA chimeric macromolecules |
US5565552A (en) | 1992-01-21 | 1996-10-15 | Pharmacyclics, Inc. | Method of expanded porphyrin-oligonucleotide conjugate synthesis |
US5595726A (en) | 1992-01-21 | 1997-01-21 | Pharmacyclics, Inc. | Chromophore probe for detection of nucleic acid |
FR2687679B1 (en) | 1992-02-05 | 1994-10-28 | Centre Nat Rech Scient | OLIGOTHIONUCLEOTIDES. |
DE4203923A1 (en) | 1992-02-11 | 1993-08-12 | Henkel Kgaa | METHOD FOR PRODUCING POLYCARBOXYLATES ON A POLYSACCHARIDE BASE |
US5633360A (en) | 1992-04-14 | 1997-05-27 | Gilead Sciences, Inc. | Oligonucleotide analogs capable of passive cell membrane permeation |
US20040127446A1 (en) | 1992-05-14 | 2004-07-01 | Lawrence Blatt | Oligonucleotide mediated inhibition of hepatitis B virus and hepatitis C virus replication |
US5434257A (en) | 1992-06-01 | 1995-07-18 | Gilead Sciences, Inc. | Binding compentent oligomers containing unsaturated 3',5' and 2',5' linkages |
EP0646178A1 (en) | 1992-06-04 | 1995-04-05 | The Regents Of The University Of California | expression cassette with regularoty regions functional in the mammmlian host |
EP0648265A4 (en) | 1992-06-18 | 1996-12-04 | Genpharm Int | Methods for producing transgenic non-human animals harboring a yeast artificial chromosome. |
EP0577558A2 (en) | 1992-07-01 | 1994-01-05 | Ciba-Geigy Ag | Carbocyclic nucleosides having bicyclic rings, oligonucleotides therefrom, process for their preparation, their use and intermediates |
US5272250A (en) | 1992-07-10 | 1993-12-21 | Spielvogel Bernard F | Boronated phosphoramidate compounds |
EP1251170A3 (en) | 1992-07-17 | 2002-10-30 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for treatment of NF-kappaB dependent animal diseases |
US6346614B1 (en) | 1992-07-23 | 2002-02-12 | Hybridon, Inc. | Hybrid oligonucleotide phosphorothioates |
US5574142A (en) | 1992-12-15 | 1996-11-12 | Microprobe Corporation | Peptide linkers for improved oligonucleotide delivery |
US5476925A (en) | 1993-02-01 | 1995-12-19 | Northwestern University | Oligodeoxyribonucleotides including 3'-aminonucleoside-phosphoramidate linkages and terminal 3'-amino groups |
GB9304618D0 (en) | 1993-03-06 | 1993-04-21 | Ciba Geigy Ag | Chemical compounds |
EP0691968B1 (en) | 1993-03-30 | 1997-07-16 | Sanofi | Acyclic nucleoside analogs and oligonucleotide sequences containing them |
EP0691977B1 (en) | 1993-03-31 | 1997-11-26 | Sanofi | Oligonucleotides with amide linkages replacing phosphodiester linkages |
DE4311944A1 (en) | 1993-04-10 | 1994-10-13 | Degussa | Coated sodium percarbonate particles, process for their preparation and detergent, cleaning and bleaching compositions containing them |
US5955591A (en) | 1993-05-12 | 1999-09-21 | Imbach; Jean-Louis | Phosphotriester oligonucleotides, amidites and method of preparation |
US6015886A (en) | 1993-05-24 | 2000-01-18 | Chemgenes Corporation | Oligonucleotide phosphate esters |
US6294664B1 (en) | 1993-07-29 | 2001-09-25 | Isis Pharmaceuticals, Inc. | Synthesis of oligonucleotides |
US5502177A (en) | 1993-09-17 | 1996-03-26 | Gilead Sciences, Inc. | Pyrimidine derivatives for labeled binding partners |
EP0729474A4 (en) | 1993-11-16 | 1998-10-21 | Genta Inc | Synthetic oligomers having chirally pure phosphonate internucleosidyl linkages mixed with non-phosphonate internucleosidyl linkages |
US5457187A (en) | 1993-12-08 | 1995-10-10 | Board Of Regents University Of Nebraska | Oligonucleotides containing 5-fluorouracil |
US5446137B1 (en) | 1993-12-09 | 1998-10-06 | Behringwerke Ag | Oligonucleotides containing 4'-substituted nucleotides |
US5519134A (en) | 1994-01-11 | 1996-05-21 | Isis Pharmaceuticals, Inc. | Pyrrolidine-containing monomers and oligomers |
US5596091A (en) | 1994-03-18 | 1997-01-21 | The Regents Of The University Of California | Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides |
US5599922A (en) | 1994-03-18 | 1997-02-04 | Lynx Therapeutics, Inc. | Oligonucleotide N3'-P5' phosphoramidates: hybridization and nuclease resistance properties |
US5627053A (en) | 1994-03-29 | 1997-05-06 | Ribozyme Pharmaceuticals, Inc. | 2'deoxy-2'-alkylnucleotide containing nucleic acid |
US5625050A (en) | 1994-03-31 | 1997-04-29 | Amgen Inc. | Modified oligonucleotides and intermediates useful in nucleic acid therapeutics |
US6054299A (en) | 1994-04-29 | 2000-04-25 | Conrad; Charles A. | Stem-loop cloning vector and method |
US5525711A (en) | 1994-05-18 | 1996-06-11 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Pteridine nucleotide analogs as fluorescent DNA probes |
US5543152A (en) | 1994-06-20 | 1996-08-06 | Inex Pharmaceuticals Corporation | Sphingosomes for enhanced drug delivery |
US5597696A (en) | 1994-07-18 | 1997-01-28 | Becton Dickinson And Company | Covalent cyanine dye oligonucleotide conjugates |
US5580731A (en) | 1994-08-25 | 1996-12-03 | Chiron Corporation | N-4 modified pyrimidine deoxynucleotides and oligonucleotide probes synthesized therewith |
US5597909A (en) | 1994-08-25 | 1997-01-28 | Chiron Corporation | Polynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use |
US5556752A (en) | 1994-10-24 | 1996-09-17 | Affymetrix, Inc. | Surface-bound, unimolecular, double-stranded DNA |
US6608035B1 (en) | 1994-10-25 | 2003-08-19 | Hybridon, Inc. | Method of down-regulating gene expression |
US6166197A (en) | 1995-03-06 | 2000-12-26 | Isis Pharmaceuticals, Inc. | Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions |
US6222025B1 (en) | 1995-03-06 | 2001-04-24 | Isis Pharmaceuticals, Inc. | Process for the synthesis of 2′-O-substituted pyrimidines and oligomeric compounds therefrom |
EP0833613A1 (en) | 1995-05-26 | 1998-04-08 | Somatix Therapy Corporation | Delivery vehicles comprising stable lipid/nucleic acid complexes |
US7422902B1 (en) | 1995-06-07 | 2008-09-09 | The University Of British Columbia | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
US5981501A (en) | 1995-06-07 | 1999-11-09 | Inex Pharmaceuticals Corp. | Methods for encapsulating plasmids in lipid bilayers |
US5545531A (en) | 1995-06-07 | 1996-08-13 | Affymax Technologies N.V. | Methods for making a device for concurrently processing multiple biological chip assays |
JP4335310B2 (en) | 1995-06-07 | 2009-09-30 | ザ ユニバーシティ オブ ブリティッシュ コロンビア | Lipid-nucleic acid particles prepared through hydrophobic lipid-nucleic acid complex intermediates and use for gene transfer |
US5858397A (en) | 1995-10-11 | 1999-01-12 | University Of British Columbia | Liposomal formulations of mitoxantrone |
US6160109A (en) | 1995-10-20 | 2000-12-12 | Isis Pharmaceuticals, Inc. | Preparation of phosphorothioate and boranophosphate oligomers |
US5854033A (en) | 1995-11-21 | 1998-12-29 | Yale University | Rolling circle replication reporter systems |
US6444423B1 (en) | 1996-06-07 | 2002-09-03 | Molecular Dynamics, Inc. | Nucleosides comprising polydentate ligands |
US6172209B1 (en) | 1997-02-14 | 2001-01-09 | Isis Pharmaceuticals Inc. | Aminooxy-modified oligonucleotides and methods for making same |
US6639062B2 (en) | 1997-02-14 | 2003-10-28 | Isis Pharmaceuticals, Inc. | Aminooxy-modified nucleosidic compounds and oligomeric compounds prepared therefrom |
US6576752B1 (en) | 1997-02-14 | 2003-06-10 | Isis Pharmaceuticals, Inc. | Aminooxy functionalized oligomers |
US6034135A (en) | 1997-03-06 | 2000-03-07 | Promega Biosciences, Inc. | Dimeric cationic lipids |
JP3756313B2 (en) | 1997-03-07 | 2006-03-15 | 武 今西 | Novel bicyclonucleosides and oligonucleotide analogues |
US6770748B2 (en) | 1997-03-07 | 2004-08-03 | Takeshi Imanishi | Bicyclonucleoside and oligonucleotide analogue |
WO1999001579A1 (en) | 1997-07-01 | 1999-01-14 | Isis Pharmaceuticals, Inc. | Compositions and methods for the delivery of oligonucleotides via the alimentary canal |
CA2303299C (en) | 1997-09-12 | 2016-02-23 | Exiqon A/S | Oligonucleotide analogues |
US6794499B2 (en) | 1997-09-12 | 2004-09-21 | Exiqon A/S | Oligonucleotide analogues |
US6617438B1 (en) | 1997-11-05 | 2003-09-09 | Sirna Therapeutics, Inc. | Oligoribonucleotides with enzymatic activity |
US6528640B1 (en) | 1997-11-05 | 2003-03-04 | Ribozyme Pharmaceuticals, Incorporated | Synthetic ribonucleic acids with RNAse activity |
US6320017B1 (en) | 1997-12-23 | 2001-11-20 | Inex Pharmaceuticals Corp. | Polyamide oligomers |
US7273933B1 (en) | 1998-02-26 | 2007-09-25 | Isis Pharmaceuticals, Inc. | Methods for synthesis of oligonucleotides |
US7045610B2 (en) | 1998-04-03 | 2006-05-16 | Epoch Biosciences, Inc. | Modified oligonucleotides for mismatch discrimination |
US6531590B1 (en) | 1998-04-24 | 2003-03-11 | Isis Pharmaceuticals, Inc. | Processes for the synthesis of oligonucleotide compounds |
US6867294B1 (en) | 1998-07-14 | 2005-03-15 | Isis Pharmaceuticals, Inc. | Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages |
CA2335393C (en) | 1998-07-20 | 2008-09-23 | Inex Pharmaceuticals Corporation | Liposomal encapsulated nucleic acid-complexes |
BR9914773A (en) | 1998-10-09 | 2002-02-05 | Ingene Inc | Set of generic elements, method for the production of single-stranded DNA, mrna transcription, nucleic acid construction, ssdna transcription, vector, vector system, host cell, set for the production of a single-stranded nucleic acid sequence, method for in vivo or in vitro production of a single-stranded nucleic acid sequence, transcription of single-stranded cdna, inhibitory nucleic acid, heteroduplex molecule, and pharmaceutical composition |
AU6430599A (en) | 1998-10-09 | 2000-05-01 | Cytogenix, Inc. | Enzymatic synthesis of ssdna |
US6465628B1 (en) | 1999-02-04 | 2002-10-15 | Isis Pharmaceuticals, Inc. | Process for the synthesis of oligomeric compounds |
EP1156812A4 (en) | 1999-02-23 | 2004-09-29 | Isis Pharmaceuticals Inc | Multiparticulate formulation |
US7084125B2 (en) | 1999-03-18 | 2006-08-01 | Exiqon A/S | Xylo-LNA analogues |
ATE356824T1 (en) | 1999-05-04 | 2007-04-15 | Santaris Pharma As | L-RIBO-LNA ANALOGUE |
US6525191B1 (en) | 1999-05-11 | 2003-02-25 | Kanda S. Ramasamy | Conformationally constrained L-nucleosides |
US6593466B1 (en) | 1999-07-07 | 2003-07-15 | Isis Pharmaceuticals, Inc. | Guanidinium functionalized nucleotides and precursors thereof |
US6147200A (en) | 1999-08-19 | 2000-11-14 | Isis Pharmaceuticals, Inc. | 2'-O-acetamido modified monomers and oligomers |
US7321029B2 (en) | 2000-01-21 | 2008-01-22 | Geron Corporation | 2′-arabino-fluorooligonucleotide N3′→P5′ phosphoramidates: their synthesis and use |
WO2002028875A2 (en) | 2000-10-04 | 2002-04-11 | Cureon A/S | Improved synthesis of purine locked nucleic acid analogues |
US6878805B2 (en) | 2002-08-16 | 2005-04-12 | Isis Pharmaceuticals, Inc. | Peptide-conjugated oligomeric compounds |
AU2003291753B2 (en) | 2002-11-05 | 2010-07-08 | Isis Pharmaceuticals, Inc. | Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation |
EP1578765A4 (en) | 2002-11-05 | 2008-04-23 | Isis Pharmaceuticals Inc | Sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation |
US7427672B2 (en) | 2003-08-28 | 2008-09-23 | Takeshi Imanishi | Artificial nucleic acids of n-o bond crosslinkage type |
PL1866414T3 (en) | 2005-03-31 | 2012-10-31 | Calando Pharmaceuticals Inc | Inhibitors of ribonucleotide reductase subunit 2 and uses thereof |
US7569686B1 (en) | 2006-01-27 | 2009-08-04 | Isis Pharmaceuticals, Inc. | Compounds and methods for synthesis of bicyclic nucleic acid analogs |
EP2314594B1 (en) | 2006-01-27 | 2014-07-23 | Isis Pharmaceuticals, Inc. | 6-modified bicyclic nucleic acid analogs |
DK2066684T3 (en) | 2006-05-11 | 2012-10-22 | Isis Pharmaceuticals Inc | 5'-Modified Bicyclic Nucleic Acid Analogs |
ES2611924T3 (en) | 2006-10-03 | 2017-05-11 | Arbutus Biopharma Corporation | Formulations containing lipids |
AU2008260277C1 (en) | 2007-05-30 | 2014-04-17 | Isis Pharmaceuticals, Inc. | N-substituted-aminomethylene bridged bicyclic nucleic acid analogs |
DK2173760T4 (en) | 2007-06-08 | 2016-02-08 | Isis Pharmaceuticals Inc | Carbocyclic bicyclic nukleinsyreanaloge |
ES2376507T5 (en) | 2007-07-05 | 2015-08-31 | Isis Pharmaceuticals, Inc. | 6-disubstituted bicyclic nucleic acid analogs |
CA2910760C (en) | 2007-12-04 | 2019-07-09 | Muthiah Manoharan | Targeting lipids |
NZ588583A (en) | 2008-04-15 | 2012-08-31 | Protiva Biotherapeutics Inc | Novel lipid formulations for nucleic acid delivery |
US20110288147A1 (en) | 2008-09-22 | 2011-11-24 | Bob Dale Brown | Compositions and methods for the specific inhibition of gene expression by DSRNA containing a tetraloop |
KR20220150995A (en) | 2008-11-10 | 2022-11-11 | 알닐람 파마슈티칼스 인코포레이티드 | Novel lipids and compositions for the delivery of therapeutics |
CA2751342C (en) | 2009-01-29 | 2019-05-07 | Alnylam Pharmaceuticals, Inc. | Lipid formulations comprising cationic lipid and a targeting lipid comprising n-acetyl galactosamine for delivery of nucleic acid |
SG10201402054UA (en) | 2009-05-05 | 2014-09-26 | Muthiah Manoharan | Lipid compositions |
CN104873464B (en) | 2009-06-10 | 2018-06-22 | 阿布特斯生物制药公司 | Improved lipid formulations |
US8927513B2 (en) | 2009-07-07 | 2015-01-06 | Alnylam Pharmaceuticals, Inc. | 5′ phosphate mimics |
US9512164B2 (en) | 2009-07-07 | 2016-12-06 | Alnylam Pharmaceuticals, Inc. | Oligonucleotide end caps |
US8598334B2 (en) | 2009-10-16 | 2013-12-03 | Glaxo Group Limited | HBV antisense inhibitors |
US8765148B2 (en) | 2010-02-19 | 2014-07-01 | Valneva Austria Gmbh | 1C31 nanoparticles |
US20130190383A1 (en) | 2010-04-26 | 2013-07-25 | Marina Biotech, Inc. | Nucleic acid compounds with conformationally restricted monomers and uses thereof |
RU2624045C2 (en) | 2010-08-17 | 2017-06-30 | Сирна Терапьютикс,Инк | RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
GB201022147D0 (en) | 2010-12-31 | 2011-02-16 | Immune Targeting Systems Its Ltd | Formulation |
WO2012129295A1 (en) | 2011-03-21 | 2012-09-27 | Vaxin Inc. | Rapid and prolonged immunologic-therapeutic |
EP2699583A4 (en) | 2011-04-21 | 2015-04-15 | Isis Pharmaceuticals Inc | Modulation of hepatitis b virus (hbv) expression |
CA2839896A1 (en) | 2011-06-21 | 2012-12-27 | Alnylam Pharmaceuticals, Inc. | Assays and methods for determining activity of a therapeutic agent in a subject |
TW202244278A (en) | 2011-06-30 | 2022-11-16 | 美商艾羅海德製藥公司 | Compositions and methods for inhibiting gene expression of hepatitis b virus |
AU2012304358B2 (en) | 2011-09-07 | 2017-07-20 | Marina Biotech Inc. | Synthesis and uses of nucleic acid compounds with conformationally restricted monomers |
EA031393B1 (en) | 2013-05-01 | 2018-12-28 | Ионис Фармасьютикалз, Инк. | Compositions and methods for modulating hbv and ttr expression |
JOP20200092A1 (en) * | 2014-11-10 | 2017-06-16 | Alnylam Pharmaceuticals Inc | HEPATITIS B VIRUS (HBV) iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
KR20180038465A (en) | 2015-08-07 | 2018-04-16 | 애로우헤드 파마슈티컬스 인코포레이티드 | RNAi therapy for hepatitis B virus infection |
US10912827B2 (en) | 2016-01-12 | 2021-02-09 | Helmholtz Zentrum München—Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Means and methods for treating HBV |
-
2018
- 2018-04-18 KR KR1020197033885A patent/KR20200015895A/en not_active Application Discontinuation
- 2018-04-18 TW TW107113207A patent/TWI801377B/en active
- 2018-04-18 AU AU2018254437A patent/AU2018254437A1/en active Pending
- 2018-04-18 BR BR112019021852-1A patent/BR112019021852A2/en unknown
- 2018-04-18 WO PCT/US2018/028116 patent/WO2018195165A1/en unknown
- 2018-04-18 CN CN201880035565.XA patent/CN110913898B/en active Active
- 2018-04-18 MA MA050278A patent/MA50278A/en unknown
- 2018-04-18 EP EP18722367.2A patent/EP3612219A1/en active Pending
- 2018-04-18 CA CA3059446A patent/CA3059446A1/en active Pending
- 2018-04-18 SG SG11201909572Q patent/SG11201909572QA/en unknown
-
2019
- 2019-10-17 PH PH12019550220A patent/PH12019550220A1/en unknown
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113398261A (en) * | 2021-07-16 | 2021-09-17 | 山西医科大学 | Application of poly-sarcosine in preparing biological preparation for improving HBsAg positive mother infant hepatitis B vaccine response level |
Also Published As
Publication number | Publication date |
---|---|
SG11201909572QA (en) | 2019-11-28 |
MA50278A (en) | 2020-02-26 |
WO2018195165A8 (en) | 2018-11-22 |
TW201906617A (en) | 2019-02-16 |
KR20200015895A (en) | 2020-02-13 |
TWI801377B (en) | 2023-05-11 |
CN110913898B (en) | 2024-04-05 |
BR112019021852A2 (en) | 2020-06-02 |
CN110913898A (en) | 2020-03-24 |
WO2018195165A1 (en) | 2018-10-25 |
EP3612219A1 (en) | 2020-02-26 |
AU2018254437A1 (en) | 2019-11-28 |
PH12019550220A1 (en) | 2020-07-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI801377B (en) | Methods for the treatment of subjects having a hepatitis b virus (hbv) infection | |
AU2021277625B2 (en) | Hepatitis B virus (HBV) iRNA compositions and methods of use thereof | |
AU2016315584B2 (en) | Programmed cell death 1 ligand 1 (PD-L1) iRNA compositions and methods of use thereof | |
US11324820B2 (en) | Methods for the treatment of subjects having a hepatitis b virus (HBV) infection | |
JP2023123449A (en) | Methods for treating subjects having hepatitis b virus (hbv) infection | |
OA19808A (en) | Methods for the treatment of subjects having a hepatitis B virus (HBV) infection. | |
TWI834187B (en) | HEPATITIS B VIRUS (HBV) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | |
JP2024056714A (en) | Hepatitis B virus (HBV) iRNA compositions and methods of use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |
Effective date: 20230418 |
|
EEER | Examination request |
Effective date: 20230418 |